Rsid Chr Position Ref P_value Gwas_trait Gene_symbol Variant_type Pubmedid rs568632519 chr1 565596 G A 7.28E-05 Cognitive impairment induced by topiramate / / 22091778 rs10751454 chr1 807512 A G 2.20E-13 Health and aging,CVD and cancer age of onset FAM41C intron 22174011 rs10751454 chr1 807512 A G 5.40E-21 Health and aging,CVD and cancer age of onset FAM41C intron 22174011 rs10751454 chr1 807512 A G 7.70E-09 Health and aging,CVD and cancer age of onset FAM41C intron 22174011 rs3748592 chr1 880238 A G 1.09E-04 Smoking initiation NOC2L intron 24665060 rs7526076 chr1 998395 A G 2.84E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs3934834 chr1 1005806 C T 6.00E-07 Body mass index / / 19851299 rs6689308 chr1 1029805 A G 5.62E-04 Eating disorders C1orf159 intron 23568457 rs6687776 chr1 1030565 C T 9.40E-05 Post-operative nausea and vomiting C1orf159 intron 21694509 rs7545952 chr1 1031060 A G 1.68E-04 Eating disorders (purging via substances) C1orf159 intron 23568457 rs12145826 chr1 1066029 G A 6.14E-05 Celiac disease / / 23936387 rs11260603 chr1 1079198 T C 4.00E-07 IgG glycosylation / / 23382691 rs4442317 chr1 1106784 T C 5.26E-04 Smoking initiation / / 24665060 rs11260542 chr1 1110019 A G 8.24E-04 Alcohol dependence TTLL10 intron 20201924 rs3819001 chr1 1138913 T C 5.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) TNFRSF18 UTR-3 23648065 rs11260562 chr1 1165310 G A 6.12E-04 Multiple complex diseases SDF4 intron 17554300 rs715643 chr1 1172907 C T 2.61E-04 Celiac disease / / 23936387 rs6697886 chr1 1173611 G A 9.70E-05 Alcohol dependence / / 21703634 rs11804831 chr1 1194804 T C 2.46E-05 Waist Circumference UBE2J2 intron pha003023 rs12103 chr1 1247494 T C 8.00E-13 Inflammatory bowel disease CPSF3L cds-synon 23128233 rs151152085 chr1 1322654 C T 0.000061 Breast cancer(er negative) CCNL2 missense 23555315 rs1695824 chr1 1365570 A C 4.23E-04 Multiple complex diseases / / 17554300 rs819976 chr1 1421531 C A 1.30E-05 Odorant perception ATAD3B cds-synon 23910658 rs9439462 chr1 1462766 C T 7.57E-05 Cognitive impairment induced by topiramate ATAD3A intron 22091778 rs3766178 chr1 1478180 T C 3.26E-05 Glucose levels SSU72 intron pha003058 rs880051 chr1 1493727 G A 1.89E-05 Glucose levels SSU72 intron pha003058 rs880051 chr1 1493727 G A 6.44E-05 Glucose levels SSU72 intron pha003061 rs2296716 chr1 1497824 C T 8.76E-07 Glucose levels SSU72 intron pha003058 rs2296716 chr1 1497824 C T 2.54E-05 Glucose levels SSU72 intron pha003061 rs4648782 chr1 1542186 G A 5.44E-04 Smoking initiation / / 24665060 rs28464684 chr1 1566160 T C 1.64E-04 Intracranial aneurysm / / 22286173 rs7531583 chr1 1706160 A G 9.21E-04 Acute lung injury /DK intron 22295056 rs9786963 chr1 1759026 T C 3.01E-04 Alzheimer's disease GNB1 intron 17998437 rs10907192 chr1 1793111 A G 7.59E-05 Cognitive performance GNB1 intron 19734545 rs7511905 chr1 1793786 A C 1.64E-04 Alzheimer's disease GNB1 intron 17998437 rs3855951 chr1 1804302 C T 1.55E-04 Alzheimer's disease GNB1 intron 17998437 rs7525092 chr1 1810090 C T 9.86E-05 Lung function (forced expiratory volume in 1 second) GNB1 intron pha003103 rs6688000 chr1 1823922 A G 3.16E-04 Alzheimer's disease / / 17998437 rs3820011 chr1 1888193 C A 4.91E-04 Smoking initiation KIAA1751 missense 24665060 rs2803291 chr1 1892325 T C 7.55E-04 Acute lung injury KIAA1751 intron 22295056 rs3795277 chr1 1981118 A C 1.11E-05 Celiac disease PRKCZ nearGene-5 23936387 rs884080 chr1 2026749 A G 4.53E-04 Urate levels PRKCZ intron 23263486 rs3128296 chr1 2068906 G T 2.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) PRKCZ intron 23648065 rs425277 chr1 2069172 C T 2.00E-08 Height PRKCZ intron 20881960 rs3753242 chr1 2069681 C T 8.80E-05 Response to lithium treatment in bipolar disorder PRKCZ intron 19448189 rs3753242 chr1 2069681 C T 1.00E-06 Response to antipsychotic treatment in schizophrenia (reasoning) PRKCZ intron 21107309 rs424079 chr1 2071340 C A 8.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PRKCZ intron 20877124 rs262669 chr1 2082489 G A 8.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PRKCZ intron 20877124 rs262683 chr1 2155869 C T 1.33E-05 Cognitive test performance / / 20125193 rs2460000 chr1 2156362 A G 1.36E-04 HIV-1 progression to AIDS and death / / 21811574 rs2460000 chr1 2156362 A G 1.51E-04 HIV-1 progression to AIDS and death / / 21811574 rs2460000 chr1 2156362 A G 3.14E-05 HIV-1 progression to AIDS and death / / 21811574 rs10797416 chr1 2182342 T C 0.0000837 Coronary artery disease SKI intron 23202125 rs6673129 chr1 2202774 C T 1.37E-05 Cognitive test performance SKI intron 20125193 rs12045693 chr1 2205581 C A 3.00E-06 IgG glycosylation SKI intron 23382691 rs2843163 chr1 2227422 C T 7.45E-04 Response to cytidine analogues (gemcitabine) SKI intron 24483146 rs12562937 chr1 2229478 C T 3.50E-06 Urinary metabolites SKI intron 21572414 rs2173049 chr1 2240006 T C 8.49E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) SKI UTR-3 20877124 rs2643902 chr1 2245439 T C 3.77E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2645077 chr1 2249236 G A 1.68E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs12080256 chr1 2251357 C A 1.98E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2055204 chr1 2280661 G A 4.19E-04 Smoking initiation MORN1 intron 24665060 rs7527871 chr1 2281726 A C 8.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) MORN1 intron 23648065 rs2843130 chr1 2283313 C G 4.06E-04 Body mass index MORN1 intron 21701565 rs2840528 chr1 2283896 A G 1.22E-04 Body mass index MORN1 intron 21701565 rs2840528 chr1 2283896 A G 9.85E-05 Blood Pressure MORN1 intron pha003039 rs2840531 chr1 2286408 C T 3.69E-04 Body mass index MORN1 intron 21701565 rs2494428 chr1 2339074 C T 9.97E-04 HIV-1 viral setpoint PEX10 intron 17641165 rs7556447 chr1 2346099 C G 7.90E-06 Parkinson's disease (age of onset) / / 19772629 rs4648843 chr1 2366316 C T 1.20E-05 Monocyte chemoattractant protein-1 / / pha003071 rs10910078 chr1 2390588 T C 3.13E-07 Non-obstructive azoospermia / / 22197933 rs10910078 chr1 2390588 T C 0.00000663 Autism spectrum disorders / / 22412387 rs2477686 chr1 2392648 G C 6.00E-12 Non-obstructive azoospermia / / 22197933 rs11588930 chr1 2408834 G A 0.000055 Coronary artery calcification PLCH2 intron 23727086 rs2477703 chr1 2425992 C T 9.99E-04 Amyotrophic lateral sclerosis (sporadic) PLCH2 intron 24529757 rs2236395 chr1 2446880 A G 6.30E-05 Rheumatoid arthritis PANK4 intron 22446963 rs12073504 chr1 2452979 C G 5.00E-06 Obesity-related traits PANK4 intron 23251661 rs10797431 chr1 2501222 G T 0.0000144 Primary biliary cirrhosis / / 22961000 rs10797432 chr1 2501338 C T 3.00E-12 Ulcerative colitis / / 23128233 rs734999 chr1 2513216 C T 3.00E-09 Ulcerative colitis / / 21297633 rs10910097 chr1 2521430 C T 1.29E-04 Multiple complex diseases FAM213B UTR-3 17554300 rs10752747 chr1 2524915 G T 6.31E-10 Celiac disease and Rheumatoid arthritis MMEL1 intron 21383967 rs3748816 chr1 2526746 A G 3.00E-09 Celiac disease MMEL1 missense 20190752 rs3748816 chr1 2526746 A G 3.00E-09 Asthma MMEL1 missense 21150878 rs3748816 chr1 2526746 A G 3.28E-09 Celiac disease and Rheumatoid arthritis MMEL1 missense 21383967 rs3748816 chr1 2526746 A G 1.60E-12 Multiple sclerosis MMEL1 missense 21833088 rs3748816 chr1 2526746 A G 3.28E-09 Multiple sclerosis MMEL1 missense 22190364 rs3748816 chr1 2526746 A G 0.000000021 Primary sclerosing cholangitis MMEL1 missense 22521342 rs3748816 chr1 2526746 A G 7.41E-12 Primary sclerosing cholangitis MMEL1 missense 23603763 rs2843401 chr1 2528133 T C 6.60E-09 Rheumatoid arthritis MMEL1 intron 23143596 rs2843401 chr1 2528133 T C 7.24E-10 Rheumatoid arthritis (CCP positive) MMEL1 intron 23143596 rs2843403 chr1 2529097 T C 0.000000794 Graves' disease MMEL1 intron 22922229 rs2843403 chr1 2529097 T C 0.00000563 Graves' disease and Hashimoto's thyroiditis MMEL1 intron 22922229 rs10910099 chr1 2533552 A C 5.40E-07 Multiple complex diseases MMEL1 intron 17554300 rs12138909 chr1 2538738 C T 5.61E-08 Celiac disease and Rheumatoid arthritis MMEL1 intron 21383967 rs12138909 chr1 2538738 C T 9.18E-05 Cognitive impairment induced by topiramate MMEL1 intron 22091778 rs4445406 chr1 2539400 T C 5.40E-12 Celiac disease MMEL1 intron 22057235 rs4445406 chr1 2539400 T C 5.40E-12 Celiac disease MMEL1 intron 23143596 rs10910108 chr1 2539532 A G 0.000331 Primary biliary cirrhosis (anti-mitochondrial antibody positive) MMEL1 intron 22936693 rs6684865 chr1 2546229 G A 5.37E-06 Multiple complex diseases MMEL1 intron 17554300 rs4648654 chr1 2553083 G A 0.00067 Primary biliary cirrhosis MMEL1 intron 22936693 rs3890745 chr1 2553624 T C 5.73E-06 Multiple complex diseases MMEL1 intron 17554300 rs3890745 chr1 2553624 T C 1.00E-07 Rheumatoid arthritis MMEL1 intron 18794853 rs3890745 chr1 2553624 T C 4.00E-06 Rheumatoid arthritis MMEL1 intron 20453842 rs3890745 chr1 2553624 T C 1.00E-07 Celiac disease and Rheumatoid arthritis MMEL1 intron 21383967 rs3890745 chr1 2553624 T C 5.60E-06 Rheumatoid arthritis MMEL1 intron 22446963 rs3890745 chr1 2553624 T C 1.00E-06 Rheumatoid arthritis MMEL1 intron 24449572 rs4474198 chr1 2553758 C T 4.75E-06 Multiple complex diseases MMEL1 intron 17554300 rs4648356 chr1 2709164 C A 4.28E-10 Celiac disease and Rheumatoid arthritis / / 21383967 rs4648356 chr1 2709164 C A 1.00E-14 Multiple sclerosis / / 21833088 rs2377041 chr1 2713327 C T 8.89E-05 Serum metabolites / / 19043545 rs4648482 chr1 2749921 T C 7.74E-05 Aortic root size / / 21223598 rs11580768 chr1 2799480 C T 3.85E-06 Ankle-brachial index / / 22199011 rs2842909 chr1 2859724 C T 7.79E-04 Taste perception / / 22132133 rs7548727 chr1 2865778 T C 4.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2485944 chr1 2883858 C T 7.27E-05 Major depressive disorder / / 22472876 rs12044030 chr1 2889577 C T 3.62E-05 ldl cholesterol / / pha003076 rs7533362 chr1 2896735 A G 1.91E-06 ldl cholesterol / / pha003076 rs7533362 chr1 2896735 A G 5.97E-05 Cholesterol / / pha003078 rs1572657 chr1 2902128 C T 3.33E-05 Fibrinogen / / pha003068 rs7534897 chr1 2928421 C T 0.0000755 Salmonella-induced pyroptosis / / 22837397 rs2142569 chr1 2944527 G A 4.00E-06 Substance dependence phenotypes / / 24832863 rs12409277 chr1 2957600 T C 1.00E-06 Body mass (lean) / / 24863034 rs2297829 chr1 2984087 C A 6.38E-04 White matter integrity / / 22425255 rs6695131 chr1 3000924 T C 0.00069 Salmonella-induced pyroptosis PRDM16 intron 22837397 rs2981884 chr1 3002072 A G 9.40E-06 Panic disorder PRDM16 intron 19165232 rs7538096 chr1 3057661 T C 1.92E-05 Hemoglobin PRDM16 intron pha003098 rs7538096 chr1 3057661 T C 1.71E-05 Erythrocyte counts PRDM16 intron pha003099 rs2651899 chr1 3083712 T C 4.00E-09 Migraine PRDM16 intron 21666692 rs2651899 chr1 3083712 T C 4.20E-04 Migraine PRDM16 intron 22683712 rs2651899 chr1 3083712 T C 1.56E-05 Migraine without aura PRDM16 intron 23793025 rs2651899 chr1 3083712 T C 2.54E-04 Migraine with aura PRDM16 intron 23793025 rs2651899 chr1 3083712 T C 3.06E-04 Migraine - clinic-based PRDM16 intron 23793025 rs2651899 chr1 3083712 T C 4.00E-14 Migraine PRDM16 intron 23793025 rs2651899 chr1 3083712 T C 4.34E-14 Migraine PRDM16 intron 23793025 rs17390062 chr1 3089849 T C 5.26E-05 Coronary heart disease PRDM16 intron 21606135 rs12737500 chr1 3094708 C T 7.67E-04 Suicide attempts in bipolar disorder PRDM16 intron 21423239 rs12737500 chr1 3094708 C T 1.90E-05 White matter hyperintensity burden PRDM16 intron 21681796 rs17390167 chr1 3094831 C G 1.70E-05 White matter hyperintensity burden PRDM16 intron 21681796 rs12750165 chr1 3095491 A G 1.80E-05 White matter hyperintensity burden PRDM16 intron 21681796 rs12733843 chr1 3097073 G A 1.80E-05 White matter hyperintensity burden PRDM16 intron 21681796 rs12072073 chr1 3130016 T C 6.49E-04 Alzheimer's disease PRDM16 intron 22005930 rs10909901 chr1 3131235 C T 4.80E-04 Alzheimer's disease PRDM16 intron 22005930 rs2817145 chr1 3133422 T A 7.54E-04 Alzheimer's disease PRDM16 intron 22005930 rs10492940 chr1 3197747 C A 4.12E-04 Suicide attempts in bipolar disorder PRDM16 intron 21423239 rs16823802 chr1 3199217 C T 3.43E-05 Tunica Media PRDM16 intron pha003036 rs12565013 chr1 3203137 A C 3.43E-05 Tunica Media PRDM16 intron pha003036 rs4648377 chr1 3211458 A C 9.21E-04 Tourette syndrome PRDM16 intron 22889924 rs2455136 chr1 3218329 A T 9.75E-05 Self-reported allergy PRDM16 intron 23817569 rs2500283 chr1 3218923 G C 1.49E-04 Self-reported allergy PRDM16 intron 23817569 rs2500282 chr1 3219497 A G 1.18E-04 Self-reported allergy PRDM16 intron 23817569 rs4233025 chr1 3223280 C T 9.54E-05 Self-reported allergy PRDM16 intron 23817569 rs4648473 chr1 3223764 A G 9.91E-05 Self-reported allergy PRDM16 intron 23817569 rs4145901 chr1 3223955 A G 9.18E-05 Self-reported allergy PRDM16 intron 23817569 rs2500278 chr1 3225940 C T 8.60E-04 Amyotrophic Lateral Sclerosis PRDM16 intron 17362836 rs2483261 chr1 3227416 C G 1.48E-04 Self-reported allergy PRDM16 intron 23817569 rs2483262 chr1 3229134 G T 1.49E-04 Self-reported allergy PRDM16 intron 23817569 rs12409315 chr1 3229258 A G 5.57E-05 Multiple complex diseases PRDM16 intron 17554300 rs16824089 chr1 3230544 T C 3.61E-06 Tunica Media PRDM16 intron pha003036 rs4648477 chr1 3251975 G A 1.29E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs4648477 chr1 3251975 G A 1.29E-08 Facial morphology PRDM16 intron 23028347 rs4648478 chr1 3252007 C T 1.12E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs4648478 chr1 3252007 C T 1.12E-08 Facial morphology PRDM16 intron 23028347 rs7516150 chr1 3253889 C T 2.52E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs7516150 chr1 3253889 C T 2.52E-08 Facial morphology PRDM16 intron 23028347 rs7552331 chr1 3253941 G A 3.97E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs7552331 chr1 3253941 G A 3.97E-08 Facial morphology PRDM16 intron 23028347 rs1572037 chr1 3254369 T C 2.45E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs1572037 chr1 3254369 T C 2.45E-08 Facial morphology PRDM16 intron 23028347 rs1999527 chr1 3256108 C A 1.72E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs1999527 chr1 3256108 C A 1.72E-08 Facial morphology PRDM16 intron 23028347 rs4648379 chr1 3261516 C T 1.13E-08 Primary biliary cirrhosis PRDM16 intron 23000144 rs4648379 chr1 3261516 C T 1.13E-08 Facial morphology PRDM16 intron 23028347 rs12748963 chr1 3275149 C T 1.74E-04 Epilepsy PRDM16 intron 22116939 rs17399569 chr1 3278959 C T 4.00E-05 Response to statin therapy PRDM16 intron 20339536 rs11807862 chr1 3279268 T A 2.20E-06 Response to statin therapy PRDM16 intron 20339536 rs6658356 chr1 3280253 G A 2.00E-06 Response to statin therapy PRDM16 intron 20339536 rs6424073 chr1 3285628 G A 3.21E-04 Cognitive decline PRDM16 intron 23732972 rs12135987 chr1 3289524 G A 5.22E-05 Cognitive performance PRDM16 intron 19734545 rs868688 chr1 3300807 C T 8.70E-04 Response to cytadine analogues (cytosine arabinoside) PRDM16 intron 24483146 rs10492939 chr1 3302871 G A 9.12E-06 Bilirubin levels,in serum PRDM16 intron 19389676 rs2493278 chr1 3307746 T C 7.17E-04 Parkinson's disease PRDM16 intron 17052657 rs11578011 chr1 3318532 T C 5.41E-05 Elbow pain PRDM16 intron pha003008 rs2493285 chr1 3333595 G A 4.01E-04 Sudden cardiac arrest PRDM16 intron 21658281 rs3806164 chr1 3380057 G A 2.66E-04 Smoking quantity ARHGEF16 missense 24665060 rs2185639 chr1 3389727 C T 9.17E-05 Relative hand skill in reading disability ARHGEF16 missense 24068947 rs2821041 chr1 3404227 C T 9.71E-05 Relative hand skill in reading disability / / 24068947 rs4648505 chr1 3405296 T C 4.13E-05 Relative hand skill in reading disability MEGF6 UTR-3 24068947 rs10909969 chr1 3480149 C T 8.03E-05 Bipolar disorder MEGF6 intron 17486107 rs2821017 chr1 3520871 G A 5.18E-05 Caffeine consumption MEGF6 intron 21490707 rs4276857 chr1 3544346 T C 1.22E-04 Bipolar disorder TPRG1L intron 18317468 rs2208993 chr1 3575833 C G,T 4.05E-04 Response to cytadine analogues (cytosine arabinoside) TP73 intron 24483146 rs2224718 chr1 3576060 T C 6.86E-04 Response to cytadine analogues (cytosine arabinoside) TP73 intron 24483146 rs3765696 chr1 3587505 T C 2.50E-04 Body mass index TP73 intron 17255346 rs12027041 chr1 3591448 G C 1.08E-05 Multiple complex diseases TP73 intron 17554300 rs12027041 chr1 3591448 G C 3.50E-09 Progranulin levels TP73 intron 21087763 rs12027041 chr1 3591448 G C 3.50E-09 Myocardial infarction TP73 intron 21211798 rs3765736 chr1 3616601 C T 2.10E-05 Heart Rate TP73 intron pha003054 rs6424090 chr1 3628677 A G 4.33E-04 Sarcoidosis TP73 intron 19165924 rs9662633 chr1 3649562 G A 6.00E-06 Visceral adipose tissue adjusted for BMI TP73 cds-synon 22589738 rs12562437 chr1 3651031 C T 2.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio TP73 UTR-3 22589738 rs10910018 chr1 3651409 G A 2.00E-06 Visceral fat TP73 UTR-3 22589738 rs3737589 chr1 3662845 A G 4.33E-04 Lung function (forced expiratory volume in 1 second) TP73-AS1 intron 24023788 rs12120656 chr1 3665867 G T 1.06E-04 Type 2 diabetes / / 17463246 rs12120656 chr1 3665867 G T 9.39E-04 Lymphocyte counts / / 22286170 rs76597070 chr1 3669356 G A 3.00E-06 Obesity-related traits CCDC27 missense 23251661 rs1181889 chr1 3671027 T C 3.29E-04 Type 2 diabetes CCDC27 intron 17463246 rs2275837 chr1 3686318 G A 9.72E-04 Multiple complex diseases CCDC27 intron 17554300 rs1175550 chr1 3691528 A G 8.62E-15 Red blood cell traits LOC388588 intron 23222517 rs1175550 chr1 3691528 A G 5.00E-10 Blood trace element (Cu levels) LOC388588 intron 23720494 rs1175549 chr1 3691727 A C 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes LOC388588 intron 22628534 rs1175549 chr1 3691727 A C 0.0000265 Otitis media (children 3 years old or younger) LOC388588 intron 23133572 rs1175549 chr1 3691727 A C 1.35E-14 Red blood cell traits LOC388588 intron 23222517 rs2799182 chr1 3696000 T C 1.06E-07 Red blood cell traits / / 23222517 rs8379 chr1 3696890 A C 1.76E-08 Red blood cell traits LRRC47 UTR-3 23222517 rs9424283 chr1 3705226 C G 3.14E-04 Lymphocyte counts LRRC47 intron 22286170 rs7513053 chr1 3709487 A G 4.26E-13 Red blood cell traits LRRC47 intron 23222517 rs6667255 chr1 3711689 T C 1.74E-13 Red blood cell traits LRRC47 intron 23222517 rs7535775 chr1 3719057 G A 3.90E-07 Red blood cell traits / / 23222517 rs2154068 chr1 3720965 A G 9.34E-08 Red blood cell traits / / 23222517 rs12135894 chr1 3728061 C T 1.93E-09 Red blood cell traits / / 23222517 rs2027548 chr1 3739512 G A 7.99E-04 Amyotrophic Lateral Sclerosis CEP104 intron 17362836 rs6688969 chr1 3743391 C T 4.48E-09 Red blood cell traits CEP104 intron 23222517 rs7511793 chr1 3744249 A G 2.21E-12 Red blood cell traits CEP104 intron 23222517 rs7545274 chr1 3744261 C A 8.86E-04 Alcohol dependence CEP104 intron 21314694 rs7545274 chr1 3744261 C A 3.25E-13 Red blood cell traits CEP104 intron 23222517 rs2275833 chr1 3745721 C T 3.34E-11 Red blood cell traits CEP104 intron 23222517 rs2298224 chr1 3756155 T C 4.91E-04 Multiple complex diseases CEP104 intron 17554300 rs17412654 chr1 3758493 T C 6.42E-09 Red blood cell traits CEP104 intron 23222517 rs7538067 chr1 3761772 C T 3.69E-08 Red blood cell traits CEP104 intron 23222517 rs10492942 chr1 3764216 C T 8.34E-12 Red blood cell traits CEP104 intron 23222517 rs16824230 chr1 3766240 A G 6.22E-13 Red blood cell traits CEP104 intron 23222517 rs10909804 chr1 3770929 C T 8.20E-13 Red blood cell traits CEP104 intron 23222517 rs10797348 chr1 3781096 C A 4.39E-10 Red blood cell traits DFFB intron 23222517 rs4074709 chr1 3796948 G T 1.00E-04 Information processing speed DFFB intron 21130836 rs4073324 chr1 3797995 C T 2.17E-04 Cholesterol DFFB intron 17255346 rs4131373 chr1 3807388 G A 9.14E-06 HIV-1 viral setpoint C1orf174 cds-synon 17641165 rs4131373 chr1 3807388 G A 1.29E-05 AIDS progression C1orf174 cds-synon 19115949 rs6701422 chr1 3808171 T C 6.03E-05 Epilepsy (remission after treatment) C1orf174 intron 23962720 rs12082157 chr1 3811810 T C 1.01E-05 HIV-1 viral setpoint C1orf174 intron 17641165 rs6687869 chr1 3821216 G A 1.81E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100133612 intron 20877124 rs6687869 chr1 3821216 G A 4.24E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100133612 intron 20877124 rs35583447 chr1 3829614 A G 5.48E-05 Epilepsy (remission after treatment) LOC100133612 intron 23962720 rs35241263 chr1 3831232 A G 8.64E-05 Epilepsy (remission after treatment) / / 23962720 rs10737395 chr1 4007558 C A 3.62E-04 Blood pressure LOC728716 intron 17255346 rs10737395 chr1 4007558 C A 2.69E-05 Common variable immunodeficiency LOC728716 intron 21497890 rs4654479 chr1 4009694 G A 3.36E-04 Blood pressure LOC728716 intron 17255346 rs12031275 chr1 4026068 G A,T 9.20E-06 Serum metabolites / / 19043545 rs4654521 chr1 4028282 C T 1.49E-05 Serum metabolites / / 19043545 rs3935162 chr1 4031327 G A 9.20E-05 Serum metabolites / / 19043545 rs12722968 chr1 4065348 C T 1.48E-04 Birth weight / / 17255346 rs79004239 chr1 4080348 C T 0.00006336 Sarcoidosis / / 22952805 rs7514530 chr1 4120311 C T 9.16E-05 Coronary heart disease / / pha003030 rs7524800 chr1 4121584 A G 5.17E-05 Coronary heart disease / / pha003030 rs6669278 chr1 4123099 C T 0.00004214 Sarcoidosis / / 22952805 rs6673959 chr1 4123117 A G 7.97E-06 Hearing function / / 21493956 rs4391636 chr1 4130684 T C 7.17E-04 Multiple complex diseases / / 17554300 rs12021796 chr1 4133241 T G 6.22E-04 Multiple complex diseases / / 17554300 rs10915417 chr1 4137042 C G 2.54E-04 Multiple complex diseases / / 17554300 rs10915421 chr1 4145615 T C 2.94E-05 Coronary heart disease / / pha003030 rs10915424 chr1 4146369 G A 3.59E-05 Coronary heart disease / / pha003030 rs4600014 chr1 4157198 A G 6.61E-05 Alzheimer's disease / / 17998437 rs10915428 chr1 4158955 G T 3.67E-05 Kawasaki disease / / 22446961 rs4400585 chr1 4182785 G T 7.00E-04 Alzheimer's disease / / 17998437 rs4400585 chr1 4182785 G T 1.58E-04 Alzheimer's disease / / pha002879 rs10915437 chr1 4183006 A G 1.56E-04 Migraine with aura / / 23793025 rs10915437 chr1 4183006 A G 3.00E-08 Migraine - clinic-based / / 23793025 rs10915437 chr1 4183006 A G 6.13E-04 Migraine / / 23793025 rs12409803 chr1 4193426 G A 0.00000354 HDL cholesterol particle diameter / / 23263444 rs6663939 chr1 4197256 C T 0.00000387 HDL cholesterol particle diameter / / 23263444 rs10915445 chr1 4197642 G A 0.00000389 HDL cholesterol particle diameter / / 23263444 rs10915445 chr1 4197642 G A 2.86E-05 Waist Circumference / / pha003024 rs16840838 chr1 4201349 G A 1.54E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4654492 chr1 4201815 C T 2.79E-04 Multiple complex diseases / / 17554300 rs12143662 chr1 4202993 C T 0.00000395 HDL cholesterol particle diameter / / 23263444 rs4654497 chr1 4224558 T C 1.09E-04 Type 2 diabetes / / 17463246 rs4654497 chr1 4224558 T C 9.22E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3890729 chr1 4230712 A T 2.16E-04 Suicide attempts in bipolar disorder / / 21423239 rs16840958 chr1 4285991 T C 5.45E-04 Multiple complex diseases / / 17554300 rs12132422 chr1 4295304 A G 4.32E-04 Alcohol dependence / / 20201924 rs1908490 chr1 4312205 C T 7.20E-06 Coronary heart disease / / pha003035 rs966321 chr1 4315204 G T 8.00E-06 Factor VII / / 17903294 rs966321 chr1 4315204 G T 2.20E-08 Tanning / / 19340012 rs966321 chr1 4315204 G T 8.84E-04 Common variable immunodeficiency / / 21497890 rs966321 chr1 4315204 G T 1.05E-05 Coronary heart disease / / pha003035 rs964715 chr1 4316784 T C 4.10E-05 Bladder cancer / / 24163127 rs2411738 chr1 4326368 G A 6.22E-06 Coronary heart disease / / pha003035 rs6677984 chr1 4330287 A G 2.84E-05 Coronary heart disease / / pha003035 rs16838549 chr1 4343581 G A 7.23E-05 Multiple complex diseases / / 17554300 rs351615 chr1 4370385 G A 2.68E-05 Alzheimer's disease / / 17998437 rs351596 chr1 4377911 C T 9.71E-04 Multiple complex diseases / / 17554300 rs351596 chr1 4377911 C T 6.11E-05 Suicide attempts in bipolar disorder / / 21423239 rs7418164 chr1 4380518 G A 2.78E-04 Multiple complex diseases / / 17554300 rs2171985 chr1 4381253 G T 3.35E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs496925 chr1 4396552 C T 2.12E-04 Multiple complex diseases / / 17554300 rs528291 chr1 4414045 A G 3.53E-04 Taste perception / / 22132133 rs349390 chr1 4423896 T C 8.00E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs16838812 chr1 4424115 A G 4.02E-04 Multiple complex diseases / / 17554300 rs16838813 chr1 4424145 G A 2.17E-04 Multiple complex diseases / / 17554300 rs16838813 chr1 4424145 G A 7.10E-07 Glioma (high-grade) / / 19578366 rs75411 chr1 4425414 C T 3.63E-06 Obesity-related traits / / 23251661 rs589870 chr1 4440749 C T 6.09E-06 Obesity-related traits / / 23251661 rs12037374 chr1 4443108 C T 1.50E-05 Urinary metabolites / / 21572414 rs239339 chr1 4444539 G T 3.00E-06 Obesity-related traits / / 23251661 rs6679220 chr1 4459689 T C 1.00E-04 Diabetic nephropathy / / pha002866 rs12116790 chr1 4464933 A G 7.14E-04 Type 2 diabetes / / 17463246 rs349403 chr1 4474002 A G 9.50E-05 Body mass index LOC284661 intron 20818722 rs4654432 chr1 4481215 C T 7.84E-04 Multiple complex diseases LOC284661 intron 17554300 rs4654432 chr1 4481215 C T 7.20E-05 Diabetic nephropathy LOC284661 intron pha002866 rs4654433 chr1 4481632 G A 9.90E-05 Diabetic nephropathy LOC284661 intron pha002866 rs1762814 chr1 4496256 C T 1.70E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10737409 chr1 4522466 G A 7.03E-04 Type 2 diabetes / / 17463246 rs4654438 chr1 4559901 T C 2.00E-06 Smooth-surface caries / / 24556642 rs9660574 chr1 4560405 G A 3.22E-06 Smooth-surface caries / / 24556642 rs4654548 chr1 4562476 G A 4.09E-06 Smooth-surface caries / / 24556642 rs10753381 chr1 4565906 C T 1.76E-06 Smooth-surface caries / / 24556642 rs1762826 chr1 4572778 C T 7.89E-05 Waist Circumference / / pha003023 rs608203 chr1 4581585 T C 5.94E-04 Stroke / / pha002886 rs608492 chr1 4598001 G C 2.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs592726 chr1 4599243 C T 2.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs542688 chr1 4600621 C G 2.37E-04 Suicide attempts in bipolar disorder / / 21041247 rs694935 chr1 4603324 T A 2.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs241215 chr1 4604104 T A 2.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs17348839 chr1 4605403 C A 3.22E-08 Multiple complex diseases / / 17554300 rs241220 chr1 4608204 G A 2.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs241221 chr1 4609050 T C 5.79E-04 Suicide attempts in bipolar disorder / / 21041247 rs241278 chr1 4629408 T C 9.31E-04 Type 2 diabetes / / 17463246 rs7526879 chr1 4630483 C T 6.15E-04 Type 2 diabetes / / 17463246 rs1541318 chr1 4634978 A G 1.79E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1541318 chr1 4634978 A G 4.33E-04 Smoking initiation / / 24665060 rs1157688 chr1 4636767 T C 4.79E-05 Obesity (extreme) / / 21935397 rs515279 chr1 4643688 T A,C,G 9.32E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs504274 chr1 4648573 C T 2.18E-05 Suicide attempts in bipolar disorder / / 21041247 rs504274 chr1 4648573 C T 5.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs589176 chr1 4660552 A G 5.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs11590266 chr1 4668423 A G 2.50E-05 Urinary metabolites / / 21572414 rs3896439 chr1 4668670 G A 2.00E-08 Dental caries / / 23064961 rs6668002 chr1 4682104 T C 9.98E-05 Asthma / / pha003127 rs12403290 chr1 4682532 C A 2.50E-05 Urinary metabolites / / 21572414 rs875807 chr1 4685672 A G 4.20E-05 Triglycerides / / pha003080 rs7553610 chr1 4687874 G A 5.72E-04 Smoking initiation / / 24665060 rs2101195 chr1 4697300 C T 4.27E-04 Type 2 diabetes / / 17463246 rs7533451 chr1 4705931 G A 5.59E-04 Alzheimer's disease / / 17998437 rs3947662 chr1 4718551 G T 1.10E-04 Primary sclerosing cholangitis AJAP1 intron 19944697 rs12409187 chr1 4733793 G A 6.54E-05 Aging (time to event) AJAP1 intron 21782286 rs11588881 chr1 4737383 C T 3.47E-04 Type 2 diabetes AJAP1 intron 17463246 rs11588881 chr1 4737383 C T 1.30E-04 Primary sclerosing cholangitis AJAP1 intron 19944697 rs11588881 chr1 4737383 C T 3.84E-05 Homeostasis model assessment of beta-cell function (interaction) AJAP1 intron 24204828 rs2071995 chr1 4738678 C T 3.79E-05 QT interval AJAP1 intron 22726844 rs1076944 chr1 4748305 G T 2.04E-04 Epilepsy AJAP1 intron 22116939 rs7525374 chr1 4754057 A G 4.43E-04 Myopia (pathological) AJAP1 intron 21095009 rs7518469 chr1 4756276 G T 2.44E-04 Alzheimer's disease (late onset) AJAP1 intron 21379329 rs3766964 chr1 4792184 T C 1.10E-05 Urinary metabolites AJAP1 intron 21572414 rs16839536 chr1 4793580 C G 6.27E-04 Multiple complex diseases AJAP1 intron 17554300 rs414176 chr1 4805106 A C 1.60E-06 Urinary metabolites AJAP1 intron 21572414 rs422988 chr1 4819117 A C 5.06E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) AJAP1 intron 20877124 rs397559 chr1 4820799 C T 9.92E-04 Multiple complex diseases AJAP1 intron 17554300 rs397559 chr1 4820799 C T 5.24E-04 Alzheimer's disease AJAP1 intron 17998437 rs397559 chr1 4820799 C T 4.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) AJAP1 intron 20877124 rs424723 chr1 4824742 C T 7.60E-05 Intelligence AJAP1 intron 21826061 rs2743979 chr1 4825152 G A 6.44E-05 Intelligence AJAP1 intron 21826061 rs7518471 chr1 4828606 C T 7.27E-05 Hepatocellular carcinoma AJAP1 intron 22807686 rs423285 chr1 4831076 C T 0.0000586 Follicular lymphoma AJAP1 intron 23025665 rs11805709 chr1 4847594 C T 1.21E-06 Serum metabolites / / 19043545 rs12028290 chr1 4889912 C A 3.99E-06 Multiple complex diseases / / 17554300 rs12094945 chr1 4933154 T G 1.17E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2031246 chr1 4959786 A G 1.48E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2031246 chr1 4959786 A G 3.45E-05 Waist-Hip Ratio / / pha003013 rs2031246 chr1 4959786 A G 7.70E-05 Waist-Hip Ratio / / pha003028 rs41524347 chr1 4972186 T G 9.00E-04 Multiple complex diseases / / 17554300 rs10915670 chr1 4975417 G A 1.60E-05 Diabetes Mellitus / / pha003060 rs10915671 chr1 4983217 G A 6.25E-05 Type 1 diabetes / / 18978792 rs12045266 chr1 4996275 G T 3.30E-06 Urinary metabolites / / 21572414 rs12048035 chr1 4996307 C G 2.20E-06 Urinary metabolites / / 21572414 rs17349719 chr1 5001809 A G 4.47E-04 Multiple complex diseases / / 17554300 rs12754637 chr1 5023321 G A 5.33E-05 Colorectal cancer / / 19723657 rs7525837 chr1 5030660 G A 9.29E-26 Narcolepsy / / 19629137 rs7518523 chr1 5031561 A G 5.44E-05 Serum metabolites / / 19043545 rs12757902 chr1 5036234 G A 3.86E-05 Cardiovascular disease / / pha003064 rs10915307 chr1 5063293 G A 3.13E-04 Type 2 diabetes / / 17463246 rs10915310 chr1 5068210 A G 1.06E-04 Type 2 diabetes / / 17463246 rs10799151 chr1 5068245 A G 2.44E-04 Type 2 diabetes / / 17463246 rs12047764 chr1 5077552 T C 8.99E-04 Type 2 diabetes / / 17463246 rs9439507 chr1 5090997 A G 4.35E-04 Alzheimer's disease (late onset) / / 21379329 rs10915329 chr1 5114102 C T 9.18E-05 Glucose levels / / pha003058 rs6603832 chr1 5127543 A G 4.72E-05 Personality dimensions / / 18957941 rs10915336 chr1 5137666 G A 3.70E-05 Parkinson's disease (familial) / / 18985386 rs12047111 chr1 5142784 A G 6.69E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs2334263 chr1 5142818 T C 4.87E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs6680801 chr1 5145066 G A 6.20E-04 Aortic root size / / 21223598 rs3101225 chr1 5156245 A C 7.66E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7513590 chr1 5170712 A G 5.00E-06 Anthropometric traits / / 19260139 rs12743573 chr1 5204164 G A 9.47E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10753353 chr1 5211134 T C 0.000505473 Hypertension (early onset hypertension) / / 22479346 rs12026977 chr1 5231170 T C 5.97E-04 Smoking initiation / / 24665060 rs12041491 chr1 5253436 G A 4.03E-04 Multiple complex diseases / / 17554300 rs16840183 chr1 5280502 T G 1.15E-05 Alcohol consumption / / 23953852 rs677735 chr1 5295176 A G 5.84E-05 Alcohol consumption / / 23953852 rs2353169 chr1 5296844 T C 9.98E-05 stroke (ischemic) / / 17434096 rs12135834 chr1 5309667 C T 7.50E-04 Coronary heart disease / / 21606135 rs4465222 chr1 5310258 T C 4.93E-06 Alcohol consumption / / 23953852 rs6686714 chr1 5310609 G T 8.90E-04 Coronary heart disease / / 21606135 rs12732868 chr1 5334637 T G 4.55E-07 Schizophrenia / / 21926974 rs17423547 chr1 5341464 T C 4.98E-05 Orofacial clefts / / 22419666 rs604664 chr1 5343032 T C 1.73E-04 Cholesterol / / 17255346 rs557477 chr1 5346474 T G 1.90E-06 Urinary metabolites / / 21572414 rs7530063 chr1 5352492 T C 3.10E-05 Cognitive function / / 24684796 rs912988 chr1 5354844 C T 6.00E-06 Major depressive disorder / / 23377640 rs9439521 chr1 5368589 G A 3.37E-04 Multiple complex diseases / / 17554300 rs9439522 chr1 5368747 T G 2.09E-04 Multiple complex diseases / / 17554300 rs9439523 chr1 5368769 A G 3.14E-04 Multiple complex diseases / / 17554300 rs9439525 chr1 5369177 G A 4.52E-04 Multiple complex diseases / / 17554300 rs12040942 chr1 5371159 C A 3.33E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs10915413 chr1 5371579 C T 2.13E-04 Multiple complex diseases / / 17554300 rs4478820 chr1 5371934 A G 2.40E-04 Multiple complex diseases / / 17554300 rs874995 chr1 5386597 A T 9.96E-04 Type 2 diabetes / / 17463246 rs16840538 chr1 5390209 A G 7.97E-04 Multiple complex diseases / / 17554300 rs1326005 chr1 5403585 A G 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7364349 chr1 5421533 G A 5.89E-04 Smoking initiation / / 24665060 rs11801594 chr1 5426110 T C 7.56E-05 Platelet counts / / pha003100 rs6603835 chr1 5475663 C A 1.00E-04 Prostate cancer / / 21743057 rs6688540 chr1 5478901 C T 5.33E-04 Multiple complex diseases / / 17554300 rs6688540 chr1 5478901 C T 8.00E-05 Prostate cancer / / 21743057 rs6603839 chr1 5480101 C T 5.02E-04 Multiple complex diseases / / 17554300 rs10907211 chr1 5492043 C A 5.52E-04 Rheumatoid arthritis / / 21452313 rs9787315 chr1 5544659 G C 5.31E-04 Multiple complex diseases / / 17554300 rs9787315 chr1 5544659 G C 0.000192 Salmonella-induced pyroptosis / / 22837397 rs9729637 chr1 5545452 G T 0.0000295 Uterine leiomyomata / / 23040493 rs9786944 chr1 5548512 G A 0.0000824 Uterine leiomyomata / / 23040493 rs9786944 chr1 5548512 G A 4.20E-04 Myasthenia gravis / / 23055271 rs12128558 chr1 5569491 C A 2.61E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17028213 chr1 5615931 C T 4.75E-04 Multiple complex diseases / / 17554300 rs7523214 chr1 5625929 C G 2.30E-07 Urinary metabolites / / 21572414 rs7528859 chr1 5661009 T A 2.34E-05 Migraine - clinic-based / / 23793025 rs7528859 chr1 5661009 T A 5.00E-06 Migraine with aura / / 23793025 rs11260661 chr1 5671493 G C 9.34E-04 Type 2 diabetes / / 17463246 rs17426290 chr1 5683697 C T 4.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs1775401 chr1 5686132 C T 4.82E-04 Multiple complex diseases / / 17554300 rs770683 chr1 5689702 A G 7.54E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs17028416 chr1 5689921 G C 4.94E-04 Multiple complex diseases / / 17554300 rs17426695 chr1 5696425 G A 3.87E-05 Cognitive test performance / / 20125193 rs6670965 chr1 5696677 A G 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10492947 chr1 5699475 C A 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs11260666 chr1 5699634 G A 2.67E-04 Multiple complex diseases / / 17554300 rs4845812 chr1 5707816 C T 5.00E-06 Metabolite levels (MHPG) / / 23319000 rs1775408 chr1 5717138 A G 7.59E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12038771 chr1 5723643 G A 1.60E-05 Multiple complex diseases / / 17554300 rs707580 chr1 5724940 T C 3.18E-04 Multiple complex diseases / / 17554300 rs2649071 chr1 5753350 G A 0.0002 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs796396 chr1 5764879 A G 1.40E-05 Urinary metabolites / / 21572414 rs2649086 chr1 5782769 T C 8.96E-05 Diabetes (gestational) / / 22233651 rs2842258 chr1 5790498 A G 8.72E-04 Type 2 diabetes / / 17463246 rs17028719 chr1 5795008 A G 8.90E-07 Alcohol dependence / / 22096494 rs17028719 chr1 5795008 A G 3.20E-06 Alcohol and nictotine co-dependence / / 22488850 rs17429690 chr1 5814135 G A 4.58E-04 Multiple complex diseases / / 17554300 rs9661578 chr1 5881752 C T 4.53E-05 Cocaine dependence / / 23958962 rs9661578 chr1 5881752 C T 6.10E-05 Cocaine dependence / / 23958962 rs548726 chr1 5913621 T C 5.00E-07 Response to taxane treatment (placlitaxel) / / 23006423 rs4908559 chr1 5944138 A G 1.77E-04 Smoking cessation NPHP4 intron 18519826 rs4908559 chr1 5944138 A G 6.32E-04 Smoking cessation NPHP4 intron 18519826 rs2282281 chr1 5948677 G A 3.19E-07 Smoking cessation NPHP4 intron 18519826 rs3747987 chr1 5966119 T C 5.74E-05 Smoking cessation NPHP4 intron 18519826 rs551207 chr1 6007446 C T 9.65E-05 Height NPHP4 intron pha003011 rs4908458 chr1 6033973 C T 0.000085 Panic disorder NPHP4 intron 23149450 rs4908458 chr1 6033973 C T 8.50E-05 Serum tamsulosin hydrochloride concentration NPHP4 intron 23151678 rs4908639 chr1 6038583 G C 1.32E-06 Smoking cessation NPHP4 intron 18519826 rs806104 chr1 6042934 G A 2.40E-04 Bipolar disorder NPHP4 intron 19259986 rs4908728 chr1 6102419 C T 9.28E-05 Femoral neck bone geometry KC/B2 intron 22087292 rs6685332 chr1 6109173 G A 3.40E-04 Response to cytadine analogues (cytosine arabinoside) KC/B2 intron 24483146 rs3789541 chr1 6141325 G A 1.54E-05 Bone mineral density KC/B2 intron 19181680 rs3789541 chr1 6141325 G A 1.69E-04 Alzheimer's disease (late onset) KC/B2 intron 21379329 rs7531562 chr1 6177202 G T 5.66E-04 Multiple complex diseases CHD5 intron 17554300 rs731975 chr1 6222501 C A 4.80E-05 Cognitive function CHD5 intron 24684796 rs709209 chr1 6278414 A G 1.07E-07 QT interval RNF207 missense 19305409 rs846111 chr1 6279370 G C 1.00E-16 QT interval RNF207 missense 19305408 rs846111 chr1 6279370 G C 4.00E-16 QT interval RNF207 missense 19305409 rs4908541 chr1 6291810 A G 8.58E-05 Cognitive test performance ICMT intron 20125193 rs114389068 chr1 6314183 C T 0.0000607 Menopause (age at onset) GPR153 cds-synon 23424626 rs10489535 chr1 6343825 G A 6.69E-04 Multiple complex diseases ACOT7 intron 17554300 rs17029376 chr1 6409979 A G 4.80E-04 Multiple complex diseases ACOT7 intron 17554300 rs4582826 chr1 6461530 T C 6.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs373598296 chr1 6511582 AG A 6.32E-04 Smoking quantity ESPN intron 24665060 rs9434774 chr1 6511582 A G 6.32E-04 Smoking quantity ESPN intron 24665060 rs3007421 chr1 6530189 G A 7.70E-05 Alzheimer's disease PLEKHG5 intron 19136949 rs3007421 chr1 6530189 G A 7.79E-05 Waist Circumference PLEKHG5 intron pha003025 rs3935435 chr1 6572175 G A 1.10E-04 Myasthenia gravis PLEKHG5 intron 23055271 rs7540913 chr1 6581877 G A 7.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 UTR-3 20877124 rs13513 chr1 6585804 C T 5.21E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 UTR-3 20877124 rs7548042 chr1 6586070 C T 4.27E-04 Multiple complex diseases NOL9 intron 17554300 rs11122083 chr1 6593532 G A 1.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 intron 20877124 rs6679649 chr1 6606608 C T 3.42E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 intron 20877124 rs6679649 chr1 6606608 C T 4.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 intron 20877124 rs10746502 chr1 6607199 T C 2.61E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 intron 20877124 rs10864625 chr1 6614230 G A 3.42E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 cds-synon 20877124 rs10864625 chr1 6614230 G A 4.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NOL9 cds-synon 20877124 rs925745 chr1 6615690 A G 0.00008794 Sarcoidosis TAS1R1 intron 22952805 rs11587438 chr1 6631431 C T 4.00E-06 White blood cell types TAS1R1 intron 21738478 rs11122100 chr1 6638064 T C 3.94E-05 Cognitive performance TAS1R1 intron 19734545 rs4908932 chr1 6639847 G T 1.37E-04 Tourette syndrome / / 22889924 rs731024 chr1 6644723 G A 4.58E-04 Alcohol dependence ZBTB48 intron 24277619 rs731024 chr1 6644723 G A 7.96E-04 Response to alcohol consumption (flushing response) ZBTB48 intron 24277619 rs1556036 chr1 6651728 C T 1.06E-04 Multiple complex diseases KLHL21 UTR-3 17554300 rs1556036 chr1 6651728 C T 4.54E-05 Heart Rate KLHL21 UTR-3 pha003051 rs4587589 chr1 6657355 C T 1.07E-04 Multiple complex diseases KLHL21 intron 17554300 rs11583755 chr1 6672729 A C 2.30E-05 Crohn's disease (time to surgery) / / 23665963 rs10779795 chr1 6677064 A G 8.53E-04 Alcohol dependence PHF13 intron 24277619 rs2072948 chr1 6679848 C T 6.73E-05 Blood Pressure PHF13 intron pha003049 rs2235564 chr1 6713114 C T 5.97E-05 Multiple complex diseases D/JC11 intron 17554300 rs2235564 chr1 6713114 C T 1.81E-05 Blood Pressure D/JC11 intron pha003049 rs6577584 chr1 6715390 T G 1.86E-05 Blood Pressure D/JC11 intron pha003049 rs2281190 chr1 6720990 C A 2.23E-05 Blood Pressure D/JC11 intron pha003049 rs6659873 chr1 6723806 T G 2.23E-05 Blood Pressure D/JC11 intron pha003049 rs277686 chr1 6747897 C G 9.43E-05 Multiple complex diseases D/JC11 intron 17554300 rs278020 chr1 6764643 C T 9.62E-04 Alcohol dependence / / 24277619 rs278021 chr1 6764663 T C 2.90E-05 Kidney function and endocine traits / / 17903292 rs277672 chr1 6771607 G T 5.32E-04 Multiple complex diseases / / 17554300 rs202577 chr1 6784053 A G 5.59E-04 Multiple complex diseases / / 17554300 rs449250 chr1 6797684 G A 5.90E-05 Coronary restenosis / / 21878436 rs422111 chr1 6823923 A G 2.50E-05 Urinary metabolites / / 21572414 rs448886 chr1 6829582 C A 2.50E-05 Malaria / / 19465909 rs12088027 chr1 6884248 T C 4.20E-04 Heart Failure CAMTA1 intron pha002884 rs10864244 chr1 6908448 G A 5.40E-05 Coffee consumption CAMTA1 intron 21357676 rs17029988 chr1 6938689 C T 1.03E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CAMTA1 intron 20031582 rs12751613 chr1 6978622 A C 6.74E-04 Heart Failure CAMTA1 intron pha002884 rs11586158 chr1 7002266 A G 7.97E-04 Smoking quantity CAMTA1 intron 24665060 rs7538627 chr1 7006698 T A 4.45E-04 Smoking quantity CAMTA1 intron 24665060 rs7554752 chr1 7014444 G A 3.15E-04 Smoking quantity CAMTA1 intron 24665060 rs884736 chr1 7015105 T C 0.0001 Gains in maximal O2 uptake response CAMTA1 intron 21183627 rs884736 chr1 7015105 T C 7.45E-05 Coronary restenosis CAMTA1 intron 21878436 rs1013248 chr1 7019816 T G 4.96E-04 Alzheimer's disease CAMTA1 intron 17998437 rs17030082 chr1 7029262 G A 4.28E-04 Alzheimer's disease CAMTA1 intron 17998437 rs6679134 chr1 7035830 A G 2.02E-04 Alzheimer's disease CAMTA1 intron 17998437 rs1317016 chr1 7048043 C G 5.01E-05 Blood pressure CAMTA1 intron 24001895 rs12043302 chr1 7055024 C T 6.95E-05 Waist Circumference CAMTA1 intron pha003023 rs17030152 chr1 7083719 T C 3.46E-04 Barrett's esophagus CAMTA1 intron 24121790 rs6686587 chr1 7099660 G A 1.68E-04 Heart Failure CAMTA1 intron pha002884 rs4908591 chr1 7110510 G A 2.71E-04 Alzheimer's disease (late onset) CAMTA1 intron 21379329 rs11120822 chr1 7113112 G C 1.00E-06 Stearic acid (18:0) plasma levels CAMTA1 intron 23362303 rs7553100 chr1 7117542 A G 5.80E-06 Urinary metabolites CAMTA1 intron 21572414 rs10779671 chr1 7119489 A G 4.60E-06 Urinary metabolites CAMTA1 intron 21572414 rs9434833 chr1 7144893 C T 2.30E-06 Urinary metabolites CAMTA1 intron 21572414 rs4908443 chr1 7179721 T C 1.08E-04 Parkinson's disease CAMTA1 intron 17052657 rs4908443 chr1 7179721 T C 6.68E-06 Coronary heart disease CAMTA1 intron pha003030 rs7527889 chr1 7213619 C T 4.33E-05 Multiple complex diseases CAMTA1 intron 17554300 rs6680365 chr1 7236810 A G 0.0000538 Migraine CAMTA1 intron 22678113 rs6680365 chr1 7236810 A G 5.38E-05 Migraine CAMTA1 intron 22683712 rs1304711 chr1 7270320 A C 9.95E-04 Type 2 diabetes CAMTA1 intron 17463246 rs17030589 chr1 7278776 C G 5.86E-04 Multiple complex diseases CAMTA1 intron 17554300 rs4908449 chr1 7292700 T C 2.00E-05 Episodic memory CAMTA1 intron 17470457 rs6577427 chr1 7314231 T C 6.86E-04 Multiple complex diseases CAMTA1 intron 17554300 rs7547519 chr1 7316136 A G 7.00E-09 Episodic memory CAMTA1 intron 17470457 rs7549382 chr1 7320903 C G 1.00E-04 Episodic memory CAMTA1 intron 17470457 rs2071924 chr1 7352974 G A 4.84E-04 Lung function (forced vital capacity) CAMTA1 intron 24023788 rs10489142 chr1 7363310 A G 7.16E-04 Alcohol dependence CAMTA1 intron 21314694 rs6668927 chr1 7377498 C T 8.98E-04 Alzheimer's disease CAMTA1 intron 22005930 rs12563394 chr1 7380747 A G 4.56E-04 Alzheimer's disease CAMTA1 intron 22005930 rs12739426 chr1 7386456 C A 4.91E-04 Alzheimer's disease CAMTA1 intron 22005930 rs2301460 chr1 7389944 A C 3.25E-04 Alzheimer's disease CAMTA1 intron 22005930 rs2301461 chr1 7389977 T C 1.50E-04 Type 2 diabetes and 6 quantitative traits CAMTA1 intron 17848626 rs705680 chr1 7402502 T C 6.68E-04 Multiple complex diseases CAMTA1 intron 17554300 rs845244 chr1 7406114 A G 7.96E-04 Multiple complex diseases CAMTA1 intron 17554300 rs705677 chr1 7409910 A C 2.00E-04 Episodic memory CAMTA1 intron 17470457 rs845237 chr1 7412051 A G 7.94E-04 Smoking cessation CAMTA1 intron 24665060 rs1894655 chr1 7417290 T C 8.38E-04 Alzheimer's disease CAMTA1 intron 22005930 rs4908626 chr1 7422216 G T 5.54E-04 Alzheimer's disease CAMTA1 intron 22005930 rs6677597 chr1 7422919 G T 5.45E-04 Alzheimer's disease CAMTA1 intron 22005930 rs1418489 chr1 7425064 A G 2.52E-06 Asthma (childhood onset) CAMTA1 intron 23829686 rs845222 chr1 7429092 T G 7.74E-04 Type 2 diabetes CAMTA1 intron 17463246 rs3752543 chr1 7430394 T C 5.39E-04 Alzheimer's disease CAMTA1 intron 22005930 rs11579620 chr1 7432615 G A 4.71E-04 Alzheimer's disease CAMTA1 intron 22005930 rs845218 chr1 7433862 T C 4.04E-04 Smoking cessation CAMTA1 intron 24665060 rs6677949 chr1 7445435 C A 2.30E-04 Smoking cessation CAMTA1 intron 24665060 rs845233 chr1 7446240 T C 2.26E-04 Smoking cessation CAMTA1 intron 24665060 rs7524314 chr1 7449971 G A 6.85E-05 Body Mass Index CAMTA1 intron pha003020 rs2097518 chr1 7460433 G A 3.67E-04 Alzheimer's disease CAMTA1 intron 17998437 rs11120917 chr1 7478076 C T 1.45E-05 Anxiety in major depressive disorder CAMTA1 intron 24047446 rs11120917 chr1 7478076 C T 9.19E-04 Heart Failure CAMTA1 intron pha002884 rs11120921 chr1 7485306 C T 4.90E-04 Response to taxane treatment (placlitaxel) CAMTA1 intron 23006423 rs17030828 chr1 7491320 C T 3.81E-04 Type 2 diabetes CAMTA1 intron 17463246 rs947678 chr1 7492616 A C 6.00E-04 Episodic memory CAMTA1 intron 17470457 rs1193221 chr1 7492991 T G 4.72E-04 Suicide attempts in bipolar disorder CAMTA1 intron 21423239 rs1307984 chr1 7497547 C T 9.31E-04 Suicide attempts in bipolar disorder CAMTA1 intron 21423239 rs2185789 chr1 7500182 G A 7.26E-04 Suicide attempts in bipolar disorder CAMTA1 intron 21423239 rs17030881 chr1 7502288 A C,G 5.13E-05 Type 2 diabetes CAMTA1 intron 17463246 rs17030881 chr1 7502288 A C,G 2.06E-04 Multiple complex diseases CAMTA1 intron 17554300 rs12119558 chr1 7504737 G A 5.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CAMTA1 intron 20877124 rs1616122 chr1 7521585 C T 5.00E-06 Periodontal microbiota CAMTA1 intron 22699663 rs1149332 chr1 7528846 C T 5.00E-06 Puberty onset CAMTA1 intron 24770850 rs1149336 chr1 7532290 C T 5.79E-06 Puberty onset CAMTA1 intron 24770850 rs1149336 chr1 7532290 C T 9.00E-07 Puberty onset (breast development) CAMTA1 intron 24770850 rs2796483 chr1 7541345 C T 9.70E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) CAMTA1 intron 24236485 rs17030993 chr1 7549488 T C 7.91E-05 Coronary heart disease CAMTA1 intron pha003056 rs1750849 chr1 7552326 G C 4.30E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) CAMTA1 intron 24236485 rs12033734 chr1 7566789 C G 9.48E-04 Insulin resistance CAMTA1 intron 21901158 rs12063665 chr1 7568588 T G 1.70E-05 Non-word repetition CAMTA1 intron 23738518 rs1193179 chr1 7569602 C T 6.30E-07 Type 2 diabetes CAMTA1 intron 17293876 rs1193179 chr1 7569602 C T 6.30E-07 Type 2 diabetes CAMTA1 intron 19184112 rs7536730 chr1 7635253 G T 4.99E-04 Multiple complex diseases CAMTA1 intron 17554300 rs941017 chr1 7655998 T C 4.87E-05 Cognitive impairment induced by topiramate CAMTA1 intron 22091778 rs6691275 chr1 7670013 T C 3.10E-04 Cisplatin and carboplatin cytotoxicity,in blood cell lines CAMTA1 intron 21844884 rs2056674 chr1 7670217 T A 5.40E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CAMTA1 intron 21844884 rs4908663 chr1 7712132 G A 1.90E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) CAMTA1 intron 24023788 rs17376559 chr1 7718093 G A 9.40E-05 Serum metabolites CAMTA1 intron 19043545 rs3011925 chr1 7721360 G A 3.00E-06 PR interval in Tripanosoma cruzi seropositivity CAMTA1 intron 24324551 rs1891215 chr1 7727854 T C 7.64E-05 Brain derived neurotrophic factor levels,in serum CAMTA1 intron 22047184 rs1891216 chr1 7728391 T G 9.66E-06 Brain derived neurotrophic factor levels,in serum CAMTA1 intron 22047184 rs6661392 chr1 7735950 C T 1.37E-05 Brain derived neurotrophic factor levels,in serum CAMTA1 intron 22047184 rs6673977 chr1 7736097 A G 1.37E-05 Brain derived neurotrophic factor levels,in serum CAMTA1 intron 22047184 rs2995032 chr1 7753132 T C 4.39E-06 Multiple complex diseases CAMTA1 intron 17554300 rs2995034 chr1 7770901 C T 4.43E-06 Multiple complex diseases CAMTA1 intron 17554300 rs12563101 chr1 7777673 G A 1.15E-11 Metabolite levels CAMTA1 intron 22286219 rs2032563 chr1 7801288 G A 4.02E-04 Longevity CAMTA1 intron 22279548 rs9919223 chr1 7812398 A G 9.18E-04 Multiple complex diseases CAMTA1 intron 17554300 rs12093175 chr1 7818318 G T 2.53E-04 Multiple complex diseases CAMTA1 intron 17554300 rs41402249 chr1 7822723 G C 3.37E-04 Multiple complex diseases CAMTA1 intron 17554300 rs11587479 chr1 7823085 A C 5.40E-05 Stroke CAMTA1 intron pha002886 rs707458 chr1 7832212 C T 6.82E-05 Crohn's disease VAMP3 intron 18587394 rs697673 chr1 7837842 T C 2.64E-05 Stroke VAMP3 intron pha002886 rs228641 chr1 7862899 T C 6.93E-04 Smoking initiation PER3 intron 24665060 rs35426314 chr1 7869968 G A 4.28E-16 HDL cholesterol PER3 missense 23063622 rs4908482 chr1 7877488 A G 8.48E-04 Suicide attempts in bipolar disorder PER3 intron 21423239 rs2797685 chr1 7879063 C T 7.00E-09 Crohn's disease PER3 intron 21102463 rs228688 chr1 7879130 T G 7.40E-04 Suicide attempts in bipolar disorder PER3 intron 21423239 rs228691 chr1 7880469 A G 9.71E-04 Suicide attempts in bipolar disorder PER3 intron 21423239 rs10462020 chr1 7880683 T G 8.39E-06 Type 2 diabetes PER3 missense 21647700 rs228694 chr1 7883834 A G 9.73E-04 Suicide attempts in bipolar disorder PER3 intron 21423239 rs707472 chr1 7906008 G T 3.63E-06 Crohn's disease / / 18587394 rs12566535 chr1 7924094 G A 7.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs504560 chr1 7926542 A G 9.16E-05 Asthma / / pha003127 rs228725 chr1 7929819 T C 0.000130044 Primary sclerosing cholangitis / / 23603763 rs228703 chr1 7944264 A G 4.96E-04 Aortic root size / / 21223598 rs227163 chr1 7961206 C T 3.00E-09 Rheumatoid arthritis / / 24390342 rs227163 chr1 7961206 C T 3.90E-04 Rheumatoid arthritis / / 24390342 rs664673 chr1 7970075 C T 7.70E-05 Endometriosis / / 21151130 rs679563 chr1 7971078 G A 6.40E-04 Endometriosis / / 23104006 rs161811 chr1 7999602 C T 5.65E-04 Multiple complex diseases TNFRSF9 intron 17554300 rs9657955 chr1 8001358 G A 0.000000484 Triglycerides TNFRSF9 intron 23063622 rs226473 chr1 8008968 T C 9.52E-05 Atrial fibrillation / / 21846873 rs35675666 chr1 8021973 G T 5.00E-09 Ulcerative colitis PARK7 intron 21297633 rs35675666 chr1 8021973 G T 1.00E-15 Inflammatory bowel disease PARK7 intron 23128233 rs161802 chr1 8042826 G T 2.00E-07 Stroke (ischemic) PARK7 intron 24262325 rs12727642 chr1 8046672 C A 9.00E-08 Celiac disease / / 20190752 rs12727642 chr1 8046672 C A 5.94E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs225132 chr1 8095500 T G 6.00E-08 Stroke (ischemic) / / 24262325 rs12748993 chr1 8129507 A G 9.00E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7539255 chr1 8133352 T C 6.76E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10864330 chr1 8168564 C T 8.00E-05 Lung adenocarcinoma / / 22797724 rs7527904 chr1 8189854 T C 0.0000861 Primary sclerosing cholangitis / / 23603763 rs7542367 chr1 8199263 T C 2.66E-04 Alzheimer's disease (late onset) / / 21379329 rs9434617 chr1 8200328 T C 3.67E-04 Alzheimer's disease (late onset) / / 21379329 rs1455701 chr1 8213010 T C 6.99E-05 HDL cholesterol / / pha003075 rs11121129 chr1 8268095 G A 2.16E-04 Scoliosis / / 21216876 rs11121129 chr1 8268095 G A 0.000000017 Psoriasis / / 23143594 rs411654 chr1 8274807 A G 5.64E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs385137 chr1 8274963 T C 4.35E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs421490 chr1 8275284 A G 3.00E-06 Plasma omega-6 polyunsaturated fatty acid levels / / 24823311 rs7513908 chr1 8302619 G A 1.90E-05 Major depressive disorder / / 21042317 rs438895 chr1 8338355 G A 7.00E-06 Economic and political preferences / / 22566634 rs11121152 chr1 8357221 C T 8.04E-04 Multiple complex diseases / / 17554300 rs12727604 chr1 8365102 G A 4.37E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs9628987 chr1 8386730 A C 5.00E-06 Breast cancer SLC45A1 intron 23468962 rs2305016 chr1 8395441 T C 9.43E-05 Non-alcoholic fatty liver disease histology (other) SLC45A1 intron 20708005 rs202161082 chr1 8397995 G A 0.00015 Breast cancer SLC45A1 missense 23555315 rs2252865 chr1 8422676 T C 3.00E-06 Schizophrenia RERE intron 21926974 rs2252865 chr1 8422676 T C 1.78E-08 Glaucoma-related traits RERE intron 22058429 rs2252865 chr1 8422676 T C 2.38E-09 Glaucoma-related traits RERE intron 22058429 rs2252865 chr1 8422676 T C 3.54E-09 Glaucoma-related traits RERE intron 22058429 rs2252865 chr1 8422676 T C 5.26E-08 Glaucoma-related traits RERE intron 22058429 rs2252865 chr1 8422676 T C 8.16E-09 Glaucoma-related traits RERE intron 22058429 rs2252865 chr1 8422676 T C 9.41E-09 Glaucoma-related traits RERE intron 22058429 rs2252865 chr1 8422676 T C 5.00E-07 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) RERE intron 23453885 rs2252865 chr1 8422676 T C 0.000219 Bipolar disorder RERE intron 23637625 rs2252865 chr1 8422676 T C 0.000476 Schizophrenia RERE intron 23637625 rs10779702 chr1 8423510 A G 4.75E-04 Prostate cancer mortality RERE intron 20978177 rs894875 chr1 8432136 C T 3.85E-04 Self-reported allergy RERE intron 23817569 rs6678140 chr1 8436802 C T 2.81E-04 Self-reported allergy RERE intron 23817569 rs2708633 chr1 8439625 C A 2.68E-04 Self-reported allergy RERE intron 23817569 rs3765971 chr1 8445360 C T 2.61E-04 Self-reported allergy RERE intron 23817569 rs2120461 chr1 8447722 C T 3.00E-06 Bone mineral density RERE intron 22504420 rs2120461 chr1 8447722 C T 2.15E-04 Self-reported allergy RERE intron 23817569 rs2661863 chr1 8452725 T C 2.55E-04 Self-reported allergy RERE intron 23817569 rs301791 chr1 8468372 A T 8.20E-05 Prostate cancer mortality RERE intron 20978177 rs301791 chr1 8468372 A T 2.59E-04 Self-reported allergy RERE intron 23817569 rs301790 chr1 8469284 G C 1.93E-04 Self-reported allergy RERE intron 23817569 rs301789 chr1 8469337 A G 2.59E-04 Self-reported allergy RERE intron 23817569 rs1763839 chr1 8473336 G A 3.35E-04 Self-reported allergy RERE intron 23817569 rs302714 chr1 8486131 A C 1.74E-04 Self-reported allergy RERE intron 23817569 rs301797 chr1 8487323 C A 2.66E-04 Self-reported allergy RERE intron 23817569 rs301798 chr1 8488565 A G 8.07E-07 Glaucoma-related traits RERE intron 22058429 rs301798 chr1 8488565 A G 2.53E-04 Self-reported allergy RERE intron 23817569 rs301799 chr1 8489302 C T 3.00E-06 Thyroid peroxidase antibody positivity RERE intron 24586183 rs302719 chr1 8490320 T G 5.03E-05 Prostate cancer mortality RERE intron 20978177 rs172531 chr1 8495590 A G 4.03E-05 Schizophrenia RERE intron 19571811 rs172531 chr1 8495590 A G 4.11E-05 Prostate cancer mortality RERE intron 20978177 rs172531 chr1 8495590 A G 2.32E-04 Self-reported allergy RERE intron 23817569 rs301801 chr1 8495945 T C 4.11E-05 Prostate cancer mortality RERE intron 20978177 rs301801 chr1 8495945 T C 2.33E-04 Self-reported allergy RERE intron 23817569 rs2784739 chr1 8497558 T G 6.76E-04 Self-reported allergy RERE intron 23817569 rs301803 chr1 8498680 A T 2.08E-04 Self-reported allergy RERE intron 23817569 rs2784740 chr1 8501057 T A 6.11E-04 Self-reported allergy RERE intron 23817569 rs301819 chr1 8501786 A G 5.84E-05 Vitiligo RERE intron 20410501 rs301819 chr1 8501786 A G 8.85E-09 Vitiligo RERE intron 21326295 rs301818 chr1 8503242 G A 2.78E-04 Self-reported allergy RERE intron 23817569 rs11121182 chr1 8522553 C A 1.70E-05 Urinary metabolites RERE intron 21572414 rs4908760 chr1 8526142 G A 7.00E-15 Vitiligo RERE intron 20410501 rs4908760 chr1 8526142 G A 3.54E-14 Vitiligo RERE intron 22561518 rs11806357 chr1 8526642 T C 1.85E-05 Multiple complex diseases RERE intron 17554300 rs11121194 chr1 8569906 C T 5.77E-04 Vitiligo RERE intron 20410501 rs17386406 chr1 8643497 G A 9.71E-04 Type 2 diabetes RERE intron 17463246 rs6679128 chr1 8702530 C T 9.07E-05 Multiple complex diseases RERE intron 17554300 rs7547833 chr1 8742451 C T 8.18E-05 Alzheimer's disease RERE intron 22005930 rs11121220 chr1 8755282 A G 1.61E-05 Multiple complex diseases RERE intron 17554300 rs12025126 chr1 8759554 T C 6.00E-08 Vertical cup-disc ratio RERE intron 20548946 rs12025126 chr1 8759554 T C 2.66E-04 Glaucoma-related traits RERE intron 22058429 rs12025126 chr1 8759554 T C 3.18E-04 Glaucoma-related traits RERE intron 22058429 rs4908773 chr1 8769728 T C 4.95E-04 Type 2 diabetes RERE intron 17463246 rs4908778 chr1 8804888 C G 5.85E-04 Smoking initiation RERE intron 24665060 rs12024032 chr1 8808185 C T 4.82E-04 Type 2 diabetes RERE intron 17463246 rs4908511 chr1 8812390 G C 5.28E-04 Type 2 diabetes RERE intron 17463246 rs12410886 chr1 8878809 A C 7.90E-05 Birth weight / / 17255346 rs11582339 chr1 8898807 G T 1.43E-04 Birth weight / / 17255346 rs10864368 chr1 8918313 T C 2.50E-05 Urinary metabolites / / 21572414 rs4418632 chr1 8994112 T C 1.23E-06 Response to platinum-based chemotherapy in small-cell lung cancer / / 20463552 rs12091891 chr1 9000220 A G 8.56E-04 Alcohol dependence / / 20201924 rs1475734 chr1 9000628 G T 0.000695441 Hypertension (early onset hypertension) / / 22479346 rs11809994 chr1 9005269 A C 0.000013 Mean arterial pressure / / 22510845 rs1409147 chr1 9005320 A G 0.0000063 Panic disorder / / 23149450 rs1409147 chr1 9005320 A G 6.30E-06 Serum tamsulosin hydrochloride concentration / / 23151678 rs2274327 chr1 9009406 C T 7.10E-04 Multiple complex diseases CA6 missense 17554300 rs2274327 chr1 9009406 C T 3.74E-04 Smoking initiation CA6 missense 24665060 rs2274328 chr1 9009444 A C 1.96E-04 Body mass index CA6 missense 17255346 rs7513804 chr1 9045124 C T 1.10E-04 Multiple complex diseases / / 17554300 rs9803645 chr1 9049872 C T 4.90E-05 Cognitive test performance / / 20125193 rs12031065 chr1 9079154 C T 2.73E-05 Non-small cell lung cancer SLC2A7 intron 21866343 rs12145292 chr1 9118596 C A 7.96E-05 Orofacial clefts SLC2A5 intron 22419666 rs6694527 chr1 9119028 G A 1.32E-11 HDL cholesterol SLC2A5 intron 23063622 rs3820034 chr1 9129867 G A 1.24E-05 Follicle stimulating hormone SLC2A5 UTR-5 24049095 rs12080794 chr1 9151325 C T 9.00E-06 Response to antidepressant treatment (citalopram) / / 23726668 rs1001567 chr1 9194614 G T 3.08E-05 Atopy / / 21625490 rs11802925 chr1 9228624 T C 9.09E-05 Schizophrenia / / 19571809 rs4908527 chr1 9234143 C T 1.80E-05 Urinary metabolites / / 21572414 rs10489436 chr1 9285721 A G 8.83E-04 Longevity / / 22279548 rs6662509 chr1 9317604 C T 3.00E-10 Height H6PD intron 23563607 rs9435168 chr1 9331952 A G 7.64E-06 Fibrinogen / / pha003068 rs7517538 chr1 9332703 T C 1.06E-07 Lymphocyte counts / / 22286170 rs1294028 chr1 9364634 A G 2.00E-04 Schizophrenia SPSB1 intron 19197363 rs630075 chr1 9370911 A G 7.00E-05 Triglycerides SPSB1 intron 19074352 rs9660159 chr1 9382469 G A 5.27E-04 Amyotrophic lateral sclerosis (sporadic) SPSB1 intron 24529757 rs4908842 chr1 9387311 T C 5.90E-05 Triglycerides SPSB1 intron 19074352 rs926247 chr1 9394008 T C 2.97E-04 Type 2 diabetes SPSB1 intron 17463246 rs478103 chr1 9402403 T C 2.02E-05 Sudden cardiac arrest SPSB1 intron 21658281 rs11121380 chr1 9408959 A C 5.00E-08 Response to tocilizumab in rheumatoid arthritis SPSB1 intron 22491018 rs11121382 chr1 9411469 G C 4.09E-06 Parkinson's disease (motor and cognition) SPSB1 intron 22658654 rs11121382 chr1 9411469 G C 4.00E-06 Immune response to anthrax vaccine SPSB1 intron 22658931 rs9435244 chr1 9417946 G A 1.90E-05 Urinary metabolites SPSB1 intron 21572414 rs9435245 chr1 9419290 T C 2.80E-06 Urinary metabolites SPSB1 intron 21572414 rs9308447 chr1 9432390 C T 5.00E-07 Dental caries / / 23064961 rs17393334 chr1 9432911 G A 1.45E-05 Major depressive disorder / / 19107115 rs17393468 chr1 9438540 T C 1.49E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs9787285 chr1 9499246 G A 7.24E-05 Myopia (pathological) / / 23049088 rs9787285 chr1 9499246 G A 4.57E-05 Hodgkin's lymphoma / / 24149102 rs10735516 chr1 9507004 T G 0.000098 Salmonella-induced pyroptosis / / 22837397 rs12034064 chr1 9508955 T C 5.23E-04 Hodgkin's lymphoma / / 24149102 rs10864424 chr1 9510088 G T 5.14E-05 Glucose levels / / pha003057 rs10746490 chr1 9525697 G A 2.57E-04 Common variable immunodeficiency / / 21497890 rs6679380 chr1 9533238 C T 8.33E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) / / 23648065 rs12023288 chr1 9602962 C A 2.77E-04 Alzheimer's disease SLC25A33 intron 24755620 rs11121441 chr1 9610125 C T 9.12E-05 Multiple complex diseases SLC25A33 intron 17554300 rs6660810 chr1 9615158 G A 7.02E-04 Alzheimer's disease SLC25A33 intron 24755620 rs4423053 chr1 9621407 A G 3.75E-04 Alzheimer's disease SLC25A33 intron 24755620 rs9430273 chr1 9624113 C A 3.84E-04 Alzheimer's disease SLC25A33 intron 24755620 rs9430274 chr1 9624285 A G 4.22E-04 Alzheimer's disease SLC25A33 intron 24755620 rs12124860 chr1 9627103 G A 7.74E-04 Alzheimer's disease SLC25A33 intron 24755620 rs9430152 chr1 9632396 T G 3.29E-04 Alzheimer's disease SLC25A33 intron 24755620 rs9430153 chr1 9637227 A G 3.18E-04 Alzheimer's disease SLC25A33 intron 24755620 rs9430332 chr1 9645372 C T 3.18E-04 Alzheimer's disease / / 24755620 rs9430174 chr1 9647137 G A 3.28E-04 Alzheimer's disease / / 24755620 rs6669846 chr1 9650571 C T 1.91E-04 Multiple complex diseases TMEM201 intron 17554300 rs6540961 chr1 9650729 A G 4.60E-04 Alzheimer's disease TMEM201 intron 24755620 rs3923984 chr1 9653835 A G 7.57E-04 Alzheimer's disease TMEM201 intron 24755620 rs7544083 chr1 9654197 T C 5.89E-04 Alzheimer's disease TMEM201 intron 24755620 rs4073710 chr1 9655795 G A 1.71E-04 Glycosylated haemoglobin levels TMEM201 intron 17255346 rs11121464 chr1 9695888 T C 4.60E-05 Intracerebral hemorrhage / / 24656865 rs12568084 chr1 9734287 G A 1.99E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIK3CD intron 20877124 rs12568084 chr1 9734287 G A 3.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PIK3CD intron 20877124 rs9430635 chr1 9738786 C G 3.63E-04 Multiple complex diseases PIK3CD intron 17554300 rs4240910 chr1 9750457 T C 9.15E-04 Multiple complex diseases PIK3CD intron 17554300 rs11121482 chr1 9777529 A G 0.00000146 Cholesterol,total PIK3CD intron 23063622 rs12032209 chr1 9897001 A C 1.10E-05 Urinary metabolites / / 21572414 rs1933734 chr1 9902128 T C 9.36E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs1220421 chr1 10008221 G A 2.80E-04 Response to statin treatment (atorvastatin),change in cholesterol levels NM/T1 intron 20031582 rs7516611 chr1 10013014 A C,G,T 8.80E-06 Urinary metabolites NM/T1 intron 21572414 rs2890358 chr1 10027540 G A 3.00E-06 Lymphocyte counts NM/T1 intron 22286170 rs12082318 chr1 10036009 G A 9.07E-05 Cognitive impairment induced by topiramate NM/T1 intron 22091778 rs12136213 chr1 10046460 A G 4.05E-04 Alzheimer's disease (late onset) / / 21379329 rs12140058 chr1 10049177 T G 0.000858 Antisocial behavior / / 23077488 rs2295294 chr1 10190884 A T 0.0000086 Lumbar spine bone mineral density UBE4B intron 22692763 rs2295294 chr1 10190884 A T 0.000377 Lumbar spine bone mineral density (males) UBE4B intron 22692763 rs12092513 chr1 10231463 C T 1.18E-05 Coronary heart disease UBE4B intron pha003032 rs11121524 chr1 10232534 C G 5.45E-04 Alcohol dependence UBE4B intron 21314694 rs2180184 chr1 10235946 T C 5.36E-04 Self-reported allergy UBE4B intron 23817569 rs6541080 chr1 10236039 G A 2.50E-05 Urinary metabolites UBE4B intron 21572414 rs7418410 chr1 10236402 C T 4.34E-04 Alzheimer's disease (late onset) UBE4B intron 21379329 rs7418410 chr1 10236402 C T 1.10E-05 Urinary metabolites UBE4B intron 21572414 rs2180185 chr1 10246129 G C 1.40E-05 Urinary metabolites / / 21572414 rs4348727 chr1 10265606 G A 1.51E-04 Self-reported allergy / / 23817569 rs17396340 chr1 10286176 G A 3.00E-08 Mean platelet volume KIF1B intron 22139419 rs10492969 chr1 10286358 T C 8.90E-04 Type 2 diabetes and 6 quantitative traits KIF1B intron 17848626 rs12751375 chr1 10291874 C G 1.25E-04 Self-reported allergy KIF1B intron 23817569 rs374529040 chr1 10291874 C CAG 1.25E-04 Self-reported allergy KIF1B intron 23817569 rs12136376 chr1 10296452 C T 1.22E-04 Self-reported allergy KIF1B intron 23817569 rs12755094 chr1 10305711 T C 1.21E-04 Self-reported allergy KIF1B intron 23817569 rs6700866 chr1 10306038 A G 1.21E-04 Self-reported allergy KIF1B intron 23817569 rs946501 chr1 10309580 G C 4.52E-04 Self-reported allergy KIF1B intron 23817569 rs4846207 chr1 10313811 T C 4.50E-04 Self-reported allergy KIF1B intron 23817569 rs4846208 chr1 10313839 T C 1.39E-04 Self-reported allergy KIF1B intron 23817569 rs12402052 chr1 10318652 C G 1.24E-04 Self-reported allergy KIF1B cds-synon 23817569 rs4846210 chr1 10322153 A G 1.27E-04 Self-reported allergy KIF1B intron 23817569 rs12757288 chr1 10323921 T C 4.14E-04 Self-reported allergy KIF1B intron 23817569 rs12064209 chr1 10326184 C G 1.02E-04 Multiple complex diseases KIF1B intron 17554300 rs1339458 chr1 10328338 C T 1.31E-04 Self-reported allergy KIF1B intron 23817569 rs12131785 chr1 10341516 C T 1.50E-05 Bulimia nervosa KIF1B intron 23568457 rs912962 chr1 10348712 A C 9.60E-05 Triglycerides KIF1B intron 19074352 rs10492972 chr1 10353112 T C 3.00E-10 Multiple sclerosis KIF1B intron 18997785 rs7520935 chr1 10354271 G T 1.48E-04 Self-reported allergy KIF1B intron 23817569 rs3753037 chr1 10355834 C T 1.48E-04 Self-reported allergy KIF1B intron 23817569 rs2275424 chr1 10356562 C A 1.44E-04 Self-reported allergy KIF1B intron 23817569 rs1536263 chr1 10378914 T C 1.23E-04 Self-reported allergy KIF1B intron 23817569 rs17401924 chr1 10384439 A G 1.26E-04 Self-reported allergy KIF1B intron 23817569 rs17401966 chr1 10385471 A G 2.00E-18 Hepatocellular carcinoma KIF1B intron 20676096 rs17401966 chr1 10385471 A G 1.70E-18 Hepatitis B KIF1B intron 21750111 rs17401966 chr1 10385471 A G 1.70E-18 Hepatocellular carcinoma (hepatitis B virus related) KIF1B intron 23242368 rs17401966 chr1 10385471 A G 1.26E-04 Self-reported allergy KIF1B intron 23817569 rs12734551 chr1 10391536 T G 1.10E-04 Self-reported allergy KIF1B intron 23817569 rs1556916 chr1 10403482 G A 3.80E-04 Self-reported allergy KIF1B intron 23817569 rs11576866 chr1 10414432 A G 1.01E-04 Self-reported allergy KIF1B intron 23817569 rs7546364 chr1 10418815 G A 3.67E-04 Self-reported allergy KIF1B intron 23817569 rs3748578 chr1 10420918 G A 1.12E-04 Self-reported allergy KIF1B intron 23817569 rs12403443 chr1 10423988 A G 5.81E-06 Self-reported allergy KIF1B intron 23817569 rs17411502 chr1 10431158 T C 9.65E-05 Self-reported allergy KIF1B intron 23817569 rs11121551 chr1 10435170 T C 3.89E-04 Self-reported allergy KIF1B intron 23817569 rs11121552 chr1 10435324 C A 1.15E-04 Self-reported allergy KIF1B cds-synon 23817569 rs4846216 chr1 10447792 T A 5.16E-04 Lymphocyte counts LOC100287506 intron 22286170 rs6679596 chr1 10454502 A T 6.43E-04 Type 2 diabetes LOC100287506 intron 17463246 rs3737155 chr1 10459779 G A 5.70E-04 Type 2 diabetes and 6 quantitative traits PGD intron 17848626 rs3737155 chr1 10459779 G A 2.39E-04 Self-reported allergy PGD intron 23817569 rs1889309 chr1 10479678 G A 1.23E-04 Self-reported allergy PGD intron 23817569 rs544289 chr1 10499236 A G 2.19E-04 Alzheimer's disease APITD1 intron 24755620 rs2847337 chr1 10502710 A G 4.80E-05 Alzheimer's disease APITD1 UTR-3 24755620 rs1307489 chr1 10507236 A G 4.80E-05 Alzheimer's disease APITD1-CORT intron 24755620 rs1307490 chr1 10508679 T C 5.17E-05 Alzheimer's disease APITD1-CORT intron 24755620 rs1307494 chr1 10509703 C T 5.27E-05 Alzheimer's disease APITD1-CORT intron 24755620 rs666103 chr1 10511589 T C 1.01E-04 Alzheimer's disease CORT cds-synon 24755620 rs1307497 chr1 10512056 T C 8.91E-06 Alzheimer's disease CORT UTR-3 21627779 rs1307497 chr1 10512056 T C 9.03E-04 Self-reported allergy CORT UTR-3 23817569 rs1307497 chr1 10512056 T C 1.78E-04 Alzheimer's disease CORT UTR-3 24755620 rs6540931 chr1 10512509 T C 9.11E-04 Self-reported allergy / / 23817569 rs2483686 chr1 10515414 T C 1.03E-04 Alzheimer's disease / / 24755620 rs944973 chr1 10516393 C G 3.35E-06 Alzheimer's disease / / 21627779 rs685746 chr1 10537437 C G 2.33E-06 Self-reported allergy PEX14 intron 23817569 rs607941 chr1 10539543 C T 1.01E-05 Self-reported allergy PEX14 intron 23817569 rs668805 chr1 10544547 G A 7.24E-07 Self-reported allergy PEX14 intron 23817569 rs669701 chr1 10544725 A G 1.53E-06 Self-reported allergy PEX14 intron 23817569 rs596537 chr1 10554709 G T 2.49E-06 Self-reported allergy PEX14 intron 23817569 rs620405 chr1 10554794 T C 2.41E-06 Self-reported allergy PEX14 intron 23817569 rs622623 chr1 10555257 C T 1.76E-06 Self-reported allergy PEX14 intron 23817569 rs636291 chr1 10556097 G A 3.21E-06 Self-reported allergy PEX14 intron 23817569 rs648324 chr1 10556447 G T 1.55E-06 Self-reported allergy PEX14 intron 23817569 rs648399 chr1 10556485 T C 1.66E-06 Self-reported allergy PEX14 intron 23817569 rs662064 chr1 10557251 T C 1.59E-06 Self-reported allergy PEX14 intron 23817569 rs660725 chr1 10557544 A G 1.84E-06 Self-reported allergy PEX14 intron 23817569 rs647281 chr1 10558210 G A 9.25E-05 Alzheimer's disease PEX14 intron 24755620 rs589400 chr1 10561282 A G 1.06E-06 Self-reported allergy PEX14 intron 23817569 rs2506901 chr1 10563492 A G 1.76E-06 Self-reported allergy PEX14 intron 23817569 rs10864459 chr1 10563609 A G 2.01E-06 Self-reported allergy PEX14 intron 23817569 rs10864460 chr1 10563671 G C 4.48E-06 Self-reported allergy PEX14 intron 23817569 rs2506902 chr1 10563681 C T 2.10E-04 Primary sclerosing cholangitis PEX14 intron 19944697 rs2506902 chr1 10563681 C T 1.62E-06 Self-reported allergy PEX14 intron 23817569 rs2781230 chr1 10563717 G A 2.94E-06 Self-reported allergy PEX14 intron 23817569 rs2847344 chr1 10564675 G A 7.47E-07 Self-reported allergy PEX14 intron 23817569 rs616488 chr1 10566215 A G 2.00E-10 Breast cancer PEX14 intron 23535729 rs616488 chr1 10566215 A G 1.00E-08 Breast cancer PEX14 intron 23535733 rs616488 chr1 10566215 A G 3.79E-06 Self-reported allergy PEX14 intron 23817569 rs616402 chr1 10566272 C T 5.50E-07 Self-reported allergy PEX14 intron 23817569 rs12129512 chr1 10572967 G T 1.40E-04 Self-reported allergy PEX14 intron 23817569 rs1411402 chr1 10579545 G T 4.64E-07 Self-reported allergy PEX14 intron 23817569 rs2483677 chr1 10580891 C T 3.99E-07 Self-reported allergy PEX14 intron 23817569 rs2056417 chr1 10581658 G A 4.00E-07 Self-reported allergy PEX14 intron 23817569 rs2480782 chr1 10593296 G T 6.77E-04 Alzheimer's disease PEX14 intron 24755620 rs2026792 chr1 10594790 A G 7.02E-06 Self-reported allergy PEX14 intron 23817569 rs12375 chr1 10596341 C T 8.28E-06 Self-reported allergy PEX14 cds-synon 23817569 rs2480777 chr1 10597551 C T 9.76E-06 Self-reported allergy PEX14 intron 23817569 rs2506892 chr1 10598216 G A 1.27E-05 Self-reported allergy PEX14 intron 23817569 rs2480775 chr1 10606996 G T 3.09E-05 Neuroblastoma PEX14 intron pha002895 rs12120962 chr1 10609505 G A 5.26E-05 Hearing function PEX14 intron 17255346 rs10864463 chr1 10613560 A G 9.93E-05 Neuroblastoma PEX14 intron pha002895 rs12127400 chr1 10613660 C T 4.55E-05 Hearing function PEX14 intron 17255346 rs17035305 chr1 10616505 C A 1.53E-05 Self-reported allergy PEX14 intron 23817569 rs12028449 chr1 10617034 G A 1.62E-05 Self-reported allergy PEX14 intron 23817569 rs11121587 chr1 10618109 A G 1.38E-05 Self-reported allergy PEX14 intron 23817569 rs11121594 chr1 10626922 G C 4.04E-04 Alzheimer's disease PEX14 intron 17998437 rs6687502 chr1 10633273 G A 4.10E-04 Alzheimer's disease PEX14 intron 17998437 rs12741973 chr1 10638604 C T 7.00E-06 optic disc size (rim) PEX14 intron 20395239 rs284272 chr1 10653628 G T 5.48E-04 Smoking cessation PEX14 intron 24665060 rs10864468 chr1 10655709 G A 3.76E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs284267 chr1 10656351 C A 1.20E-04 Multiple complex diseases PEX14 intron 17554300 rs11121598 chr1 10658202 G A 3.76E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs11121599 chr1 10666735 A G 3.08E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs12722934 chr1 10668379 A T 3.08E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs6666075 chr1 10669098 C G 3.08E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs3790630 chr1 10673094 C T 6.83E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs284238 chr1 10678488 A T 1.61E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs284237 chr1 10678610 G A 2.08E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs284235 chr1 10678843 C T 7.11E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs190775 chr1 10683683 G T 2.39E-06 Alcohol dependence (age at onset) PEX14 intron 24962325 rs185864 chr1 10687726 G C 9.06E-07 Alcohol dependence (age at onset) PEX14 intron 24962325 rs284303 chr1 10690883 C T 9.06E-07 Alcohol dependence (age at onset) PEX14 nearGene-3 24962325 rs284301 chr1 10694125 G A 1.12E-06 Alcohol dependence (age at onset) / / 24962325 rs61776290 chr1 10694907 C T 2.00E-07 Alcohol dependence (age at onset) / / 24962325 rs284243 chr1 10705880 A G 2.90E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs778228 chr1 10708142 A G 1.64E-06 Alcohol dependence (age at onset) CASZ1 cds-synon 24962325 rs284300 chr1 10709309 C G 8.55E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs284298 chr1 10710255 G A 8.55E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs284296 chr1 10712089 A G 1.37E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs284295 chr1 10712097 A G 1.37E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs2242287 chr1 10714911 T C 6.42E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs476164 chr1 10719566 T C 7.42E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs284322 chr1 10725498 G A 5.54E-06 Alcohol dependence (age at onset) CASZ1 cds-synon 24962325 rs284320 chr1 10727020 T C 4.30E-04 Obesity,menopause CASZ1 intron 21424828 rs284320 chr1 10727020 T C 2.02E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs11121604 chr1 10730002 A G 3.11E-06 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs61776326 chr1 10742120 G A 7.20E-07 Alcohol dependence (age at onset) CASZ1 intron 24962325 rs284261 chr1 10743749 G A 2.80E-04 Multiple complex diseases CASZ1 intron 17554300 rs516243 chr1 10750432 A G 9.00E-06 Migraine - clinic-based CASZ1 intron 23793025 rs11805515 chr1 10767785 T C 7.44E-05 Cognitive test performance CASZ1 intron 20125193 rs710133 chr1 10771488 C T 1.86E-04 Type 2 diabetes CASZ1 intron 17463246 rs284233 chr1 10777260 G A 9.38E-05 Cognitive impairment induced by topiramate CASZ1 intron 22091778 rs284254 chr1 10786314 A G 6.14E-05 Cognitive impairment induced by topiramate CASZ1 intron 22091778 rs880315 chr1 10796866 T C 3.00E-10 Blood pressure CASZ1 intron 21572416 rs880315 chr1 10796866 T C 7.00E-07 Blood pressure CASZ1 intron 21572416 rs880315 chr1 10796866 T C 1.52E-04 Blood pressure (age interaction) CASZ1 intron 24954895 rs880315 chr1 10796866 T C 5.45E-05 Blood pressure (age interaction) CASZ1 intron 24954895 rs12046278 chr1 10799577 T C 5.00E-06 Systolic blood pressure CASZ1 intron 19430479 rs12046278 chr1 10799577 T C 5.00E-06 Coronary heart disease CASZ1 intron 21347282 rs4845843 chr1 10801585 G A 3.63E-05 Multiple complex diseases CASZ1 intron 17554300 rs205483 chr1 10814938 C T 0.0000725 Nonsyndromic striae distensae (stretch marks) CASZ1 intron 23633020 rs205484 chr1 10815421 T C 4.49E-05 Blood pressure CASZ1 intron 17255346 rs205472 chr1 10832322 G A 7.73E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CASZ1 intron 21844884 rs205474 chr1 10832861 C T 3.87E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CASZ1 intron 21844884 rs1613696 chr1 10838798 C T 2.41E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CASZ1 intron 21844884 rs1776219 chr1 10874152 T G 3.62E-04 Multiple complex diseases / / 17554300 rs527676 chr1 10891777 G A 3.71E-04 Lymphocyte counts / / 22286170 rs4845960 chr1 10947580 G A 9.25E-05 ldl cholesterol / / pha003076 rs10864479 chr1 10968730 T G 9.01E-04 Type 2 diabetes / / 17463246 rs1280985 chr1 10984406 T A 1.90E-05 Coffee consumption / / 21357676 rs1281014 chr1 11009543 G A 4.47E-04 Multiple complex diseases C1orf127 intron 17554300 rs138476809 chr1 11009844 G A 0.00044 Breast cancer C1orf127 missense 23555315 rs2003046 chr1 11032827 C A 9.60E-07 Ewing sarcoma C1orf127 intron 22327514 rs2003046 chr1 11032827 C A 1.99E-10 Male-pattern baldness C1orf127 intron 22693459 rs12565727 chr1 11033082 A G 9.00E-11 Male-pattern baldness C1orf127 intron 22693459 rs9659356 chr1 11034817 A G 1.29E-09 Male-pattern baldness C1orf127 intron 22693459 rs11576658 chr1 11037736 C T 9.20E-08 Ewing sarcoma C1orf127 intron 22327514 rs11576658 chr1 11037736 C T 1.06E-09 Male-pattern baldness C1orf127 intron 22693459 rs11121667 chr1 11038476 C T 1.17E-09 Male-pattern baldness C1orf127 intron 22693459 rs7542158 chr1 11040193 G A 1.20E-09 Male-pattern baldness C1orf127 intron 22693459 rs11121671 chr1 11043780 C A,T 4.48E-04 Alcohol dependence / / 24277619 rs9430158 chr1 11043861 G C 2.43E-08 Male-pattern baldness / / 22693459 rs7547568 chr1 11044829 T A 2.20E-08 Male-pattern baldness / / 22693459 rs9430161 chr1 11046855 G T 5.80E-05 Glioma (high-grade) / / 19578366 rs9430161 chr1 11046855 G T 1.00E-20 Ewing sarcoma / / 22327514 rs12085877 chr1 11087687 C T 0.00000166 Triglycerides MASP2 missense 23063622 rs12072993 chr1 11094362 A G 0.000000013 Cholesterol,total MASP2 intron 23063622 rs12142107 chr1 11097867 C T 0.00031 Prostate cancer (non-advanced prostate cancer) MASP2 cds-synon 23555315 rs12139042 chr1 11167146 G A 1.00E-11 Corneal curvature MTOR UTR-3 24963161 rs17036350 chr1 11171226 C T 4.00E-13 Corneal curvature MTOR intron 21665993 rs2300095 chr1 11265717 A G 3.69E-06 Obesity MTOR intron 22484627 rs74225573 chr1 11280994 T C 6.00E-18 Corneal curvature MTOR intron 24963161 rs12124983 chr1 11286178 T C 8.11E-04 Type 2 diabetes MTOR intron 17463246 rs17036631 chr1 11347492 C T 5.41E-06 Job-related exhaustion UBIAD1 UTR-3 23620144 rs11121720 chr1 11364920 T C 2.00E-04 Job-related exhaustion / / 23620144 rs4845992 chr1 11383839 A T 9.32E-05 Type 2 diabetes / / 17463246 rs4845992 chr1 11383839 A T 4.90E-04 Multiple complex diseases / / 17554300 rs2982384 chr1 11401745 G A 6.00E-04 Multiple complex diseases / / 17554300 rs2744854 chr1 11419868 C T 1.64E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs6661145 chr1 11485666 T C 9.60E-05 White matter hyperintensity burden / / 21681796 rs3123602 chr1 11489175 G A 7.90E-05 White matter hyperintensity burden / / 21681796 rs877309 chr1 11489678 A G 7.80E-05 White matter hyperintensity burden / / 21681796 rs3099624 chr1 11496994 C T 2.08E-07 Alopecia areata / / 22027810 rs3099627 chr1 11499388 A G 3.80E-28 Narcolepsy / / 19629137 rs11577773 chr1 11516521 C T 1.08E-04 Smoking initiation / / 24665060 rs12026602 chr1 11518397 C T 5.25E-04 Smoking initiation / / 24665060 rs12046038 chr1 11525533 A G 1.68E-04 Heart Failure / / pha002885 rs6674692 chr1 11533011 C T 7.40E-04 Multiple complex diseases / / 17554300 rs10159458 chr1 11534053 A C 5.59E-04 Multiple complex diseases / / 17554300 rs6674713 chr1 11550632 G C 6.32E-05 Multiple complex diseases PTCHD2 intron 17554300 rs2745276 chr1 11641283 G A 2.40E-05 Triglycerides / / 19074352 rs2817644 chr1 11647669 C T 7.80E-06 Triglycerides / / 19074352 rs1810483 chr1 11671329 C A 9.15E-04 Aortic root size / / 21223598 rs7550768 chr1 11680283 C T 1.96E-07 Schizophrenia / / 21926974 rs17037122 chr1 11689663 A G 5.20E-04 Schizophrenia / / 19197363 rs2336030 chr1 11736600 C T 1.00E-06 Visceral adipose tissue adjusted for BMI MAD2L2 intron 22589738 rs4846033 chr1 11788564 A G 4.00E-06 Schizophrenia / / 18347602 rs4075033 chr1 11811234 A G 4.94E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11121822 chr1 11814216 G A 4.10E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1133398 chr1 11814631 A G 6.43E-04 Schizophrenia / / 19197363 rs12132479 chr1 11836450 A G 2.90E-07 Natriuretic peptide levels C1orf167 intron 21273288 rs7538516 chr1 11836682 C T 8.70E-10 Natriuretic peptide levels C1orf167 missense 21273288 rs140362679 chr1 11836811 G A 6.87E-05 Acne (severe) C1orf167 intron 24927181 rs6541001 chr1 11837367 C T 8.60E-07 Natriuretic peptide levels C1orf167 UTR-3 21273288 rs10864540 chr1 11838099 A G 1.72E-05 Alcohol and nictotine co-dependence C1orf167 UTR-3 20158304 rs12134663 chr1 11838646 A C 2.70E-07 Natriuretic peptide levels LOC100506310 intron 21273288 rs12134663 chr1 11838646 A C 3.00E-21 Homocysteine levels LOC100506310 intron 23824729 rs6697244 chr1 11838848 G T 7.40E-10 Natriuretic peptide levels LOC100506310 missense 21273288 rs4845882 chr1 11843167 A G 7.20E-10 Natriuretic peptide levels LOC100506310 intron 21273288 rs4846047 chr1 11843632 C G 6.10E-04 Natriuretic peptide levels LOC100506310 intron 21273288 rs4846048 chr1 11846252 G A 6.10E-04 Natriuretic peptide levels MTHFR UTR-3 21273288 rs3737967 chr1 11847449 G A 2.00E-04 Natriuretic peptide levels LOC100506310 missense 21273288 rs1537516 chr1 11847861 G A 1.10E-06 Natriuretic peptide levels MTHFR UTR-3 21273288 rs1537514 chr1 11848068 G C 1.90E-07 Natriuretic peptide levels LOC100506310 missense 21273288 rs1537514 chr1 11848068 G C 1.36E-04 Blood pressure LOC100506310 missense 22100073 rs4846049 chr1 11850365 T G 9.70E-12 Natriuretic peptide levels MTHFR UTR-3 21273288 rs4846049 chr1 11850365 T G 1.48E-08 Blood pressure MTHFR UTR-3 22100073 rs4846049 chr1 11850365 T G 1.60E-08 Blood pressure MTHFR UTR-3 22100073 rs4846049 chr1 11850365 T G 1.90E-82 Blood pressure MTHFR UTR-3 22100073 rs4846049 chr1 11850365 T G 2.90E-19 Blood pressure MTHFR UTR-3 22100073 rs4846049 chr1 11850365 T G 2.96E-10 Blood pressure MTHFR UTR-3 22100073 rs4846049 chr1 11850365 T G 3.71E-10 Blood pressure MTHFR UTR-3 22100073 rs4846049 chr1 11850365 T G 5.20E-07 Blood pressure MTHFR UTR-3 22100073 rs2274976 chr1 11850927 C T 2.30E-06 Natriuretic peptide levels MTHFR missense 21273288 rs3818762 chr1 11851003 G C 3.10E-14 Natriuretic peptide levels MTHFR intron 21273288 rs3818762 chr1 11851003 G C 1.30E-25 Blood pressure MTHFR intron 22100073 rs3818762 chr1 11851003 G C 1.60E-05 Blood pressure MTHFR intron 22100073 rs3818762 chr1 11851003 G C 3.20E-99 Blood pressure MTHFR intron 22100073 rs3818762 chr1 11851003 G C 8.80E-15 Blood pressure MTHFR intron 22100073 rs576853093 chr1 11851003 G GCACACACACACAC 3.10E-14 Natriuretic peptide levels MTHFR intron 21273288 rs576853093 chr1 11851003 G GCACACACACACAC 1.30E-25 Blood pressure MTHFR intron 22100073 rs576853093 chr1 11851003 G GCACACACACACAC 1.60E-05 Blood pressure MTHFR intron 22100073 rs576853093 chr1 11851003 G GCACACACACACAC 3.20E-99 Blood pressure MTHFR intron 22100073 rs576853093 chr1 11851003 G GCACACACACACAC 8.80E-15 Blood pressure MTHFR intron 22100073 rs13306556 chr1 11852110 C T 1.70E-06 Natriuretic peptide levels MTHFR intron 21273288 rs13306556 chr1 11852110 C T 2.90E-04 Atrial fibrillation MTHFR intron 21846873 rs13306556 chr1 11852110 C T 1.27E-04 Blood pressure MTHFR intron 22100073 rs1476413 chr1 11852300 C T 7.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MTHFR intron 20877124 rs1476413 chr1 11852300 C T 2.90E-12 Natriuretic peptide levels MTHFR intron 21273288 rs1476413 chr1 11852300 C T 1.20E-04 Blood pressure MTHFR intron 22100073 rs1476413 chr1 11852300 C T 1.70E-45 Blood pressure MTHFR intron 22100073 rs1476413 chr1 11852300 C T 2.28E-05 Coronary heart disease MTHFR intron pha003030 rs17375901 chr1 11852516 C T 6.00E-07 Atrial fibrillation MTHFR intron 19597492 rs4846051 chr1 11854457 G A 1 Drug response to Methotrexate MTHFR cds-synon 16439441 rs1801131 chr1 11854476 T G 1 Drug response to Folic Acid MTHFR missense 16572443 rs1801131 chr1 11854476 T G 1 Drug response to Methotrexate MTHFR missense 16572443 rs1801131 chr1 11854476 T G 1 Drug response to Nitrous Oxide MTHFR missense 18580170 rs1801131 chr1 11854476 T G 1 Drug response to Folic Acid MTHFR missense 19016697 rs1801131 chr1 11854476 T G 1 Drug response to Methotrexate MTHFR missense 19016697 rs1801131 chr1 11854476 T G 8.30E-12 Natriuretic peptide levels MTHFR missense 21273288 rs1801131 chr1 11854476 T G 3.10E-36 Blood pressure MTHFR missense 22100073 rs1801131 chr1 11854476 T G 8.40E-06 Blood pressure MTHFR missense 22100073 rs12121543 chr1 11854671 C A 1.80E-15 Natriuretic peptide levels MTHFR intron 21273288 rs12121543 chr1 11854671 C A 3.20E-05 Blood pressure MTHFR intron 22100073 rs1994798 chr1 11854755 G A 2.40E-09 Natriuretic peptide levels MTHFR intron 21273288 rs1994798 chr1 11854755 G A 5.60E-04 Blood pressure MTHFR intron 22100073 rs2066462 chr1 11854896 G A 1.50E-07 Natriuretic peptide levels MTHFR cds-synon 21273288 rs6541003 chr1 11855867 G A 2.20E-09 Natriuretic peptide levels MTHFR intron 21273288 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 11418485 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 11710708 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 12453860 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 12915598 rs1801133 chr1 11856378 G A 1 Drug response to Folic Acid MTHFR missense 16572443 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 16572443 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 17488658 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 18381794 rs1801133 chr1 11856378 G A 1 Drug response to Nitrous Oxide MTHFR missense 18580170 rs1801133 chr1 11856378 G A 1 Drug response to Folic Acid MTHFR missense 19016697 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 19016697 rs1801133 chr1 11856378 G A 1 Drug response to Methotrexate MTHFR missense 19208607 rs1801133 chr1 11856378 G A 4.36E-13 Folate pathway vitamin levels MTHFR missense 19303062 rs1801133 chr1 11856378 G A 9.30E-05 Homocysteine levels,in plasma MTHFR missense 19525478 rs1801133 chr1 11856378 G A 8.00E-35 Homocysteine levels MTHFR missense 20031578 rs1801133 chr1 11856378 G A 2.36E-07 Schizophrenia MTHFR missense 22037552 rs1801133 chr1 11856378 G A 1.75E-11 homocysteine levels MTHFR missense 23696881 rs1801133 chr1 11856378 G A 4.00E-104 Homocysteine levels MTHFR missense 23824729 rs1801133 chr1 11856378 G A 5.42E-04 Schizophrenia MTHFR missense 24043878 rs17421511 chr1 11857788 G A 2.90E-07 Natriuretic peptide levels MTHFR intron 21273288 rs4846052 chr1 11857951 T C 2.20E-09 Natriuretic peptide levels MTHFR intron 21273288 rs4846052 chr1 11857951 T C 9.38E-05 Response to mTOR inhibitor (rapamycin) MTHFR intron 24009623 rs17037388 chr1 11858036 A G 3.00E-06 Blood pressure MTHFR intron 21060006 rs17037388 chr1 11858036 A G 4.00E-04 Blood pressure MTHFR intron 21060006 rs17037388 chr1 11858036 A G 6.20E-05 Blood pressure MTHFR intron 21060006 rs17037388 chr1 11858036 A G 8.80E-06 Blood pressure MTHFR intron 21060006 rs17037388 chr1 11858036 A G 1.00E-04 Blood pressure MTHFR intron 22100073 rs17421560 chr1 11858324 G A 1.60E-06 Natriuretic peptide levels MTHFR intron 21273288 rs13306553 chr1 11860117 A G 2.40E-04 Atrial fibrillation MTHFR intron 21846873 rs11121832 chr1 11860120 T C 3.00E-05 Natriuretic peptide levels MTHFR intron 21273288 rs2066471 chr1 11860458 C T 2.80E-07 Natriuretic peptide levels MTHFR intron 21273288 rs7533315 chr1 11860683 T C 1.90E-04 Natriuretic peptide levels MTHFR intron 21273288 rs17037390 chr1 11860843 G A 3.10E-06 Blood pressure MTHFR intron 21060006 rs17037390 chr1 11860843 G A 6.00E-04 Blood pressure MTHFR intron 21060006 rs17037390 chr1 11860843 G A 6.70E-05 Blood pressure MTHFR intron 21060006 rs17037390 chr1 11860843 G A 9.60E-06 Blood pressure MTHFR intron 21060006 rs17037390 chr1 11860843 G A 2.30E-04 Natriuretic peptide levels MTHFR intron 21273288 rs17037390 chr1 11860843 G A 8.00E-04 Atrial fibrillation MTHFR intron 21846873 rs17037390 chr1 11860843 G A 3.71E-06 Blood pressure MTHFR intron 22100073 rs17037396 chr1 11862047 C T 1.00E-07 Natriuretic peptide levels MTHFR intron 21273288 rs17037396 chr1 11862047 C T 2.80E-04 Atrial fibrillation MTHFR intron 21846873 rs17037396 chr1 11862047 C T 1.81E-04 Blood pressure MTHFR intron 22100073 rs17037397 chr1 11862163 C A 1.80E-06 Natriuretic peptide levels MTHFR intron 21273288 rs9651118 chr1 11862214 T C 2.30E-04 Natriuretic peptide levels MTHFR intron 21273288 rs9651118 chr1 11862214 T C 2.48E-05 Esophageal cancer (squamous cell) MTHFR intron 22960999 rs17367504 chr1 11862778 A G 2.00E-13 Systolic blood pressure MTHFR intron 19430483 rs17367504 chr1 11862778 A G 6.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MTHFR intron 20877124 rs17367504 chr1 11862778 A G 1.10E-04 Blood pressure MTHFR intron 21060006 rs17367504 chr1 11862778 A G 1.80E-05 Blood pressure MTHFR intron 21060006 rs17367504 chr1 11862778 A G 3.00E-04 Blood pressure MTHFR intron 21060006 rs17367504 chr1 11862778 A G 3.60E-06 Blood pressure MTHFR intron 21060006 rs17367504 chr1 11862778 A G 2.10E-04 Natriuretic peptide levels MTHFR intron 21273288 rs17367504 chr1 11862778 A G 2.00E-13 Coronary heart disease MTHFR intron 21347282 rs17367504 chr1 11862778 A G 2.00E-13 Blood pressure MTHFR intron 21378095 rs17367504 chr1 11862778 A G 3.80E-04 Atrial fibrillation MTHFR intron 21846873 rs17367504 chr1 11862778 A G 2.00E-16 Blood pressure MTHFR intron 21909110 rs17367504 chr1 11862778 A G 8.72E-22 Systolic blood pressure MTHFR intron 21909115 rs17367504 chr1 11862778 A G 1.20E-06 Blood pressure MTHFR intron 22100073 rs2066470 chr1 11863057 G A 4.20E-07 Natriuretic peptide levels MTHFR cds-synon 21273288 rs2066470 chr1 11863057 G A 1.40E-04 Atrial fibrillation MTHFR cds-synon 21846873 rs2066470 chr1 11863057 G A 7.74E-05 Blood pressure MTHFR cds-synon 22100073 rs7553194 chr1 11864149 G A 5.80E-08 Natriuretic peptide levels MTHFR intron 21273288 rs3753582 chr1 11865542 A C 1.30E-08 Natriuretic peptide levels MTHFR intron 21273288 rs13306561 chr1 11865804 A G 1.70E-04 Blood pressure MTHFR intron 21060006 rs13306561 chr1 11865804 A G 3.00E-05 Blood pressure MTHFR intron 21060006 rs13306561 chr1 11865804 A G 6.00E-04 Blood pressure MTHFR intron 21060006 rs13306561 chr1 11865804 A G 7.90E-06 Blood pressure MTHFR intron 21060006 rs13306561 chr1 11865804 A G 1.70E-05 Natriuretic peptide levels MTHFR intron 21273288 rs13306561 chr1 11865804 A G 3.00E-04 Atrial fibrillation MTHFR intron 21846873 rs13306561 chr1 11865804 A G 3.24E-06 Blood pressure MTHFR intron 22100073 rs13306560 chr1 11866183 C T 1.20E-08 Blood pressure CLCN6 UTR-5 21060006 rs13306560 chr1 11866183 C T 2.90E-11 Blood pressure CLCN6 UTR-5 21060006 rs13306560 chr1 11866183 C T 3.40E-05 Blood pressure CLCN6 UTR-5 21060006 rs13306560 chr1 11866183 C T 5.40E-06 Blood pressure CLCN6 UTR-5 21060006 rs13306560 chr1 11866183 C T 6.10E-06 Blood pressure CLCN6 UTR-5 21060006 rs3737965 chr1 11866451 G A 1.30E-07 Natriuretic peptide levels CLCN6 intron 21273288 rs3737964 chr1 11867044 T A,C,G 4.00E-05 Natriuretic peptide levels CLCN6 intron 21273288 rs4846054 chr1 11869230 C T 6.70E-11 Natriuretic peptide levels CLCN6 intron 21273288 rs4846056 chr1 11869578 T C 4.00E-05 Natriuretic peptide levels CLCN6 intron 21273288 rs17037425 chr1 11870383 G A 1.70E-05 Natriuretic peptide levels CLCN6 intron 21273288 rs17037425 chr1 11870383 G A 4.30E-04 Atrial fibrillation CLCN6 intron 21846873 rs17037425 chr1 11870383 G A 1.22E-05 Blood pressure CLCN6 intron 22100073 rs6687229 chr1 11872656 C T 8.70E-09 Natriuretic peptide levels CLCN6 intron 21273288 rs12123964 chr1 11872714 A C 2.00E-07 Natriuretic peptide levels CLCN6 intron 21273288 rs12404124 chr1 11873869 G T 3.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) CLCN6 intron 20877124 rs12404124 chr1 11873869 G T 1.80E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs198391 chr1 11876417 C T 1.30E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs2076001 chr1 11879267 A G 9.00E-09 Natriuretic peptide levels CLCN6 intron 21273288 rs2076002 chr1 11879360 G A 9.00E-09 Natriuretic peptide levels CLCN6 intron 21273288 rs198393 chr1 11879685 C T 4.30E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs2050265 chr1 11879699 A G 6.30E-05 Natriuretic peptide levels CLCN6 intron 21273288 rs198399 chr1 11883629 T A 4.30E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs12567136 chr1 11883731 C T 6.30E-05 Natriuretic peptide levels CLCN6 intron 21273288 rs2076003 chr1 11884147 T C 1.10E-07 Natriuretic peptide levels CLCN6 intron 21273288 rs2076004 chr1 11886813 G A 8.90E-09 Natriuretic peptide levels CLCN6 intron 21273288 rs7537765 chr1 11887303 A G 6.50E-05 Natriuretic peptide levels CLCN6 intron 21273288 rs535107 chr1 11889468 A G 1.80E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs503040 chr1 11890695 C T 1.70E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs2236797 chr1 11892650 C T 1.40E-08 Natriuretic peptide levels CLCN6 intron 21273288 rs17037452 chr1 11895675 A G 1.40E-08 Natriuretic peptide levels CLCN6 intron 21273288 rs2075538 chr1 11896602 T C 9.00E-09 Natriuretic peptide levels CLCN6 intron 21273288 rs198406 chr1 11897592 A G 3.00E-08 Natriuretic peptide levels CLCN6 intron 21273288 rs2075539 chr1 11897758 G A 1.10E-07 Natriuretic peptide levels CLCN6 intron 21273288 rs198408 chr1 11898130 T A 5.50E-10 Natriuretic peptide levels CLCN6 intron 21273288 rs2272803 chr1 11898789 G T 1.10E-07 Natriuretic peptide levels CLCN6 intron 21273288 rs1023252 chr1 11899033 G T 4.00E-16 Natriuretic peptide levels CLCN6 intron 21273288 rs198413 chr1 11900802 T C 1.68E-04 Multiple complex diseases CLCN6 UTR-3 17554300 rs17350396 chr1 11900838 A G 1.80E-07 Natriuretic peptide levels CLCN6 UTR-3 21273288 rs14078 chr1 11903010 G A 4.28E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines CLCN6 UTR-3 21844884 rs198358 chr1 11904076 T C 3.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs198358 chr1 11904076 T C 1.15E-05 Atrial fibrillation / / 21846873 rs7552330 chr1 11904092 G A 8.20E-08 Natriuretic peptide levels / / 21273288 rs5068 chr1 11905974 A G 2.10E-04 Atrial fibrillation NPPA UTR-3 21846873 rs5068 chr1 11905974 A G 3.18E-05 Blood pressure NPPA UTR-3 22100073 rs5065 chr1 11906068 A G 1 Drug response to Amlodipine NPPA-AS1 intron 18212314 rs5065 chr1 11906068 A G 1 Drug response to Chlorthalidone NPPA-AS1 intron 18212314 rs5065 chr1 11906068 A G 1 Drug response to Doxazosin NPPA-AS1 intron 18212314 rs5065 chr1 11906068 A G 1 Drug response to Lisinopril NPPA-AS1 intron 18212314 rs5063 chr1 11907648 C T 8.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NPPA missense 20877124 rs5063 chr1 11907648 C T 5.00E-08 Natriuretic peptide levels NPPA missense 21273288 rs198372 chr1 11909514 G A 3.00E-04 Blood pressure NPPA nearGene-5 21060006 rs632793 chr1 11910677 A G 2.14E-15 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs632793 chr1 11910677 A G 3.60E-11 Natriuretic peptide levels / / 21273288 rs198375 chr1 11913757 T C 4.00E-11 Natriuretic peptide levels / / 21273288 rs198375 chr1 11913757 T C 1.10E-04 Blood pressure / / 22100073 rs6668352 chr1 11914829 G A 1.70E-18 Natriuretic peptide levels / / 21273288 rs198388 chr1 11917340 C T 1.95E-13 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs198388 chr1 11917340 C T 3.90E-10 Natriuretic peptide levels / / 21273288 rs198388 chr1 11917340 C T 7.10E-04 Blood pressure / / 22100073 rs198389 chr1 11919271 A G 1.70E-12 Natriuretic peptide levels / / 21273288 rs12406089 chr1 11921181 C G 3.50E-16 Natriuretic peptide levels / / 21273288 rs12406383 chr1 11921993 C A 3.70E-18 Natriuretic peptide levels / / 21273288 rs6668659 chr1 11922298 T G 5.30E-16 Natriuretic peptide levels / / 21273288 rs6668659 chr1 11922298 T G 2.00E-05 Blood pressure / / 22100073 rs6676300 chr1 11925300 A G 5.75E-14 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6676300 chr1 11925300 A G 9.30E-14 Natriuretic peptide levels / / 21273288 rs116228357 chr1 11925732 C T 6.00E-04 Polycystic ovary syndrome / / 22178785 rs1318408 chr1 11925781 A G 8.60E-05 Natriuretic peptide levels / / 21273288 rs12562952 chr1 11927056 T C 3.39E-11 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12562952 chr1 11927056 T C 3.60E-04 Natriuretic peptide levels / / 21273288 rs1009592 chr1 11928714 C G 4.00E-11 Natriuretic peptide levels / / 21273288 rs11801879 chr1 11928819 T C 1.80E-05 Blood pressure / / 21060006 rs11801879 chr1 11928819 T C 4.00E-04 Blood pressure / / 21060006 rs11801879 chr1 11928819 T C 6.00E-06 Blood pressure / / 21060006 rs1009591 chr1 11928830 T C 2.60E-08 Natriuretic peptide levels / / 21273288 rs1009591 chr1 11928830 T C 9.95E-05 Monocyte chemoattractant protein-1 / / pha003071 rs11803049 chr1 11928895 G A 1.07E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11803049 chr1 11928895 G A 5.90E-06 Natriuretic peptide levels / / 21273288 rs11804222 chr1 11936514 G A 3.23E-05 Alcohol withdrawal symptoms / / 22072270 rs12724129 chr1 11957639 C T 6.83E-06 Asthma / / 20698975 rs12085006 chr1 11958723 A G 6.00E-10 Folate pathway vitamin levels / / 19744961 rs11800086 chr1 11971749 G A 2.53E-04 Glycosylated haemoglobin levels / / 17255346 rs7554547 chr1 11973888 A G 3.47E-04 Tourette syndrome / / 22889924 rs6682554 chr1 11986621 T C 7.16E-05 Neuroblastoma / / pha002895 rs2273289 chr1 12018290 T C 0.000000129 Major depressive disorder age at onset<15 PLOD1 intron 22915352 rs2273289 chr1 12018290 T C 0.000000448 Major depressive disorder age at onset<20 PLOD1 intron 22915352 rs2273289 chr1 12018290 T C 0.00000134 Major depressive disorder age at onset<35 PLOD1 intron 22915352 rs2273289 chr1 12018290 T C 0.00000392 Major depressive disorder age at onset<25 PLOD1 intron 22915352 rs2273289 chr1 12018290 T C 0.00000436 Major depressive disorder age at onset<30 PLOD1 intron 22915352 rs2273289 chr1 12018290 T C 3.19E-05 Anxiety and major depressive disorder PLOD1 intron 24047446 rs1540923 chr1 12032030 A G 4.09E-04 Myocardial Infarction PLOD1 intron pha002873 rs1474868 chr1 12044164 C T 8.97E-04 Myocardial Infarction MFN2 intron pha002873 rs2336384 chr1 12046063 G T 1.00E-08 Platelet counts MFN2 intron 22139419 rs2878677 chr1 12053264 T C 1.61E-05 Schizophrenia MFN2 intron 19571811 rs2295283 chr1 12082926 A G 0.0002 Migraine MIIP missense 22678113 rs17037598 chr1 12153413 G T 1.13E-04 Response to cytidine analogues (gemcitabine) TNFRSF8 intron 24483146 rs11569837 chr1 12157740 C T 7.64E-04 Smoking quantity TNFRSF8 intron 24665060 rs11121868 chr1 12170974 C T 9.52E-04 Type 2 diabetes TNFRSF8 intron 17463246 rs2230624 chr1 12175658 G A,T 0.00026 Breast cancer TNFRSF8 missense 23555315 rs646249 chr1 12180124 G A 2.60E-05 Urinary metabolites TNFRSF8 intron 21572414 rs2230625 chr1 12186058 A G 3.47E-04 Taste perception TNFRSF8 missense 22132133 rs535068 chr1 12189561 G A 5.32E-06 Carotenoid and tocopherol levels TNFRSF8 intron 19185284 rs1148472 chr1 12194451 T C 0.0000922 post-traumatic stress disorder TNFRSF8 intron 22869035 rs1148472 chr1 12194451 T C 9.22E-05 Schizophrenia TNFRSF8 intron 22883433 rs686190 chr1 12223839 T C 8.58E-04 Multiple complex diseases / / 17554300 rs1061622 chr1 12252955 T G 1 Drug response to Infliximab TNFRSF1B missense 18565259 rs1061622 chr1 12252955 T G 0.0003 Stroke TNFRSF1B missense 23422753 rs5746059 chr1 12262792 A G 4.42E-04 Response to TNF antagonist treatment TNFRSF1B intron 21061259 rs235219 chr1 12264355 A G 1.26E-05 Type 1 diabetes TNFRSF1B intron 21980299 rs5746068 chr1 12267555 C G 0.00000154 HDL cholesterol TNFRSF1B UTR-3 23063622 rs1061628 chr1 12267999 C T 1.30E-05 Urinary metabolites TNFRSF1B UTR-3 21572414 rs235216 chr1 12269624 C T 1.25E-11 HDL cholesterol TNFRSF1B nearGene-3 23063622 rs235216 chr1 12269624 C T 4.12E-10 Cholesterol,total TNFRSF1B nearGene-3 23063622 rs374450 chr1 12305286 G A 9.50E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) VPS13D intron 20877124 rs374450 chr1 12305286 G A 8.75E-05 Myopia (pathological) VPS13D intron 21095009 rs235243 chr1 12319994 G T 9.55E-05 Major depressive disorder VPS13D intron 21621269 rs148728975 chr1 12419883 G A 7.00E-07 Asthma VPS13D intron 24406073 rs11121906 chr1 12488475 C A 7.95E-05 Acute lymphoblastic leukemia (childhood) VPS13D intron 19684603 rs6683371 chr1 12492582 A G 8.69E-05 Acute lymphoblastic leukemia (childhood) VPS13D intron 19684603 rs12406819 chr1 12577209 G A 5.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12406819 chr1 12577209 G A 6.34E-05 Myopia (pathological) / / 21095009 rs760943 chr1 12598434 T C 6.20E-05 Alcoholism (heaviness of drinking) / / 21529783 rs6659122 chr1 12615069 G T 8.43E-05 Smoking initiation / / 24665060 rs3128451 chr1 12641488 G T 2.80E-04 Amyotrophic Lateral Sclerosis DHRS3 intron 17827064 rs12045736 chr1 12654035 C T 9.86E-05 Glycosylated haemoglobin levels DHRS3 intron 17255346 rs13376289 chr1 12661179 G T 2.04E-04 Celiac disease DHRS3 intron 23936387 rs6689733 chr1 12680180 G A 3.40E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs3000896 chr1 12682574 T C 6.42E-05 Monocyte chemoattractant protein-1 / / pha003071 rs3010931 chr1 12684324 C T 3.90E-04 Alcohol dependence / / 20201924 rs12070206 chr1 12689692 G A 4.52E-05 Cognitive test performance / / 20125193 rs4845911 chr1 12693125 G A 1.33E-05 Non-obstructive azoospermia / / 22541561 rs2489258 chr1 12700815 T C 7.45E-04 Obesity (extreme) / / 21935397 rs7512542 chr1 12702393 C T 6.38E-06 Multiple complex diseases / / 17554300 rs7512542 chr1 12702393 C T 1.36E-28 Narcolepsy / / 19629137 rs17458785 chr1 12709554 G A 1.29E-05 Waist-Hip Ratio AADACL4 intron pha003013 rs17458785 chr1 12709554 G A 2.09E-05 Waist-Hip Ratio AADACL4 intron pha003028 rs11121955 chr1 12723184 G A 9.09E-05 Blood Pressure AADACL4 intron pha003047 rs2489260 chr1 12741240 G A 8.00E-06 Obesity-related traits / / 23251661 rs3010948 chr1 12754569 C T 5.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17038464 chr1 12786444 G A 8.56E-05 Response to mTOR inhibitor (rapamycin) AADACL3 UTR-3 24009623 rs3010903 chr1 12796044 G T 4.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17038489 chr1 12805936 T C 4.26E-04 Multiple complex diseases / / 17554300 rs1812242 chr1 12835868 T C 8.68E-05 Glycosylated haemoglobin levels PRAMEF12 missense 17255346 rs111797423 chr1 12836235 C T 2.20E-11 Metabolite levels PRAMEF12 cds-synon 22286219 rs1856638 chr1 12910136 A G 6.59E-06 Multiple complex diseases / / 17554300 rs41468748 chr1 12911096 G T 4.22E-06 Multiple complex diseases / / 17554300 rs11580598 chr1 13783354 C T 2.90E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2940310 chr1 13805706 C T 0.000690619 Hypertension (early onset hypertension) LRRC38 intron 22479346 rs3845607 chr1 13806039 T C 2.25E-04 Alzheimer's disease (late onset) LRRC38 intron 21379329 rs2990683 chr1 13841055 T C 9.87E-04 Alzheimer's disease / / 17998437 rs3856278 chr1 13859570 A G 5.06E-04 Multiple complex diseases / / 17554300 rs11805703 chr1 13861990 G C 5.87E-04 Multiple complex diseases / / 17554300 rs11805703 chr1 13861990 G C 8.61E-04 Response to TNF antagonist treatment / / 21061259 rs10927872 chr1 13885203 C T 5.07E-04 Obesity (extreme) / / 21935397 rs12735797 chr1 13905218 G A 1.36E-04 White matter integrity / / 22425255 rs2885135 chr1 13906527 G C 9.00E-06 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2361030 chr1 13906554 C T 7.98E-04 Coronary Artery Disease / / 17634449 rs2361030 chr1 13906554 C T 9.37E-05 White matter integrity / / 22425255 rs2361030 chr1 13906554 C T 7.72E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10927903 chr1 13912887 G A 3.11E-05 Response to cytadine analogues (cytosine arabinoside) PDPN intron 24483146 rs10927905 chr1 13916997 T C 2.53E-04 Celiac disease PDPN intron 23936387 rs16852000 chr1 13920167 T G 5.12E-04 Multiple complex diseases PDPN intron 17554300 rs11587701 chr1 13946497 A G 8.61E-04 Bipolar disorder,schizoaffective / / 19567891 rs11587701 chr1 13946497 A G 1.50E-05 Urinary metabolites / / 21572414 rs11587701 chr1 13946497 A G 0.0000267 Coronary artery calcification / / 23394302 rs10927910 chr1 13948765 G A 9.37E-04 Multiple complex diseases / / 17554300 rs17390405 chr1 13949087 G A 6.99E-04 Depression (quantitative trait) / / 20800221 rs12143609 chr1 13957405 C T 5.83E-04 Type 2 diabetes / / 17463246 rs16852640 chr1 13971360 G A 9.91E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2495057 chr1 14035513 T C 8.15E-04 Suicide attempts in bipolar disorder PRDM2 intron 21423239 rs2495053 chr1 14040030 T C 3.80E-04 Type 2 diabetes PRDM2 intron 17463246 rs2495053 chr1 14040030 T C 2.60E-05 Anger PRDM2 intron 24489884 rs6429794 chr1 14045394 T G 1.41E-04 Multiple complex diseases PRDM2 intron 17554300 rs1203631 chr1 14067208 A G 3.20E-04 Multiple complex diseases PRDM2 intron 17554300 rs2359756 chr1 14096420 A G 4.17E-04 Response to alcohol consumption (flushing response) PRDM2 intron 24277619 rs1203651 chr1 14109114 A G 9.46E-04 Multiple complex diseases PRDM2 cds-synon 17554300 rs1980471 chr1 14118119 C G 9.94E-04 Multiple complex diseases PRDM2 intron 17554300 rs1203639 chr1 14120432 C T 8.44E-04 Multiple complex diseases PRDM2 intron 17554300 rs1203638 chr1 14121892 G T 1.29E-04 Parkinson's disease PRDM2 intron 17052657 rs2744692 chr1 14125227 T C 5.11E-05 Vaspin levels PRDM2 intron 22907691 rs2697992 chr1 14125496 G C 4.97E-05 Vaspin levels PRDM2 intron 22907691 rs2245218 chr1 14139826 C T 4.61E-05 Parkinson's disease PRDM2 intron 16252231 rs1203690 chr1 14162023 T G 6.80E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2744671 chr1 14195122 T C 6.64E-05 Suicide attempts in bipolar disorder / / 21423239 rs16853069 chr1 14196212 T C 4.89E-04 Insulin resistance / / 21901158 rs17350970 chr1 14216150 C T 6.50E-06 Urinary metabolites / / 21572414 rs2697979 chr1 14221528 G A 4.61E-05 Atopic dermatitis / / 23042114 rs6429800 chr1 14228077 G A 1.40E-06 Urinary metabolites / / 21572414 rs7536590 chr1 14232891 C T 7.17E-04 Insulin resistance / / 21901158 rs7543809 chr1 14232929 T C 4.40E-04 Insulin resistance / / 21901158 rs12745720 chr1 14240110 C T 1.10E-05 HIV-1 viral setpoint / / 17641165 rs12122426 chr1 14240350 A C 9.28E-05 Elbow pain / / pha003008 rs10489150 chr1 14253566 A G 4.00E-05 Body Mass Index / / pha003019 rs6661262 chr1 14254750 G A 1.30E-04 Schizophrenia / / 19197363 rs7538374 chr1 14255978 T G 1.72E-04 Multiple complex diseases / / 17554300 rs16853208 chr1 14257199 T C 3.11E-04 Multiple complex diseases / / 17554300 rs2206585 chr1 14261909 G T 7.12E-05 Body Mass Index / / pha003019 rs4662054 chr1 14268523 A G 2.87E-05 Body Mass Index / / pha003019 rs4662054 chr1 14268523 A G 6.73E-05 Body Mass Index / / pha003022 rs4661455 chr1 14277864 T C 4.54E-04 Type 2 diabetes / / 17463246 rs2359896 chr1 14280562 G A 8.82E-06 Body Mass Index / / pha003019 rs2359896 chr1 14280562 G A 2.44E-05 Body Mass Index / / pha003022 rs12024045 chr1 14297220 A G 9.77E-04 Multiple complex diseases / / 17554300 rs10489148 chr1 14313480 G T 2.00E-05 Multiple complex diseases / / 17554300 rs6691183 chr1 14320651 C A 1.44E-04 Multiple complex diseases / / 17554300 rs12129723 chr1 14331940 G A 8.66E-04 Alzheimer's disease / / 22005930 rs6429822 chr1 14342347 G A 2.89E-05 Rheumatoid arthritis / / 17804836 rs4661465 chr1 14345544 G A 9.62E-05 Hypertension / / 19609347 rs3929673 chr1 14353071 T G 3.94E-04 Alzheimer's disease / / 22005930 rs4662075 chr1 14353195 C G 9.77E-04 Alzheimer's disease / / 22005930 rs4662076 chr1 14357851 T G 5.90E-06 Alzheimer's disease (late onset) / / 21460841 rs7527934 chr1 14358424 G T 5.87E-06 Alzheimer's disease (late onset) / / 21460841 rs10754905 chr1 14361699 C T 6.89E-06 Alzheimer's disease (late onset) / / 21460841 rs7551069 chr1 14361749 A G 6.65E-06 Alzheimer's disease (late onset) / / 21460841 rs2359909 chr1 14364585 G T 7.53E-06 Alzheimer's disease (late onset) / / 21460841 rs2359910 chr1 14364963 A G 9.67E-06 Alzheimer's disease (late onset) / / 21460841 rs10733140 chr1 14365171 C A 7.70E-06 Alzheimer's disease (late onset) / / 21460841 rs7514368 chr1 14368784 T C 8.25E-06 Alzheimer's disease (late onset) / / 21460841 rs6662320 chr1 14370368 A G 7.80E-05 Major depressive disorder / / 21042317 rs6671878 chr1 14372093 T A 9.67E-06 Alzheimer's disease (late onset) / / 21460841 rs10737917 chr1 14372776 T A 9.71E-06 Alzheimer's disease (late onset) / / 21460841 rs10737918 chr1 14385135 A G 8.10E-05 Major depressive disorder / / 21042317 rs16853528 chr1 14388300 T C 2.23E-04 Multiple complex diseases / / 17554300 rs10733143 chr1 14390137 A G 7.60E-05 Major depressive disorder / / 21042317 rs7515917 chr1 14439042 T C 6.83E-04 Type 2 diabetes / / 17463246 rs10429936 chr1 14450545 T C 9.58E-04 Type 2 diabetes / / 17463246 rs16853613 chr1 14455748 A G 4.38E-04 Multiple complex diseases / / 17554300 rs929125 chr1 14477944 G A 8.92E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs568434 chr1 14523180 C A 3.85E-04 Aortic root size / / 21223598 rs4478803 chr1 14559081 C T 3.97E-04 Insulin resistance / / 21901158 rs4478803 chr1 14559081 C T 7.70E-04 Intelligence (childhood) / / 23358156 rs10928056 chr1 14585648 G A 8.20E-04 Alcohol dependence / / 20201924 rs12406699 chr1 14598055 C T 2.58E-04 IgE levels / / 17255346 rs1416623 chr1 14649876 T C 0.000566716 Hypertension (early onset hypertension) / / 22479346 rs12121975 chr1 14673385 G T 7.25E-04 Substance dependence / / 21818250 rs12134023 chr1 14677729 C A 3.75E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4113453 chr1 14680899 G A 9.33E-05 Major depressive disorder / / 21621269 rs820671 chr1 14692271 A G 1.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs10803270 chr1 14700804 A G 4.89E-06 Alzheimer's disease (late onset) / / 21460841 rs10927416 chr1 14708719 A C 2.59E-04 Multiple complex diseases / / 17554300 rs12085004 chr1 14773232 G A 1.16E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4450012 chr1 14775550 C T 9.80E-06 Urinary metabolites / / 21572414 rs16850285 chr1 14787410 C T 5.87E-04 Obesity (extreme) / / 21935397 rs2480054 chr1 14792535 A G 4.00E-06 Chagas cardiomyopathy in Tripanosoma cruzi seropositivity / / 24324551 rs16850320 chr1 14795469 G C 3.36E-04 Type 2 diabetes / / 17463246 rs16850332 chr1 14796547 T A 4.44E-05 Type 2 diabetes / / 17463246 rs16850384 chr1 14822916 T C 5.88E-05 Multiple complex diseases / / 17554300 rs11807837 chr1 14841189 A C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs12733185 chr1 14842486 G A 5.37E-05 Fibrinogen / / pha003068 rs2105239 chr1 14857643 A G 3.00E-04 Chronic fatigue syndrome / / 21912186 rs4661292 chr1 14915147 G A 7.72E-04 Multiple complex diseases / / 17554300 rs10803289 chr1 14934220 G A 8.92E-04 Multiple complex diseases KAZN intron 17554300 rs11579756 chr1 14947920 T C 0.000117 Schizophrenia KAZN intron 23637625 rs4661295 chr1 14999190 C T 2.41E-04 Multiple complex diseases KAZN intron 17554300 rs6429673 chr1 15025974 A G 1.51E-05 Response to tocilizumab in rheumatoid arthritis KAZN intron 22491018 rs4661300 chr1 15038771 T G 5.58E-04 Multiple complex diseases KAZN intron 17554300 rs4661515 chr1 15038791 A T 7.03E-04 Multiple complex diseases KAZN intron 17554300 rs12136961 chr1 15039673 G A 8.30E-04 Multiple complex diseases KAZN intron 17554300 rs6698433 chr1 15065915 G C 8.86E-04 Alzheimer's disease KAZN intron 22005930 rs6690550 chr1 15066365 T C 8.93E-04 Alzheimer's disease KAZN intron 22005930 rs10803311 chr1 15066944 T C 9.91E-04 Alzheimer's disease KAZN intron 22005930 rs4661302 chr1 15092813 G A 1.30E-05 Urinary metabolites KAZN intron 21572414 rs4661303 chr1 15101472 C T 5.33E-04 Multiple complex diseases KAZN intron 17554300 rs804125 chr1 15111927 G T 7.91E-05 Coronary heart disease KAZN intron pha003055 rs1721831 chr1 15115510 T C 3.11E-05 Birth weight KAZN intron 17255346 rs1630519 chr1 15116208 G T 6.49E-05 Coronary heart disease KAZN intron pha003055 rs1721829 chr1 15117060 A G 2.26E-05 Coronary heart disease KAZN intron pha003055 rs10489353 chr1 15140362 G A 9.54E-06 Serum metabolites KAZN intron 19043545 rs17368807 chr1 15153369 G A 1.80E-05 Urinary metabolites KAZN intron 21572414 rs3845593 chr1 15162350 A G 8.77E-05 Non-alcoholic fatty liver disease histology (other) KAZN intron 20708005 rs7416912 chr1 15194562 G T 3.78E-04 Response to cytadine analogues (cytosine arabinoside) KAZN intron 24483146 rs2803396 chr1 15197909 T C 4.80E-06 Glioma (high-grade) KAZN intron 19578366 rs12029721 chr1 15216489 A G 7.91E-06 Retinopathy in non-diabetics KAZN intron 23393555 rs12410007 chr1 15264270 A G 0.00000003 Brain microstructure and intellectual performance KAZN intron 22723713 rs10927602 chr1 15295333 A G 5.42E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) KAZN intron 20877124 rs7544674 chr1 15297249 T A 1.61E-04 Multiple complex diseases KAZN intron 17554300 rs4661553 chr1 15304859 C T 2.23E-04 Multiple complex diseases KAZN intron 17554300 rs7529561 chr1 15328151 A C 3.53E-04 Alcohol consumption (maxi-drinks) KAZN intron 24277619 rs7539545 chr1 15331603 A T 8.30E-06 Urinary metabolites KAZN intron 21572414 rs6681053 chr1 15334782 T C 6.26E-05 Fibrinogen KAZN intron pha003068 rs11578349 chr1 15338903 G T 9.20E-04 Response to cytadine analogues (cytosine arabinoside) KAZN intron 24483146 rs6429702 chr1 15339902 T G 7.39E-04 Response to statin treatment (atorvastatin),change in cholesterol levels KAZN intron 20031582 rs6429703 chr1 15339960 T C 8.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) KAZN intron 23648065 rs10927631 chr1 15346330 T C 4.70E-06 Urinary metabolites KAZN intron 21572414 rs6657768 chr1 15346891 T A 3.00E-07 Urinary metabolites KAZN intron 21572414 rs6667220 chr1 15347640 G A 8.00E-06 Chronic obstructive pulmonary disease-related biomarkers KAZN intron 23144326 rs4520412 chr1 15359967 C T 4.01E-04 Multiple complex diseases KAZN intron 17554300 rs6674129 chr1 15363223 A C 1.83E-05 Blood Pressure KAZN intron pha003046 rs12138732 chr1 15377554 G A 8.70E-06 Urinary metabolites KAZN intron 21572414 rs1513548 chr1 15379185 T C 8.66E-05 Aortic root size KAZN intron 21223598 rs476859 chr1 15428508 C T 8.25E-05 Aortic root size KAZN intron 21223598 rs496567 chr1 15435257 A G 3.84E-04 Type 2 diabetes KAZN intron 17463246 rs6659639 chr1 15440156 G A 5.17E-05 Crohn's disease KAZN intron 17684544 rs761301 chr1 15471992 T G 9.70E-05 Psoriasis C1orf126 intron 19169255 rs10927689 chr1 15484465 A G 1.33E-04 Type 2 diabetes TMEM51 intron 17463246 rs16851354 chr1 15495620 T C 4.84E-05 Tuberculosis TMEM51 intron 24057671 rs7539166 chr1 15495905 T G 4.57E-98 Multiple complex diseases TMEM51 intron 17554300 rs16851358 chr1 15500332 C T 1.43E-04 Type 2 diabetes TMEM51 intron 17463246 rs16851358 chr1 15500332 C T 2.50E-05 Urinary metabolites TMEM51 intron 21572414 rs10754886 chr1 15502481 C T 2.30E-05 Urinary metabolites TMEM51 intron 21572414 rs10754887 chr1 15502539 A G 2.30E-05 Urinary metabolites TMEM51 intron 21572414 rs4661326 chr1 15527323 C T 4.65E-05 Bipolar disorder and schizophrenia TMEM51 intron 20889312 rs3820064 chr1 15542073 G A 4.05E-04 Multiple complex diseases TMEM51 intron 17554300 rs10927733 chr1 15543268 C G 3.90E-04 Smoking initiation TMEM51 intron 24665060 rs549 chr1 15546825 A G 1.60E-04 Osteoarthritis TMEM51 UTR-3 19508968 rs12124285 chr1 15548397 G A 9.72E-04 Multiple complex diseases / / 17554300 rs10737909 chr1 15548636 G T 2.00E-07 Migraine / / 23793025 rs10737909 chr1 15548636 G T 8.91E-05 Migraine without aura / / 23793025 rs11585832 chr1 15569822 G A 3.13E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1752020 chr1 15572133 A G 1.00E-05 Urinary metabolites / / 21572414 rs12144738 chr1 15591641 T C 7.25E-04 Tourette syndrome FHAD1 intron 22889924 rs12725686 chr1 15608418 C T 2.00E-11 Brain microstructure and intellectual performance FHAD1 intron 22723713 rs10803378 chr1 15626718 G A 6.91E-05 Socioeconomic Factors FHAD1 intron pha003066 rs10127456 chr1 15653872 G A 3.18E-05 Serum metabolites FHAD1 intron 19043545 rs7532826 chr1 15677932 A G 5.23E-05 Gallstones FHAD1 intron 17632509 rs16851617 chr1 15699117 G A 3.78E-04 Insulin resistance FHAD1 intron 21901158 rs2249097 chr1 15699327 G C 5.25E-06 Multiple complex diseases FHAD1 intron 17554300 rs2496330 chr1 15718470 T G 6.66E-05 Multiple complex diseases FHAD1 intron 17554300 rs1883426 chr1 15726116 A T 6.20E-05 Primary sclerosing cholangitis / / 19944697 rs742361 chr1 15726566 G A 6.11E-05 Cardiovascular disease / / pha003065 rs742362 chr1 15726791 A G 2.34E-04 Multiple complex diseases / / 17554300 rs2473344 chr1 15728289 T C 4.10E-05 Primary sclerosing cholangitis / / 19944697 rs2092324 chr1 15733394 G A 9.19E-05 Serum metabolites / / 19043545 rs2092324 chr1 15733394 G A 7.56E-05 Insulin resistance / / 21901158 rs2496321 chr1 15743884 A C 2.75E-04 Alcohol dependence EFHD2 intron 20201924 rs2496320 chr1 15744271 T C 5.26E-04 Alcohol dependence EFHD2 intron 20201924 rs11579489 chr1 15790639 G A 3.00E-06 Stroke (ischemic) CELA2A intron 22384361 rs2901964 chr1 15792426 C G 5.00E-06 Erectile dysfunction and prostate cancer treatment CELA2A intron 20932654 rs6675825 chr1 15811346 C T 7.95E-05 Serum metabolites CELA2B intron 19043545 rs4233533 chr1 15829187 G A 0.0000734 Cholesterol,total CASP9 intron 23063622 rs4646043 chr1 15832110 T G 1.10E-04 Coronary heart disease CASP9 intron 21966275 rs2308939 chr1 15833450 G A,C,T 3.36E-11 Cholesterol,total CASP9 missense 23063622 rs2308939 chr1 15833450 G A,C,T 4.29E-09 HDL cholesterol CASP9 missense 23063622 rs2308941 chr1 15844718 G A 2.14E-04 Acute lung injury CASP9 missense 22295056 rs12124078 chr1 15869899 A G 9.49E-22 Chronic kidney disease D/JC16 intron 22479191 rs78309148 chr1 15871023 G A 0.00067 Prostate cancer D/JC16 missense 23555315 rs59905655 chr1 16071010 C T 2.00E-06 Obesity-related traits TMEM82 missense 23251661 rs12725198 chr1 16080171 G A 3.00E-06 Cardiac Troponin-T levels / / 23247143 rs938295 chr1 16087260 C T 6.30E-04 Endometriosis FBLIM1 intron 23104006 rs10737910 chr1 16109669 C T 2.99E-04 Type 2 diabetes FBLIM1 intron 17463246 rs4661661 chr1 16161836 T C 3.20E-04 Smoking cessation / / 24665060 rs4661663 chr1 16161958 G T 1.23E-04 Smoking cessation / / 24665060 rs10737911 chr1 16167855 T C 1.90E-05 Type 2 diabetes FLJ37453 intron 17463246 rs6668183 chr1 16173814 G C 2.06E-04 Heart rate FLJ37453 intron 23583979 rs7552077 chr1 16196759 A G 3.30E-05 Type 2 diabetes SPEN intron 17463246 rs4661670 chr1 16212219 G T 4.63E-04 Smoking cessation SPEN intron 24665060 rs10927873 chr1 16251900 C T 4.90E-04 Heart Failure SPEN intron pha002885 rs848210 chr1 16259813 A G 4.41E-05 Type 2 diabetes SPEN missense 17463246 rs926619 chr1 16279386 C G 3.40E-04 Smoking cessation ZBTB17 intron 24665060 rs4661346 chr1 16282776 G C 8.81E-05 Serum metabolites ZBTB17 intron 19043545 rs10927875 chr1 16299312 C T 1.00E-09 Dilated cardiomyopathy ZBTB17 intron 21459883 rs4661681 chr1 16321523 T C 2.34E-04 Smoking cessation / / 24665060 rs1739843 chr1 16343254 T C 5.28E-13 Dilated cardiomyopathy HSPB7 intron 20975947 rs1056207 chr1 16344827 G A 6.97E-05 Smoking cessation HSPB7 UTR-5 24665060 rs1889785 chr1 16348729 G A 4.45E-06 Heart rate CLCNKA intron 23583979 rs1972359 chr1 16356187 C T 4.12E-04 Smoking cessation CLCNKA intron 24665060 rs1805152 chr1 16356501 G A 5.96E-05 Cholesterol CLCNKA missense pha003078 rs883867 chr1 16358085 C A 1.11E-04 Smoking cessation CLCNKA intron 24665060 rs9442193 chr1 16367339 G A 1.50E-04 Suicide attempts in bipolar disorder / / 21423239 rs9442235 chr1 16393357 T G 6.00E-06 Cognitive performance FAM131C intron 19734545 rs17416878 chr1 16446980 A G 3.70E-07 Kawasaki disease / / 22446962 rs17416878 chr1 16446980 A G 0.000486 Salmonella-induced pyroptosis / / 22837397 rs1497406 chr1 16505320 A G 3.00E-19 Liver enzyme levels (gamma-glutamyl transferase) / / 22001757 rs1497406 chr1 16505320 A G 4.00E-08 Gamma gluatamyl transferase levels / / 22010049 rs6677710 chr1 16507618 T C 1.30E-04 Multiple complex diseases / / 17554300 rs4537547 chr1 16510798 A G 1.12E-04 Multiple complex diseases / / 17554300 rs12740413 chr1 16515879 C T 0.000013 Aging / / 22445811 rs6697459 chr1 16518866 T G 1.23E-04 Multiple complex diseases / / 17554300 rs221032 chr1 16525549 C T 5.73E-05 Multiple complex diseases ARHGEF19 intron 17554300 rs221035 chr1 16526529 G A 3.20E-12 Lymphocyte counts ARHGEF19 intron 22286170 rs221049 chr1 16530850 T G 4.75E-05 Multiple complex diseases ARHGEF19 intron 17554300 rs10489599 chr1 16585818 A G 6.00E-04 Chronic fatigue syndrome FBXO42 intron 21912186 rs6603859 chr1 16706075 G T 1 Drug response to Daunorubicin C1orf144 intron 18451141 rs12138174 chr1 16715466 T C 9.36E-04 Acute lung injury C1orf144 intron 22295056 rs11543230 chr1 16785564 C T 4.96E-04 Multiple complex diseases NECAP2 UTR-3 17554300 rs156851 chr1 16814994 C T 2.80E-04 Height CROCCP3 intron 17255346 rs156869 chr1 16830508 G A 3.19E-04 Height / / 17255346 rs4316363 chr1 16924151 T C 5.73E-04 Multiple complex diseases / / 17554300 rs3851919 chr1 16924335 A G 9.69E-05 Multiple complex diseases / / 17554300 rs1977269 chr1 17004850 C A,G,T 4.06E-05 Platelet counts / / pha003100 rs12563353 chr1 17037560 A G 3.00E-05 Psoriasis ESPNP intron 20953190 rs3915536 chr1 17045646 C T 1.05E-04 Type 2 diabetes ESPNP intron 17463246 rs6586513 chr1 17216331 C A 4.00E-06 Allergic rhinitis / / 22036096 rs9435730 chr1 17305903 G A 3.97E-04 Response to taxane treatment (placlitaxel) MFAP2 intron 23006423 rs2284746 chr1 17306675 C G 4.00E-29 Height MFAP2 intron 20881960 rs2284746 chr1 17306675 C G 1.10E-19 Height MFAP2 intron 21194676 rs2284746 chr1 17306675 C G 1.90E-08 Height MFAP2 intron 21194676 rs2284746 chr1 17306675 C G 4.10E-13 Height MFAP2 intron 21194676 rs2284746 chr1 17306675 C G 8.00E-16 Pulmonary function MFAP2 intron 21946350 rs2284746 chr1 17306675 C G 6.40E-04 Coronary heart disease MFAP2 intron 21966275 rs2284746 chr1 17306675 C G 2.00E-11 Pulmonary function (interaction) MFAP2 intron 23284291 rs2284746 chr1 17306675 C G 5.00E-15 Height MFAP2 intron 23563607 rs3754511 chr1 17310019 G A 1.72E-04 Response to taxane treatment (placlitaxel) MFAP2 nearGene-5 23006423 rs9435736 chr1 17323449 T C 7.78E-04 Response to taxane treatment (placlitaxel) ATP13A2 intron 23006423 rs6684770 chr1 17325955 G A 2.54E-04 Multiple complex diseases ATP13A2 intron 17554300 rs3738814 chr1 17331676 A G 2.00E-07 Height ATP13A2 intron 20189936 rs2647168 chr1 17340878 C T 1.96E-04 Lymphocyte counts / / 22286170 rs34916635 chr1 17371298 C T 1.20E-04 Atrial fibrillation SDHB missense 21846873 rs2746533 chr1 17394046 A G 8.23E-05 Menopause (age at onset) PADI2 UTR-3 22267201 rs2235927 chr1 17394775 G A 1.21E-06 Asthma PADI2 UTR-3 23181788 rs3818042 chr1 17398849 G A 5.31E-04 Pulmonary function PADI2 intron 20010834 rs730387 chr1 17410557 G A 9.52E-06 Rheumatoid arthritis PADI2 intron 19503088 rs2977272 chr1 17536952 C T 7.66E-04 Obesity (extreme) PADI1 intron 21935397 rs2977235 chr1 17557178 C T 1.90E-05 Urinary metabolites PADI1 intron 21572414 rs4268393 chr1 17559196 T C 4.60E-06 Urinary metabolites PADI1 intron 21572414 rs3003412 chr1 17564847 C T 3.85E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) PADI1 intron 24192120 rs2977310 chr1 17564990 T C 5.28E-05 Age-related macular degeneration PADI1 intron pha002890 rs2977225 chr1 17573439 T C 2.13E-04 Vaspin levels / / 22907691 rs2977225 chr1 17573439 T C 0.000213 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs3003419 chr1 17573988 G A 3.59E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs12562867 chr1 17576638 A C 1.00E-04 Prostate cancer PADI3 intron 21743057 rs4363467 chr1 17586653 C T 9.70E-04 Type 2 diabetes and 6 quantitative traits PADI3 intron 17848626 rs3003426 chr1 17588162 G A 1.39E-05 Serum metabolites PADI3 intron 19043545 rs3003429 chr1 17591679 T C 4.00E-07 Pulmonary function (interaction) PADI3 intron 23284291 rs2977293 chr1 17599444 C T 8.79E-05 Cognitive test performance PADI3 intron 20125193 rs2977293 chr1 17599444 C T 5.77E-05 Heart Rate PADI3 intron pha003053 rs2977293 chr1 17599444 C T 1.14E-06 Heart Rate PADI3 intron pha003054 rs11585118 chr1 17605774 C A 2.24E-08 Common traits (Other) PADI3 intron 20585627 rs12568771 chr1 17613809 A G 1.94E-04 Age-related macular degeneration / / 22125219 rs7548900 chr1 17622654 C A 3.83E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1886302 chr1 17635396 A G 1.63E-04 Age-related macular degeneration PADI4 intron 22125219 rs10788664 chr1 17647475 C T 0.00076 fMRI brain tests in schizophrenia PADI4 intron 22440650 rs10888024 chr1 17649796 A G 0.000224 fMRI brain tests in schizophrenia PADI4 intron 22440650 rs1748041 chr1 17655407 C T 0.000268 Schizophrenia PADI4 intron 22440650 rs11203366 chr1 17657534 G A 1.57E-07 Rheumatoid arthritis PADI4 missense 21452313 rs11203366 chr1 17657534 G A 0.000436 fMRI brain tests in schizophrenia PADI4 missense 22440650 rs11203367 chr1 17657616 T C 0.000285 fMRI brain tests in schizophrenia PADI4 missense 22440650 rs1635597 chr1 17659556 A G 9.19E-04 Multiple complex diseases PADI4 intron 17554300 rs874881 chr1 17660499 G C 8.18E-04 Response to taxane treatment (placlitaxel) PADI4 missense 23006423 rs1635594 chr1 17661805 A G 7.30E-05 Rheumatoid arthritis PADI4 intron 24782177 rs1748035 chr1 17661996 T C 7.05E-04 Multiple complex diseases PADI4 intron 17554300 rs1748035 chr1 17661996 T C 0.000313 fMRI brain tests in schizophrenia PADI4 intron 22440650 rs1748033 chr1 17662662 T C 0.000313 fMRI brain tests in schizophrenia PADI4 cds-synon 22440650 rs1635586 chr1 17664770 A G 5.23E-05 Rheumatoid arthritis PADI4 intron 21452313 rs11203368 chr1 17666508 C T 6.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PADI4 intron 20877124 rs11203368 chr1 17666508 C T 2.61E-08 Rheumatoid arthritis PADI4 intron 21452313 rs2301888 chr1 17672730 G A 1.00E-18 Rheumatoid arthritis PADI4 intron 24390342 rs2301888 chr1 17672730 G A 6.00E-09 Rheumatoid arthritis PADI4 intron 24390342 rs2301888 chr1 17672730 G A 8.00E-13 Rheumatoid arthritis PADI4 intron 24390342 rs2240339 chr1 17674108 C T 1.46E-10 Rheumatoid arthritis (CCP positive) PADI4 intron 23143596 rs2240339 chr1 17674108 C T 2.57E-10 Rheumatoid arthritis PADI4 intron 23143596 rs2240336 chr1 17674402 C T 5.90E-09 Rheumatoid arthritis PADI4 intron 23143596 rs2240336 chr1 17674402 C T 5.91E-09 Rheumatoid arthritis (CCP positive) PADI4 intron 23143596 rs2240335 chr1 17674537 C A 8.01E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PADI4 cds-synon 20877124 rs2240335 chr1 17674537 C A 2.00E-08 Rheumatoid arthritis PADI4 cds-synon 21452313 rs2240335 chr1 17674537 C A 2.00E-08 Rheumatoid arthritis PADI4 cds-synon 21505073 rs2240335 chr1 17674537 C A 2.30E-05 Rheumatoid arthritis PADI4 cds-synon 21673997 rs7538876 chr1 17722363 G A 4.00E-12 Basal cell carcinoma PADI6 intron 18849993 rs7538876 chr1 17722363 G A 4.00E-12 Nasopharyngeal carcinoma PADI6 intron 20512145 rs7538876 chr1 17722363 G A 7.00E-14 Basal cell carcinoma PADI6 intron 24403052 rs6586542 chr1 17763566 G C 8.56E-05 Lymphocyte counts RCC2 intron 22286170 rs2883272 chr1 17773159 G A 1.41E-05 Intelligence / / 21826061 rs2883272 chr1 17773159 G A 9.42E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6659366 chr1 17800419 A G 2.69E-05 Body mass index / / 17255346 rs2254135 chr1 17834742 C T 3.00E-06 Response to hepatitis C treatment / / 22095909 rs2248129 chr1 17855824 C T 8.09E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs2244300 chr1 17857601 G A 4.73E-05 Aging (time to event) / / 21782286 rs2477735 chr1 17869179 T C 2.70E-04 Alcohol dependence ARHGEF10L intron 20201924 rs10788679 chr1 17916962 A G 5.11E-06 Esophageal cancer (squamous cell) ARHGEF10L intron 22960999 rs6693036 chr1 17919817 T C 3.00E-06 Obesity-related traits ARHGEF10L intron 23251661 rs17469160 chr1 17998920 G C 6.95E-04 Type 2 diabetes ARHGEF10L intron 17463246 rs7522419 chr1 18033499 A G 3.58E-05 Cognitive impairment induced by topiramate / / 22091778 rs7522419 chr1 18033499 A G 6.46E-06 Height / / pha003010 rs7522419 chr1 18033499 A G 9.95E-07 Height / / pha003011 rs2185324 chr1 18040004 C T 2.18E-06 Height / / pha003011 rs1553400 chr1 18042035 A G 4.64E-06 Height / / pha003010 rs1553400 chr1 18042035 A G 6.10E-07 Height / / pha003011 rs260514 chr1 18052645 G A 0.0001 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer / / 21245432 rs7512028 chr1 18059244 T C 5.76E-04 Multiple complex diseases / / 17554300 rs7534822 chr1 18086999 T G 2.15E-04 Alzheimer's disease (late onset) ACTL8 intron 21379329 rs7547331 chr1 18090929 T C 5.86E-05 Multiple complex diseases ACTL8 intron 17554300 rs10888060 chr1 18099283 G A 3.07E-04 Alzheimer's disease (late onset) ACTL8 intron 21379329 rs11577496 chr1 18105498 G A 2.60E-04 Alzheimer's disease (late onset) ACTL8 intron 21379329 rs16830757 chr1 18124527 C T 0.0000596 Primary sclerosing cholangitis ACTL8 intron 23603763 rs500035 chr1 18132269 G A 4.29E-04 Multiple complex diseases ACTL8 intron 17554300 rs1890788 chr1 18156864 A G 5.50E-06 Urinary metabolites / / 21572414 rs7545559 chr1 18158156 C T 5.50E-06 Urinary metabolites / / 21572414 rs12097284 chr1 18159342 C T 2.46E-05 Intelligence / / 21826061 rs12097284 chr1 18159342 C T 0.0002 Migraine / / 22678113 rs495347 chr1 18163922 C T 6.06E-05 Sarcoidosis / / 19165924 rs807455 chr1 18171347 C T 6.91E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs697760 chr1 18179816 G T 6.54E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs647619 chr1 18183424 G A 3.00E-04 Personality dimensions / / 23903073 rs587276 chr1 18193604 C T 2.10E-06 Urinary metabolites / / 21572414 rs11203223 chr1 18196800 T G 6.90E-07 Urinary metabolites / / 21572414 rs11203224 chr1 18201633 G A 2.30E-06 Urinary metabolites / / 21572414 rs7538231 chr1 18202181 G A 1.30E-06 Urinary metabolites / / 21572414 rs578987 chr1 18203380 C G 3.13E-04 Type 2 diabetes / / 17463246 rs1339934 chr1 18236459 A G 6.78E-06 Obesity-related traits / / 23251661 rs1339934 chr1 18236459 A G 9.18E-04 Alcohol dependence / / 24277619 rs12087706 chr1 18241309 C T 9.12E-04 Alzheimer's disease / / 17998437 rs6686929 chr1 18244707 C T 3.00E-06 Obesity-related traits / / 23251661 rs673567 chr1 18278257 G A 2.70E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs673567 chr1 18278257 G A 4.89E-05 Osteoarthritis (knee and hip) / / 21177295 rs673567 chr1 18278257 G A 8.00E-04 Osteoarthritis (knee and hip) / / 21177295 rs1192573 chr1 18286068 G A 0.00008906 Sarcoidosis / / 22952805 rs794229 chr1 18289233 G T 1.98E-04 Type 2 diabetes / / 17463246 rs4920402 chr1 18289481 G A 8.20E-04 Multiple complex diseases / / 17554300 rs4920402 chr1 18289481 G A 2.71E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs16861326 chr1 18294487 G A 2.00E-06 Erectile dysfunction and prostate cancer treatment / / 20932654 rs2095842 chr1 18297407 A G 2.56E-04 Multiple complex diseases / / 17554300 rs2095842 chr1 18297407 A G 8.25E-05 Alzheimer's disease / / 17998437 rs2095842 chr1 18297407 A G 8.95E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs871644 chr1 18297688 G A 2.40E-04 Multiple complex diseases / / 17554300 rs871644 chr1 18297688 G A 8.56E-05 Alzheimer's disease / / 17998437 rs871644 chr1 18297688 G A 8.95E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1192633 chr1 18304543 G A 9.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs11588830 chr1 18314621 C T 1.87E-04 Multiple complex diseases / / 17554300 rs11588830 chr1 18314621 C T 5.83E-04 Alzheimer's disease / / 17998437 rs16861410 chr1 18335597 C G 0.0001988 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16861410 chr1 18335597 C G 1.99E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1192621 chr1 18337250 T A 8.20E-05 Thyroid peroxidase antibody levels / / 24586183 rs1192622 chr1 18337268 A G 6.93E-04 Type 2 diabetes / / 17463246 rs1192625 chr1 18339791 T C 7.52E-06 Carotenoid and tocopherol levels / / 19185284 rs1108624 chr1 18342807 G A 0.0002527 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1108624 chr1 18342807 G A 2.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs794237 chr1 18342964 A G 3.99E-04 Alzheimer's disease / / 24755620 rs16861446 chr1 18348784 C T 0.0002954 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16861446 chr1 18348784 C T 2.95E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs16861481 chr1 18360161 G A 0.0001653 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16861481 chr1 18360161 G A 1.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs16861517 chr1 18374542 G A 0.0004773 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16861517 chr1 18374542 G A 4.77E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs9659407 chr1 18387310 G A 8.58E-04 Heart Failure / / pha002884 rs9286088 chr1 18391974 A C 1.30E-05 stroke (ischemic) / / 17434096 rs4920421 chr1 18392608 C T 5.50E-05 Endometriosis / / 21151130 rs4920422 chr1 18392752 C A 2.52E-04 Alcohol dependence / / 21314694 rs4920425 chr1 18408139 C T 8.06E-06 Heart Failure / / pha002884 rs9804128 chr1 18425011 A G 2.00E-09 Venous thromboembolism (gene x gene interaction) / / 23509962 rs12739708 chr1 18426428 C T 3.27E-04 Myopia (pathological) / / 21095009 rs12724674 chr1 18431501 G A 5.96E-13 Multiple complex diseases / / 17554300 rs1342569 chr1 18438351 T C 4.17E-04 Myopia (pathological) IGSF21 intron 21095009 rs10443386 chr1 18444514 C A 4.10E-05 White matter hyperintensity burden IGSF21 intron 21681796 rs16861578 chr1 18447490 C A 2.99E-04 Response to taxane treatment (placlitaxel) IGSF21 intron 23006423 rs12735521 chr1 18450321 C T 4.70E-05 White matter hyperintensity burden IGSF21 intron 21681796 rs987293 chr1 18451900 A G 2.20E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) IGSF21 intron 24023788 rs9726285 chr1 18484945 G C 2.50E-05 Urinary metabolites IGSF21 intron 21572414 rs17435018 chr1 18487906 C T 2.01E-05 Response to citalopram treatment IGSF21 intron 19846067 rs4920300 chr1 18490061 C T 1.34E-04 Vaspin levels IGSF21 intron 22907691 rs4920300 chr1 18490061 C T 0.0001343 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit IGSF21 intron 22907730 rs9728569 chr1 18510033 T G 9.75E-05 Cholesterol IGSF21 intron pha003083 rs1033190 chr1 18528848 G T 6.15E-04 Alcohol dependence IGSF21 intron 20201924 rs4920311 chr1 18563991 G C 6.60E-04 Atrial fibrillation IGSF21 intron 21846873 rs371505 chr1 18586420 C A 8.88E-04 Alzheimer's disease IGSF21 intron 17998437 rs516656 chr1 18589743 C G 5.37E-04 Alzheimer's disease IGSF21 intron 17998437 rs1555219 chr1 18630150 T C 8.84E-04 Coronary Artery Disease IGSF21 intron 17634449 rs11260978 chr1 18632801 A G 3.91E-04 Atopy IGSF21 intron 21625490 rs761585 chr1 18633940 G A 7.70E-04 Coronary Artery Disease IGSF21 intron 17634449 rs4920475 chr1 18643335 C T 9.09E-04 Multiple complex diseases IGSF21 intron 17554300 rs4920478 chr1 18655339 G A 5.00E-06 Urinary metabolites IGSF21 intron 21572414 rs33947700 chr1 18665124 C T 9.55E-04 Multiple complex diseases IGSF21 intron 17554300 rs542634 chr1 18672774 G A 4.08E-05 Height IGSF21 intron pha003011 rs16861827 chr1 18678170 C T 2.00E-04 Pancreatic cancer IGSF21 intron 23180869 rs16861827 chr1 18678170 C T 5.91E-05 Tuberculosis IGSF21 intron 24057671 rs12125819 chr1 18696135 G A 3.94E-04 Suicide attempts in bipolar disorder IGSF21 intron 21423239 rs12566510 chr1 18705694 A G 9.18E-04 Multiple complex diseases / / 17554300 rs10492995 chr1 18707373 A C 2.71E-04 Fibrinogen / / 17255346 rs10492995 chr1 18707373 A C 4.67E-04 HIV-1 viral setpoint / / 17641165 rs7538442 chr1 18716278 A G 7.04E-05 Orofacial clefts / / 20023658 rs1336131 chr1 18722737 G T 5.74E-05 Diabetes (gestational) / / 22233651 rs1336122 chr1 18761124 A G 8.66E-05 Bipolar disorder and schizophrenia / / 20889312 rs1336128 chr1 18765308 A G 5.35E-04 Multiple complex diseases / / 17554300 rs1568339 chr1 18766761 C A 2.48E-05 Bipolar disorder and schizophrenia / / 20889312 rs7535812 chr1 18786779 C G 1.12E-04 Coronary heart disease / / 21606135 rs1414642 chr1 18787446 C T 2.88E-06 Phospholipid levels (plasma) / / 21829377 rs3007728 chr1 18794241 C T 1.67E-06 Phospholipid levels (plasma) / / 21829377 rs3007729 chr1 18795255 T C 8.46E-06 Lung adenocarcinoma / / 19836008 rs3007729 chr1 18795255 T C 5.00E-06 Diabetic retinopathy / / 21441570 rs16862008 chr1 18801486 G A 3.33E-06 Phospholipid levels (plasma) / / 21829377 rs7528206 chr1 18807117 T C 5.06E-04 Response to alcohol consumption (flushing response) / / 24277619 rs2992745 chr1 18809896 A T 8.60E-05 Response to statin therapy KLHDC7A UTR-3 20339536 rs3007719 chr1 18811668 T C 8.70E-05 Response to statin therapy KLHDC7A UTR-3 20339536 rs72646406 chr1 18815045 A G 0.0000556 Sarcoidosis / / 22952805 rs909950 chr1 18824363 G A 3.12E-04 Type 2 diabetes / / 17463246 rs17351871 chr1 18838322 G C 8.75E-04 Obesity (extreme) / / 21935397 rs12401403 chr1 18863502 A G 2.34E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs114799364 chr1 18900554 C T 2.72E-06 Prostate cancer / / 24185611 rs4920334 chr1 18913558 T C 7.68E-04 Multiple complex diseases / / 17554300 rs4920516 chr1 18913618 G C 7.63E-04 Multiple complex diseases / / 17554300 rs6684839 chr1 18920685 G A 8.60E-06 Urinary metabolites / / 21572414 rs4920520 chr1 18929842 G A 8.22E-05 Cleft lip / / 20436469 rs4920520 chr1 18929842 G A 6.45E-06 Orofacial clefts / / 22863734 rs4920522 chr1 18940380 C T 4.61E-06 Cleft lip / / 20436469 rs4920522 chr1 18940380 C T 9.41E-07 Orofacial clefts / / 22863734 rs7541797 chr1 18951985 G C 8.70E-06 Urinary metabolites / / 21572414 rs17352100 chr1 18952112 C T 6.55E-07 Cleft lip / / 20436469 rs17352100 chr1 18952112 C T 8.70E-06 Urinary metabolites / / 21572414 rs17352100 chr1 18952112 C T 3.25E-07 Orofacial clefts / / 22863734 rs766325 chr1 18956458 G A 2.21E-06 Cleft lip PAX7 nearGene-5 20436469 rs766325 chr1 18956458 G A 7.39E-07 Orofacial clefts PAX7 nearGene-5 22863734 rs10907325 chr1 18964021 A T 2.54E-04 Body mass index PAX7 intron 21701565 rs10907325 chr1 18964021 A T 5.31E-04 Body mass index PAX7 intron 21701565 rs7364475 chr1 18965061 C T 2.77E-04 Orofacial clefts PAX7 intron 22863734 rs10907326 chr1 18965360 T G 2.90E-04 Body mass index PAX7 intron 21701565 rs10907326 chr1 18965360 T G 6.00E-04 Body mass index PAX7 intron 21701565 rs11583072 chr1 18966007 G T 1.42E-06 Orofacial clefts PAX7 intron 22863734 rs56675509 chr1 18971634 G C 1.03E-05 Orofacial clefts PAX7 intron 22863734 rs9439713 chr1 18972776 G A 2.87E-06 Orofacial clefts PAX7 intron 22863734 rs9439714 chr1 18976489 T C 7.02E-08 Orofacial clefts PAX7 intron 22863734 rs4920524 chr1 18978372 T G 4.94E-08 Orofacial clefts PAX7 intron 22863734 rs6695765 chr1 18979320 T C 2.43E-06 Cleft lip PAX7 intron 20436469 rs6695765 chr1 18979320 T C 1.12E-06 Orofacial clefts PAX7 intron 22863734 rs742071 chr1 18979874 G T 1.57E-07 Cleft lip PAX7 intron 20436469 rs742071 chr1 18979874 G T 7.00E-09 Orofacial clefts PAX7 intron 22863734 rs6659735 chr1 18983697 G A,C,T 8.13E-06 Cleft lip PAX7 intron 20436469 rs6659735 chr1 18983697 G A,C,T 1.36E-06 Orofacial clefts PAX7 intron 22863734 rs56075776 chr1 18986508 G A 2.16E-06 Orofacial clefts PAX7 intron 22863734 rs1339063 chr1 18989575 A T 5.84E-06 Orofacial clefts PAX7 intron 22863734 rs2236835 chr1 18990251 G A 8.00E-06 Body mass index PAX7 intron 23669352 rs4920338 chr1 18990793 C T 2.36E-05 Cleft lip PAX7 intron 20436469 rs4920338 chr1 18990793 C T 8.39E-07 Orofacial clefts PAX7 intron 22863734 rs4920339 chr1 18991005 C T 1.29E-06 Orofacial clefts PAX7 intron 22863734 rs12141588 chr1 18995326 C T 2.84E-04 Suicide attempts in bipolar disorder PAX7 intron 21423239 rs16862125 chr1 18999794 C A 5.00E-04 Smoking initiation PAX7 intron 24665060 rs2236832 chr1 18999831 A G 9.70E-05 Waist Circumference PAX7 intron pha003025 rs545793 chr1 19016522 G C 3.05E-04 Smoking initiation PAX7 intron 24665060 rs2236826 chr1 19019980 T C 5.34E-04 Smoking initiation PAX7 intron 24665060 rs2236824 chr1 19032272 G C 2.00E-06 Response to amphetamines PAX7 intron 22952603 rs624761 chr1 19044877 C T 7.65E-05 Amyotrophic Lateral Sclerosis PAX7 intron 17827064 rs2743189 chr1 19056382 C T 6.91E-04 Alcohol dependence PAX7 intron 21314694 rs2236805 chr1 19057730 G A 2.98E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) PAX7 intron 24023788 rs1160680 chr1 19080506 A G 8.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7414734 chr1 19094738 G A 5.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4920344 chr1 19104381 A G 6.19E-04 Multiple complex diseases / / 17554300 rs6669544 chr1 19109036 C G 4.40E-06 Urinary metabolites / / 21572414 rs4920537 chr1 19109183 C T 4.87E-05 Cognitive impairment induced by topiramate / / 22091778 rs12566799 chr1 19123033 G A 2.26E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7411058 chr1 19134260 A G 2.51E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs7411577 chr1 19134834 A C 8.12E-05 Alzheimer's disease (age of onset) / / 22005931 rs7417542 chr1 19135214 G A 8.18E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12063142 chr1 19139517 C T 5.00E-07 Parkinson's disease / / 20070850 rs72651812 chr1 19141142 C G 1.88E-05 Acne (severe) / / 24927181 rs6662718 chr1 19169613 G A 2.37E-05 Alzheimer's disease (age of onset) TAS1R2 intron 22005931 rs28441017 chr1 19206334 G A 9.00E-06 Anorexia nervosa ALDH4A1 intron 23568457 rs4911977 chr1 19239515 T C 3.55E-05 Multiple complex diseases IFFO2 intron 17554300 rs6698642 chr1 19255671 C T 2.32E-07 Facial morphology IFFO2 intron 22341974 rs4912013 chr1 19284564 T C 1.45E-04 Alcohol dependence / / 21314694 rs16862426 chr1 19321495 C T 9.00E-08 Methotrexate phramacokinetics (acute lymphoblastic leukemia) / / 19901119 rs6690097 chr1 19323050 G C 5.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs7523455 chr1 19332076 A G 2.00E-07 Methotrexate phramacokinetics (acute lymphoblastic leukemia) / / 19901119 rs28829049 chr1 19349281 C T 6.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs7527580 chr1 19378508 G A 7.67E-05 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs7527580 chr1 19378508 G A 8.72E-04 Response to radiotherapy in cancer (late toxicity) / / 24785509 rs7527580 chr1 19378508 G A 7.13E-04 Stroke / / pha002887 rs12123383 chr1 19386585 A C 4.00E-06 Response to amphetamines / / 22952603 rs3748761 chr1 19400691 C G 8.54E-04 Alzheimer's disease UBR4 nearGene-3 17998437 rs10158468 chr1 19402390 T C 9.95E-04 Response to cytidine analogues (gemcitabine) UBR4 intron 24483146 rs2146866 chr1 19405237 A G 8.46E-04 Response to cytidine analogues (gemcitabine) UBR4 intron 24483146 rs12740975 chr1 19437923 G A 6.43E-04 Schizophrenia UBR4 intron 19197363 rs2274001 chr1 19464773 C T 5.94E-04 Response to cytidine analogues (gemcitabine) UBR4 intron 24483146 rs1009806 chr1 19500551 T C 8.07E-04 Schizophrenia UBR4 intron 19197363 rs710880 chr1 19564049 G A 4.84E-04 Multiple complex diseases KIAA0090 intron 17554300 rs710865 chr1 19568972 A G 1.00E-07 Brain structure KIAA0090 intron 20171287 rs10917275 chr1 19576035 T C 6.83E-06 Serum metabolites KIAA0090 intron 19043545 rs2073102 chr1 19583330 G C 9.98E-04 Alzheimer's disease MRTO4 intron 24755620 rs1042380 chr1 19584004 G A 1.54E-05 Serum metabolites MRTO4 cds-synon 19043545 rs7527253 chr1 19593199 T C 7.79E-04 Alzheimer's disease / / 24755620 rs10917331 chr1 19604101 G A 6.88E-04 Alzheimer's disease / / 24755620 rs1738025 chr1 19609254 T C 1.42E-04 Height AKR7A3 missense 17255346 rs1738023 chr1 19611241 T C 1.26E-04 Height AKR7A3 missense 17255346 rs859217 chr1 19640698 G A 9.37E-04 Multiple complex diseases PQLC2 intron 17554300 rs2064378 chr1 19644855 G A 3.70E-04 Suicide attempts in bipolar disorder PQLC2 intron 21041247 rs4912069 chr1 19645673 G A 3.98E-04 Suicide attempts in bipolar disorder PQLC2 intron 21041247 rs2268809 chr1 19667552 C T 3.83E-04 Multiple complex diseases CAPZB intron 17554300 rs72651465 chr1 19671766 T A 4.06E-04 Acne (severe) CAPZB intron 24927181 rs191942 chr1 19691754 G A 8.33E-04 Multiple complex diseases CAPZB intron 17554300 rs214321 chr1 19693128 C A 5.71E-05 Multiple complex diseases CAPZB intron 17554300 rs10917434 chr1 19707302 G A 8.72E-04 Type 2 diabetes CAPZB intron 17463246 rs7667 chr1 19718824 G A 8.00E-06 Crohn's disease and psoriasis CAPZB intron 22482804 rs12403041 chr1 19730927 A G 8.03E-04 Multiple complex diseases CAPZB intron 17554300 rs4244002 chr1 19738190 C T 5.80E-04 Multiple complex diseases CAPZB intron 17554300 rs1472565 chr1 19755030 T C 6.30E-05 Hypothyroidism CAPZB intron 22493691 rs2088828 chr1 19757646 C A 2.59E-04 Alzheimer's disease (late onset) CAPZB intron 21379329 rs12137160 chr1 19763379 C T 8.47E-04 Multiple complex diseases CAPZB intron 17554300 rs12137162 chr1 19763396 C A 8.25E-04 Multiple complex diseases CAPZB intron 17554300 rs10799810 chr1 19764032 G A 2.43E-04 Alzheimer's disease (late onset) CAPZB intron 21379329 rs4911995 chr1 19765004 G C 1.70E-04 Multiple complex diseases CAPZB intron 17554300 rs4911996 chr1 19765205 G C 8.24E-04 Multiple complex diseases CAPZB intron 17554300 rs12045440 chr1 19765518 T G 5.48E-04 Type 2 diabetes CAPZB intron 17463246 rs12045440 chr1 19765518 T G 2.00E-11 Thyroid volume CAPZB intron 21565293 rs12045440 chr1 19765518 T G 3.00E-14 Thyroid volume CAPZB intron 21565293 rs4911997 chr1 19765669 G A 3.22E-04 Multiple complex diseases CAPZB intron 17554300 rs10492997 chr1 19769371 C T 3.49E-04 Multiple complex diseases CAPZB intron 17554300 rs1002365 chr1 19797248 T C 9.90E-05 Hypothyroidism CAPZB intron 22493691 rs3813986 chr1 19801268 C T 2.76E-04 Multiple complex diseases CAPZB intron 17554300 rs10799817 chr1 19805997 C G 8.22E-04 Type 2 diabetes CAPZB intron 17463246 rs924519 chr1 19806259 C T 7.67E-04 Type 2 diabetes CAPZB intron 17463246 rs6664461 chr1 19809171 C T 9.57E-06 Insulin Resistance CAPZB intron pha003062 rs6664461 chr1 19809171 C T 1.27E-05 Insulin-related traits CAPZB intron pha003063 rs1995311 chr1 19820119 T G 1.87E-04 Tuberculosis / / 22306650 rs873095 chr1 19823329 G A 4.70E-08 Thyroid function / / 20826269 rs2314146 chr1 19824008 A G 5.80E-06 Thyroid stimulating hormone / / 24852370 rs6683419 chr1 19827780 G A 3.00E-07 Thyroid stimulating hormone / / 24852370 rs16822442 chr1 19827970 A G 3.30E-08 Thyroid function / / 20826269 rs11807599 chr1 19831939 C T 6.00E-08 Thyroid function / / 20826269 rs11806434 chr1 19832437 G A 5.70E-08 Thyroid function / / 20826269 rs12136721 chr1 19832987 C G 5.70E-08 Thyroid function / / 20826269 rs4394682 chr1 19837537 A G 4.00E-08 Thyroid function / / 20826269 rs12138950 chr1 19839115 A C 3.50E-08 Thyroid function / / 20826269 rs12138950 chr1 19839115 A C 3.00E-18 Thyroid volume / / 21565293 rs568931048 chr1 19839115 A AC 3.50E-08 Thyroid function / / 20826269 rs568931048 chr1 19839115 A AC 3.00E-18 Thyroid volume / / 21565293 rs10799824 chr1 19841174 G A 3.50E-08 Thyroid function / / 20826269 rs10799824 chr1 19841174 G A 1.00E-08 Thyroid hormone levels / / 23408906 rs10799824 chr1 19841174 G A 3.00E-14 Thyroid hormone levels / / 23408906 rs10799824 chr1 19841174 G A 4.00E-21 Thyroid hormone levels / / 23408906 rs10917468 chr1 19843354 T C 1.00E-14 Thyroid volume / / 21565293 rs10917468 chr1 19843354 T C 0.00025 Prostate cancer / / 23555315 rs10917469 chr1 19843576 A G 9.95E-04 Multiple complex diseases / / 17554300 rs10917469 chr1 19843576 A G 3.20E-08 Thyroid function / / 20826269 rs6426809 chr1 19858271 C T 4.51E-04 Alzheimer's disease / / 17998437 rs10917477 chr1 19861106 A G 2.00E-08 Thyroid function / / 22494929 rs10917477 chr1 19861106 A G 6.80E-05 Blood Pressure / / pha003048 rs4912122 chr1 19876438 A G 8.79E-04 Multiple complex diseases / / 17554300 rs10917493 chr1 19882170 T G 2.42E-05 Insulin Resistance / / pha003062 rs717536 chr1 19905646 G C 4.42E-04 Multiple complex diseases / / 17554300 rs1770480 chr1 19916784 C T 4.41E-08 Thyroid function / / 22494929 rs2745217 chr1 19921747 C T 1.46E-08 Thyroid function / / 22494929 rs2792043 chr1 19924662 A C 2.77E-08 Thyroid function MINOS1 intron 22494929 rs860847 chr1 19927553 C A 7.04E-05 Adipocyte fatty acid-binding protein concentration,in serum MINOS1 intron 21863005 rs1770483 chr1 19930252 T A 7.03E-04 Multiple complex diseases MINOS1 intron 17554300 rs1770483 chr1 19930252 T A 9.34E-05 Adipocyte fatty acid-binding protein concentration,in serum MINOS1 intron 21863005 rs1320978 chr1 19947973 A G 2.25E-08 Thyroid function MINOS1 intron 22494929 rs10917504 chr1 19965927 C A 1.00E-04 Prostate cancer C1orf151-NBL1 intron 21743057 rs6693503 chr1 19987294 A G 0.0000161 Uterine leiomyomata / / 23040493 rs16822732 chr1 20015300 G A 5.30E-05 Asthma TMCO4 intron 11022011 rs2050121 chr1 20016849 G A 6.76E-05 Blood pressure (response to calcium channel blocker) TMCO4 intron 24192120 rs3748748 chr1 20018195 G A 6.63E-05 Asthma TMCO4 intron 11022011 rs3748748 chr1 20018195 G A 4.78E-04 Orofacial clefts TMCO4 intron 22863734 rs3934191 chr1 20026572 A G 3.51E-04 Response to cytidine analogues (gemcitabine) TMCO4 intron 24483146 rs3929668 chr1 20052373 C T 6.97E-04 Lymphocyte counts TMCO4 intron 22286170 rs10917526 chr1 20056933 G A 2.30E-05 Urinary metabolites TMCO4 intron 21572414 rs3850533 chr1 20061456 T C 2.40E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) TMCO4 intron 23648065 rs12140071 chr1 20110436 T C 9.81E-05 Parent of origin effect on language impairment (paternal) TMCO4 intron 24571439 rs10799837 chr1 20135612 G A 8.67E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1317209 chr1 20140036 G A 2.00E-10 Ulcerative colitis / / 20228799 rs1317209 chr1 20140036 G A 2.00E-10 Asthma / / 21907864 rs3767216 chr1 20140340 A G 2.77E-05 Sudden cardiac arrest / / 21658281 rs3806308 chr1 20142866 C T 7.00E-09 Ulcerative colitis / / 19122664 rs10799839 chr1 20148249 C T 4.43E-05 Blood Pressure / / pha003045 rs10799839 chr1 20148249 C T 4.51E-05 Blood Pressure / / pha003047 rs10917552 chr1 20158334 T C 0.0005392 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs10917552 chr1 20158334 T C 5.39E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2314762 chr1 20158604 T G 6.46E-05 Blood pressure / / 24001895 rs4271183 chr1 20163290 T G 2.48E-05 Pulmonary function / / 19300500 rs12137940 chr1 20165383 C A 2.72E-05 Pulmonary function / / 19300500 rs6426833 chr1 20171860 G A 5.00E-13 Ulcerative colitis / / 19122664 rs6426833 chr1 20171860 G A 2.00E-11 Ulcerative colitis / / 19915572 rs6426833 chr1 20171860 G A 2.00E-21 Ulcerative colitis / / 20228799 rs6426833 chr1 20171860 G A 4.00E-35 Ulcerative colitis / / 21297633 rs6426833 chr1 20171860 G A 2.00E-68 Ulcerative colitis / / 23128233 rs6426833 chr1 20171860 G A 7.22E-08 Ulcerative colitis / / 23511034 rs10917558 chr1 20173972 C T 2.99E-05 Pulmonary function / / 19300500 rs6690967 chr1 20183342 C T 4.42E-04 Blood pressure / / 17255346 rs12117495 chr1 20183445 A G 6.54E-05 Pulmonary function / / 19300500 rs16823043 chr1 20184603 G A 2.88E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7531128 chr1 20187321 G A 2.00E-05 Urinary metabolites / / 21572414 rs6686814 chr1 20187511 C T 7.44E-05 Longevity / / 20304771 rs16823061 chr1 20190672 G A 7.05E-05 Longevity / / 20304771 rs7517912 chr1 20192876 A T 6.64E-05 Longevity / / 20304771 rs12064952 chr1 20197978 G C 5.00E-05 Longevity / / 20304771 rs4654903 chr1 20200990 A G 7.00E-09 Ulcerative colitis / / 23511034 rs12124726 chr1 20209469 A C 2.55E-08 Sickle cell anemia (severity) OTUD3 intron 20029952 rs4654910 chr1 20213087 C A 4.70E-05 Longevity OTUD3 intron 20304771 rs1339717 chr1 20222500 G A 8.52E-04 Alzheimer's disease OTUD3 intron 22005930 rs4654925 chr1 20227723 G C,T 9.00E-22 Ulcerative colitis OTUD3 intron 20228798 rs4654925 chr1 20227723 G C,T 9.00E-22 Multiple sclerosis OTUD3 intron 22190364 rs10916668 chr1 20233086 G A 7.82E-05 Pulmonary function OTUD3 missense 19300500 rs10492999 chr1 20237760 A G 7.83E-05 Pulmonary function OTUD3 UTR-3 19300500 rs1046548 chr1 20238343 A G 9.66E-04 Suicide attempts in bipolar disorder OTUD3 UTR-3 21423239 rs17401847 chr1 20238466 A G 1.35E-05 Longevity OTUD3 UTR-3 20304771 rs12028511 chr1 20247674 C A 1.97E-04 Alzheimer's disease (late onset) PLA2G2E intron 21379329 rs2233687 chr1 20250799 C T 3.89E-05 Waist-Hip Ratio / / pha003029 rs1093733 chr1 20258473 T C 6.72E-04 Alzheimer's disease / / 22005930 rs818968 chr1 20279405 C T 4.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs4655010 chr1 20287919 C A 1.14E-05 Post-operative nausea and vomiting / / 21694509 rs12568139 chr1 20311676 A G 3.33E-04 Smoking quantity / / 24665060 rs3767225 chr1 20399643 T C 6.64E-04 Type 2 diabetes PLA2G5 intron 17463246 rs10916704 chr1 20400991 G T 1.47E-10 Cholesterol,total PLA2G5 intron 23063622 rs10916704 chr1 20400991 G T 4.52E-08 LDL cholesterol PLA2G5 intron 23063622 rs11573213 chr1 20402010 A C 0.000000331 Cholesterol,total PLA2G5 intron 23063622 rs576634 chr1 20406545 C T 0.000000425 Triglycerides PLA2G5 intron 23063622 rs576634 chr1 20406545 C T 1.60E-10 Cholesterol,total PLA2G5 intron 23063622 rs11573244 chr1 20407582 C T 1.39E-08 LDL cholesterol PLA2G5 intron 23063622 rs11573244 chr1 20407582 C T 1.45E-08 Cholesterol,total PLA2G5 intron 23063622 rs10916705 chr1 20413887 C G 8.65E-04 Depression (quantitative trait) PLA2G5 intron 20800221 rs11573288 chr1 20416794 C T 9.05E-04 Depression (quantitative trait) PLA2G5 intron 20800221 rs11573288 chr1 20416794 C T 2.18E-04 Smoking quantity PLA2G5 intron 24665060 rs11573291 chr1 20417765 G A 2.55E-04 Multiple complex diseases PLA2G5 UTR-3 17554300 rs6699362 chr1 20423099 T G 7.55E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4655155 chr1 20427541 C T 1.08E-04 Alzheimer's disease (late onset) / / 21379329 rs492738 chr1 20429861 C A 4.17E-04 Alzheimer's disease (late onset) / / 21379329 rs1567102 chr1 20444473 C T 0.00079897 Hypertension (early onset hypertension) PLA2G2D intron 22479346 rs623784 chr1 20452434 A C,G,T 8.67E-06 Obesity-related traits / / 23251661 rs12722987 chr1 20455220 C A 7.00E-06 Obesity-related traits / / 23251661 rs12745152 chr1 20469854 G A 3.58E-05 Cardiovascular disease PLA2G2F intron pha003064 rs12025316 chr1 20494741 C G 4.32E-04 Response to cytidine analogues (gemcitabine) PLA2G2C intron 24483146 rs2301472 chr1 20498914 C T 4.41E-04 Response to cytidine analogues (gemcitabine) PLA2G2C intron 24483146 rs2301475 chr1 20499168 T C 1.06E-05 Response to cytidine analogues (gemcitabine) PLA2G2C intron 24483146 rs2301475 chr1 20499168 T C 8.65E-04 Response to cytadine analogues (cytosine arabinoside) PLA2G2C intron 24483146 rs10916718 chr1 20501442 T C 1.57E-05 Platelet counts PLA2G2C intron 21507922 rs2301478 chr1 20501974 G A 1.87E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10799612 chr1 20502761 C G 3.30E-05 Blood pressure (response to angiotensin II receptor blocker) / / 24192120 rs3179690 chr1 20518226 G A 3.11E-08 Secreted IFN-gamma response to smallpox vaccine UBXN10 UTR-3 22661280 rs7517797 chr1 20532401 T C 7.11E-04 Multiple complex diseases / / 17554300 rs10799615 chr1 20541370 A G 0.0002 Migraine / / 22678113 rs7533370 chr1 20542980 A G 9.51E-04 Multiple complex diseases / / 17554300 rs6692412 chr1 20561095 C T 8.85E-04 Multiple complex diseases / / 17554300 rs4655165 chr1 20562389 G A 2.74E-05 Cleft lip / / 20436469 rs2157508 chr1 20572621 T C 4.65E-05 Serum metabolites / / 19043545 rs2157508 chr1 20572621 T C 1.11E-04 Smoking cessation / / 24665060 rs6426624 chr1 20572638 A G 8.55E-05 Serum metabolites / / 19043545 rs2157510 chr1 20572894 A G 4.65E-05 Serum metabolites / / 19043545 rs743983 chr1 20583322 T G 4.10E-05 Serum metabolites / / 19043545 rs17354986 chr1 20585773 C T 6.84E-04 Acute lung injury / / 22295056 rs966366 chr1 20592340 T C 8.54E-07 Type 2 diabetes / / 17463246 rs966366 chr1 20592340 T C 1.62E-04 Acute lung injury / / 22295056 rs2017456 chr1 20598351 C T 8.14E-04 Type 2 diabetes / / 17463246 rs4655183 chr1 20604014 A C 1.24E-04 Type 2 diabetes / / 17463246 rs12116793 chr1 20625777 C A 1.76E-04 Suicide attempts in bipolar disorder VWA5B1 intron 21423239 rs12134413 chr1 20630594 A C 1.42E-04 Suicide attempts in bipolar disorder VWA5B1 intron 21423239 rs16823838 chr1 20631012 C G 8.65E-04 Multiple complex diseases VWA5B1 intron 17554300 rs12140623 chr1 20632815 G A 3.06E-04 Suicide attempts in bipolar disorder VWA5B1 intron 21423239 rs11809335 chr1 20635722 A G 6.67E-05 Height VWA5B1 intron pha003011 rs12124623 chr1 20667464 G T 5.67E-04 Suicide attempts in bipolar disorder VWA5B1 intron 21423239 rs10916782 chr1 20726556 G A 7.79E-04 Response to cytidine analogues (gemcitabine) LOC339505 intron 24483146 rs912813 chr1 20728889 T A 1.50E-05 Urinary metabolites LOC339505 intron 21572414 rs879484 chr1 20729212 T C 4.85E-04 Response to cytidine analogues (gemcitabine) LOC339505 intron 24483146 rs10753498 chr1 20733376 T C 1.10E-05 Urinary metabolites LOC339505 intron 21572414 rs7514144 chr1 20735869 C T 9.09E-05 Common variable immunodeficiency LOC339505 intron 21497890 rs10799633 chr1 20740016 C A 2.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC339505 intron 20877124 rs1886737 chr1 20745074 C A 2.00E-04 Type 2 diabetes LOC339505 intron 17463246 rs974332 chr1 20745485 T C 3.47E-04 Multiple complex diseases LOC339505 intron 17554300 rs10916799 chr1 20767524 C T 4.90E-06 Blood Pressure / / pha003040 rs750070 chr1 20769184 A C 4.81E-05 Blood Pressure / / pha003040 rs10799636 chr1 20770887 T C 6.06E-05 Body Mass Index / / pha003006 rs97922 chr1 20804065 T G 1.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs609210 chr1 20849079 C T 4.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6698887 chr1 20857064 G A 7.91E-04 Multiple complex diseases / / 17554300 rs660423 chr1 20865703 T C 6.17E-04 Aortic root size / / 21223598 rs561411 chr1 20866328 C T 8.50E-04 Aortic root size / / 21223598 rs667357 chr1 20872694 C T 2.29E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12072199 chr1 20877812 T C 4.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs675397 chr1 20883422 T C 3.47E-05 Bladder cancer / / 19648920 rs677214 chr1 20883816 C T 4.19E-04 Iron levels / / pha002876 rs639400 chr1 20900123 C T 2.10E-05 Urinary metabolites / / 21572414 rs532545 chr1 20915172 C T 1 Drug response to Cytarabine / / 19458626 rs532545 chr1 20915172 C T 1 Drug response to Daunorubicin / / 19458626 rs2072671 chr1 20915701 A C 1 Drug response to Gemcitabine CDA missense 15224082 rs2072671 chr1 20915701 A C 1 Drug response to Carboplatin CDA missense 17194903 rs2072671 chr1 20915701 A C 1 Drug response to Cisplatin CDA missense 17194903 rs2072671 chr1 20915701 A C 1 Drug response to Fluorouracil CDA missense 17194903 rs2072671 chr1 20915701 A C 1 Drug response to Gemcitabine CDA missense 17194903 rs2072671 chr1 20915701 A C 1 Drug response to Cytarabine CDA missense 19458626 rs2072671 chr1 20915701 A C 1 Drug response to Daunorubicin CDA missense 19458626 rs517483 chr1 20930035 C T 2.69E-05 Leukocyte Counts CDA intron pha003091 rs60369023 chr1 20931474 G A 1 Drug response to Gemcitabine CDA missense 15224082 rs60369023 chr1 20931474 G A 1 Drug response to Carboplatin CDA missense 17194903 rs60369023 chr1 20931474 G A 1 Drug response to Cisplatin CDA missense 17194903 rs60369023 chr1 20931474 G A 1 Drug response to Fluorouracil CDA missense 17194903 rs60369023 chr1 20931474 G A 1 Drug response to Gemcitabine CDA missense 17194903 rs527912 chr1 20934283 G A 9.40E-05 Type 2 diabetes CDA intron 17463248 rs527912 chr1 20934283 G A 7.42E-05 Adipocyte fatty acid-binding protein concentration,in serum CDA intron 21863005 rs573337 chr1 20936233 C G 1.00E-05 Urinary metabolites CDA intron 21572414 rs12404655 chr1 20943195 A G 2.70E-05 Urinary metabolites CDA intron 21572414 rs12404655 chr1 20943195 A G 1.17E-04 Acute lung injury CDA intron 22295056 rs1048977 chr1 20945055 C T 1 Drug response to Gemcitabine CDA cds-synon 15224082 rs3820321 chr1 20962827 G A 4.00E-05 Type 2 diabetes PINK1 intron 17463248 rs2298298 chr1 20964328 A G 9.00E-05 Personality dimensions PINK1 intron 18957941 rs3102071 chr1 20968011 A G 8.90E-05 Personality dimensions PINK1 intron 18957941 rs2298299 chr1 20974802 A G 2.00E-04 Acute lung injury PINK1 intron 22295056 rs1573132 chr1 20978024 C A 3.20E-04 Schizophrenia(treatment response to risperidone) DDOST nearGene-3 19850283 rs622525 chr1 20979818 A T 8.90E-05 Personality dimensions DDOST intron 18957941 rs607254 chr1 20980880 G A 3.40E-05 Type 2 diabetes DDOST intron 17463248 rs589709 chr1 20983987 G A 2.90E-05 Type 2 diabetes DDOST intron 17463248 rs640742 chr1 20984554 A C 2.90E-05 Type 2 diabetes DDOST intron 17463248 rs623817 chr1 20986078 G A 3.10E-05 Type 2 diabetes DDOST intron 17463248 rs674114 chr1 20989672 G A 6.80E-05 Type 2 diabetes DDOST nearGene-5 17463248 rs630484 chr1 20992606 G T 4.80E-05 Type 2 diabetes KIF17 intron 17463248 rs12118760 chr1 20999804 T C 2.20E-05 Type 2 diabetes KIF17 intron 17463248 rs12025912 chr1 21002699 T C 2.35E-04 Acute lung injury KIF17 intron 22295056 rs12025916 chr1 21002726 T C 2.17E-04 Acute lung injury KIF17 intron 22295056 rs2296223 chr1 21011182 G A 0.0005775 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) KIF17 intron 23233654 rs2296223 chr1 21011182 G A 5.78E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIF17 intron 23233662 rs17407280 chr1 21020405 C T 3.60E-04 Type 2 diabetes KIF17 intron 17463246 rs149579175 chr1 21051116 G A 0.00022 Breast cancer SH2D5 missense 23555315 rs10916852 chr1 21052693 G T 3.26E-04 Coronary heart disease SH2D5 intron 21971053 rs35472344 chr1 21052693 GC G 3.26E-04 Coronary heart disease SH2D5 intron 21971053 rs951805 chr1 21060356 G A 2.90E-05 Urinary metabolites / / 21572414 rs1021077 chr1 21106016 T C 1.20E-05 Urinary metabolites HP1BP3 intron 21572414 rs10916891 chr1 21199974 T G 1.51E-04 Multiple complex diseases EIF4G3 intron 17554300 rs10916891 chr1 21199974 T G 2.02E-04 Lymphocyte counts EIF4G3 intron 22286170 rs4654885 chr1 21220491 T C 4.21E-09 Multiple complex diseases EIF4G3 intron 17554300 rs10157616 chr1 21244582 T C 1.88E-04 Multiple complex diseases EIF4G3 intron 17554300 rs10916901 chr1 21245001 A G 0.000041 Mean arterial pressure EIF4G3 intron 22510845 rs3767248 chr1 21276854 A G 4.14E-04 Coronary heart disease EIF4G3 intron 21971053 rs12021529 chr1 21306161 T C 7.25E-05 Multiple complex diseases EIF4G3 intron 17554300 rs10916930 chr1 21395357 T C 2.70E-04 Multiple complex diseases EIF4G3 intron 17554300 rs2282714 chr1 21587849 G A 1.53E-04 Myopia (pathological) ECE1 intron 21095009 rs3026862 chr1 21604387 C G 3.18E-10 LDL cholesterol ECE1 intron 23063622 rs213010 chr1 21639167 A G 3.89E-04 Alzheimer's disease (late onset) ECE1 intron 21379329 rs213032 chr1 21654735 T C 6.00E-06 Obesity-related traits ECE1 intron 23251661 rs3026815 chr1 21664475 C T 3.08E-06 Personality dimensions ECE1 intron 18957941 rs3026815 chr1 21664475 C T 1.77E-05 Depression (quantitative trait) ECE1 intron 20800221 rs213006 chr1 21678600 T G 2.00E-05 Depression (quantitative trait) / / 20800221 rs12736884 chr1 21725505 G C 3.90E-04 Alcohol dependence / / 20201924 rs12750103 chr1 21736327 A G 9.00E-11 Brain activation patterns in response to human facial expressions-for the negative faces task / / 22828495 rs12750103 chr1 21736327 A G 9.00E-11 Airflow obstruction / / 22837378 rs1566524 chr1 21737466 C A,G,T 4.01E-04 Insulin resistance / / 21901158 rs10916983 chr1 21742737 T C 3.19E-04 Bipolar disorder,schizoaffective / / 19567891 rs10916983 chr1 21742737 T C 9.15E-06 Creutzfeldt-Jakob disease (variant) / / 22137330 rs1976403 chr1 21766453 A C 2.00E-50 Liver enzyme levels (alkaline phosphatase) / / 22001757 rs4654748 chr1 21786068 C T 8.00E-18 Folate pathway vitamin levels NBPF3 intron 19303062 rs4654748 chr1 21786068 C T 4.00E-11 Folate pathway vitamin levels NBPF3 intron 19744961 rs4654748 chr1 21786068 C T 6.73E-09 Vitamin B6 NBPF3 intron 23696881 rs10799701 chr1 21820990 A G 3.00E-20 Metabolic traits / / 21886157 rs1780324 chr1 21821757 A G 7.00E-15 Liver enzyme levels / / 18940312 rs1780324 chr1 21821757 A G 7.14E-05 Blood cell counts and other traits / / 20139978 rs1697421 chr1 21823292 C T 1.00E-27 Phosphorus levels / / 20558539 rs1697421 chr1 21823292 C T 0.00082 Prostate cancer / / 23555315 rs1697421 chr1 21823292 C T 2.00E-20 Blood metabolite ratios / / 24816252 rs1697421 chr1 21823292 C T 3.00E-14 Blood metabolite ratios / / 24816252 rs6667242 chr1 21826566 A G 1.11E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs16825455 chr1 21837755 A G 9.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) ALPL intron 23648065 rs7535497 chr1 21840709 T G 6.43E-04 Type 2 diabetes ALPL intron 17463246 rs7523855 chr1 21840886 C T 6.04E-04 Type 2 diabetes ALPL intron 17463246 rs1890431 chr1 21852078 C T 6.48E-05 Tunica Media ALPL intron pha003036 rs1697414 chr1 21874996 T A 6.98E-04 Multiple complex diseases ALPL intron 17554300 rs885814 chr1 21875916 C T 6.00E-06 Response to TNF-alpha inhibitors in rheumatoid arthritis ALPL intron 22569225 rs885813 chr1 21877074 C T 3.49E-05 Lactate dehydrogenase levels ALPL intron 20981236 rs3767155 chr1 21885195 C T 3.09E-04 Alzheimer's disease ALPL intron 24755620 rs1767429 chr1 21889340 A G 1.93E-04 Alzheimer's disease ALPL intron 24755620 rs1256335 chr1 21890386 G A 1.00E-15 Folate pathway vitamin levels ALPL intron 19744961 rs3738097 chr1 21894816 T C 9.86E-04 Type 2 diabetes ALPL intron 17463246 rs3767142 chr1 21901558 G A 3.27E-04 Alzheimer's disease ALPL intron 24755620 rs2242420 chr1 21904529 C T 5.00E-13 Blood cell counts and other traits ALPL UTR-3 20139978 rs2242420 chr1 21904529 C T 5.08E-13 Blood cell counts and other traits ALPL UTR-3 20139978 rs7515386 chr1 21921736 G A 7.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4654973 chr1 21927820 C G 7.22E-04 Obesity (extreme) RAP1GAP intron 21935397 rs829370 chr1 21933193 C T 3.99E-05 Socioeconomic Factors RAP1GAP intron pha003066 rs861212 chr1 21935433 G T 8.91E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RAP1GAP intron 20877124 rs829417 chr1 21943136 C T 1 Drug response to Etoposide RAP1GAP intron 17537913 rs829418 chr1 21943504 A G 7.54E-05 Socioeconomic Factors RAP1GAP intron pha003066 rs829406 chr1 21949462 A G 1.36E-04 Fibrinogen RAP1GAP intron 17255346 rs829406 chr1 21949462 A G 9.04E-04 Coronary heart disease RAP1GAP intron 21606135 rs829411 chr1 21953138 A G 6.91E-04 Acute lung injury RAP1GAP intron 22295056 rs1531829 chr1 21953304 G A 7.69E-04 Multiple complex diseases RAP1GAP intron 17554300 rs829412 chr1 21953436 A G 2.71E-04 Type 2 diabetes RAP1GAP intron 17463246 rs829412 chr1 21953436 A G 7.03E-04 Multiple complex diseases RAP1GAP intron 17554300 rs4654974 chr1 21954294 T C 7.64E-05 Cognitive test performance RAP1GAP intron 20125193 rs4654974 chr1 21954294 T C 2.59E-04 Suicide attempts in bipolar disorder RAP1GAP intron 21041247 rs9426770 chr1 21955744 G C 2.61E-04 Suicide attempts in bipolar disorder RAP1GAP intron 21041247 rs9426674 chr1 21957239 G C 2.69E-04 Suicide attempts in bipolar disorder RAP1GAP intron 21041247 rs11591167 chr1 21958536 C T 2.14E-05 Mammographic density RAP1GAP intron 22532574 rs9426771 chr1 21958739 G A,C,T 3.87E-04 Suicide attempts in bipolar disorder RAP1GAP intron 21041247 rs9426772 chr1 21959590 T C 8.84E-04 Suicide attempts in bipolar disorder RAP1GAP intron 21041247 rs6679565 chr1 21962551 G A 2.13E-04 Coronary heart disease RAP1GAP intron 21606135 rs12142081 chr1 21966833 G T 4.92E-05 Cognitive test performance RAP1GAP intron 20125193 rs6426721 chr1 21972480 G A 2.23E-04 Multiple complex diseases RAP1GAP intron 17554300 rs12128325 chr1 22002867 G A 3.50E-06 Urinary metabolites / / 21572414 rs333188 chr1 22040294 T C 9.43E-05 Non-alcoholic fatty liver disease histology (other) USP48 intron 20708005 rs7554400 chr1 22052387 T C 1.58E-05 Cognitive performance USP48 intron 19734545 rs6664218 chr1 22055917 A G 1.29E-05 Cognitive performance USP48 intron 19734545 rs333204 chr1 22080775 A G 3.00E-05 Cognitive performance USP48 intron 19734545 rs541552 chr1 22081011 T C 3.00E-05 Cognitive performance USP48 intron 19734545 rs6667223 chr1 22088841 G A 3.74E-05 Lymphocyte counts USP48 intron 22286170 rs884726 chr1 22110418 T C 1.21E-05 Cognitive performance / / 19734545 rs10917047 chr1 22124166 C T 4.34E-05 Cognitive performance / / 19734545 rs12737091 chr1 22174518 G T 3.78E-05 Aortic root size HSPG2 cds-synon 21223598 rs142149919 chr1 22188296 G A 0.00000049 Breast cancer HSPG2 missense 23555315 rs1869780 chr1 22222455 G T 1.42E-04 Multiple complex diseases HSPG2 missense 17554300 rs3820285 chr1 22336277 C G 7.30E-04 Iris characteristics CELA3A missense 21835309 rs3117048 chr1 22345093 A G 7.25E-04 Kawasaki disease / / 21326860 rs3117048 chr1 22345093 A G 8.28E-05 Major depressive disorder / / 22472876 rs2501299 chr1 22345647 C T 5.47E-05 Major depressive disorder / / 22472876 rs760923 chr1 22357217 G T 2.30E-04 Endometriosis / / 23104006 rs2473277 chr1 22361845 G A 5.88E-04 Schizophrenia / / 19197363 rs2473277 chr1 22361845 G A 3.75E-06 Schizophrenia / / 19571811 rs2473277 chr1 22361845 G A 1.00E-04 Endometriosis / / 21151130 rs2501279 chr1 22368342 C T 1.90E-05 Endometriosis / / 21151130 rs2501276 chr1 22373624 C T 2.00E-07 Immune response to smallpox vaccine (IL-6) / / 22610502 rs2056975 chr1 22408527 A G 5.53E-04 Multiple complex diseases CDC42 intron 17554300 rs2268179 chr1 22414785 G T 0.00000134 Uterine leiomyomata CDC42 intron 23040493 rs2268177 chr1 22415410 A T 1.50E-08 Bone mineral density (paediatric,total body less head) CDC42 intron 24945404 rs2268177 chr1 22415410 A T 9.70E-11 Bone mineral density (paediatric,skull) CDC42 intron 24945404 rs10917151 chr1 22422721 G A 7.00E-09 Endometriosis / / 23472165 rs7412010 chr1 22436446 G C 2.30E-08 Bone mineral density (paediatric,upper limb) / / 24945404 rs7412010 chr1 22436446 G C 2.50E-12 Bone mineral density (paediatric,skull) / / 24945404 rs7412010 chr1 22436446 G C 2.60E-09 Bone mineral density (paediatric,total body less head) / / 24945404 rs4654783 chr1 22439520 T C 2.00E-04 Endometriosis / / 23104006 rs3765350 chr1 22447316 A G 3.00E-08 Bone mineral density (paediatric,lower limb) WNT4 intron 24945404 rs3765350 chr1 22447316 A G 3.60E-11 Bone mineral density (paediatric,skull) WNT4 intron 24945404 rs3765350 chr1 22447316 A G 4.00E-09 Bone mineral density (paediatric,total body less head) WNT4 intron 24945404 rs3765350 chr1 22447316 A G 6.00E-08 Bone mineral density (paediatric,lower limb) WNT4 intron 24945404 rs3765350 chr1 22447316 A G 7.00E-10 Bone mineral density (paediatric,total body less head) WNT4 intron 24945404 rs2235529 chr1 22450487 C T 3.00E-09 Endometriosis WNT4 intron 23472165 rs2235529 chr1 22450487 C T 1.00E-08 Bone mineral density (paediatric,upper limb) WNT4 intron 24945404 rs2235529 chr1 22450487 C T 1.20E-09 Bone mineral density (paediatric,total body less head) WNT4 intron 24945404 rs2235529 chr1 22450487 C T 3.00E-07 Bone mineral density (paediatric,upper limb) WNT4 intron 24945404 rs2235529 chr1 22450487 C T 3.00E-12 Bone mineral density (paediatric,skull) WNT4 intron 24945404 rs3820282 chr1 22468215 C T 2.00E-09 Bone mineral density (paediatric,total body less head) WNT4 intron 24945404 rs3820282 chr1 22468215 C T 2.10E-08 Bone mineral density (paediatric,upper limb) WNT4 intron 24945404 rs3820282 chr1 22468215 C T 9.70E-12 Bone mineral density (paediatric,skull) WNT4 intron 24945404 rs12042083 chr1 22472732 G A 1.10E-08 Bone mineral density (paediatric,total body less head) / / 24945404 rs12042083 chr1 22472732 G A 3.30E-10 Bone mineral density (paediatric,skull) / / 24945404 rs7515106 chr1 22473410 T C 3.60E-05 Endometriosis / / 21151130 rs7515106 chr1 22473410 T C 2.10E-06 Endometriosis / / 23104006 rs7515106 chr1 22473410 T C 1.50E-09 Bone mineral density (paediatric,skull) / / 24945404 rs7515106 chr1 22473410 T C 7.80E-09 Bone mineral density (paediatric,total body less head) / / 24945404 rs7542242 chr1 22477493 C T 2.90E-06 Endometriosis / / 21151130 rs7517829 chr1 22480159 A G 2.30E-05 Coffee consumption / / 21357676 rs16826658 chr1 22485871 T G 2.00E-06 Endometriosis / / 20601957 rs16826658 chr1 22485871 T G 3.50E-05 Endometriosis / / 21151130 rs16826658 chr1 22485871 T G 4.61E-05 Calcium levels / / pha003085 rs7521902 chr1 22490724 C A 5.00E-06 Ovarian cancer / / 20852632 rs7521902 chr1 22490724 C A 4.20E-05 Endometriosis / / 21151130 rs7521902 chr1 22490724 C A 1.00E-10 Bone mineral density / / 22504420 rs7521902 chr1 22490724 C A 3.00E-11 Endometriosis / / 23104006 rs7521902 chr1 22490724 C A 1.58E-05 Bone mineral density (paediatric,total body less head) / / 24945404 rs7521902 chr1 22490724 C A 3.30E-12 Bone mineral density (paediatric,skull) / / 24945404 rs7521902 chr1 22490724 C A 3.32E-12 Bone mineral density (paediatric,skull) / / 24945404 rs7521902 chr1 22490724 C A 3.81E-07 Bone mineral density (paediatric,upper limb) / / 24945404 rs2807357 chr1 22491984 A G 5.42E-04 Multiple complex diseases / / 17554300 rs3920498 chr1 22492887 G C 1.00E-10 Bone mineral density (paediatric,skull) / / 24945404 rs3920498 chr1 22492887 G C 2.00E-12 Bone mineral density (paediatric,skull) / / 24945404 rs2807356 chr1 22493672 T C 3.59E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) / / 23648065 rs909813 chr1 22496703 G A 8.82E-04 Multiple complex diseases / / 17554300 rs17360053 chr1 22499530 T C 9.00E-06 Obesity-related traits / / 23251661 rs12568557 chr1 22500228 T C 5.35E-04 Smoking cessation / / 24665060 rs16826705 chr1 22501716 C T 3.83E-04 Multiple complex diseases / / 17554300 rs742356 chr1 22501846 A G 3.10E-06 Endometriosis / / 23104006 rs2744704 chr1 22503550 A T 7.16E-05 Aging (time to event) / / 21782286 rs2744718 chr1 22523727 T C 2.88E-04 Osteoarthritis (knee and hip) / / 21177295 rs2744718 chr1 22523727 T C 3.66E-05 Osteoarthritis (knee and hip) / / 21177295 rs2473249 chr1 22537071 C T 1.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs2473250 chr1 22537649 A G 7.77E-04 Alcohol dependence / / 24277619 rs2473256 chr1 22539529 G A 1.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs1883418 chr1 22540161 G A 1.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs760917 chr1 22545088 T A 1.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs1569583 chr1 22547352 T C 4.26E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2505709 chr1 22547479 C T 1.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs2473268 chr1 22549172 G A 1.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs2491213 chr1 22549397 G A 1.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs732266 chr1 22550624 C T 1.82E-04 Suicide attempts in bipolar disorder / / 21423239 rs2505711 chr1 22551925 G A 1.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs3856181 chr1 22552969 C G 6.13E-04 Suicide attempts in bipolar disorder / / 21423239 rs2744747 chr1 22571462 T C 7.60E-04 Testosterone levels / / 22675492 rs909814 chr1 22573942 T C 9.00E-07 Testosterone levels / / 22675492 rs909814 chr1 22573942 T C 7.00E-06 IgG glycosylation / / 23382691 rs2744757 chr1 22577937 C G 5.20E-04 Testosterone levels / / 22675492 rs2807339 chr1 22578063 T C 7.82E-04 Bipolar disorder,schizoaffective / / 19567891 rs2807339 chr1 22578063 T C 3.10E-04 Testosterone levels / / 22675492 rs2143101 chr1 22578436 G A 5.14E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2744759 chr1 22579798 T G 6.47E-05 Cleft lip / / 20436469 rs12737805 chr1 22612690 A G 7.37E-04 HIV-1 viral setpoint / / 17641165 rs6690148 chr1 22648411 C T 2.12E-04 Type 2 diabetes / / 17463246 rs1934477 chr1 22664774 T C 9.62E-04 Acute lung injury / / 22295056 rs1934478 chr1 22665210 G A 9.99E-04 Acute lung injury / / 22295056 rs10493012 chr1 22672846 A G 2.65E-04 Multiple complex diseases / / 17554300 rs12742784 chr1 22682366 C T 1.10E-09 Bone mineral density (spine) / / 19801982 rs12756978 chr1 22684755 G C 1.50E-08 Bone mineral density (spine) / / 19801982 rs10753536 chr1 22685251 G A 8.90E-05 Endometriosis / / 21151130 rs11810369 chr1 22687651 G A 1.50E-08 Bone mineral density (spine) / / 19801982 rs12750721 chr1 22689273 G A 1.20E-08 Bone mineral density (spine) / / 19801982 rs12723796 chr1 22691606 G A 4.50E-10 Bone mineral density (spine) / / 19801982 rs12723796 chr1 22691606 G A 9.00E-06 Endometriosis / / 21151130 rs7537281 chr1 22692078 A T 4.90E-10 Bone mineral density (spine) / / 19801982 rs7524102 chr1 22698447 A G 5.00E-16 Bone mineral density (hip) / / 18445777 rs7524102 chr1 22698447 A G 9.00E-09 Bone mineral density (spine) / / 18445777 rs7524102 chr1 22698447 A G 1.00E-16 Bone mineral density (hip) / / 19079262 rs7524102 chr1 22698447 A G 3.00E-10 Bone mineral density (spine) / / 19801982 rs7524102 chr1 22698447 A G 3.00E-07 Ulcerative colitis / / 19915572 rs7524102 chr1 22698447 A G 3.80E-06 Endometriosis / / 21151130 rs7524102 chr1 22698447 A G 2.00E-13 Ulcerative colitis / / 21297633 rs7524102 chr1 22698447 A G 1.00E-06 Bone mineral density / / 21533022 rs7524102 chr1 22698447 A G 9.00E-07 Bone mineral density / / 21533022 rs7524102 chr1 22698447 A G 3.00E-09 Dupuytren's disease / / 21732829 rs7524102 chr1 22698447 A G 0.00038 Prostate cancer / / 23555315 rs34920465 chr1 22700351 A G 3.00E-08 Bone mineral density / / 24249740 rs34920465 chr1 22700351 A G 3.00E-13 Bone mineral density / / 24249740 rs34920465 chr1 22700351 A G 6.01E-10 Bone mineral density / / 24249740 rs12568930 chr1 22702231 T C 4.60E-10 Bone mineral density (spine) / / 19801982 rs12568930 chr1 22702231 T C 1.40E-07 Ulcerative colitis / / 19915572 rs12568930 chr1 22702231 T C 2.80E-06 Endometriosis / / 21151130 rs12568930 chr1 22702231 T C 1.00E-17 Inflammatory bowel disease / / 23128233 rs12561997 chr1 22702280 G A 6.30E-10 Bone mineral density (spine) / / 19801982 rs6696981 chr1 22702858 G T 2.00E-08 Bone mineral density (spine) / / 19079262 rs6696981 chr1 22702858 G T 6.40E-10 Bone mineral density (spine) / / 19801982 rs6696981 chr1 22702858 G T 3.70E-06 Endometriosis / / 21151130 rs6696981 chr1 22702858 G T 7.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs6696981 chr1 22702858 G T 0.00063 Prostate cancer / / 23555315 rs10493013 chr1 22703035 T C 4.80E-10 Bone mineral density (spine) / / 19801982 rs11803476 chr1 22703325 C T 6.40E-10 Bone mineral density (spine) / / 19801982 rs6684375 chr1 22706434 C T 4.80E-10 Bone mineral density (spine) / / 19801982 rs6684479 chr1 22706534 C T 7.60E-10 Bone mineral density (spine) / / 19801982 rs6426748 chr1 22707565 C T 7.60E-10 Bone mineral density (spine) / / 19801982 rs10917221 chr1 22709136 T C 4.83E-04 Aortic root size / / 21223598 rs7550872 chr1 22711378 T C 2.00E-09 Bone mineral density (spine) / / 19801982 rs7550872 chr1 22711378 T C 2.70E-06 Endometriosis / / 21151130 rs6426749 chr1 22711473 G C 9.00E-08 Bone mineral density (hip) / / 19801982 rs6426749 chr1 22711473 G C 3.98E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6426749 chr1 22711473 G C 7.00E-57 Bone mineral density / / 22504420 rs6426749 chr1 22711473 G C 0.00018 Prostate cancer / / 23555315 rs6426749 chr1 22711473 G C 1.06E-07 Bone mineral density / / 24249740 rs6426749 chr1 22711473 G C 7.58E-07 Bone mineral density / / 24249740 rs6426749 chr1 22711473 G C 9.79E-09 Bone mineral density / / 24249740 rs6426749 chr1 22711473 G C 2.27E-04 Bone mineral density (paediatric,total body less head) / / 24945404 rs2185341 chr1 22725825 C T 2.10E-05 Caffeine consumption / / 21490707 rs2185341 chr1 22725825 C T 9.63E-04 Tourette syndrome / / 22889924 rs7543680 chr1 22731269 G A 1.00E-10 Bone mineral density (spine) / / 19079262 rs10917225 chr1 22733144 T C 4.50E-05 Cognitive impairment induced by topiramate / / 22091778 rs4655059 chr1 22735906 A C 1.29E-05 Cognitive impairment induced by topiramate / / 22091778 rs111724808 chr1 22737946 T G 4.00E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs113487266 chr1 22737951 T C 4.03E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs111245681 chr1 22737964 T C 8.71E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs76652604 chr1 22738033 G T 4.33E-07 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs4515757 chr1 22744686 T C 7.29E-05 Body Mass Index / / pha003020 rs10917234 chr1 22782602 A G 4.78E-04 Type 2 diabetes ZBTB40 intron 17463246 rs4233289 chr1 22790455 A C 6.40E-04 Type 2 diabetes ZBTB40 intron 17463246 rs4655067 chr1 22814289 T C 3.98E-04 Type 2 diabetes ZBTB40 intron 17463246 rs4655068 chr1 22814354 C T 4.13E-04 Type 2 diabetes ZBTB40 intron 17463246 rs209753 chr1 22821968 T C 9.94E-04 Lymphocyte counts ZBTB40 intron 22286170 rs209722 chr1 22843428 G A 4.72E-04 Type 2 diabetes ZBTB40 intron 17463246 rs7551801 chr1 22846452 C G 4.51E-04 Type 2 diabetes ZBTB40 intron 17463246 rs209709 chr1 22877813 G A 1.56E-04 Heart Failure / / pha002885 rs606002 chr1 22915753 T C 7.40E-05 Lipoproteins EPHA8 missense pha003079 rs209693 chr1 22922026 T G 4.32E-04 Type 2 diabetes EPHA8 intron 17463246 rs209705 chr1 22934644 A G 4.42E-04 Type 2 diabetes / / 17463246 rs158761 chr1 22954372 C A 8.58E-04 Alcohol dependence / / 24277619 rs12033074 chr1 22966609 C G 1.05E-04 Type 2 diabetes C1QA nearGene-3 17463246 rs6690827 chr1 22967496 G A 1.05E-04 Type 2 diabetes / / 17463246 rs2935537 chr1 22970514 G A 0.000000125 Triglycerides C1QC UTR-5 23063622 rs294189 chr1 22983464 G T 0.00008678 Sarcoidosis C1QB intron 22952805 rs631090 chr1 22986403 T C 8.80E-05 Systemic sclerosis C1QB intron 21750679 rs631090 chr1 22986403 T C 5.91E-04 Response to cytidine analogues (gemcitabine) C1QB intron 24483146 rs201673207 chr1 22991643 C CAG 1 Drug response to Etoposide / / 17537913 rs647955 chr1 22991643 C G 1 Drug response to Etoposide / / 17537913 rs1010011 chr1 23056136 C A 2.08E-04 Taste perception EPHB2 intron 22132133 rs12732926 chr1 23057190 G A 3.83E-05 Cognitive test performance EPHB2 intron 20125193 rs10753541 chr1 23061992 T C 8.71E-05 Serum metabolites EPHB2 intron 19043545 rs7516175 chr1 23096818 A C 5.27E-04 Schizophrenia EPHB2 intron 19197363 rs6692683 chr1 23102856 G A 3.95E-04 Suicide attempts in bipolar disorder EPHB2 intron 21423239 rs893961 chr1 23118173 T C 3.85E-04 Multiple complex diseases EPHB2 intron 17554300 rs4506436 chr1 23127876 T C 3.71E-04 Gallstones EPHB2 intron 17632509 rs12723359 chr1 23137761 G A 5.67E-05 Testicular dysgenesis syndrome EPHB2 intron 22140272 rs7536195 chr1 23142496 C T 3.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EPHB2 intron 20877124 rs893966 chr1 23144006 C T 3.91E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) EPHB2 intron 20877124 rs4654821 chr1 23160272 T A,C,G 4.40E-05 Crohn's disease EPHB2 intron 20570966 rs4654824 chr1 23183130 C T 5.49E-04 Schizophrenia EPHB2 intron 19197363 rs10799771 chr1 23206684 A G 8.35E-05 Insulin Resistance EPHB2 intron pha003062 rs10799771 chr1 23206684 A G 6.63E-05 Insulin-related traits EPHB2 intron pha003063 rs309543 chr1 23225322 A G 4.35E-04 Suicide attempts in bipolar disorder EPHB2 intron 21041247 rs1832047 chr1 23266939 G A 7.20E-04 Alcohol dependence / / 20201924 rs587168 chr1 23371608 A C 1.42E-04 Oral cancers (chewing tobacco related) KDM1A intron 22503698 rs5027299 chr1 23375693 A G 1.19E-18 Multiple complex diseases KDM1A intron 17554300 rs5027299 chr1 23375693 A G 2.88E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers KDM1A intron 21775533 rs11587694 chr1 23477511 T C 3.31E-04 Myocardial Infarction LUZP1 intron pha002873 rs2806561 chr1 23504795 A G 6.89E-05 Panic disorder / / 19165232 rs674386 chr1 23521835 G A 0.0000442 LDL cholesterol / / 23063622 rs1738475 chr1 23536891 C G 3.00E-12 Height / / 20881960 rs10917360 chr1 23539010 G A 7.19E-06 Myocardial Infarction / / pha002873 rs1047694 chr1 23628436 C T 8.89E-06 Height / / 22021425 rs2849021 chr1 23631714 T G 6.15E-06 Height / / 22021425 rs665977 chr1 23696152 G A 0.0004 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes ZNF436 UTR-5 22628534 rs649458 chr1 23712528 T A 1.64E-04 QT interval TCEA3 intron 22726844 rs2275355 chr1 23724183 C T 3.51E-05 Response to platinum-based chemotherapy in non-small-cell lung cancer TCEA3 intron 21483023 rs6682786 chr1 23743296 A G 7.30E-05 Schizophrenia(treatment response to risperidone) TCEA3 intron 19850283 rs1077514 chr1 23766233 C T 7.39E-04 Multiple complex diseases ASAP3 intron 17554300 rs1077514 chr1 23766233 C T 6.00E-09 Cholesterol,total ASAP3 intron 24097068 rs7522616 chr1 23794914 A G 6.30E-05 Alcohol dependence ASAP3 intron 21703634 rs12142232 chr1 23816120 T G 2.19E-05 Blood Pressure / / pha003044 rs2282720 chr1 23839769 A G 1.68E-04 Schizophrenia(treatment response to risperidone) E2F2 intron 19850283 rs3218148 chr1 23851787 G A 1.97E-04 Bulimia nervosa E2F2 intron 23568457 rs11574 chr1 23885498 T C 1.24E-04 Height ID3 missense 17255346 rs4514282 chr1 23912167 C T 2.66E-04 Alzheimer's disease / / 17998437 rs6677615 chr1 23942802 G A 2.60E-04 Alcohol dependence / / 20201924 rs6677615 chr1 23942802 G A 7.20E-04 Alcohol dependence / / 20201924 rs6677615 chr1 23942802 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1317329 chr1 23966837 C T 5.69E-04 Intracranial aneurysm MDS2 intron 20613766 rs12084240 chr1 23980452 C G 3.66E-05 Parkinson's disease (motor and cognition) / / 22658654 rs11577033 chr1 24038231 T C 4.10E-04 Alcohol dependence / / 20201924 rs11577033 chr1 24038231 T C 5.70E-04 Alcohol dependence / / 20201924 rs10917420 chr1 24062987 C T 0.00000183 HIV-1 infection (natural long-term nonprogression) / / 22238471 rs10917420 chr1 24062987 C T 3.25E-05 Tuberculosis / / 24057671 rs11591202 chr1 24102080 A C 6.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC100506963 intron 20877124 rs7521571 chr1 24281021 G A 1.09E-04 Vaspin levels / / 22907691 rs7521571 chr1 24281021 G A 0.0001089 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs17338135 chr1 24286897 C T 9.49E-06 Obesity-related traits PNRC2 intron 23251661 rs114176962 chr1 24290676 G A 1.10E-04 Obesity-related traits / / 17903300 rs6667686 chr1 24300849 T C 2.00E-06 Obesity-related traits SRSF10 intron 23251661 rs7553231 chr1 24347103 T C 2.30E-04 Alcohol dependence / / 20201924 rs7553231 chr1 24347103 T C 5.00E-04 Alcohol dependence / / 20201924 rs11586125 chr1 24377326 T C 4.20E-04 Alcohol dependence / / 20201924 rs11586125 chr1 24377326 T C 7.90E-04 Alcohol dependence / / 20201924 rs7540557 chr1 24377944 T C 2.50E-04 Alcohol dependence / / 20201924 rs7540557 chr1 24377944 T C 5.90E-04 Alcohol dependence / / 20201924 rs4649163 chr1 24379601 T C 4.70E-05 Vaspin levels / / 22907691 rs4649163 chr1 24379601 T C 0.000047 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks / / 22907730 rs4649163 chr1 24379601 T C 0.0002016 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs4649171 chr1 24395575 A G 1.25E-04 Vaspin levels MYOM3 intron 22907691 rs4649171 chr1 24395575 A G 0.0001247 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit MYOM3 intron 22907730 rs4276861 chr1 24412447 T C 1.41E-04 Vaspin levels MYOM3 intron 22907691 rs4276861 chr1 24412447 T C 0.000141 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks MYOM3 intron 22907730 rs11249132 chr1 24413907 C A 2.35E-04 Alzheimer's disease MYOM3 intron 22005930 rs4276859 chr1 24416133 C T 4.20E-04 Alcohol dependence MYOM3 cds-synon 20201924 rs4276859 chr1 24416133 C T 4.90E-04 Alcohol dependence MYOM3 cds-synon 20201924 rs4276859 chr1 24416133 C T 2.80E-04 Alzheimer's disease MYOM3 cds-synon 22005930 rs12568789 chr1 24422626 C T 1.78E-04 Suicide attempts in bipolar disorder MYOM3 intron 21423239 rs3934861 chr1 24431956 G A 4.00E-06 Bipolar disorder (mood-incongruent) MYOM3 intron 23092984 rs3934861 chr1 24431956 G A 7.41E-05 Body Mass Index MYOM3 intron pha003009 rs12062136 chr1 24433006 C A 6.69E-04 Parkinson's disease MYOM3 intron 17052657 rs12062136 chr1 24433006 C A 2.55E-05 AIDS progression MYOM3 intron 19115949 rs12062136 chr1 24433006 C A 4.48E-06 Height MYOM3 intron pha003011 rs7534564 chr1 24437063 A G 9.83E-05 Non-alcoholic fatty liver disease histology (other) MYOM3 intron 20708005 rs7534564 chr1 24437063 A G 1.36E-06 Body Mass Index MYOM3 intron pha003009 rs7534564 chr1 24437063 A G 2.58E-07 Height MYOM3 intron pha003010 rs7534564 chr1 24437063 A G 7.83E-10 Height MYOM3 intron pha003011 rs11249175 chr1 24440043 C T 9.96E-04 Acute lung injury / / 22295056 rs6686007 chr1 24442907 T C 8.12E-04 Acute lung injury / / 22295056 rs11249201 chr1 24452399 T C 1.21E-04 Multiple complex diseases IL22RA1 intron 17554300 rs7513249 chr1 24472083 C T 1.25E-04 Hearing function / / 17255346 rs4648940 chr1 24475177 C T 3.50E-05 Alcohol dependence / / 24277619 rs4330872 chr1 24476370 C T 4.55E-05 Height / / pha003011 rs10903032 chr1 24480864 G A 1.90E-04 Suicidal ideation with citalopram treatment IL28RA UTR-3 19724244 rs10903034 chr1 24480905 C T 3.02E-06 Suicidal ideation with citalopram treatment IL28RA UTR-3 19724244 rs12028945 chr1 24482004 G A 1.60E-04 Endometriosis IL28RA UTR-3 21151130 rs11249006 chr1 24482474 G A 4.20E-05 Suicidal ideation with citalopram treatment IL28RA UTR-3 19724244 rs4649195 chr1 24485941 T C 3.20E-04 Suicidal ideation with citalopram treatment IL28RA intron 19724244 rs1416834 chr1 24486660 G A 3.60E-06 Suicidal ideation with citalopram treatment IL28RA intron 19724244 rs6698365 chr1 24497823 G T 1.18E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines IL28RA intron 21844884 rs6698365 chr1 24497823 G T 6.50E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines IL28RA intron 21844884 rs3893318 chr1 24505944 G T 2.52E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines IL28RA intron 21844884 rs3893319 chr1 24506049 A G 1.63E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines IL28RA intron 21844884 rs3893319 chr1 24506049 A G 9.84E-07 Cisplatin and carboplatin cytotoxicity,in blood cell lines IL28RA intron 21844884 rs7552167 chr1 24518643 A G 8.50E-12 Psoriasis / / 23143594 rs7552167 chr1 24518643 A G 6.00E-05 Erythrocyte counts / / pha003099 rs4649203 chr1 24519920 G A 7.00E-08 Psoriasis / / 20953190 rs12046369 chr1 24526135 G T 5.60E-05 Blood Pressure / / pha003048 rs16860738 chr1 24532144 T C 9.67E-04 Alcohol dependence LOC284632 intron 21314694 rs11249039 chr1 24552835 A G 8.30E-05 Creatinine levels / / 20222955 rs10903062 chr1 24556756 G A 2.60E-05 Creatinine levels / / 20222955 rs7517309 chr1 24572806 A G 2.80E-05 Creatinine levels / / 20222955 rs12407356 chr1 24578011 G A 3.36E-05 Bipolar disorder and schizophrenia / / 20889312 rs6670533 chr1 24584490 G A 6.00E-06 Fasting insulin-related traits (interaction with BMI) / / 22581228 rs7535789 chr1 24607419 T C 1.88E-04 Multiple complex diseases / / 17554300 rs10794657 chr1 24626174 A G 2.00E-07 Adiponectin levels / / 22479202 rs2248219 chr1 24645356 A G 7.72E-05 Orofacial clefts GRHL3 nearGene-5 22419666 rs16829445 chr1 24659047 G C 5.76E-04 Multiple complex diseases GRHL3 intron 17554300 rs9424363 chr1 24773803 T A 7.68E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) NIPAL3 intron 24192120 rs11249117 chr1 24780356 C A 1.00E-04 Information processing speed NIPAL3 intron 21130836 rs195717 chr1 24826104 G A 5.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RCAN3AS intron 20877124 rs196402 chr1 24838493 A G 1.50E-05 Reading and spelling RCAN3 intron 23738518 rs11801912 chr1 24861373 T C 1.47E-04 Suicide attempts in bipolar disorder RCAN3 intron 21423239 rs11801547 chr1 24861399 A G 1.40E-04 Suicide attempts in bipolar disorder RCAN3 intron 21423239 rs11799673 chr1 24861471 G A 2.57E-04 Suicide attempts in bipolar disorder RCAN3 intron 21423239 rs6669881 chr1 24862749 A G 1.30E-04 Suicide attempts in bipolar disorder RCAN3 UTR-3 21423239 rs10489444 chr1 24863530 C T 9.06E-05 Suicide attempts in bipolar disorder LOC100506985 intron 21423239 rs7540973 chr1 24864576 G T 1.32E-04 Suicide attempts in bipolar disorder LOC100506985 intron 21423239 rs6697800 chr1 24867540 G A 1.30E-04 Suicide attempts in bipolar disorder LOC100506985 intron 21423239 rs2809964 chr1 24875490 C T 3.88E-05 Lung adenocarcinoma LOC100506985 intron 19836008 rs6424099 chr1 24881126 C T 6.00E-05 Asthma LOC100506985 intron 20698975 rs2809963 chr1 24889450 A T 3.12E-04 Suicide attempts in bipolar disorder C1orf130 intron 21423239 rs2809963 chr1 24889450 A T 0.0000137 HDL cholesterol particle diameter C1orf130 intron 23263444 rs9729036 chr1 24917543 A G 4.43E-04 Multiple complex diseases C1orf130 intron 17554300 rs12072370 chr1 24967165 G A 1.30E-04 Insulin resistance / / 21901158 rs4601530 chr1 25044111 C T 2.00E-12 Height / / 20881960 rs3131499 chr1 25076296 A T 9.20E-04 Multiple complex diseases CLIC4 intron 17554300 rs10732912 chr1 25128123 A C 3.39E-04 Multiple complex diseases CLIC4 intron 17554300 rs3131513 chr1 25193155 G A 2.00E-06 Alcohol dependence / / 23942779 rs3131513 chr1 25193155 G A 3.20E-04 Nicotine use / / 23942779 rs3131513 chr1 25193155 G A 3.50E-04 Illicit drug use / / 23942779 rs4648881 chr1 25197155 G A 0.000000466 Juvenile idiopathic arthritis (including oligoarticular and rheumatoid factor-negative polyarticular JIA) / / 23603761 rs4648881 chr1 25197155 G A 0.000084 Oligoarticular juvenile idiopathic arthritis / / 23603761 rs4648881 chr1 25197155 G A 0.000213 Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis / / 23603761 rs11249196 chr1 25216152 T A 7.52E-04 Multiple complex diseases / / 17554300 rs2236851 chr1 25243554 C T 4.30E-05 Taste perception RUNX3 intron 22132133 rs7551188 chr1 25273200 T C 9.00E-06 Crohn's disease RUNX3 intron 23266558 rs876109 chr1 25273288 T C 9.49E-04 Alzheimer's disease RUNX3 intron 22005930 rs72657048 chr1 25289734 C G 3.80E-06 Celiac disease RUNX3 intron 22057235 rs7536201 chr1 25293084 T C 2.30E-12 Psoriasis / / 23143594 rs10903118 chr1 25294878 T C 7.00E-04 Ankylosing spondylitis / / 21743469 rs10751776 chr1 25296743 A C 7.00E-06 IgG glycosylation / / 23382691 rs11249215 chr1 25297184 G A 9.23E-04 Type 2 diabetes / / 17463246 rs11249215 chr1 25297184 G A 9.00E-11 Ankylosing spondylitis / / 21743469 rs11581762 chr1 25298408 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10903122 chr1 25303576 A G 2.00E-10 Celiac disease / / 20190752 rs10903122 chr1 25303576 A G 2.00E-10 Asthma / / 21150878 rs10903122 chr1 25303576 A G 1.73E-10 Celiac disease and Rheumatoid arthritis / / 21383967 rs10903122 chr1 25303576 A G 2.00E-10 Asthma / / 21907864 rs10903122 chr1 25303576 A G 1.73E-10 Multiple sclerosis / / 22190364 rs12567208 chr1 25308531 T G 1.31E-04 Prion diseases / / 22210626 rs9438880 chr1 25322574 A G 1.14E-04 Prion diseases / / 22210626 rs11249232 chr1 25331585 A G 3.09E-04 Aortic root size / / 21223598 rs755394 chr1 25333899 T C 7.75E-04 Aortic root size / / 21223598 rs10903126 chr1 25344155 A G 9.76E-05 Cognitive test performance / / 20125193 rs387240 chr1 25359929 T C 1.00E-05 Urinary metabolites / / 21572414 rs4649057 chr1 25375177 T C 1.70E-05 Urinary metabolites / / 21572414 rs11248971 chr1 25375583 G A 1.19E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs369427 chr1 25378444 A G 5.60E-06 Urinary metabolites / / 21572414 rs10489162 chr1 25379395 C G 2.00E-05 Urinary metabolites / / 21572414 rs10903024 chr1 25397349 T C 2.25E-04 Body mass index / / 17255346 rs16830335 chr1 25400812 T C 0.0005013 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs16830335 chr1 25400812 T C 5.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs427614 chr1 25401437 G A 3.25E-09 HDL cholesterol particle diameter / / 23263444 rs380337 chr1 25401850 A G 3.08E-09 HDL cholesterol particle diameter / / 23263444 rs10903027 chr1 25402624 C T 5.00E-06 IgG glycosylation / / 23382691 rs12076534 chr1 25405012 G A 0.0004577 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12076534 chr1 25405012 G A 4.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7514299 chr1 25405809 T A 0.0004568 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7514299 chr1 25405809 T A 4.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs10493026 chr1 25407854 G T 7.31E-05 Waist-Hip Ratio / / pha003028 rs12091321 chr1 25407933 C G 0.0004562 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12091321 chr1 25407933 C G 4.56E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12081177 chr1 25408685 G T 0.0004574 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12081177 chr1 25408685 G T 4.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7533661 chr1 25413466 G A 0.0004311 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7533661 chr1 25413466 G A 4.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11588172 chr1 25421990 T C 9.02E-06 Chronic obstructive pulmonary disease / / 19300482 rs803313 chr1 25434242 T C 8.23E-05 Major depressive disorder / / 21621269 rs7530932 chr1 25467161 G A 8.20E-04 Alcohol dependence / / 20201924 rs2064251 chr1 25469913 G A 9.72E-06 Anorexia nervosa / / 21079607 rs6600257 chr1 25472465 G A 0.0000344 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12736858 chr1 25521090 C T 1.20E-05 Hypothyroidism / / 22493691 rs11248998 chr1 25529362 C T 5.60E-05 Hypothyroidism / / 22493691 rs77353590 chr1 25535051 C T 0.0000542 Menopause (age at onset) / / 23424626 rs1043879 chr1 25570081 T C 2.00E-09 Erythrocyte sedimentation rate C1orf63 missense 21700265 rs1043879 chr1 25570081 T C 1.34E-04 Myocardial Infarction C1orf63 missense pha002883 rs1830962 chr1 25623967 A G 4.20E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines RHD intron 21844884 rs3091242 chr1 25674785 C T 2.00E-13 Erythrocyte sedimentation rate TMEM50A intron 21700265 rs1293259 chr1 25695835 G A 2.90E-71 Rhesus system E antigen RHCE intron 22611595 rs926438 chr1 25753638 C T 5.57E-04 Multiple complex diseases / / 17554300 rs926438 chr1 25753638 C T 8.77E-05 Smoking behavior / / 20418889 rs873308 chr1 25758655 G A 4.64E-09 Triglycerides TMEM57 intron 19060911 rs873308 chr1 25758655 G A 0.00000113 LDL cholesterol TMEM57 intron 23063622 rs11802413 chr1 25760920 C T 3.03E-04 Multiple complex diseases TMEM57 intron 17554300 rs11802413 chr1 25760920 C T 4.11E-05 Smoking behavior TMEM57 intron 20418889 rs7541095 chr1 25761291 T C 4.73E-05 Smoking behavior TMEM57 intron 20418889 rs10903129 chr1 25768937 A G 3.95E-04 Multiple complex diseases TMEM57 intron 17554300 rs10903129 chr1 25768937 A G 5.00E-10 Cholesterol,total TMEM57 intron 19060911 rs10903129 chr1 25768937 A G 2.30E-04 Lipid levels TMEM57 intron 19936222 rs10903129 chr1 25768937 A G 3.87E-05 Smoking behavior TMEM57 intron 20418889 rs10903129 chr1 25768937 A G 5.00E-13 Erythrocyte sedimentation rate TMEM57 intron 21700265 rs12027135 chr1 25775733 A T 3.98E-05 Smoking behavior TMEM57 intron 20418889 rs12027135 chr1 25775733 A T 1.00E-10 LDL cholesterol TMEM57 intron 20686565 rs12027135 chr1 25775733 A T 4.00E-11 Cholesterol,total TMEM57 intron 20686565 rs12027135 chr1 25775733 A T 2.00E-14 LDL cholesterol TMEM57 intron 24097068 rs12027135 chr1 25775733 A T 5.00E-12 Cholesterol,total TMEM57 intron 24097068 rs61776821 chr1 25885528 G A 0.0000781 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs61776822 chr1 25885592 G A 0.0000664 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs61776823 chr1 25887525 G A 0.0000744 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs12096438 chr1 25889422 C T 0.0000417 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs6687605 chr1 25889632 T C 0.0000396 Nonsyndromic striae distensae (stretch marks) LDLRAP1 missense 23633020 rs6701596 chr1 25889917 T C 0.0000365 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs6661159 chr1 25890050 A G 0.0000392 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs28969504 chr1 25890189 A G 0.0000387 Nonsyndromic striae distensae (stretch marks) LDLRAP1 cds-synon 23633020 rs4075184 chr1 25890835 G A 0.0000348 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs3856239 chr1 25891174 G A 0.000038 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs56214942 chr1 25891959 G A 0.0000417 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs11799800 chr1 25891971 C T 0.0000386 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs4400597 chr1 25892298 G T 0.0000381 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs3856240 chr1 25892525 T C 0.0000424 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs4523506 chr1 25893221 G T 0.0000382 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs4603124 chr1 25893243 G A 0.0000652 Nonsyndromic striae distensae (stretch marks) LDLRAP1 intron 23633020 rs11563 chr1 25894853 G T 0.00005 Nonsyndromic striae distensae (stretch marks) LDLRAP1 UTR-3 23633020 rs7491 chr1 25895238 C T 0.0000527 Nonsyndromic striae distensae (stretch marks) LDLRAP1 UTR-3 23633020 rs3924236 chr1 25895406 C T 0.0000714 Nonsyndromic striae distensae (stretch marks) LDLRAP1 nearGene-3 23633020 rs3924235 chr1 25895526 G A 0.0000637 Nonsyndromic striae distensae (stretch marks) LDLRAP1 nearGene-3 23633020 rs4659357 chr1 25900240 G A 5.69E-05 Cognitive impairment induced by topiramate / / 22091778 rs2065970 chr1 26051523 A G 8.48E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) MAN1C1 intron 20877124 rs2065970 chr1 26051523 A G 6.02E-08 Common variable immunodeficiency MAN1C1 intron 21497890 rs2744768 chr1 26057309 T G 9.90E-05 Hypothyroidism MAN1C1 intron 22493691 rs2786876 chr1 26073443 T C 7.97E-04 Smoking quantity MAN1C1 intron 24665060 rs12130495 chr1 26085398 G T 1.10E-04 Pulmonary emphysema MAN1C1 intron 24383474 rs17163225 chr1 26087669 T G 1.50E-04 Multiple complex diseases MAN1C1 intron 17554300 rs17163225 chr1 26087669 T G 0.0000029 Mean arterial pressure MAN1C1 intron 22510845 rs3820514 chr1 26110065 A G 7.14E-04 Smoking quantity MAN1C1 intron 24665060 rs11247740 chr1 26137025 T A 1.34E-04 Multiple complex diseases SEPN1 intron 17554300 rs6872 chr1 26144674 G A 2.98E-06 Phospholipid levels (plasma) SEPN1 UTR-3 21829377 rs7552868 chr1 26155201 G T 4.48E-05 HDL cholesterol FAM54B intron pha003075 rs213627 chr1 26172111 A G 3.38E-05 HDL cholesterol C1orf135 intron pha003075 rs11247815 chr1 26176728 C T 4.95E-04 Multiple complex diseases C1orf135 intron 17554300 rs1257163 chr1 26250059 C T 0.000162905 Hypertension (early onset hypertension) / / 22479346 rs2275101 chr1 26310213 T C 3.19E-04 Intracranial aneurysm PAFAH2 intron 20613766 rs12743484 chr1 26335929 G A 1.50E-04 Intracranial aneurysm / / 20613766 rs17163470 chr1 26351382 T C 2.10E-04 Multiple complex diseases EXTL1 intron 17554300 rs12072473 chr1 26353367 G A 7.87E-05 Cognitive impairment induced by topiramate EXTL1 intron 22091778 rs1938404 chr1 26358202 G A 7.17E-04 Bipolar disorder EXTL1 intron 19259986 rs1317709 chr1 26384690 T G 5.18E-04 Alzheimer's disease TRIM63 intron 17998437 rs1317709 chr1 26384690 T G 8.27E-04 Bipolar disorder TRIM63 intron 19259986 rs2275949 chr1 26385150 G C 2.39E-04 Alzheimer's disease TRIM63 intron 17998437 rs2997447 chr1 26387423 G A 2.91E-06 Waist-hip ratio TRIM63 intron 20935629 rs2783681 chr1 26441207 A C 5.76E-04 Multiple complex diseases PDIK1L intron 17554300 rs868551 chr1 26475521 A G 6.90E-05 Malaria / / 19465909 rs11247864 chr1 26517667 T C 0.00000311 Lumbar spine bone mineral density (premenopausal) CATSPER4 intron 23074152 rs11247864 chr1 26517667 T C 0.000805 Femoral neck bone mineral density (premenopausal) CATSPER4 intron 23074152 rs11809207 chr1 26521140 G A 6.00E-08 Height CATSPER4 intron 19343178 rs17257155 chr1 26526439 A G 4.53E-04 Alzheimer's disease CATSPER4 missense 17998437 rs17257155 chr1 26526439 A G 7.68E-32 Narcolepsy CATSPER4 missense 19629137 rs4585968 chr1 26535146 G A 2.25E-04 Heart Failure / / pha002884 rs11579247 chr1 26549637 G A 6.93E-05 Cognitive performance / / 19734545 rs10493028 chr1 26552921 T C 3.73E-05 Cognitive performance / / 19734545 rs2050473 chr1 26554096 C G 5.01E-06 Statin-induced myopathy / / 21826682 rs2050475 chr1 26565665 G A 6.89E-04 Multiple complex diseases CEP85 intron 17554300 rs17163749 chr1 26568165 A G 3.80E-04 Primary sclerosing cholangitis CEP85 intron 19944697 rs10902723 chr1 26568542 T C 9.00E-06 Obesity-related traits CEP85 intron 23251661 rs3795686 chr1 26582091 G A 0.00076 Breast cancer CEP85 missense 23555315 rs12757113 chr1 26597144 G A 2.88E-04 Alzheimer's disease CEP85 intron 17998437 rs3795685 chr1 26601385 G A 9.99E-04 Alzheimer's disease CEP85 intron 17998437 rs6598955 chr1 26619649 C T 4.00E-06 Obesity-related traits UBXN11 intron 23251661 rs6598955 chr1 26619649 C T 7.00E-06 Obesity-related traits UBXN11 intron 23251661 rs12068388 chr1 26621596 G A 1 Drug response to Etoposide UBXN11 intron 17537913 rs7541416 chr1 26622911 G A 2.40E-05 Tuberculosis UBXN11 intron 24057671 rs4290051 chr1 26624327 G A 2.72E-04 Multiple complex diseases UBXN11 intron 17554300 rs12726972 chr1 26639634 G A 1.08E-04 Alzheimer's disease UBXN11 intron 17998437 rs11247915 chr1 26650550 C A 5.00E-06 Obesity-related traits AIM1L intron 23251661 rs7544018 chr1 26651132 C G 6.86E-04 Lymphocyte counts AIM1L intron 22286170 rs12563321 chr1 26666502 C T 0.0000287 Uterine leiomyomata AIM1L intron 23040493 rs10902742 chr1 26676257 G T 0.0000591 Uterine leiomyomata AIM1L intron 23040493 rs4233461 chr1 26681306 G A 6.24E-05 Elbow pain / / pha003008 rs9438620 chr1 26716136 C T 8.21E-04 Schizophrenia / / 19197363 rs11587947 chr1 26719264 C T 9.69E-06 Obesity-related traits / / 23251661 rs12722898 chr1 26721287 G A 1.13E-04 Vaspin levels / / 22907691 rs12722898 chr1 26721287 G A 0.0000728 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs12722898 chr1 26721287 G A 0.0001126 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at last visit / / 22907730 rs7532866 chr1 26741544 A G 3.00E-08 Height LIN28A intron 20881960 rs12728900 chr1 26746807 G A 0.0000228 Otitis media (children 3 years old or younger) LIN28A intron 23133572 rs6656196 chr1 26758773 G A 2.93E-08 Red blood cell traits DHDDS UTR-5 23222517 rs3811461 chr1 26759149 A G 1.06E-07 Red blood cell traits DHDDS intron 23222517 rs11247958 chr1 26767367 C T 6.01E-08 Red blood cell traits DHDDS intron 23222517 rs4659374 chr1 26779270 C T 4.95E-06 Leprosy DHDDS intron 22019778 rs3816539 chr1 26786627 G A 1.33E-07 Red blood cell traits DHDDS missense 23222517 rs6690458 chr1 26789787 T C 1.25E-07 Red blood cell traits DHDDS intron 23222517 rs6675469 chr1 26789813 G A 1.44E-07 Red blood cell traits DHDDS intron 23222517 rs2290588 chr1 26797508 C T 8.13E-08 Red blood cell traits DHDDS UTR-3 23222517 rs4659375 chr1 26804090 G A 7.92E-08 Red blood cell traits / / 23222517 rs7530096 chr1 26820218 G A 2.35E-07 Red blood cell traits / / 23222517 rs4970498 chr1 26844195 G A 1.69E-07 Red blood cell traits / / 23222517 rs12046497 chr1 26847640 C T 2.01E-07 Red blood cell traits / / 23222517 rs12094989 chr1 26848386 C T 2.96E-07 Red blood cell traits / / 23222517 rs4970466 chr1 26849312 G A 2.17E-07 Red blood cell traits / / 23222517 rs7539320 chr1 26850665 C T 1.97E-07 Red blood cell traits / / 23222517 rs6670311 chr1 26865485 C G 0.000000201 Triglycerides RPS6KA1 intron 23063622 rs282177 chr1 26899125 C T 6.39E-05 Multiple sclerosis RPS6KA1 intron 17660530 rs190737 chr1 26899444 C A 4.40E-04 Nonalcoholic fatty liver disease RPS6KA1 intron 21423719 rs2229714 chr1 26900708 G A 1.51E-06 Dilated cardiomyopathy RPS6KA1 UTR-3 20975947 rs6699237 chr1 26925843 C T 2.69E-05 Multiple complex diseases / / 17554300 rs17162257 chr1 26929002 T G 1.00E-06 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6598860 chr1 27021684 G A 7.73E-04 Alzheimer's disease ARID1A nearGene-5 24755620 rs4589135 chr1 27041714 T C 9.58E-04 Alzheimer's disease ARID1A intron 24755620 rs12742115 chr1 27079931 T C 8.94E-05 Response to mTOR inhibitor (rapamycin) ARID1A intron 24009623 rs12748152 chr1 27138393 C T 1.00E-09 Triglycerides / / 24097068 rs12748152 chr1 27138393 C T 1.00E-15 HDL cholesterol / / 24097068 rs12748152 chr1 27138393 C T 3.00E-12 LDL cholesterol / / 24097068 rs17162339 chr1 27252823 C A 3.36E-04 Multiple complex diseases NUDC intron 17554300 rs12239134 chr1 27272864 C T 5.66E-05 Multiple complex diseases NUDC UTR-3 17554300 rs6669265 chr1 27361219 G A 5.97E-07 Hearing function / / 21493956 rs2256674 chr1 27375717 A G 4.30E-04 Blood pressure / / 17255346 rs5810 chr1 27426219 A G 9.25E-04 Suicide attempts in bipolar disorder SLC9A1 UTR-3 21423239 rs6598870 chr1 27428321 T C 9.25E-04 Suicide attempts in bipolar disorder SLC9A1 intron 21423239 rs12118026 chr1 27432745 A G 9.25E-04 Suicide attempts in bipolar disorder SLC9A1 intron 21423239 rs12123077 chr1 27437217 A G 9.51E-04 Suicide attempts in bipolar disorder SLC9A1 intron 21423239 rs11806219 chr1 27448048 G A 5.57E-11 Triglycerides SLC9A1 intron 23063622 rs11807614 chr1 27464917 A G 1.15E-13 Triglycerides SLC9A1 intron 23063622 rs11247611 chr1 27467984 C T 8.73E-06 Post-operative nausea and vomiting SLC9A1 intron 21694509 rs12751422 chr1 27493679 T C 5.50E-04 Type 2 diabetes / / 17463246 rs12117956 chr1 27497582 A G 0.0000397 Uterine leiomyomata / / 23040493 rs6687674 chr1 27537101 G A 0.0000467 Uterine leiomyomata / / 23040493 rs12565684 chr1 27661037 T C 7.81E-05 Response to mTOR inhibitor (rapamycin) TMEM222 intron 24009623 rs187197622 chr1 27677375 G A 0.000038 Breast cancer(er negative) SYTL1 missense 23555315 rs1138294 chr1 27688633 G A 6.79E-04 Premature ovarian failure MAP3K6 missense 19508998 rs11548323 chr1 27731651 C T 2.00E-06 Estradiol plasma levels (breast cancer) WASF2 UTR-3 23518928 rs2474293 chr1 27755669 A C 7.08E-04 Multiple complex diseases WASF2 intron 17554300 rs6598886 chr1 27849300 T C 8.20E-05 Multiple complex diseases / / 17554300 rs6598886 chr1 27849300 T C 2.04E-05 Myocardial Infarction / / pha002873 rs7512595 chr1 27857171 A G 9.40E-05 Myocardial Infarction / / pha002873 rs17357586 chr1 27873001 G C 1.10E-04 Multiple complex diseases AHDC1 intron 17554300 rs17162040 chr1 27883227 T C 3.18E-04 Response to taxane treatment (placlitaxel) AHDC1 intron 23006423 rs4908343 chr1 27931698 G A 1.21E-07 Esophageal cancer (squamous cell) / / 20729853 rs6658795 chr1 27960011 C T 3.92E-04 Multiple complex diseases FGR intron 17554300 rs73494 chr1 27975384 A G 3.86E-06 Bipolar disorder / / 17486107 rs17162722 chr1 27997568 C T 5.95E-04 Multiple complex diseases IFI6 intron 17554300 rs10902662 chr1 27998394 C T 6.86E-04 Type 2 diabetes IFI6 intron 17463246 rs2788686 chr1 28012280 G C 1.37E-04 Type 2 diabetes / / 17463246 rs6598902 chr1 28105709 T C 6.57E-08 Gallstones STX12 intron 17632509 rs1467464 chr1 28211650 T C 3.99E-04 Smoking initiation C1orf38 intron 24665060 rs6564 chr1 28212975 C T 5.78E-04 Smoking initiation C1orf38 UTR-3 24665060 rs3766396 chr1 28221554 A G 2.09E-04 Lymphocyte counts RPA2 intron 22286170 rs2295367 chr1 28224312 C T 2.04E-07 Lymphocyte counts RPA2 intron 22286170 rs6679432 chr1 28227665 T C 6.36E-04 Smoking initiation RPA2 intron 24665060 rs2474470 chr1 28234999 C T 5.36E-04 Smoking initiation RPA2 intron 24665060 rs6700473 chr1 28236682 G A 2.20E-04 Smoking initiation RPA2 intron 24665060 rs4409675 chr1 28262409 A T 2.00E-06 Corneal astigmatism SMPDL3B intron 23322567 rs12565238 chr1 28299346 C T 3.39E-04 Type 2 diabetes EYA3 UTR-3 17463246 rs7529792 chr1 28306250 C T 8.12E-04 Schizophrenia EYA3 intron 19197363 rs2492958 chr1 28314423 A G 5.51E-07 Multiple complex diseases EYA3 intron 17554300 rs10493035 chr1 28315461 C T 1.98E-04 Type 2 diabetes EYA3 intron 17463246 rs17162928 chr1 28343518 G T 3.40E-04 Type 2 diabetes EYA3 intron 17463246 rs2311587 chr1 28416898 G A 3.40E-04 Type 2 diabetes / / 17463246 rs2486674 chr1 28420384 A G 4.65E-05 Post-operative nausea and vomiting / / 21694509 rs11247752 chr1 28426001 T G 2.10E-05 Urinary metabolites / / 21572414 rs1769711 chr1 28455037 A G 8.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10751727 chr1 28461661 T C 4.08E-04 Alzheimer's disease (late onset) / / 21379329 rs6679420 chr1 28500834 G A 0.000000146 LDL cholesterol PTAFR intron 23063622 rs17162987 chr1 28521479 T C 2.59E-04 Multiple complex diseases PTAFR nearGene-5 17554300 rs12129745 chr1 28572317 G C 1.96E-05 Lymphocyte counts / / 22286170 rs4252976 chr1 28962633 G A 6.97E-04 Smoking initiation TAF12 intron 24665060 rs9426394 chr1 29007729 G T 2.09E-05 Smoking initiation GMEB1 intron 24665060 rs2236861 chr1 29139756 G A 0.0005 Coronary artery calcification OPRD1 intron 23727086 rs2236861 chr1 29139756 G A 7.31E-05 Height OPRD1 intron pha003011 rs678849 chr1 29145188 C T 9.36E-06 Amyotrophic Lateral Sclerosis OPRD1 intron 17827064 rs797397 chr1 29151183 G A 0.0005 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes OPRD1 intron 22628534 rs419335 chr1 29151844 A G 6.81E-04 Response to statin treatment (atorvastatin),change in cholesterol levels OPRD1 intron 20031582 rs538485 chr1 29164561 T G 8.30E-06 Urinary metabolites OPRD1 intron 21572414 rs4654323 chr1 29168957 G T 6.61E-04 Response to statin treatment (atorvastatin),change in cholesterol levels OPRD1 intron 20031582 rs595725 chr1 29172715 C A 5.30E-04 Breast cancer and prostate cancer OPRD1 intron 17903305 rs16837730 chr1 29180014 C T 4.00E-04 Upper aerodigestive tract cancers OPRD1 intron 21437268 rs6690810 chr1 29186859 A G 3.18E-12 Multiple complex diseases OPRD1 intron 17554300 rs157217 chr1 29208997 A G 1.81E-04 Multiple complex diseases / / 17554300 rs203279 chr1 29242454 T A 2.41E-04 Multiple complex diseases EPB41 intron 17554300 rs157208 chr1 29245406 T C 3.14E-04 Birth weight EPB41 intron 17255346 rs150088 chr1 29262533 A G 8.32E-05 Serum metabolites EPB41 intron 19043545 rs204057 chr1 29272057 C A 1.82E-04 Birth weight EPB41 intron 17255346 rs1038493 chr1 29288078 A G 4.55E-05 Response to statin treatment (atorvastatin),change in cholesterol levels EPB41 intron 20031582 rs2985334 chr1 29345027 T G 3.50E-05 Sleep and circadian phenotypes EPB41 intron 17903308 rs2985334 chr1 29345027 T G 6.00E-06 Amyotrophic lateral sclerosis (sporadic) EPB41 intron 24529757 rs2788890 chr1 29352653 G C 6.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels EPB41 intron 20031582 rs4654388 chr1 29397790 A G 5.75E-04 Multiple complex diseases EPB41 intron 17554300 rs2503015 chr1 29407230 T A 7.33E-04 Response to statin treatment (atorvastatin),change in cholesterol levels EPB41 intron 20031582 rs2254241 chr1 29418033 A G 2.19E-04 Response to statin treatment (atorvastatin),change in cholesterol levels EPB41 intron 20031582 rs12039988 chr1 29425833 G A 8.63E-04 Tourette syndrome EPB41 intron 22889924 rs12045777 chr1 29429004 C T 2.43E-04 Sleep time EPB41 intron 23728906 rs578800 chr1 29437106 G A 1.68E-04 Multiple complex diseases EPB41 intron 17554300 rs1994859 chr1 29497820 C T 1.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels SRSF4 intron 20031582 rs3094740 chr1 29507647 G C 9.25E-04 Multiple complex diseases SRSF4 intron 17554300 rs1128400 chr1 29542637 A G 8.80E-05 Response to statin treatment (atorvastatin),change in cholesterol levels MECR missense 20031582 rs2640467 chr1 29556158 T C 4.72E-05 Amyotrophic lateral sclerosis (sporadic) MECR intron 24529757 rs12057666 chr1 29571758 T G 2.13E-04 Multiple complex diseases PTPRU intron 17554300 rs1032425 chr1 29575605 C A 3.79E-04 Amyotrophic lateral sclerosis (sporadic) PTPRU intron 24529757 rs7550930 chr1 29594563 T C 8.03E-06 Asthma PTPRU intron 21790008 rs7518159 chr1 29621460 C T 1.72E-07 Multiple complex diseases PTPRU intron 17554300 rs9426315 chr1 29625375 G A 2.32E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PTPRU intron 20031582 rs3737606 chr1 29630956 A G 5.24E-05 Bipolar disorder and schizophrenia PTPRU intron 20889312 rs12735793 chr1 29636976 G A 1.60E-06 Primary sclerosing cholangitis PTPRU intron 21151127 rs1997865 chr1 29643881 T A 2.50E-05 Urinary metabolites PTPRU intron 21572414 rs761429 chr1 29678592 G A 7.10E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs761430 chr1 29678774 C A 3.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4654339 chr1 29742743 T C 0.00004661 Sarcoidosis / / 22952805 rs6426360 chr1 29743391 T C 0.00002399 Sarcoidosis / / 22952805 rs6657309 chr1 29743408 A G 0.0000793 Sarcoidosis / / 22952805 rs1408857 chr1 29743630 C T 0.000007098 Sarcoidosis / / 22952805 rs10799133 chr1 29745602 A G 0.00002337 Sarcoidosis / / 22952805 rs4431811 chr1 29746380 A G 0.00006519 Sarcoidosis / / 22952805 rs6686991 chr1 29747162 G T 0.00006337 Sarcoidosis / / 22952805 rs10753338 chr1 29747573 A C 0.00003257 Sarcoidosis / / 22952805 rs9426341 chr1 29747979 G T 0.00001326 Sarcoidosis / / 22952805 rs6700562 chr1 29748777 C T 0.00006355 Sarcoidosis / / 22952805 rs2182112 chr1 29749659 T C 0.00001413 Sarcoidosis / / 22952805 rs2147782 chr1 29749776 T C 0.0000468 Sarcoidosis / / 22952805 rs1408863 chr1 29750255 A G 0.00008708 Sarcoidosis / / 22952805 rs1408862 chr1 29750448 T C 0.00008833 Sarcoidosis / / 22952805 rs9426445 chr1 29752947 A G 0.00005496 Sarcoidosis / / 22952805 rs10915268 chr1 29753610 G A 3.10E-06 Urinary metabolites / / 21572414 rs977497 chr1 29754433 A G 0.00004048 Sarcoidosis / / 22952805 rs10915272 chr1 29754708 G A 2.40E-06 Urinary metabolites / / 21572414 rs1359465 chr1 29756066 C T 0.00002194 Sarcoidosis / / 22952805 rs10915275 chr1 29761294 G T 0.00007444 Sarcoidosis / / 22952805 rs2182111 chr1 29764800 A T 0.00006852 Sarcoidosis / / 22952805 rs4654355 chr1 29794279 G A 4.95E-05 Serum metabolites / / 19043545 rs6426365 chr1 29806634 A G 3.53E-04 Schizophrenia / / 19197363 rs6664690 chr1 29827798 C T 6.15E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12069708 chr1 29854675 A C 3.88E-04 Alzheimer's disease / / 17998437 rs12071830 chr1 29854740 T G 6.67E-04 Alzheimer's disease / / 17998437 rs7547083 chr1 29859057 G A 4.27E-04 Alzheimer's disease / / 17998437 rs6426342 chr1 29859764 G C 6.06E-04 Alzheimer's disease / / 17998437 rs10914282 chr1 30062973 G A 8.99E-04 Multiple complex diseases / / 17554300 rs1932397 chr1 30063197 C T 7.10E-05 Type 2 diabetes / / 17463248 rs1932397 chr1 30063197 C T 5.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs6603927 chr1 30064009 A G 2.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs6603926 chr1 30066155 A G 7.00E-05 Type 2 diabetes / / 17463248 rs6603926 chr1 30066155 A G 6.09E-04 Suicide attempts in bipolar disorder / / 21423239 rs9660251 chr1 30068857 T C 1.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs9662524 chr1 30070403 G C 7.30E-05 Type 2 diabetes / / 17463248 rs9662524 chr1 30070403 G C 4.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs915409 chr1 30071270 T C 7.30E-05 Type 2 diabetes / / 17463248 rs915409 chr1 30071270 T C 3.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs4949306 chr1 30072549 A G 6.06E-05 Suicide attempts in bipolar disorder / / 21423239 rs1932392 chr1 30074983 T C 3.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs9286938 chr1 30077101 T C 9.10E-05 Type 2 diabetes / / 17463248 rs9286938 chr1 30077101 T C 4.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs9659523 chr1 30077600 A C 1.00E-04 Type 2 diabetes / / 17463248 rs9659523 chr1 30077600 A C 1.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs4949293 chr1 30078801 T C 3.38E-04 Suicide attempts in bipolar disorder / / 21423239 rs436400 chr1 30079888 T A 3.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs4949178 chr1 30081323 G A 2.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs4949291 chr1 30081359 C T 2.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs271306 chr1 30082664 G C 1.00E-04 Type 2 diabetes / / 17463248 rs271306 chr1 30082664 G C 2.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs10798895 chr1 30086662 G A 3.30E-05 Type 2 diabetes / / 17460697 rs10798895 chr1 30086662 G A 2.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs4949283 chr1 30090260 A G 8.54E-05 Suicide attempts in bipolar disorder / / 21423239 rs2044073 chr1 30093697 G T 2.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs2044072 chr1 30093908 G A 3.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs16832700 chr1 30094324 C T 8.44E-04 Multiple complex diseases / / 17554300 rs4949611 chr1 30103858 G A 4.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs502545 chr1 30109482 G A 5.56E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs9442466 chr1 30111858 C T 6.60E-04 Myopia (pathological) / / 21095009 rs271327 chr1 30115843 A G 4.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs175249 chr1 30116035 C G 4.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs692787 chr1 30117517 A G 6.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs271385 chr1 30119005 T C 7.56E-04 Suicide attempts in bipolar disorder / / 21423239 rs271383 chr1 30120287 A C 3.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs271372 chr1 30126979 A G 6.50E-04 Type 2 diabetes / / 17463246 rs271372 chr1 30126979 A G 7.40E-06 Urinary metabolites / / 21572414 rs187954 chr1 30134604 C A 8.65E-06 Alcohol and nictotine co-dependence / / 20158304 rs175250 chr1 30134671 T C 5.14E-04 Type 2 diabetes / / 17463246 rs271364 chr1 30136721 C T 3.83E-04 Type 2 diabetes / / 17463246 rs271364 chr1 30136721 C T 9.80E-06 Urinary metabolites / / 21572414 rs166604 chr1 30148652 T C 2.60E-04 Type 2 diabetes / / 17463246 rs520527 chr1 30149566 T C 2.73E-04 Type 2 diabetes / / 17463246 rs271351 chr1 30152120 G A,C,T 9.17E-04 Multiple complex diseases / / 17554300 rs4259710 chr1 30184426 A G 5.03E-04 Multiple complex diseases / / 17554300 rs1866967 chr1 30185662 A G 3.49E-05 Pulmonary function / / 19300500 rs1866967 chr1 30185662 A G 5.00E-06 Prostate cancer (gene x gene interaction) / / 22219177 rs4949268 chr1 30186956 T C 8.03E-05 Pulmonary function / / 19300500 rs6673417 chr1 30188608 T C 7.94E-05 Pulmonary function / / 19300500 rs17262657 chr1 30191649 T C 3.39E-05 Pulmonary function / / 19300500 rs10914271 chr1 30213840 T C 8.05E-05 Height / / pha003010 rs10914271 chr1 30213840 T C 4.99E-05 Height / / pha003011 rs920600 chr1 30222525 A G 5.31E-05 Height / / pha003010 rs920600 chr1 30222525 A G 3.03E-05 Height / / pha003011 rs12045312 chr1 30234753 A G 5.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12145316 chr1 30245413 C T 6.30E-05 Height / / pha003011 rs6691847 chr1 30265652 T C 7.00E-06 Non-alcoholic fatty liver disease / / 23535911 rs10914475 chr1 30278550 C T 4.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs2166884 chr1 30288207 G A 1.53E-04 Schizophrenia / / 19197363 rs12748731 chr1 30301308 T C 8.61E-06 IgE levels / / 17255346 rs12145293 chr1 30314005 A G 3.89E-04 Smoking initiation / / 24665060 rs12145156 chr1 30318156 G T 4.43E-04 Smoking initiation / / 24665060 rs921197 chr1 30319889 G A 8.03E-04 Schizophrenia / / 19197363 rs7512834 chr1 30322046 C T 3.69E-04 Schizophrenia / / 19197363 rs12134222 chr1 30348925 C A 3.77E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2197783 chr1 30359165 T C 3.65E-04 Type 2 diabetes / / 17463246 rs1001709 chr1 30359862 G A 5.50E-07 Urinary metabolites / / 21572414 rs12090063 chr1 30360122 C T 9.45E-04 Alzheimer's disease / / 22005930 rs10798921 chr1 30399109 A G 7.45E-04 Multiple complex diseases / / 17554300 rs4949232 chr1 30410502 A C 1.98E-06 Major depressive disorder / / 22472876 rs16833076 chr1 30414182 T G 1.70E-05 Urinary metabolites / / 21572414 rs16833076 chr1 30414182 T G 3.02E-05 Major depressive disorder / / 22472876 rs1498243 chr1 30415026 G A 3.89E-05 Major depressive disorder / / 22472876 rs1354366 chr1 30415774 G C 2.15E-04 Type 2 diabetes / / 17463246 rs10798928 chr1 30417560 C T 2.00E-04 Type 2 diabetes / / 17463246 rs11583644 chr1 30419370 G A 4.41E-04 Type 2 diabetes / / 17463246 rs4949522 chr1 30420739 A G 6.52E-04 Type 2 diabetes / / 17463246 rs4949237 chr1 30420873 T C 2.45E-04 Type 2 diabetes / / 17463246 rs4949238 chr1 30422596 A G 3.20E-05 Major depressive disorder / / 22472876 rs10914667 chr1 30423829 T A 2.22E-04 Type 2 diabetes / / 17463246 rs12407717 chr1 30426014 C T 4.00E-05 Major depressive disorder / / 21042317 rs12407717 chr1 30426014 C T 1.20E-06 Major depressive disorder / / 22472876 rs267700 chr1 30430366 T G 3.11E-06 Bipolar disorder and schizophrenia / / 20889312 rs1009080 chr1 30431560 G A 8.50E-07 Bipolar disorder and schizophrenia / / 20889312 rs1009080 chr1 30431560 G A 3.00E-06 Schizophrenia / / 21926974 rs4949526 chr1 30432219 T C 4.00E-07 Bipolar disorder and schizophrenia / / 20889312 rs4949526 chr1 30432219 T C 0.000111 Schizophrenia / / 23637625 rs6694545 chr1 30437268 A G 1.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs6694545 chr1 30437268 A G 3.91E-04 Smoking cessation / / 24665060 rs12401298 chr1 30439760 A G 3.95E-05 Major depressive disorder / / 22472876 rs10753284 chr1 30445050 T C 3.25E-04 Smoking cessation / / 24665060 rs904300 chr1 30459412 T C 7.64E-04 Smoking cessation / / 24665060 rs4949241 chr1 30459797 G A 9.93E-05 Major depressive disorder / / 22472876 rs409226 chr1 30472960 A G 5.46E-05 Heart Rate / / pha003053 rs452132 chr1 30478996 A G 3.35E-05 Heart Rate / / pha003053 rs404170 chr1 30485741 A G 6.23E-05 Suicide attempts in bipolar disorder / / 21423239 rs397310 chr1 30486849 C A 5.33E-05 Suicide attempts in bipolar disorder / / 21423239 rs387055 chr1 30486853 A G 7.31E-05 Suicide attempts in bipolar disorder / / 21423239 rs373073 chr1 30491129 G A 5.77E-05 Suicide attempts in bipolar disorder / / 21423239 rs267721 chr1 30496978 A G 6.69E-05 Suicide attempts in bipolar disorder / / 21423239 rs267720 chr1 30497242 G T 6.68E-05 Suicide attempts in bipolar disorder / / 21423239 rs12732511 chr1 30501138 C T 6.43E-05 Suicide attempts in bipolar disorder / / 21423239 rs12140391 chr1 30506347 C T 1.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs17341620 chr1 30508461 G A 5.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs12145453 chr1 30513725 T C 8.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs2860031 chr1 30525714 A G 3.00E-06 Bipolar disorder (mood-incongruent) / / 23092984 rs11580589 chr1 30529289 A G 9.29E-06 Bipolar disorder / / 19488044 rs11580589 chr1 30529289 A G 1.35E-05 Bipolar disorder and schizophrenia / / 20889312 rs11580589 chr1 30529289 A G 2.48E-05 Bipolar Disorder / / pha002858 rs11580622 chr1 30529446 A C 7.24E-05 Bipolar disorder and schizophrenia / / 20889312 rs391479 chr1 30530885 T C 2.35E-05 Bipolar disorder and schizophrenia / / 20889312 rs433112 chr1 30531039 T C 1.10E-05 Bipolar disorder and schizophrenia / / 20889312 rs391725 chr1 30532738 C A 1.33E-05 Bipolar disorder and schizophrenia / / 20889312 rs419527 chr1 30532849 T G 1.33E-05 Bipolar disorder and schizophrenia / / 20889312 rs16833203 chr1 30533883 C T 5.53E-04 Nicotine dependence / / 17158188 rs746758 chr1 30536711 T C 3.19E-05 Bipolar disorder and schizophrenia / / 20889312 rs369715 chr1 30554684 G A 5.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs12755901 chr1 30561353 G A 0.000094 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6670744 chr1 30561697 C G 0.0000991 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11584193 chr1 30565805 G C 0.0000872 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs61759065 chr1 30565900 A T 0.0000943 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs910696 chr1 30567596 G A 3.00E-06 Smoking behavior / / 19247474 rs2076977 chr1 30574158 T C 1.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs2376909 chr1 30574667 T G 1.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs12088570 chr1 30575319 C T 9.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs12742458 chr1 30576573 T C 5.40E-05 Endometriosis / / 21151130 rs10915026 chr1 30578274 C T 0.0000786 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10915029 chr1 30578922 C T 5.26E-04 Multiple complex diseases / / 17554300 rs12122307 chr1 30606563 G A 0.0007337 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12122307 chr1 30606563 G A 7.34E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs2180233 chr1 30627712 C T 9.00E-06 Attention deficit hyperactivity disorder and conduct disorder / / 18951430 rs6425881 chr1 30659586 G A 2.02E-05 Cognitive impairment induced by topiramate / / 22091778 rs7523165 chr1 30660403 A G 7.83E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs12072928 chr1 30660839 T G 3.99E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs10915040 chr1 30663554 A G 4.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs16833396 chr1 30687128 C A 4.13E-05 Body Mass Index / / pha003007 rs13375139 chr1 30691713 C T 6.94E-05 Alcohol consumption / / 23743675 rs59765152 chr1 30691817 C T 6.03E-05 Alcohol consumption / / 23743675 rs2142714 chr1 30692598 G A 6.69E-04 Smoking cessation / / 24665060 rs2142713 chr1 30692648 T C 6.54E-04 Smoking cessation / / 24665060 rs11806668 chr1 30694698 C T 3.76E-05 Body Mass Index / / pha003007 rs11806668 chr1 30694698 C T 8.44E-05 Body Mass Index / / pha003015 rs2179163 chr1 30709045 C T 6.72E-04 Smoking cessation / / 24665060 rs58267302 chr1 30731997 T C 5.75E-05 Alcohol consumption / / 23743675 rs459233 chr1 30750679 A G 3.86E-04 Aortic root size / / 21223598 rs376299 chr1 30754821 T G 5.29E-06 Intelligence / / 21826061 rs58245 chr1 30755532 G A 1.34E-06 Intelligence / / 21826061 rs463128 chr1 30759956 T C 2.65E-05 Intelligence / / 21826061 rs463128 chr1 30759956 T C 7.23E-04 Heart Failure / / pha002884 rs460911 chr1 30761304 G A 2.29E-05 Intelligence / / 21826061 rs411238 chr1 30787227 G A 5.87E-05 Intelligence / / 21826061 rs411238 chr1 30787227 G A 8.52E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs411238 chr1 30787227 G A 9.70E-05 Heart Failure / / pha002884 rs117311 chr1 30789341 C A 3.27E-04 Alzheimer's disease / / 17998437 rs437709 chr1 30792212 G A 4.19E-05 Triglycerides / / pha002904 rs6688031 chr1 30802598 C T 7.97E-04 Multiple complex diseases / / 17554300 rs10799104 chr1 30883503 C T 3.77E-04 Multiple complex diseases / / 17554300 rs11577262 chr1 30918166 T C 4.01E-04 Endometrial cancer / / 24096698 rs11577262 chr1 30918166 T C 7.90E-05 Endometrial cancer / / 24096698 rs454774 chr1 30923203 G T 2.10E-05 Malaria / / 19465909 rs262603 chr1 30941636 A C 2.74E-04 Multiple complex diseases / / 17554300 rs262584 chr1 30946775 C A 2.42E-04 Taste perception / / 22132133 rs12408702 chr1 30975928 C T 3.40E-06 Urinary metabolites / / 21572414 rs16833790 chr1 30980131 A G 4.20E-06 Urinary metabolites / / 21572414 rs3104429 chr1 30985076 T C 1.50E-05 Urinary metabolites / / 21572414 rs72650565 chr1 30993931 T C 9.07E-06 Stroke (ischemic) / / 21957438 rs6692098 chr1 30998096 A C 2.19E-04 Multiple complex diseases / / 17554300 rs4949613 chr1 31006103 A G 2.47E-04 Multiple complex diseases / / 17554300 rs51397 chr1 31013775 T C 8.97E-04 Body mass index / / 21701565 rs1484837 chr1 31017683 C T 7.00E-04 Acute lymphoblastic leukemia (childhood) / / 20189245 rs904257 chr1 31022237 A G 2.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs3104434 chr1 31023291 G T 4.97E-04 Smoking initiation / / 24665060 rs2377368 chr1 31024967 G A 7.94E-04 Type 2 diabetes / / 17463246 rs3104425 chr1 31034663 C T 2.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs530973 chr1 31062295 C T 8.93E-05 Dengue shock syndrome / / 22001756 rs609015 chr1 31070154 A G 7.19E-04 Multiple complex diseases / / 17554300 rs6426041 chr1 31074793 T G 6.14E-06 Serum metabolites / / 19043545 rs633832 chr1 31081441 G A 5.13E-04 Multiple complex diseases / / 17554300 rs544789 chr1 31083478 A G 3.01E-04 Multiple complex diseases / / 17554300 rs1188446 chr1 31163456 A G 3.76E-04 Body mass index / / 21701565 rs1188445 chr1 31163876 G A 1.10E-05 Obesity-related traits / / 17658951 rs1188444 chr1 31164624 T C 8.27E-04 White matter integrity / / 22425255 rs716486 chr1 31167561 G A 1.90E-06 Urinary metabolites / / 21572414 rs1033867 chr1 31167998 T C 3.97E-05 Longevity / / 20304771 rs1149023 chr1 31176942 G T 9.93E-04 Multiple complex diseases / / 17554300 rs912218 chr1 31180714 G A 7.03E-04 Type 2 diabetes / / 17463246 rs4949290 chr1 31203860 G A 2.36E-05 Colorectal cancer / / 21242260 rs3795437 chr1 31206806 T C 8.09E-05 Longevity LAPTM5 intron 20304771 rs12404920 chr1 31206957 T C 7.88E-05 Longevity LAPTM5 intron 20304771 rs10914189 chr1 31207781 C T 6.26E-04 Smoking initiation LAPTM5 intron 24665060 rs1188349 chr1 31223657 G A 5.00E-04 Acute lymphoblastic leukemia (childhood) LAPTM5 intron 20189245 rs12063364 chr1 31272051 A G 2.37E-04 Osteoarthritis / / 19508968 rs2377570 chr1 31298769 A G 0.000063 Primary sclerosing cholangitis / / 22521342 rs4949316 chr1 31315593 G C 9.00E-06 Metabolite levels (5-HIAA) / / 23319000 rs2488230 chr1 31320651 G A 3.63E-05 Prostate cancer / / 22923026 rs3935266 chr1 31330844 G A 9.68E-05 Prostate cancer / / 22923026 rs947643 chr1 31461438 G A 2.17E-04 Type 2 diabetes PUM1 intron 17463246 rs7536851 chr1 31471702 A C 2.29E-05 Systemic lupus erythematosus PUM1 intron pha002867 rs10753241 chr1 31490614 A G 2.20E-05 Systemic lupus erythematosus PUM1 intron pha002867 rs10753242 chr1 31494475 T G 2.16E-05 Systemic lupus erythematosus PUM1 intron pha002867 rs6694709 chr1 31520472 A C 7.75E-04 Tourette syndrome PUM1 intron 22889924 rs7526662 chr1 31539051 A G 1.86E-05 Systemic lupus erythematosus / / pha002867 rs11577241 chr1 31647583 G C 2.95E-04 Depression (quantitative trait) / / 20800221 rs2066163 chr1 31650749 A G 2.92E-04 Depression (quantitative trait) / / 20800221 rs4949356 chr1 31653988 A G 2.91E-04 Depression (quantitative trait) NKAIN1 UTR-3 20800221 rs6425715 chr1 31658678 A G 2.89E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs6693735 chr1 31659496 C G 5.26E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs2377717 chr1 31673263 C T 7.79E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs4949197 chr1 31676938 A G 9.22E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs10798827 chr1 31682312 T G 8.72E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs2889710 chr1 31682380 G A 5.03E-04 Response to cytidine analogues (gemcitabine) NKAIN1 intron 24483146 rs10753244 chr1 31683500 A G 6.74E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs10798828 chr1 31683890 C T 7.23E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs12033154 chr1 31686085 A G 6.69E-04 Depression (quantitative trait) NKAIN1 intron 20800221 rs6699372 chr1 31704333 G A 9.47E-04 Coronary Artery Disease NKAIN1 intron 17634449 rs17440445 chr1 31722562 A G 7.84E-05 Multiple complex diseases / / 17554300 rs17440445 chr1 31722562 A G 6.19E-04 Taste perception / / 22132133 rs7515867 chr1 31724744 T C 5.83E-05 Multiple complex diseases / / 17554300 rs7515988 chr1 31731061 A G 2.59E-06 Multiple complex diseases / / 17554300 rs10753245 chr1 31731208 T C 1.16E-04 Multiple complex diseases / / 17554300 rs12725881 chr1 31736123 T C 9.55E-05 Multiple complex diseases SNRNP40 intron 17554300 rs41412349 chr1 31769752 T G 1.41E-04 Multiple complex diseases / / 17554300 rs6696341 chr1 31782052 A G 7.82E-04 Taste perception ZCCHC17 intron 22132133 rs6679365 chr1 31787866 G T 6.34E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs7523438 chr1 31788313 A G 6.26E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs7556340 chr1 31788453 T A 2.94E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs10914355 chr1 31796985 G A 3.82E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs10798845 chr1 31822636 G A 4.29E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs4949389 chr1 31824023 G A 2.74E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs3795432 chr1 31829873 C T 9.66E-05 Multiple complex diseases ZCCHC17 intron 17554300 rs4949391 chr1 31833706 G T 2.88E-04 Multiple complex diseases ZCCHC17 intron 17554300 rs17495262 chr1 31837632 C T 2.63E-04 Multiple complex diseases ZCCHC17 UTR-3 17554300 rs7523777 chr1 31839136 A G 0.0000017 Cholesterol,total FABP3 intron 23063622 rs11578034 chr1 31842153 C T 3.36E-04 Iron levels FABP3 intron pha002876 rs951545 chr1 31844665 G A 4.86E-04 Multiple complex diseases FABP3 intron 17554300 rs951545 chr1 31844665 G A 1.70E-05 Urinary metabolites FABP3 intron 21572414 rs6425744 chr1 31850657 A G 2.50E-05 Urinary metabolites / / 21572414 rs1995585 chr1 31855474 A G 2.84E-04 Multiple complex diseases / / 17554300 rs10914372 chr1 31857998 A G 4.83E-04 Iron levels / / pha002876 rs12122236 chr1 31858901 T C 2.84E-04 Multiple complex diseases / / 17554300 rs905929 chr1 31862917 G C 4.50E-06 Urinary metabolites / / 21572414 rs7534378 chr1 31863558 G A 5.21E-04 Multiple complex diseases / / 17554300 rs7534465 chr1 31863663 G A 3.85E-04 Multiple complex diseases / / 17554300 rs6659255 chr1 31869669 C T 0.000072 Carotid intima media thickness / / 23152477 rs1039630 chr1 31881472 T C 8.72E-05 Alcohol dependence SERINC2 nearGene-5 21703634 rs2839939 chr1 31881637 T C 7.80E-05 Multiple complex diseases SERINC2 nearGene-5 17554300 rs4478858 chr1 31883925 T C 8.96E-05 Alcohol dependence SERINC2 intron 21703634 rs4478858 chr1 31883925 T C 3.00E-08 Alcohol dependence SERINC2 intron 23455491 rs1934290 chr1 31884180 T C 1.40E-04 Multiple complex diseases SERINC2 intron 17554300 rs12037108 chr1 31895394 T C 5.93E-04 Multiple complex diseases SERINC2 intron 17554300 rs4949402 chr1 31898234 T C 9.44E-05 Alcohol dependence SERINC2 cds-synon 21703634 rs2275435 chr1 31898536 C T 9.53E-05 Alcohol dependence SERINC2 intron 21703634 rs7548985 chr1 31915981 C T 3.08E-04 Multiple complex diseases / / 17554300 rs4261154 chr1 31921862 G A 7.25E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10798854 chr1 31934343 G A 3.63E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4949419 chr1 31977336 A G 1.40E-05 Multiple complex diseases / / 17554300 rs10914424 chr1 31980298 C T 5.89E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs10914427 chr1 31982584 G A 8.91E-04 Response to cytidine analogues (gemcitabine) LOC284551 nearGene-5 24483146 rs6667261 chr1 31992493 T C 6.18E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6669615 chr1 31997793 C T 9.57E-04 Multiple complex diseases / / 17554300 rs12125499 chr1 32000490 G T 1.20E-05 Cognitive performance / / 19734545 rs12125499 chr1 32000490 G T 8.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs4949437 chr1 32012283 T C 8.25E-04 Coronary Artery Disease / / 17634449 rs6425775 chr1 32034245 A C 0.00063 Salmonella-induced pyroptosis / / 22837397 rs10914446 chr1 32054094 A C 2.65E-04 Type 2 diabetes / / 17463246 rs4949448 chr1 32062066 G T 2.36E-04 Type 2 diabetes / / 17463246 rs6681414 chr1 32070234 G A 2.47E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2271933 chr1 32092525 A G 8.29E-04 Type 2 diabetes HCRTR1 missense 17463246 rs2271933 chr1 32092525 A G 9.80E-05 Speech perception in dyslexia HCRTR1 missense 19786962 rs10798882 chr1 32108547 C G 6.99E-04 Type 2 diabetes PEF1 intron 17463246 rs7524405 chr1 32108579 C A 6.62E-04 Type 2 diabetes PEF1 intron 17463246 rs4949455 chr1 32114793 G A 4.32E-04 Type 2 diabetes / / 17463246 rs909002 chr1 32139635 C T 9.30E-04 Type 2 diabetes COL16A1 intron 17463246 rs4949458 chr1 32142332 T G 4.67E-05 Pulmonary function COL16A1 intron 20010835 rs4949459 chr1 32142354 G T 2.22E-05 Pulmonary function COL16A1 intron 20010835 rs2297679 chr1 32157009 G T 3.00E-05 Educational attainment COL16A1 intron 21694764 rs12040661 chr1 32209650 G A 8.13E-04 Taste perception BAI2 intron 22132133 rs10914477 chr1 32240262 G A 3.68E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs8179509 chr1 32273434 A G 5.69E-04 Smoking initiation SPOCD1 intron 24665060 rs16834735 chr1 32276442 C T 6.26E-05 Orofacial clefts SPOCD1 intron 20023658 rs11589992 chr1 32300130 T C 3.65E-05 Serum metabolites / / 19043545 rs16834744 chr1 32312698 T G 5.80E-04 Multiple complex diseases / / 17554300 rs7521293 chr1 32315551 C A 2.20E-06 Urinary metabolites / / 21572414 rs671101 chr1 32336098 A G 1.70E-04 Myasthenia gravis / / 23055271 rs671101 chr1 32336098 A G 7.83E-05 Alcohol consumption / / 23953852 rs682654 chr1 32371523 C A 2.36E-06 Alcohol consumption / / 23953852 rs639233 chr1 32372881 C T 2.06E-06 Alcohol consumption PTP4A2 UTR-3 23953852 rs563978 chr1 32390324 C T 2.08E-05 Tunica Media PTP4A2 intron pha003037 rs591833 chr1 32397890 G A 1.98E-06 Alcohol consumption PTP4A2 intron 23953852 rs646370 chr1 32401166 A G 4.06E-05 Alcohol consumption PTP4A2 intron 23953852 rs680327 chr1 32438231 A G 0.000622 Height (Pygmy height) / / 22570615 rs680328 chr1 32438234 A G 0.000622 Height (Pygmy height) / / 22570615 rs16834895 chr1 32602531 A C 6.95E-04 Multiple complex diseases KP/6 intron 17554300 rs6425793 chr1 32668428 A G 9.63E-06 Anorexia nervosa CCDC28B intron 23568457 rs12032332 chr1 32672932 G A 1.60E-05 Schizophrenia IQCC missense 19571808 rs747020 chr1 32697934 G A 6.98E-04 Coronary Artery Disease MTMR9LP intron 17634449 rs747020 chr1 32697934 G A 7.54E-04 Schizophrenia MTMR9LP intron 19197363 rs747020 chr1 32697934 G A 8.20E-06 Schizophrenia MTMR9LP intron 19571808 rs747020 chr1 32697934 G A 1.40E-05 Urinary metabolites MTMR9LP intron 21572414 rs587707 chr1 32699227 T C 4.15E-04 Multiple complex diseases MTMR9LP intron 17554300 rs669538 chr1 32711360 C T 0.00042 Endometrial cancer / / 22426144 rs16834954 chr1 32784954 T C 1.27E-04 Multiple complex diseases HDAC1 intron 17554300 rs7532909 chr1 32826793 T C 8.22E-04 Multiple complex diseases / / 17554300 rs2270537 chr1 32829281 G A 4.00E-05 HIV-1 control TSSK3 cds-synon 20041166 rs11588497 chr1 33030461 A G 2.21E-05 Height ZBTB8A intron pha003010 rs11588497 chr1 33030461 A G 9.53E-06 Height ZBTB8A intron pha003011 rs359955 chr1 33134774 A C 2.27E-05 Coronary heart disease RBBP4 intron pha003056 rs696626 chr1 33195429 G A 7.61E-04 Suicide attempts in bipolar disorder / / 21423239 rs699006 chr1 33199367 C G 7.88E-04 Suicide attempts in bipolar disorder / / 21423239 rs4951771 chr1 33233223 C T 9.32E-04 Multiple complex diseases KIAA1522 intron 17554300 rs881393 chr1 33256645 G C 2.73E-04 Multiple complex diseases YARS intron 17554300 rs10914621 chr1 33277080 C T 1.59E-04 Multiple complex diseases YARS intron 17554300 rs12760548 chr1 33280648 T G 2.73E-04 Multiple complex diseases YARS intron 17554300 rs61739743 chr1 33292008 G A 0.00025 Prostate cancer S100PBP missense 23555315 rs16835198 chr1 33326681 G T 2.19E-04 Multiple complex diseases / / 17554300 rs11811702 chr1 33350183 G A 5.82E-06 Multiple sclerosis / / 19525953 rs1284373 chr1 33355923 C T 6.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HPCA intron 20877124 rs7527330 chr1 33380108 T G 7.64E-04 HIV-1 viral setpoint / / 17641165 rs194655 chr1 33421461 T C 4.17E-04 Multiple complex diseases RNF19B intron 17554300 rs10914658 chr1 33530750 G A 6.06E-15 Gender / / 22362730 rs638130 chr1 33585070 A G 1.97E-04 Blood pressure (response to angiotensin-converting enzyme inhibitor) ADC intron 24192120 rs654947 chr1 33599915 T C 1.90E-05 Urinary metabolites / / 21572414 rs689187 chr1 33611890 C A,G,T 8.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TRIM62 UTR-3 20877124 rs3912145 chr1 33614162 T C 1.40E-04 Iris characteristics TRIM62 intron 21835309 rs676069 chr1 33622077 T C 7.10E-04 Alcohol dependence TRIM62 intron 21314694 rs587042 chr1 33638736 C T 8.81E-05 Hypertension (early onset hypertension) TRIM62 intron 22479346 rs587910 chr1 33643361 A G 2.40E-05 Urinary metabolites TRIM62 intron 21572414 rs636561 chr1 33645971 C T 9.80E-06 Urinary metabolites TRIM62 intron 21572414 rs9729837 chr1 33673559 T G 6.51E-05 Coronary Artery Disease / / 17634449 rs6425809 chr1 33702965 G C 4.38E-04 Multiple complex diseases / / 17554300 rs4653002 chr1 33770526 T C 0.000689932 Hypertension (early onset hypertension) / / 22479346 rs10914692 chr1 33832933 G A 0.000525414 Hypertension (early onset hypertension) PHC2 missense 22479346 rs12127097 chr1 33850890 T C 6.68E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs6661037 chr1 33872593 T C 2.21E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs1998623 chr1 33893290 G A 6.60E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4653135 chr1 33893830 C T 5.92E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs12032996 chr1 33920586 G A 7.10E-06 Urinary metabolites / / 21572414 rs12565140 chr1 33928758 T C 3.00E-07 Estradiol plasma levels (breast cancer) / / 23518928 rs4653152 chr1 33931116 G A 3.88E-05 Prostate cancer / / pha002878 rs10798953 chr1 33937135 T C 2.04E-05 Alcohol dependence / / 19581569 rs16835496 chr1 33938845 A G 9.09E-04 Response to cytidine analogues (gemcitabine) ZSCAN20 intron 24483146 rs10798959 chr1 33983019 C T 8.00E-06 Metabolite levels (HVA/MHPG ratio) CSMD2 intron 23319000 rs12751162 chr1 34014134 C A 1.26E-05 Common variable immunodeficiency CSMD2 intron 21497890 rs915108 chr1 34023749 T C 5.88E-05 Lung cancer CSMD2 intron 18978787 rs6701268 chr1 34041191 T G 2.20E-04 Alcohol dependence CSMD2 intron 20201924 rs6701268 chr1 34041191 T G 1.43E-04 Schizophrenia CSMD2 intron 21747397 rs6425830 chr1 34044616 A G 6.40E-06 Urinary metabolites CSMD2 intron 21572414 rs416391 chr1 34048268 C T 3.40E-04 Alcohol dependence CSMD2 intron 20201924 rs416391 chr1 34048268 C T 4.00E-05 Alcohol dependence CSMD2 intron 20201924 rs416391 chr1 34048268 C T 3.99E-05 Alcoholism CSMD2 intron pha002892 rs1493988 chr1 34068364 G T 8.80E-04 Alzheimer's disease CSMD2 intron 22005930 rs564148 chr1 34173820 C T 9.00E-06 Response to amphetamines CSMD2 intron 22952603 rs612279 chr1 34173973 A G 8.91E-06 Response to amphetamines CSMD2 intron 22952603 rs570408 chr1 34174424 G A 8.03E-06 Response to amphetamines CSMD2 intron 22952603 rs16835742 chr1 34180842 G T 8.00E-08 Intelligence CSMD2 intron 22449649 rs7533254 chr1 34181830 G A 9.45E-04 Alcohol dependence CSMD2 intron 21314694 rs667892 chr1 34189552 C T 6.03E-06 Prion diseases CSMD2 intron 22210626 rs555733 chr1 34194736 T C 4.34E-05 Prion diseases CSMD2 intron 22210626 rs508796 chr1 34197058 T C 1.36E-05 Prion diseases CSMD2 intron 22210626 rs554862814 chr1 34203689 TACTC T 8.69E-06 Prion diseases CSMD2 intron 22210626 rs6661190 chr1 34203689 T C 8.69E-06 Prion diseases CSMD2 intron 22210626 rs512332 chr1 34206933 A G 2.02E-04 Response to cytadine analogues (cytosine arabinoside) CSMD2 intron 24483146 rs513049 chr1 34206979 G C 8.44E-04 Multiple complex diseases CSMD2 intron 17554300 rs475622 chr1 34207470 G A 1.12E-05 Prion diseases CSMD2 intron 22210626 rs1550545 chr1 34210087 G A 9.91E-06 Prion diseases CSMD2 intron 22210626 rs4578181 chr1 34210532 G A 9.47E-06 Prion diseases CSMD2 intron 22210626 rs9943159 chr1 34213077 A G 3.05E-06 Prion diseases CSMD2 intron 22210626 rs989661 chr1 34217931 C T 3.08E-04 Multiple complex diseases CSMD2 intron 17554300 rs474474 chr1 34238283 T C 0.00087 Prostate cancer CSMD2 missense 23555315 rs476463 chr1 34248064 G A 1.00E-06 Brain structure CSMD2 intron 20171287 rs717030 chr1 34249330 T C 5.37E-05 Lipoproteins CSMD2 intron pha003079 rs6425838 chr1 34254416 C T 6.04E-05 Cognitive test performance CSMD2 intron 20125193 rs545170 chr1 34256734 T C 3.32E-05 Body mass (lean) CSMD2 intron 19268274 rs10914782 chr1 34267945 T C 9.19E-05 Serum metabolites CSMD2 intron 19043545 rs12567192 chr1 34270994 T C 6.06E-04 Smoking quantity CSMD2 intron 24665060 rs10914783 chr1 34271055 G A 2.71E-06 Multiple complex diseases CSMD2 intron 17554300 rs10798993 chr1 34276880 A G 6.06E-04 Smoking quantity CSMD2 intron 24665060 rs10798994 chr1 34277174 T C 2.16E-04 Smoking quantity CSMD2 intron 24665060 rs11587451 chr1 34277979 A G 4.66E-04 Smoking quantity CSMD2 intron 24665060 rs3845473 chr1 34282691 G A 5.18E-05 Smoking quantity CSMD2 intron 24665060 rs3845476 chr1 34283894 A G 1.57E-04 Smoking quantity CSMD2 intron 24665060 rs3842834 chr1 34284118 G A 5.19E-04 Premature ovarian failure CSMD2 intron 19508998 rs3842834 chr1 34284118 G A 2.30E-04 Smoking quantity CSMD2 intron 24665060 rs12067054 chr1 34291676 C T 7.60E-05 Smoking quantity CSMD2 intron 24665060 rs3845477 chr1 34291836 A G 1.29E-04 Smoking quantity CSMD2 intron 24665060 rs10914789 chr1 34294874 T C 8.40E-04 Primary sclerosing cholangitis CSMD2 intron 19944697 rs6425850 chr1 34308585 T G 7.28E-04 Smoking initiation CSMD2 intron 24665060 rs746667 chr1 34312179 C G 7.78E-04 Alzheimer's disease CSMD2 intron 17998437 rs11542686 chr1 34329968 A G 1.40E-36 Health and aging,CVD and cancer age of onset HMGB4 missense 22174011 rs11542686 chr1 34329968 A G 3.00E-20 Health and aging,CVD and cancer age of onset HMGB4 missense 22174011 rs11542686 chr1 34329968 A G 4.00E-14 Health and aging,CVD and cancer age of onset HMGB4 missense 22174011 rs11542686 chr1 34329968 A G 6.80E-08 Health and aging,CVD and cancer age of onset HMGB4 missense 22174011 rs1321627 chr1 34331390 C G 6.43E-04 Alzheimer's disease CSMD2 intron 17998437 rs1108927 chr1 34333267 T G 7.79E-05 Cognitive impairment induced by topiramate CSMD2 intron 22091778 rs12122958 chr1 34340819 C G 7.76E-04 Multiple complex diseases CSMD2 intron 17554300 rs6425855 chr1 34346361 G T 3.99E-04 Smoking cessation CSMD2 intron 24665060 rs4653358 chr1 34349815 C A 4.67E-04 Smoking cessation CSMD2 intron 24665060 rs2281597 chr1 34359858 G C 5.00E-07 Attention deficit hyperactivity disorder CSMD2 intron 18839057 rs911216 chr1 34375199 A C 7.30E-04 Alcohol dependence CSMD2 intron 20201924 rs7536114 chr1 34379375 T G 1.20E-04 Alcohol dependence CSMD2 intron 20201924 rs12029535 chr1 34383662 T C 7.71E-04 Multiple complex diseases CSMD2 intron 17554300 rs12031839 chr1 34386710 A G 3.10E-06 Urinary metabolites CSMD2 intron 21572414 rs7555410 chr1 34394682 C A 4.13E-05 Lung function (forced expiratory volume in 1 second) CSMD2 intron 17255346 rs7555410 chr1 34394682 C A 5.56E-04 Suicide attempts in bipolar disorder CSMD2 intron 21423239 rs504471 chr1 34418942 A G 2.93E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) CSMD2 intron 23648065 rs7529498 chr1 34472274 T C 0.000802662 Hypertension (early onset hypertension) CSMD2 intron 22479346 rs504527 chr1 34473608 A C 3.20E-05 Lipid traits CSMD2 intron 17903299 rs2358756 chr1 34479922 T C 2.73E-05 Alcoholism CSMD2 intron pha002893 rs12563211 chr1 34486225 C T 6.55E-07 Post-operative nausea and vomiting CSMD2 intron 21694509 rs16836204 chr1 34486486 C T 4.30E-04 Type 2 diabetes CSMD2 intron 17463246 rs2118109 chr1 34490918 C T 6.41E-07 Post-operative nausea and vomiting CSMD2 intron 21694509 rs2164581 chr1 34491558 A G 6.82E-05 Alcoholism CSMD2 intron pha002893 rs10914850 chr1 34496094 T C 3.57E-04 Alzheimer's disease (late onset) CSMD2 intron 21379329 rs10914851 chr1 34496126 T C 3.57E-04 Alzheimer's disease (late onset) CSMD2 intron 21379329 rs12035502 chr1 34499772 C T 4.28E-04 Alzheimer's disease (late onset) CSMD2 intron 21379329 rs2625684 chr1 34505115 T C 7.65E-04 Alcohol consumption (maxi-drinks) CSMD2 intron 24277619 rs9426003 chr1 34602870 G A 4.93E-04 Amyotrophic lateral sclerosis (sporadic) CSMD2 intron 24529757 rs1335855 chr1 34648046 T C 5.80E-04 Type 2 diabetes C1orf94 intron 17463246 rs11584467 chr1 34665219 G A 8.00E-07 Urinary metabolites C1orf94 intron 21572414 rs12128858 chr1 34723928 T C 2.01E-05 Response to metformin / / 21186350 rs771404 chr1 34726167 G A,C,T 6.21E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs12039643 chr1 34727726 G T 1.20E-05 Urinary metabolites / / 21572414 rs10914894 chr1 34734066 G A 3.42E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1414470 chr1 34736287 G A 3.00E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs880017 chr1 34741605 A G 2.07E-04 Kawasaki disease / / 21326860 rs771392 chr1 34748815 C G 1.64E-08 Corneal structure / / 22003120 rs771390 chr1 34750936 T C 6.00E-07 Epilepsy (generalized) / / 22949513 rs6704508 chr1 34756509 T G 2.17E-04 White matter integrity / / 22425255 rs11588801 chr1 34761911 T C 2.59E-04 White matter integrity / / 22425255 rs1404350 chr1 34764974 A C 4.66E-04 Heart Failure / / pha002884 rs7523842 chr1 34765880 T G 4.49E-04 Heart Failure / / pha002884 rs10732274 chr1 34790295 A G 5.84E-04 Heart Failure / / pha002884 rs1917247 chr1 34805625 C A 1.87E-04 Type 2 diabetes / / 17463246 rs6695784 chr1 34815393 A G 2.98E-04 Acute lung injury / / 22295056 rs2294193 chr1 34866656 C T 7.40E-04 White matter integrity / / 22425255 rs2092028 chr1 34872737 A G 2.35E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs2092028 chr1 34872737 A G 7.00E-05 Lung function (forced vital capacity) / / 24023788 rs1883109 chr1 34892913 C A 8.92E-05 Potassium levels / / pha003086 rs17385253 chr1 34895009 T C 3.30E-05 Neuroticism / / 17667963 rs2142534 chr1 34900172 A G 9.16E-05 Myopia (pathological) / / 21095009 rs4653032 chr1 34902910 C A 1.82E-05 Asthma / / 23181788 rs10753308 chr1 34907148 A G 7.61E-04 Nicotine dependence / / 17158188 rs10489377 chr1 34915676 G A 0.0000836 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs67211730 chr1 34917267 T A 0.0000837 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10914952 chr1 34919213 G A 1.64E-04 Attention deficit hyperactivity disorder / / pha002875 rs2075933 chr1 34921075 C T 8.35E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1016091 chr1 34924596 C T 7.41E-04 Taste perception / / 22132133 rs4653040 chr1 34930403 G A 0.0000792 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs798076 chr1 34936568 G A 3.00E-04 Smoking quantity / / 24665060 rs10914956 chr1 34938132 C A 0.0000659 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs3845485 chr1 34985459 A G 1.63E-28 Narcolepsy / / 19629137 rs7556065 chr1 34988276 A T 7.78E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs10914967 chr1 34989237 G A 6.00E-06 Visceral adipose tissue adjusted for BMI / / 22589738 rs4587532 chr1 34994991 C G 1.80E-05 Urinary metabolites / / 21572414 rs4653054 chr1 35009882 C T 2.10E-05 Urinary metabolites / / 21572414 rs6665029 chr1 35040991 T C 2.51E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs1886340 chr1 35069285 G A 1.11E-05 Coronary heart disease / / pha003030 rs12048230 chr1 35070977 G A 1.88E-04 Alzheimer's disease (late onset) / / 21460841 rs4653061 chr1 35072298 G A 4.77E-05 Coronary heart disease / / pha003030 rs10914991 chr1 35074860 A T 8.76E-05 Schizophrenia(age at onset) / / 21688384 rs12117895 chr1 35079250 G A 4.01E-05 Schizophrenia(age at onset) / / 21688384 rs2147384 chr1 35082968 A C 3.62E-05 Schizophrenia(age at onset) / / 21688384 rs7544557 chr1 35084074 T C 3.06E-05 Coronary heart disease / / pha003030 rs10799074 chr1 35087725 G A 1.57E-04 Alzheimer's disease (late onset) / / 21460841 rs4653067 chr1 35088484 C A 2.97E-05 Schizophrenia(age at onset) / / 21688384 rs2359631 chr1 35090073 T C 6.37E-05 Pancreatic cancer / / pha002889 rs7547341 chr1 35090895 A C 2.74E-04 Alzheimer's disease (late onset) / / 21460841 rs6667879 chr1 35094437 G A 5.14E-04 Acute lung injury / / 22295056 rs7548924 chr1 35095368 C T 5.56E-04 Acute lung injury / / 22295056 rs868501 chr1 35097520 C T 5.56E-04 Acute lung injury / / 22295056 rs612353 chr1 35113184 A G 9.05E-05 Attention deficit hyperactivity disorder / / pha002875 rs12048853 chr1 35119247 C T 8.14E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs725790 chr1 35148448 A C 0.00000693 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs41495144 chr1 35149756 G C 9.00E-04 Multiple complex diseases / / 17554300 rs10915020 chr1 35157716 T A 0.00000054 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs16836898 chr1 35159859 C T 0.000000728 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs16836900 chr1 35159912 T C 9.63E-04 Multiple complex diseases / / 17554300 rs12030047 chr1 35160305 A C 3.47E-04 Multiple complex diseases / / 17554300 rs1932768 chr1 35165972 G A 0.00000136 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs2145390 chr1 35283939 T C 1.85E-05 Formal thought disorder in schizophrenia / / 22648509 rs7526035 chr1 35289039 G A 9.00E-06 Formal thought disorder in schizophrenia / / 22648509 rs11264139 chr1 35303369 A G 8.75E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6703979 chr1 35315737 C T 3.00E-05 Lung cancer / / 18978790 rs7525948 chr1 35353904 G A 4.12E-04 Iron levels DLGAP3 intron pha002876 rs10493064 chr1 35369014 T A 1.00E-04 Information processing speed DLGAP3 intron 21130836 rs11263872 chr1 35446830 G A 1.50E-05 HIV-1 control / / 20041166 rs12407202 chr1 35462487 C T 1.50E-05 HIV-1 control ZMYM6 intron 20041166 rs2335466 chr1 35617631 A C 8.32E-04 Multiple complex diseases / / 17554300 rs1498111 chr1 35641608 A G 9.97E-04 Multiple complex diseases / / 17554300 rs11264112 chr1 35645343 A C 2.39E-04 Hearing function / / 17255346 rs11264112 chr1 35645343 A C 2.58E-04 Multiple complex diseases / / 17554300 rs3738694 chr1 35648316 C T 2.38E-04 Hearing function / / 17255346 rs10908385 chr1 35654725 G A 7.55E-05 Multiple complex diseases SFPQ intron 17554300 rs11264114 chr1 35656064 T A 5.07E-04 Multiple complex diseases SFPQ intron 17554300 rs11264115 chr1 35656664 G A 7.04E-04 Multiple complex diseases SFPQ intron 17554300 rs7543044 chr1 35674311 A G 1.23E-04 Type 2 diabetes / / 17463246 rs673604 chr1 35687815 T C 6.00E-06 Endometrial cancer / / 21499250 rs593461 chr1 35709777 G A 5.54E-06 Rheumatoid arthritis / / 17804836 rs659215 chr1 35843029 C T 7.45E-05 Multiple complex diseases ZMYM4 intron 17554300 rs10908393 chr1 35854157 G C 5.52E-04 Multiple complex diseases ZMYM4 intron 17554300 rs10157137 chr1 35901222 A G 1.27E-06 Multiple complex diseases KIAA0319L intron 17554300 rs2275247 chr1 35908451 T C 1.00E-10 Systemic lupus erythematosus and Systemic sclerosis KIAA0319L intron 23740937 rs1203137 chr1 35951038 A G 2.42E-04 Type 2 diabetes KIAA0319L intron 17463246 rs1635718 chr1 35974469 C G 5.87E-04 Type 2 diabetes KIAA0319L intron 17463246 rs2074676 chr1 36027711 G A 8.76E-04 Multiple complex diseases NCDN intron 17554300 rs11264179 chr1 36056721 T C 2.70E-05 Coffee consumption TFAP2E intron 21357676 rs953035 chr1 36079508 G A 2.00E-05 Rheumatoid arthritis PSMB2 intron 17804836 rs676614 chr1 36107510 C A 6.34E-04 Multiple complex diseases / / 17554300 rs11264186 chr1 36149745 A G 5.70E-04 Multiple complex diseases / / 17554300 rs636658 chr1 36151125 C G 4.26E-04 Multiple complex diseases / / 17554300 rs2095247 chr1 36153830 C T 9.26E-04 Multiple complex diseases / / 17554300 rs12048483 chr1 36159594 A C 6.00E-04 Colorectal cancer (drug response in metastatic colorectal cancer) / / 21239504 rs1333647 chr1 36161383 C A,G,T 5.15E-04 Lymphocyte counts / / 22286170 rs6688464 chr1 36172195 G A 4.40E-05 Bipolar disorder / / 19488044 rs6688464 chr1 36172195 G A 6.00E-05 Bipolar Disorder / / pha002858 rs6696354 chr1 36176509 T C 0.000006 Mean arterial pressure / / 22510845 rs577483 chr1 36205166 A G 9.16E-04 Multiple complex diseases CLSPN intron 17554300 rs577483 chr1 36205166 A G 2.37E-05 Bipolar disorder CLSPN intron 19488044 rs577483 chr1 36205166 A G 3.31E-05 Bipolar Disorder CLSPN intron pha002858 rs535638 chr1 36216835 C T 5.87E-04 Multiple complex diseases CLSPN intron 17554300 rs535638 chr1 36216835 C T 2.80E-05 Bipolar disorder CLSPN intron 19488044 rs535638 chr1 36216835 C T 3.92E-05 Bipolar Disorder CLSPN intron pha002858 rs16822339 chr1 36220558 C A 7.50E-04 Multiple complex diseases CLSPN intron 17554300 rs11263830 chr1 36345798 G A 9.82E-04 Multiple complex diseases / / 17554300 rs645383 chr1 36373823 C G 7.06E-04 Multiple complex diseases EIF2C1 intron 17554300 rs581459 chr1 36375110 C T 1.96E-04 Multiple complex diseases EIF2C1 intron 17554300 rs12031138 chr1 36407806 A G 8.51E-04 Multiple complex diseases EIF2C3 intron 17554300 rs12041193 chr1 36412760 C T 5.31E-04 Multiple complex diseases EIF2C3 intron 17554300 rs683622 chr1 36443569 A G 4.52E-04 Multiple complex diseases EIF2C3 intron 17554300 rs7542179 chr1 36461122 G A 3.23E-04 Multiple complex diseases EIF2C3 intron 17554300 rs491603 chr1 36532316 T C 8.45E-10 Central corneal thickness / / 21098505 rs3767703 chr1 36555758 C T 5.94E-09 Central corneal thickness ADPRHL2 intron 21098505 rs7550047 chr1 36567343 A G 2.26E-09 Central corneal thickness COL8A2 nearGene-5 21098505 rs7553155 chr1 36568236 A T 2.90E-05 Urinary metabolites / / 21572414 rs96067 chr1 36571920 G A 5.40E-13 Central corneal thickness / / 21098505 rs96067 chr1 36571920 G A 3.00E-11 Corneal structure / / 23291589 rs274137 chr1 36577945 T C 1.30E-05 Urinary metabolites / / 21572414 rs12074848 chr1 36585077 C T 9.98E-09 Central corneal thickness / / 21098505 rs4653160 chr1 36599547 C T 1.24E-06 Central corneal thickness / / 21098505 rs7522400 chr1 36613380 A G 6.68E-07 Central corneal thickness TRAPPC3 intron 21098505 rs522468 chr1 36653677 T G 3.80E-04 Alcohol dependence / / 20201924 rs200307550 chr1 36786521 A G 0.00014 Breast cancer (ER positive) SH3D21 missense 23555315 rs200307550 chr1 36786521 A G 0.00026 Breast cancer SH3D21 missense 23555315 rs12116935 chr1 36789546 A G 0.00000698 Alcohol dependence / / 23691058 rs3795498 chr1 36807481 C T 8.47E-04 Glycosylated haemoglobin levels STK40 missense 17255346 rs10796882 chr1 36818066 G A 2.26E-04 Glycosylated haemoglobin levels STK40 intron 17255346 rs11583322 chr1 36822312 T C 3.20E-04 Alcohol dependence STK40 intron 20201924 rs11583322 chr1 36822312 T C 0.000000011 Alcohol dependence STK40 intron 23691058 rs4451521 chr1 36831264 C G 1.56E-04 Alcohol dependence STK40 intron 21314694 rs11577980 chr1 36836476 C T 7.05E-04 Suicide attempts in bipolar disorder STK40 intron 21423239 rs1339767 chr1 36855957 G C 2.14E-04 Glycosylated haemoglobin levels / / 17255346 rs884925 chr1 36861993 A G 4.51E-04 Alzheimer's disease LSM10 intron 22005930 rs884925 chr1 36861993 A G 7.27E-04 Smoking initiation LSM10 intron 24665060 rs4653186 chr1 36862929 T G 2.55E-04 Alzheimer's disease LSM10 intron 22005930 rs16822823 chr1 36874242 A G 7.44E-04 Alcohol dependence / / 21314694 rs6702784 chr1 36904720 A C 4.00E-06 Diabetic retinopathy OSCP1 intron 21441570 rs953517 chr1 36910277 C T 5.51E-04 Alzheimer's disease OSCP1 intron 22005930 rs11263898 chr1 36912531 G A 7.51E-04 Alzheimer's disease OSCP1 intron 22005930 rs6425987 chr1 36924676 A G 6.00E-04 Alzheimer's disease MRPS15 intron 22005930 rs3917991 chr1 36934805 C G 6.30E-04 Atrial fibrillation CSF3R missense 21846873 rs3917989 chr1 36935128 G A 2.53E-04 Lymphocyte counts CSF3R intron 22286170 rs3917924 chr1 36945653 G A 2.33E-05 Hemoglobin CSF3R intron pha003096 rs3917924 chr1 36945653 G A 3.60E-05 Hematocrit CSF3R intron pha003097 rs11263901 chr1 36960626 G A 2.04E-06 Hearing function / / 21493956 rs4481816 chr1 36977811 G C 5.34E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs11263915 chr1 37019556 G A 5.54E-05 Waist Circumference / / pha003023 rs7540413 chr1 37040374 T C 9.59E-04 Heart Failure / / pha002884 rs4653197 chr1 37041069 C T 9.10E-04 Multiple complex diseases / / 17554300 rs12567252 chr1 37041357 A C 1.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs4653210 chr1 37074351 T G 2.60E-05 Systemic sclerosis / / 21750679 rs12090333 chr1 37077776 C T 6.64E-04 Alzheimer's disease / / 17998437 rs6685372 chr1 37126710 G A 4.43E-04 Multiple complex diseases / / 17554300 rs1076773 chr1 37136423 C T 4.37E-04 Type 2 diabetes / / 17463246 rs743012 chr1 37136670 G A 5.01E-04 Multiple complex diseases / / 17554300 rs7528341 chr1 37141174 C T 4.91E-04 Multiple complex diseases / / 17554300 rs34305923 chr1 37144140 C T 4.86E-04 Multiple complex diseases / / 17554300 rs589249 chr1 37162352 A G 3.00E-07 Schizophrenia / / 23894747 rs7515535 chr1 37182396 T A 8.19E-04 Multiple complex diseases / / 17554300 rs1395455 chr1 37185190 A G 3.99E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs1002655 chr1 37192677 C G 3.20E-05 Schizophrenia / / 19571811 rs1002656 chr1 37192741 C T 8.65E-04 Multiple complex diseases / / 17554300 rs6425998 chr1 37197720 T C 6.29E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7549591 chr1 37198352 T C 5.81E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs502808 chr1 37212617 G A 5.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1472823 chr1 37220721 G A 2.30E-05 Urinary metabolites / / 21572414 rs1472823 chr1 37220721 G A 6.06E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12083196 chr1 37233430 T C 2.70E-05 Urinary metabolites / / 21572414 rs12083196 chr1 37233430 T C 4.76E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs525798 chr1 37240886 G T 1.60E-05 Urinary metabolites / / 21572414 rs11801494 chr1 37250088 C T 0.0002 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs528137 chr1 37280785 C T 2.75E-05 Amyotrophic lateral sclerosis (sporadic) GRIK3 intron 24529757 rs484017 chr1 37303737 T C 4.95E-04 Multiple complex diseases GRIK3 intron 17554300 rs547390 chr1 37317442 G A 8.95E-04 Multiple complex diseases GRIK3 intron 17554300 rs1587526 chr1 37362476 T C 6.90E-04 Cognitive impairment induced by topiramate GRIK3 intron 22091778 rs41344852 chr1 37398177 G C 8.34E-05 Multiple complex diseases GRIK3 intron 17554300 rs613720 chr1 37525676 C A 4.00E-05 Serum metabolites / / 19043545 rs218422 chr1 37537709 T C 1.37E-04 Cholesterol / / 17255346 rs760964 chr1 37574864 G A 6.94E-04 Multiple complex diseases / / 17554300 rs215773 chr1 37596240 G T 6.01E-04 Multiple complex diseases / / 17554300 rs215792 chr1 37605441 T C 3.30E-04 Multiple complex diseases / / 17554300 rs215792 chr1 37605441 T C 1.72E-04 Arthritis (juvenile idiopathic) / / 22354554 rs215791 chr1 37606291 T C 2.80E-04 Multiple complex diseases / / 17554300 rs41387646 chr1 37612620 A G 1.00E-04 Multiple complex diseases / / 17554300 rs4653252 chr1 37622070 C A 2.22E-05 Serum metabolites / / 19043545 rs998176 chr1 37636117 G A 3.84E-05 Serum metabolites / / 19043545 rs4653254 chr1 37644737 T C 1.06E-05 Serum metabolites / / 19043545 rs1501540 chr1 37723078 A G 2.24E-04 Multiple complex diseases / / 17554300 rs905108 chr1 37724364 A T 5.63E-04 Multiple complex diseases / / 17554300 rs6426015 chr1 37770623 A G 6.96E-06 Common variable immunodeficiency / / 21497890 rs6426016 chr1 37773586 T C 9.57E-05 Femoral neck bone geometry / / 22087292 rs3898790 chr1 37774697 T G 6.70E-05 Femoral neck bone geometry / / 22087292 rs11264024 chr1 37777759 G A 8.84E-05 Femoral neck bone geometry / / 22087292 rs1411931 chr1 37782874 A G 5.80E-05 Lipid traits / / 17903299 rs761158 chr1 37787733 A G 7.70E-06 Urinary metabolites / / 21572414 rs6659871 chr1 37794345 G A 4.77E-04 Type 2 diabetes / / 17463246 rs2811615 chr1 37861304 G C 7.01E-04 Type 2 diabetes / / 17463246 rs875361 chr1 37865954 G A 1.96E-04 Myopia (pathological) / / 21095009 rs2811626 chr1 37880752 T C 1.60E-05 Myopia (pathological) / / 21095009 rs16824119 chr1 37888656 G A 9.31E-05 Myopia (pathological) / / 21095009 rs4428850 chr1 37889172 G T 7.85E-05 Myopia (pathological) / / 21095009 rs10796907 chr1 37900173 A G 2.81E-05 Lymphocyte counts / / pha003094 rs10796907 chr1 37900173 A G 6.75E-06 Neutrophil count / / pha003095 rs11264049 chr1 37902135 T C 1.49E-04 Multiple complex diseases / / 17554300 rs6700586 chr1 37957376 G A 4.80E-06 Alopecia areata / / 22027810 rs9253 chr1 37958813 C G 4.00E-06 Hemostatic factors and hematological phenotypes MEAF6 UTR-3 17903294 rs215864 chr1 37967774 C A 3.30E-05 Chronic obstructive pulmonary disease MEAF6 intron 19300482 rs116251390 chr1 38032607 C T 0.00026 Breast cancer (ER positive) GNL2 missense 23555315 rs10908355 chr1 38035286 G T 1.58E-04 Lymphocyte counts GNL2 intron 22286170 rs4074961 chr1 38092723 C T 4.00E-13 Axial length RSPO1 intron 24144296 rs4653314 chr1 38117562 T C 1.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs573381957 chr1 38117562 TC T 1.31E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs615530 chr1 38161694 A G 8.41E-04 Alcohol dependence CDCA8 intron 20201924 rs3790623 chr1 38169578 G A 3.42E-05 HIV-1 progression to AIDS and death CDCA8 intron 21811574 rs3790623 chr1 38169578 G A 6.54E-04 HIV-1 progression to AIDS and death CDCA8 intron 21811574 rs531454 chr1 38173597 A G 5.22E-04 Alcohol dependence CDCA8 intron 20201924 rs7822 chr1 38174987 T C 4.84E-04 Suicide attempts in bipolar disorder CDCA8 UTR-3 21423239 rs7541350 chr1 38191538 T C 7.58E-06 Prostate cancer EPHA10 intron pha002878 rs17464981 chr1 38192537 T C 8.93E-06 Prostate cancer EPHA10 intron pha002878 rs731174 chr1 38196841 T C 5.00E-06 Prostate cancer (gene x gene interaction) EPHA10 intron 22219177 rs482818 chr1 38233399 C G 9.59E-04 Multiple complex diseases / / 17554300 rs12117544 chr1 38247153 T A 8.00E-06 Cognitive performance / / 20125193 rs579689 chr1 38256166 G A 6.54E-04 Multiple complex diseases / / 17554300 rs12563037 chr1 38258644 G C 2.29E-04 Multiple complex diseases / / 17554300 rs2291297 chr1 38272660 G A 6.90E-05 Hypothyroidism YRDC intron 22493691 rs28411352 chr1 38278579 C T 3.00E-12 Rheumatoid arthritis MTF1 UTR-3 24390342 rs28411352 chr1 38278579 C T 6.00E-09 Rheumatoid arthritis MTF1 UTR-3 24390342 rs28411352 chr1 38278579 C T 7.80E-05 Rheumatoid arthritis MTF1 UTR-3 24390342 rs3748682 chr1 38279987 T C 9.00E-06 Hypothyroidism MTF1 UTR-3 22493691 rs12751325 chr1 38289383 T C 8.40E-05 Hypothyroidism MTF1 cds-synon 22493691 rs12742756 chr1 38347417 A G 1.50E-05 Hypothyroidism INPP5B intron 22493691 rs12728438 chr1 38349400 G A 6.00E-05 Hypothyroidism INPP5B intron 22493691 rs4634868 chr1 38465315 G A 4.70E-05 Inflammatory demyelinating disease FHL3 intron 19850125 rs11211383 chr1 38482356 T G 1.12E-05 Alcohol consumption UTP11L intron 23953852 rs535056 chr1 38522092 T C 1.85E-05 Cognitive test performance / / 20125193 rs1108183 chr1 38559394 C G 7.69E-04 Multiple complex diseases / / 17554300 rs11206585 chr1 38568328 T C 5.29E-05 Erythrocyte counts / / pha003099 rs7547921 chr1 38602073 C A 6.13E-05 Type 2 diabetes / / 17463246 rs7547921 chr1 38602073 C A 8.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs883220 chr1 38616871 C A 2.83E-05 Rheumatoid arthritis / / 17804836 rs883220 chr1 38616871 C A 9.63E-07 Rheumatoid arthritis / / 19503088 rs883220 chr1 38616871 C A 0.000000021 Rheumatoid arthritis / / 23143596 rs883220 chr1 38616871 C A 2.09E-08 Rheumatoid arthritis (CCP positive) / / 23143596 rs12131057 chr1 38624129 G A 4.00E-07 Rheumatoid arthritis / / 20453842 rs6693777 chr1 38630862 A G 3.72E-06 Panic disorder / / 19165232 rs12140275 chr1 38633879 A T 2.00E-09 Rheumatoid arthritis / / 24390342 rs12140275 chr1 38633879 A T 4.00E-09 Rheumatoid arthritis / / 24390342 rs7544568 chr1 38639208 G A 3.21E-05 ECG dimensions,brachial artery endothelial function,treadmill exercise responses / / 17903301 rs17534243 chr1 38650917 A G 8.45E-04 Multiple complex diseases / / 17554300 rs898978 chr1 38667704 T G 2.86E-04 Multiple complex diseases / / 17554300 rs7537377 chr1 38682207 A G 4.24E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6685558 chr1 38687060 T C 8.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1755302 chr1 38704189 A G 9.58E-04 Suicide attempts in bipolar disorder / / 21423239 rs12095190 chr1 38711632 G A 9.69E-04 Suicide attempts in bipolar disorder / / 21423239 rs11802770 chr1 38721663 T C 3.00E-06 Waist-to-hip circumference ratio (interaction) / / 23192594 rs12075234 chr1 38738214 A G 1.95E-05 Cognitive impairment induced by topiramate / / 22091778 rs12075234 chr1 38738214 A G 3.27E-05 Coronary heart disease / / pha003032 rs1543632 chr1 38747960 C T 6.97E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs2798809 chr1 38792565 A G 3.33E-16 Triglycerides / / 23063622 rs11210569 chr1 38805929 T C 4.40E-05 Chronic obstructive pulmonary disease / / 19300482 rs6679637 chr1 38806630 G A 6.29E-05 Systemic sclerosis / / 21750679 rs6701668 chr1 38845585 C A 9.87E-04 Type 2 diabetes / / 17463246 rs17478958 chr1 38851959 A C 6.29E-04 Tourette syndrome / / 22889924 rs12132779 chr1 38876635 A G 5.79E-04 Suicide attempts in bipolar disorder / / 21423239 rs11806392 chr1 38876866 A G 6.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs6678251 chr1 38880715 T C 7.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs6600426 chr1 38884018 A G 6.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs6600426 chr1 38884018 A G 7.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs4290027 chr1 38884529 G A 9.42E-06 Cognitive decline / / 23207651 rs1932362 chr1 38910848 G A 5.20E-04 Tourette syndrome / / 22889924 rs2252153 chr1 38919423 G A 3.00E-05 Prostate cancer / / 21743057 rs2252059 chr1 38919983 G A 3.00E-05 Prostate cancer / / 21743057 rs11590421 chr1 38994115 G A 2.00E-07 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs4970603 chr1 39041667 T C 4.05E-05 Coronary heart disease / / pha003030 rs4970605 chr1 39047119 G A 1.92E-19 Multiple complex diseases / / 17554300 rs12026014 chr1 39060495 G A 5.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2985763 chr1 39065974 G A 1.64E-06 Schizophrenia / / 20185149 rs2985763 chr1 39065974 G A 2.83E-05 Bipolar disorder / / 20451256 rs1925382 chr1 39077100 G A 4.44E-04 HIV-1 viral setpoint / / 17641165 rs3011197 chr1 39079046 A G 1.83E-04 Glycosylated haemoglobin levels / / 17255346 rs3011199 chr1 39079150 A C 4.15E-04 Multiple complex diseases / / 17554300 rs12077396 chr1 39080101 G C 1.46E-05 Glycosylated haemoglobin levels / / 17255346 rs4970606 chr1 39081829 A G 5.32E-05 Glycosylated haemoglobin levels / / 17255346 rs11211081 chr1 39115477 A G 8.00E-05 Coronary heart disease / / pha003030 rs724321 chr1 39123603 G A 1.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17484092 chr1 39147240 T C 2.46E-04 Multiple complex diseases / / 17554300 rs17484306 chr1 39159100 T C 6.12E-04 Type 2 diabetes / / 17463246 rs17484306 chr1 39159100 T C 5.11E-04 Multiple complex diseases / / 17554300 rs10493084 chr1 39164153 G A 1.40E-04 Crohn's disease / / 17684544 rs4970620 chr1 39165402 G C 5.14E-04 Multiple complex diseases / / 17554300 rs10890338 chr1 39166659 G A 1.05E-04 Multiple complex diseases / / 17554300 rs12409323 chr1 39169671 G A 9.74E-05 Type 2 diabetes and other traits / / 19734900 rs17556883 chr1 39197064 T C 0.000065 Endometrial cancer / / 22426144 rs12065672 chr1 39199381 C A 3.78E-04 Multiple complex diseases / / 17554300 rs4246510 chr1 39217894 G C 2.19E-04 Multiple complex diseases / / 17554300 rs4970625 chr1 39221925 C A 4.06E-05 Duodenal ulcer / / 22387998 rs4970625 chr1 39221925 C A 4.96E-05 Monocyte counts / / pha003089 rs12043383 chr1 39229313 T C 3.91E-04 Alzheimer's disease / / 17998437 rs4970627 chr1 39238597 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1320454 chr1 39291144 C A 5.11E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs16825583 chr1 39302499 A G 4.95E-04 Multiple complex diseases / / 17554300 rs7541734 chr1 39302880 C T 4.36E-05 Bipolar disorder / / 17486107 rs4494114 chr1 39339682 T C 6.07E-05 Type 2 diabetes GJA9-MYCBP intron 17463246 rs4491033 chr1 39352083 T G 8.83E-05 Type 2 diabetes RHBDL2 UTR-3 17463246 rs9438980 chr1 39355371 A G 2.50E-04 Type 2 diabetes RHBDL2 intron 17463246 rs6674910 chr1 39357157 A G 1.02E-04 Type 2 diabetes RHBDL2 intron 17463246 rs7539067 chr1 39359694 T C 1.08E-04 Type 2 diabetes RHBDL2 intron 17463246 rs4246511 chr1 39380385 T C 9.00E-17 Menopause (age at onset) RHBDL2 intron 22267201 rs6422258 chr1 39406644 T C 9.16E-04 Suicide attempts in bipolar disorder RHBDL2 intron 21423239 rs6600281 chr1 39412766 C G 1.87E-04 Suicide attempts in bipolar disorder / / 21423239 rs4475740 chr1 39425489 A G 1.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs7550511 chr1 39427374 A C 8.00E-05 Suicide attempts in bipolar disorder / / 21423239 rs12127660 chr1 39434565 C T 1.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs7537437 chr1 39439538 G A 8.20E-07 Menopause (age at onset) / / 22267201 rs7537437 chr1 39439538 G A 2.38E-10 Lymphocyte counts / / 22286170 rs7538228 chr1 39477635 T G 4.81E-04 Schizophrenia / / 19197363 rs6663155 chr1 39498491 G A 4.81E-04 Schizophrenia NDUFS5 intron 19197363 rs10465799 chr1 39518006 G A 3.03E-04 Schizophrenia / / 19197363 rs260970 chr1 39551242 G A 0.000680168 Hypertension (early onset hypertension) MACF1 intron 22479346 rs11580989 chr1 39583686 T C 4.17E-05 Birth weight MACF1 intron 17255346 rs628523 chr1 39624761 A G 8.49E-04 Type 2 diabetes MACF1 intron 17463246 rs7538300 chr1 39652764 C A 8.33E-05 HDL particle features MACF1 intron pha002900 rs663978 chr1 39679685 A G 1.15E-04 Multiple complex diseases MACF1 intron 17554300 rs16826012 chr1 39719519 T C 8.57E-04 Multiple complex diseases MACF1 intron 17554300 rs16826012 chr1 39719519 T C 4.24E-04 Aortic root size MACF1 intron 21223598 rs3120282 chr1 39772180 T C 8.07E-04 Response to cytadine analogues (cytosine arabinoside) MACF1 intron 24483146 rs2296172 chr1 39835817 A G 7.80E-05 HDL particle features MACF1 missense pha002900 rs587404 chr1 39908506 G A 7.10E-05 Rheumatoid arthritis MACF1 missense 21673997 rs587404 chr1 39908506 G A 6.18E-05 HDL particle features MACF1 missense pha002900 rs2296173 chr1 39913351 A G 8.82E-05 HDL particle features MACF1 intron pha002900 rs1180379 chr1 39915035 G A 3.04E-04 Coronary Artery Disease MACF1 intron 17634449 rs687848 chr1 39919234 A G 5.10E-05 Rheumatoid arthritis MACF1 intron 21673997 rs4660762 chr1 39926824 G A 7.53E-05 Response to hepatitis C treatment MACF1 intron 19684573 rs3738676 chr1 39991588 G T 8.03E-04 Stroke BMP8A UTR-3 pha002886 rs17264866 chr1 40022777 C G 1.56E-07 Multiple complex diseases / / 17554300 rs4660293 chr1 40028180 A G 1.37E-04 Multiple complex diseases PABPC4 intron 17554300 rs4660293 chr1 40028180 A G 4.00E-10 HDL cholesterol PABPC4 intron 20686565 rs4660293 chr1 40028180 A G 3.00E-18 HDL cholesterol PABPC4 intron 24097068 rs4660293 chr1 40028180 A G 2.65E-05 HDL particle features PABPC4 intron pha002900 rs11577939 chr1 40036669 G C 4.54E-05 Longevity PABPC4 intron 20304771 rs2293476 chr1 40036847 G C 1.94E-04 Multiple complex diseases PABPC4 intron 17554300 rs11206377 chr1 40049104 A G 3.00E-04 Behcet's disease / / 19442274 rs11206377 chr1 40049104 A G 7.00E-04 Behcet's disease / / 19442274 rs11206377 chr1 40049104 A G 7.00E-04 Behcet's disease / / 19442274 rs7539261 chr1 40050503 A T 1.28E-04 Multiple complex diseases / / 17554300 rs12037222 chr1 40064961 G A 6.00E-11 C-reactive protein / / 21300955 rs3916164 chr1 40069939 G A 3.00E-10 Red blood cell traits / / 23222517 rs6600293 chr1 40083819 C A 3.87E-05 Lymphocyte counts / / 22286170 rs1148945 chr1 40096053 T C 5.50E-04 Body mass index HEYL intron 21701565 rs784611 chr1 40125988 T A 9.30E-05 Response to lithium treatment in bipolar disorder NT5C1A intron 19448189 rs873917 chr1 40132795 T G 8.00E-06 Amyotrophic lateral sclerosis NT5C1A intron 19451621 rs784600 chr1 40139553 C T 3.22E-04 Multiple complex diseases / / 17554300 rs784600 chr1 40139553 C T 7.97E-05 Caffeine consumption / / 21490707 rs785108 chr1 40152676 T C 9.64E-04 Multiple complex diseases HPCAL4 intron 17554300 rs538302 chr1 40153748 T C 5.49E-04 Coronary Artery Disease HPCAL4 intron 17634449 rs538758 chr1 40155188 A G 1.70E-04 Multiple complex diseases HPCAL4 intron 17554300 rs546422 chr1 40158828 C T 5.20E-05 Lung function (forced expiratory volume in 1 second) / / pha003103 rs7553968 chr1 40222660 G C 0.0000882 post-traumatic stress disorder PPIE intron 22869035 rs7553968 chr1 40222660 G C 8.82E-05 Schizophrenia PPIE intron 22883433 rs12123153 chr1 40248931 A G 2.03E-04 Smoking initiation BMP8B intron 24665060 rs7531010 chr1 40275071 G A 7.03E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1999574 chr1 40288051 G A 2.60E-04 Intelligence (childhood) / / 23358156 rs11206937 chr1 40290011 A G 7.30E-06 Osteoarthritis / / 22566624 rs17569868 chr1 40292911 A C 5.74E-04 Multiple complex diseases / / 17554300 rs230275 chr1 40301897 G C 1.00E-04 Response to interferon beta in multiple sclerosis / / 18195134 rs12123609 chr1 40303627 C T 9.76E-04 Multiple complex diseases / / 17554300 rs230310 chr1 40307719 A G 6.00E-05 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) TRIT1 intron 24325915 rs3134615 chr1 40362066 C A 5.56E-04 Response to taxane treatment (placlitaxel) MYCL1 UTR-3 23006423 rs3134613 chr1 40364803 C A 8.76E-04 Schizophrenia MYCL1 intron 19197363 rs3117088 chr1 40369232 T C 7.53E-04 Schizophrenia / / 19197363 rs3117096 chr1 40389966 A G 3.70E-04 Smoking initiation / / 24665060 rs3131706 chr1 40413098 T C 2.37E-04 Nicotine dependence / / 17158188 rs3131703 chr1 40419681 A G 4.34E-04 Smoking initiation / / 24665060 rs3103778 chr1 40433771 A G 3.29E-04 Schizophrenia(treatment response to risperidone) MFSD2A intron 19850283 rs3103778 chr1 40433771 A G 2.40E-05 Urinary metabolites MFSD2A intron 21572414 rs3103778 chr1 40433771 A G 9.00E-06 PR interval MFSD2A intron 23534349 rs12402428 chr1 40503725 T C 6.52E-04 Alcohol dependence / / 21314694 rs16826852 chr1 40531094 A G 6.47E-04 Alcohol dependence CAP1 intron 21314694 rs16826856 chr1 40534842 T A 8.52E-04 Type 2 diabetes CAP1 intron 17463246 rs6688203 chr1 40549930 C A 6.60E-04 Alcohol dependence PPT1 intron 21314694 rs7513553 chr1 40553333 G T 6.43E-04 Rheumatoid arthritis PPT1 intron 21452313 rs12118846 chr1 40553444 A G 6.98E-04 Smoking cessation PPT1 intron 24665060 rs3131651 chr1 40555321 C T 1.44E-05 Osteoarthritis (knee and hip) PPT1 intron 21177295 rs3131651 chr1 40555321 C T 3.33E-04 Osteoarthritis (knee and hip) PPT1 intron 21177295 rs3131651 chr1 40555321 C T 3.50E-04 Osteoarthritis (knee and hip) PPT1 intron 21177295 rs3122438 chr1 40555802 G A 3.48E-04 Rheumatoid arthritis PPT1 intron 21452313 rs4660390 chr1 40560399 C T 9.30E-04 HIV-1 viral setpoint PPT1 intron 17641165 rs10889147 chr1 40561471 C T 2.88E-04 Rheumatoid arthritis PPT1 intron 21452313 rs6700346 chr1 40588548 C T 4.30E-05 Glioma (high-grade) / / 19578366 rs6600318 chr1 40601636 T C 5.52E-04 Alcohol dependence / / 20201924 rs12074893 chr1 40628119 C T 4.43E-04 Alcohol dependence RLF intron 20201924 rs4600036 chr1 40636387 G T 1.10E-05 Glioma (high-grade) RLF intron 19578366 rs6600320 chr1 40647407 A G 4.20E-05 Glioma (high-grade) RLF intron 19578366 rs12144950 chr1 40680128 A G 4.80E-04 Iris characteristics RLF intron 21835309 rs16827120 chr1 40765561 G A 0.00000194 HDL cholesterol / / 23063622 rs41480445 chr1 40766618 C T 8.20E-04 Multiple complex diseases COL9A2 UTR-3 17554300 rs407752 chr1 40803855 G A 7.30E-04 Bipolar disorder / / 19259986 rs2235701 chr1 40883095 C T 7.00E-06 Ejection fraction in Tripanosoma cruzi seropositivity SMAP2 intron 24324551 rs427371 chr1 40883266 A G 6.80E-04 Multiple complex diseases SMAP2 intron 17554300 rs427371 chr1 40883266 A G 1.87E-04 Orofacial clefts SMAP2 intron 22863734 rs10489434 chr1 40922062 T C 9.10E-04 Alzheimer's disease ZNF643 intron 24755620 rs10489435 chr1 40922377 C T 5.12E-04 Body mass index ZNF643 intron 21701565 rs736861 chr1 40931003 A G 3.78E-04 Multiple complex diseases / / 17554300 rs736861 chr1 40931003 A G 5.21E-04 Schizophrenia / / 19197363 rs10789144 chr1 40955156 A T 6.64E-05 Multiple sclerosis ZNF642 intron 17660530 rs4604685 chr1 40976258 T C 7.24E-05 Cognitive test performance DEM1 intron 20125193 rs2184878 chr1 40994050 T C 8.67E-05 Cognitive test performance / / 20125193 rs1999822 chr1 41026749 G A 3.00E-05 Response to antidepressants / / 19736353 rs6677621 chr1 41053260 C T 9.68E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs16827403 chr1 41057570 A C 8.32E-05 Cognitive test performance / / 20125193 rs16827403 chr1 41057570 A C 1.99E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs16827403 chr1 41057570 A C 2.05E-05 Lipoproteins / / pha003079 rs590775 chr1 41065744 A G 7.85E-04 Type 2 diabetes / / 17463246 rs3767955 chr1 41104475 G A 3.60E-04 Response to taxane treatment (placlitaxel) RIMS3 intron 23006423 rs12562229 chr1 41105238 A G 8.97E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RIMS3 intron 20877124 rs1534955 chr1 41107699 C G 8.97E-04 Depression (quantitative trait) RIMS3 intron 20800221 rs11208590 chr1 41108149 T C 1.80E-05 Age-related macular degeneration RIMS3 intron 20861866 rs11208590 chr1 41108149 T C 5.49E-05 Age-related macular degeneration RIMS3 intron 21197116 rs11208590 chr1 41108149 T C 1.97E-05 Age-related macular degeneration RIMS3 intron pha000001 rs11208590 chr1 41108149 T C 6.28E-06 Age-related macular degeneration RIMS3 intron pha002856 rs2780944 chr1 41115608 C T 4.60E-04 Depression (quantitative trait) RIMS3 intron 20800221 rs12728027 chr1 41115671 T C 4.35E-04 Depression (quantitative trait) RIMS3 intron 20800221 rs200548994 chr1 41115671 TG T 4.35E-04 Depression (quantitative trait) RIMS3 intron 20800221 rs10458576 chr1 41117899 G A 4.20E-04 Depression (quantitative trait) RIMS3 intron 20800221 rs4332353 chr1 41130424 G A 4.42E-04 Depression (quantitative trait) RIMS3 intron 20800221 rs965949 chr1 41154407 G A 9.17E-04 Major depressive disorder / / 22472876 rs2274956 chr1 41212950 G A 5.51E-04 Schizophrenia NFYC intron 19197363 rs2361651 chr1 41230214 G A 3.37E-04 Body mass index NFYC intron 17255346 rs823682 chr1 41231057 C T 6.34E-04 Schizophrenia NFYC intron 19197363 rs4660456 chr1 41239511 A G 4.00E-06 Platelet counts / / 21507922 rs823673 chr1 41240519 C T 3.94E-05 Pulmonary function in asthmatics / / 23541324 rs2769255 chr1 41245354 C T 5.17E-06 Aging (time to event) / / 21782286 rs2251413 chr1 41245859 C A 3.53E-04 Birth weight / / 17255346 rs11806175 chr1 41292969 C T 0.000007 HDL cholesterol particle diameter KCNQ4 intron 23263444 rs3767943 chr1 41293419 G A 9.18E-05 Chronic obstructive pulmonary disease KCNQ4 intron 19300482 rs11801911 chr1 41293857 C A 0.000007 HDL cholesterol particle diameter KCNQ4 intron 23263444 rs3754175 chr1 41294897 G A 8.49E-04 Multiple complex diseases KCNQ4 intron 17554300 rs913378 chr1 41298652 T C 8.60E-04 Amyotrophic lateral sclerosis (sporadic) KCNQ4 intron 24529757 rs12402583 chr1 41306571 T C 0.000059 Prostate cancer (advanced) / / 23555315 rs12564411 chr1 41319052 A G 1.35E-04 Type 2 diabetes / / 17463246 rs6600354 chr1 41348072 C A 3.68E-05 HDL cholesterol / / pha003074 rs11209104 chr1 41349252 A T 4.80E-04 Type 2 diabetes / / 17463246 rs1576100 chr1 41367298 T A 2.68E-04 IgE levels / / 17255346 rs12407657 chr1 41396308 A T 9.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs11580126 chr1 41421336 G A 3.87E-05 Serum albumin level / / pha003084 rs12067645 chr1 41425864 G A 2.54E-04 Response to alcohol consumption (flushing response) / / 24277619 rs12408576 chr1 41464437 A G 9.51E-04 Response to taxane treatment (placlitaxel) CTPS intron 23006423 rs17357905 chr1 41484317 T C 4.85E-04 Alcohol dependence SLFNL1 intron 21314694 rs6678816 chr1 41485589 G T 4.95E-04 Response to taxane treatment (placlitaxel) SLFNL1 intron 23006423 rs1138293 chr1 41486245 C T 4.43E-04 Fibrinogen SLFNL1 missense 17255346 rs17357954 chr1 41487337 G T 5.45E-04 Response to taxane treatment (placlitaxel) SLFNL1 UTR-5 23006423 rs6686842 chr1 41530871 T C 2.00E-08 Height SCMH1 intron 18391952 rs2268677 chr1 41542504 A C 2.45E-04 Type 2 diabetes SCMH1 intron 17463246 rs2024860 chr1 41562243 C T 6.92E-04 Response to taxane treatment (placlitaxel) SCMH1 intron 23006423 rs721651 chr1 41563329 A C 7.54E-04 Response to taxane treatment (placlitaxel) SCMH1 intron 23006423 rs213753 chr1 41607331 A G 5.45E-04 Response to taxane treatment (placlitaxel) SCMH1 intron 23006423 rs12127030 chr1 41638398 A C 8.06E-04 Response to taxane treatment (placlitaxel) SCMH1 intron 23006423 rs6672508 chr1 41666571 C G 9.53E-04 Alcohol dependence SCMH1 intron 21314694 rs6672914 chr1 41666929 C T 6.34E-04 Response to taxane treatment (placlitaxel) SCMH1 intron 23006423 rs11209718 chr1 41688938 C T 3.00E-09 Height SCMH1 intron 23563607 rs3845571 chr1 41716039 A C 5.39E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2154319 chr1 41745770 T C 2.00E-12 Height / / 20881960 rs12035913 chr1 41757057 C T 1.62E-04 Type 2 diabetes / / 17463246 rs2364535 chr1 41766236 G A 2.76E-05 Type 2 diabetes / / 17463246 rs4233488 chr1 41781013 T C 0.000000976 Triglycerides / / 23063622 rs2363810 chr1 41783873 G A 5.04E-04 Type 2 diabetes / / 17463246 rs2363810 chr1 41783873 G A 1.02E-05 Lipid levels / / 19016617 rs2363810 chr1 41783873 G A 2.35E-05 Lipid levels / / 19016617 rs12042464 chr1 41786854 G A 8.05E-04 Type 2 diabetes / / 17463246 rs12042464 chr1 41786854 G A 5.79E-04 Bipolar disorder,schizoaffective / / 19567891 rs12043581 chr1 41788265 G A 7.11E-04 Type 2 diabetes / / 17463246 rs12043581 chr1 41788265 G A 5.43E-04 Bipolar disorder,schizoaffective / / 19567891 rs17362424 chr1 41794403 G T 8.56E-04 Type 2 diabetes / / 17463246 rs4660187 chr1 41799160 G A 8.52E-04 Alzheimer's disease / / 24755620 rs12757611 chr1 41808972 G A 6.52E-04 Type 2 diabetes / / 17463246 rs12757611 chr1 41808972 G A 5.43E-04 Bipolar disorder,schizoaffective / / 19567891 rs12047439 chr1 41809640 T A 9.06E-04 Type 2 diabetes / / 17463246 rs12047439 chr1 41809640 T A 4.95E-04 Bipolar disorder,schizoaffective / / 19567891 rs6660265 chr1 41818676 T C 6.75E-04 Bipolar disorder,schizoaffective / / 19567891 rs4660527 chr1 41821779 G A 2.09E-05 Recombination rate / / 21698098 rs7547654 chr1 41831361 G C 5.15E-05 Obesity (extreme) FOXO6 intron 21935397 rs1317558 chr1 41839083 C T 6.17E-04 Suicide attempts in bipolar disorder FOXO6 intron 21423239 rs4660531 chr1 41839822 G T 3.00E-06 Bipolar disorder FOXO6 intron 21926972 rs2810583 chr1 41880343 C T 9.68E-05 IgE levels / / 17255346 rs10493095 chr1 41881922 A G 3.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs114174493 chr1 41892201 G A 0.00035944 Sarcoidosis / / 22952805 rs12142181 chr1 41912985 C T 1.92E-06 Prion diseases / / 22210626 rs11590973 chr1 41926652 C T 9.45E-06 Bipolar disorder / / 18317468 rs2492074 chr1 41933422 C T 1.25E-04 Self-reported allergy / / 23817569 rs10789371 chr1 41938428 A G 6.20E-06 Dietary macronutrient intake / / 23372041 rs734359 chr1 41945902 C T 1.98E-14 Cholesterol,total EDN2 intron 23063622 rs734359 chr1 41945902 C T 2.44E-15 LDL cholesterol EDN2 intron 23063622 rs734359 chr1 41945902 C T 8.42E-12 Triglycerides EDN2 intron 23063622 rs11210344 chr1 41972880 G T 4.19E-04 Multiple complex diseases HIVEP3 UTR-3 17554300 rs3738577 chr1 41973349 G A 2.92E-04 Multiple complex diseases HIVEP3 UTR-3 17554300 rs11809423 chr1 41976529 C T 0.0003424 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) HIVEP3 missense 23233654 rs11809423 chr1 41976529 C T 3.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) HIVEP3 missense 23233662 rs633297 chr1 41985453 C A,T 1.36E-04 Alzheimer's disease HIVEP3 intron 17998437 rs646228 chr1 41986066 C A 7.82E-04 Alzheimer's disease HIVEP3 intron 17998437 rs679449 chr1 41988634 C A 9.16E-04 Alzheimer's disease HIVEP3 intron 17998437 rs687766 chr1 41998849 C G 3.21E-04 Alzheimer's disease HIVEP3 intron 17998437 rs12121881 chr1 42002738 C T 5.65E-04 Type 2 diabetes HIVEP3 intron 17463246 rs182676510 chr1 42003977 C T 0.00037173 Sarcoidosis HIVEP3 intron 22952805 rs114060246 chr1 42004054 C A 0.00038402 Sarcoidosis HIVEP3 intron 22952805 rs10493102 chr1 42008521 G T 7.95E-04 Type 2 diabetes HIVEP3 intron 17463246 rs10789394 chr1 42026023 G A 8.10E-05 Malaria HIVEP3 intron 19465909 rs4509569 chr1 42037875 T C 4.16E-04 Type 2 diabetes HIVEP3 intron 17463246 rs1815257 chr1 42041479 A C 3.83E-04 Intracranial aneurysm HIVEP3 intron 22286173 rs1570355 chr1 42042317 C T 2.35E-04 Alzheimer's disease HIVEP3 intron 17998437 rs6600380 chr1 42054814 A G 3.92E-04 Alzheimer's disease HIVEP3 intron 17998437 rs943374 chr1 42056194 A G 4.78E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs6700352 chr1 42071438 T G 6.76E-04 Rheumatoid arthritis HIVEP3 intron 21452313 rs12045563 chr1 42073905 T C 5.86E-04 Rheumatoid arthritis HIVEP3 intron 21452313 rs17363834 chr1 42076607 C T 9.59E-04 Rheumatoid arthritis HIVEP3 intron 21452313 rs11210498 chr1 42077958 T G 7.58E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs2148635 chr1 42082452 T C 1.10E-05 Urinary metabolites HIVEP3 intron 21572414 rs7519983 chr1 42083369 G A 6.75E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs6600384 chr1 42085141 G A 6.50E-06 Urinary metabolites HIVEP3 intron 21572414 rs16828495 chr1 42085437 A G 9.00E-05 Multiple complex diseases HIVEP3 intron 17554300 rs6658500 chr1 42088344 C T 8.70E-06 Urinary metabolites HIVEP3 intron 21572414 rs11210499 chr1 42089703 T C 5.80E-06 Urinary metabolites HIVEP3 intron 21572414 rs11210501 chr1 42091634 T C 7.28E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs1109255 chr1 42091708 C T 5.45E-04 Disc degeneration (lumbar) HIVEP3 intron 24216480 rs752010 chr1 42093015 C T 2.00E-06 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs2077172 chr1 42093340 A G 2.31E-06 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs6664724 chr1 42093821 G A 4.27E-06 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs2038978 chr1 42094719 A G 2.65E-06 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs6681441 chr1 42098321 G A 1.90E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs4083593 chr1 42099583 A G 6.77E-06 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs11210503 chr1 42101134 A G 2.26E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs10890151 chr1 42101843 C A 6.92E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs10789405 chr1 42101962 C T 2.13E-05 Lupus nephritis in systemic lupus erythematosus HIVEP3 intron 24925725 rs11210509 chr1 42109311 T C 4.96E-04 Alzheimer's disease HIVEP3 intron 17998437 rs1123483 chr1 42114198 A G 6.33E-04 Alzheimer's disease HIVEP3 intron 17998437 rs1123483 chr1 42114198 A G 5.40E-05 Cognitive function HIVEP3 intron 24684796 rs2148636 chr1 42119844 T C 9.10E-06 Urinary metabolites HIVEP3 intron 21572414 rs12077598 chr1 42172773 T A 5.22E-05 Self-reported allergy HIVEP3 intron 23817569 rs2036962 chr1 42177347 C T 1.00E-04 Self-reported allergy HIVEP3 intron 23817569 rs2036961 chr1 42178084 G A 5.05E-05 Multiple complex diseases HIVEP3 intron 17554300 rs4526604 chr1 42182144 T C 1.04E-04 Self-reported allergy HIVEP3 intron 23817569 rs6600388 chr1 42189456 A G 1.22E-04 Self-reported allergy HIVEP3 intron 23817569 rs11210517 chr1 42198081 C T 8.34E-04 Multiple complex diseases HIVEP3 intron 17554300 rs710235 chr1 42202714 T C 1.78E-05 Asthma HIVEP3 intron 20920776 rs4284254 chr1 42213076 G A 1.98E-06 Asthma HIVEP3 intron 20920776 rs12126740 chr1 42223909 C T 7.38E-04 Alzheimer's disease HIVEP3 intron 17998437 rs2165303 chr1 42228019 A G 8.78E-05 Self-reported allergy HIVEP3 intron 23817569 rs732554 chr1 42230644 C G 1.08E-04 Self-reported allergy HIVEP3 intron 23817569 rs4660206 chr1 42234757 A G 2.09E-04 Self-reported allergy HIVEP3 intron 23817569 rs7517484 chr1 42250456 T C 3.16E-06 Asthma HIVEP3 intron 20920776 rs12137296 chr1 42251918 G A 7.25E-06 Type 2 diabetes HIVEP3 intron 21573907 rs349439 chr1 42259008 G T 6.08E-04 Lymphocyte counts HIVEP3 intron 22286170 rs17373758 chr1 42259133 C A 8.29E-04 Multiple complex diseases HIVEP3 intron 17554300 rs10493098 chr1 42261889 T C 6.91E-04 Schizophrenia HIVEP3 intron 19197363 rs10493097 chr1 42262138 C A 1.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) HIVEP3 intron 20877124 rs16828722 chr1 42270666 C T 5.63E-05 Major depressive disorder HIVEP3 intron 22472876 rs349423 chr1 42297124 C T 9.00E-06 Bronchopulmonary dysplasia HIVEP3 intron 23897914 rs972352 chr1 42297604 A C 6.73E-04 Insulin resistance HIVEP3 intron 21901158 rs655198 chr1 42326017 A G 8.87E-05 Asthma HIVEP3 intron 20159242 rs525382 chr1 42329120 T G 2.76E-04 Type 2 diabetes HIVEP3 intron 17463246 rs609572 chr1 42329303 C T 2.42E-04 Type 2 diabetes HIVEP3 intron 17463246 rs12734651 chr1 42330585 C A 3.75E-04 Schizophrenia HIVEP3 intron 19197363 rs12734651 chr1 42330585 C A 9.46E-05 Orofacial clefts HIVEP3 intron 22419666 rs11210537 chr1 42345723 G A 6.39E-05 IgE levels in asthmatics (D.p. specific) HIVEP3 intron 23967269 rs11210537 chr1 42345723 G A 6.99E-05 IgE levels in asthmatics (D.f. specific) HIVEP3 intron 23967269 rs2993120 chr1 42350837 A C 5.17E-05 IgE levels in asthmatics (D.p. specific) HIVEP3 intron 23967269 rs2993120 chr1 42350837 A C 6.00E-05 IgE levels in asthmatics (D.f. specific) HIVEP3 intron 23967269 rs12024772 chr1 42353344 A G 4.55E-05 IgE levels in asthmatics (D.p. specific) HIVEP3 intron 23967269 rs12024772 chr1 42353344 A G 5.73E-05 IgE levels in asthmatics (D.f. specific) HIVEP3 intron 23967269 rs1408946 chr1 42364249 G C 1.08E-05 Personality dimensions HIVEP3 intron 18957941 rs6600391 chr1 42371447 C T 2.73E-06 Asthma (childhood onset) HIVEP3 intron 23829686 rs661428 chr1 42451518 A C 4.52E-04 Smoking initiation HIVEP3 intron 24665060 rs642112 chr1 42453317 C A,G,T 7.88E-04 Multiple complex diseases HIVEP3 intron 17554300 rs7546128 chr1 42473659 C A 1.88E-04 Smoking initiation HIVEP3 intron 24665060 rs10736422 chr1 42480320 C T 2.27E-04 Smoking initiation HIVEP3 intron 24665060 rs6689536 chr1 42487523 T C 2.24E-04 Smoking initiation HIVEP3 intron 24665060 rs4660212 chr1 42496399 A G 2.27E-04 Smoking initiation HIVEP3 intron 24665060 rs12042133 chr1 42499365 C A 3.54E-04 Smoking initiation HIVEP3 intron 24665060 rs6696291 chr1 42500421 A G 5.62E-04 Smoking initiation HIVEP3 intron 24665060 rs12758407 chr1 42507013 T G 4.29E-05 Self-reported allergy / / 23817569 rs10437061 chr1 42515695 C T 1.94E-04 Multiple complex diseases / / 17554300 rs2042065 chr1 42516770 A C 6.30E-04 Smoking initiation / / 24665060 rs11210581 chr1 42556915 T C 5.33E-04 Smoking initiation / / 24665060 rs6672120 chr1 42577444 T C 5.13E-04 Multiple complex diseases / / 17554300 rs4660218 chr1 42597873 A G 7.78E-04 Smoking initiation / / 24665060 rs7542228 chr1 42598964 A G 7.76E-04 Smoking initiation / / 24665060 rs7539864 chr1 42601648 C G,T 7.76E-05 Self-reported allergy / / 23817569 rs12119339 chr1 42608400 G A 6.04E-04 Smoking initiation / / 24665060 rs11210601 chr1 42613302 T C 1.21E-04 Smoking initiation / / 24665060 rs4660610 chr1 42616910 G A 1.49E-04 Smoking initiation / / 24665060 rs3754283 chr1 42617032 A G 1.35E-04 Smoking initiation / / 24665060 rs11210604 chr1 42623672 T G 3.01E-07 Panic disorder / / 19165232 rs11210604 chr1 42623672 T G 3.64E-23 Narcolepsy / / 19629137 rs624614 chr1 42647914 A G 4.66E-05 Erythrocyte counts FOXJ3 intron pha003101 rs12402117 chr1 42738366 G A 2.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) FOXJ3 intron 23648065 rs12402117 chr1 42738366 G A 2.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (epirubicin) FOXJ3 intron 23648065 rs2494366 chr1 42798204 C T 1.80E-04 Type 2 diabetes and 6 quantitative traits FOXJ3 intron 17848626 rs2494366 chr1 42798204 C T 4.66E-05 Erythrocyte counts FOXJ3 intron pha003101 rs913426 chr1 42806191 A G 2.73E-04 Taste perception / / 22132133 rs6679533 chr1 42835396 C T 5.56E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9803864 chr1 42879737 T G 8.36E-04 Response to taxane treatment (placlitaxel) RIMKLA intron 23006423 rs1055055 chr1 42880516 T C 5.97E-04 Type 2 diabetes RIMKLA cds-synon 17463246 rs16829473 chr1 42885523 C A,G,T 2.84E-04 Multiple complex diseases RIMKLA UTR-3 17554300 rs11210643 chr1 42893164 G A 8.28E-04 Multiple complex diseases / / 17554300 rs3748845 chr1 42901082 A C 5.11E-04 Multiple complex diseases ZMYND12 intron 17554300 rs4660634 chr1 42901173 C T 4.92E-04 Multiple complex diseases ZMYND12 intron 17554300 rs10890197 chr1 42902906 C T 7.07E-04 Multiple complex diseases ZMYND12 intron 17554300 rs10493108 chr1 42908102 A C 6.15E-04 Multiple complex diseases ZMYND12 intron 17554300 rs4622104 chr1 42978242 C T 3.64E-04 Multiple complex diseases / / 17554300 rs4607934 chr1 42983413 G A 2.10E-04 Multiple complex diseases / / 17554300 rs7411957 chr1 43008018 G A 5.33E-04 Multiple complex diseases CCDC30 intron 17554300 rs16829623 chr1 43009319 T C 7.70E-04 Multiple complex diseases CCDC30 intron 17554300 rs12408987 chr1 43052471 T G 5.32E-04 Multiple complex diseases CCDC30 intron 17554300 rs16829846 chr1 43133657 C T 3.60E-04 Smoking initiation PPIH intron 24665060 rs12046563 chr1 43137280 A G 9.42E-05 Oral cancers (chewing tobacco related) PPIH intron 22503698 rs3895305 chr1 43154492 G T 6.19E-04 Lymphocyte counts YBX1 intron 22286170 rs4660656 chr1 43197508 G A,C,T 7.55E-04 Parkinson's disease / / 17052657 rs323716 chr1 43277312 T C 9.80E-06 Glioma (high-grade) CCDC23 intron 19578366 rs17381767 chr1 43281728 C T 7.01E-04 Insulin resistance CCDC23 intron 21901158 rs7540604 chr1 43299835 T C 6.56E-05 Bipolar disorder ERMAP intron 19488044 rs7520697 chr1 43315966 G A 4.96E-05 Cognitive test performance ZNF691 intron 20125193 rs4660234 chr1 43319272 C T 2.66E-06 Gallstones / / 17632509 rs12070405 chr1 43357369 G T 5.93E-06 Asthma (childhood onset) / / 23829686 rs16830039 chr1 43366503 T G 1.52E-04 Cholesterol / / 17255346 rs3820548 chr1 43398396 A G 3.78E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) SLC2A1 intron 24023788 rs5031048 chr1 43406154 C G 4.74E-04 Multiple complex diseases SLC2A1 intron 17554300 rs11808361 chr1 43419215 C T 0.00029 Coronary artery calcification SLC2A1 intron 23727086 rs841839 chr1 43430084 C A 5.64E-04 Type 2 diabetes FLJ32224 intron 17463246 rs2367159 chr1 43432589 T C 5.64E-04 Type 2 diabetes FLJ32224 intron 17463246 rs841572 chr1 43436051 G A 1.58E-05 Cardiovascular disease / / pha003065 rs11210774 chr1 43450729 C T 3.84E-05 Serum metabolites / / 19043545 rs1754154 chr1 43470766 G T 5.95E-05 Blood Pressure / / pha002903 rs634669 chr1 43505440 T C 4.17E-04 Insulin resistance / / 21901158 rs588662 chr1 43530154 A G 8.35E-04 Multiple complex diseases / / 17554300 rs1198394 chr1 43540338 G A 9.07E-04 Alcohol dependence / / 21314694 rs519789 chr1 43580261 G A 0.00039631 Sarcoidosis / / 22952805 rs16830359 chr1 43596384 G A 8.59E-31 Narcolepsy / / 19629137 rs16830359 chr1 43596384 G A 1.00E-07 Cardiac hypertrophy / / 21348951 rs585655 chr1 43597014 G A 1.36E-04 Insulin resistance / / 21901158 rs490876 chr1 43600931 T C 1.32E-04 Insulin resistance / / 21901158 rs601504 chr1 43603715 G C 5.77E-04 Type 2 diabetes / / 17463246 rs601504 chr1 43603715 G C 4.64E-04 Insulin resistance / / 21901158 rs545220 chr1 43605870 G A 7.84E-04 Insulin resistance / / 21901158 rs16830399 chr1 43610139 C G 8.61E-05 Multiple complex diseases / / 17554300 rs16830399 chr1 43610139 C G 9.36E-04 Insulin resistance / / 21901158 rs475093 chr1 43616337 G C 9.80E-05 Gallstones FAM183A intron 17632509 rs12033506 chr1 43618969 G T 7.43E-05 Insulin resistance FAM183A intron 21901158 rs76382232 chr1 43628307 T C 0.0004086 Sarcoidosis / / 22952805 rs621559 chr1 43645411 G A 2.00E-06 Telomere length WDR65 intron 21460395 rs663824 chr1 43649508 A G 0.0000819 Atypical cytochrome P450 3A4 (CYP3A4) enzyme activity WDR65 missense 22945461 rs513009 chr1 43663376 A G 9.69E-04 Insulin resistance WDR65 intron 21901158 rs150404479 chr1 43688550 T C 1.00E-06 Bipolar disorder (body mass index interaction) WDR65 missense 24322204 rs2484714 chr1 43699970 G A 2.56E-05 Alzheimer's disease WDR65 cds-synon 17998437 rs3862227 chr1 43720994 A G 5.53E-05 Response to treatment for acute lymphoblastic leukemia / / 19176441 rs11210819 chr1 43721710 G A 9.26E-04 Alzheimer's disease / / 17998437 rs2151673 chr1 43741224 G A 8.51E-04 Aortic root size / / 21223598 rs6697017 chr1 43751701 C T 2.18E-04 Celiac disease / / 23936387 rs34783763 chr1 43757762 T C 2.52E-05 Celiac disease / / 23936387 rs1098182 chr1 43785768 G C 4.51E-05 Response to taxane treatment (placlitaxel) TIE1 intron 23006423 rs11210834 chr1 43787437 A G 5.40E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TIE1 intron 20877124 rs17292650 chr1 43803807 G T 1.64E-05 Platelet counts MPL missense 21507922 rs12731981 chr1 43804340 G A 3.66E-04 Smoking initiation MPL missense 24665060 rs2069387 chr1 43828080 T G 1.64E-05 Platelet counts CDC20 intron 21507922 rs1999674 chr1 43881941 A G 8.41E-05 Serum metabolites SZT2 intron 19043545 rs2782651 chr1 43920686 C G 4.98E-05 Serum metabolites HYI nearGene-5 19043545 rs12069733 chr1 43941508 G A 1.37E-07 Parkinson's disease / / 17052657 rs6429604 chr1 43955148 A G 1.52E-04 Depression (quantitative trait) / / 20800221 rs6687571 chr1 43957515 G A 3.56E-05 Personality dimensions / / 18957941 rs6687571 chr1 43957515 G A 1.60E-04 Depression (quantitative trait) / / 20800221 rs7417538 chr1 43959942 G A 1.61E-04 Depression (quantitative trait) / / 20800221 rs2039529 chr1 43960479 A G 7.57E-05 Depression (quantitative trait) / / 20800221 rs2039528 chr1 43960530 A G 1.60E-05 Personality dimensions / / 18957941 rs2039528 chr1 43960530 A G 7.25E-05 Depression (quantitative trait) / / 20800221 rs2039528 chr1 43960530 A G 1.60E-05 Personality dimensions / / 21173776 rs6675341 chr1 43970956 C T 1.18E-04 Depression (quantitative trait) / / 20800221 rs10749849 chr1 43974489 G A 1.87E-04 Depression (quantitative trait) / / 20800221 rs1413937 chr1 43975238 G A 1.63E-04 Depression (quantitative trait) / / 20800221 rs10890251 chr1 43976266 A C 2.24E-05 Personality dimensions / / 18957941 rs10890251 chr1 43976266 A C 3.10E-04 Depression (quantitative trait) / / 20800221 rs11210858 chr1 43978837 T C 3.05E-04 Depression (quantitative trait) / / 20800221 rs11210859 chr1 43979782 G A 3.04E-04 Depression (quantitative trait) / / 20800221 rs1413938 chr1 43981265 C T 3.08E-04 Depression (quantitative trait) / / 20800221 rs2367617 chr1 43981961 A G 3.08E-04 Depression (quantitative trait) / / 20800221 rs11210862 chr1 43984142 C T 3.18E-04 Depression (quantitative trait) / / 20800221 rs1413939 chr1 43984627 G C 1.66E-04 Depression (quantitative trait) / / 20800221 rs11210863 chr1 43985678 C T 3.21E-04 Depression (quantitative trait) / / 20800221 rs11210864 chr1 43991832 G A 2.23E-05 Personality dimensions / / 18957941 rs11210864 chr1 43991832 G A 4.91E-04 Depression (quantitative trait) / / 20800221 rs11577317 chr1 43992893 A G 4.07E-04 Depression (quantitative trait) / / 20800221 rs11590627 chr1 43999120 T C 2.12E-04 Depression (quantitative trait) PTPRF intron 20800221 rs2819332 chr1 44005280 G A 5.00E-06 Amyotrophic lateral sclerosis (age of onset) PTPRF intron 22959728 rs2782640 chr1 44009033 C T 5.04E-04 Smoking initiation PTPRF intron 24665060 rs2782641 chr1 44013355 G A 1.56E-04 Smoking initiation PTPRF intron 24665060 rs2819333 chr1 44014573 A T 5.34E-04 Smoking initiation PTPRF intron 24665060 rs11582876 chr1 44062827 C T 6.75E-04 Alcohol dependence PTPRF intron 21314694 rs11210886 chr1 44071546 G A 8.15E-04 Multiple complex diseases PTPRF intron 17554300 rs11210886 chr1 44071546 G A 6.48E-04 Obesity (extreme) PTPRF intron 21935397 rs11210888 chr1 44076630 C T 5.55E-04 Obesity (extreme) PTPRF intron 21935397 rs11804031 chr1 44081912 A G 5.40E-04 Obesity (extreme) PTPRF intron 21935397 rs16831024 chr1 44084620 G T 5.36E-04 Obesity (extreme) PTPRF intron 21935397 rs11210893 chr1 44101767 T G 4.61E-04 Obesity (extreme) / / 21935397 rs11210894 chr1 44102587 C T 4.60E-04 Obesity (extreme) / / 21935397 rs11210896 chr1 44103275 G A 4.59E-04 Obesity (extreme) / / 21935397 rs660899 chr1 44117006 G T 4.00E-06 Hypertension risk in short sleep duration KDM4A intron 22322875 rs4336891 chr1 44126440 G A 5.47E-04 Obesity (extreme) KDM4A intron 21935397 rs669446 chr1 44129779 A G 7.08E-04 Parkinson's disease KDM4A intron 17052657 rs669446 chr1 44129779 A G 5.00E-06 Amyotrophic lateral sclerosis (age of onset) KDM4A intron 22959728 rs10789441 chr1 44130564 A G 5.98E-04 Obesity (extreme) KDM4A intron 21935397 rs304303 chr1 44178070 T G 1.29E-05 Alopecia areata ST3GAL3 intron 22027810 rs12410155 chr1 44188465 A C 2.00E-04 Information processing speed ST3GAL3 intron 21130836 rs4660260 chr1 44195353 T C 2.55E-06 Alopecia areata ST3GAL3 intron 22027810 rs12733500 chr1 44208306 T G 6.11E-05 Pulmonary function ST3GAL3 intron 20010835 rs2367725 chr1 44215828 C A,G,T 9.00E-06 Aging (time to event) ST3GAL3 intron 21782286 rs7520053 chr1 44226657 A G 8.93E-04 Schizophrenia (cytomegalovirus infection interaction) ST3GAL3 intron 23358160 rs12760274 chr1 44249344 A G 8.33E-05 Alcohol consumption ST3GAL3 intron 23953852 rs6701645 chr1 44254514 C T 6.84E-07 Red blood cell traits ST3GAL3 intron 23222517 rs12741964 chr1 44254586 G A 1.12E-04 Schizophrenia (cytomegalovirus infection interaction) ST3GAL3 intron 23358160 rs16831192 chr1 44255687 G A 3.42E-05 Cognitive impairment induced by topiramate ST3GAL3 intron 22091778 rs12122504 chr1 44256819 C G 7.70E-07 Red blood cell traits ST3GAL3 intron 23222517 rs11210927 chr1 44266420 A G 7.27E-07 Red blood cell traits ST3GAL3 intron 23222517 rs12133508 chr1 44277746 C T 6.06E-07 Red blood cell traits ST3GAL3 intron 23222517 rs37458 chr1 44290530 A G 0.00014 Breast cancer ST3GAL3 missense 23555315 rs3791073 chr1 44297673 T C 3.58E-04 Insulin resistance ST3GAL3 intron 21901158 rs3011217 chr1 44303266 A G 7.64E-05 Receptive language ability ST3GAL3 intron 24687471 rs3011225 chr1 44319373 G A 7.00E-08 Amyotrophic lateral sclerosis (age of onset) ST3GAL3 intron 22959728 rs2906466 chr1 44322220 A G 3.90E-05 Brain structure ST3GAL3 intron 22504417 rs2906457 chr1 44338575 A C 5.59E-05 Cognitive performance ST3GAL3 intron 19734545 rs2906457 chr1 44338575 A C 9.84E-06 Brain structure ST3GAL3 intron 22504417 rs2428853 chr1 44343173 C G 3.20E-05 Response to statin therapy ST3GAL3 intron 20339536 rs2788371 chr1 44343962 A G 9.20E-05 Response to statin therapy ST3GAL3 intron 20339536 rs2527776 chr1 44345292 G A 1.17E-05 Brain structure ST3GAL3 intron 22504417 rs803676 chr1 44352458 A G 7.60E-05 Response to statin therapy ST3GAL3 intron 20339536 rs2428854 chr1 44356185 C A 7.90E-05 Response to statin therapy ST3GAL3 intron 20339536 rs803683 chr1 44358148 G T 8.00E-05 Response to statin therapy ST3GAL3 intron 20339536 rs16831389 chr1 44363143 C T 1.47E-04 Alzheimer's disease ST3GAL3 intron 24755620 rs783304 chr1 44365457 A G 5.85E-04 Alzheimer's disease ST3GAL3 intron 24755620 rs16831424 chr1 44387353 C T 3.42E-05 Cognitive impairment induced by topiramate ST3GAL3 intron 22091778 rs12569336 chr1 44391288 T A 2.31E-04 Alzheimer's disease ST3GAL3 intron 24755620 rs12561948 chr1 44396196 A G 2.54E-04 Alzheimer's disease ST3GAL3 UTR-3 24755620 rs4448553 chr1 44411589 A G 3.90E-05 Brain structure / / 22504417 rs7556565 chr1 44416090 C T 3.46E-05 Brain structure IPO13 intron 22504417 rs6675620 chr1 44417630 C T 3.60E-05 Brain structure IPO13 intron 22504417 rs2301993 chr1 44426025 G A 4.10E-05 Brain structure IPO13 intron 22504417 rs7161 chr1 44438974 C T 2.75E-06 Systemic lupus erythematosus and Systemic sclerosis DPH2 UTR-3 23740937 rs1362153 chr1 44469031 T C 7.00E-06 Alcohol dependence (age at onset) SLC6A9 intron 24962325 rs2485993 chr1 44503040 A G 8.60E-05 Schizophrenia / / 24253340 rs751442 chr1 44509551 A C 5.44E-04 Nicotine dependence / / 17158188 rs751442 chr1 44509551 A C 8.78E-05 Schizophrenia / / 24253340 rs2158822 chr1 44519447 G C 4.50E-06 Urinary metabolites / / 21572414 rs11210949 chr1 44535401 T C 0.0000629 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs942755 chr1 44537401 G A 0.0000803 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6662888 chr1 44602159 G A 2.68E-04 Type 2 diabetes / / 17463246 rs2799480 chr1 44684995 T C 9.11E-04 Alzheimer's disease DMAP1 intron 22005930 rs4660781 chr1 44700764 A G 8.86E-05 Stroke ERI3 intron pha002887 rs1778905 chr1 44724788 A G 7.40E-04 Alzheimer's disease ERI3 intron 22005930 rs2799475 chr1 44727612 T C 8.48E-04 Alzheimer's disease ERI3 intron 22005930 rs325168 chr1 44731068 T G 7.03E-04 Type 2 diabetes ERI3 intron 17463246 rs10890295 chr1 44745450 T A 3.72E-04 Type 2 diabetes ERI3 intron 17463246 rs459358 chr1 44745624 C T 5.82E-04 Alzheimer's disease ERI3 intron 22005930 rs325163 chr1 44751710 T C 5.87E-04 Alzheimer's disease ERI3 intron 22005930 rs325160 chr1 44759392 C G 1.70E-04 Type 2 diabetes ERI3 intron 17463246 rs325160 chr1 44759392 C G 1.30E-05 Lipid levels ERI3 intron 18193043 rs325154 chr1 44764677 C T 9.33E-04 Alzheimer's disease ERI3 intron 22005930 rs12058010 chr1 44765646 C T 1.50E-05 Urinary metabolites ERI3 intron 21572414 rs6429535 chr1 44766071 C T 2.22E-04 Type 2 diabetes ERI3 intron 17463246 rs11210982 chr1 44793760 G A 1.97E-04 Alzheimer's disease ERI3 intron 22005930 rs2524353 chr1 44807164 C T 8.52E-04 Type 2 diabetes ERI3 intron 17463246 rs172853 chr1 44809445 T G 6.35E-04 Alzheimer's disease ERI3 intron 22005930 rs226065 chr1 44819375 A G 5.69E-04 Alzheimer's disease ERI3 intron 22005930 rs226069 chr1 44822097 G A 4.05E-04 Alzheimer's disease / / 22005930 rs4660790 chr1 44828525 G T 8.60E-05 Stroke / / pha002887 rs3888585 chr1 44856052 C A 9.06E-05 Cognitive test performance / / 20125193 rs7555873 chr1 44912147 T C 4.95E-04 Multiple complex diseases RNF220 intron 17554300 rs12071805 chr1 44921331 C G 1.29E-04 Multiple complex diseases RNF220 intron 17554300 rs9804150 chr1 44951245 A G 8.67E-05 Lung function (forced expiratory volume in 1 second) RNF220 intron pha003102 rs781775 chr1 44972309 G A 3.82E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) RNF220 intron 23648065 rs781774 chr1 44972337 G A 5.00E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma RNF220 intron 22205395 rs781771 chr1 44974082 T C 1.40E-06 Interleukin levels (IL10,IL1Ra,IL6),in plasma RNF220 intron 22205395 rs781770 chr1 44974119 C T 2.71E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) RNF220 intron 23648065 rs12138940 chr1 44974796 A G 2.50E-05 Anxiety in major depressive disorder RNF220 intron 24047446 rs781790 chr1 44976806 A G 5.91E-05 Cognitive impairment induced by topiramate RNF220 intron 22091778 rs781790 chr1 44976806 A G 2.85E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) RNF220 intron 23648065 rs272531 chr1 44988433 G A 3.66E-04 Schizophrenia RNF220 intron 19197363 rs272531 chr1 44988433 G A 6.68E-05 Insulin resistance RNF220 intron 21901158 rs272537 chr1 44992714 A T 5.40E-06 Urinary metabolites RNF220 intron 21572414 rs746733 chr1 44999614 G A 3.55E-05 F-cell distribution RNF220 intron 21326311 rs7525212 chr1 45029679 G A,T 3.92E-04 Schizophrenia RNF220 intron 19197363 rs270716 chr1 45054866 A G 1.20E-05 Urinary metabolites RNF220 intron 21572414 rs459160 chr1 45080932 T C 1.73E-04 Body mass index RNF220 intron 17255346 rs459160 chr1 45080932 T C 8.20E-04 Multiple complex diseases RNF220 intron 17554300 rs461043 chr1 45081101 T C 1.56E-11 Multiple complex diseases RNF220 intron 17554300 rs1051648 chr1 45116935 C T 6.82E-05 Cognitive test performance RNF220 UTR-3 20125193 rs17391430 chr1 45234389 G A 2.24E-04 Multiple complex diseases / / 17554300 rs12072767 chr1 45258232 C T 0.00042089 Sarcoidosis / / 22952805 rs6676749 chr1 45264545 T G 3.01E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs11584440 chr1 45268356 C A 3.73E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PLK3 intron 21844884 rs11211036 chr1 45270024 G C 2.32E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PLK3 cds-synon 21844884 rs11211037 chr1 45275551 A C 1.75E-04 Longevity BTBD19 intron 22279548 rs11211040 chr1 45291908 G A 5.98E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PTCH2 intron 21844884 rs3795720 chr1 45307506 G A 0.00004 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer PTCH2 intron 21245432 rs6429550 chr1 45311749 G A 1.89E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6429550 chr1 45311749 G A 9.73E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs7517439 chr1 45312867 G A 2.16E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs7517639 chr1 45313150 G A 3.91E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs6692487 chr1 45317392 G A 4.79E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines EIF2B3 intron 21844884 rs11579580 chr1 45318718 C G 5.92E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines EIF2B3 intron 21844884 rs11211044 chr1 45318752 C T 0.00002 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer EIF2B3 intron 21245432 rs12733586 chr1 45327230 G A 7.88E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines EIF2B3 intron 21844884 rs7528461 chr1 45331753 G A 5.74E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines EIF2B3 intron 21844884 rs263975 chr1 45358527 T C 0.00002 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer EIF2B3 intron 21245432 rs263977 chr1 45360287 T G 0.00002 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer EIF2B3 intron 21245432 rs3767490 chr1 45360658 A C 4.40E-04 Multiple complex diseases EIF2B3 intron 17554300 rs608649 chr1 45363887 T C 2.69E-04 Multiple complex diseases EIF2B3 intron 17554300 rs1572379 chr1 45369086 A G 6.38E-04 Response to cytadine analogues (cytosine arabinoside) EIF2B3 intron 24483146 rs12093313 chr1 45371160 G A 9.53E-04 Response to cytadine analogues (cytosine arabinoside) EIF2B3 intron 24483146 rs11211053 chr1 45373666 G A 5.51E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines EIF2B3 intron 21844884 rs263966 chr1 45376737 G A 0.00004 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer EIF2B3 intron 21245432 rs452989 chr1 45417184 T C 0.00004 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer EIF2B3 intron 21245432 rs11211059 chr1 45430218 C T 7.16E-05 Multiple complex diseases EIF2B3 intron 17554300 rs489676 chr1 45452227 G C 0.00003 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer EIF2B3 UTR-5 21245432 rs264011 chr1 45460832 A G 0.00003 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer / / 21245432 rs7528534 chr1 45470130 T C 1.98E-05 Type 2 diabetes HECTD3 intron 17463246 rs7528534 chr1 45470130 T C 9.52E-04 Multiple complex diseases HECTD3 intron 17554300 rs2050869 chr1 45503639 G A 9.85E-05 Serum metabolites ZSWIM5 intron 19043545 rs3850855 chr1 45523893 T C 5.45E-04 Cocaine dependence ZSWIM5 intron 23958962 rs3850855 chr1 45523893 T C 6.09E-06 Cocaine dependence ZSWIM5 intron 23958962 rs11211074 chr1 45530509 T C 2.39E-04 Cocaine dependence ZSWIM5 intron 23958962 rs11211074 chr1 45530509 T C 3.43E-06 Cocaine dependence ZSWIM5 intron 23958962 rs346733 chr1 45585207 C T 1.57E-04 HIV-1 viral setpoint ZSWIM5 intron 17641165 rs1226757 chr1 45592886 G A 1.57E-04 Smoking quantity ZSWIM5 intron 24665060 rs346718 chr1 45610429 G T 4.07E-04 Multiple complex diseases ZSWIM5 intron 17554300 rs1938300 chr1 45672783 T C 1.38E-05 Cocaine dependence / / 23958962 rs1938300 chr1 45672783 T C 1.71E-04 Cocaine dependence / / 23958962 rs2997460 chr1 45694796 C T 1.55E-04 HIV-1 viral setpoint / / 17641165 rs2997460 chr1 45694796 C T 4.18E-06 Cocaine dependence / / 23958962 rs2997460 chr1 45694796 C T 7.66E-05 Cocaine dependence / / 23958962 rs1938407 chr1 45722622 A G 1.49E-05 Cocaine dependence / / 23958962 rs1938407 chr1 45722622 A G 2.66E-04 Cocaine dependence / / 23958962 rs1938297 chr1 45740469 T C 2.55E-05 Smoking quantity / / 24665060 rs4233497 chr1 45763753 T C 3.00E-04 HIV-1 viral setpoint / / 17641165 rs3219487 chr1 45798555 T C 4.19E-04 Insulin resistance MUTYH intron 21901158 rs3219487 chr1 45798555 T C 2.78E-05 Lymphocyte counts MUTYH intron 22286170 rs9429157 chr1 45808863 G A 0.00079 Prostate cancer TOE1 missense 23555315 rs9429072 chr1 45810091 A G 6.26E-05 Femoral neck bone geometry TESK2 UTR-3 22087292 rs2153608 chr1 45813941 A G 5.72E-05 Femoral neck bone geometry TESK2 intron 22087292 rs9429076 chr1 45819489 T C 6.88E-04 Insulin resistance TESK2 intron 21901158 rs7543428 chr1 45839643 A G 3.70E-05 Femoral neck bone geometry TESK2 intron 22087292 rs11211101 chr1 45849311 G C 3.16E-07 Lymphocyte counts TESK2 intron 22286170 rs2487442 chr1 45857176 G C 2.26E-04 Insulin resistance TESK2 intron 21901158 rs2487442 chr1 45857176 G C 8.78E-05 Femoral neck bone geometry TESK2 intron 22087292 rs1771551 chr1 45883643 C G 9.06E-04 Insulin resistance TESK2 intron 21901158 rs1771551 chr1 45883643 C G 5.95E-05 Femoral neck bone geometry TESK2 intron 22087292 rs4660306 chr1 45978675 T C 2.00E-09 Homocysteine levels PRDX1 intron 23824729 rs16832557 chr1 45978923 T C 6.62E-06 Multiple complex diseases PRDX1 intron 17554300 rs10736426 chr1 45984353 G A 9.85E-04 Amyotrophic lateral sclerosis (sporadic) PRDX1 intron 24529757 rs487174 chr1 46009536 A G 1.70E-05 Urinary metabolites / / 21572414 rs3748645 chr1 46035470 G A 4.97E-05 Amyotrophic lateral sclerosis (sporadic) AKR1A1 intron 24529757 rs1053941 chr1 46084383 G T 5.00E-11 Blood metabolite levels /SP UTR-3 24816252 rs11211176 chr1 46223086 G A 6.48E-06 Multiple sclerosis / / 17660530 rs6680211 chr1 46315007 C G 7.11E-04 Nicotine dependence MAST2 intron 17158188 rs6429582 chr1 46321843 T C 3.76E-04 Multiple complex diseases MAST2 intron 17554300 rs6429582 chr1 46321843 T C 6.00E-05 Malaria MAST2 intron 19465909 rs12732188 chr1 46333358 G A 2.00E-04 Cognitive impairment induced by topiramate MAST2 intron 22091778 rs10890361 chr1 46346234 T A 6.46E-04 Multiple complex diseases MAST2 intron 17554300 rs10890361 chr1 46346234 T A 9.40E-06 Malaria MAST2 intron 19465909 rs10890363 chr1 46356148 A G 6.28E-04 Multiple complex diseases MAST2 intron 17554300 rs10890363 chr1 46356148 A G 9.10E-05 Malaria MAST2 intron 19465909 rs4545281 chr1 46360054 C T 5.82E-04 Multiple complex diseases MAST2 intron 17554300 rs7556436 chr1 46363880 A G 6.63E-04 Multiple complex diseases MAST2 intron 17554300 rs7556436 chr1 46363880 A G 5.20E-05 Malaria MAST2 intron 19465909 rs4660905 chr1 46461587 A G 3.83E-04 Hearing function MAST2 intron 17255346 rs4073846 chr1 46462881 A G 7.46E-04 Multiple complex diseases MAST2 intron 17554300 rs11579634 chr1 46466391 C T 6.98E-04 Multiple complex diseases MAST2 intron 17554300 rs2236560 chr1 46495434 G A 8.02E-04 Type 2 diabetes MAST2 intron 17463246 rs1622208 chr1 46498375 A G 9.69E-04 Hearing function MAST2 cds-synon 17255346 rs1052607 chr1 46499526 A G 9.34E-05 Calcium levels MAST2 missense pha003085 rs1768809 chr1 46502836 A C 1.15E-04 Multiple complex diseases / / 17554300 rs1768808 chr1 46503217 C T 1.18E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) / / 23648065 rs7538978 chr1 46505054 G A 2.86E-04 Hearing function / / 17255346 rs1707322 chr1 46505147 A G 3.78E-04 Hearing function / / 17255346 rs1707321 chr1 46505309 A G 2.08E-04 Multiple complex diseases / / 17554300 rs785467 chr1 46521559 A T 8.02E-04 Hearing function PIK3R3 missense 17255346 rs785465 chr1 46522577 A C 3.78E-04 Hearing function PIK3R3 intron 17255346 rs1613296 chr1 46546852 T G 3.73E-04 Hearing function PIK3R3 intron 17255346 rs785495 chr1 46587887 T C 5.14E-04 Multiple complex diseases PIK3R3 intron 17554300 rs1983261 chr1 46617981 G A 4.95E-04 Multiple complex diseases / / 17554300 rs17102048 chr1 46622385 G A 0.000749 Height (Pygmy height) / / 22570615 rs3855959 chr1 46633874 T C 3.00E-05 Breast cancer (estrogen-receptor negative,progesterone-receptor negative,and human epidermal growth factor-receptor negative) / / 24325915 rs7538871 chr1 46671997 A G 6.20E-05 Multiple complex diseases POMGNT1 intron 17554300 rs9793263 chr1 46722389 A G 5.33E-04 Coronary heart disease RAD54L intron 21606135 rs2295465 chr1 46726057 A C 3.87E-05 Multiple complex diseases RAD54L intron 17554300 rs12410307 chr1 46730398 G A 1.94E-04 Coronary heart disease RAD54L intron 21606135 rs17102098 chr1 46741211 A G 0.0000116 Cholesterol,total RAD54L intron 23696881 rs12142240 chr1 46747301 T C 4.70E-05 Menopause (age at onset) LRRC41 intron 22267201 rs4660344 chr1 46805222 A G 2.24E-05 Osteoarthritis (knee and hip) / / 21177295 rs4660344 chr1 46805222 A G 2.25E-05 Osteoarthritis (knee and hip) / / 21177295 rs4660344 chr1 46805222 A G 6.80E-04 Osteoarthritis (knee and hip) / / 21177295 rs2145408 chr1 46861907 A G 7.42E-04 Type 2 diabetes FAAH intron 17463246 rs2145408 chr1 46861907 A G 7.96E-04 Suicide attempts in bipolar disorder FAAH intron 21041247 rs6429600 chr1 46864511 G A 8.06E-04 Suicide attempts in bipolar disorder FAAH intron 21041247 rs324423 chr1 46885104 A G 7.92E-04 Multiple complex diseases / / 17554300 rs116435220 chr1 46890686 C T 2.18E-08 Cholesterol,total / / 23696881 rs1571138 chr1 46895641 A G 2.53E-04 Multiple complex diseases / / 17554300 rs10890398 chr1 46925594 T C 3.93E-04 Smoking quantity / / 24665060 rs11211287 chr1 46939999 G C 8.10E-05 Immunoglobulin A / / 20694011 rs7542172 chr1 46990681 G A 2.00E-12 Blood metabolite levels / / 24816252 rs1267301 chr1 46992853 C G 3.45E-04 Multiple complex diseases / / 17554300 rs12564756 chr1 47018447 C T 6.60E-04 Smoking quantity LOC100507423 intron 24665060 rs1054743 chr1 47035643 T C 8.45E-04 Type 2 diabetes MKNK1 intron 17463246 rs744096 chr1 47107390 A G 5.04E-04 Multiple complex diseases ATPAF1 intron 17554300 rs744096 chr1 47107390 A G 9.25E-05 Serum metabolites ATPAF1 intron 19043545 rs1933932 chr1 47109328 C T 8.90E-04 Alcohol dependence ATPAF1 intron 21314694 rs2289447 chr1 47118168 C T 2.20E-08 Asthma (childhood onset) ATPAF1 intron 21696813 rs620431 chr1 47118189 G T 4.00E-04 Asthma (childhood onset) ATPAF1 intron 21696813 rs1150068 chr1 47118918 A G 2.00E-04 Asthma (childhood onset) ATPAF1 intron 21696813 rs11211334 chr1 47121419 T C 1.69E-04 Multiple complex diseases ATPAF1 intron 17554300 rs11211334 chr1 47121419 T C 1.76E-05 Serum metabolites ATPAF1 intron 19043545 rs611468 chr1 47124479 A G 5.11E-04 Multiple complex diseases ATPAF1 intron 17554300 rs611468 chr1 47124479 A G 6.63E-05 Serum metabolites ATPAF1 intron 19043545 rs7354865 chr1 47124999 C T 4.68E-04 Multiple complex diseases ATPAF1 intron 17554300 rs12094663 chr1 47134321 T G 3.42E-04 Multiple complex diseases / / 17554300 rs1025806 chr1 47139103 C T 5.24E-04 Multiple complex diseases ATPAF1-AS1 missense 17554300 rs1025806 chr1 47139103 C T 3.59E-05 Alzheimer's disease (late onset) ATPAF1-AS1 missense 23565137 rs1025806 chr1 47139103 C T 9.73E-04 Alzheimer's disease (late onset) ATPAF1-AS1 missense 23565137 rs625590 chr1 47139675 C T 4.55E-04 Multiple complex diseases / / 17554300 rs1048380 chr1 47142538 G A 1.00E-04 Asthma (childhood onset) KIAA0494 UTR-3 21696813 rs1048351 chr1 47143480 C T 3.08E-05 Alzheimer's disease (late onset) KIAA0494 UTR-3 23565137 rs1048351 chr1 47143480 C T 8.72E-04 Alzheimer's disease (late onset) KIAA0494 UTR-3 23565137 rs7412469 chr1 47146533 T C 5.46E-04 Multiple complex diseases KIAA0494 intron 17554300 rs7412469 chr1 47146533 T C 3.59E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs7412469 chr1 47146533 T C 9.73E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs2275380 chr1 47147728 C T 1.25E-04 Multiple complex diseases KIAA0494 intron 17554300 rs2275380 chr1 47147728 C T 4.99E-05 Serum metabolites KIAA0494 intron 19043545 rs1150064 chr1 47148044 T A 8.79E-05 Asthma (childhood onset) KIAA0494 intron 21696813 rs2119301 chr1 47153547 C A,G,T 6.54E-04 Multiple complex diseases KIAA0494 intron 17554300 rs2304745 chr1 47154272 C T 3.60E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs2304745 chr1 47154272 C T 9.76E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs61782563 chr1 47158266 A G 3.59E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs61782563 chr1 47158266 A G 9.68E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs61782564 chr1 47158649 C T 3.62E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs61782564 chr1 47158649 C T 9.78E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs3766217 chr1 47159109 G T 3.97E-04 Multiple complex diseases KIAA0494 intron 17554300 rs3766217 chr1 47159109 G T 3.59E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs3766217 chr1 47159109 G T 9.73E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs34932727 chr1 47161275 G A 4.38E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs2405026 chr1 47162648 T C 3.44E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs2405026 chr1 47162648 T C 9.26E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs4274009 chr1 47165879 G A 3.26E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs4274009 chr1 47165879 G A 8.75E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs55914029 chr1 47166848 G A 3.10E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs55914029 chr1 47166848 G A 8.29E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs1440486 chr1 47167238 C T 2.26E-05 Asthma (childhood onset) KIAA0494 intron 21696813 rs1440486 chr1 47167238 C T 3.11E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs1440486 chr1 47167238 C T 8.20E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs60675294 chr1 47169845 C G 3.07E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs60675294 chr1 47169845 C G 8.04E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs61782568 chr1 47171101 T C 3.06E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs61782568 chr1 47171101 T C 8.01E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs10158678 chr1 47176606 C T 1.81E-04 Multiple complex diseases KIAA0494 intron 17554300 rs2218189 chr1 47176818 T C 1.00E-04 Asthma (childhood onset) KIAA0494 intron 21696813 rs12071983 chr1 47178065 T C 1.52E-04 Multiple complex diseases KIAA0494 intron 17554300 rs6688195 chr1 47178195 C T 2.98E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs6688195 chr1 47178195 C T 7.82E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs10789491 chr1 47179310 A G 1.00E-06 Response to hepatitis C treatment KIAA0494 intron 22095909 rs3766215 chr1 47181022 C T 2.94E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs3766215 chr1 47181022 C T 7.60E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs3737731 chr1 47182206 C T 2.92E-05 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs3737731 chr1 47182206 C T 7.36E-04 Alzheimer's disease (late onset) KIAA0494 intron 23565137 rs3766212 chr1 47184181 C T 3.04E-04 Multiple complex diseases KIAA0494 UTR-5 17554300 rs3766212 chr1 47184181 C T 9.27E-05 Serum metabolites KIAA0494 UTR-5 19043545 rs3766211 chr1 47184196 A G 4.54E-04 Multiple complex diseases KIAA0494 UTR-5 17554300 rs8851 chr1 47184569 G C 3.33E-05 Alzheimer's disease (late onset) KIAA0494 UTR-5 23565137 rs8851 chr1 47184569 G C 7.96E-04 Alzheimer's disease (late onset) KIAA0494 UTR-5 23565137 rs17102473 chr1 47185155 G A 2.65E-05 Alzheimer's disease (late onset) / / 23565137 rs17102473 chr1 47185155 G A 6.41E-04 Alzheimer's disease (late onset) / / 23565137 rs6429608 chr1 47187036 A G 3.26E-04 Alzheimer's disease (late onset) / / 23565137 rs6429608 chr1 47187036 A G 9.80E-06 Alzheimer's disease (late onset) / / 23565137 rs7519866 chr1 47187255 A G 2.89E-04 Alzheimer's disease (late onset) / / 23565137 rs7519866 chr1 47187255 A G 9.66E-06 Alzheimer's disease (late onset) / / 23565137 rs6670495 chr1 47187908 T A 7.93E-06 Asthma (childhood onset) / / 21696813 rs4660957 chr1 47188150 G T 1.48E-05 Multiple complex diseases / / 17554300 rs6662321 chr1 47220059 C T 9.00E-04 Asthma (childhood onset) / / 21696813 rs201934421 chr1 47226827 TC T 2.21E-05 HDL cholesterol / / pha003075 rs986034 chr1 47226827 T G 2.21E-05 HDL cholesterol / / pha003075 rs11583588 chr1 47234335 G A 6.44E-05 Schizophrenia / / pha002859 rs1572603 chr1 47272403 G A 3.19E-04 White matter integrity CYP4B1 intron 22425255 rs4646486 chr1 47278997 T C 5.76E-05 White matter integrity CYP4B1 intron 22425255 rs4646487 chr1 47279175 C T 1 Drug response to Docetaxel CYP4B1 missense 20038957 rs4646487 chr1 47279175 C T 1 Drug response to Thalidomide CYP4B1 missense 20038957 rs4646487 chr1 47279175 C T 6.68E-05 White matter integrity CYP4B1 missense 22425255 rs4646492 chr1 47281183 C T 2.91E-05 White matter integrity CYP4B1 intron 22425255 rs4646493 chr1 47281302 A G 3.22E-05 White matter integrity CYP4B1 intron 22425255 rs17102599 chr1 47283344 G T 0.000000147 Triglycerides CYP4B1 intron 23063622 rs17102599 chr1 47283344 G T 0.000000176 Cholesterol,total CYP4B1 intron 23063622 rs4646495 chr1 47283505 G A,T 5.03E-05 White matter integrity CYP4B1 intron 22425255 rs12059860 chr1 47284923 T C 8.00E-06 Testosterone levels CYP4B1 UTR-3 22675492 rs17102644 chr1 47318400 G A 1.51E-05 White matter integrity CYP4Z2P intron 22425255 rs6665009 chr1 47321982 T C 1.78E-05 White matter integrity CYP4Z2P intron 22425255 rs6678639 chr1 47331966 A G 8.00E-86 Blood metabolite ratios CYP4Z2P intron 24816252 rs6663731 chr1 47347427 A T 1.00E-14 Blood metabolite levels CYP4Z2P intron 24816252 rs6663731 chr1 47347427 A T 5.00E-11 Blood metabolite levels CYP4Z2P intron 24816252 rs6687264 chr1 47374039 T C 1.51E-05 White matter integrity / / 22425255 rs11587251 chr1 47392596 G A 1.70E-04 White matter integrity / / 22425255 rs9333029 chr1 47396162 A G 2.00E-61 Blood metabolite levels CYP4A11 intron 24816252 rs9333016 chr1 47399034 C T 2.62E-05 Diabetes Mellitus CYP4A11 intron pha003059 rs9332998 chr1 47404186 T C 5.00E-32 Metabolic traits CYP4A11 intron 21886157 rs10789496 chr1 47416441 T C 9.30E-05 HIV-1 control / / 20041166 rs10789496 chr1 47416441 T C 4.32E-05 Diabetes Mellitus / / pha003059 rs150968551 chr1 47428558 T G 4.00E-07 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs9727862 chr1 47481616 G A 5.82E-04 Alcohol dependence / / 20201924 rs9727862 chr1 47481616 G A 9.43E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12140581 chr1 47517960 G C 8.07E-04 Smoking quantity / / 24665060 rs4926805 chr1 47572046 C T 4.01E-05 Orofacial clefts CYP4Z1 intron 22419666 rs7531972 chr1 47661620 A C 5.53E-05 Prion diseases / / 22210626 rs741959 chr1 47676233 A G 4.36E-07 Red blood cell traits / / 23222517 rs2070930 chr1 47683464 G A 6.03E-04 Insulin resistance TAL1 UTR-3 21901158 rs977747 chr1 47684677 T G 6.32E-07 Red blood cell traits TAL1 UTR-3 23222517 rs2984618 chr1 47690438 G T 8.50E-07 Red blood cell traits TAL1 intron 23222517 rs11211480 chr1 47693220 A G 3.22E-08 Red blood cell traits TAL1 intron 23222517 rs7534271 chr1 47693981 C G 8.61E-09 Red blood cell traits TAL1 intron 23222517 rs11211481 chr1 47694167 A G 5.30E-09 Red blood cell traits TAL1 intron 23222517 rs2798349 chr1 47698703 G A 2.50E-04 Multiple complex diseases / / 17554300 rs6700838 chr1 47700027 C T 1.01E-08 Red blood cell traits / / 23222517 rs1015890 chr1 47702229 G A 8.55E-07 Red blood cell traits / / 23222517 rs911910 chr1 47706970 G A 2.15E-08 Red blood cell traits / / 23222517 rs11211483 chr1 47707435 G C 1.04E-04 Insulin resistance / / 21901158 rs10890472 chr1 47708112 G T 4.96E-08 Red blood cell traits / / 23222517 rs13376679 chr1 47726087 T C 0.00013 Prostate cancer STIL missense 23555315 rs9436412 chr1 47766604 A G 6.58E-04 Multiple complex diseases STIL intron 17554300 rs17103186 chr1 47854514 C T 3.00E-12 Corneal curvature / / 24963161 rs60078183 chr1 47857307 G A 8.20E-12 Corneal curvature / / 24963161 rs6673934 chr1 47870564 G C 1.75E-05 Intracerebral hemorrhage / / 24656865 rs4926854 chr1 47870661 C T 4.31E-05 Intracerebral hemorrhage / / 24656865 rs55718554 chr1 47871581 C G 2.35E-05 Intracerebral hemorrhage / / 24656865 rs17103227 chr1 47889417 T C 9.78E-04 Coronary heart disease / / 21971053 rs2820972 chr1 47891585 T C 1.00E-33 Metabolite levels / / 22286219 rs527430 chr1 47918821 G A 4.00E-07 Response to antidepressant treatment / / 22041458 rs6588397 chr1 47943032 C T 1.49E-04 Response to alcohol consumption (flushing response) / / 24277619 rs11582540 chr1 48009997 C A 3.00E-06 Response to amphetamines / / 22952603 rs502392 chr1 48017067 T C 2.21E-05 stroke (ischemic) / / 17434096 rs17420782 chr1 48019222 A G 9.00E-06 Anxiety in major depressive disorder / / 24047446 rs685001 chr1 48025063 C A 9.00E-06 Obesity-related traits / / 23251661 rs2507007 chr1 48046320 G T 2.40E-04 Major depressive disorder / / 21042317 rs12402772 chr1 48062278 C T 1.81E-05 Type 2 diabetes / / 17463246 rs10890492 chr1 48063350 G A 1.41E-04 Renal cell carcinoma / / 22010048 rs12742768 chr1 48065019 A G 3.37E-04 Stroke / / pha002886 rs11211579 chr1 48095100 A G 4.24E-04 Insulin resistance / / 21901158 rs2506991 chr1 48098406 A G 2.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs2506987 chr1 48100829 A G 3.94E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (etoposide) / / 23648065 rs1876598 chr1 48102145 A C 2.69E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2457058 chr1 48102692 A G 3.39E-05 Follicular lymphoma / / 21533074 rs12133618 chr1 48215337 C T 8.00E-06 Urinary metabolites / / 21572414 rs1561572 chr1 48216886 G A 8.95E-04 Taste perception / / 22132133 rs11584807 chr1 48220454 C T 3.95E-05 Bilirubin levels,in serum / / 19389676 rs12085966 chr1 48229395 C T 2.92E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) LOC388630 UTR-3 24023788 rs12038866 chr1 48234217 G C 8.36E-04 Suicide attempts in bipolar disorder LOC388630 intron 21041247 rs6588505 chr1 48254782 C T 1.51E-04 White matter integrity LOC388630 intron 22425255 rs6588505 chr1 48254782 C T 9.00E-06 Obesity-related traits LOC388630 intron 23251661 rs4927069 chr1 48262619 A C 8.29E-04 White matter integrity LOC388630 intron 22425255 rs10890501 chr1 48270907 T G 5.35E-04 White matter integrity LOC388630 intron 22425255 rs6698119 chr1 48274987 A G 7.00E-06 Bone mineral density (BMD),in women LOC388630 intron 20164292 rs875398 chr1 48275263 G A 7.45E-05 White matter integrity LOC388630 intron 22425255 rs6667893 chr1 48287014 C T 1.58E-05 White matter integrity LOC388630 intron 22425255 rs11211611 chr1 48288016 C A 7.45E-05 White matter integrity LOC388630 intron 22425255 rs10890506 chr1 48295033 A G 1.72E-05 White matter integrity LOC388630 intron 22425255 rs12031340 chr1 48299660 T C 7.73E-06 Testosterone levels LOC388630 intron 22675492 rs10890507 chr1 48309587 T C 2.81E-04 White matter integrity LOC388630 intron 22425255 rs11211621 chr1 48319515 C T 9.94E-05 White matter integrity LOC388630 intron 22425255 rs946836 chr1 48321221 C T 5.00E-06 White matter integrity LOC388630 intron 22425255 rs367993311 chr1 48331522 CA CCA,CTG 5.64E-04 Taste perception LOC388630 intron 22132133 rs7536189 chr1 48331522 C T 5.64E-04 Taste perception LOC388630 intron 22132133 rs10890510 chr1 48334490 A C 1.58E-04 White matter integrity LOC388630 intron 22425255 rs884133 chr1 48335405 T C 7.26E-04 Insulin resistance LOC388630 intron 21901158 rs7556536 chr1 48335976 T A 7.32E-05 Serum metabolites LOC388630 intron 19043545 rs10493130 chr1 48341005 G A 1.92E-04 White matter integrity LOC388630 intron 22425255 rs12048888 chr1 48343224 T C 1.54E-05 White matter integrity LOC388630 intron 22425255 rs1497095 chr1 48386888 C T 3.79E-04 White matter integrity LOC388630 intron 22425255 rs10493131 chr1 48387427 C T 4.68E-04 Intracranial aneurysm LOC388630 intron 20613766 rs11211632 chr1 48406460 A G 1.44E-05 White matter integrity LOC388630 intron 22425255 rs11584659 chr1 48444398 C T 7.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) LOC388630 intron 20877124 rs17103980 chr1 48445208 C A 7.25E-04 Insulin resistance LOC388630 intron 21901158 rs6695419 chr1 48479075 G A 9.69E-06 Multiple complex diseases / / 17554300 rs303925 chr1 48503280 C T 5.00E-04 Type 2 diabetes / / 17463246 rs6588642 chr1 48507037 C G 4.27E-04 Type 2 diabetes / / 17463246 rs7549671 chr1 48512119 C T 4.59E-04 Type 2 diabetes / / 17463246 rs560004 chr1 48549673 T C 8.91E-04 Bone mass and geometry / / 17903296 rs555774 chr1 48556111 G A 5.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs17428691 chr1 48567117 G A 7.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs12741362 chr1 48606878 G A 4.47E-04 Smoking initiation SKINTL intron 24665060 rs17104225 chr1 48630940 C T 2.36E-05 Multiple complex diseases SKINTL intron 17554300 rs11205449 chr1 48647124 T G 5.92E-05 Serum metabolites SKINTL intron 19043545 rs11205449 chr1 48647124 T G 3.57E-05 Orofacial clefts SKINTL intron 22419666 rs1740109 chr1 48672113 C A,G 8.93E-04 Obesity (extreme) / / 21935397 rs533598 chr1 48673521 C A 4.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs537303 chr1 48673936 T C 6.45E-04 Obesity (extreme) / / 21935397 rs490631 chr1 48683405 A T 5.96E-04 Obesity (extreme) / / 21935397 rs960722 chr1 48683611 C T 1.28E-05 Orofacial clefts / / 22419666 rs212989 chr1 48695081 G A 9.84E-04 Obesity (extreme) SLC5A9 missense 21935397 rs540944 chr1 48705879 T C 5.78E-04 Obesity (extreme) SLC5A9 intron 21935397 rs850763 chr1 48708228 G T 8.96E-04 Obesity (extreme) SLC5A9 STOP-GAIN 21935397 rs986027 chr1 48713394 C T 9.10E-06 Stroke (ischemic) SLC5A9 UTR-3 22384361 rs498502 chr1 48725096 G C 6.36E-04 Multiple complex diseases / / 17554300 rs12085605 chr1 48784409 C G 6.31E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs1418105 chr1 48785665 C T 6.35E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2067692 chr1 48796120 C A 6.30E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs11205475 chr1 48802740 C A 6.64E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs3767614 chr1 48804443 G C 5.86E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs968183 chr1 48818458 T C 6.66E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs17429004 chr1 48823047 A G 8.92E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs932087 chr1 48824156 A T 7.30E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs11205480 chr1 48839282 A T 5.70E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs11205481 chr1 48843171 C G 6.02E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2252984 chr1 48867985 C T 2.32E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2803280 chr1 48880280 G A 1.89E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs1416048 chr1 48882926 A G 2.07E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2255264 chr1 48911430 C T 3.16E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2255525 chr1 48925577 T G 2.01E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2803282 chr1 48932772 C G 3.07E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2245681 chr1 48937351 G C 1.91E-04 Suicide attempts in bipolar disorder SPATA6 intron 21423239 rs2798127 chr1 48951377 T A 7.87E-05 Suicide attempts in bipolar disorder / / 21423239 rs17470284 chr1 48959577 G A 3.78E-06 Gallstones / / 17632509 rs12032082 chr1 48965583 C T 6.64E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) / / 23648065 rs12722731 chr1 48988124 T C 4.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs12078199 chr1 48992153 A C 4.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs2798119 chr1 48996065 T C 7.29E-04 Suicide attempts in bipolar disorder / / 21423239 rs2246557 chr1 49001780 C T 5.34E-04 Acute lung injury AGBL4 intron 22295056 rs2803270 chr1 49031238 C T 9.16E-07 Esophageal cancer (squamous cell) AGBL4 intron 22960999 rs11802042 chr1 49033734 A C 9.73E-04 Acute lung injury AGBL4 intron 22295056 rs2798095 chr1 49036512 G A 5.40E-06 Urinary metabolites AGBL4 intron 21572414 rs17373183 chr1 49037217 C T 3.04E-04 Type 2 diabetes AGBL4 intron 17463246 rs17104522 chr1 49040423 C T 1.21E-04 Suicide attempts in bipolar disorder AGBL4 intron 21423239 rs10493134 chr1 49042952 A G 4.92E-05 Suicide attempts in bipolar disorder AGBL4 intron 21423239 rs6665839 chr1 49043877 C T 1.80E-06 Urinary metabolites AGBL4 intron 21572414 rs319960 chr1 49059615 C T 1.91E-04 Response to taxane treatment (placlitaxel) AGBL4 intron 23006423 rs11583036 chr1 49064097 T C 2.67E-04 Osteoarthritis (knee and hip) AGBL4 intron 21177295 rs11583036 chr1 49064097 T C 2.70E-05 Osteoarthritis (knee and hip) AGBL4 intron 21177295 rs11583036 chr1 49064097 T C 3.11E-04 Osteoarthritis (knee and hip) AGBL4 intron 21177295 rs319978 chr1 49067379 C T 1.45E-06 Osteoarthritis (knee and hip) AGBL4 intron 21177295 rs319978 chr1 49067379 C T 1.70E-06 Osteoarthritis (knee and hip) AGBL4 intron 21177295 rs319978 chr1 49067379 C T 7.74E-05 Osteoarthritis (knee and hip) AGBL4 intron 21177295 rs320027 chr1 49082023 C T 2.20E-05 Urinary metabolites AGBL4 intron 21572414 rs12566140 chr1 49087404 G A 7.85E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs11205517 chr1 49092039 T C 2.82E-04 Type 2 diabetes AGBL4 intron 17463246 rs7516699 chr1 49098326 A G 1.50E-05 Urinary metabolites AGBL4 intron 21572414 rs12562662 chr1 49104486 T C 7.33E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs7535727 chr1 49106290 G T 8.74E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs7535727 chr1 49106290 G T 9.10E-06 Urinary metabolites AGBL4 intron 21572414 rs12058997 chr1 49107826 T C 8.69E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs973886 chr1 49120520 T G 2.57E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs6674328 chr1 49122201 C T 2.70E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs7556311 chr1 49123567 G A 3.06E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs7556329 chr1 49123618 G C 3.07E-04 Suicide attempts in bipolar disorder AGBL4 intron 21041247 rs444167 chr1 49138646 A G 9.44E-04 Myopia (pathological) AGBL4 intron 21095009 rs319959 chr1 49145514 G T 0.000268 Salmonella-induced pyroptosis AGBL4 intron 22837397 rs319981 chr1 49151886 A G 0.000494 Salmonella-induced pyroptosis AGBL4 intron 22837397 rs6695778 chr1 49164688 A C 3.12E-05 Multiple complex diseases AGBL4 intron 17554300 rs4926747 chr1 49165860 C T 4.60E-05 Lung adenocarcinoma AGBL4 intron 22797724 rs320062 chr1 49179307 T C 1.83E-04 Amyotrophic lateral sclerosis (sporadic) AGBL4 intron 24529757 rs17104710 chr1 49179498 G A 8.94E-05 Cognitive impairment induced by topiramate AGBL4 intron 22091778 rs1385152 chr1 49193394 G T 5.76E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) AGBL4 intron 20877124 rs6661901 chr1 49196060 G A 5.30E-05 Asthma (bronchodilator response) BEND5 intron 22792082 rs4926749 chr1 49203349 C A 5.80E-05 Creatinine levels BEND5 intron 20222955 rs11588373 chr1 49215159 T A 1.79E-04 Insulin resistance BEND5 intron 21901158 rs12407980 chr1 49220637 G A 4.23E-04 Insulin resistance BEND5 intron 21901158 rs12086219 chr1 49221303 G A 6.95E-05 Multiple complex diseases BEND5 intron 17554300 rs1934377 chr1 49237975 C A 7.38E-04 Multiple complex diseases BEND5 intron 17554300 rs7514802 chr1 49268066 T C 7.43E-04 Multiple complex diseases AGBL4 intron 17554300 rs4457622 chr1 49346828 C T 3.96E-04 Body mass index AGBL4 intron 17255346 rs4457622 chr1 49346828 C T 1.02E-04 Type 2 diabetes AGBL4 intron 17463246 rs2032022 chr1 49388622 T G 9.34E-05 Alzheimer's disease AGBL4 intron 22832961 rs1343432 chr1 49396989 G C 1.82E-04 Major depressive disorder AGBL4 intron 22472876 rs17105335 chr1 49436107 T C 5.42E-05 Amyotrophic Lateral Sclerosis AGBL4 intron 18057069 rs3121514 chr1 49451272 T C 6.41E-05 Bipolar disorder and schizophrenia AGBL4 intron 20889312 rs3118223 chr1 49463801 G A 8.20E-04 Crohn's disease AGBL4 intron 17684544 rs3127556 chr1 49468025 G A 9.12E-04 Multiple complex diseases AGBL4 intron 17554300 rs6669433 chr1 49482703 A C 7.67E-04 Multiple complex diseases AGBL4 intron 17554300 rs7536787 chr1 49525465 C T 9.39E-04 Multiple complex diseases AGBL4 intron 17554300 rs11205596 chr1 49541827 G T 7.84E-04 Type 2 diabetes AGBL4 intron 17463246 rs11205596 chr1 49541827 G T 9.20E-05 Personality dimensions AGBL4 intron 18957941 rs6588238 chr1 49552036 C T 3.95E-05 Multiple complex diseases AGBL4 intron 17554300 rs7527364 chr1 49566557 A G 5.64E-05 Bipolar disorder and schizophrenia AGBL4 intron 20889312 rs590503 chr1 49581006 C T 8.42E-04 Alzheimer's disease AGBL4 intron 22005930 rs483330 chr1 49591977 G A 5.11E-05 Bipolar disorder and schizophrenia AGBL4 intron 20889312 rs11591141 chr1 49664304 C T 2.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) AGBL4 intron 23648065 rs925043 chr1 49695123 G A,C,T 4.99E-12 Gout AGBL4 intron pha001406 rs1431638 chr1 49762418 C T 2.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) AGBL4 intron 23648065 rs17105629 chr1 49799321 T C 2.89E-04 Multiple complex diseases AGBL4 intron 17554300 rs6659225 chr1 49822433 T C 2.50E-04 Primary sclerosing cholangitis AGBL4 intron 19944697 rs1415985 chr1 49930749 T C 1.20E-05 Alzheimer's disease (late onset) AGBL4 intron 21460841 rs1933271 chr1 49949006 C T 2.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) AGBL4 intron 23648065 rs1949995 chr1 49975795 G C 0.0004159 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) AGBL4 intron 23233654 rs1949995 chr1 49975795 G C 4.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) AGBL4 intron 23233662 rs2178085 chr1 50023956 C T 2.70E-05 Response to lithium treatment in bipolar disorder AGBL4 intron 19448189 rs17105712 chr1 50052684 T C 3.45E-04 Multiple complex diseases AGBL4 intron 17554300 rs10888663 chr1 50081573 A C 7.91E-04 Alzheimer's disease AGBL4 intron 24755620 rs2211459 chr1 50104642 G A 6.40E-04 Alzheimer's disease AGBL4 intron 24755620 rs2051086 chr1 50105201 T A,C 9.08E-04 Response to taxane treatment (placlitaxel) AGBL4 intron 23006423 rs2051086 chr1 50105201 T A,C 0.0005304 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) AGBL4 intron 23233654 rs2051086 chr1 50105201 T A,C 5.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) AGBL4 intron 23233662 rs2051086 chr1 50105201 T A,C 5.30E-04 Response to antipsychotic treatment AGBL4 intron 23241943 rs1343161 chr1 50110850 G A 3.30E-04 Primary sclerosing cholangitis AGBL4 intron 19944697 rs4408195 chr1 50128198 G A 2.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) AGBL4 intron 23648065 rs12135410 chr1 50141741 T C 6.96E-04 Alzheimer's disease AGBL4 intron 24755620 rs11205641 chr1 50185075 A G 8.40E-06 Alzheimer's disease (late onset) AGBL4 intron 20885792 rs11205641 chr1 50185075 A G 8.40E-06 Alzheimer's disease (late onset) AGBL4 intron 21460841 rs4926829 chr1 50220117 C T 7.32E-04 Alzheimer's disease AGBL4 intron 24755620 rs12144042 chr1 50229397 G A 7.74E-04 Alzheimer's disease AGBL4 intron 24755620 rs4926831 chr1 50290101 C T 1.20E-05 Alzheimer's disease (late onset) AGBL4 intron 20885792 rs4926831 chr1 50290101 C T 1.20E-05 Alzheimer's disease (late onset) AGBL4 intron 21460841 rs6675647 chr1 50308556 C T 6.08E-04 Multiple complex diseases AGBL4 intron 17554300 rs4926833 chr1 50311454 G A 0.0008306 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) AGBL4 intron 23233654 rs4926833 chr1 50311454 G A 8.31E-04 Methotrexate clearance (acute lymphoblastic leukemia) AGBL4 intron 23233662 rs12067197 chr1 50366482 A G 6.50E-04 Alzheimer's disease AGBL4 intron 24755620 rs7518987 chr1 50426542 A G 6.34E-04 Alzheimer's disease AGBL4 intron 24755620 rs9659092 chr1 50443589 A G 4.50E-06 Alzheimer's disease (late onset) AGBL4 intron 20885792 rs9659092 chr1 50443589 A G 4.50E-06 Alzheimer's disease (late onset) AGBL4 intron 21460841 rs12758298 chr1 50484613 C A 1.80E-05 Response to lithium treatment in bipolar disorder AGBL4 intron 19448189 rs10888678 chr1 50509729 G A 9.07E-04 Alzheimer's disease / / 24755620 rs4525085 chr1 50534526 A G 6.40E-04 Alzheimer's disease ELAVL4 intron 24755620 rs4926548 chr1 50547166 T A 6.54E-04 Alzheimer's disease ELAVL4 intron 24755620 rs6673246 chr1 50554373 G A 6.54E-04 Alzheimer's disease ELAVL4 intron 24755620 rs11583200 chr1 50559820 C T 1.80E-05 Alzheimer's disease (late onset) ELAVL4 intron 20885792 rs11583200 chr1 50559820 C T 1.80E-05 Alzheimer's disease (late onset) ELAVL4 intron 21460841 rs11205682 chr1 50567676 T C 6.94E-04 Alzheimer's disease ELAVL4 intron 24755620 rs11205683 chr1 50570665 G A 7.92E-04 Alzheimer's disease ELAVL4 intron 24755620 rs2480693 chr1 50588665 C T 7.58E-04 Multiple complex diseases ELAVL4 intron 17554300 rs9436447 chr1 50590732 G A 7.90E-04 Alcohol dependence ELAVL4 intron 20201924 rs9436447 chr1 50590732 G A 8.10E-04 Alcohol dependence ELAVL4 intron 20201924 rs2494884 chr1 50591405 G T 2.43E-04 Multiple complex diseases ELAVL4 intron 17554300 rs2494884 chr1 50591405 G T 7.70E-05 Creatinine levels ELAVL4 intron pha003069 rs12092053 chr1 50607029 T G 6.00E-06 Obesity-related traits ELAVL4 intron 23251661 rs12081193 chr1 50698759 C A 8.70E-05 Coffee consumption / / 21357676 rs4926853 chr1 50709222 A G 8.56E-04 Type 2 diabetes / / 17463246 rs4926853 chr1 50709222 A G 0.0003 Migraine / / 22678113 rs1393637 chr1 50753599 C T 5.13E-04 Bipolar disorder / / 19259986 rs1875635 chr1 50765982 G A 8.60E-05 Body Mass Index / / pha003009 rs12566635 chr1 50791465 T C 4.81E-04 Smoking cessation / / 24665060 rs6689749 chr1 50800516 G T 4.58E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs6657279 chr1 50808295 A G 5.90E-05 Panic disorder / / 19165232 rs1110220 chr1 50815397 A G 7.30E-05 Lung adenocarcinoma / / 22797724 rs11205712 chr1 50817701 G A 5.24E-05 Multiple complex diseases / / 17554300 rs7517924 chr1 50844929 T G 8.34E-04 Multiple complex diseases / / 17554300 rs2055491 chr1 50852769 T C 4.77E-04 Multiple complex diseases / / 17554300 rs2484676 chr1 50872673 A T 1.88E-04 Multiple complex diseases / / 17554300 rs2484676 chr1 50872673 A T 8.88E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs1278537 chr1 50882159 G T 7.10E-04 Alcohol dependence / / 20201924 rs1278530 chr1 50889255 G A 1.40E-04 Alcohol dependence / / 20201924 rs1278530 chr1 50889255 G A 1.60E-04 Alcohol dependence / / 20201924 rs7550594 chr1 50891093 C T 9.64E-07 Schizophrenia / / 21926974 rs7550594 chr1 50891093 C T 1.33E-04 Self-reported allergy / / 23817569 rs4381241 chr1 50907438 T C 1.50E-04 Alcohol dependence FAF1 intron 20201924 rs4381241 chr1 50907438 T C 1.70E-04 Alcohol dependence FAF1 intron 20201924 rs17106184 chr1 50909985 G A 4.00E-09 Type 2 diabetes FAF1 intron 24509480 rs956084 chr1 50911347 C T 1.50E-10 HDL cholesterol FAF1 intron 23063622 rs12134715 chr1 50912441 A C 2.38E-05 Personality dimensions FAF1 intron 22628180 rs12134715 chr1 50912441 A C 1.37E-05 Self-reported allergy FAF1 intron 23817569 rs12565493 chr1 50917596 T C 2.47E-05 Personality dimensions FAF1 intron 22628180 rs12565493 chr1 50917596 T C 1.57E-05 Self-reported allergy FAF1 intron 23817569 rs12142848 chr1 50918388 C T 2.41E-05 Personality dimensions FAF1 intron 22628180 rs12142848 chr1 50918388 C T 1.60E-05 Self-reported allergy FAF1 intron 23817569 rs12133928 chr1 50919942 T C 2.66E-05 Personality dimensions FAF1 intron 22628180 rs12133928 chr1 50919942 T C 1.48E-05 Self-reported allergy FAF1 intron 23817569 rs12063722 chr1 50931102 C T 5.85E-04 Multiple complex diseases FAF1 intron 17554300 rs12562938 chr1 50931160 C T 3.25E-05 Personality dimensions FAF1 intron 22628180 rs3827730 chr1 50937848 T C 1.40E-06 Alcohol dependence FAF1 intron 20201924 rs3827730 chr1 50937848 T C 4.10E-05 Alcohol dependence FAF1 intron 20201924 rs3827730 chr1 50937848 T C 4.00E-06 Depression and alcohol dependence FAF1 intron 22064162 rs3827730 chr1 50937848 T C 1.42E-06 Alcoholism FAF1 intron pha002892 rs3827730 chr1 50937848 T C 4.08E-05 Alcoholism FAF1 intron pha002893 rs3789576 chr1 50945526 G T 9.78E-04 Response to cytidine analogues (gemcitabine) FAF1 intron 24483146 rs12116432 chr1 50949724 A T 3.65E-05 Personality dimensions FAF1 intron 22628180 rs12116432 chr1 50949724 A T 2.14E-05 Self-reported allergy FAF1 intron 23817569 rs9645408 chr1 50983135 T C 3.28E-05 Self-reported allergy FAF1 intron 23817569 rs11205726 chr1 50986057 C T 4.30E-05 Self-reported allergy FAF1 intron 23817569 rs10888691 chr1 50991426 G C 4.37E-05 Self-reported allergy FAF1 intron 23817569 rs12135541 chr1 50997461 T C 4.82E-05 Self-reported allergy FAF1 intron 23817569 rs12137729 chr1 50999860 T C 4.44E-05 Self-reported allergy FAF1 intron 23817569 rs3789584 chr1 51029387 T C 2.22E-04 Multiple complex diseases FAF1 intron 17554300 rs12118892 chr1 51029609 G T 2.00E-05 Urinary metabolites FAF1 intron 21572414 rs12118892 chr1 51029609 G T 4.88E-05 Self-reported allergy FAF1 intron 23817569 rs12073534 chr1 51034926 T C 6.90E-05 Self-reported allergy FAF1 intron 23817569 rs12122697 chr1 51043243 G T 6.04E-05 Self-reported allergy FAF1 intron 23817569 rs3789585 chr1 51051105 G C 6.13E-05 Self-reported allergy FAF1 intron 23817569 rs11205738 chr1 51060054 G A 6.10E-05 Self-reported allergy FAF1 intron 23817569 rs12568008 chr1 51076822 G A 2.00E-05 Urinary metabolites FAF1 intron 21572414 rs12568008 chr1 51076822 G A 5.47E-05 Self-reported allergy FAF1 intron 23817569 rs17106336 chr1 51078564 T C 2.78E-04 Multiple complex diseases FAF1 intron 17554300 rs17106336 chr1 51078564 T C 1.20E-05 Urinary metabolites FAF1 intron 21572414 rs17106336 chr1 51078564 T C 5.65E-05 Self-reported allergy FAF1 intron 23817569 rs11205741 chr1 51079296 C A 6.93E-05 Self-reported allergy FAF1 intron 23817569 rs10888700 chr1 51086337 T C 1.22E-04 Multiple complex diseases FAF1 intron 17554300 rs11577903 chr1 51086847 T C 4.45E-05 Self-reported allergy FAF1 intron 23817569 rs11205743 chr1 51087465 C G 9.30E-06 Multiple complex diseases FAF1 intron 17554300 rs11205743 chr1 51087465 C G 4.72E-05 Self-reported allergy FAF1 intron 23817569 rs10788929 chr1 51090942 T C 8.81E-05 Self-reported allergy FAF1 intron 23817569 rs12120719 chr1 51092829 T C 1.95E-05 Self-reported allergy FAF1 intron 23817569 rs11577260 chr1 51094117 G A 6.61E-05 Self-reported allergy FAF1 intron 23817569 rs11205748 chr1 51100042 A G 7.42E-05 Self-reported allergy FAF1 intron 23817569 rs12567589 chr1 51110167 C T 7.73E-05 Self-reported allergy FAF1 intron 23817569 rs11205750 chr1 51113531 A G 7.60E-05 Self-reported allergy FAF1 intron 23817569 rs11205752 chr1 51116645 T C 7.12E-05 Self-reported allergy FAF1 intron 23817569 rs10888703 chr1 51118706 C A 6.58E-05 Self-reported allergy FAF1 intron 23817569 rs12117653 chr1 51123315 C A 7.42E-05 Self-reported allergy FAF1 intron 23817569 rs11205760 chr1 51174330 C T 1.67E-05 Multiple complex diseases FAF1 intron 17554300 rs11205760 chr1 51174330 C T 3.40E-05 Alcohol dependence FAF1 intron 20201924 rs11205760 chr1 51174330 C T 6.90E-04 Alcohol dependence FAF1 intron 20201924 rs11205760 chr1 51174330 C T 3.37E-05 Alcoholism FAF1 intron pha002892 rs6680846 chr1 51188674 G C 3.16E-04 Multiple complex diseases FAF1 intron 17554300 rs12239279 chr1 51304834 G A 1.48E-05 Height FAF1 intron 22021425 rs12092977 chr1 51410517 T C 6.40E-15 HDL cholesterol FAF1 intron 23063622 rs3813634 chr1 51475488 G A 7.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs3813634 chr1 51475488 G A 4.50E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs12092511 chr1 51477088 G A 6.85E-04 Multiple complex diseases / / 17554300 rs12092511 chr1 51477088 G A 7.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs7555006 chr1 51480258 A G 3.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs17391905 chr1 51546140 T G 3.00E-10 Ventricular conduction / / 21076409 rs11807353 chr1 51615023 C A 1.40E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11205821 chr1 51631884 C T 5.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17106443 chr1 51644702 A G 5.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17106443 chr1 51644702 A G 8.91E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12728955 chr1 51709522 T C 8.27E-05 Schizophrenia (cytomegalovirus infection interaction) RNF11 intron 23358160 rs6701572 chr1 51719315 G A 6.26E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) RNF11 intron 20877124 rs3748615 chr1 51753722 G A 1.91E-04 Response to cytidine analogues (gemcitabine) TTC39A UTR-3 24483146 rs17392930 chr1 51753904 G A,C,T 0.0000104 LDL cholesterol particle diameter TTC39A missense 23263444 rs11205836 chr1 51804731 C T 3.40E-05 Diabetes Mellitus TTC39A intron pha003060 rs6659736 chr1 51814274 C T 1.30E-07 Lymphocyte counts / / 22286170 rs6673480 chr1 51859242 C T 2.00E-06 IgE grass sensitization EPS15 intron 22036096 rs7411629 chr1 52005824 T C 0.0000684 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10399893 chr1 52010157 G A 2.50E-05 Urinary metabolites / / 21572414 rs10399889 chr1 52010203 C T 1.60E-05 Urinary metabolites / / 21572414 rs12732738 chr1 52032789 A G 2.80E-05 Urinary metabolites / / 21572414 rs13375698 chr1 52059408 T A 2.26E-04 Multiple complex diseases / / 17554300 rs856614 chr1 52252006 A G 2.32E-05 Body Mass Index OSBPL9 intron pha003006 rs856614 chr1 52252006 A G 2.26E-05 Body Mass Index OSBPL9 intron pha003019 rs856614 chr1 52252006 A G 2.42E-05 Body Mass Index OSBPL9 intron pha003020 rs1004815 chr1 52258725 T A,C,G 3.00E-05 Alcohol dependence NRD1 intron 21703634 rs1417364 chr1 52263082 G A 9.18E-06 Alcohol dependence NRD1 intron 21703634 rs8375 chr1 52266242 G A,C,T 2.00E-05 Smoking behavior NRD1 cds-synon 20418888 rs7551758 chr1 52274078 T G 1.30E-05 Smoking behavior NRD1 intron 20418888 rs2747525 chr1 52284018 A C 4.80E-06 Smoking behavior NRD1 intron 20418888 rs11205896 chr1 52290984 T G 1.70E-05 Smoking behavior NRD1 cds-synon 20418888 rs2077725 chr1 52293570 G A 1.60E-05 Smoking behavior NRD1 intron 20418888 rs2077725 chr1 52293570 G A 8.92E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) NRD1 intron 23648065 rs11205897 chr1 52298151 C T 2.50E-05 Smoking behavior NRD1 intron 20418888 rs6702037 chr1 52310756 A G 6.30E-06 Smoking behavior NRD1 intron 20418888 rs4422953 chr1 52310882 C T 8.70E-06 Smoking behavior NRD1 intron 20418888 rs6676789 chr1 52316785 T C 6.40E-06 Smoking behavior NRD1 intron 20418888 rs6676789 chr1 52316785 T C 8.92E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) NRD1 intron 23648065 rs883058 chr1 52317231 T A 1.10E-05 Smoking behavior NRD1 intron 20418888 rs7526552 chr1 52320559 T C 1.90E-05 Smoking behavior NRD1 intron 20418888 rs6691091 chr1 52323772 G C 4.60E-05 Smoking behavior NRD1 intron 20418888 rs2842576 chr1 52324228 C T 6.07E-06 Alcohol dependence NRD1 intron 20202923 rs2842576 chr1 52324228 C T 7.90E-06 Alcohol dependence NRD1 intron 21703634 rs2842576 chr1 52324228 C T 2.50E-04 Alcohol dependence NRD1 intron 21956439 rs6588415 chr1 52334047 A G 1.10E-05 Smoking behavior NRD1 intron 20418888 rs1538881 chr1 52337039 T C 6.30E-06 Smoking behavior NRD1 intron 20418888 rs1538881 chr1 52337039 T C 5.42E-05 Prostate cancer NRD1 intron pha002878 rs1890946 chr1 52342427 T C 6.00E-06 Smoking behavior NRD1 intron 20418888 rs6663305 chr1 52343297 A G 8.40E-06 Smoking behavior NRD1 intron 20418888 rs6663305 chr1 52343297 A G 8.98E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) NRD1 intron 23648065 rs138608728 chr1 52344157 G A 0.000012 Breast cancer (ER positive) NRD1 missense 23555315 rs736756 chr1 52344414 A C 2.90E-05 Smoking behavior NRD1 UTR-5 20418888 rs11205902 chr1 52348769 G T 2.91E-04 Alzheimer's disease / / 17998437 rs11205902 chr1 52348769 G T 5.00E-05 Smoking behavior / / 20418888 rs6588416 chr1 52375424 T C 2.94E-04 Alzheimer's disease RAB3B UTR-3 17998437 rs6588416 chr1 52375424 T C 7.80E-05 Serum metabolites RAB3B UTR-3 19043545 rs1954260 chr1 52391032 C T 4.70E-06 Smoking behavior RAB3B intron 20418888 rs11205911 chr1 52396312 A G 6.30E-07 Smoking behavior RAB3B intron 20418888 rs12566236 chr1 52396943 G T 7.10E-07 Smoking behavior RAB3B intron 20418888 rs10888740 chr1 52400097 A G 2.60E-06 Smoking behavior RAB3B intron 20418888 rs6698110 chr1 52404141 T C 2.10E-07 Smoking behavior RAB3B intron 20418888 rs1935289 chr1 52406872 T C 4.60E-06 Smoking behavior RAB3B intron 20418888 rs2809943 chr1 52416140 C T 4.18E-04 Alzheimer's disease RAB3B intron 17998437 rs2809943 chr1 52416140 C T 5.15E-05 Serum metabolites RAB3B intron 19043545 rs2809944 chr1 52417538 T C 6.91E-05 Multiple sclerosis RAB3B intron 20598377 rs7541308 chr1 52418121 G T 1.70E-06 Smoking behavior RAB3B intron 20418888 rs6686975 chr1 52423134 G A 6.70E-06 Smoking behavior RAB3B intron 20418888 rs10888743 chr1 52423167 C T 4.20E-06 Smoking behavior RAB3B intron 20418888 rs12039206 chr1 52569002 A G 7.09E-04 Multiple complex diseases / / 17554300 rs1288706 chr1 52754871 G A 7.59E-05 Erythrocyte counts ZFYVE9 intron pha003099 rs2753399 chr1 52774357 T C 0.0000116 Menopause (age at onset) ZFYVE9 intron 23424626 rs2762819 chr1 52798033 G A 9.21E-04 Insulin resistance ZFYVE9 intron 21901158 rs9633423 chr1 52836139 G A 1.70E-05 Smoking behavior / / 20418888 rs9633423 chr1 52836139 G A 4.71E-11 Lymphocyte counts / / 22286170 rs3087476 chr1 52854961 G A 2.57E-04 Insulin resistance ORC1 missense 21901158 rs835036 chr1 52997240 T C 1.40E-05 Smoking behavior ZCCHC11 intron 20418888 rs12138419 chr1 53056187 G A 3.98E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs17374258 chr1 53110002 C T 2.46E-05 Menopause (age at onset) FAM159A intron 22267201 rs706497 chr1 53114736 T C 4.70E-05 Myasthenia gravis FAM159A intron 23055271 rs856721 chr1 53162156 C A 0.00056 Salmonella-induced pyroptosis SELRC1 intron 22837397 rs374662 chr1 53164549 C A 0.00022 Salmonella-induced pyroptosis / / 22837397 rs440871 chr1 53173052 C T 0.000303 Salmonella-induced pyroptosis / / 22837397 rs425520 chr1 53179805 C G 0.000312 Salmonella-induced pyroptosis / / 22837397 rs6703127 chr1 53180565 C T 0.000235 Salmonella-induced pyroptosis / / 22837397 rs146750 chr1 53183447 C G 0.000403 Salmonella-induced pyroptosis / / 22837397 rs374849 chr1 53185631 G A 0.000378 Salmonella-induced pyroptosis / / 22837397 rs269293 chr1 53187767 A C 0.000454 Salmonella-induced pyroptosis / / 22837397 rs4926930 chr1 53217335 A G 0.000789 Salmonella-induced pyroptosis ZYG11B intron 22837397 rs505444 chr1 53251860 T C 4.68E-30 Narcolepsy ZYG11B intron 19629137 rs12731800 chr1 53286967 A G 2.10E-06 Urinary metabolites ZYG11B intron 21572414 rs551591 chr1 53301876 A G 0.0000573 Salmonella-induced pyroptosis / / 22837397 rs504816 chr1 53307957 T G 0.000035 Salmonella-induced pyroptosis / / 22837397 rs514406 chr1 53330458 A G 5.73E-04 Multiple complex diseases ZYG11A intron 17554300 rs514881 chr1 53336737 C T 0.000561 Salmonella-induced pyroptosis ZYG11A intron 22837397 rs481440 chr1 53344976 C T 8.08E-04 Alcohol dependence ZYG11A intron 21314694 rs139969883 chr1 53377291 C T 0.000069 Breast cancer ECHDC2 missense 23555315 rs11206061 chr1 53455899 T C 7.43E-04 Suicide attempts in bipolar disorder SCP2 intron 21423239 rs11581638 chr1 53459690 C T 6.00E-04 Multiple complex diseases SCP2 UTR-3 17554300 rs11588200 chr1 53512519 G T 5.07E-04 Multiple complex diseases SCP2 intron 17554300 rs6664845 chr1 53514497 C G 8.84E-04 Multiple complex diseases SCP2 intron 17554300 rs4926946 chr1 53515101 C A 5.51E-04 Multiple complex diseases SCP2 intron 17554300 rs17107767 chr1 53517997 T C 7.30E-04 Multiple complex diseases / / 17554300 rs12096165 chr1 53518049 T G 9.29E-04 Multiple complex diseases / / 17554300 rs11584649 chr1 53530487 C T 3.75E-04 Multiple complex diseases PODN intron 17554300 rs17107812 chr1 53532920 C A 5.08E-04 Insulin resistance PODN intron 21901158 rs6697308 chr1 53534687 C G 8.47E-04 Multiple complex diseases PODN intron 17554300 rs2275456 chr1 53536025 T C 0.0000031 Chronic obstructive pulmonary disease (moderate to severe) PODN intron 22986903 rs11583585 chr1 53554406 T C 2.98E-04 Type 2 diabetes SLC1A7 intron 17463246 rs4926953 chr1 53569492 T C 2.57E-04 Type 2 diabetes SLC1A7 intron 17463246 rs17108032 chr1 53580585 G A 0.000000667 Triglycerides SLC1A7 cds-synon 23063622 rs17108032 chr1 53580585 G A 5.41E-10 Cholesterol,total SLC1A7 cds-synon 23063622 rs3820201 chr1 53581670 A G 1.00E-06 Hippocampal atrophy SLC1A7 intron 22745009 rs3753600 chr1 53591287 G A 1.37E-11 Triglycerides SLC1A7 intron 23063622 rs3753600 chr1 53591287 G A 2.85E-11 HDL cholesterol SLC1A7 intron 23063622 rs34418279 chr1 53608425 C A 3.33E-04 Multiple complex diseases / / 17554300 rs7556421 chr1 53619482 C T 8.42E-05 Height / / pha003011 rs6695567 chr1 53629585 G A 3.62E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6695567 chr1 53629585 G A 4.00E-06 Systemic lupus erythematosus / / 21408207 rs1288331 chr1 53631049 T C 2.93E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs7531337 chr1 53641911 C A 6.66E-04 Type 2 diabetes / / 17463246 rs12058755 chr1 53670451 G A 2.46E-08 Cholesterol,total CPT2 intron 23063622 rs11578832 chr1 53674542 G A 5.20E-04 Coronary heart disease CPT2 intron 21966275 rs13375749 chr1 53695882 T C 8.30E-04 Myocardial infarction MAGOH intron 21107343 rs13375749 chr1 53695882 T C 3.00E-28 Blood metabolite levels MAGOH intron 24816252 rs2297656 chr1 53701581 A G 5.28E-05 Bipolar disorder and schizophrenia MAGOH intron 20889312 rs17785382 chr1 53707953 A G 2.73E-05 Bipolar disorder and schizophrenia LOC100507564 intron 20889312 rs17785382 chr1 53707953 A G 5.59E-07 Bipolar disorder LOC100507564 intron 22182935 rs17785382 chr1 53707953 A G 1.74E-05 Schizophrenia LOC100507564 intron pha002857 rs5177 chr1 53711735 G C 8.10E-05 Bipolar disorder and schizophrenia LRP8 UTR-3 20889312 rs5177 chr1 53711735 G C 5.00E-05 Schizophrenia LRP8 UTR-3 pha002857 rs5176 chr1 53711809 T G 3.44E-37 LDL cholesterol LRP8 UTR-3 23063622 rs5176 chr1 53711809 T G 5.12E-52 HDL cholesterol LRP8 UTR-3 23063622 rs5176 chr1 53711809 T G 6.51E-78 Cholesterol,total LRP8 UTR-3 23063622 rs5176 chr1 53711809 T G 8.86E-21 Triglycerides LRP8 UTR-3 23063622 rs5174 chr1 53712727 C T 3.40E-05 Schizophrenia LRP8 missense 21791550 rs5174 chr1 53712727 C T 0.000000094 Psychosis LRP8 missense 23164818 rs10788950 chr1 53713336 A G 5.50E-04 Response to taxane treatment (placlitaxel) LRP8 intron 23006423 rs11206127 chr1 53713549 G A 4.25E-05 Bipolar disorder and schizophrenia LRP8 intron 20889312 rs11206127 chr1 53713549 G A 3.16E-05 Schizophrenia LRP8 intron pha002857 rs869987 chr1 53723190 G T 3.86E-05 Bipolar disorder and schizophrenia LRP8 intron 20889312 rs869987 chr1 53723190 G T 4.54E-05 Schizophrenia LRP8 intron pha002857 rs869988 chr1 53723349 T C 5.85E-05 Bipolar disorder and schizophrenia LRP8 intron 20889312 rs2297661 chr1 53723965 C G 0.00000038 Cholesterol,total LRP8 intron 23063622 rs1288489 chr1 53772544 C G 1.60E-04 Type 2 diabetes LRP8 intron 17463246 rs2788032 chr1 53777631 A C 6.00E-06 Body mass index (interaction) LRP8 intron 23192594 rs2788032 chr1 53777631 A C 1.18E-04 Amyotrophic lateral sclerosis (sporadic) LRP8 intron 24529757 rs872314 chr1 53787483 A G 5.92E-06 Multiple complex diseases LRP8 intron 17554300 rs3820198 chr1 53792651 A C 2.70E-05 Alcohol dependence LRP8 missense 22096494 rs12354192 chr1 53796783 C T 2.39E-04 Multiple complex diseases / / 17554300 rs1416095 chr1 53808693 A G 1.20E-05 Alcohol dependence / / 22096494 rs10888780 chr1 53813684 A G 3.72E-05 Cognitive test performance / / 20125193 rs12041966 chr1 53832697 T C 9.88E-05 Type 2 diabetes / / 17463246 rs17108398 chr1 53845985 G A 2.50E-05 Urinary metabolites / / 21572414 rs6660818 chr1 53857444 T A 7.30E-06 Urinary metabolites / / 21572414 rs114216682 chr1 53871085 G C 7.00E-08 Chronic obstructive pulmonary disease / / 21685187 rs1776421 chr1 53884457 C T 6.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs9436924 chr1 53913080 C T 7.30E-06 Nicotine use / / 23942779 rs41366756 chr1 53917443 C T 5.48E-04 Multiple complex diseases / / 17554300 rs41443646 chr1 53921571 T C 8.18E-04 Multiple complex diseases / / 17554300 rs1108989 chr1 53929463 T A 6.69E-05 Arthritis (juvenile idiopathic) DMRTB1 intron 22354554 rs1288632 chr1 53929536 C G 5.71E-05 Arthritis (juvenile idiopathic) DMRTB1 intron 22354554 rs11579575 chr1 53936718 G T 9.24E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1296438 chr1 53937177 A G 7.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1296438 chr1 53937177 A G 1.00E-04 Illicit drug use / / 23942779 rs1296438 chr1 53937177 A G 6.20E-04 Non-substance related behavioral disinhibition / / 23942779 rs1296438 chr1 53937177 A G 7.90E-06 Nicotine use / / 23942779 rs17108559 chr1 53947868 C T 1.48E-04 Multiple complex diseases / / 17554300 rs1298637 chr1 53958603 C T 1.60E-04 Illicit drug use / / 23942779 rs1298637 chr1 53958603 C T 3.80E-04 Non-substance related behavioral disinhibition / / 23942779 rs1298637 chr1 53958603 C T 5.00E-06 Nicotine use / / 23942779 rs943519 chr1 53965546 C T 5.17E-05 Cognitive test performance / / 20125193 rs10749691 chr1 53974987 G T 1.30E-05 Response to statin therapy GLIS1 intron 20339536 rs10749691 chr1 53974987 G T 2.85E-05 Smoking initiation GLIS1 intron 24665060 rs475322 chr1 53975436 C A 5.19E-04 Smoking initiation GLIS1 intron 24665060 rs2280511 chr1 53976188 C T 2.60E-05 Response to statin therapy GLIS1 intron 20339536 rs6588480 chr1 53978119 A G 8.00E-06 Response to statin therapy GLIS1 intron 20339536 rs11206169 chr1 54005060 C T 8.02E-04 Type 2 diabetes GLIS1 intron 17463246 rs3889128 chr1 54009233 G C 3.10E-05 Anger GLIS1 intron 24489884 rs2986655 chr1 54011192 A G 2.96E-05 stroke (ischemic) GLIS1 intron 17434096 rs41488848 chr1 54011503 G C 2.83E-04 Multiple complex diseases GLIS1 intron 17554300 rs12141264 chr1 54020542 C T 2.75E-05 Myopia (pathological) GLIS1 intron 23049088 rs2873096 chr1 54029856 C A 3.83E-04 Lung function (forced vital capacity) GLIS1 intron 24023788 rs2091407 chr1 54032698 G A 2.50E-05 Urinary metabolites GLIS1 intron 21572414 rs11206174 chr1 54038523 G C 2.40E-05 Urinary metabolites GLIS1 intron 21572414 rs10788958 chr1 54040670 C G 2.50E-06 Digit length ratio GLIS1 intron 20303062 rs4926603 chr1 54041558 G A 6.00E-06 Digit length ratio GLIS1 intron 20303062 rs2950250 chr1 54042714 T G 9.50E-07 Digit length ratio GLIS1 intron 20303062 rs3108391 chr1 54042889 C T 6.40E-06 Digit length ratio GLIS1 intron 20303062 rs4634849 chr1 54043110 C T 8.40E-06 Digit length ratio GLIS1 intron 20303062 rs11585273 chr1 54043386 G A 6.80E-06 Digit length ratio GLIS1 intron 20303062 rs11585344 chr1 54043786 G A 6.70E-06 Digit length ratio GLIS1 intron 20303062 rs12089978 chr1 54045180 T C 6.80E-06 Digit length ratio GLIS1 intron 20303062 rs12084713 chr1 54045226 G A 7.10E-06 Digit length ratio GLIS1 intron 20303062 rs17386087 chr1 54045624 T C 4.90E-04 Alzheimer's disease GLIS1 intron 17998437 rs17386087 chr1 54045624 T C 7.00E-06 Digit length ratio GLIS1 intron 20303062 rs17386108 chr1 54045718 T A 4.93E-04 Alzheimer's disease GLIS1 intron 17998437 rs17386108 chr1 54045718 T A 7.10E-06 Digit length ratio GLIS1 intron 20303062 rs12137291 chr1 54046217 G T 8.50E-06 Digit length ratio GLIS1 intron 20303062 rs941129 chr1 54046556 T C 7.89E-05 Cognitive test performance GLIS1 intron 20125193 rs3006884 chr1 54047225 G A 7.00E-06 Digit length ratio GLIS1 intron 20303062 rs12140369 chr1 54047882 A T 8.20E-06 Digit length ratio GLIS1 intron 20303062 rs2950252 chr1 54048719 C G 8.20E-06 Digit length ratio GLIS1 intron 20303062 rs2948045 chr1 54051898 T C 1.20E-06 Digit length ratio GLIS1 intron 20303062 rs4926604 chr1 54051924 T C 1.30E-06 Digit length ratio GLIS1 intron 20303062 rs6588482 chr1 54054618 T A 1.30E-06 Digit length ratio GLIS1 intron 20303062 rs1879735 chr1 54055693 A G 1.40E-06 Digit length ratio GLIS1 intron 20303062 rs4927011 chr1 54058231 C T 1.30E-06 Digit length ratio GLIS1 intron 20303062 rs7551844 chr1 54061333 T C 2.90E-06 Digit length ratio GLIS1 intron 20303062 rs7551844 chr1 54061333 T C 2.14E-04 Sensory disturbances after bilateral sagittal split ramus osteotomy GLIS1 intron 23834954 rs10888795 chr1 54061446 G A 8.70E-06 Digit length ratio GLIS1 intron 20303062 rs6588483 chr1 54061779 G A 6.80E-06 Digit length ratio GLIS1 intron 20303062 rs3013754 chr1 54061978 A C 2.80E-06 Digit length ratio GLIS1 intron 20303062 rs2948053 chr1 54062273 A G 2.80E-06 Digit length ratio GLIS1 intron 20303062 rs10159298 chr1 54064240 C T 3.19E-05 Body Composition GLIS1 intron pha003012 rs10159298 chr1 54064240 C T 9.02E-05 Body Mass Index GLIS1 intron pha003021 rs17382220 chr1 54066599 A T 6.20E-06 Digit length ratio GLIS1 intron 20303062 rs4927012 chr1 54068016 C T 6.20E-06 Digit length ratio GLIS1 intron 20303062 rs6663966 chr1 54070013 C T 0.000052 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 GLIS1 intron 21873659 rs17382457 chr1 54071428 G A 4.50E-06 Digit length ratio GLIS1 intron 20303062 rs12563871 chr1 54071610 A G 4.50E-06 Digit length ratio GLIS1 intron 20303062 rs3013749 chr1 54072759 A T 5.00E-05 Height GLIS1 intron 19396169 rs2948048 chr1 54074729 G A 6.35E-05 Body Composition GLIS1 intron pha003012 rs7542387 chr1 54078923 A G 5.80E-06 Digit length ratio GLIS1 intron 20303062 rs11801290 chr1 54079964 G A 6.80E-06 Digit length ratio GLIS1 intron 20303062 rs3006898 chr1 54083312 T C 9.79E-05 Body Composition GLIS1 intron pha003012 rs2141079 chr1 54120873 C T 5.37E-04 Parkinson's disease GLIS1 intron 17052657 rs17109076 chr1 54129705 A G 7.00E-04 Multiple complex diseases GLIS1 intron 17554300 rs2950243 chr1 54135651 A G 5.80E-04 Multiple complex diseases GLIS1 intron 17554300 rs797913 chr1 54198562 C T 9.28E-04 Alcohol dependence GLIS1 intron 21314694 rs12075528 chr1 54199484 C T 4.88E-04 Alcohol dependence GLIS1 intron 21314694 rs761490 chr1 54216654 C G 3.00E-05 Social communication problems / / 24047820 rs4354491 chr1 54314043 C T 3.27E-06 Body Mass Index / / pha003019 rs4354491 chr1 54314043 C T 4.20E-05 Body Mass Index / / pha003020 rs4354491 chr1 54314043 C T 5.98E-05 Body Mass Index / / pha003022 rs11206226 chr1 54320337 A G 5.00E-06 Nonalcoholic fatty liver disease YIPF1 intron 22719876 rs6588492 chr1 54328025 G A 4.23E-05 Blood pressure (response to angiotensin II receptor blocker) YIPF1 intron 24192120 rs6681549 chr1 54328814 G A 8.83E-04 Type 2 diabetes YIPF1 intron 17463246 rs6588493 chr1 54328988 C A 8.41E-04 Type 2 diabetes YIPF1 intron 17463246 rs7541049 chr1 54343294 T C 7.11E-04 Type 2 diabetes YIPF1 intron 17463246 rs7541170 chr1 54343462 T C 6.46E-04 Type 2 diabetes YIPF1 intron 17463246 rs6680026 chr1 54345792 C T 4.23E-05 Blood pressure (response to angiotensin II receptor blocker) YIPF1 intron 24192120 rs12131461 chr1 54366364 G A 1.27E-05 Body Mass Index DIO1 intron pha003019 rs12131461 chr1 54366364 G A 6.05E-05 Body Mass Index DIO1 intron pha003020 rs3766467 chr1 54373185 G A,C,T 7.76E-05 Obesity (extreme) DIO1 intron 21935397 rs2235544 chr1 54375570 C A 3.00E-18 Thyroid hormone levels DIO1 intron 23408906 rs2235544 chr1 54375570 C A 5.00E-15 Thyroid hormone levels DIO1 intron 23408906 rs2235544 chr1 54375570 C A 8.00E-32 Thyroid hormone levels DIO1 intron 23408906 rs2235544 chr1 54375570 C A 6.00E-07 Multiple myeloma (hyperdiploidy) DIO1 intron 23502783 rs12073655 chr1 54393492 C A 6.11E-05 Obesity (extreme) HSPB11 intron 21935397 rs11206252 chr1 54397240 G A 6.14E-05 Obesity (extreme) HSPB11 intron 21935397 rs12092723 chr1 54422901 C G 2.77E-04 Multiple complex diseases LRRC42 intron 17554300 rs12092723 chr1 54422901 C G 7.00E-05 Obesity (extreme) LRRC42 intron 21935397 rs10888828 chr1 54441756 A G 2.20E-04 Obesity (extreme) / / 21935397 rs114147144 chr1 54443865 T C 3.00E-06 PR interval in Tripanosoma cruzi seropositivity / / 24324551 rs11206266 chr1 54443867 C T 2.21E-04 Obesity (extreme) / / 21935397 rs638749 chr1 54450490 A G 9.82E-04 Myopia (pathological) / / 21095009 rs7515322 chr1 54450901 A G 7.26E-05 Multiple complex diseases / / 17554300 rs7515322 chr1 54450901 A G 1.91E-04 Obesity (extreme) / / 21935397 rs7525809 chr1 54451080 G A 3.62E-04 Multiple complex diseases / / 17554300 rs7525809 chr1 54451080 G A 1.91E-04 Obesity (extreme) / / 21935397 rs145889899 chr1 54476084 C T 0.00000014 Breast cancer(er negative) LDLRAD1 splice-5 23555315 rs145889899 chr1 54476084 C T 0.00000025 Breast cancer LDLRAD1 splice-5 23555315 rs17109656 chr1 54476147 G A 9.03E-05 Multiple complex diseases LDLRAD1 intron 17554300 rs17109656 chr1 54476147 G A 1.68E-04 Obesity (extreme) LDLRAD1 intron 21935397 rs11805505 chr1 54480410 T A 6.49E-04 Obesity (extreme) LDLRAD1 intron 21935397 rs12047169 chr1 54487417 C T 6.61E-04 Myopia (pathological) / / 21095009 rs6694292 chr1 54566190 G A 4.75E-04 Coronary Artery Disease / / 17634449 rs6694397 chr1 54566310 G A 5.03E-04 Coronary Artery Disease / / 17634449 rs12063422 chr1 54585415 T C 1.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs581554 chr1 54614409 C T 7.91E-04 Coronary heart disease CDCP2 intron 21606135 rs11587789 chr1 54615599 A C 4.50E-04 Alzheimer's disease CDCP2 intron 22005930 rs7519887 chr1 54619404 C T 7.27E-05 Cognitive test performance CDCP2 UTR-5 20125193 rs10493175 chr1 54636977 T C 8.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs625643 chr1 54637167 T C 8.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs625643 chr1 54637167 T C 3.23E-04 Coronary heart disease / / 21606135 rs682705 chr1 54637417 G A 9.07E-06 Parkinson's disease / / 16252231 rs7520966 chr1 54645262 T C 2.96E-05 Parkinson's disease CYB5RL intron 16252231 rs1890566 chr1 54668278 A G 8.00E-07 Migraine MRPL37 intron 23793025 rs17392549 chr1 54677786 G A 8.16E-04 Telomere length MRPL37 intron 23900074 rs4061073 chr1 54696743 A G 0.0000131 Carotid intima media thickness SSBP3 intron 23152477 rs4061073 chr1 54696743 A G 3.29E-04 Stroke SSBP3 intron pha002887 rs688383 chr1 54718489 T C 3.34E-04 Amyotrophic Lateral Sclerosis SSBP3 intron 17362836 rs655274 chr1 54721930 C T 2.61E-04 Amyotrophic Lateral Sclerosis SSBP3 intron 17362836 rs3766432 chr1 54729952 G C 6.98E-13 Metabolite levels SSBP3 intron 22286219 rs3766431 chr1 54730036 G A 1.60E-05 Smoking behavior SSBP3 intron 20418888 rs679200 chr1 54732940 A G 1.65E-04 Amyotrophic Lateral Sclerosis SSBP3 intron 17362836 rs603901 chr1 54741767 C T 4.21E-04 Amyotrophic Lateral Sclerosis SSBP3 intron 17362836 rs11206315 chr1 54743408 G A 0.00000625 Child behavior checklist/1.5-5 pervasive developmental problems SSBP3 intron 23049896 rs9326028 chr1 54750625 T C 9.68E-04 Aortic root size SSBP3 intron 21223598 rs4927081 chr1 54756342 T C 5.81E-04 Alcohol dependence SSBP3 intron 20201924 rs6678619 chr1 54762350 G A 6.85E-04 HIV-1 viral setpoint SSBP3 intron 17641165 rs4927086 chr1 54766101 T C 3.89E-04 Taste perception SSBP3 intron 22132133 rs7523947 chr1 54766816 C T 2.21E-04 Parkinson's disease SSBP3 intron 17052657 rs17390642 chr1 54768377 A G 2.00E-04 Taste perception SSBP3 intron 22132133 rs11206329 chr1 54777562 A G 6.31E-05 Major depressive disorder (broad) SSBP3 intron 20038947 rs7524749 chr1 54779243 G A 6.34E-05 Major depressive disorder (broad) SSBP3 intron 20038947 rs12021758 chr1 54787049 T C 5.96E-04 Multiple complex diseases SSBP3 intron 17554300 rs12021758 chr1 54787049 T C 1.62E-04 Gallstones SSBP3 intron 17632509 rs17110393 chr1 54790576 G A 1.10E-05 Urinary metabolites SSBP3 intron 21572414 rs12404565 chr1 54796148 T C 4.32E-04 Multiple complex diseases SSBP3 intron 17554300 rs2317387 chr1 54830569 A C 4.00E-04 Acute lymphoblastic leukemia (childhood) SSBP3 intron 20189245 rs11206344 chr1 54852994 C A 7.49E-05 Longevity SSBP3 intron 20304771 rs6690450 chr1 54854079 C A 9.09E-05 Longevity SSBP3 intron 20304771 rs213490 chr1 54854984 G A 8.02E-05 Longevity SSBP3 intron 20304771 rs213496 chr1 54869816 T C 2.68E-04 Body mass index SSBP3 intron 21701565 rs213496 chr1 54869816 T C 3.16E-04 Body mass index SSBP3 intron 21701565 rs4244644 chr1 54883163 C T 9.65E-05 Response to citalopram treatment / / 19846067 rs4927107 chr1 54888245 A C 3.85E-05 Response to citalopram treatment / / 19846067 rs7550485 chr1 54928493 G A 9.63E-06 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs190963 chr1 54946847 G A 1.70E-06 Glioma (high-grade) / / 19578366 rs4927133 chr1 54953523 T C 4.98E-05 Cognitive test performance / / 20125193 rs299895 chr1 54962448 C T 7.60E-04 Multiple complex diseases / / 17554300 rs1888182 chr1 54967890 C T 8.64E-04 Taste perception / / 22132133 rs299881 chr1 54968494 T C 3.17E-04 Taste perception / / 22132133 rs4927134 chr1 54984107 A C 0.000000041 Dependent (behavior influenced) stressful life events / / 23237013 rs4927134 chr1 54984107 A C 0.000000058 Stressful life events / / 23237013 rs11809810 chr1 55023706 A G 5.07E-09 Triglycerides ACOT11 intron 23063622 rs449484 chr1 55030530 A G 1.51E-04 Body mass index ACOT11 intron 21701565 rs449484 chr1 55030530 A G 4.97E-05 Body mass index ACOT11 intron 21701565 rs537696 chr1 55031313 C A 3.26E-04 Blood pressure ACOT11 intron 17255346 rs300280 chr1 55033869 T C 4.74E-06 Waist Circumference ACOT11 intron pha003023 rs300271 chr1 55046039 G T 5.23E-05 Waist Circumference ACOT11 intron pha003023 rs17110757 chr1 55049806 G A 7.90E-07 Glioma (high-grade) ACOT11 intron 19578366 rs1702002 chr1 55060548 C T 1.32E-04 Body mass index ACOT11 intron 21701565 rs1702002 chr1 55060548 C T 3.74E-04 Body mass index ACOT11 intron 21701565 rs4927139 chr1 55061254 T G 1.91E-04 Body mass index ACOT11 intron 21701565 rs4927139 chr1 55061254 T G 4.11E-04 Body mass index ACOT11 intron 21701565 rs732509 chr1 55067992 A G 1.20E-04 Body mass index ACOT11 intron 21701565 rs732509 chr1 55067992 A G 2.45E-04 Body mass index ACOT11 intron 21701565 rs17398958 chr1 55071769 G T 4.47E-05 Coronary heart disease ACOT11 intron pha003031 rs2289015 chr1 55075062 C T 1.74E-05 Response to treatment for acute lymphoblastic leukemia FAM151A missense 19176441 rs2117262 chr1 55089880 A G 8.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ACOT11 intron 20877124 rs10736390 chr1 55103945 A G 1.88E-05 Pancreatic cancer / / 23180869 rs1368882 chr1 55107019 G A 2.00E-06 Non-substance related behavioral disinhibition / / 23942779 rs1368882 chr1 55107019 G A 2.10E-04 Nicotine use / / 23942779 rs1368882 chr1 55107019 G A 2.90E-04 Alcohol dependence / / 23942779 rs10888859 chr1 55117520 G A 2.00E-04 Cognitive impairment induced by topiramate HEATR8 intron 22091778 rs558184 chr1 55123936 C T 3.50E-07 Urinary metabolites HEATR8 intron 21572414 rs1529783 chr1 55129564 T C 4.62E-04 Multiple complex diseases HEATR8 intron 17554300 rs1180937 chr1 55191644 T C 8.38E-05 Prostate cancer TTC4 intron pha002878 rs61768793 chr1 55193477 A G 7.40E-11 Metabolite levels TTC4 intron 22286219 rs2873551 chr1 55217907 T C 2.60E-05 Type 2 diabetes / / 19184112 rs2108035 chr1 55218155 C T 2.41E-04 Blood pressure / / 17255346 rs2108035 chr1 55218155 C T 7.47E-04 Schizophrenia / / 19197363 rs2240396 chr1 55223190 C T 2.98E-06 Blood pressure PARS2 UTR-3 17255346 rs1180955 chr1 55225846 T C 1.22E-05 Serum metabolites PARS2 intron 19043545 rs1180948 chr1 55228159 C G 1.11E-05 Serum metabolites PARS2 intron 19043545 rs10430114 chr1 55234711 G T 1.76E-06 Blood pressure / / 17255346 rs10888879 chr1 55243590 G T 1.35E-05 Multiple complex diseases / / 17554300 rs12740946 chr1 55244197 T C 7.52E-05 Stroke / / pha002887 rs619476 chr1 55263551 T C 5.39E-04 Response to cytidine analogues (gemcitabine) TTC22 intron 24483146 rs671108 chr1 55266797 G C 5.72E-04 Response to cytidine analogues (gemcitabine) TTC22 missense 24483146 rs689322 chr1 55267509 G A 6.94E-04 Schizophrenia TTC22 nearGene-5 21674006 rs616315 chr1 55278841 G A 3.26E-04 Response to cytidine analogues (gemcitabine) C1orf177 intron 24483146 rs7549251 chr1 55304970 G A 1.80E-06 Stroke (ischemic) C1orf177 intron 22384361 rs17111100 chr1 55307693 C A 2.73E-04 Response to cytadine analogues (cytosine arabinoside) C1orf177 UTR-3 24483146 rs11206451 chr1 55311452 C T 2.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs687912 chr1 55312440 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs683737 chr1 55314142 C T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1138030 chr1 55317685 G A 2.16E-04 Response to cytadine analogues (cytosine arabinoside) DHCR24 UTR-3 24483146 rs642737 chr1 55333453 A G 5.51E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DHCR24 intron 20877124 rs1469344 chr1 55386167 C T 1.30E-05 Urinary metabolites / / 21572414 rs677321 chr1 55387362 C T 5.67E-04 Type 2 diabetes / / 17463246 rs678358 chr1 55387637 G T 7.04E-04 Type 2 diabetes / / 17463246 rs41517445 chr1 55389569 A G 4.47E-04 Type 2 diabetes / / 17463246 rs7522847 chr1 55394678 A G 3.42E-04 Cocaine dependence / / 23958962 rs7522847 chr1 55394678 A G 4.22E-04 Cocaine dependence / / 23958962 rs604778 chr1 55397406 T C 9.21E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6588538 chr1 55398277 C T 1.10E-06 Urinary metabolites / / 21572414 rs11206473 chr1 55398932 G A 9.20E-07 Urinary metabolites / / 21572414 rs1889209 chr1 55404022 A G 1.30E-05 Urinary metabolites / / 21572414 rs1889209 chr1 55404022 A G 2.11E-06 LDL cholesterol / / 23726366 rs11206476 chr1 55405850 G T 9.37E-04 Suicide attempts in bipolar disorder / / 21423239 rs11206480 chr1 55416827 G T 1.92E-04 Cholesterol / / 17255346 rs11206482 chr1 55419855 C T 2.97E-04 Cholesterol / / 17255346 rs10218716 chr1 55425286 A G,T 7.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs7523658 chr1 55428397 C T 2.35E-04 Cholesterol / / 17255346 rs7551937 chr1 55430634 G A 7.91E-04 Suicide attempts in bipolar disorder / / 21423239 rs2317948 chr1 55434443 T G 5.50E-06 Type 2 diabetes / / 17293876 rs2317948 chr1 55434443 T G 5.50E-06 Type 2 diabetes / / 19184112 rs2317948 chr1 55434443 T G 9.78E-05 Lactate dehydrogenase levels / / 20981236 rs1015979 chr1 55449273 C T 6.43E-04 Alzheimer's disease TMEM61 intron 17998437 rs13374752 chr1 55453391 A G 6.11E-06 Asthma (childhood onset) TMEM61 intron 23829686 rs2495513 chr1 55457815 C T 3.98E-05 Longevity / / 21612516 rs34561376 chr1 55464986 G A 0.0008 Prostate cancer BSND missense 23555315 rs759914 chr1 55465594 G T 6.16E-05 Atopy BSND intron 21625490 rs6682884 chr1 55474325 A C 1.00E-05 Urinary metabolites BSND UTR-3 21572414 rs4339899 chr1 55474476 C G 1.10E-05 Urinary metabolites BSND nearGene-3 21572414 rs2495505 chr1 55484810 C T 4.23E-05 Cognitive test performance / / 20125193 rs2479418 chr1 55494877 A G 5.28E-05 LDL lipoproteins / / pha002902 rs11206510 chr1 55496039 T C 4.00E-11 LDL cholesterol / / 18193043 rs11206510 chr1 55496039 T C 7.50E-06 Lipid levels / / 18193044 rs11206510 chr1 55496039 T C 4.00E-08 LDL cholesterol / / 19060906 rs11206510 chr1 55496039 T C 1.00E-08 Myocardial infarction (early onset) / / 19198609 rs11206510 chr1 55496039 T C 1.00E-10 LDL cholesterol / / 20864672 rs11206510 chr1 55496039 T C 1.00E-08 Coronary heart disease / / 21347282 rs11206510 chr1 55496039 T C 9.00E-08 Coronary heart disease / / 21378990 rs11206510 chr1 55496039 T C 2.44E-11 Metabolite levels / / 22286219 rs11206510 chr1 55496039 T C 9.10E-08 Pericardial fat / / 22589742 rs11206510 chr1 55496039 T C 1.66E-14 Cholesterol,total / / 23063622 rs11206510 chr1 55496039 T C 1.89E-15 LDL cholesterol / / 23063622 rs11206510 chr1 55496039 T C 0.00000015 LDL cholesterol / / 23100282 rs11206510 chr1 55496039 T C 0.0000076 Apolipoprotein B levels / / 23100282 rs11206510 chr1 55496039 T C 1.50E-07 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) / / 23103227 rs11206510 chr1 55496039 T C 0.0000703 Coronary artery disease with myocardial infarction / / 23202125 rs11206510 chr1 55496039 T C 0.000207 Triglycerides / / 23202125 rs11206510 chr1 55496039 T C 1.55E-21 Coronary artery disease (CAD) (males) / / 23202125 rs11206510 chr1 55496039 T C 2.04E-21 Coronary artery disease (CAD) age <=50 / / 23202125 rs11206510 chr1 55496039 T C 3.54E-20 Cholesterol,total / / 23202125 rs11206510 chr1 55496039 T C 4.07E-11 Coronary artery disease (CAD) (females) / / 23202125 rs11206510 chr1 55496039 T C 5.23E-20 LDL cholesterol / / 23202125 rs11206510 chr1 55496039 T C 7.12E-41 Coronary artery disease (CAD) age >50 / / 23202125 rs11206510 chr1 55496039 T C 2.03E-04 Coronary artery disease / / 24262325 rs2479415 chr1 55498745 C T 0.0000206 Circulating PCSK9 levels / / 22460556 rs2182833 chr1 55500429 A G 2.19E-09 Cholesterol,total / / 23063622 rs2182833 chr1 55500429 A G 2.76E-09 LDL cholesterol / / 23063622 rs10788994 chr1 55500976 C T 1.06E-09 Cholesterol,total / / 23063622 rs10788994 chr1 55500976 C T 5.40E-10 LDL cholesterol / / 23063622 rs2149041 chr1 55502137 C G 1.11E-09 LDL cholesterol / / 23063622 rs2149041 chr1 55502137 C G 1.68E-09 Cholesterol,total / / 23063622 rs17111503 chr1 55503448 A G 1.86E-11 Cholesterol,total PCSK9 nearGene-5 23063622 rs17111503 chr1 55503448 A G 6.29E-11 LDL cholesterol PCSK9 nearGene-5 23063622 rs2479409 chr1 55504650 G A 2.00E-28 LDL cholesterol PCSK9 nearGene-5 20686565 rs2479409 chr1 55504650 G A 4.00E-24 Cholesterol,total PCSK9 nearGene-5 20686565 rs2479409 chr1 55504650 G A 0.000179 Circulating PCSK9 levels PCSK9 nearGene-5 22460556 rs2479409 chr1 55504650 G A 1.03E-09 LDL cholesterol PCSK9 nearGene-5 23063622 rs2479409 chr1 55504650 G A 3.64E-09 Cholesterol,total PCSK9 nearGene-5 23063622 rs2479409 chr1 55504650 G A 2.00E-39 Cholesterol,total PCSK9 nearGene-5 24097068 rs2479409 chr1 55504650 G A 3.00E-50 LDL cholesterol PCSK9 nearGene-5 24097068 rs11591147 chr1 55505647 G T 2.00E-44 LDL cholesterol PCSK9 missense 18193044 rs11591147 chr1 55505647 G T 1.60E-07 Lipid levels PCSK9 missense 19802338 rs11591147 chr1 55505647 G T 1.80E-10 Lipid levels PCSK9 missense 19802338 rs11591147 chr1 55505647 G T 1.08E-10 Lipid levels PCSK9 missense 19913121 rs11591147 chr1 55505647 G T 4.95E-12 Lipid levels PCSK9 missense 19913121 rs11591147 chr1 55505647 G T 1.10E-09 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 1.15E-10 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 1.29E-28 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 1.30E-23 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 2.20E-13 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 2.30E-13 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 3.00E-08 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 3.57E-08 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 4.59E-12 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 5.30E-23 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 7.00E-22 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 7.75E-28 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 8.20E-18 Lipid levels PCSK9 missense 19936222 rs11591147 chr1 55505647 G T 2.86E-04 Response to statin treatment (atorvastatin),change in cholesterol levels PCSK9 missense 20031582 rs11591147 chr1 55505647 G T 2.00E-44 Coronary heart disease PCSK9 missense 21347282 rs11591147 chr1 55505647 G T 5.00E-09 Response to statin therapy (LDL-C) PCSK9 missense 22331829 rs11591147 chr1 55505647 G T 2.05E-14 LDL cholesterol PCSK9 missense 22460556 rs11591147 chr1 55505647 G T 2.20E-15 Circulating PCSK9 levels PCSK9 missense 22460556 rs11591147 chr1 55505647 G T 1.73E-28 LDL cholesterol PCSK9 missense 22629316 rs11591147 chr1 55505647 G T 2.74E-14 LDL cholesterol (female) PCSK9 missense 22629316 rs11591147 chr1 55505647 G T 8.15E-18 LDL cholesterol (male) PCSK9 missense 22629316 rs11591147 chr1 55505647 G T 2.46E-52 Cholesterol,total PCSK9 missense 23063622 rs11591147 chr1 55505647 G T 3.11E-59 LDL cholesterol PCSK9 missense 23063622 rs11591147 chr1 55505647 G T 0.000836 LDL cholesterol PCSK9 missense 23236364 rs2479410 chr1 55505861 G A 1.38E-10 Cholesterol,total PCSK9 intron 23063622 rs2479410 chr1 55505861 G A 3.92E-11 LDL cholesterol PCSK9 intron 23063622 rs644000 chr1 55511995 A G 1.58E-10 LDL cholesterol PCSK9 intron 23063622 rs644000 chr1 55511995 A G 6.41E-09 Cholesterol,total PCSK9 intron 23063622 rs499718 chr1 55512549 T C 0.000165996 Primary sclerosing cholangitis PCSK9 intron 23603763 rs2495478 chr1 55512995 G A 1.00E-07 Wilms tumor PCSK9 intron 22544364 rs28362225 chr1 55513358 C A 5.81E-09 Triglycerides PCSK9 intron 23063622 rs11206514 chr1 55516004 C A 0.000000198 Cholesterol,total PCSK9 intron 23063622 rs11206514 chr1 55516004 C A 0.000000253 LDL cholesterol PCSK9 intron 23063622 rs10888898 chr1 55516508 A G 3.63E-08 Cholesterol,total PCSK9 intron 23063622 rs10888898 chr1 55516508 A G 5.85E-08 LDL cholesterol PCSK9 intron 23063622 rs11800231 chr1 55517940 G A,T 1.02E-10 LDL cholesterol PCSK9 intron 23236364 rs11806638 chr1 55518160 C A 0.000000108 LDL cholesterol (female) PCSK9 intron 22629316 rs11806638 chr1 55518160 C A 0.0000308 LDL cholesterol (male) PCSK9 intron 22629316 rs11806638 chr1 55518160 C A 4.65E-11 LDL cholesterol PCSK9 intron 22629316 rs11806638 chr1 55518160 C A 2.38E-14 Cholesterol,total PCSK9 intron 23236364 rs11806638 chr1 55518160 C A 6.85E-08 LDL cholesterol PCSK9 intron 23236364 rs2483205 chr1 55518316 C T 0.00000119 LDL cholesterol PCSK9 intron 23063622 rs2495477 chr1 55518467 A G 0.000000166 LDL cholesterol PCSK9 intron 23063622 rs2495477 chr1 55518467 A G 3.51E-09 Cholesterol,total PCSK9 intron 23063622 rs2479413 chr1 55518682 C T 1.09E-13 LDL cholesterol PCSK9 intron 23063622 rs2479413 chr1 55518682 C T 2.83E-13 Cholesterol,total PCSK9 intron 23063622 rs7552841 chr1 55518752 C T 7.90E-05 Coronary heart disease PCSK9 intron 21966275 rs499883 chr1 55519174 G A 1.45E-11 LDL cholesterol PCSK9 intron 22629316 rs499883 chr1 55519174 G A 1.29E-18 LDL cholesterol PCSK9 intron 23063622 rs499883 chr1 55519174 G A 7.16E-17 Cholesterol,total PCSK9 intron 23063622 rs1165287 chr1 55520212 G A 1.44E-09 LDL cholesterol PCSK9 intron 23063622 rs1165287 chr1 55520212 G A 3.03E-12 Cholesterol,total PCSK9 intron 23063622 rs1165287 chr1 55520212 G A 0.00000742 LDL cholesterol PCSK9 intron 23236364 rs634272 chr1 55520265 T C 3.57E-10 LDL cholesterol PCSK9 intron 23063622 rs634272 chr1 55520265 T C 4.16E-11 Cholesterol,total PCSK9 intron 23063622 rs557435 chr1 55520864 A G 0.000000133 LDL cholesterol PCSK9 intron 23063622 rs557435 chr1 55520864 A G 0.000000247 LDL cholesterol (male) PCSK9 intron 23063622 rs557435 chr1 55520864 A G 0.000000369 Total cholesterol in males PCSK9 intron 23063622 rs557435 chr1 55520864 A G 5.92E-08 Cholesterol,total PCSK9 intron 23063622 rs557435 chr1 55520864 A G 4.34E-05 LDL lipoproteins PCSK9 intron pha002902 rs471705 chr1 55521242 T G 3.23E-14 LDL cholesterol PCSK9 intron 23063622 rs471705 chr1 55521242 T G 7.84E-16 Cholesterol,total PCSK9 intron 23063622 rs7525407 chr1 55522425 G A 0.00000124 Cholesterol,total PCSK9 intron 23063622 rs7525407 chr1 55522425 G A 2.18E-08 LDL cholesterol PCSK9 intron 23063622 rs533375 chr1 55523361 A G 0.00000111 Cholesterol,total PCSK9 intron 23063622 rs533375 chr1 55523361 A G 1.16E-08 LDL cholesterol PCSK9 intron 23063622 rs562556 chr1 55524237 G A 0.00000029 LDL cholesterol PCSK9 missense 23063622 rs565436 chr1 55524601 G A 1.17E-09 LDL cholesterol PCSK9 intron 23063622 rs565436 chr1 55524601 G A 1.32E-09 Cholesterol,total PCSK9 intron 23063622 rs483462 chr1 55525400 G A 7.99E-04 Substance dependence PCSK9 intron 21818250 rs11206517 chr1 55526428 T G 1.34E-08 LDL cholesterol PCSK9 intron 23063622 rs631220 chr1 55527479 A G 0.000000207 LDL cholesterol PCSK9 intron 23063622 rs643257 chr1 55527918 C T 0.000000359 LDL cholesterol PCSK9 intron 23063622 rs505151 chr1 55529187 G A 9.88E-10 LDL cholesterol PCSK9 missense 22629316 rs505151 chr1 55529187 G A 1.91E-10 LDL cholesterol PCSK9 missense 23236364 rs505151 chr1 55529187 G A 3.09E-09 Cholesterol,total PCSK9 missense 23236364 rs17111568 chr1 55537198 G A 1.74E-04 Multiple complex diseases USP24 intron 17554300 rs17111584 chr1 55546696 T C 5.80E-04 Response to statin therapy (LDL-C) USP24 intron 22331829 rs683880 chr1 55546895 T C 5.67E-04 Substance dependence USP24 intron 21818250 rs17111652 chr1 55590465 C T 9.36E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) USP24 intron 22566498 rs17111657 chr1 55591283 C A 8.89E-04 Suicide attempts in bipolar disorder USP24 intron 21423239 rs17111684 chr1 55625548 C T 2.00E-17 LDL cholesterol USP24 intron 23726366 rs17111689 chr1 55627525 C G 5.07E-04 Suicide attempts in bipolar disorder USP24 intron 21423239 rs1115058 chr1 55653588 C T 8.79E-04 Suicide attempts in bipolar disorder USP24 intron 21423239 rs4926670 chr1 55662680 C T 3.07E-05 LDL lipoproteins USP24 intron pha002902 rs6671533 chr1 55670896 G C 3.94E-04 Suicide attempts in bipolar disorder USP24 intron 21041247 rs6703366 chr1 55673420 T G 6.08E-04 Suicide attempts in bipolar disorder USP24 intron 21041247 rs6668777 chr1 55683807 A C 6.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs7529366 chr1 55685344 A G 6.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs17111725 chr1 55686616 A G 8.95E-05 Serum metabolites / / 19043545 rs17111725 chr1 55686616 A G 5.65E-04 Suicide attempts in bipolar disorder / / 21041247 rs7512894 chr1 55696547 G A 1.97E-04 Suicide attempts in bipolar disorder / / 21041247 rs10788998 chr1 55699023 G A 8.57E-04 Suicide attempts in bipolar disorder / / 21041247 rs11206538 chr1 55715412 C T 1.13E-05 Esophageal cancer (squamous cell) / / 22960999 rs12409228 chr1 55725176 C T 0.0000692 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1018101 chr1 55725288 A G 0.0000641 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs10888908 chr1 55726519 T C 1.42E-14 Metabolite levels / / 22286219 rs6662286 chr1 55730327 T C 1.46E-11 Metabolite levels / / 22286219 rs2088487 chr1 55739925 T C 1.97E-11 Metabolite levels / / 22286219 rs4927214 chr1 55742322 T C 6.59E-04 Type 2 diabetes / / 17463246 rs12239436 chr1 55742837 G A 5.00E-06 Coronary heart disease / / 21347282 rs1874774 chr1 55743297 T G 2.90E-04 Type 2 diabetes / / 17463246 rs12071742 chr1 55747825 G A 6.03E-04 Alzheimer's disease / / 22005930 rs17111834 chr1 55748606 G A 6.07E-04 Alzheimer's disease / / 22005930 rs17111847 chr1 55749478 T C 6.10E-04 Alzheimer's disease / / 22005930 rs10493202 chr1 55764106 A C 2.96E-04 Type 2 diabetes / / 17846124 rs207154 chr1 55781281 T C 1.18E-04 Blood pressure / / 17255346 rs207154 chr1 55781281 T C 1.79E-11 Metabolite levels / / 22286219 rs6676932 chr1 55785672 T C 3.20E-04 Blood pressure / / 17255346 rs17111925 chr1 55789351 G A 2.46E-05 Diabetic nephropathy / / pha002852 rs17111925 chr1 55789351 G A 6.56E-05 Diabetic nephropathy / / pha002864 rs726815 chr1 55790861 C T 3.88E-04 Blood pressure / / 17255346 rs10489488 chr1 55792722 G A 2.90E-04 Blood pressure / / 17255346 rs964219 chr1 55793244 A G 6.78E-05 Blood pressure / / 17255346 rs207167 chr1 55798859 T C 3.63E-12 Metabolite levels / / 22286219 rs207160 chr1 55803411 C T 8.67E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs207155 chr1 55804902 T C 2.40E-05 Blood pressure / / 17255346 rs207155 chr1 55804902 T C 1.28E-10 Metabolite levels / / 22286219 rs207150 chr1 55806465 T C 1.38E-05 Blood pressure / / 17255346 rs207150 chr1 55806465 T C 1.10E-06 LDL lipoproteins / / pha002902 rs207145 chr1 55808143 C T 4.68E-05 Blood pressure / / 17255346 rs207138 chr1 55811215 C T 1.84E-04 Vaspin levels / / 22907691 rs207138 chr1 55811215 C T 0.0001842 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at last visit / / 22907730 rs207136 chr1 55814164 C T 2.06E-05 Blood pressure / / 17255346 rs207136 chr1 55814164 C T 3.39E-04 Type 2 diabetes / / 17463246 rs207135 chr1 55814244 C T 2.06E-05 Blood pressure / / 17255346 rs207135 chr1 55814244 C T 4.76E-04 Type 2 diabetes / / 17463246 rs207129 chr1 55814908 A G 1.48E-10 Metabolite levels / / 22286219 rs207127 chr1 55815584 G A 2.26E-05 Blood pressure / / 17255346 rs207127 chr1 55815584 G A 3.92E-06 LDL lipoproteins / / pha002902 rs880385 chr1 55820099 T G 7.69E-04 Multiple complex diseases / / 17554300 rs2179853 chr1 55820713 A C 1.06E-05 Blood pressure / / 17255346 rs2802881 chr1 55831918 T C 6.60E-06 Blood pressure / / 17255346 rs7520205 chr1 55834309 G A 1.80E-06 Urinary metabolites / / 21572414 rs2746685 chr1 55837603 A G 6.60E-06 Blood pressure / / 17255346 rs3946077 chr1 55838572 G A 2.50E-05 Urinary metabolites / / 21572414 rs2746683 chr1 55841735 A C 3.76E-05 Blood pressure / / 17255346 rs2802877 chr1 55843810 C T 3.76E-05 Blood pressure / / 17255346 rs2802857 chr1 55863658 A G 3.00E-04 Blood pressure / / 17255346 rs761483 chr1 55874284 C T 1.42E-04 Blood pressure / / 17255346 rs6673648 chr1 55894893 C A 7.39E-05 Blood pressure / / 17255346 rs17406602 chr1 55909030 A G 3.84E-04 Sarcoidosis / / 19165924 rs12068336 chr1 55929930 G A 6.51E-05 Multiple complex diseases / / 17554300 rs11206601 chr1 55931747 T C 1.08E-04 Multiple complex diseases / / 17554300 rs874664 chr1 55933344 A G 1.58E-04 Multiple complex diseases / / 17554300 rs12568687 chr1 55934389 C T 1.58E-04 Multiple complex diseases / / 17554300 rs7532502 chr1 55938887 G A 3.22E-04 Multiple complex diseases / / 17554300 rs2649629 chr1 55953290 G A 5.48E-05 Blood pressure / / 17255346 rs1998013 chr1 55958030 C T 5.00E-13 Metabolite levels (atherosclerosis) / / 22916037 rs1780542 chr1 55963519 A G 2.09E-04 Blood pressure / / 17255346 rs1740125 chr1 55965199 C T 3.30E-04 Blood pressure / / 17255346 rs1740123 chr1 55969501 C T 3.25E-04 Blood pressure / / 17255346 rs1740118 chr1 55981250 G A 1.45E-04 Blood pressure / / 17255346 rs1695960 chr1 55983525 G A 3.27E-04 Blood pressure / / 17255346 rs356086 chr1 55994302 A G 2.85E-07 Common variable immunodeficiency / / 21497890 rs2649627 chr1 55998405 C T 4.21E-04 Blood pressure / / 17255346 rs6658576 chr1 56035952 T C 0.00039 Prostate cancer / / 23555315 rs17416739 chr1 56055848 C T 4.17E-08 Multiple complex diseases / / 17554300 rs17416739 chr1 56055848 C T 3.78E-07 Adipocyte fatty acid-binding protein concentration,in serum / / 21863005 rs4926690 chr1 56056400 G A 6.88E-05 Lymphocyte counts / / pha003094 rs4926690 chr1 56056400 G A 8.54E-05 Neutrophil count / / pha003095 rs10888935 chr1 56060951 T A 7.00E-07 Inflammatory biomarkers / / 22228203 rs6704127 chr1 56070382 A C 2.16E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1587432 chr1 56074120 A G 2.42E-04 Acute lung injury / / 22295056 rs1392132 chr1 56079739 T G 1.84E-04 Schizophrenia / / 20832056 rs17418151 chr1 56102010 C G 6.84E-05 Multiple sclerosis / / 17660530 rs1165472 chr1 56108604 A G 4.00E-06 Paclitaxel-induced neuropathy / / 23776197 rs10443215 chr1 56112774 C T 9.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (docetaxel) / / 24025145 rs72669744 chr1 56116505 C T 1.00E-19 Lipid metabolism phenotypes / / 22286219 rs17112596 chr1 56120296 C T 5.02E-20 Metabolite levels / / 22286219 rs9436520 chr1 56137245 A G 8.73E-05 Hemoglobin concentration / / 20534544 rs2767503 chr1 56152725 T G 7.09E-05 Hemoglobin concentration / / 20534544 rs12565309 chr1 56157154 G A 1.82E-04 Alzheimer's disease (late onset) / / 21379329 rs9326037 chr1 56163458 G A 1.63E-04 Alzheimer's disease (late onset) / / 21379329 rs1183736 chr1 56183163 A C 3.76E-04 Hemoglobin concentration / / 20534544 rs11206661 chr1 56191097 C G 7.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs76831627 chr1 56198190 G T 6.66E-05 Acne (severe) / / 24927181 rs1165500 chr1 56219293 A C 3.59E-05 Telomere length / / 23900074 rs12061007 chr1 56233601 A G 7.54E-04 Multiple complex diseases / / 17554300 rs12061007 chr1 56233601 A G 2.84E-05 Lymphocyte counts / / 22286170 rs12092608 chr1 56240702 T C 4.81E-05 Telomere length / / 23900074 rs3122555 chr1 56263555 T C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6588574 chr1 56287724 G T 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6659096 chr1 56292073 C A 4.24E-04 Multiple complex diseases / / 17554300 rs4497258 chr1 56317834 G A 9.72E-05 Bipolar disorder / / 19259986 rs9326038 chr1 56326293 G A 5.56E-06 Serum metabolites / / 19043545 rs6656739 chr1 56351783 T G 4.91E-04 Multiple complex diseases / / 17554300 rs6684428 chr1 56359813 T A 5.00E-07 Airflow obstruction / / 22837378 rs6699599 chr1 56405040 T C 7.31E-04 Smoking quantity LOC100507652 intron 24665060 rs7534660 chr1 56421196 G C 7.00E-04 Multiple complex diseases / / 17554300 rs7512875 chr1 56421399 C T 7.54E-04 Multiple complex diseases / / 17554300 rs6694316 chr1 56425121 G T 1.06E-05 Tuberculosis / / 24057671 rs2192102 chr1 56429031 C A 4.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs12409063 chr1 56432184 G A 4.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) / / 23648065 rs11206704 chr1 56444449 C T 6.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11206709 chr1 56448410 T C 5.86E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11206729 chr1 56516424 T C 1.31E-04 Aortic root size / / 21223598 rs7512228 chr1 56574395 C T 5.67E-04 Aortic root size / / 21223598 rs778126 chr1 56605334 T G 6.54E-04 Aortic root size / / 21223598 rs1537226 chr1 56615004 G T 2.49E-04 Multiple complex diseases / / 17554300 rs2792788 chr1 56740723 T C 9.08E-04 Insulin resistance / / 21901158 rs1581995 chr1 56745004 C T 1.44E-05 Leprosy / / 22019778 rs10888965 chr1 56750081 T C 5.28E-04 Insulin resistance / / 21901158 rs12118755 chr1 56750366 C T 4.62E-05 Cognitive test performance / / 20125193 rs1341347 chr1 56763781 A G 5.81E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs3005884 chr1 56771709 C T 6.41E-04 Eye color / / 23118974 rs3005885 chr1 56776172 T A 6.00E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2994553 chr1 56785889 T G 2.42E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs3005897 chr1 56786595 C T 3.78E-04 Barrett's esophagus / / 24121790 rs12138574 chr1 56790773 C T 9.64E-06 Biliary atresia / / 20460270 rs3005907 chr1 56790785 T A 1.76E-04 Type 2 diabetes / / 17463246 rs3005914 chr1 56797754 T C 7.17E-05 Erythrocyte counts / / pha003101 rs3121168 chr1 56798123 G T 9.62E-05 Erythrocyte counts / / pha003101 rs2994565 chr1 56798308 A G 7.29E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2994565 chr1 56798308 A G 2.25E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cyclophosphamide) / / 23648065 rs6670695 chr1 56799648 T A,C 0.00043318 Sarcoidosis / / 22952805 rs11206793 chr1 56802112 A T 8.66E-04 Depression (quantitative trait) / / 20800221 rs12079898 chr1 56804358 G A 7.34E-05 Depression (quantitative trait) / / 20800221 rs17113792 chr1 56829396 A G 7.88E-04 Depression (quantitative trait) / / 20800221 rs17113795 chr1 56840459 T A 7.85E-04 Depression (quantitative trait) / / 20800221 rs17113799 chr1 56844652 T C 5.47E-04 Depression (quantitative trait) / / 20800221 rs7539724 chr1 56845274 A G 5.42E-04 Depression (quantitative trait) / / 20800221 rs7538333 chr1 56848954 C T 1.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11206801 chr1 56850686 C A 6.00E-08 AB1-42 levels / / 20932310 rs11206802 chr1 56851200 G A 4.72E-04 Depression (quantitative trait) / / 20800221 rs4373790 chr1 56852348 C T 4.53E-04 Depression (quantitative trait) / / 20800221 rs7521622 chr1 56869084 T A 1.48E-04 Spine bone size / / 23207799 rs1931077 chr1 56870735 T C 5.64E-04 Spine bone size / / 23207799 rs3005922 chr1 56873524 G A 5.97E-04 Smoking quantity / / 24665060 rs11206803 chr1 56877509 C T 3.12E-04 Type 2 diabetes / / 17463246 rs884277 chr1 56881763 A G 1.43E-04 Type 2 diabetes / / 17463246 rs4363444 chr1 56898998 C T 2.17E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs875153 chr1 56900270 C T 4.30E-05 Celiac disease / / 17558408 rs7550882 chr1 56903392 C T 8.33E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2780293 chr1 56905072 A G 9.71E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2780293 chr1 56905072 A G 1.61E-10 Tumor biomarkers / / 23300138 rs2780293 chr1 56905072 A G 1.61E-10 Type 2 diabetes / / 23300278 rs6588628 chr1 56905211 A G 4.26E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6421495 chr1 56905445 T A 4.09E-04 Alcohol dependence / / 21314694 rs4319365 chr1 56907720 G A 5.59E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6694114 chr1 56909550 G A 9.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11206814 chr1 56918048 C T 0.0000267 Aging / / 22445811 rs7525717 chr1 56927638 G A 0.00000576 Aging / / 22445811 rs17114036 chr1 56962821 A G 4.00E-19 Coronary heart disease PPAP2B intron 21378990 rs17114036 chr1 56962821 A G 3.81E-19 Pericardial fat PPAP2B intron 22589742 rs17114036 chr1 56962821 A G 0.000266 Coronary artery disease (CAD) (females) PPAP2B intron 23202125 rs17114036 chr1 56962821 A G 0.000823 Coronary artery disease (CAD) age <=50 PPAP2B intron 23202125 rs17114036 chr1 56962821 A G 1.43E-09 Coronary artery disease (CAD) age >50 PPAP2B intron 23202125 rs17114036 chr1 56962821 A G 2.16E-08 Coronary artery disease with myocardial infarction PPAP2B intron 23202125 rs17114036 chr1 56962821 A G 5.80E-12 Coronary artery disease PPAP2B intron 23202125 rs17114036 chr1 56962821 A G 8.07E-08 Coronary artery disease (CAD) (males) PPAP2B intron 23202125 rs17114036 chr1 56962821 A G 1.00E-08 Coronary artery disease PPAP2B intron 24262325 rs17114036 chr1 56962821 A G 2.00E-08 Coronary artery disease or large artery stroke PPAP2B intron 24262325 rs17114036 chr1 56962821 A G 3.00E-08 Coronary artery disease or ischemic stroke PPAP2B intron 24262325 rs17114046 chr1 56966350 A G 2.00E-07 Coronary heart disease PPAP2B intron 21378988 rs17114046 chr1 56966350 A G 3.00E-07 Coronary heart disease PPAP2B intron 21846871 rs17114046 chr1 56966350 A G 4.04E-06 Coronary heart disease PPAP2B intron 22319020 rs4912314 chr1 56968477 C T 2.02E-05 Sickle cell anemia (severity) PPAP2B intron 20029952 rs4912314 chr1 56968477 C T 2.90E-05 Urinary metabolites PPAP2B intron 21572414 rs1361823 chr1 56990399 G A 7.52E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines PPAP2B intron 21844884 rs2404715 chr1 57008778 C T 3.75E-15 Coronary heart disease PPAP2B intron 21378990 rs1041602 chr1 57013198 C T 4.06E-04 Schizophrenia PPAP2B intron 19197363 rs1261411 chr1 57017739 C T 2.10E-05 Urinary metabolites PPAP2B intron 21572414 rs1777275 chr1 57032468 A C 1.10E-05 Lymphocyte counts PPAP2B intron 22286170 rs12038246 chr1 57069614 A T 3.26E-04 Multiple complex diseases / / 17554300 rs12038246 chr1 57069614 A T 5.10E-04 Coronary heart disease / / 21966275 rs2404986 chr1 57084155 T C 7.86E-04 Multiple complex diseases / / 17554300 rs2404987 chr1 57088605 T C 8.61E-05 Blood Pressure / / pha003045 rs2404987 chr1 57088605 T C 6.21E-05 Blood Pressure / / pha003047 rs10888995 chr1 57094025 T A 6.98E-04 Multiple complex diseases / / 17554300 rs10888995 chr1 57094025 T A 2.60E-05 Urinary metabolites / / 21572414 rs10889000 chr1 57100380 G A 9.96E-06 Lymphocyte counts / / 22286170 rs2746349 chr1 57126650 C T 7.80E-06 Urinary metabolites PRKAA2 intron 21572414 rs2746347 chr1 57126919 C T 4.00E-07 Lymphocyte counts PRKAA2 intron 22286170 rs2179761 chr1 57157544 G A 2.20E-05 Urinary metabolites PRKAA2 intron 21572414 rs1342382 chr1 57177388 T A 0.00007 Asthma PRKAA2 UTR-3 18401594 rs1342382 chr1 57177388 T A 2.10E-05 Urinary metabolites PRKAA2 UTR-3 21572414 rs6656021 chr1 57202872 A T 4.48E-04 Multiple complex diseases C1orf168 intron 17554300 rs6658790 chr1 57203011 T C 3.20E-04 Multiple complex diseases C1orf168 intron 17554300 rs12137718 chr1 57203226 A G 1.70E-05 Urinary metabolites C1orf168 intron 21572414 rs1156845 chr1 57209695 T C 1.99E-04 Schizophrenia C1orf168 intron 21674006 rs11206912 chr1 57211204 C G 1.70E-04 Multiple complex diseases C1orf168 intron 17554300 rs7555378 chr1 57218159 G A 6.55E-04 Multiple complex diseases C1orf168 intron 17554300 rs857107 chr1 57222599 T C 2.74E-05 Lymphocyte counts C1orf168 intron 22286170 rs17372114 chr1 57243454 T C 1.20E-05 Urinary metabolites C1orf168 intron 21572414 rs17372114 chr1 57243454 T C 5.00E-07 Resistin levels C1orf168 intron 22843503 rs1738403 chr1 57246559 G A 3.79E-04 Multiple complex diseases C1orf168 intron 17554300 rs1774825 chr1 57249558 A C 1.99E-05 Response to cholinesterase inhibitors in Alzheimer's disease C1orf168 intron 23374588 rs10889017 chr1 57259632 C G 2.70E-05 Urinary metabolites C1orf168 intron 21572414 rs6662617 chr1 57269521 A G 9.00E-06 Obesity-related traits C1orf168 intron 23251661 rs10489622 chr1 57275653 T C 8.18E-04 Alzheimer's disease C1orf168 intron 17998437 rs10489622 chr1 57275653 T C 2.45E-04 Alzheimer's disease C1orf168 intron pha002879 rs12048846 chr1 57291520 A G 4.49E-04 Type 2 diabetes / / 17463246 rs10489623 chr1 57317559 A G 7.14E-05 Major depressive disorder (broad) / / 20038947 rs1329449 chr1 57319629 G A 8.14E-05 Major depressive disorder (broad) C8A nearGene-5 20038947 rs6697767 chr1 57326073 A G 3.88E-11 LDL cholesterol C8A intron 23063622 rs7339932 chr1 57333483 G T 0.000000109 LDL cholesterol C8A intron 23063622 rs2269119 chr1 57336775 G C 9.78E-05 Major depressive disorder (broad) C8A intron 20038947 rs1885002 chr1 57340381 A G 1.71E-05 Major depressive disorder (broad) C8A intron 20038947 rs6588657 chr1 57348436 C T 5.32E-05 Lymphocyte counts C8A intron 22286170 rs6694643 chr1 57349407 A T 6.23E-05 Major depressive disorder (broad) C8A intron 20038947 rs6697228 chr1 57349464 T C 9.14E-05 Major depressive disorder (broad) C8A intron 20038947 rs6683663 chr1 57356476 A G 5.69E-05 Major depressive disorder (broad) C8A intron 20038947 rs11206932 chr1 57362007 T A 6.27E-05 Major depressive disorder (broad) C8A intron 20038947 rs3768215 chr1 57362787 C T 6.89E-05 Major depressive disorder (broad) C8A intron 20038947 rs6697608 chr1 57363037 G A 1.02E-15 LDL cholesterol C8A intron 23063622 rs17114548 chr1 57367041 T A 2.26E-04 Insulin resistance C8A intron 21901158 rs17114555 chr1 57373778 G A 0.00000179 LDL cholesterol C8A missense 23063622 rs17373091 chr1 57391310 C T 1.50E-05 Urinary metabolites / / 21572414 rs17301090 chr1 57391429 G C 1.50E-05 Urinary metabolites / / 21572414 rs605648 chr1 57395251 T C 8.94E-04 Alcohol dependence C8B intron 24277619 rs2025006 chr1 57396276 C T 2.10E-05 Urinary metabolites C8B intron 21572414 rs9661996 chr1 57401110 C A 4.16E-04 Alzheimer's disease (late onset) C8B intron 21379329 rs1013579 chr1 57422484 C T 5.15E-05 Glycosylated haemoglobin levels C8B missense 17255346 rs856843 chr1 57427251 C A 9.96E-04 Alcohol dependence C8B intron 21314694 rs1774909 chr1 57447740 T C 9.61E-04 Coronary Artery Disease / / 17634449 rs1774908 chr1 57447820 T C 4.50E-04 Coronary Artery Disease / / 17634449 rs11206948 chr1 57450486 T C 2.06E-22 Narcolepsy / / 19629137 rs11206955 chr1 57467935 A G 5.79E-05 Alzheimer's disease DAB1 intron 17998437 rs11206955 chr1 57467935 A G 2.19E-04 Alzheimer's disease DAB1 intron pha002879 rs12035887 chr1 57468791 G T 8.06E-05 Alzheimer's disease DAB1 intron 17998437 rs697580 chr1 57477034 G C 3.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs1854508 chr1 57478856 A G 8.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs11810899 chr1 57481284 T C 7.02E-04 Alzheimer's disease DAB1 intron 17998437 rs11810899 chr1 57481284 T C 3.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs11810899 chr1 57481284 T C 2.01E-04 Alzheimer's disease DAB1 intron pha002879 rs6668269 chr1 57481828 T C 6.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs17114816 chr1 57481883 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs3754268 chr1 57484663 A G 3.75E-04 Alzheimer's disease DAB1 intron 17998437 rs3754268 chr1 57484663 A G 1.70E-05 Urinary metabolites DAB1 intron 21572414 rs706360 chr1 57490074 C T 1.30E-05 Urinary metabolites DAB1 intron 21572414 rs706361 chr1 57490333 T C 3.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs3768206 chr1 57498094 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs4912233 chr1 57498643 C T 7.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs12118564 chr1 57500176 G C 6.00E-04 Acute lymphoblastic leukemia (childhood) DAB1 intron 20189245 rs11206964 chr1 57524101 T C 9.79E-04 Multiple complex diseases DAB1 intron 17554300 rs476744 chr1 57535630 G A 1.36E-05 Epilepsy (remission after treatment) DAB1 intron 23962720 rs534080 chr1 57584721 G A 4.33E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DAB1 intron 20877124 rs17541203 chr1 57625932 T C 2.00E-06 Pubertal anthropometrics DAB1 intron 23449627 rs4124453 chr1 57633048 C G 0.0008539 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DAB1 intron 23233654 rs4124453 chr1 57633048 C G 8.54E-04 Methotrexate clearance (acute lymphoblastic leukemia) DAB1 intron 23233662 rs7533282 chr1 57633496 T G 4.19E-05 Cognitive performance DAB1 intron 19734545 rs7533282 chr1 57633496 T G 0.0008524 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DAB1 intron 23233654 rs7533282 chr1 57633496 T G 8.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) DAB1 intron 23233662 rs17115233 chr1 57636071 G A 0.0008644 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DAB1 intron 23233654 rs17115233 chr1 57636071 G A 8.64E-04 Methotrexate clearance (acute lymphoblastic leukemia) DAB1 intron 23233662 rs6680429 chr1 57637497 G A 6.60E-09 Vitamin D concentrations DAB1 intron 20600896 rs6680429 chr1 57637497 G A 6.60E-09 Vitamin D concentrations DAB1 intron 20600896 rs17115240 chr1 57640066 T C 0.000584 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) DAB1 intron 23233654 rs17115240 chr1 57640066 T C 5.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) DAB1 intron 23233662 rs17541479 chr1 57640721 C T 2.06E-04 Hearing function DAB1 intron 17255346 rs11810300 chr1 57654660 C T 9.01E-06 PR interval in Tripanosoma cruzi seropositivity DAB1 intron 24324551 rs1394397 chr1 57656611 A G 3.00E-06 PR interval in Tripanosoma cruzi seropositivity DAB1 intron 24324551 rs480836 chr1 57662361 G A 2.00E-04 Cognitive impairment induced by topiramate DAB1 intron 22091778 rs17115341 chr1 57665932 C T 7.39E-04 Alcohol dependence DAB1 intron 21314694 rs197597 chr1 57683417 C T 3.00E-04 Cognitive impairment induced by topiramate DAB1 intron 22091778 rs1504584 chr1 57690336 T C 4.00E-04 Multiple complex diseases DAB1 intron 17554300 rs1504584 chr1 57690336 T C 7.52E-04 Response to cytadine analogues (cytosine arabinoside) DAB1 intron 24483146 rs1604885 chr1 57690668 C A 1.36E-04 Multiple complex diseases DAB1 intron 17554300 rs1604885 chr1 57690668 C A 7.52E-04 Response to cytadine analogues (cytosine arabinoside) DAB1 intron 24483146 rs12130571 chr1 57698001 C A 8.78E-04 Alcohol dependence DAB1 intron 21314694 rs2764664 chr1 57741163 T C 1.56E-04 Taste perception DAB1 intron 22132133 rs12057381 chr1 57769516 G A 8.44E-06 Prostate cancer DAB1 intron 24185611 rs736109 chr1 57783651 C T 3.93E-06 Non-small cell lung cancer DAB1 intron 21866343 rs12401342 chr1 57793948 C A 4.32E-04 Response to cytadine analogues (cytosine arabinoside) DAB1 intron 24483146 rs90940 chr1 57795436 T C 1.30E-06 Non-small cell lung cancer DAB1 intron 21866343 rs267650 chr1 57795780 T C 4.94E-07 Non-small cell lung cancer DAB1 intron 21866343 rs6587767 chr1 57800285 C T 8.24E-06 Non-small cell lung cancer DAB1 intron 21866343 rs12061812 chr1 57802603 C A 7.19E-07 Non-small cell lung cancer DAB1 intron 21866343 rs12087888 chr1 57802759 T C 4.61E-07 Non-small cell lung cancer DAB1 intron 21866343 rs12087888 chr1 57802759 T C 1.64E-05 Blood Pressure DAB1 intron pha003039 rs12087888 chr1 57802759 T C 1.14E-05 Blood Pressure DAB1 intron pha003045 rs12087888 chr1 57802759 T C 6.72E-05 Blood Pressure DAB1 intron pha003047 rs11207010 chr1 57802886 G C 3.54E-07 Non-small cell lung cancer DAB1 intron 21866343 rs11207011 chr1 57803349 G A 1.57E-05 Blood Pressure DAB1 intron pha003039 rs11207011 chr1 57803349 G A 1.11E-05 Blood Pressure DAB1 intron pha003045 rs11207011 chr1 57803349 G A 6.50E-05 Blood Pressure DAB1 intron pha003047 rs10159302 chr1 57805550 A C 9.00E-06 HIV-1 control DAB1 intron 20041166 rs1077424 chr1 57810304 G C 6.50E-07 Non-small cell lung cancer DAB1 intron 21866343 rs6687842 chr1 57815932 C A 2.66E-05 Non-small cell lung cancer DAB1 intron 21866343 rs11207016 chr1 57816224 C A 5.88E-06 Non-small cell lung cancer DAB1 intron 21866343 rs1424467 chr1 57816489 G A 9.47E-06 Non-small cell lung cancer DAB1 intron 21866343 rs1862925 chr1 57822311 C T 1.01E-05 Non-small cell lung cancer DAB1 intron 21866343 rs10889038 chr1 57826766 T C 8.18E-06 Non-small cell lung cancer DAB1 intron 21866343 rs10889038 chr1 57826766 T C 6.60E-05 Blood Pressure DAB1 intron pha003039 rs10889039 chr1 57828545 C T 1.65E-05 Non-small cell lung cancer DAB1 intron 21866343 rs2216808 chr1 57837089 G A 1.90E-06 Non-small cell lung cancer DAB1 intron 21866343 rs10047073 chr1 57841631 G C 1.90E-06 Non-small cell lung cancer DAB1 intron 21866343 rs10047071 chr1 57841662 C T 3.66E-05 Blood Pressure DAB1 intron pha003039 rs2405697 chr1 57843007 G A 1.76E-05 Non-small cell lung cancer DAB1 intron 21866343 rs3909556 chr1 57846985 C T 6.55E-07 Non-small cell lung cancer DAB1 intron 21866343 rs3738552 chr1 57852513 C A,G,T 1.11E-04 Multiple complex diseases DAB1 intron 17554300 rs3861834 chr1 57854103 G A 2.83E-05 Non-small cell lung cancer DAB1 intron 21866343 rs17115722 chr1 57855219 T C 4.04E-04 Multiple complex diseases DAB1 intron 17554300 rs507466 chr1 57855425 A G 5.14E-04 Multiple complex diseases DAB1 intron 17554300 rs532926 chr1 57855876 T C 7.66E-05 Serum metabolites DAB1 intron 19043545 rs566847 chr1 57857310 T G 9.02E-04 Multiple complex diseases DAB1 intron 17554300 rs566847 chr1 57857310 T G 6.66E-05 Serum metabolites DAB1 intron 19043545 rs567773 chr1 57857390 C A 2.23E-05 Non-small cell lung cancer DAB1 intron 21866343 rs540431 chr1 57859521 G A 1.25E-05 Non-small cell lung cancer DAB1 intron 21866343 rs11207026 chr1 57860215 A T 9.61E-05 Serum metabolites DAB1 intron 19043545 rs17425189 chr1 57862949 T C 5.99E-07 Non-small cell lung cancer DAB1 intron 21866343 rs2405994 chr1 57871016 G A 8.95E-06 Non-small cell lung cancer DAB1 intron 21866343 rs11585751 chr1 57872987 G A 9.67E-06 Non-small cell lung cancer DAB1 intron 21866343 rs269042 chr1 57874048 T A 2.27E-05 Non-small cell lung cancer DAB1 intron 21866343 rs17115765 chr1 57874866 C T 2.00E-04 Cognitive impairment induced by topiramate DAB1 intron 22091778 rs269060 chr1 57881463 T C 0.0000865 Salmonella-induced pyroptosis DAB1 intron 22837397 rs11207036 chr1 57904853 A G 4.12E-04 Rheumatoid arthritis DAB1 intron 21452313 rs12045017 chr1 57914548 C G 6.92E-04 Response to statin treatment (atorvastatin),change in cholesterol levels DAB1 intron 20031582 rs17426429 chr1 57920416 G A 9.11E-05 Bipolar disorder and schizophrenia DAB1 intron 20889312 rs17115807 chr1 57921505 T C 1.76E-04 Height DAB1 intron 17255346 rs10493223 chr1 57934034 C T 3.03E-04 Lung function (forced vital capacity) DAB1 intron 24023788 rs10493223 chr1 57934034 C T 5.92E-05 Eosinophil counts DAB1 intron pha003088 rs2691462 chr1 57954416 C T 3.42E-04 Response to taxane treatment (placlitaxel) DAB1 intron 23006423 rs1341320 chr1 57966528 G A 7.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DAB1 intron 20877124 rs1341320 chr1 57966528 G A 5.00E-06 Plasma amyloid beta peptide concentrations (ABx-40) DAB1 intron 24535457 rs1524715 chr1 58003409 A T 6.15E-04 Coronary Artery Disease DAB1 intron 17634449 rs11207058 chr1 58003804 C A 6.73E-04 Coronary Artery Disease DAB1 intron 17634449 rs1524716 chr1 58005178 A C 2.82E-04 Coronary Artery Disease DAB1 intron 17634449 rs1880443 chr1 58015312 G A 9.88E-04 Coronary Artery Disease DAB1 intron 17634449 rs12083422 chr1 58049270 C T 1.97E-21 Multiple complex diseases DAB1 intron 17554300 rs1572945 chr1 58069523 C T 7.85E-06 Blood pressure DAB1 intron 17255346 rs1935046 chr1 58075285 C T 1.39E-05 Blood pressure DAB1 intron 17255346 rs10493231 chr1 58075542 C A 1.77E-04 Blood pressure DAB1 intron 17255346 rs1524721 chr1 58079584 G A 4.56E-05 Blood pressure DAB1 intron 17255346 rs1341316 chr1 58087789 A G 8.24E-05 Type 2 diabetes and other traits DAB1 intron 19734900 rs17116134 chr1 58093163 C T 3.40E-04 Multiple complex diseases DAB1 intron 17554300 rs1539053 chr1 58099707 A G 7.09E-06 Type 2 diabetes and other traits DAB1 intron 19734900 rs1539053 chr1 58099707 A G 7.10E-06 Alzheimer's disease (late onset) DAB1 intron 21460841 rs7522826 chr1 58126517 T C 8.33E-05 Response to mTOR inhibitor (rapamycin) DAB1 intron 24009623 rs3131729 chr1 58198767 C T 9.87E-06 Kawasaki disease DAB1 intron 21221998 rs10493232 chr1 58229635 C G 7.30E-04 Type 2 diabetes DAB1 intron 17463246 rs1886140 chr1 58231158 A G 0.0000065 Asthma (exacerbation) DAB1 intron 23706709 rs2406282 chr1 58232329 T G 7.58E-04 Type 2 diabetes DAB1 intron 17463246 rs1323827 chr1 58232720 A G 8.72E-04 Type 2 diabetes DAB1 intron 17463246 rs1408141 chr1 58245641 A C 6.24E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs1924268 chr1 58249119 A C 3.61E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs1581762 chr1 58251060 A G 5.86E-05 Intelligence DAB1 intron 21826061 rs1581763 chr1 58251248 T C 3.59E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs1323835 chr1 58253042 G A 3.58E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs12565523 chr1 58256148 T G 4.04E-06 Alcohol dependence (age at onset) DAB1 intron 24962325 rs12568292 chr1 58256191 C A 4.04E-06 Alcohol dependence (age at onset) DAB1 intron 24962325 rs1408146 chr1 58256479 T C 6.61E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs35738462 chr1 58256544 T C 2.00E-06 Alcohol dependence (age at onset) DAB1 intron 24962325 rs1323836 chr1 58256909 T G 6.59E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs1323838 chr1 58257250 T C 2.41E-06 Alcohol dependence (age at onset) DAB1 intron 24962325 rs7554147 chr1 58257587 T C 2.41E-06 Alcohol dependence (age at onset) DAB1 intron 24962325 rs1886143 chr1 58258134 G T 6.57E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs7544843 chr1 58263767 G A 3.53E-06 Alcohol dependence (age at onset) DAB1 intron 24962325 rs2406284 chr1 58269042 T C 6.96E-04 Suicide attempts in bipolar disorder DAB1 intron 21423239 rs706412 chr1 58317833 A G 4.41E-04 Parkinson's disease DAB1 intron 17052657 rs706412 chr1 58317833 A G 1.26E-04 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs985795 chr1 58319828 T G 2.00E-06 Bulimia nervosa DAB1 intron 23568457 rs852801 chr1 58321909 G A 4.00E-06 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs852802 chr1 58323943 T C 4.00E-06 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs852806 chr1 58324779 A G 6.48E-04 Parkinson's disease DAB1 intron 17052657 rs852806 chr1 58324779 A G 1.01E-04 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs764742 chr1 58326194 G A 6.95E-05 Obesity (extreme) DAB1 intron 21935397 rs852807 chr1 58329157 A G 9.39E-04 Parkinson's disease DAB1 intron 17052657 rs852807 chr1 58329157 A G 2.77E-04 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs2038379 chr1 58336058 C T 1.06E-04 Mammographic density DAB1 intron 22532574 rs722187 chr1 58339643 C T 5.35E-04 Parkinson's disease DAB1 intron 17052657 rs722187 chr1 58339643 C T 1.50E-04 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs1202824 chr1 58349005 T C 1.50E-05 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs1202834 chr1 58360111 T C 4.82E-04 Multiple complex diseases DAB1 intron 17554300 rs1022636 chr1 58360565 C G 1.50E-04 Multiple complex diseases DAB1 intron 17554300 rs1202835 chr1 58362123 C T 3.04E-04 Multiple complex diseases DAB1 intron 17554300 rs1202837 chr1 58365396 G A 4.83E-04 Multiple complex diseases DAB1 intron 17554300 rs6679454 chr1 58367236 A G 3.00E-07 Immune reponse to smallpox (secreted IL-10) DAB1 intron 22610502 rs1202849 chr1 58370098 T C 4.48E-04 Amyotrophic Lateral Sclerosis DAB1 intron 17362836 rs12118826 chr1 58373450 G A 2.49E-06 Mammographic density DAB1 intron 22532574 rs1884487 chr1 58375966 T C 7.78E-04 Smoking quantity DAB1 intron 24665060 rs12125894 chr1 58376445 T C 3.26E-06 Mammographic density DAB1 intron 22532574 rs4412616 chr1 58422760 A C 7.39E-05 Serum metabolites DAB1 intron 19043545 rs1343635 chr1 58431135 T C 8.66E-04 Schizophrenia DAB1 intron 19197363 rs1343635 chr1 58431135 T C 6.49E-05 Cognitive performance DAB1 intron 19734545 rs1343635 chr1 58431135 T C 7.70E-04 Response to taxane treatment (placlitaxel) DAB1 intron 23006423 rs1187981 chr1 58441667 T C 5.05E-05 Cognitive performance DAB1 intron 19734545 rs1187984 chr1 58443065 T A,G 1.73E-05 Multiple complex diseases DAB1 intron 17554300 rs4912290 chr1 58452314 G A 5.77E-05 Antineutrophil cytoplasmic antibody-associated vasculitis DAB1 intron 22808956 rs1187995 chr1 58454436 C G 4.13E-05 Multiple complex diseases DAB1 intron 17554300 rs17434789 chr1 58457604 T C 1.72E-04 Multiple complex diseases DAB1 intron 17554300 rs17131774 chr1 58514090 A G 6.98E-05 Major depressive disorder DAB1 intron 21621269 rs2764675 chr1 58522420 T G 2.66E-05 Bipolar disorder and schizophrenia DAB1 intron 20889312 rs17116805 chr1 58531206 C T 1.32E-04 Multiple complex diseases DAB1 intron 17554300 rs17116836 chr1 58537102 G A 1.00E-04 Prostate cancer DAB1 intron 21743057 rs3121907 chr1 58540836 T C 9.13E-04 Type 2 diabetes DAB1 intron 17463246 rs873989 chr1 58556598 T C 1.30E-04 Neuroticism DAB1 intron 17667963 rs1776184 chr1 58563007 C T 7.15E-04 Multiple complex diseases DAB1 intron 17554300 rs1213770 chr1 58571279 T C 3.12E-05 QT interval DAB1 intron 22726844 rs1342876 chr1 58578612 T C 6.56E-04 Multiple complex diseases DAB1 intron 17554300 rs558475 chr1 58601866 C A 2.28E-04 Glycosylated haemoglobin levels DAB1 intron 17255346 rs6667829 chr1 58610928 T G 2.60E-05 Urinary metabolites DAB1 intron 21572414 rs637081 chr1 58631192 G A 0.00044547 Sarcoidosis DAB1 intron 22952805 rs3905539 chr1 58651750 C T 5.33E-04 Multiple complex diseases DAB1 intron 17554300 rs1953811 chr1 58654363 C T 7.41E-04 Multiple complex diseases DAB1 intron 17554300 rs507981 chr1 58656147 T G 8.49E-05 Body Fat Distribution DAB1 intron pha003016 rs507981 chr1 58656147 T G 2.43E-05 Body Fat Distribution DAB1 intron pha003017 rs507981 chr1 58656147 T G 1.46E-05 Body Fat Distribution DAB1 intron pha003018 rs17117101 chr1 58671217 G T 2.60E-04 Multiple complex diseases DAB1 intron 17554300 rs1832489 chr1 58673515 G C 2.32E-04 Multiple complex diseases DAB1 intron 17554300 rs10889086 chr1 58673708 T C 4.14E-05 Body Fat Distribution DAB1 intron pha003017 rs10889086 chr1 58673708 T C 2.53E-05 Body Fat Distribution DAB1 intron pha003018 rs946311 chr1 58676997 G A 2.30E-05 Body Fat Distribution DAB1 intron pha003017 rs946311 chr1 58676997 G A 2.08E-05 Body Fat Distribution DAB1 intron pha003018 rs2185166 chr1 58684088 T C 2.85E-05 Body Fat Distribution DAB1 intron pha003017 rs2185166 chr1 58684088 T C 2.38E-05 Body Fat Distribution DAB1 intron pha003018 rs17117148 chr1 58693743 G C 1.05E-06 Retinopathy in non-diabetics DAB1 intron 23393555 rs574802 chr1 58730127 T C 8.11E-04 HIV-1 viral setpoint / / 17641165 rs17117233 chr1 58743154 C T 1.70E-06 Thyroid function / / 20826269 rs6668411 chr1 58746316 T C 1.42E-04 Multiple complex diseases / / 17554300 rs11576201 chr1 58756648 G A 9.00E-07 Thyroid function / / 20826269 rs527409 chr1 58757915 T C 1.00E-06 Kawasaki disease / / 21221998 rs10493251 chr1 58764081 C T 5.80E-07 Thyroid function / / 20826269 rs1924565 chr1 58779442 T G 3.55E-04 Alzheimer's disease / / 24755620 rs10493240 chr1 58784150 G T 5.62E-04 Alzheimer's disease / / 24755620 rs1213640 chr1 58794017 A C 8.20E-04 Alzheimer's disease / / 24755620 rs3861824 chr1 58807217 G A 6.29E-05 HIV(mother-to-child transmission) / / 20487506 rs6587811 chr1 58826916 G A 7.35E-04 Multiple complex diseases / / 17554300 rs4912335 chr1 58834962 C T 9.38E-04 Multiple complex diseases / / 17554300 rs6699998 chr1 58845645 G A 9.50E-04 Multiple complex diseases / / 17554300 rs17496683 chr1 58848671 G A 2.76E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs849492 chr1 58857598 C A 9.44E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs338934 chr1 58857666 A G 7.20E-04 Tourette syndrome / / 22889924 rs338934 chr1 58857666 A G 3.32E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) / / 23648065 rs849481 chr1 58866940 G A 2.29E-04 Multiple complex diseases / / 17554300 rs3850540 chr1 58872823 G C 6.27E-04 Multiple complex diseases / / 17554300 rs849469 chr1 58894050 T C 3.30E-06 Urinary metabolites / / 21572414 rs706430 chr1 58903338 A G 8.02E-06 Cardiovascular disease / / 18179892 rs12086988 chr1 58903733 C G 6.17E-07 Lymphocyte counts / / 22286170 rs706457 chr1 58920920 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1000476 chr1 58921516 T C 7.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs12407003 chr1 58939634 G A 8.46E-05 Height / / pha003011 rs338228 chr1 58943030 G C 1.36E-04 Multiple complex diseases / / 17554300 rs2271004 chr1 58996203 T C 5.74E-04 Lymphocyte counts OMA1 intron 22286170 rs12139475 chr1 59005187 G A 4.01E-04 Multiple complex diseases OMA1 intron 17554300 rs638065 chr1 59036625 C T 8.00E-06 Word reading / / 23738518 rs6683669 chr1 59041092 G A 2.90E-05 Rheumatoid arthritis (ACPA-negative) TACSTD2 nearGene-3 24532677 rs201254365 chr1 59042425 C A 0.000000163 Prostate-specific antigen TACSTD2 missense 23555315 rs17117889 chr1 59055724 A G 2.78E-04 Depression (quantitative trait) / / 20800221 rs11579447 chr1 59100106 T G 6.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs232907 chr1 59102834 C A 2.64E-04 Suicide attempts in bipolar disorder / / 21423239 rs232905 chr1 59104500 G A 3.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs232904 chr1 59105260 C T 6.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs232902 chr1 59106153 A G 4.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs232899 chr1 59107652 G A 2.23E-04 Depression (quantitative trait) / / 20800221 rs232895 chr1 59108799 C T 2.47E-04 Depression (quantitative trait) / / 20800221 rs232894 chr1 59109001 T C 2.56E-04 Depression (quantitative trait) / / 20800221 rs232892 chr1 59110018 C T 2.56E-04 Depression (quantitative trait) / / 20800221 rs7527235 chr1 59110167 A C 9.57E-04 Multiple complex diseases / / 17554300 rs232891 chr1 59110502 C T 4.41E-04 Depression (quantitative trait) / / 20800221 rs232885 chr1 59112057 C A 8.53E-04 Multiple complex diseases / / 17554300 rs232885 chr1 59112057 C A 5.70E-04 Lipid traits / / 17903299 rs232885 chr1 59112057 C A 2.58E-04 Depression (quantitative trait) / / 20800221 rs232882 chr1 59113033 G A 2.60E-04 Depression (quantitative trait) / / 20800221 rs17117956 chr1 59114347 T C,G 2.58E-04 Depression (quantitative trait) / / 20800221 rs232877 chr1 59115293 A T 3.00E-04 Suicide attempts in bipolar disorder / / 21423239 rs232876 chr1 59115781 C T 2.52E-04 Depression (quantitative trait) / / 20800221 rs232874 chr1 59118656 T G 2.50E-04 Depression (quantitative trait) / / 20800221 rs232871 chr1 59119072 A G 2.50E-04 Depression (quantitative trait) / / 20800221 rs232867 chr1 59119180 A T 3.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs232863 chr1 59119701 C A 3.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs232862 chr1 59119881 T C 1.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs232860 chr1 59120563 A G 2.93E-04 Depression (quantitative trait) MYSM1 UTR-3 20800221 rs232857 chr1 59120650 C T 3.97E-04 Suicide attempts in bipolar disorder MYSM1 UTR-3 21423239 rs232777 chr1 59125683 C T 2.80E-04 Depression (quantitative trait) MYSM1 missense 20800221 rs232778 chr1 59126616 A G 1.97E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs232779 chr1 59126676 A C 5.01E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs232780 chr1 59127207 T C 2.80E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs6587835 chr1 59127936 G A 2.80E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs10430103 chr1 59128193 A C 8.66E-04 Multiple complex diseases MYSM1 intron 17554300 rs232782 chr1 59128237 G A 2.80E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs232783 chr1 59129516 G T 5.18E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs232784 chr1 59129644 A C 9.18E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs232786 chr1 59130229 A C 2.83E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs232787 chr1 59130407 C T 2.83E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs232788 chr1 59130614 C T 5.14E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs232790 chr1 59131311 G T 5.13E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs232794 chr1 59133024 T G 2.82E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs232795 chr1 59133268 A G 2.82E-04 Depression (quantitative trait) MYSM1 intron 20800221 rs675871 chr1 59136875 C T 5.05E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs513436 chr1 59137273 C T 5.46E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs542750 chr1 59138172 C T 5.46E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs17118097 chr1 59141365 G A 1.44E-04 Multiple complex diseases MYSM1 intron 17554300 rs4912369 chr1 59145958 C A 6.72E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs4912372 chr1 59146221 A G 5.98E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs2746083 chr1 59161678 C A 5.19E-04 Suicide attempts in bipolar disorder MYSM1 intron 21423239 rs2811893 chr1 59162148 T C 3.00E-07 Diabetic retinopathy MYSM1 intron 21310492 rs2811893 chr1 59162148 T C 2.50E-05 Urinary metabolites MYSM1 intron 21572414 rs6677560 chr1 59162793 A G 1.50E-05 Urinary metabolites MYSM1 intron 21572414 rs11207296 chr1 59165042 A C 5.67E-04 Multiple complex diseases MYSM1 intron 17554300 rs4912202 chr1 59174026 G A 2.96E-04 Depression (quantitative trait) / / 20800221 rs11582157 chr1 59177924 A G 6.17E-05 Suicide attempts in bipolar disorder / / 21423239 rs17264915 chr1 59180394 C A 4.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs2811856 chr1 59184738 T C 1.00E-04 Prostate cancer / / 21743057 rs11583201 chr1 59186777 G A 6.04E-04 Depression (quantitative trait) / / 20800221 rs12747063 chr1 59190140 C A 7.22E-04 Depression (quantitative trait) / / 20800221 rs12405774 chr1 59191545 G A 8.91E-04 Depression (quantitative trait) / / 20800221 rs7524931 chr1 59197556 G C 8.86E-04 Depression (quantitative trait) / / 20800221 rs1323281 chr1 59201820 A T 8.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs2760480 chr1 59203121 T C 4.48E-04 Suicide attempts in bipolar disorder / / 21423239 rs2760482 chr1 59204825 T C 7.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs1969772 chr1 59205102 G A 1.53E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12137541 chr1 59209416 G A 1.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs6677589 chr1 59230033 G A 1.90E-04 Lipid traits / / 17903299 rs17356414 chr1 59319508 C T 1.70E-05 Type 2 diabetes LOC100131060 intron 17463248 rs4601609 chr1 59325626 T C 5.00E-06 Cognitive performance LOC100131060 intron 19734545 rs6676059 chr1 59329756 G A 1.70E-05 Type 2 diabetes LOC100131060 intron 17463248 rs12133457 chr1 59330763 G A 1.70E-05 Type 2 diabetes LOC100131060 intron 17463248 rs17118349 chr1 59351143 C T 8.07E-04 Alcohol dependence LOC100131060 intron 20201924 rs927743 chr1 59368947 G T 1.00E-04 Schizophrenia / / 19197363 rs6699576 chr1 59422826 G T 1.19E-04 Multiple complex diseases / / 17554300 rs3949912 chr1 59423103 G A 9.17E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs7543260 chr1 59435688 T C 2.35E-05 Response to mTOR inhibitor (everolimus) / / 24009623 rs7543260 chr1 59435688 T C 9.78E-05 Response to mTOR inhibitor (rapamycin) / / 24009623 rs7537319 chr1 59443050 G A 4.03E-04 Taste perception / / 22132133 rs2985883 chr1 59464838 G A 9.89E-05 Type 2 diabetes / / 17463246 rs2716139 chr1 59471986 A C 1.57E-04 Type 2 diabetes / / 17463246 rs12031587 chr1 59472053 C T 2.66E-04 Type 2 diabetes / / 17463246 rs2716140 chr1 59472397 A C 1.37E-04 Type 2 diabetes / / 17463246 rs2716121 chr1 59474554 C T 1.63E-04 Type 2 diabetes / / 17463246 rs17464532 chr1 59483091 G C 8.17E-04 Multiple complex diseases / / 17554300 rs2716133 chr1 59483255 T A 1.28E-04 Type 2 diabetes / / 17463246 rs12030196 chr1 59483320 A C 1.98E-04 Type 2 diabetes / / 17463246 rs17118549 chr1 59484327 C T 1.40E-05 Amyotrophic lateral sclerosis / / 17671248 rs2764924 chr1 59484502 G A 9.95E-05 Type 2 diabetes / / 17463246 rs11207369 chr1 59485091 G T 2.28E-04 Type 2 diabetes / / 17463246 rs2764922 chr1 59485277 G A 1.26E-04 Type 2 diabetes / / 17463246 rs3010334 chr1 59485823 C T 1.58E-04 Type 2 diabetes / / 17463246 rs12748496 chr1 59486551 G A 2.23E-04 Type 2 diabetes / / 17463246 rs9436591 chr1 59489803 A G 2.57E-05 Fibrinogen / / 17255346 rs6587843 chr1 59540811 C T 3.21E-05 Fibrinogen / / 17255346 rs4424536 chr1 59544435 G A 1.80E-05 Fibrinogen / / 17255346 rs2989868 chr1 59553662 G A 3.72E-05 Fibrinogen / / 17255346 rs3010322 chr1 59567199 G A 5.61E-05 Prion diseases / / 22210626 rs1114505 chr1 59572316 T C 6.75E-04 Depression (quantitative trait) / / 20800221 rs6704170 chr1 59582235 G A 8.69E-05 Height / / pha003011 rs3861829 chr1 59590817 G A 2.29E-05 Cognitive test performance / / 20125193 rs11207409 chr1 59606640 G A 7.30E-04 Type 2 diabetes HSD52 intron 17463246 rs17118876 chr1 59616910 C G 0.0000149 Polycystic ovary syndrome / / 22951595 rs17118876 chr1 59616910 C G 1.49E-05 Intracranial aneurysm / / 22961961 rs474103 chr1 59619571 T G 6.42E-05 Response to hepatitis C treatment / / 19684573 rs331645 chr1 59637387 G A 3.06E-05 Response to hepatitis C treatment / / 19684573 rs17119055 chr1 59658543 G A 1.78E-04 Bipolar disorder / / 18317468 rs17119087 chr1 59669115 T C 2.47E-04 Bipolar disorder / / 18317468 rs331633 chr1 59680579 A G 2.94E-04 Insulin resistance / / 21901158 rs12402265 chr1 59690602 G A 6.67E-04 Heart Failure / / pha002884 rs6700125 chr1 59702797 T C 1.80E-05 Amyotrophic lateral sclerosis / / 17671248 rs6690993 chr1 59703982 G A 2.00E-04 Amyotrophic lateral sclerosis / / 17671248 rs12142820 chr1 59716043 A T 5.10E-04 Alcohol dependence / / 21314694 rs835367 chr1 59762468 A G 2.00E-06 Obesity-related traits FGGY nearGene-5 23251661 rs9787234 chr1 59796808 C T 7.79E-06 Obesity-related traits FGGY intron 23251661 rs17119280 chr1 59799161 G A 7.00E-06 Response to antipsychotic therapy (extrapyramidal side effects) FGGY intron 19875103 rs835382 chr1 59799511 A T 9.66E-04 Multiple complex diseases FGGY intron 17554300 rs835441 chr1 59823244 C T 2.38E-04 IgE levels FGGY intron 17255346 rs17119329 chr1 59830402 G A 8.54E-05 IgE levels FGGY intron 17255346 rs17119329 chr1 59830402 G A 2.94E-04 Multiple complex diseases FGGY intron 17554300 rs7539697 chr1 59832762 G A 6.40E-06 Obesity-related traits FGGY intron 23251661 rs835435 chr1 59844471 G A 6.88E-06 Obesity-related traits FGGY cds-synon 23251661 rs7534016 chr1 59853319 A G 5.00E-06 Obesity-related traits FGGY intron 23251661 rs11583924 chr1 59858582 G A 0.00047 Salmonella-induced pyroptosis FGGY intron 22837397 rs835425 chr1 59860544 G A 2.02E-04 IgE levels FGGY intron 17255346 rs1390694 chr1 59865755 A G 1.30E-13 Health and aging,CVD and cancer age of onset FGGY intron 22174011 rs1390694 chr1 59865755 A G 2.00E-14 Health and aging,CVD and cancer age of onset FGGY intron 22174011 rs1390694 chr1 59865755 A G 3.20E-23 Health and aging,CVD and cancer age of onset FGGY intron 22174011 rs1390694 chr1 59865755 A G 5.60E-18 Health and aging,CVD and cancer age of onset FGGY intron 22174011 rs17096906 chr1 59868942 A G 5.82E-04 Multiple complex diseases FGGY intron 17554300 rs17119472 chr1 59919752 A G 5.70E-04 Multiple complex diseases FGGY intron 17554300 rs648883 chr1 59979255 C A 6.28E-04 Response to statin treatment (atorvastatin),change in cholesterol levels FGGY intron 20031582 rs2798652 chr1 60007275 T C 1.54E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FGGY intron 20877124 rs11583338 chr1 60033913 T C 7.63E-06 Platelet counts FGGY intron 21507922 rs11583825 chr1 60034402 T C 7.63E-06 Platelet counts FGGY intron 21507922 rs4497239 chr1 60045220 A G 7.10E-04 Bipolar disorder,schizoaffective FGGY intron 19567891 rs2407603 chr1 60045290 G A 5.59E-04 Bipolar disorder,schizoaffective FGGY intron 19567891 rs10493267 chr1 60058706 A G 3.53E-04 Bipolar disorder,schizoaffective FGGY intron 19567891 rs12745808 chr1 60068731 A G 7.63E-06 Platelet counts FGGY intron 21507922 rs12727131 chr1 60084516 G A 3.00E-06 Neutrophil count FGGY intron 21507922 rs4522023 chr1 60111987 G A 6.09E-04 Smoking quantity FGGY intron 24665060 rs10889148 chr1 60119961 T C 3.48E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) FGGY intron 20877124 rs10889148 chr1 60119961 T C 1.12E-05 Smoking quantity FGGY intron 24665060 rs6587867 chr1 60134050 A G 1.22E-05 Smoking quantity FGGY intron 24665060 rs4072736 chr1 60142112 G C 1.99E-05 Multiple complex diseases FGGY intron 17554300 rs4357555 chr1 60161256 G A 9.52E-05 Blood pressure (response to angiotensin II receptor blocker) FGGY intron 24192120 rs11207507 chr1 60166147 G C 7.36E-04 Multiple complex diseases FGGY intron 17554300 rs6661666 chr1 60168554 A C 4.37E-05 Hodgkin's lymphoma FGGY intron 24149102 rs1933213 chr1 60183673 G T 5.00E-04 Obesity (extreme) FGGY intron 21935397 rs9436182 chr1 60185680 C A 5.37E-04 Obesity (extreme) FGGY intron 21935397 rs1890211 chr1 60198238 A T 9.05E-05 Multiple complex diseases FGGY intron 17554300 rs1890212 chr1 60198430 G A 6.28E-04 Coronary heart disease FGGY intron 21971053 rs674949 chr1 60240601 G A 2.30E-05 Urinary metabolites / / 21572414 rs9436605 chr1 60243182 T G 0.00000409 Common carotid artery thickness (average of near and far wall measures) / / 23487405 rs9436605 chr1 60243182 T G 9.65E-04 Self-reported allergy / / 23817569 rs9436188 chr1 60257931 A G 5.61E-05 Parkinson's disease / / 17052657 rs9436188 chr1 60257931 A G 1.04E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12057866 chr1 60272522 A G 4.68E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11207520 chr1 60275095 T G 2.93E-04 Parkinson's disease / / 17052657 rs11207520 chr1 60275095 T G 6.85E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11207520 chr1 60275095 T G 1.52E-04 Common variable immunodeficiency / / 21497890 rs3767996 chr1 60281712 A G 5.08E-04 Response to cytidine analogues (gemcitabine) HOOK1 intron 24483146 rs3767999 chr1 60289241 T G 2.48E-04 Schizophrenia HOOK1 intron 19197363 rs1155002 chr1 60373775 T C 1.11E-04 Dental caries CYP2J2 intron 21940522 rs11572245 chr1 60381437 C G 9.73E-04 Type 2 diabetes CYP2J2 intron 17463246 rs890291 chr1 60437812 C T 1.50E-05 Urinary metabolites / / 21572414 rs7411728 chr1 60446789 G A 6.30E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs642307 chr1 60460733 C A 1.87E-04 IgE levels C1orf87 intron 17255346 rs12041866 chr1 60484531 C T 7.93E-04 Suicide attempts in bipolar disorder C1orf87 intron 21423239 rs17120013 chr1 60494107 G A 9.12E-04 Type 2 diabetes C1orf87 intron 17463246 rs17120017 chr1 60495735 G A 3.86E-04 Multiple complex diseases C1orf87 intron 17554300 rs677129 chr1 60499928 A G 6.49E-04 Suicide attempts in bipolar disorder C1orf87 intron 21423239 rs680390 chr1 60505578 A G 4.19E-04 Suicide attempts in bipolar disorder C1orf87 intron 21423239 rs7543186 chr1 60531017 C A 1.45E-04 Alzheimer's disease (late onset) C1orf87 intron 21379329 rs17120082 chr1 60534428 C G 1.04E-04 Hearing function C1orf87 intron 17255346 rs17120143 chr1 60559382 A G 8.66E-04 Multiple complex diseases / / 17554300 rs583848 chr1 60568038 T A 1.90E-06 Urinary metabolites / / 21572414 rs686119 chr1 60579899 A T 4.62E-04 Weight loss (gastric bypass surgery) / / 23643386 rs6677345 chr1 60581154 T C 1.45E-04 Alzheimer's disease (late onset) / / 21379329 rs684867 chr1 60586930 C A 2.70E-05 Urinary metabolites / / 21572414 rs688026 chr1 60587677 C T 1.90E-05 Urinary metabolites / / 21572414 rs634161 chr1 60589775 T C 2.17E-04 Alzheimer's disease / / 17998437 rs616637 chr1 60593303 G A 2.40E-05 Urinary metabolites / / 21572414 rs87061 chr1 60594980 G T 5.80E-05 Glioma (high-grade) / / 19578366 rs646860 chr1 60598301 G A 6.50E-04 Volumetric brain MRI / / 17903297 rs601344 chr1 60600945 A G 2.90E-05 Glioma (high-grade) / / 19578366 rs656464 chr1 60601856 T C 5.97E-04 Multiple complex diseases / / 17554300 rs619806 chr1 60602824 A C 7.06E-04 Alzheimer's disease / / 22005930 rs671094 chr1 60602865 G C 7.04E-04 Alzheimer's disease / / 22005930 rs582695 chr1 60607442 A G 6.77E-04 Alzheimer's disease / / 22005930 rs609462 chr1 60609043 C T 9.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs609462 chr1 60609043 C T 8.68E-04 Alzheimer's disease / / 22005930 rs655146 chr1 60611029 G T 3.20E-05 Glioma (high-grade) / / 19578366 rs656416 chr1 60611269 A G 7.54E-04 Alzheimer's disease / / 22005930 rs618570 chr1 60615397 G C 4.98E-06 Periodontitis (PAL4Q3) / / 24024966 rs620794 chr1 60615839 G C 4.99E-06 Periodontitis (PAL4Q3) / / 24024966 rs11207574 chr1 60626168 A G 8.74E-04 Multiple complex diseases / / 17554300 rs922356 chr1 60631000 G A 4.68E-06 Periodontitis (PAL4Q3) / / 24024966 rs17120284 chr1 60634158 G T 4.54E-06 Periodontitis (PAL4Q3) / / 24024966 rs12072323 chr1 60639683 G T 4.65E-06 Periodontitis (PAL4Q3) / / 24024966 rs7534167 chr1 60661493 G T 4.35E-06 Periodontitis (PAL4Q3) / / 24024966 rs12125049 chr1 60667702 C T 4.20E-07 Glioma (high-grade) / / 19578366 rs7530841 chr1 60667936 A C 4.35E-06 Periodontitis (PAL4Q3) / / 24024966 rs1381890 chr1 60669529 T C 4.55E-06 Periodontitis (PAL4Q3) / / 24024966 rs17120349 chr1 60671732 G T 3.83E-06 Periodontitis (PAL4Q3) / / 24024966 rs12122772 chr1 60672543 A C 7.54E-04 Multiple complex diseases / / 17554300 rs12081932 chr1 60681873 C T 4.32E-06 Periodontitis (PAL4Q3) / / 24024966 rs11207580 chr1 60691150 G T 4.31E-06 Periodontitis (PAL4Q3) / / 24024966 rs17120400 chr1 60691588 G A 4.00E-06 Periodontitis (PAL4Q3) / / 24024966 rs4529739 chr1 60704783 T C 2.69E-06 Breast cancer (survival) / / 20332263 rs12741643 chr1 60752854 A G 0.000247 Salmonella-induced pyroptosis / / 22837397 rs298171 chr1 60785950 A T 4.60E-05 Response to statin therapy / / 20339536 rs298170 chr1 60787155 A G 4.30E-05 Response to statin therapy / / 20339536 rs454776 chr1 60794707 C T 4.00E-05 Response to statin therapy / / 20339536 rs2992354 chr1 60795185 T C 4.00E-05 Response to statin therapy / / 20339536 rs390331 chr1 60800662 T C 1.60E-05 Response to statin therapy / / 20339536 rs298166 chr1 60806703 T G 1.84E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs427970 chr1 60815042 C T 2.20E-05 Response to statin therapy / / 20339536 rs12137879 chr1 60815316 C T 5.41E-05 LDL lipoproteins / / pha002902 rs11585396 chr1 60817360 C A 6.19E-06 Diabetes Mellitus / / pha003059 rs17120557 chr1 60817919 T A 9.73E-04 Multiple complex diseases / / 17554300 rs298128 chr1 60848538 A G 6.50E-05 Information processing speed / / 21130836 rs298137 chr1 60855214 C T 4.82E-05 Eosinophil counts / / pha003088 rs403304 chr1 60869362 G T 6.27E-04 Smoking initiation / / 24665060 rs298157 chr1 60872291 C T 9.55E-04 Stroke / / pha002887 rs298154 chr1 60874869 C G 2.23E-04 Multiple complex diseases / / 17554300 rs298152 chr1 60875777 G A 2.79E-04 Multiple complex diseases / / 17554300 rs298151 chr1 60875812 T C 2.98E-04 Multiple complex diseases / / 17554300 rs298149 chr1 60875939 C T 2.47E-04 Multiple complex diseases / / 17554300 rs626286 chr1 60876100 C G 6.59E-04 Multiple complex diseases / / 17554300 rs7529292 chr1 60876146 T C 1.52E-04 Multiple complex diseases / / 17554300 rs7529292 chr1 60876146 T C 8.76E-05 Leukocyte Counts / / pha003091 rs298160 chr1 60879175 G A 1.63E-05 Basophils / / pha003087 rs7551363 chr1 60888999 T G 6.94E-04 Obesity (extreme) / / 21935397 rs1501227 chr1 60907394 G A 7.10E-05 Response to statin therapy / / 20339536 rs12760685 chr1 60909142 C T 5.37E-04 Smoking initiation / / 24665060 rs4915695 chr1 60962168 A G 6.10E-05 Cognitive test performance / / 20125193 rs4915695 chr1 60962168 A G 1.70E-05 Cortisol secretion,in saliva / / 21316860 rs4636500 chr1 60975806 T C 1.08E-04 Multiple complex diseases / / 17554300 rs4915697 chr1 60983285 T C 1.47E-04 Multiple complex diseases / / 17554300 rs12138423 chr1 60986573 G A 7.53E-05 Major depressive disorder / / 22472876 rs4515823 chr1 60993142 T G 3.09E-04 Multiple complex diseases / / 17554300 rs10889182 chr1 60998195 T G 1.62E-07 Bipolar disorder / / 22182935 rs10889182 chr1 60998195 T G 6.94E-05 Major depressive disorder / / 22472876 rs10889184 chr1 61006050 G A 7.33E-05 Major depressive disorder / / 22472876 rs11207633 chr1 61007182 A G 1.54E-07 Bipolar disorder / / 22182935 rs11207633 chr1 61007182 A G 4.65E-05 Major depressive disorder / / 22472876 rs10889187 chr1 61010758 G A 1.30E-07 Bipolar disorder / / 22182935 rs10889187 chr1 61010758 G A 4.44E-05 Major depressive disorder / / 22472876 rs10889189 chr1 61025026 C G 5.51E-05 Multiple complex diseases / / 17554300 rs10889189 chr1 61025026 C G 7.56E-07 Bipolar disorder / / 22182935 rs4564178 chr1 61030369 C T 6.73E-05 Body mass (lean) / / 19268274 rs1461356 chr1 61037015 G A 4.42E-07 Multiple complex diseases / / 17554300 rs12565755 chr1 61041875 T C 5.00E-08 Response to tocilizumab in rheumatoid arthritis / / 22491018 rs12565755 chr1 61041875 T C 0.000153 Salmonella-induced pyroptosis / / 22837397 rs1381171 chr1 61042598 T C 1.79E-05 Major depressive disorder / / 22472876 rs1572358 chr1 61056625 T C 1.86E-05 Major depressive disorder / / 22472876 rs2989476 chr1 61059259 G C 1.71E-07 Multiple complex diseases / / 17554300 rs2989476 chr1 61059259 G C 2.00E-06 Bipolar disorder / / 21254220 rs2989476 chr1 61059259 G C 3.00E-06 Bipolar disorder / / 21738484 rs3896178 chr1 61061996 G A 1.30E-05 Multiple complex diseases / / 17554300 rs3896178 chr1 61061996 G A 4.62E-05 Serum metabolites / / 19043545 rs3896178 chr1 61061996 G A 2.03E-04 Bipolar disorder,schizoaffective / / 19567891 rs484743 chr1 61062474 G A 3.70E-07 Multiple complex diseases / / 17554300 rs537110 chr1 61084790 T C 7.35E-04 Schizophrenia / / 19197363 rs2987775 chr1 61087726 A G 4.89E-05 Multiple complex diseases / / 17554300 rs2447043 chr1 61087920 A G 7.36E-05 Multiple complex diseases / / 17554300 rs472913 chr1 61095558 G C 2.00E-07 Bipolar disorder / / 19416921 rs555070 chr1 61099680 G A 1.09E-05 Multiple complex diseases / / 17554300 rs1399162 chr1 61169395 A G 8.79E-04 Type 2 diabetes / / 17463246 rs10493294 chr1 61170724 G A 2.92E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1514178 chr1 61205469 T C 3.01E-04 Type 2 diabetes / / 17463246 rs1514178 chr1 61205469 T C 2.00E-07 Phospholipid levels (plasma) / / 21829377 rs6650097 chr1 61264342 A G 4.66E-04 Smoking cessation / / 24665060 rs17302852 chr1 61274799 T C 9.87E-04 Coronary heart disease / / 21606135 rs1877734 chr1 61282089 G A 0.000636172 Hypertension (early onset hypertension) / / 22479346 rs648787 chr1 61296240 G A 1.11E-05 Body Mass Index / / pha003006 rs643397 chr1 61300983 A G 7.73E-04 Acute lung injury / / 22295056 rs574095 chr1 61327635 G A 2.90E-05 Urinary metabolites / / 21572414 rs12138640 chr1 61338655 G A 7.94E-04 Multiple complex diseases / / 17554300 rs12028543 chr1 61368719 G A 8.80E-04 Obesity (extreme) / / 21935397 rs575726 chr1 61369313 G A 2.70E-05 Urinary metabolites / / 21572414 rs12035256 chr1 61463825 C T 3.38E-05 Coronary heart disease / / pha003031 rs12035256 chr1 61463825 C T 9.78E-05 Coronary heart disease / / pha003056 rs1779865 chr1 61483042 T G 1.86E-05 Myopia (severe) / / 23933737 rs2173345 chr1 61485568 A C 9.59E-05 Myopia (severe) / / 23933737 rs11207695 chr1 61554927 C T 1.86E-04 Type 2 diabetes NFIA intron 17463246 rs964091 chr1 61567939 G A 1.52E-04 Type 2 diabetes NFIA intron 17463246 rs10493302 chr1 61571392 T C 2.27E-05 Type 2 diabetes NFIA intron 17463246 rs6693597 chr1 61582546 T G 7.01E-05 Parkinson's disease NFIA intron 21248740 rs12403502 chr1 61606969 T A 8.97E-05 Type 2 diabetes NFIA intron 17463246 rs2008968 chr1 61607034 C T 1.01E-04 Response to taxane treatment (placlitaxel) NFIA intron 23006423 rs334728 chr1 61609007 C T 8.60E-04 Coronary Artery Disease NFIA intron 17634449 rs334699 chr1 61620496 A G 2.00E-07 Thyroid hormone levels NFIA intron 23408906 rs334699 chr1 61620496 A G 5.00E-12 Thyroid hormone levels NFIA intron 23408906 rs334699 chr1 61620496 A G 6.00E-07 Thyroid hormone levels NFIA intron 23408906 rs168022 chr1 61629453 G A 8.63E-04 Rheumatoid arthritis NFIA intron 21452313 rs334716 chr1 61639503 G A 7.09E-04 Coronary Artery Disease NFIA intron 17634449 rs12086591 chr1 61647156 T G 2.53E-04 Type 2 diabetes NFIA intron 17463246 rs7552300 chr1 61688282 C T 5.82E-06 Asthma (childhood onset) NFIA intron 23829686 rs17121853 chr1 61708978 C G 5.07E-04 Prostate cancer mortality NFIA intron 20978177 rs17377428 chr1 61729721 G A 9.70E-06 Urinary metabolites NFIA intron 21572414 rs17121875 chr1 61731652 A C 7.10E-07 Urinary metabolites NFIA intron 21572414 rs437021 chr1 61738270 C T 1.00E-06 Biomarkers NFIA intron 17903293 rs41492448 chr1 61769989 T C 4.40E-04 Multiple complex diseases NFIA intron 17554300 rs2363876 chr1 61776742 C T 3.61E-04 Smoking initiation NFIA intron 24665060 rs41423747 chr1 61781106 C T 3.80E-06 Urinary metabolites NFIA intron 21572414 rs6691768 chr1 61791863 G A 1.00E-07 Celiac disease NFIA intron 20190752 rs6691941 chr1 61792008 G A 3.43E-04 Smoking initiation NFIA intron 24665060 rs11801720 chr1 61798624 A G 0.000287 Salmonella-induced pyroptosis NFIA intron 22837397 rs9436636 chr1 61812773 G A 5.30E-05 Breast cancer NFIA intron 22452962 rs41350144 chr1 61815799 A T 3.00E-07 Bipolar disorder NFIA intron 22925353 rs2364467 chr1 61816354 C G 8.99E-07 Bipolar disorder NFIA intron 22925353 rs2364467 chr1 61816354 C G 1.61E-04 Response to cytadine analogues (cytosine arabinoside) NFIA intron 24483146 rs2024789 chr1 61817001 G C 2.00E-06 Bipolar disorder NFIA intron 22925353 rs7528918 chr1 61818422 A G 1.57E-04 Response to cytadine analogues (cytosine arabinoside) NFIA intron 24483146 rs17121983 chr1 61820072 C G 4.00E-07 Bipolar disorder NFIA intron 22925353 rs7556462 chr1 61821819 T C 4.00E-07 Bipolar disorder NFIA intron 22925353 rs4915737 chr1 61822283 G C 4.00E-07 Bipolar disorder NFIA intron 22925353 rs4915737 chr1 61822283 G C 1.57E-04 Response to cytadine analogues (cytosine arabinoside) NFIA intron 24483146 rs7553582 chr1 61824375 C T 4.00E-06 Bipolar disorder NFIA intron 22925353 rs41453448 chr1 61824389 G A 2.00E-07 Bipolar disorder NFIA intron 22925353 rs1125777 chr1 61831890 C T 2.00E-07 Bipolar disorder NFIA intron 22925353 rs12568010 chr1 61831938 A G 2.00E-07 Bipolar disorder NFIA intron 22925353 rs10489911 chr1 61838509 C T 8.25E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NFIA intron 20877124 rs17356748 chr1 61843343 C G 5.69E-04 Multiple complex diseases NFIA intron 17554300 rs2474388 chr1 61859802 G T 1.89E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs10889219 chr1 61861554 T C 8.36E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs2180201 chr1 61864119 G C 2.18E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs1474872 chr1 61864231 C A 2.29E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs2474384 chr1 61868766 C T 5.15E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs7535730 chr1 61871356 A G 8.06E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs9436640 chr1 61873677 T G 5.00E-18 Ventricular conduction NFIA intron 21076409 rs9436640 chr1 61873677 T G 7.44E-04 Suicide attempts in bipolar disorder NFIA intron 21423239 rs6587924 chr1 61895257 C A 8.05E-05 Major depressive disorder (broad) NFIA intron 20038947 rs2207790 chr1 61897967 G A 9.49E-05 Major depressive disorder (broad) NFIA intron 20038947 rs2207790 chr1 61897967 G A 6.00E-18 Electrocardiographic conduction measures NFIA intron 23463857 rs12404081 chr1 61941846 A G 9.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs4281350 chr1 61949463 T G 6.72E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4915748 chr1 61954169 C T 2.70E-05 Methamphetamine dependence / / 23594818 rs10889228 chr1 61958583 C T 9.94E-04 Multiple complex diseases / / 17554300 rs3890764 chr1 61961953 G A 7.61E-04 Parkinson's disease / / 16252231 rs3890764 chr1 61961953 G A 1.08E-05 Body Mass Index / / pha003009 rs3890764 chr1 61961953 G A 9.39E-05 Weight / / pha003027 rs35231142 chr1 61964427 C T 4.47E-04 Multiple complex diseases / / 17554300 rs12036419 chr1 61971449 G A 5.92E-04 Multiple complex diseases / / 17554300 rs2499516 chr1 61977297 G T 5.42E-04 Multiple complex diseases / / 17554300 rs7512200 chr1 61978694 A G 5.82E-04 Multiple complex diseases / / 17554300 rs1933299 chr1 62000281 T G 6.05E-05 Taste perception / / 22132133 rs2365269 chr1 62060213 A G 6.47E-05 Lactate dehydrogenase levels / / 20981236 rs12036661 chr1 62077191 C T 7.93E-04 Suicide attempts in bipolar disorder / / 21423239 rs7545391 chr1 62078347 T C 3.23E-05 Body Mass Index / / pha003014 rs12137416 chr1 62087783 C T 2.71E-04 Alzheimer's disease / / 17998437 rs1933293 chr1 62089261 T C 7.07E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12118986 chr1 62103814 C A 4.43E-05 Height / / pha003010 rs12118986 chr1 62103814 C A 7.23E-05 Height / / pha003011 rs2886326 chr1 62111054 A G 0.0005946 Hypertension (early onset hypertension) / / 22479346 rs6681890 chr1 62114181 G A 3.94E-06 Psoriasis / / 20953190 rs10889249 chr1 62119809 T C 1.63E-04 Stroke / / pha002886 rs11207801 chr1 62126262 G A 6.91E-05 Hypertension (early onset hypertension) / / 22479346 rs6694023 chr1 62130167 A G 7.90E-05 Major depressive disorder / / 21621269 rs9783018 chr1 62135356 T C 2.52E-22 Narcolepsy / / 19629137 rs12117475 chr1 62142097 G A 9.59E-04 Alzheimer's disease / / 17998437 rs17122715 chr1 62190897 A G 5.49E-04 Multiple complex diseases TM2D1 UTR-5 17554300 rs2365498 chr1 62312654 G A 6.90E-04 Myocardial Infarction I/DL intron pha002883 rs4598521 chr1 62341157 T C 7.05E-04 Coronary Artery Disease I/DL intron 17634449 rs6685516 chr1 62342230 T C 4.80E-04 Myasthenia gravis I/DL intron 23055271 rs9326052 chr1 62356590 G A 3.00E-04 Acute lymphoblastic leukemia (childhood) I/DL intron 20189245 rs4915788 chr1 62357407 T G 1.62E-04 Type 2 diabetes I/DL intron 17463246 rs1056513 chr1 62380298 G A 1.00E-07 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 2.00E-07 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 2.00E-07 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 3.00E-06 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 3.00E-07 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 3.00E-07 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 6.00E-06 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 7.00E-06 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 7.00E-06 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 7.00E-06 Obesity-related traits I/DL missense 23251661 rs1056513 chr1 62380298 G A 8.00E-06 Obesity-related traits I/DL missense 23251661 rs11207864 chr1 62380658 C T 6.34E-04 Iron levels I/DL intron pha002876 rs2482863 chr1 62387598 T C 9.34E-05 Response to taxane treatment (placlitaxel) I/DL intron 23006423 rs11207865 chr1 62387652 A G 3.99E-04 Myocardial Infarction I/DL intron pha002883 rs10889271 chr1 62400487 C T 1.39E-04 Type 2 diabetes I/DL intron 17463246 rs10889272 chr1 62402549 C T 1.00E-04 Alcoholism (heaviness of drinking) I/DL intron 21529783 rs11207877 chr1 62426771 C T 3.45E-04 Type 2 diabetes I/DL intron 17463246 rs7512525 chr1 62427888 C T 2.60E-04 Type 2 diabetes I/DL intron 17463246 rs1123777 chr1 62488522 T C 2.10E-05 Urinary metabolites I/DL intron 21572414 rs2499818 chr1 62489450 A G 9.32E-05 Smoking initiation I/DL intron 24665060 rs11585888 chr1 62499673 G A 3.38E-04 Alzheimer's disease I/DL intron 22005930 rs6673889 chr1 62504123 T C 3.40E-04 Alzheimer's disease I/DL intron 22005930 rs6685442 chr1 62504194 A G 7.78E-04 Alzheimer's disease I/DL intron 22005930 rs6661849 chr1 62504715 G C 4.01E-04 Alzheimer's disease I/DL intron 22005930 rs17378995 chr1 62504841 T C 6.34E-04 Alzheimer's disease I/DL intron 22005930 rs7539653 chr1 62504958 A G 4.72E-04 Alzheimer's disease I/DL intron 22005930 rs7519802 chr1 62505280 G A 4.69E-04 Alzheimer's disease I/DL intron 22005930 rs10493313 chr1 62511018 T A 5.46E-04 Alzheimer's disease I/DL intron 22005930 rs11576777 chr1 62512735 T G 5.49E-04 Alzheimer's disease I/DL intron 22005930 rs11579010 chr1 62513239 A G 8.21E-04 Alzheimer's disease I/DL intron 22005930 rs2498982 chr1 62516683 G C 8.72E-04 Response to taxane treatment (placlitaxel) I/DL missense 23006423 rs12072096 chr1 62523223 A G 8.82E-04 Alzheimer's disease I/DL intron 17998437 rs6682776 chr1 62556579 A T 6.99E-04 Alzheimer's disease I/DL intron 22005930 rs10127438 chr1 62560928 C T 9.32E-04 Multiple complex diseases I/DL intron 17554300 rs6700644 chr1 62575981 T C 7.77E-04 Alzheimer's disease I/DL intron 17998437 rs12044746 chr1 62580201 G A 1.44E-04 Multiple complex diseases I/DL intron 17554300 rs2476194 chr1 62594593 C T 5.93E-04 Myopia (pathological) I/DL cds-synon 21095009 rs11207909 chr1 62607786 G A 1.00E-04 Multiple complex diseases I/DL intron 17554300 rs17123151 chr1 62623177 G A 0.0002 Migraine I/DL intron 22678113 rs10889294 chr1 62630362 A C 2.41E-04 Multiple complex diseases / / 17554300 rs6684324 chr1 62635058 C T 8.14E-04 Multiple complex diseases / / 17554300 rs6684324 chr1 62635058 C T 9.86E-04 Alzheimer's disease / / 22005930 rs2457832 chr1 62635116 C T 6.87E-04 Multiple complex diseases / / 17554300 rs6687095 chr1 62635246 G T 8.57E-04 Alzheimer's disease / / 22005930 rs2481703 chr1 62644118 A G 7.60E-05 Cognitive test performance / / 20125193 rs2481703 chr1 62644118 A G 3.68E-04 Acute lung injury / / 22295056 rs4019803 chr1 62687104 A G 3.20E-05 Cognitive test performance / / 20125193 rs2067994 chr1 62708339 A G 8.39E-05 Cognitive performance KANK4 intron 19734545 rs958802 chr1 62723566 C T 1.45E-04 Celiac disease KANK4 intron 23936387 rs17123303 chr1 62733826 T C 8.27E-04 Body mass index KANK4 intron 21701565 rs12038843 chr1 62736841 A G 4.90E-04 Alzheimer's disease (late onset) KANK4 intron 21379329 rs17123324 chr1 62741296 G A 4.07E-04 Suicide attempts in bipolar disorder KANK4 intron 21041247 rs765691 chr1 62759848 T A 8.25E-05 Serum metabolites KANK4 intron 19043545 rs2765265 chr1 62761379 C T 5.82E-04 Multiple complex diseases KANK4 intron 17554300 rs201504584 chr1 62761907 CAGAGT C 1.72E-05 Waist Circumference KANK4 intron pha003023 rs6704270 chr1 62761907 C A 1.72E-05 Waist Circumference KANK4 intron pha003023 rs2182241 chr1 62805139 G C 2.10E-04 Multiple complex diseases / / 17554300 rs6675459 chr1 62818217 T C 7.82E-04 Insulin resistance / / 21901158 rs997532 chr1 62842677 G A 5.57E-04 White matter integrity / / 22425255 rs3949904 chr1 62848090 G A 8.50E-05 Celiac disease / / 17558408 rs3949904 chr1 62848090 G A 1.20E-05 Urinary metabolites / / 21572414 rs3949904 chr1 62848090 G A 7.22E-05 Tunica Media / / pha003036 rs7523497 chr1 62853146 A G 6.76E-08 Non-obstructive azoospermia / / 22197933 rs7523622 chr1 62890510 C A 8.62E-04 Alcohol dependence / / 21314694 rs10493324 chr1 62898142 C T 0.00045776 Sarcoidosis / / 22952805 rs626787 chr1 62901243 C G 4.41E-05 Multiple complex diseases / / 17554300 rs626787 chr1 62901243 C G 6.01E-12 Metabolite levels / / 22286219 rs631106 chr1 62901807 C A 4.67E-12 Metabolite levels / / 22286219 rs9436221 chr1 62903359 T C 1.47E-11 Metabolite levels USP1 intron 22286219 rs9436222 chr1 62903363 C G 1.48E-11 Metabolite levels USP1 intron 22286219 rs9436223 chr1 62903547 C T 1.60E-11 Metabolite levels USP1 intron 22286219 rs12029068 chr1 62904295 C T 5.69E-12 Metabolite levels USP1 intron 22286219 rs9436661 chr1 62904575 T G 9.09E-11 Metabolite levels USP1 intron 22286219 rs10493322 chr1 62905893 C T 8.40E-12 Metabolite levels USP1 intron 22286219 rs638714 chr1 62906489 G T 8.44E-12 Metabolite levels USP1 intron 22286219 rs638305 chr1 62906537 G T 8.46E-12 Metabolite levels USP1 intron 22286219 rs637723 chr1 62906728 C T 6.25E-12 Metabolite levels USP1 intron 22286219 rs656297 chr1 62907595 A G 5.90E-12 Metabolite levels USP1 intron 22286219 rs642845 chr1 62908235 T C 8.35E-12 Metabolite levels USP1 intron 22286219 rs641540 chr1 62908538 A G 8.35E-12 Metabolite levels USP1 intron 22286219 rs598253 chr1 62911341 T C 8.45E-12 Metabolite levels USP1 intron 22286219 rs11207969 chr1 62911751 A G 5.65E-12 Metabolite levels USP1 intron 22286219 rs659656 chr1 62912120 C G 8.46E-12 Metabolite levels USP1 intron 22286219 rs10158897 chr1 62912919 C T 4.91E-12 Metabolite levels USP1 intron 22286219 rs10158897 chr1 62912919 C T 9.00E-06 Lipid traits USP1 intron 24386095 rs783291 chr1 62914978 G A 2.97E-11 Metabolite levels USP1 intron 22286219 rs11207970 chr1 62915473 C T 8.34E-12 Metabolite levels USP1 intron 22286219 rs583609 chr1 62916796 T C 5.80E-12 Metabolite levels USP1 UTR-3 22286219 rs583609 chr1 62916796 T C 3.23E-08 Cholesterol,total USP1 UTR-3 23063622 rs597470 chr1 62917796 T G 1.46E-11 Metabolite levels / / 22286219 rs597078 chr1 62917857 G A,C,T 8.35E-12 Metabolite levels / / 22286219 rs597078 chr1 62917857 G A,C,T 4.25E-08 Cholesterol,total / / 23063622 rs597076 chr1 62917865 T A 1.44E-11 Metabolite levels / / 22286219 rs630144 chr1 62918864 A G 8.36E-12 Metabolite levels / / 22286219 rs636523 chr1 62920008 A G 7.74E-12 Metabolite levels / / 22286219 rs636523 chr1 62920008 A G 5.00E-07 Lipid traits / / 24386095 rs636497 chr1 62920029 A G 8.36E-12 Metabolite levels / / 22286219 rs624660 chr1 62920388 C A 5.64E-12 Metabolite levels / / 22286219 rs634341 chr1 62921422 T C 8.46E-12 Metabolite levels DOCK7 intron 22286219 rs3913007 chr1 62921586 T C 4.16E-12 Metabolite levels DOCK7 intron 22286219 rs4350231 chr1 62922660 G A 1.40E-12 Metabolite levels DOCK7 intron 22286219 rs12023489 chr1 62923858 G A 1.63E-12 Metabolite levels DOCK7 intron 22286219 rs12037659 chr1 62923863 C T 8.47E-12 Metabolite levels DOCK7 intron 22286219 rs1305520 chr1 62926057 A T 2.08E-12 Metabolite levels DOCK7 intron 22286219 rs1167996 chr1 62927797 T G 1.58E-11 Metabolite levels DOCK7 intron 22286219 rs998403 chr1 62928549 G A 3.96E-12 Metabolite levels DOCK7 intron 22286219 rs1167998 chr1 62931632 C A 1.30E-06 Lipid levels DOCK7 intron 18193043 rs1167998 chr1 62931632 C A 2.00E-12 Triglycerides DOCK7 intron 19060911 rs1167998 chr1 62931632 C A 4.10E-09 Lipid levels DOCK7 intron 19936222 rs1167998 chr1 62931632 C A 2.21E-12 Metabolite levels DOCK7 intron 22286219 rs1167998 chr1 62931632 C A 1.20E-27 Cholesterol,total DOCK7 intron 23063622 rs1167998 chr1 62931632 C A 5.49E-27 Triglycerides DOCK7 intron 23063622 rs1167998 chr1 62931632 C A 5.78E-16 Triglycerides in males DOCK7 intron 23063622 rs1167998 chr1 62931632 C A 6.86E-09 LDL cholesterol DOCK7 intron 23063622 rs1167998 chr1 62931632 C A 8.48E-10 Triglycerides in females DOCK7 intron 23063622 rs1167998 chr1 62931632 C A 5.71E-06 Triglycerides DOCK7 intron pha003081 rs1167998 chr1 62931632 C A 8.52E-06 Lipid levels DOCK7 intron pha003082 rs1168002 chr1 62934308 A G 3.72E-12 Metabolite levels DOCK7 intron 22286219 rs1007205 chr1 62936912 T C 1.13E-10 Metabolite levels DOCK7 intron 22286219 rs10889330 chr1 62939466 G C 8.38E-12 Metabolite levels DOCK7 intron 22286219 rs1979722 chr1 62940097 G A 3.65E-12 Metabolite levels DOCK7 intron 22286219 rs10889331 chr1 62943007 G T 1.57E-11 Metabolite levels DOCK7 intron 22286219 rs1168009 chr1 62943954 G A 1.57E-11 Metabolite levels DOCK7 intron 22286219 rs1168010 chr1 62943979 G A 9.31E-11 Metabolite levels DOCK7 intron 22286219 rs1183260 chr1 62945418 A G 3.25E-11 Metabolite levels DOCK7 intron 22286219 rs6587976 chr1 62945631 C T 8.30E-12 Metabolite levels DOCK7 intron 22286219 rs1305521 chr1 62949034 A G 1.99E-11 Metabolite levels DOCK7 intron 22286219 rs11207974 chr1 62949960 T C 1.95E-11 Metabolite levels DOCK7 intron 22286219 rs10889332 chr1 62950858 C T 6.05E-12 Metabolite levels DOCK7 intron 22286219 rs10889332 chr1 62950858 C T 8.00E-15 Metabolite levels (atherosclerosis) DOCK7 intron 22916037 rs10493326 chr1 62953373 G A 5.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) DOCK7 intron 20877124 rs1690761 chr1 62955862 C T 1.28E-11 Metabolite levels DOCK7 intron 22286219 rs10889333 chr1 62957030 G A 4.55E-12 Metabolite levels DOCK7 intron 22286219 rs10889333 chr1 62957030 G A 4.85E-06 Triglycerides DOCK7 intron pha003081 rs10889333 chr1 62957030 G A 9.52E-06 Lipid levels DOCK7 intron pha003082 rs10889334 chr1 62957199 C G 5.73E-12 Metabolite levels DOCK7 intron 22286219 rs10789112 chr1 62957758 T C 5.80E-12 Metabolite levels DOCK7 intron 22286219 rs10889335 chr1 62960101 A G 3.45E-13 Metabolite levels DOCK7 cds-synon 22286219 rs1168041 chr1 62960250 T C 1.08E-12 Metabolite levels DOCK7 intron 22286219 rs1168040 chr1 62960575 T C 1.96E-12 Metabolite levels DOCK7 intron 22286219 rs1168036 chr1 62962734 A G 5.78E-12 Metabolite levels DOCK7 intron 22286219 rs1002687 chr1 62963737 G A 6.11E-13 Metabolite levels DOCK7 intron 22286219 rs1168034 chr1 62963914 G C 6.42E-11 Metabolite levels DOCK7 intron 22286219 rs35529421 chr1 62965621 T A,G 6.11E-13 Metabolite levels DOCK7 intron 22286219 rs1168032 chr1 62967747 A G 1.84E-12 Metabolite levels DOCK7 intron 22286219 rs1168031 chr1 62967987 C T 6.11E-13 Metabolite levels DOCK7 intron 22286219 rs1168030 chr1 62968491 C T 6.11E-13 Metabolite levels DOCK7 intron 22286219 rs1168029 chr1 62969402 G A 3.00E-13 Lipid metabolism phenotypes DOCK7 intron 22286219 rs1168028 chr1 62969431 G A 7.37E-12 Metabolite levels DOCK7 intron 22286219 rs1168027 chr1 62970184 T C 6.11E-13 Metabolite levels DOCK7 intron 22286219 rs1168026 chr1 62970996 T C 8.47E-13 Metabolite levels DOCK7 intron 22286219 rs1184865 chr1 62973795 A G 6.12E-13 Metabolite levels DOCK7 intron 22286219 rs1168042 chr1 62974150 A T 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs11207976 chr1 62976751 G A 7.36E-12 Metabolite levels DOCK7 intron 22286219 rs11207977 chr1 62977307 C T 3.95E-12 Metabolite levels DOCK7 intron 22286219 rs1781212 chr1 62977419 G A 1.30E-12 Metabolite levels DOCK7 intron 22286219 rs1168044 chr1 62977558 A C 5.78E-12 Metabolite levels DOCK7 intron 22286219 rs10889336 chr1 62980410 T C 5.73E-13 Metabolite levels DOCK7 intron 22286219 rs10889337 chr1 62980607 G A 2.24E-12 Metabolite levels DOCK7 intron 22286219 rs10889337 chr1 62980607 G A 5.31E-06 Triglycerides DOCK7 intron pha003081 rs10889337 chr1 62980607 G A 8.43E-06 Lipid levels DOCK7 intron pha003082 rs12090886 chr1 62981440 G A 3.97E-11 Metabolite levels DOCK7 intron 22286219 rs12090886 chr1 62981440 G A 2.42E-08 Cholesterol,total DOCK7 intron 23063622 rs1168045 chr1 62982891 C A,T 7.62E-12 Metabolite levels DOCK7 intron 22286219 rs1168045 chr1 62982891 C A,T 2.64E-08 Cholesterol,total DOCK7 intron 23063622 rs11207979 chr1 62982994 G A 4.01E-12 Metabolite levels DOCK7 intron 22286219 rs1168046 chr1 62983693 A C 5.46E-12 Metabolite levels DOCK7 intron 22286219 rs1168046 chr1 62983693 A C 1.86E-08 Cholesterol,total DOCK7 intron 23063622 rs1168047 chr1 62983751 C T 5.52E-12 Metabolite levels DOCK7 intron 22286219 rs1168047 chr1 62983751 C T 2.15E-08 Cholesterol,total DOCK7 intron 23063622 rs10889338 chr1 62984897 C T 3.95E-12 Metabolite levels DOCK7 intron 22286219 rs10889338 chr1 62984897 C T 1.45E-08 Cholesterol,total DOCK7 intron 23063622 rs1168050 chr1 62986955 C T 5.52E-12 Metabolite levels DOCK7 intron 22286219 rs1168050 chr1 62986955 C T 2.66E-08 Cholesterol,total DOCK7 intron 23063622 rs1690766 chr1 62987289 T C 5.52E-12 Metabolite levels DOCK7 intron 22286219 rs1781195 chr1 62988972 T C 5.94E-12 Metabolite levels DOCK7 intron 22286219 rs1627591 chr1 62989807 C T 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs11577840 chr1 62991369 T C 2.68E-12 Metabolite levels DOCK7 intron 22286219 rs12062275 chr1 62991905 T C 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs11207980 chr1 62992749 T C 3.95E-12 Metabolite levels DOCK7 intron 22286219 rs12403207 chr1 62993620 T C 2.18E-12 Metabolite levels DOCK7 intron 22286219 rs1168015 chr1 62996046 C G 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs1168013 chr1 62996838 C G 5.27E-04 Type 2 diabetes DOCK7 intron 17463246 rs1168013 chr1 62996838 C G 6.00E-08 Triglycerides DOCK7 intron 20864672 rs1168013 chr1 62996838 C G 5.87E-12 Metabolite levels DOCK7 intron 22286219 rs4915840 chr1 62999595 C G 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs11327850 chr1 62999675 CT C 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs7534572 chr1 62999675 C G 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs1168018 chr1 63001120 A C 2.04E-11 Metabolite levels DOCK7 intron 22286219 rs1168017 chr1 63002551 A G 2.18E-12 Metabolite levels DOCK7 intron 22286219 rs7548877 chr1 63005950 T C 5.77E-12 Metabolite levels DOCK7 intron 22286219 rs11207981 chr1 63006087 C A 5.46E-12 Metabolite levels DOCK7 intron 22286219 rs1168023 chr1 63006595 A T 5.62E-12 Metabolite levels DOCK7 intron 22286219 rs1781221 chr1 63006842 A C 5.96E-12 Metabolite levels DOCK7 intron 22286219 rs11207982 chr1 63007182 C T 3.90E-12 Metabolite levels DOCK7 intron 22286219 rs1184547 chr1 63007228 G A 5.91E-12 Metabolite levels DOCK7 intron 22286219 rs1168022 chr1 63007721 A T 5.63E-12 Metabolite levels DOCK7 intron 22286219 rs1168021 chr1 63009900 A G 5.95E-12 Metabolite levels DOCK7 intron 22286219 rs1168020 chr1 63009956 C T 5.95E-12 Metabolite levels DOCK7 intron 22286219 rs1179765 chr1 63010110 G C 5.65E-12 Metabolite levels DOCK7 intron 22286219 rs12074528 chr1 63010871 T C 5.95E-12 Metabolite levels DOCK7 intron 22286219 rs10889339 chr1 63012056 A G 5.95E-12 Metabolite levels DOCK7 intron 22286219 rs10889340 chr1 63012071 A C 4.07E-12 Metabolite levels DOCK7 intron 22286219 rs11207983 chr1 63012107 C T 5.95E-12 Metabolite levels DOCK7 intron 22286219 rs2029763 chr1 63013134 A G 5.38E-12 Metabolite levels DOCK7 intron 22286219 rs11207984 chr1 63013396 C T 5.98E-12 Metabolite levels DOCK7 intron 22286219 rs11207985 chr1 63013786 A G 6.01E-12 Metabolite levels DOCK7 intron 22286219 rs10789113 chr1 63015199 A T 3.92E-12 Metabolite levels DOCK7 intron 22286219 rs11207986 chr1 63018170 T C 6.01E-12 Metabolite levels DOCK7 intron 22286219 rs10159255 chr1 63020816 C A 5.27E-12 Metabolite levels DOCK7 intron 22286219 rs2131925 chr1 63025942 G T 3.00E-18 LDL cholesterol DOCK7 intron 20686565 rs2131925 chr1 63025942 G T 5.00E-41 Cholesterol,total DOCK7 intron 20686565 rs2131925 chr1 63025942 G T 9.00E-43 Triglycerides DOCK7 intron 20686565 rs2131925 chr1 63025942 G T 4.01E-12 Metabolite levels DOCK7 intron 22286219 rs2131925 chr1 63025942 G T 3.00E-32 LDL cholesterol DOCK7 intron 24097068 rs2131925 chr1 63025942 G T 3.00E-74 Triglycerides DOCK7 intron 24097068 rs2131925 chr1 63025942 G T 4.00E-80 Cholesterol,total DOCK7 intron 24097068 rs2131926 chr1 63026011 C T 4.01E-12 Metabolite levels DOCK7 intron 22286219 rs10889343 chr1 63026429 T G 4.01E-12 Metabolite levels DOCK7 intron 22286219 rs4329540 chr1 63027024 C T 3.29E-12 Metabolite levels DOCK7 intron 22286219 rs10889344 chr1 63033941 T C 6.14E-12 Metabolite levels DOCK7 intron 22286219 rs10789114 chr1 63034222 T C 4.13E-12 Metabolite levels DOCK7 intron 22286219 rs7555577 chr1 63034363 A C 6.27E-12 Metabolite levels DOCK7 intron 22286219 rs12116574 chr1 63037837 C T 3.95E-12 Metabolite levels DOCK7 intron 22286219 rs6696502 chr1 63039533 C T 2.42E-12 Metabolite levels DOCK7 intron 22286219 rs12038768 chr1 63040728 G T 4.21E-12 Metabolite levels DOCK7 intron 22286219 rs11207990 chr1 63041086 T C 6.21E-12 Metabolite levels DOCK7 intron 22286219 rs11207992 chr1 63041800 T G 4.15E-12 Metabolite levels DOCK7 intron 22286219 rs1472257 chr1 63042126 A G 5.17E-12 Metabolite levels DOCK7 intron 22286219 rs10789116 chr1 63042738 A G 4.00E-12 Metabolite levels DOCK7 intron 22286219 rs11207993 chr1 63044464 C T 5.70E-04 Lipid levels DOCK7 intron 19802338 rs11207993 chr1 63044464 C T 6.10E-05 Cognitive test performance DOCK7 intron 20125193 rs1748201 chr1 63045506 A C 2.56E-11 Metabolite levels DOCK7 intron 22286219 rs1748200 chr1 63046039 T C 6.24E-12 Metabolite levels DOCK7 intron 22286219 rs1629122 chr1 63046578 C A 6.26E-12 Metabolite levels DOCK7 intron 22286219 rs9436224 chr1 63048275 A C 4.26E-11 Metabolite levels DOCK7 intron 22286219 rs34465969 chr1 63048276 A C 8.93E-12 Metabolite levels DOCK7 intron 22286219 rs35194512 chr1 63048277 A C 4.14E-12 Metabolite levels DOCK7 intron 22286219 rs11207995 chr1 63049551 A C 5.02E-04 Type 2 diabetes DOCK7 intron 17463246 rs11207995 chr1 63049551 A C 3.86E-12 Metabolite levels DOCK7 intron 22286219 rs11207995 chr1 63049551 A C 6.00E-10 Lipid traits DOCK7 intron 24386095 rs1748195 chr1 63049593 C G 9.24E-04 Type 2 diabetes DOCK7 intron 17463246 rs1748195 chr1 63049593 C G 2.00E-10 Triglycerides DOCK7 intron 18193043 rs1748195 chr1 63049593 C G 6.16E-12 Metabolite levels DOCK7 intron 22286219 rs1748195 chr1 63049593 C G 1.27E-13 Cholesterol,total DOCK7 intron 23063622 rs1748195 chr1 63049593 C G 3.08E-13 Triglycerides DOCK7 intron 23063622 rs12042319 chr1 63049819 G A 5.15E-04 Type 2 diabetes DOCK7 intron 17463246 rs12042319 chr1 63049819 G A 3.24E-07 Cardiovascular disease DOCK7 intron 18179892 rs12042319 chr1 63049819 G A 5.85E-12 Metabolite levels DOCK7 intron 22286219 rs3850634 chr1 63050598 T G 3.93E-12 Metabolite levels DOCK7 intron 22286219 rs12048208 chr1 63055280 G A 0.00000003 Triglycerides DOCK7 intron 23063622 rs12048208 chr1 63055280 G A 2.05E-09 Cholesterol,total DOCK7 intron 23063622 rs12048208 chr1 63055280 G A 9.52E-05 LDL lipoproteins DOCK7 intron pha002902 rs11207996 chr1 63055470 G A 4.13E-12 Metabolite levels DOCK7 intron 22286219 rs1748197 chr1 63056112 G A 4.19E-12 Metabolite levels DOCK7 intron 22286219 rs1748197 chr1 63056112 G A 0.000000623 Triglycerides DOCK7 intron 22629316 rs1748197 chr1 63056112 G A 0.0000821 Triglycerides (males) DOCK7 intron 22629316 rs1748197 chr1 63056112 G A 0.000551 Triglycerides (females) DOCK7 intron 22629316 rs1748197 chr1 63056112 G A 1.10E-09 LDL cholesterol DOCK7 intron 23063622 rs1748197 chr1 63056112 G A 1.79E-28 Triglycerides DOCK7 intron 23063622 rs1748197 chr1 63056112 G A 5.47E-23 Triglycerides DOCK7 intron 23063622 rs1748197 chr1 63056112 G A 6.75E-29 Cholesterol,total DOCK7 intron 23063622 rs2366636 chr1 63056670 G A 4.19E-12 Metabolite levels DOCK7 intron 22286219 rs1748199 chr1 63057136 T C 3.36E-12 Metabolite levels DOCK7 intron 22286219 rs6690733 chr1 63060311 A C 5.66E-12 Metabolite levels DOCK7 intron 22286219 rs11207997 chr1 63061906 C T 8.91E-12 Metabolite levels DOCK7 intron 22286219 rs11207997 chr1 63061906 C T 1.03E-10 LDL cholesterol DOCK7 intron 23063622 rs11207997 chr1 63061906 C T 4.27E-24 Triglycerides DOCK7 intron 23063622 rs11207997 chr1 63061906 C T 6.33E-29 Cholesterol,total DOCK7 intron 23063622 rs17123725 chr1 63063830 T C 0.00000118 Triglycerides ANGPTL3 intron 23063622 rs17123725 chr1 63063830 T C 4.04E-08 LDL cholesterol ANGPTL3 intron 23063622 rs10789117 chr1 63072265 A C 6.37E-12 Metabolite levels DOCK7 intron 22286219 rs10789117 chr1 63072265 A C 0.00000021 LDL cholesterol (female) DOCK7 intron 23063622 rs10789117 chr1 63072265 A C 1.04E-09 LDL cholesterol DOCK7 intron 23063622 rs10789117 chr1 63072265 A C 1.87E-23 Triglycerides DOCK7 intron 23063622 rs10789117 chr1 63072265 A C 8.71E-29 Cholesterol,total DOCK7 intron 23063622 rs6675401 chr1 63073975 C T 6.41E-12 Metabolite levels DOCK7 intron 22286219 rs6678483 chr1 63074442 C A 6.42E-12 Metabolite levels DOCK7 intron 22286219 rs10889347 chr1 63075826 G A 6.41E-12 Metabolite levels DOCK7 intron 22286219 rs10889348 chr1 63078222 A T 8.08E-13 Metabolite levels DOCK7 intron 22286219 rs10889349 chr1 63081919 A G 4.29E-12 Metabolite levels DOCK7 intron 22286219 rs61471917 chr1 63084030 G A 4.28E-12 Metabolite levels DOCK7 intron 22286219 rs10889350 chr1 63085266 C T 4.29E-12 Metabolite levels DOCK7 intron 22286219 rs12239736 chr1 63085997 T A 3.74E-11 Metabolite levels DOCK7 intron 22286219 rs6587980 chr1 63090858 C T 6.91E-12 Metabolite levels DOCK7 intron 22286219 rs10157265 chr1 63093617 C T 4.34E-12 Metabolite levels DOCK7 intron 22286219 rs11485618 chr1 63094207 A G 4.18E-12 Metabolite levels DOCK7 intron 22286219 rs10789118 chr1 63094692 A G 4.19E-12 Metabolite levels DOCK7 intron 22286219 rs7520810 chr1 63095711 C T 4.18E-12 Metabolite levels DOCK7 intron 22286219 rs10789119 chr1 63098235 G A 4.16E-12 Metabolite levels DOCK7 intron 22286219 rs10889352 chr1 63099023 T C 4.18E-12 Metabolite levels DOCK7 intron 22286219 rs2366638 chr1 63099577 G A 4.33E-12 Metabolite levels DOCK7 intron 22286219 rs1570694 chr1 63103217 A G 4.12E-12 Metabolite levels DOCK7 intron 22286219 rs12047226 chr1 63105538 T C 4.17E-12 Metabolite levels DOCK7 intron 22286219 rs7539035 chr1 63106767 C A 5.47E-04 Type 2 diabetes DOCK7 intron 17463246 rs7539035 chr1 63106767 C A 4.54E-06 Lymphocyte counts DOCK7 intron 22286170 rs7539035 chr1 63106767 C A 6.69E-12 Metabolite levels DOCK7 intron 22286219 rs995000 chr1 63107526 C T 5.40E-04 Type 2 diabetes DOCK7 intron 17463246 rs995000 chr1 63107526 C T 1.91E-11 Metabolite levels DOCK7 intron 22286219 rs11208000 chr1 63108374 A G 5.01E-12 Metabolite levels DOCK7 intron 22286219 rs993013 chr1 63111069 G T 1.27E-11 Metabolite levels DOCK7 intron 22286219 rs1168085 chr1 63112320 C G 5.94E-12 Metabolite levels DOCK7 intron 22286219 rs1168086 chr1 63112389 A G 5.94E-12 Metabolite levels DOCK7 intron 22286219 rs746735 chr1 63113511 C A 5.91E-12 Metabolite levels DOCK7 intron 22286219 rs1168089 chr1 63113719 T C 2.34E-11 Metabolite levels DOCK7 intron 22286219 rs10889353 chr1 63118196 A C 4.36E-04 Type 2 diabetes DOCK7 intron 17463246 rs10889353 chr1 63118196 A C 3.00E-07 Triglycerides DOCK7 intron 19060906 rs10889353 chr1 63118196 A C 4.00E-12 Cholesterol,total DOCK7 intron 19060911 rs10889353 chr1 63118196 A C 8.00E-06 LDL cholesterol DOCK7 intron 19060911 rs10889353 chr1 63118196 A C 1.40E-04 Lipid levels DOCK7 intron 19802338 rs10889353 chr1 63118196 A C 1.19E-13 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 1.30E-14 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 1.40E-12 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 1.60E-11 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 2.77E-12 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 3.00E-10 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 7.30E-10 Lipid levels DOCK7 intron 19936222 rs10889353 chr1 63118196 A C 1.96E-09 Blood cell counts and other traits DOCK7 intron 20139978 rs10889353 chr1 63118196 A C 2.00E-09 Blood cell counts and other traits DOCK7 intron 20139978 rs10889353 chr1 63118196 A C 8.00E-06 Coronary heart disease DOCK7 intron 21347282 rs10889353 chr1 63118196 A C 4.41E-12 Metabolite levels DOCK7 intron 22286219 rs10889353 chr1 63118196 A C 1.41E-08 Cholesterol,total DOCK7 intron 23063622 rs10889353 chr1 63118196 A C 9.39E-10 Lipid traits DOCK7 intron 24386095 rs10889353 chr1 63118196 A C 4.07E-05 LDL lipoproteins DOCK7 intron pha002902 rs10889353 chr1 63118196 A C 4.05E-06 Triglycerides DOCK7 intron pha003081 rs10889353 chr1 63118196 A C 8.46E-06 Lipid levels DOCK7 intron pha003082 rs1168097 chr1 63120371 C T 4.27E-12 Metabolite levels DOCK7 intron 22286219 rs1168097 chr1 63120371 C T 2.34E-08 Cholesterol,total DOCK7 intron 23063622 rs1168098 chr1 63121294 G A 4.25E-12 Metabolite levels DOCK7 intron 22286219 rs1168099 chr1 63122859 C A 2.11E-11 Metabolite levels DOCK7 intron 22286219 rs4495740 chr1 63124465 T G 4.22E-12 Metabolite levels DOCK7 intron 22286219 rs1168102 chr1 63127705 C T 5.08E-12 Metabolite levels DOCK7 intron 22286219 rs1168103 chr1 63128081 C T 4.21E-12 Metabolite levels DOCK7 intron 22286219 rs10889354 chr1 63129082 T C 4.22E-12 Metabolite levels DOCK7 intron 22286219 rs11208001 chr1 63130431 C T 4.46E-12 Metabolite levels DOCK7 intron 22286219 rs2479464 chr1 63130991 G A 4.21E-12 Metabolite levels DOCK7 intron 22286219 rs1168132 chr1 63133468 T A 6.16E-12 Metabolite levels DOCK7 intron 22286219 rs4587594 chr1 63133930 G A 3.50E-12 Metabolite levels DOCK7 intron 22286219 rs4587594 chr1 63133930 G A 4.77E-06 Triglycerides DOCK7 intron pha003081 rs4587594 chr1 63133930 G A 9.92E-06 Lipid levels DOCK7 intron pha003082 rs1168124 chr1 63139730 C T 4.61E-12 Metabolite levels DOCK7 intron 22286219 rs11208004 chr1 63145439 G A 3.43E-12 Metabolite levels DOCK7 intron 22286219 rs10889356 chr1 63155349 G A 1.00E-10 Metabolite levels / / 22286219 rs1168114 chr1 63156043 A G 2.26E-11 Metabolite levels / / 22286219 rs12136083 chr1 63163073 T C 1.33E-11 Metabolite levels / / 22286219 rs2182866 chr1 63163591 G A,C,T 4.94E-04 Multiple complex diseases / / 17554300 rs880694 chr1 63173284 C T 3.29E-06 Triglycerides / / pha003081 rs880694 chr1 63173284 C T 1.07E-05 Lipid levels / / pha003082 rs4409689 chr1 63177365 C T 3.29E-06 Triglycerides / / pha003081 rs4409689 chr1 63177365 C T 1.07E-05 Lipid levels / / pha003082 rs7518497 chr1 63177696 A C 1.42E-11 Metabolite levels / / 22286219 rs9787151 chr1 63179138 C T 3.29E-06 Triglycerides / / pha003081 rs9787151 chr1 63179138 C T 1.07E-05 Lipid levels / / pha003082 rs4915849 chr1 63180740 G A 4.95E-04 Multiple complex diseases / / 17554300 rs12130333 chr1 63191777 C T 6.34E-04 Type 2 diabetes / / 17463246 rs12130333 chr1 63191777 C T 2.00E-08 Triglycerides / / 18193044 rs12130333 chr1 63191777 C T 2.25E-11 Triglycerides / / 23063622 rs12130333 chr1 63191777 C T 4.78E-16 Cholesterol,total / / 23063622 rs6679002 chr1 63199936 G T 2.00E-15 Blood metabolite levels / / 24816252 rs17316337 chr1 63268989 A G 0.000668 fMRI brain tests in schizophrenia ATG4C intron 22440650 rs6683832 chr1 63276904 G A 5.60E-05 Blood Phenotypes ATG4C intron 17903294 rs11582138 chr1 63277459 A G 4.12E-04 Lung function (forced expiratory volume in 1 second) ATG4C intron 17255346 rs12042640 chr1 63366796 T C 1.71E-06 Aging (time to event) / / 21782286 rs56337244 chr1 63368615 C T 7.99E-11 Metabolite levels / / 22286219 rs200589189 chr1 63384292 T TG 1.43E-04 Alcohol dependence / / 21314694 rs7556152 chr1 63384292 T G 1.43E-04 Alcohol dependence / / 21314694 rs13376351 chr1 63389782 G A 8.00E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2780882 chr1 63405427 C A 8.57E-05 Information processing speed / / 21130836 rs2780883 chr1 63410619 A G 2.00E-04 Information processing speed / / 21130836 rs4915858 chr1 63411308 A G 9.10E-06 Urinary metabolites / / 21572414 rs1931080 chr1 63414144 G T 9.10E-06 Urinary metabolites / / 21572414 rs1931080 chr1 63414144 G T 9.10E-04 Breast cancer (survival) / / 22232737 rs2065585 chr1 63414401 G A 9.10E-06 Urinary metabolites / / 21572414 rs12121455 chr1 63433037 C T 8.79E-04 Response to alcohol consumption (flushing response) / / 24277619 rs2150031 chr1 63441761 A G 6.43E-05 Elbow pain / / pha003008 rs6696619 chr1 63452789 T C 1.89E-04 Premature ovarian failure / / 19508998 rs17124192 chr1 63456797 A G 5.76E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17124200 chr1 63459814 G A 1.28E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs3818637 chr1 63466655 A G 6.14E-06 Hemoglobin concentration / / 20534544 rs17124237 chr1 63470187 A C 4.31E-05 Suicide attempts in bipolar disorder / / 21423239 rs7541201 chr1 63478358 G A 1.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs12143251 chr1 63478914 C G 2.25E-04 Suicide attempts in bipolar disorder / / 21423239 rs12038327 chr1 63480004 T C 4.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs2026786 chr1 63480641 T A,G 4.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs17124318 chr1 63480730 C G,T 4.00E-06 Weight / / 20966902 rs17124318 chr1 63480730 C G,T 6.00E-07 Body mass index / / 20966902 rs17124399 chr1 63489983 C T 1.18E-05 Hemoglobin concentration / / 20534544 rs944188 chr1 63492959 C A 2.02E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs944188 chr1 63492959 C A 5.04E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1330221 chr1 63495975 T C 3.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1330221 chr1 63495975 T C 6.51E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6664042 chr1 63501851 C T 4.58E-05 Waist Circumference / / pha003023 rs7519367 chr1 63502030 G A 3.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs6694848 chr1 63503606 A G 7.95E-04 Multiple complex diseases / / 17554300 rs6694848 chr1 63503606 A G 7.19E-06 Waist Circumference / / pha003023 rs1874930 chr1 63507395 A C 3.10E-04 Hemoglobin concentration / / 20534544 rs881939 chr1 63517230 T C 4.60E-05 Response to TNF antagonist treatment / / 21061259 rs11208115 chr1 63521755 T C 3.10E-04 Hemoglobin concentration / / 20534544 rs17124480 chr1 63529093 A G 2.52E-05 Response to TNF antagonist treatment / / 21061259 rs12039756 chr1 63536774 T C 7.11E-04 Response to TNF antagonist treatment / / 21061259 rs11808494 chr1 63545178 A G 4.55E-04 Alzheimer's disease (late onset) / / 21379329 rs953654 chr1 63549282 C T 5.91E-06 Kawasaki disease / / 21221998 rs6673535 chr1 63562762 C T 6.58E-05 Multiple complex diseases / / 17554300 rs1498942 chr1 63566915 C T 2.43E-04 Gallstones / / 17632509 rs10493340 chr1 63591129 A G 2.00E-06 Blood pressure / / 17903302 rs6692500 chr1 63603161 C T 3.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs1887808 chr1 63614961 G A 4.62E-06 Stroke (ischemic) / / 22941190 rs6588016 chr1 63638791 G A 0.0000126 Tuberculosis with late age of onset LINC00466 intron 22551897 rs7554824 chr1 63641989 C A 6.44E-05 Obesity (extreme) LINC00466 intron 21935397 rs7515372 chr1 63643251 C A 6.39E-05 Obesity (extreme) LINC00466 intron 21935397 rs11208148 chr1 63645215 A C 3.60E-04 Alzheimer's disease (late onset) LINC00466 intron 21379329 rs4253945 chr1 63655914 C T 6.11E-04 Obesity (extreme) LINC00466 intron 21935397 rs12724092 chr1 63657649 C G 6.05E-04 Obesity (extreme) LINC00466 intron 21935397 rs1328589 chr1 63674914 T G 6.50E-05 Asthma LINC00466 intron 20159242 rs997791 chr1 63694517 G A 5.79E-05 Smoking initiation LINC00466 intron 24665060 rs12240186 chr1 63697711 A G 5.19E-05 Smoking initiation LINC00466 intron 24665060 rs1328586 chr1 63698424 T C 1.00E-04 Smoking initiation LINC00466 intron 24665060 rs1854335 chr1 63703330 C A 4.16E-04 Multiple complex diseases LINC00466 intron 17554300 rs10493343 chr1 63713524 C A 1.37E-05 Asthma LINC00466 intron 20159242 rs10493343 chr1 63713524 C A 5.12E-05 Smoking initiation LINC00466 intron 24665060 rs4915889 chr1 63719825 A G 2.61E-05 Smoking initiation LINC00466 intron 24665060 rs538071 chr1 63720224 T C 6.19E-04 Multiple complex diseases LINC00466 intron 17554300 rs952998 chr1 63743891 C G 1.41E-04 Multiple complex diseases LINC00466 intron 17554300 rs2031402 chr1 63744393 T C 1.45E-04 Response to statin treatment (atorvastatin),change in cholesterol levels LINC00466 intron 20031582 rs12747934 chr1 63767597 G A 1.87E-05 Celiac disease LINC00466 intron 23936387 rs2367270 chr1 63775056 C A 3.82E-04 Alzheimer's disease (late onset) LINC00466 intron 21379329 rs6588025 chr1 63790503 T C 3.96E-05 Celiac disease FOXD3 UTR-3 23936387 rs10749738 chr1 63793155 A G 1.99E-04 Celiac disease / / 23936387 rs12021563 chr1 63812269 C T 3.40E-05 Personality dimensions / / 18957941 rs12021563 chr1 63812269 C T 4.69E-05 Lymphocyte counts / / 22286170 rs7522426 chr1 63821329 G A 3.18E-04 Alzheimer's disease (late onset) / / 21379329 rs12135006 chr1 63861211 C A 3.33E-04 Aortic root size ALG6 intron 21223598 rs4630153 chr1 63881552 C T 5.68E-04 Glycosylated haemoglobin levels ALG6 missense 17255346 rs3009577 chr1 63914117 A G 2.54E-04 Alzheimer's disease (late onset) ITGB3BP intron 21379329 rs6588044 chr1 63958304 G A 2.25E-04 Alzheimer's disease (late onset) ITGB3BP intron 21379329 rs17391823 chr1 63986865 T C 4.89E-04 Lymphocyte counts ITGB3BP intron 22286170 rs217478 chr1 63991267 T C 3.43E-04 Alzheimer's disease (late onset) EFCAB7 cds-synon 21379329 rs17125177 chr1 64075768 T C 1.38E-04 Amyotrophic lateral sclerosis (sporadic) PGM1 intron 24529757 rs855314 chr1 64095111 A G 5.94E-05 Celiac disease PGM1 missense 23936387 rs2269252 chr1 64098065 T C 2.64E-05 Multiple complex diseases PGM1 intron 17554300 rs34922283 chr1 64100478 A AT 8.74E-04 Obesity (extreme) PGM1 intron 21935397 rs6588052 chr1 64100478 A T 8.74E-04 Obesity (extreme) PGM1 intron 21935397 rs2269248 chr1 64102114 A G 6.91E-04 Obesity (extreme) PGM1 intron 21935397 rs2301054 chr1 64107028 A G 6.81E-08 Alcohol consumption PGM1 intron 21665994 rs2269247 chr1 64107284 C T 2.98E-07 Alcohol consumption PGM1 intron 21665994 rs2269246 chr1 64107491 T C 7.45E-08 Alcohol consumption PGM1 intron 21665994 rs2269245 chr1 64107893 G A 7.43E-08 Alcohol consumption PGM1 intron 21665994 rs2269245 chr1 64107893 G A 4.47E-06 Type 1 diabetes PGM1 intron 21980299 rs2269241 chr1 64108771 T C 1.23E-05 Multiple complex diseases PGM1 intron 17554300 rs2269241 chr1 64108771 T C 4.00E-07 Type 1 diabetes PGM1 intron 19430480 rs2269241 chr1 64108771 T C 3.57E-08 Alcohol consumption PGM1 intron 21665994 rs2269240 chr1 64109264 T C 8.21E-08 Alcohol consumption PGM1 intron 21665994 rs2269239 chr1 64109359 C G 7.43E-07 Multiple complex diseases PGM1 intron 17554300 rs3790857 chr1 64111866 C T 3.37E-09 Multiple complex diseases PGM1 intron 17554300 rs3790857 chr1 64111866 C T 1.37E-07 Alcohol consumption PGM1 intron 21665994 rs11576729 chr1 64114429 G T 9.15E-08 Alcohol consumption PGM1 intron 21665994 rs2269238 chr1 64117537 G T 1.98E-06 Multiple complex diseases PGM1 intron 17554300 rs2269238 chr1 64117537 G T 7.19E-08 Alcohol consumption PGM1 intron 21665994 rs2269235 chr1 64118915 A G 3.45E-08 Alcohol consumption PGM1 intron 21665994 rs2269234 chr1 64118976 A G 4.47E-08 Alcohol consumption PGM1 intron 21665994 rs2269233 chr1 64119346 T C 3.15E-08 Alcohol consumption PGM1 intron 21665994 rs12027168 chr1 64120613 T C 6.25E-08 Alcohol consumption PGM1 intron 21665994 rs2749100 chr1 64124979 G T 4.44E-05 Multiple complex diseases PGM1 intron 17554300 rs2749100 chr1 64124979 G T 7.63E-07 Alcohol consumption PGM1 intron 21665994 rs11208264 chr1 64125072 T C 3.38E-05 Multiple complex diseases PGM1 intron 17554300 rs11208264 chr1 64125072 T C 9.37E-07 Alcohol consumption PGM1 intron 21665994 rs11208265 chr1 64125234 G T 7.24E-05 Multiple complex diseases PGM1 intron 17554300 rs8294 chr1 64125368 C T 2.32E-09 Alcohol consumption PGM1 UTR-3 21665994 rs4643 chr1 64125439 A C 2.17E-06 Multiple complex diseases PGM1 UTR-3 17554300 rs4643 chr1 64125439 A C 2.31E-09 Alcohol consumption PGM1 UTR-3 21665994 rs855350 chr1 64127004 C T 9.58E-07 Alcohol consumption / / 21665994 rs2749097 chr1 64127468 C G 2.00E-09 Alcohol consumption (transferrin glycosylation) / / 21665994 rs2013012 chr1 64128209 C T 1.99E-04 Multiple complex diseases / / 17554300 rs1506397 chr1 64145283 C G 6.01E-08 Alcohol consumption / / 21665994 rs1395246 chr1 64147162 G C 4.61E-32 Narcolepsy / / 19629137 rs1395246 chr1 64147162 G C 7.71E-06 Height / / 20400458 rs1354718 chr1 64147950 A G 7.97E-05 HIV-1 viral setpoint / / 21490045 rs7548548 chr1 64151369 G C 9.81E-05 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs7548548 chr1 64151369 G C 1.04E-07 Alcohol consumption / / 21665994 rs2819157 chr1 64166213 C T 6.98E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs12087869 chr1 64166968 T C 4.83E-05 Lung adenocarcinoma / / 19836008 rs2658407 chr1 64172809 A C 2.67E-04 Hearing function / / 17255346 rs4915914 chr1 64177299 G A 1.65E-04 Hearing function / / 17255346 rs2819172 chr1 64192575 G A 7.50E-05 Height / / pha003011 rs4915919 chr1 64195043 A C 2.09E-06 Diabetes Mellitus / / pha003059 rs11208281 chr1 64199752 C T 1.63E-04 Multiple complex diseases / / 17554300 rs1754546 chr1 64216658 A G 4.97E-05 Cognitive performance / / 19734545 rs11208285 chr1 64221643 T A 6.23E-05 Bipolar disorder / / 19488044 rs11208285 chr1 64221643 T A 9.59E-05 Bipolar Disorder / / pha002863 rs2819130 chr1 64231541 G A 2.10E-04 Crohn's disease / / 17435756 rs2819130 chr1 64231541 G A 8.84E-04 Alcohol consumption (maxi-drinks) / / 24277619 rs7552384 chr1 64237404 G C 5.30E-07 Fetal hemoglobin levels / / 18245381 rs620019 chr1 64240929 T C 8.84E-04 Alcohol consumption (maxi-drinks) ROR1 intron 24277619 rs659406 chr1 64256018 C T 1.00E-04 Serum metabolites ROR1 intron 19043545 rs659406 chr1 64256018 C T 2.01E-05 Diabetes Mellitus ROR1 intron pha003059 rs602227 chr1 64256988 A G 4.52E-05 Diabetes Mellitus ROR1 intron pha003059 rs596985 chr1 64277035 A G 4.13E-05 Crohn's disease ROR1 intron 23850713 rs631029 chr1 64312152 G A 7.97E-04 Multiple complex diseases ROR1 intron 17554300 rs675893 chr1 64317180 G T 8.59E-04 Multiple complex diseases ROR1 intron 17554300 rs7513180 chr1 64339801 G A 7.85E-05 Cognitive test performance ROR1 intron 20125193 rs11208308 chr1 64340452 T C 4.38E-05 Body Mass Index ROR1 intron pha003014 rs687578 chr1 64346361 C G,T 8.35E-04 Alzheimer's disease ROR1 intron 17998437 rs662986 chr1 64348148 A G 4.43E-04 Alzheimer's disease ROR1 intron 17998437 rs662437 chr1 64348338 T C 5.19E-04 Alzheimer's disease ROR1 intron 17998437 rs855851 chr1 64351518 T C 1.06E-04 Multiple complex diseases ROR1 intron 17554300 rs3861946 chr1 64383389 C A 6.69E-04 Heart Failure ROR1 intron pha002884 rs285339 chr1 64442169 G A 8.80E-05 Lung adenocarcinoma ROR1 intron 22797724 rs285385 chr1 64469469 G A,T 8.33E-04 Multiple complex diseases ROR1 intron 17554300 rs834485 chr1 64484485 C T 5.01E-04 Myocardial Infarction ROR1 intron pha002883 rs834487 chr1 64486207 A G 4.57E-04 Multiple complex diseases ROR1 intron 17554300 rs834487 chr1 64486207 A G 3.31E-04 Alzheimer's disease ROR1 intron 17998437 rs1260836 chr1 64488856 G A 9.31E-04 Alzheimer's disease ROR1 intron 22005930 rs1260836 chr1 64488856 G A 7.01E-04 Myocardial Infarction ROR1 intron pha002883 rs1260817 chr1 64502933 T G 3.52E-04 Type 2 diabetes ROR1 intron 17463246 rs1260773 chr1 64534922 G A 2.00E-04 Myasthenia gravis ROR1 intron 23055271 rs10493354 chr1 64541533 G A 7.68E-04 Type 2 diabetes ROR1 intron 17463246 rs10493354 chr1 64541533 G A 7.00E-06 Urinary metabolites ROR1 intron 21572414 rs12409562 chr1 64550053 A G 1.42E-04 Alzheimer's disease (late onset) ROR1 intron 21379329 rs3933251 chr1 64560848 T G 4.73E-05 Bladder cancer ROR1 intron 19648920 rs2806541 chr1 64566396 G A 6.83E-05 Bladder cancer ROR1 intron 19648920 rs2762849 chr1 64596766 T C 2.32E-05 Bipolar disorder and schizophrenia ROR1 intron 20889312 rs10489902 chr1 64607328 T G 5.55E-04 Type 2 diabetes ROR1 intron 17846124 rs12025819 chr1 64612395 C A 1.16E-05 Hearing function ROR1 intron 17255346 rs6588083 chr1 64614011 T C 9.49E-05 Schizophrenia ROR1 intron 19197363 rs3884549 chr1 64628407 T A 0.0002287 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ROR1 intron 23233654 rs3884549 chr1 64628407 T A 2.29E-04 Methotrexate clearance (acute lymphoblastic leukemia) ROR1 intron 23233662 rs4915657 chr1 64630026 G C 8.48E-05 Femoral neck bone geometry ROR1 intron 22087292 rs4915657 chr1 64630026 G C 0.0002301 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ROR1 intron 23233654 rs4915657 chr1 64630026 G C 2.30E-04 Methotrexate clearance (acute lymphoblastic leukemia) ROR1 intron 23233662 rs4915658 chr1 64630237 A G 0.0006204 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ROR1 intron 23233654 rs4915658 chr1 64630237 A G 6.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) ROR1 intron 23233662 rs6676128 chr1 64635283 T C 0.0002429 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ROR1 intron 23233654 rs6676128 chr1 64635283 T C 2.43E-04 Methotrexate clearance (acute lymphoblastic leukemia) ROR1 intron 23233662 rs7534614 chr1 64640415 C G 0.000237 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ROR1 intron 23233654 rs7534614 chr1 64640415 C G 2.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) ROR1 intron 23233662 rs11208376 chr1 64640898 T G 0.0001836 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ROR1 intron 23233654 rs11208376 chr1 64640898 T G 1.84E-04 Methotrexate clearance (acute lymphoblastic leukemia) ROR1 intron 23233662 rs10489900 chr1 64646624 A G 2.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs11208377 chr1 64647608 C T 0.0001924 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs11208377 chr1 64647608 C T 1.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4333885 chr1 64649858 A G 0.0001938 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4333885 chr1 64649858 A G 1.94E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs7546930 chr1 64649955 G A 0.0002012 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs7546930 chr1 64649955 G A 2.01E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6681495 chr1 64652405 T C 0.0002016 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs6681495 chr1 64652405 T C 2.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs11208380 chr1 64656971 A G 4.35E-04 Alzheimer's disease (late onset) / / 21379329 rs11208383 chr1 64659070 G A 9.14E-04 Multiple complex diseases / / 17554300 rs825175 chr1 64679749 C T 2.70E-05 Urinary metabolites UBE2U intron 21572414 rs41529245 chr1 64707668 G A 7.88E-04 Aortic root size UBE2U intron 21223598 rs4915956 chr1 64712355 T A 3.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs4915962 chr1 64751610 G A 2.85E-05 Body Mass Index / / pha003014 rs11583668 chr1 64785839 A T 9.75E-04 Type 2 diabetes / / 17463246 rs4915972 chr1 64791688 T C 3.49E-05 Body Mass Index / / pha003014 rs1390473 chr1 64804379 A G 1.60E-04 Renal cell carcinoma / / 24220910 rs17126437 chr1 64811160 G T 3.42E-05 Body Mass Index / / pha003014 rs10493358 chr1 64812821 A G 4.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs1390484 chr1 64831392 T C 7.91E-05 Post-operative nausea and vomiting / / 21694509 rs1514966 chr1 64834710 A G 3.33E-04 Smoking initiation / / 24665060 rs10493359 chr1 64837281 T C 2.44E-04 Smoking initiation / / 24665060 rs6588092 chr1 64855419 A G 1.16E-04 Smoking initiation / / 24665060 rs11208446 chr1 64868352 G A 9.00E-06 Bilirubin levels / / 22085899 rs305535 chr1 64914437 A C 7.77E-06 Sodium levels / / pha003093 rs305544 chr1 64918776 C T 7.69E-06 Sodium levels / / pha003093 rs12128329 chr1 64925891 G A 1.82E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs764457 chr1 64981488 C T 5.19E-04 Premature ovarian failure CACHD1 intron 19508998 rs9326061 chr1 64986799 G C 1.60E-05 Urinary metabolites CACHD1 intron 21572414 rs893075 chr1 64998367 T C 1.85E-04 Multiple complex diseases CACHD1 intron 17554300 rs17126643 chr1 65010606 T G 6.43E-05 Alcohol consumption CACHD1 intron 23953852 rs6681578 chr1 65013586 T C 5.06E-08 Schizophrenia CACHD1 intron 21926974 rs1436751 chr1 65064340 A G 2.71E-04 Aortic root size CACHD1 intron 21223598 rs2375268 chr1 65069961 A G 1.28E-04 Aortic root size CACHD1 intron 21223598 rs12407953 chr1 65084275 G C 9.65E-05 Schizophrenia(age at onset) CACHD1 intron 21688384 rs12097652 chr1 65085942 A G 8.86E-04 Aortic root size CACHD1 intron 21223598 rs2118102 chr1 65099978 G A 1.15E-05 Response to platinum-based chemotherapy in small cell and non-small cell lung cancers CACHD1 intron 21775533 rs751666 chr1 65100865 T C 8.07E-04 Smoking quantity CACHD1 intron 24665060 rs111303300 chr1 65109273 A C 0.00005063 Sarcoidosis CACHD1 intron 22952805 rs111631599 chr1 65109276 T C 0.0000501 Sarcoidosis CACHD1 intron 22952805 rs1561168 chr1 65115319 G A 3.05E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) CACHD1 intron 17982456 rs1561168 chr1 65115319 G A 1.10E-05 Urinary metabolites CACHD1 intron 21572414 rs1561167 chr1 65115513 T A 9.70E-06 Urinary metabolites CACHD1 intron 21572414 rs7552864 chr1 65119146 T C 7.10E-06 Urinary metabolites CACHD1 intron 21572414 rs7517300 chr1 65128071 T C 7.50E-06 Urinary metabolites CACHD1 intron 21572414 rs11208492 chr1 65128375 G A 1.10E-05 Urinary metabolites CACHD1 intron 21572414 rs11208493 chr1 65128395 C T 5.40E-06 Urinary metabolites CACHD1 intron 21572414 rs7513574 chr1 65135341 G T 1.75E-06 Diabetes (gestational) CACHD1 intron 22233651 rs2478156 chr1 65144191 G C 2.10E-05 Iron levels CACHD1 intron 21208937 rs17126889 chr1 65156862 T C 2.75E-04 Response to cytadine analogues (cytosine arabinoside) CACHD1 intron 24483146 rs1926304 chr1 65161230 T G 8.51E-04 Iron levels / / pha002876 rs2148323 chr1 65161633 T C 8.53E-04 Iron levels / / pha002876 rs11208510 chr1 65167537 T A 4.85E-04 Nonalcoholic fatty liver disease / / 21423719 rs11208512 chr1 65170405 T C 1.44E-04 Alzheimer's disease / / 24755620 rs7530486 chr1 65182826 T C 9.57E-05 Bipolar disorder and schizophrenia / / 20889312 rs7530486 chr1 65182826 T C 3.00E-04 Alzheimer's disease (late onset) / / 21379329 rs7530486 chr1 65182826 T C 6.92E-04 Alzheimer's disease / / 24755620 rs1926310 chr1 65188498 G C 3.70E-04 Type 2 diabetes / / 17463246 rs1926312 chr1 65193698 A T 2.91E-04 Alzheimer's disease / / 22005930 rs10493367 chr1 65206148 A G 3.50E-04 Alzheimer's disease / / 22005930 rs998125 chr1 65211521 A G 3.17E-04 Alzheimer's disease RAVER2 intron 22005930 rs12038159 chr1 65212345 G A 3.79E-04 Alzheimer's disease RAVER2 intron 22005930 rs12043554 chr1 65214034 T C 4.13E-04 Alzheimer's disease RAVER2 intron 22005930 rs12040026 chr1 65214219 G A 4.05E-04 Alzheimer's disease RAVER2 intron 22005930 rs10493368 chr1 65220035 T A 4.84E-04 Alzheimer's disease RAVER2 intron 22005930 rs10493369 chr1 65221656 G A 4.60E-04 Alzheimer's disease RAVER2 intron 22005930 rs17126970 chr1 65221766 T C 5.26E-04 Alzheimer's disease RAVER2 intron 22005930 rs12049564 chr1 65221984 A G 5.36E-04 Alzheimer's disease RAVER2 intron 22005930 rs11208518 chr1 65223510 C T 4.50E-04 Alzheimer's disease RAVER2 intron 22005930 rs11208519 chr1 65223552 T C 5.70E-04 Alzheimer's disease RAVER2 intron 22005930 rs11208520 chr1 65227239 G A 9.16E-04 Alzheimer's disease RAVER2 intron 22005930 rs11208521 chr1 65228129 G A 6.49E-04 Alzheimer's disease RAVER2 intron 22005930 rs6671355 chr1 65231009 T A 9.30E-04 Alzheimer's disease RAVER2 intron 22005930 rs12029333 chr1 65235586 A G 9.85E-04 Alzheimer's disease RAVER2 intron 22005930 rs3790529 chr1 65280620 G A 9.50E-05 HIV-1 control RAVER2 intron 20041166 rs12353950 chr1 65299088 A C 6.81E-05 Type 2 diabetes JAK1 UTR-3 17463246 rs17390055 chr1 65304953 T C 7.83E-05 Type 2 diabetes JAK1 intron 17463246 rs4916005 chr1 65309387 T C 2.98E-04 Suicide attempts in bipolar disorder JAK1 intron 21041247 rs10789166 chr1 65312813 A G 3.21E-04 Suicide attempts in bipolar disorder JAK1 intron 21041247 rs12093269 chr1 65331786 C T 3.00E-04 Suicide attempts in bipolar disorder JAK1 intron 21041247 rs3818753 chr1 65339232 A G 1.62E-08 LDL cholesterol JAK1 intron 23063622 rs10889504 chr1 65390503 G C 6.44E-04 Multiple complex diseases JAK1 intron 17554300 rs17127168 chr1 65408513 A G 8.35E-04 Suicide attempts in bipolar disorder JAK1 intron 21423239 rs11579758 chr1 65445542 G A 1.50E-05 Urinary metabolites / / 21572414 rs3014983 chr1 65460691 C T 2.30E-05 Urinary metabolites / / 21572414 rs519282 chr1 65487083 T G 5.95E-06 Glaucoma (primary open-angle) / / 22605921 rs11208575 chr1 65509848 G A 7.61E-04 Multiple complex diseases / / 17554300 rs478665 chr1 65515533 A G 1.00E-06 Estradiol plasma levels (breast cancer) / / 23518928 rs2375675 chr1 65553193 A C 4.33E-05 Varicose Veins / / pha001411 rs1572664 chr1 65580328 C A 2.25E-05 Leukocyte Counts / / pha003091 rs11208589 chr1 65580573 T C 6.06E-05 Leukocyte Counts / / pha003091 rs6588114 chr1 65585503 C T 0.0000983 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6588115 chr1 65585799 T A 0.0000983 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6695432 chr1 65586115 C T 0.000091 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6695445 chr1 65586154 C A 0.0000636 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6696301 chr1 65586815 G A 0.0000893 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7515954 chr1 65587028 T C 0.0000704 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7551568 chr1 65587239 G C 0.0000266 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7551569 chr1 65587240 G A 0.0000401 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs36003337 chr1 65587853 T C 0.0000645 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs35192521 chr1 65587857 A T 0.0000632 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12044147 chr1 65588329 C A,T 0.0000633 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12037302 chr1 65588420 A G 0.0000673 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12044210 chr1 65588500 C T 0.0000845 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7513657 chr1 65589947 G A 0.0000789 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6588117 chr1 65590511 A G 0.0000828 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6588118 chr1 65590762 A G 0.0000663 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6588119 chr1 65590965 C T 0.0000805 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs4375305 chr1 65591114 C T 0.000078 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7548217 chr1 65591956 G A 0.00008 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7548059 chr1 65591966 C T 0.0000798 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs7548222 chr1 65591969 G C 0.0000827 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs17127361 chr1 65594282 A G 6.30E-04 Type 2 diabetes / / 17463246 rs1109374 chr1 65633497 T C 7.97E-05 Nicotine smoking AK4 intron 19268276 rs4916031 chr1 65681543 T C 9.80E-05 Multiple complex diseases AK4 intron 17554300 rs4916032 chr1 65681622 G T 8.81E-05 Multiple complex diseases AK4 intron 17554300 rs1889925 chr1 65687556 G A 8.23E-04 Alcohol consumption (maxi-drinks) AK4 intron 24277619 rs1336472 chr1 65695930 G A 4.00E-10 Venous thromboembolism (gene x gene interaction) AK4 UTR-3 23509962 rs1889928 chr1 65710802 A G 1.50E-06 Urinary metabolites / / 21572414 rs10889531 chr1 65714118 G T 9.10E-07 Urinary metabolites / / 21572414 rs1613638 chr1 65716872 T C 9.36E-04 Type 2 diabetes / / 17463246 rs1613638 chr1 65716872 T C 3.40E-06 Urinary metabolites / / 21572414 rs550075 chr1 65723174 C A 3.10E-06 Urinary metabolites / / 21572414 rs2477786 chr1 65732242 C T 2.10E-24 Progranulin levels D/JC6 intron 21087763 rs2477786 chr1 65732242 C T 2.10E-24 Myocardial infarction D/JC6 intron 21211798 rs2477786 chr1 65732242 C T 4.70E-06 Urinary metabolites D/JC6 intron 21572414 rs4916041 chr1 65782658 T A 1 Drug response to Etoposide D/JC6 intron 17537913 rs2281855 chr1 65785372 G A 5.25E-05 Attention deficit hyperactivity disorder D/JC6 intron 22420046 rs6588131 chr1 65801562 C A 1 Drug response to Etoposide D/JC6 intron 17537913 rs2375699 chr1 65808281 G A 1 Drug response to Etoposide D/JC6 intron 17537913 rs1413885 chr1 65815659 C T 3.00E-07 Anticoagulant levels D/JC6 intron 22216198 rs7541003 chr1 65832352 A T 5.96E-04 Multiple complex diseases D/JC6 intron 17554300 rs6588144 chr1 65858088 T C 6.85E-04 Smoking initiation D/JC6 intron 24665060 rs4332387 chr1 65859108 G C 4.37E-04 Smoking initiation D/JC6 intron 24665060 rs11208645 chr1 65861798 A G 2.76E-05 Cognitive impairment induced by topiramate D/JC6 intron 22091778 rs4655762 chr1 65869274 C T 1.90E-04 Alzheimer's disease D/JC6 intron 22005930 rs2148682 chr1 65869489 T C 3.03E-04 Alzheimer's disease D/JC6 intron 22005930 rs11208646 chr1 65873605 A T 2.47E-04 Alzheimer's disease D/JC6 intron 22005930 rs10493377 chr1 65879252 A G 7.81E-05 Atopy D/JC6 UTR-3 21625490 rs9436735 chr1 65885061 C G 1.65E-13 LDL cholesterol LEPR nearGene-5 23063622 rs9436735 chr1 65885061 C G 3.01E-13 Cholesterol,total LEPR nearGene-5 23063622 rs9436735 chr1 65885061 C G 5.33E-08 HDL cholesterol LEPR nearGene-5 23063622 rs9436297 chr1 65888854 T C 5.90E-05 Glioma (high-grade) LEPR intron 19578366 rs9436299 chr1 65892888 C A 0.00000721 C-reactive protein LEPR intron 23505291 rs17127608 chr1 65893941 C T 3.13E-14 LDL cholesterol LEPR intron 23063622 rs3790433 chr1 65894342 C T 3.40E-06 Soluble leptin receptor levels LEPR intron 20167575 rs7534511 chr1 65895130 A G 7.23E-09 Soluble leptin receptor levels LEPR intron 20167575 rs9436300 chr1 65895264 A G 6.74E-09 Soluble leptin receptor levels LEPR intron 20167575 rs9436301 chr1 65895927 T C 1.44E-08 Soluble leptin receptor levels LEPR intron 20167575 rs9436302 chr1 65896561 G A 4.40E-10 Soluble leptin receptor levels LEPR intron 20167575 rs9436303 chr1 65896674 A G 1.19E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1887285 chr1 65897747 A G 2.90E-05 Schizophrenia LEPROT UTR-3 19571809 rs7602 chr1 65897951 G A 6.04E-10 Soluble leptin receptor levels LEPROT UTR-3 20167575 rs1045895 chr1 65897981 G A 5.10E-05 Coffee consumption LEPROT UTR-3 21357676 rs9436742 chr1 65898331 C T 2.49E-09 LDL cholesterol LEPROT UTR-3 23063622 rs1046011 chr1 65898996 C T 7.34E-09 Soluble leptin receptor levels LEPROT UTR-3 20167575 rs1046011 chr1 65898996 C T 0.00000889 C-reactive protein LEPROT UTR-3 23505291 rs11804091 chr1 65903879 A G 2.40E-06 Soluble leptin receptor levels LEPR intron 20167575 rs970468 chr1 65906490 C A 2.30E-06 Soluble leptin receptor levels LEPR intron 20167575 rs9436747 chr1 65911607 T C 2.60E-06 Soluble leptin receptor levels LEPR intron 20167575 rs6657868 chr1 65913707 A G 2.30E-06 Soluble leptin receptor levels LEPR intron 20167575 rs4655811 chr1 65923157 C G 3.40E-07 Soluble leptin receptor levels LEPR intron 20167575 rs6669354 chr1 65925349 T G 2.80E-06 Soluble leptin receptor levels LEPR intron 20167575 rs7555955 chr1 65937479 A G 0.00000894 C-reactive protein LEPR intron 23505291 rs12409877 chr1 65943872 A G 0.0000444 C-reactive protein LEPR intron 23505291 rs2025804 chr1 65946121 G A 3.10E-06 Soluble leptin receptor levels LEPR intron 20167575 rs2025804 chr1 65946121 G A 0.00000636 C-reactive protein LEPR intron 23505291 rs2025803 chr1 65946506 A G 2.61E-06 Lymphocyte counts LEPR intron 22286170 rs10158579 chr1 65950056 T C 2.81E-10 Soluble leptin receptor levels LEPR intron 20167575 rs11808888 chr1 65952781 G A 2.86E-10 Soluble leptin receptor levels LEPR intron 20167575 rs17127673 chr1 65955725 A G 3.94E-10 Soluble leptin receptor levels LEPR intron 20167575 rs10128072 chr1 65957096 A C 3.48E-10 Soluble leptin receptor levels LEPR intron 20167575 rs1327121 chr1 65957337 G A 3.10E-06 Soluble leptin receptor levels LEPR intron 20167575 rs17127677 chr1 65958274 G T 3.90E-10 Soluble leptin receptor levels LEPR intron 20167575 rs6702545 chr1 65960036 G T 0.0000615 C-reactive protein LEPR intron 23505291 rs11800909 chr1 65961780 A G 7.10E-07 Soluble leptin receptor levels LEPR intron 20167575 rs17127690 chr1 65962949 A G 4.33E-10 Soluble leptin receptor levels LEPR intron 20167575 rs6694528 chr1 65963016 C T 4.31E-10 Soluble leptin receptor levels LEPR intron 20167575 rs11800275 chr1 65963704 T A 4.31E-10 Soluble leptin receptor levels LEPR intron 20167575 rs11208654 chr1 65965566 C T 3.10E-06 Soluble leptin receptor levels LEPR intron 20167575 rs11208654 chr1 65965566 C T 0.0000046 C-reactive protein LEPR intron 23505291 rs10157275 chr1 65966503 C T 2.39E-10 Soluble leptin receptor levels LEPR intron 20167575 rs1327115 chr1 65966839 T G 6.80E-06 Soluble leptin receptor levels LEPR intron 20167575 rs2104564 chr1 65969430 C T 9.87E-13 Soluble leptin receptor levels LEPR intron 20167575 rs10889556 chr1 65969552 G A 6.02E-13 Soluble leptin receptor levels LEPR intron 20167575 rs10889556 chr1 65969552 G A 0.0000796 C-reactive protein LEPR intron 23505291 rs12062820 chr1 65970495 T C 8.09E-04 Multiple complex diseases LEPR intron 17554300 rs12062820 chr1 65970495 T C 6.17E-10 Soluble leptin receptor levels LEPR intron 20167575 rs10889557 chr1 65970704 A G,T 7.67E-13 Soluble leptin receptor levels LEPR intron 20167575 rs11208656 chr1 65970787 A G 7.72E-04 Multiple complex diseases LEPR intron 17554300 rs11208656 chr1 65970787 A G 6.17E-10 Soluble leptin receptor levels LEPR intron 20167575 rs12079231 chr1 65971155 C G 6.13E-10 Soluble leptin receptor levels LEPR intron 20167575 rs7516840 chr1 65972595 C G 5.93E-13 Soluble leptin receptor levels LEPR intron 20167575 rs11208657 chr1 65973353 G A 1.35E-12 Soluble leptin receptor levels LEPR intron 20167575 rs12068561 chr1 65973953 T C 6.21E-13 Soluble leptin receptor levels LEPR intron 20167575 rs6672331 chr1 65975847 G C 2.74E-04 Menarche (age at onset) LEPR intron 21102462 rs1327116 chr1 65976051 A C 6.30E-13 Soluble leptin receptor levels LEPR intron 20167575 rs10889558 chr1 65976966 A G 6.29E-13 Soluble leptin receptor levels LEPR intron 20167575 rs7533108 chr1 65977844 C G 6.38E-13 Soluble leptin receptor levels LEPR intron 20167575 rs2767485 chr1 65978917 T C 5.97E-10 Soluble leptin receptor levels LEPR intron 20167575 rs11208659 chr1 65979280 T C 2.00E-09 Obesity (early onset extreme) LEPR intron 23563609 rs1171274 chr1 65980838 C T 6.07E-13 Soluble leptin receptor levels LEPR intron 20167575 rs1171275 chr1 65982633 C T 1.20E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1180445 chr1 65982919 T C 1.20E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1475397 chr1 65983158 C T 3.76E-10 Soluble leptin receptor levels LEPR intron 20167575 rs1475398 chr1 65983257 C G 1.41E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1627238 chr1 65986079 G A 1.20E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1782755 chr1 65986804 C A 3.10E-04 Multiple complex diseases LEPR intron 17554300 rs1782755 chr1 65986804 C A 1.20E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1171276 chr1 65987449 A G 2.75E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1171278 chr1 65988146 C T 2.45E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1171279 chr1 65988493 C T 4.09E-09 Soluble leptin receptor levels LEPR intron 20167575 rs12135802 chr1 65992140 A G 4.87E-05 Diabetes Mellitus LEPR intron pha003060 rs1751492 chr1 65992625 C T 6.00E-13 Soluble leptin receptor levels LEPR intron 20167575 rs1782754 chr1 65993348 G A 9.66E-13 Soluble leptin receptor levels LEPR intron 20167575 rs6697315 chr1 65993556 C T 3.50E-13 Soluble leptin receptor levels LEPR intron 20167575 rs2154381 chr1 65995701 G A 7.27E-14 Soluble leptin receptor levels LEPR intron 20167575 rs1171269 chr1 65996802 T C 1.28E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171270 chr1 65997841 G A 1.28E-12 Soluble leptin receptor levels LEPR intron 20167575 rs10749753 chr1 65998467 A G 6.21E-05 Cognitive test performance LEPR intron 20125193 rs1171271 chr1 65998790 C T 1.29E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1177681 chr1 65999119 G A 1.29E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171272 chr1 65999811 G T 1.29E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1022981 chr1 66000034 G A 1.29E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1186403 chr1 66000533 C T 7.45E-14 Soluble leptin receptor levels LEPR intron 20167575 rs1171261 chr1 66001402 T C 3.79E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171262 chr1 66001746 A T 1.57E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171263 chr1 66001933 T C 1.75E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171264 chr1 66003014 C G 2.41E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171265 chr1 66003252 A G 3.54E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1171266 chr1 66003824 T C 2.42E-13 Soluble leptin receptor levels LEPR intron 20167575 rs1171267 chr1 66003854 T G 1.43E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1782763 chr1 66007900 C T 5.62E-11 Soluble leptin receptor levels LEPR intron 20167575 rs1409802 chr1 66021351 A G 5.29E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1409802 chr1 66021351 A G 0.0000249 C-reactive protein LEPR intron 23505291 rs6673324 chr1 66031063 G A 6.85E-12 Soluble leptin receptor levels LEPR intron 20167575 rs7519977 chr1 66033496 G A 1.38E-11 Soluble leptin receptor levels LEPR intron 20167575 rs10158279 chr1 66033696 T G 1.18E-11 Soluble leptin receptor levels LEPR intron 20167575 rs1137100 chr1 66036441 A G 1.87E-11 Soluble leptin receptor levels LEPR missense 20167575 rs10789184 chr1 66036962 G A 1.87E-11 Soluble leptin receptor levels LEPR intron 20167575 rs12033452 chr1 66038435 C A 1.16E-12 Soluble leptin receptor levels LEPR intron 20167575 rs6657632 chr1 66038666 A G 1.16E-12 Soluble leptin receptor levels LEPR intron 20167575 rs11208674 chr1 66039317 T C 1.16E-12 Soluble leptin receptor levels LEPR intron 20167575 rs11208674 chr1 66039317 T C 0.0000734 C-reactive protein LEPR intron 23505291 rs35919106 chr1 66039425 C CG 1.14E-11 Soluble leptin receptor levels LEPR intron 20167575 rs4655517 chr1 66039425 C T 1.14E-11 Soluble leptin receptor levels LEPR intron 20167575 rs4655518 chr1 66039858 T G 1.16E-12 Soluble leptin receptor levels LEPR intron 20167575 rs4655680 chr1 66041469 G T 7.76E-13 Soluble leptin receptor levels LEPR intron 20167575 rs3790427 chr1 66042750 T C 1.91E-11 Soluble leptin receptor levels LEPR intron 20167575 rs3790427 chr1 66042750 T C 0.0000095 C-reactive protein LEPR intron 23505291 rs3790425 chr1 66043112 A G 4.30E-12 Soluble leptin receptor levels LEPR intron 20167575 rs3790425 chr1 66043112 A G 0.0000202 C-reactive protein LEPR intron 23505291 rs3790424 chr1 66044013 A G 4.03E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1343982 chr1 66045251 C T 4.03E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1343981 chr1 66045328 A G 4.03E-12 Soluble leptin receptor levels LEPR intron 20167575 rs11208675 chr1 66045424 T A,G 4.03E-12 Soluble leptin receptor levels LEPR intron 20167575 rs10789185 chr1 66045864 G C 2.87E-11 Soluble leptin receptor levels LEPR intron 20167575 rs10493379 chr1 66045927 G A 4.02E-12 Soluble leptin receptor levels LEPR intron 20167575 rs6691346 chr1 66046397 G A 4.02E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1938487 chr1 66047267 T C 4.03E-12 Soluble leptin receptor levels LEPR intron 20167575 rs11208676 chr1 66048123 A G 3.48E-12 Soluble leptin receptor levels LEPR intron 20167575 rs6673591 chr1 66048389 A G 2.10E-11 Soluble leptin receptor levels LEPR intron 20167575 rs11208677 chr1 66048417 A G 3.52E-12 Soluble leptin receptor levels LEPR intron 20167575 rs1938489 chr1 66048622 A G 9.45E-05 Body Mass Index LEPR intron pha003009 rs12038998 chr1 66049128 C A 3.27E-12 Soluble leptin receptor levels LEPR intron 20167575 rs12038998 chr1 66049128 C A 0.0000326 C-reactive protein LEPR intron 23505291 rs10889563 chr1 66049167 A G 1.93E-11 Soluble leptin receptor levels LEPR intron 20167575 rs4655528 chr1 66049489 A G 3.31E-12 Soluble leptin receptor levels LEPR intron 20167575 rs11208679 chr1 66049738 G A 4.02E-12 Soluble leptin receptor levels LEPR intron 20167575 rs10789186 chr1 66050477 G A 2.07E-11 Soluble leptin receptor levels LEPR intron 20167575 rs6676495 chr1 66052117 G A 1.99E-12 Soluble leptin receptor levels LEPR intron 20167575 rs6676419 chr1 66052209 C T 9.15E-12 Soluble leptin receptor levels LEPR intron 20167575 rs4370791 chr1 66052228 A G 1.68E-12 Soluble leptin receptor levels LEPR intron 20167575 rs12028951 chr1 66053081 G A 1.65E-12 Soluble leptin receptor levels LEPR intron 20167575 rs12042877 chr1 66053148 C T 1.58E-12 Soluble leptin receptor levels LEPR intron 20167575 rs12042877 chr1 66053148 C T 0.0000369 C-reactive protein LEPR intron 23505291 rs12042884 chr1 66053192 C G 1.35E-12 Soluble leptin receptor levels LEPR intron 20167575 rs3828039 chr1 66053556 A G 1.31E-12 Soluble leptin receptor levels LEPR intron 20167575 rs10749754 chr1 66054640 G A 5.65E-11 Soluble leptin receptor levels LEPR intron 20167575 rs6696954 chr1 66054995 T G 2.81E-12 Soluble leptin receptor levels LEPR intron 20167575 rs6696954 chr1 66054995 T G 1.56E-08 Amyloid A Levels LEPR intron 21124955 rs12564626 chr1 66056542 G A 5.00E-11 Soluble leptin receptor levels LEPR intron 20167575 rs11208682 chr1 66056596 G A 4.91E-11 Soluble leptin receptor levels LEPR intron 20167575 rs10889567 chr1 66057050 T C 7.49E-11 Soluble leptin receptor levels LEPR intron 20167575 rs10449758 chr1 66057117 A G 4.88E-11 Soluble leptin receptor levels LEPR intron 20167575 rs2154380 chr1 66057441 T C 4.83E-11 Soluble leptin receptor levels LEPR intron 20167575 rs10736402 chr1 66058000 C T 4.86E-11 Soluble leptin receptor levels LEPR intron 20167575 rs1137101 chr1 66058513 A G 4.45E-11 Soluble leptin receptor levels LEPR missense 20167575 rs4655537 chr1 66058801 A G 3.04E-11 Soluble leptin receptor levels LEPR intron 20167575 rs4655537 chr1 66058801 A G 6.64E-10 C-reactive protein LEPR intron 23505291 rs10889568 chr1 66059445 T C 2.98E-11 Soluble leptin receptor levels LEPR intron 20167575 rs10889568 chr1 66059445 T C 0.0000198 C-reactive protein LEPR intron 23505291 rs10732836 chr1 66059460 C T 4.29E-11 Soluble leptin receptor levels LEPR intron 20167575 rs4655539 chr1 66059663 A T 4.23E-11 Soluble leptin receptor levels LEPR intron 20167575 rs6669117 chr1 66061072 T C 4.25E-11 Soluble leptin receptor levels LEPR intron 20167575 rs12405556 chr1 66063117 G T 2.96E-11 Soluble leptin receptor levels LEPR intron 20167575 rs12405556 chr1 66063117 G T 0.0000168 C-reactive protein LEPR intron 23505291 rs3762274 chr1 66064113 T C 1.28E-08 Soluble leptin receptor levels LEPR intron 20167575 rs3828033 chr1 66064710 C T 1.27E-08 Soluble leptin receptor levels LEPR intron 20167575 rs11801408 chr1 66075136 C T 0.0000753 C-reactive protein LEPR intron 23505291 rs6690625 chr1 66077590 T G 9.49E-10 Soluble leptin receptor levels LEPR intron 20167575 rs6690625 chr1 66077590 T G 2.42E-08 C-reactive protein LEPR intron 23505291 rs6678033 chr1 66077624 G A 7.70E-06 Soluble leptin receptor levels LEPR intron 20167575 rs6678033 chr1 66077624 G A 1.21E-09 Amyloid A Levels LEPR intron 21124955 rs6678033 chr1 66077624 G A 1.19E-08 C-reactive protein LEPR intron 23844046 rs12040007 chr1 66080160 G A 1.08E-09 Soluble leptin receptor levels LEPR intron 20167575 rs4655555 chr1 66080269 T A 4.76E-09 Soluble leptin receptor levels LEPR intron 20167575 rs4655555 chr1 66080269 T A 9.34E-08 C-reactive protein LEPR intron 23505291 rs4655556 chr1 66080563 G A 1.22E-09 Soluble leptin receptor levels LEPR intron 20167575 rs201721079 chr1 66080787 T TC 8.70E-06 Soluble leptin receptor levels LEPR intron 20167575 rs201721079 chr1 66080787 T TC 1.58E-08 C-reactive protein LEPR intron 23844046 rs35308591 chr1 66080787 T TC 8.70E-06 Soluble leptin receptor levels LEPR intron 20167575 rs35308591 chr1 66080787 T TC 1.58E-08 C-reactive protein LEPR intron 23844046 rs4655557 chr1 66080787 T C 8.70E-06 Soluble leptin receptor levels LEPR intron 20167575 rs4655557 chr1 66080787 T C 1.58E-08 C-reactive protein LEPR intron 23844046 rs1938484 chr1 66081282 C A 1.26E-09 Soluble leptin receptor levels LEPR intron 20167575 rs34499590 chr1 66081791 C T 5.80E-15 LDL cholesterol LEPR missense 23063622 rs34499590 chr1 66081791 C T 7.22E-09 Triglycerides LEPR missense 23063622 rs10889569 chr1 66086194 A T 4.71E-10 Amyloid A Levels LEPR intron 21124955 rs10889569 chr1 66086194 A T 9.00E-09 C-reactive protein LEPR intron 23844046 rs7516341 chr1 66088143 T C 4.27E-10 Amyloid A Levels LEPR intron 21124955 rs7516341 chr1 66088143 T C 1.57E-08 C-reactive protein LEPR intron 23844046 rs6700896 chr1 66089782 C T 3.00E-14 C-reactive protein LEPR intron 19567438 rs6700896 chr1 66089782 C T 5.93E-10 Amyloid A Levels LEPR intron 21124955 rs6700896 chr1 66089782 C T 2.71E-08 C-reactive protein LEPR intron 23844046 rs6588153 chr1 66092017 T A 4.87E-10 Amyloid A Levels LEPR intron 21124955 rs6588153 chr1 66092017 T A 8.74E-09 C-reactive protein LEPR intron 23844046 rs1892535 chr1 66097181 G A 6.24E-09 Soluble leptin receptor levels LEPR intron 20167575 rs12025906 chr1 66101384 T C 6.90E-09 Soluble leptin receptor levels LEPR intron 20167575 rs1805096 chr1 66102257 G A 1.92E-10 Amyloid A Levels LEPR cds-synon 21124955 rs1805096 chr1 66102257 G A 2.00E-09 C-reactive protein LEPR cds-synon 22939635 rs1805096 chr1 66102257 G A 2.20E-14 C-reactive protein LEPR cds-synon 23505291 rs1805096 chr1 66102257 G A 2.25E-08 C-reactive protein LEPR cds-synon 23844046 rs7518632 chr1 66103350 C A,G,T 5.03E-09 Soluble leptin receptor levels LEPR nearGene-3 20167575 rs1892534 chr1 66105944 C T 7.00E-21 C-reactive protein / / 18439548 rs1892534 chr1 66105944 C T 1.33E-09 Amyloid A Levels / / 21124955 rs1892534 chr1 66105944 C T 1.23E-07 C-reactive protein / / 23844046 rs1892534 chr1 66105944 C T 4.77E-07 Inflammation / / pha002897 rs7531867 chr1 66107546 G A 4.44E-10 Amyloid A Levels / / 21124955 rs7531867 chr1 66107546 G A 1.19E-08 C-reactive protein / / 23844046 rs1938492 chr1 66117829 A C 2.33E-10 Amyloid A Levels / / 21124955 rs1938492 chr1 66117829 A C 5.00E-14 Fibrinogen / / 23969696 rs2186245 chr1 66118064 C T 4.74E-09 Soluble leptin receptor levels / / 20167575 rs12130476 chr1 66124850 G C 4.57E-09 Soluble leptin receptor levels / / 20167575 rs12145237 chr1 66124882 C T 6.03E-09 Soluble leptin receptor levels / / 20167575 rs10789192 chr1 66125770 G A 3.27E-10 Amyloid A Levels / / 21124955 rs10789192 chr1 66125770 G A 1.78E-08 C-reactive protein / / 23844046 rs4655772 chr1 66130398 A G 0.0000336 Height (Pygmy height) / / 22570615 rs11208700 chr1 66133443 A T 2.20E-06 Soluble leptin receptor levels / / 20167575 rs11208700 chr1 66133443 A T 9.84E-09 Amyloid A Levels / / 21124955 rs12042779 chr1 66133950 T C 3.65E-10 Amyloid A Levels / / 21124955 rs12042779 chr1 66133950 T C 1.78E-08 C-reactive protein / / 23844046 rs12042807 chr1 66134052 T C 3.65E-10 Amyloid A Levels / / 21124955 rs12042807 chr1 66134052 T C 1.78E-08 C-reactive protein / / 23844046 rs12043772 chr1 66135034 T A 6.03E-09 Soluble leptin receptor levels / / 20167575 rs11807752 chr1 66138575 A G 5.08E-04 Alzheimer's disease / / 17998437 rs11208707 chr1 66139513 C T 7.24E-09 Soluble leptin receptor levels / / 20167575 rs10736403 chr1 66140396 A G 7.30E-09 Soluble leptin receptor levels / / 20167575 rs10749756 chr1 66140511 C T 7.58E-09 Soluble leptin receptor levels / / 20167575 rs12567606 chr1 66141884 A G 1.30E-09 Soluble leptin receptor levels / / 20167575 rs12117858 chr1 66142094 C T 7.61E-09 Soluble leptin receptor levels / / 20167575 rs4655778 chr1 66142336 G A 7.87E-09 Soluble leptin receptor levels / / 20167575 rs4655779 chr1 66142530 A G 7.69E-09 Soluble leptin receptor levels / / 20167575 rs4655780 chr1 66142777 C A 7.84E-09 Soluble leptin receptor levels / / 20167575 rs34796214 chr1 66142972 A AG 7.76E-09 Soluble leptin receptor levels / / 20167575 rs4655782 chr1 66142972 A G 7.76E-09 Soluble leptin receptor levels / / 20167575 rs4655783 chr1 66143044 T C 2.40E-06 Soluble leptin receptor levels / / 20167575 rs4655783 chr1 66143044 T C 9.57E-09 Amyloid A Levels / / 21124955 rs10158937 chr1 66144876 A C 1.45E-08 Soluble leptin receptor levels / / 20167575 rs11208709 chr1 66146017 G A 7.85E-09 Soluble leptin receptor levels / / 20167575 rs11208710 chr1 66146039 A G 7.32E-09 Soluble leptin receptor levels / / 20167575 rs12026918 chr1 66146246 C G 7.62E-09 Soluble leptin receptor levels / / 20167575 rs11208711 chr1 66147846 G T 3.12E-10 Amyloid A Levels / / 21124955 rs11208711 chr1 66147846 G T 3.23E-08 C-reactive protein / / 23844046 rs2375803 chr1 66152889 T C 5.74E-04 Alzheimer's disease / / 17998437 rs4655582 chr1 66153363 C G 3.20E-10 Amyloid A Levels / / 21124955 rs12022410 chr1 66153933 A G 2.60E-06 Soluble leptin receptor levels / / 20167575 rs12022410 chr1 66153933 A G 9.51E-09 Amyloid A Levels / / 21124955 rs12022410 chr1 66153933 A G 0.0000336 Height (Pygmy height) / / 22570615 rs4655583 chr1 66155407 C A 3.40E-09 Soluble leptin receptor levels / / 20167575 rs4655584 chr1 66155515 T G 2.29E-10 Amyloid A Levels / / 21124955 rs4655584 chr1 66155515 T G 3.33E-08 C-reactive protein / / 23844046 rs4655585 chr1 66155627 T C 2.30E-10 Amyloid A Levels / / 21124955 rs4655585 chr1 66155627 T C 3.53E-08 C-reactive protein / / 23844046 rs2211651 chr1 66156021 G T 1.66E-10 Amyloid A Levels / / 21124955 rs2211651 chr1 66156021 G T 1.02E-06 Inflammation / / pha002897 rs2889195 chr1 66156730 C T 6.60E-04 Lipid traits / / 17903299 rs2889195 chr1 66156730 C T 3.00E-10 Amyloid A Levels / / 21124955 rs2889195 chr1 66156730 C T 5.95E-07 Inflammation / / pha002897 rs12042379 chr1 66158464 G T 8.21E-09 Soluble leptin receptor levels / / 20167575 rs11208720 chr1 66159055 A G 7.08E-09 Soluble leptin receptor levels / / 20167575 rs4655792 chr1 66159264 T G 4.70E-09 Soluble leptin receptor levels / / 20167575 rs4655793 chr1 66159278 C A 5.07E-09 Soluble leptin receptor levels / / 20167575 rs4655794 chr1 66159301 T C 3.60E-06 Soluble leptin receptor levels / / 20167575 rs4655794 chr1 66159301 T C 5.29E-09 Amyloid A Levels / / 21124955 rs4655794 chr1 66159301 T C 0.0000336 Height (Pygmy height) / / 22570615 rs4655795 chr1 66159368 G T 4.02E-09 Soluble leptin receptor levels / / 20167575 rs6664534 chr1 66160075 T A 3.80E-09 Soluble leptin receptor levels / / 20167575 rs6588156 chr1 66160433 A G 3.13E-09 Soluble leptin receptor levels / / 20167575 rs6588158 chr1 66160621 T C 1.99E-10 Amyloid A Levels / / 21124955 rs4420065 chr1 66161461 T C 2.23E-10 Amyloid A Levels / / 21124955 rs4420065 chr1 66161461 T C 4.00E-62 C-reactive protein / / 21300955 rs4420065 chr1 66161461 T C 6.67E-07 Inflammation / / pha002897 rs6667615 chr1 66162630 A G 3.07E-09 Soluble leptin receptor levels / / 20167575 rs67564250 chr1 66162630 AA AAA,AGC 3.07E-09 Soluble leptin receptor levels / / 20167575 rs6667616 chr1 66162631 A C 3.03E-09 Soluble leptin receptor levels / / 20167575 rs4394621 chr1 66165836 G A 3.84E-09 Soluble leptin receptor levels / / 20167575 rs7524581 chr1 66166499 T C 5.10E-06 Soluble leptin receptor levels / / 20167575 rs7524581 chr1 66166499 T C 2.82E-11 Amyloid A Levels / / 21124955 rs7524581 chr1 66166499 T C 0.000301 Height (Pygmy height) / / 22570615 rs4425959 chr1 66167819 G A 5.88E-09 Soluble leptin receptor levels / / 20167575 rs4425959 chr1 66167819 G A 2.02E-08 Amyloid A Levels / / 21124955 rs7541434 chr1 66168499 A C 6.50E-06 Soluble leptin receptor levels / / 20167575 rs7541434 chr1 66168499 A C 1.35E-11 Amyloid A Levels / / 21124955 rs10889576 chr1 66168566 T C 7.26E-09 Soluble leptin receptor levels / / 20167575 rs10889576 chr1 66168566 T C 1.31E-08 Amyloid A Levels / / 21124955 rs12753193 chr1 66169679 G A 4.00E-07 Metabolic traits / / 19060910 rs12753193 chr1 66169679 G A 5.50E-06 Soluble leptin receptor levels / / 20167575 rs12753193 chr1 66169679 G A 1.22E-11 Amyloid A Levels / / 21124955 rs12753193 chr1 66169679 G A 0.000537 Height (Pygmy height) / / 22570615 rs12753193 chr1 66169679 G A 3.76E-07 Inflammation / / pha002897 rs17416194 chr1 66171192 G A 2.50E-08 Amyloid A Levels / / 21124955 rs12121677 chr1 66171970 T C 5.57E-04 Alcohol dependence / / 20201924 rs17407727 chr1 66172006 C A 1.80E-08 Amyloid A Levels / / 21124955 rs10493383 chr1 66174932 C G 9.94E-08 Pure-tone audiometry / / pha001966 rs4278348 chr1 66175395 T C 3.54E-08 Amyloid A Levels / / 21124955 rs7532805 chr1 66183130 G A 4.64E-08 Amyloid A Levels / / 21124955 rs17127955 chr1 66193548 A G 2.73E-04 Multiple complex diseases / / 17554300 rs4338330 chr1 66195239 C T 7.30E-04 Type 2 diabetes / / 17463246 rs4288572 chr1 66201022 G A 1.33E-08 Amyloid A Levels / / 21124955 rs10789198 chr1 66202755 G A 1.20E-08 Amyloid A Levels / / 21124955 rs4655800 chr1 66211691 A G 1.54E-08 Amyloid A Levels / / 21124955 rs11208728 chr1 66213043 A G 1.48E-08 Amyloid A Levels / / 21124955 rs12131840 chr1 66231771 C T 1.30E-06 Soluble leptin receptor levels / / 20167575 rs12046844 chr1 66238379 G A 5.84E-04 Adverse response to chemotherapy (neutropenia/leucopenia) (gemcitabine) / / 23648065 rs6659197 chr1 66239897 A C 8.25E-05 Coronary heart disease / / 21606135 rs4384209 chr1 66279125 A G 2.00E-06 Economic and political preferences (feminism/equality) PDE4B intron 22566634 rs10493389 chr1 66310865 T C 7.00E-06 Echocardiographic traits PDE4B intron 17903301 rs4353064 chr1 66357675 A C 3.91E-04 Stroke PDE4B intron pha002887 rs17128103 chr1 66368865 C T 4.34E-04 Alcohol dependence PDE4B intron 21314694 rs11809491 chr1 66420658 G T 8.03E-11 LDL cholesterol PDE4B intron 23063622 rs2503209 chr1 66484652 T C 2.85E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs2503215 chr1 66490013 A T 2.32E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs7553522 chr1 66492484 T A 1.36E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs2455031 chr1 66492628 C T 3.26E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs7553844 chr1 66492784 T A 2.75E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs7525758 chr1 66494755 A G 8.78E-05 Cognitive test performance PDE4B intron 20125193 rs2455033 chr1 66500466 T C 8.99E-04 Type 2 diabetes PDE4B intron 17463246 rs2455033 chr1 66500466 T C 4.48E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs2489905 chr1 66501072 A T 4.39E-04 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs2455013 chr1 66516557 A G 5.77E-05 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs12040042 chr1 66517050 A G 3.46E-06 Systemic lupus erythematosus and Systemic sclerosis PDE4B intron 23740937 rs2503222 chr1 66518697 C T 2.58E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) PDE4B intron 24236485 rs2455012 chr1 66520998 A G 3.06E-05 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs2455012 chr1 66520998 A G 7.00E-07 Staphylococcus aureus infection PDE4B intron 24847357 rs4492586 chr1 66528569 T C 3.06E-05 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs9436757 chr1 66528892 G A 6.72E-04 Multiple complex diseases PDE4B intron 17554300 rs9436757 chr1 66528892 G A 3.07E-05 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs1500963 chr1 66529821 G A 2.58E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) PDE4B intron 24236485 rs2503228 chr1 66547142 A G 2.71E-05 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs17455267 chr1 66549751 G A 3.63E-05 Suicide attempts in bipolar disorder PDE4B intron 21423239 rs4655595 chr1 66558759 A G 2.70E-06 Type 2 diabetes PDE4B intron 17463249 rs4655595 chr1 66558759 A G 2.68E-06 Multiple complex diseases PDE4B intron 17554300 rs1566527 chr1 66569098 T A 8.82E-05 Serum metabolites PDE4B intron 19043545 rs596662 chr1 66603875 A C 3.30E-05 Diabetic retinopathy PDE4B intron 21441570 rs17128445 chr1 66610968 G A 5.70E-05 Diabetic retinopathy PDE4B intron 21441570 rs673143 chr1 66620119 G A 3.70E-05 Diabetic retinopathy PDE4B intron 21441570 rs582237 chr1 66621527 A G 3.70E-05 Diabetic retinopathy PDE4B intron 21441570 rs2485381 chr1 66627732 G A 8.44E-04 Alcohol dependence PDE4B intron 24277619 rs11208807 chr1 66634921 C T 3.63E-05 Amyotrophic Lateral Sclerosis PDE4B intron 18057069 rs556303 chr1 66635795 T A 7.40E-05 Diabetic retinopathy PDE4B intron 21441570 rs6656638 chr1 66645924 G A 1.26E-04 Self-reported allergy PDE4B intron 23817569 rs490094 chr1 66647385 A G 2.08E-26 Narcolepsy PDE4B intron 19629137 rs486438 chr1 66674663 A C 0.00000182 Triglycerides PDE4B intron 23063622 rs486438 chr1 66674663 A C 3.45E-11 LDL cholesterol PDE4B intron 23063622 rs10493398 chr1 66674738 G A 6.07E-04 Schizophrenia PDE4B intron 21674006 rs567279 chr1 66688029 G T 0.00000031 Cholesterol,total PDE4B intron 23063622 rs567279 chr1 66688029 G T 1.28E-09 Triglycerides PDE4B intron 23063622 rs567279 chr1 66688029 G T 4.13E-21 LDL cholesterol PDE4B intron 23063622 rs17423910 chr1 66689109 A G 4.67E-05 Acute lymphoblastic leukemia (childhood) PDE4B intron 22076464 rs952635 chr1 66691885 C T 2.80E-04 Type 2 diabetes and 6 quantitative traits PDE4B intron 17848626 rs1358751 chr1 66725267 A G 0.00019 Coronary artery calcification PDE4B intron 23727086 rs6700403 chr1 66735601 T C 1.49E-04 Nicotine smoking PDE4B intron 19268276 rs12728294 chr1 66740467 T C 5.42E-05 Nicotine smoking PDE4B intron 19268276 rs499320 chr1 66745060 G A 3.77E-05 Lung function (forced expiratory volume in 1 second) PDE4B intron 24023788 rs499320 chr1 66745060 G A 3.79E-04 Lung function (forced vital capacity) PDE4B intron 24023788 rs12060491 chr1 66745352 A G 9.92E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) PDE4B intron 24023788 rs519044 chr1 66756717 C T 1.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE4B intron 20877124 rs546784 chr1 66762466 T C 1.12E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) PDE4B intron 20877124 rs546784 chr1 66762466 T C 9.00E-06 Acute lymphoblastic leukemia (childhood) PDE4B intron 23007406 rs2312065 chr1 66762737 C T 7.00E-04 Acute lymphoblastic leukemia (childhood) PDE4B intron 20189245 rs12030788 chr1 66768129 A G 4.09E-04 Multiple complex diseases PDE4B intron 17554300 rs6683977 chr1 66769100 G C 5.00E-06 Acute lymphoblastic leukemia (childhood) PDE4B intron 23007406 rs17427907 chr1 66805270 T C 6.20E-04 Multiple complex diseases PDE4B intron 17554300 rs2788646 chr1 66806953 T C 3.30E-04 Volumetric brain MRI PDE4B intron 17903297 rs17128817 chr1 66812100 C T 3.75E-08 LDL cholesterol PDE4B intron 23063622 rs4655835 chr1 66814826 T C 5.40E-04 Taste perception PDE4B intron 22132133 rs2275644 chr1 66831099 G A 8.13E-04 Suicide attempts in bipolar disorder PDE4B intron 21041247 rs7538869 chr1 66831322 T G 8.14E-04 Suicide attempts in bipolar disorder PDE4B intron 21041247 rs783036 chr1 66831370 G A 5.91E-04 Smoking initiation PDE4B cds-synon 24665060 rs2311985 chr1 66834815 A G 8.19E-04 Suicide attempts in bipolar disorder PDE4B intron 21041247 rs783051 chr1 66849410 C A 2.00E-05 Urinary metabolites / / 21572414 rs783050 chr1 66849448 T G 2.00E-05 Urinary metabolites / / 21572414 rs783048 chr1 66849905 C T 2.00E-05 Urinary metabolites / / 21572414 rs6701234 chr1 66851897 T G 8.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs6703929 chr1 66852161 T C 8.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs6691740 chr1 66852802 C A 8.41E-04 Suicide attempts in bipolar disorder / / 21041247 rs12239708 chr1 66854570 T A 8.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs12406429 chr1 66856026 G A 8.51E-04 Suicide attempts in bipolar disorder / / 21041247 rs1341246 chr1 66879613 C G 9.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10493405 chr1 66920877 G A 3.03E-04 Hearing function / / 17255346 rs1832420 chr1 66939920 A G 4.47E-05 Suicide attempts in bipolar disorder / / 21423239 rs10749760 chr1 66946306 G C 2.88E-04 Multiple complex diseases / / 17554300 rs4393126 chr1 66952788 G A 5.21E-04 Multiple complex diseases / / 17554300 rs4567260 chr1 66953482 G A 1.54E-05 Blood pressure / / 17255346 rs11208877 chr1 66954924 C A 5.45E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11208878 chr1 66955878 C T 6.23E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1338209 chr1 66957094 T C 6.91E-04 Multiple complex diseases / / 17554300 rs1025994 chr1 66957148 G A 7.15E-04 Multiple complex diseases / / 17554300 rs1025991 chr1 66958183 T G 8.43E-04 Multiple complex diseases / / 17554300 rs1020381 chr1 66960715 A G 6.35E-05 Blood pressure / / 17255346 rs1415975 chr1 66962193 C T 1.72E-04 Blood pressure / / 17255346 rs6588201 chr1 66963631 G T 7.86E-04 Multiple complex diseases / / 17554300 rs7544886 chr1 66968939 T C 5.90E-04 Multiple complex diseases / / 17554300 rs7555470 chr1 66969013 A C 8.14E-04 Multiple complex diseases / / 17554300 rs7533097 chr1 66969084 C T 2.11E-04 Blood pressure / / 17255346 rs7533097 chr1 66969084 C T 6.06E-04 Multiple complex diseases / / 17554300 rs7533097 chr1 66969084 C T 0.000216 Colorectal cancer vs. adenoma controls / / 22532847 rs7533837 chr1 66986781 A G 6.18E-05 Multiple complex diseases / / 17554300 rs10493408 chr1 66992054 C A 7.19E-05 Multiple complex diseases / / 17554300 rs10493408 chr1 66992054 C A 9.21E-04 Alzheimer's disease / / 17998437 rs12040232 chr1 66992277 T C 8.61E-05 Multiple complex diseases / / 17554300 rs1338203 chr1 66992613 A G 7.86E-05 Multiple complex diseases / / 17554300 rs6689313 chr1 66994889 A C 5.31E-05 Multiple complex diseases / / 17554300 rs12750223 chr1 67019819 A G 3.60E-07 Urinary metabolites SGIP1 intron 21572414 rs10889627 chr1 67023343 T C,G 9.12E-04 Suicide attempts in bipolar disorder SGIP1 intron 21423239 rs7537440 chr1 67031907 T G 9.16E-04 Type 2 diabetes SGIP1 intron 22158537 rs10889630 chr1 67034789 C T 3.74E-05 Tuberculosis SGIP1 intron 20694014 rs12125455 chr1 67034992 G A 5.70E-07 Urinary metabolites SGIP1 intron 21572414 rs12131909 chr1 67037898 C G 6.10E-07 Urinary metabolites SGIP1 intron 21572414 rs4655625 chr1 67039730 C T 5.70E-07 Urinary metabolites SGIP1 intron 21572414 rs1373909 chr1 67040875 A G 9.75E-04 Type 2 diabetes SGIP1 intron 22158537 rs6699200 chr1 67041309 T C 3.28E-05 Tuberculosis SGIP1 intron 20694014 rs1867631 chr1 67046126 C A 5.00E-06 Menopause (age at onset) SGIP1 intron 23307926 rs4147266 chr1 67048743 T G 5.58E-05 Tuberculosis SGIP1 intron 20694014 rs2166307 chr1 67052736 T C 7.16E-04 Suicide attempts in bipolar disorder SGIP1 intron 21041247 rs12049347 chr1 67061496 C T 2.50E-07 Urinary metabolites SGIP1 intron 21572414 rs12117202 chr1 67062569 C G,T 5.54E-05 Tuberculosis SGIP1 intron 20694014 rs6588207 chr1 67066555 A G 4.24E-08 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs10443224 chr1 67074053 T C 9.66E-04 Multiple complex diseases SGIP1 intron 17554300 rs10889635 chr1 67075575 G A 2.52E-08 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs11208921 chr1 67076054 C G 6.81E-05 Tuberculosis SGIP1 intron 20694014 rs12141816 chr1 67082018 G A 5.73E-05 Tuberculosis SGIP1 intron 20694014 rs11208923 chr1 67082442 A G 1.60E-06 Urinary metabolites SGIP1 intron 21572414 rs10493412 chr1 67082759 G C 5.58E-05 Tuberculosis SGIP1 intron 20694014 rs6656912 chr1 67083671 T C 4.24E-07 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs17436311 chr1 67083792 A G 5.17E-05 Tuberculosis SGIP1 intron 20694014 rs6588210 chr1 67084419 G C 9.18E-04 Multiple complex diseases SGIP1 intron 17554300 rs12129319 chr1 67084783 C G 1.20E-06 Urinary metabolites SGIP1 intron 21572414 rs12131306 chr1 67086547 C T 1.20E-06 Urinary metabolites SGIP1 intron 21572414 rs4655641 chr1 67089764 C T 1.00E-06 Urinary metabolites SGIP1 intron 21572414 rs1536112 chr1 67107225 A G 1.73E-04 Suicide attempts in bipolar disorder SGIP1 intron 21423239 rs2147776 chr1 67107403 T C 3.86E-04 Suicide attempts in bipolar disorder SGIP1 intron 21423239 rs6588213 chr1 67107894 C T 6.90E-04 Multiple complex diseases SGIP1 intron 17554300 rs17490057 chr1 67109277 G C 0.0006 Prostate cancer SGIP1 missense 23555315 rs6689755 chr1 67113050 G A 2.27E-04 Suicide attempts in bipolar disorder SGIP1 intron 21423239 rs12726588 chr1 67113648 T C 1.40E-06 Urinary metabolites SGIP1 intron 21572414 rs1925341 chr1 67115084 A G 8.23E-04 Taste perception SGIP1 intron 22132133 rs1998716 chr1 67117106 T A 1.31E-04 Suicide attempts in bipolar disorder SGIP1 intron 21423239 rs6681460 chr1 67123057 A G 7.30E-08 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs6681460 chr1 67123057 A G 7.00E-06 Presence of antiphospholipid antibodies SGIP1 intron 23509613 rs1570814 chr1 67124943 C T 2.80E-06 Urinary metabolites SGIP1 intron 21572414 rs6689451 chr1 67142852 G A 2.12E-04 Multiple complex diseases SGIP1 intron 17554300 rs11811699 chr1 67143760 A G 2.59E-04 Multiple complex diseases SGIP1 intron 17554300 rs10789215 chr1 67151185 T C 8.51E-08 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs2146904 chr1 67160336 A G 4.37E-07 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs10493414 chr1 67161716 T A 6.41E-04 Multiple complex diseases SGIP1 intron 17554300 rs4143025 chr1 67167548 C T 6.46E-04 Multiple complex diseases SGIP1 intron 17554300 rs3738167 chr1 67171266 G T 7.55E-05 Fibrinogen SGIP1 intron pha003068 rs17129365 chr1 67174554 A G 6.84E-04 Type 2 diabetes SGIP1 intron 17463246 rs10889649 chr1 67178005 G A 8.73E-04 Suicide attempts in bipolar disorder SGIP1 intron 21041247 rs1498354 chr1 67180489 T A 8.58E-04 Suicide attempts in bipolar disorder SGIP1 intron 21041247 rs11208951 chr1 67188107 C T 8.24E-04 Suicide attempts in bipolar disorder SGIP1 intron 21041247 rs536410 chr1 67191084 T C 1.69E-07 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs2483704 chr1 67195353 G A 3.63E-07 Electroencephalogram traits,in brain SGIP1 intron 20421487 rs2916 chr1 67216697 G A 1.87E-07 Electroencephalogram traits,in brain / / 20421487 rs6695554 chr1 67230205 T G 9.40E-05 Response to statin therapy TCTEX1D1 intron 20339536 rs12727422 chr1 67235320 C A 8.60E-05 Response to statin therapy TCTEX1D1 intron 20339536 rs7535868 chr1 67235541 C T 9.90E-05 Response to statin therapy TCTEX1D1 intron 20339536 rs55899951 chr1 67260378 A C 0.00009391 Sarcoidosis / / 22952805 rs56107937 chr1 67260398 G A 0.00008219 Sarcoidosis / / 22952805 rs7543667 chr1 67260854 A T 0.0000963 Sarcoidosis / / 22952805 rs17129478 chr1 67288443 T G 1.20E-05 Urinary metabolites WDR78 intron 21572414 rs1925399 chr1 67349271 G C 9.44E-04 Type 2 diabetes WDR78 intron 17463246 rs1925408 chr1 67365034 C T 9.47E-04 Multiple complex diseases WDR78 intron 17554300 rs1925411 chr1 67370292 C T 4.20E-06 Crohn's disease WDR78 intron 17804789 rs1983860 chr1 67372061 G T 3.58E-06 Crohn's disease WDR78 intron 17804789 rs12083687 chr1 67406962 G A 9.07E-04 Multiple complex diseases MIER1 intron 17554300 rs2985824 chr1 67410171 A G 8.09E-04 Multiple complex diseases MIER1 intron 17554300 rs12090955 chr1 67412261 G T 6.35E-04 Multiple complex diseases MIER1 intron 17554300 rs4655662 chr1 67416432 T C 3.57E-04 Celiac disease MIER1 intron 23936387 rs3008871 chr1 67419089 G A 7.69E-04 Multiple complex diseases MIER1 intron 17554300 rs4655663 chr1 67430103 G A 8.17E-04 Multiple complex diseases MIER1 intron 17554300 rs2985797 chr1 67431499 T C 8.12E-04 Multiple complex diseases MIER1 intron 17554300 rs12137403 chr1 67437043 C A,T 4.97E-04 Multiple complex diseases MIER1 intron 17554300 rs4620509 chr1 67449941 A G 6.13E-06 Crohn's disease MIER1 intron 17804789 rs4486425 chr1 67460791 T C 5.47E-05 Crohn's disease / / 17804789 rs2815351 chr1 67477980 A G 4.47E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2755242 chr1 67479598 T C 3.58E-04 Celiac disease SLC35D1 intron 23936387 rs2755244 chr1 67484470 T C 7.98E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2065002 chr1 67487119 C A 3.58E-04 Celiac disease SLC35D1 intron 23936387 rs2755245 chr1 67487964 C G 7.82E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2755246 chr1 67488984 A G 6.12E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2815361 chr1 67494591 G T 5.53E-05 Amyotrophic lateral sclerosis (sporadic) SLC35D1 intron 24529757 rs12091194 chr1 67495728 C T 3.30E-05 Odorant perception SLC35D1 intron 23910658 rs17129627 chr1 67503666 C G 9.17E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2815371 chr1 67504313 A G 5.43E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2815380 chr1 67510857 G A 9.25E-04 Multiple complex diseases SLC35D1 intron 17554300 rs2815380 chr1 67510857 G A 8.04E-05 Crohn's disease SLC35D1 intron 17804789 rs1024228 chr1 67512695 A G 1.23E-05 Crohn's disease SLC35D1 intron 17804789 rs1024229 chr1 67512903 G T 1.53E-04 Celiac disease SLC35D1 intron 23936387 rs1024230 chr1 67512920 A C 1.53E-04 Celiac disease SLC35D1 intron 23936387 rs2208577 chr1 67513574 A C 8.91E-05 Crohn's disease SLC35D1 intron 17804789 rs2208577 chr1 67513574 A C 3.00E-04 Celiac disease SLC35D1 intron 23936387 rs2755259 chr1 67517022 T C 1.87E-06 Crohn's disease SLC35D1 intron 17804789 rs2755262 chr1 67521736 T C 2.01E-06 Crohn's disease SLC35D1 nearGene-5 17804789 rs11208994 chr1 67525043 A G 1.51E-08 Crohn's disease / / 17804789 rs12097741 chr1 67528006 A C 8.51E-05 Rheumatoid arthritis / / 17804836 rs2755263 chr1 67529243 A G 5.13E-05 Crohn's disease / / 17804789 rs17129659 chr1 67579395 C T 8.32E-07 Crohn's disease C1orf141 intron 17804789 rs11209002 chr1 67590461 T C 2.00E-07 Crohn's disease C1orf141 intron 17804789 rs7515029 chr1 67596372 A G 1.82E-09 Multiple complex diseases / / 17554300 rs3762318 chr1 67597119 G A 4.19E-05 Psoriasis / / 20953187 rs3762318 chr1 67597119 G A 3.00E-11 Leprosy / / 22019778 rs3762318 chr1 67597119 G A 1.24E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs2024825 chr1 67597977 T C 1.86E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs4655679 chr1 67599657 C T 3.16E-12 Multiple complex diseases / / 17554300 rs4655679 chr1 67599657 C T 2.00E-07 Crohn's disease / / 17804789 rs12069782 chr1 67600101 C T 3.00E-07 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs12095536 chr1 67600142 T C 1.41E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs12090164 chr1 67600163 G A 8.76E-06 QT interval in Tripanosoma cruzi seropositivity / / 24324551 rs11209003 chr1 67601132 G T 1.00E-08 Crohn's disease / / 17804789 rs1321156 chr1 67604702 G C 9.99E-04 Coronary Artery Disease / / 17634449 rs10789224 chr1 67605134 T C 2.47E-12 Multiple complex diseases / / 17554300 rs9729046 chr1 67607082 C G 5.87E-05 Crohn's disease / / 17804789 rs7539795 chr1 67609446 A G 4.18E-07 Multiple complex diseases / / 17554300 rs4655683 chr1 67611613 G A 2.95E-04 Crohn's disease / / 17068223 rs4655683 chr1 67611613 G A 4.76E-05 Crohn's disease / / 17804789 rs4655684 chr1 67611772 C T 1.29E-11 Multiple complex diseases / / 17554300 rs6588245 chr1 67611799 C T 3.01E-07 Multiple complex diseases / / 17554300 rs10889657 chr1 67615487 T C 2.31E-05 Crohn's disease / / 17804789 rs11209008 chr1 67623298 G A 8.79E-09 Crohn's disease / / 17804789 rs10889661 chr1 67625309 T A 3.56E-05 Crohn's disease / / 17804789 rs11465759 chr1 67632404 T G 0.000000299 Triglycerides IL23R intron 23063622 rs11465759 chr1 67632404 T G 1.02E-11 LDL cholesterol IL23R intron 23063622 rs11465759 chr1 67632404 T G 5.52E-12 Cholesterol,total IL23R intron 23063622 rs10889664 chr1 67635475 C T 4.15E-05 Crohn's disease IL23R intron 17804789 rs76418789 chr1 67648596 G A 2.00E-10 Crohn's disease IL23R missense 23850713 rs6588248 chr1 67652984 T G 8.81E-06 Leprosy IL23R intron 22019778 rs2064689 chr1 67653010 G A 8.52E-05 Crohn's disease IL23R intron 17068223 rs2064689 chr1 67653010 G A 1.00E-07 Crohn's disease IL23R intron 17804789 rs17375018 chr1 67655147 G A 1.13E-08 Multiple complex diseases IL23R intron 17554300 rs17375018 chr1 67655147 G A 8.71E-05 Crohn's disease IL23R intron 17804789 rs6664119 chr1 67655895 C T 9.51E-08 Multiple complex diseases IL23R intron 17554300 rs12401432 chr1 67656931 C G 6.44E-05 Crohn's disease IL23R intron 17804789 rs10489630 chr1 67662622 A C 7.07E-05 Crohn's disease IL23R intron 17068223 rs10489630 chr1 67662622 A C 1.26E-05 Crohn's disease IL23R intron 17804789 rs714512 chr1 67664154 T G 1.60E-05 Crohn's disease IL23R intron 17804789 rs7556198 chr1 67665543 A G 1.48E-06 Crohn's disease IL23R intron 17804789 rs11209018 chr1 67667291 G A 3.17E-12 Multiple complex diseases IL23R intron 17554300 rs1004820 chr1 67670133 T G 4.58E-05 Crohn's disease IL23R intron 17804789 rs1004819 chr1 67670213 G A 1.78E-14 Crohn's disease IL23R intron 17068223 rs1004819 chr1 67670213 G A 6.25E-06 Crohn's disease IL23R intron 17804789 rs2902440 chr1 67670916 G A 8.81E-09 Crohn's disease IL23R intron 17804789 rs7539625 chr1 67672765 G A 2.15E-08 Crohn's disease IL23R intron 17804789 rs11805303 chr1 67675516 C T 6.00E-12 Crohn's disease IL23R intron 17554300 rs11805303 chr1 67675516 C T 1.82E-39 Crohn's disease IL23R intron 18587394 rs10889669 chr1 67675728 T G 6.53E-06 Crohn's disease IL23R intron 17804789 rs790632 chr1 67678922 C A 1.86E-05 Serum metabolites IL23R intron 19043545 rs2019262 chr1 67679990 G A 9.20E-05 Crohn's disease IL23R intron 17804789 rs7517847 chr1 67681669 T G 4.00E-13 Inflammatory bowel disease IL23R intron 17068223 rs7517847 chr1 67681669 T G 3.00E-12 Crohn's disease IL23R intron 17435756 rs7517847 chr1 67681669 T G 7.80E-06 Crohn's disease IL23R intron 17804789 rs7517847 chr1 67681669 T G 4.00E-06 Plasma omega-6 polyunsaturated fatty acid levels IL23R intron 24823311 rs7518660 chr1 67685443 G A 6.18E-08 Crohn's disease IL23R intron 17804789 rs11465802 chr1 67685598 A C 5.04E-07 Crohn's disease IL23R intron 17804789 rs10789228 chr1 67687064 C T 1.00E-04 Crohn's disease IL23R intron 17804789 rs10489629 chr1 67688349 T C 1.62E-11 Crohn's disease IL23R intron 17068223 rs10489629 chr1 67688349 T C 5.04E-12 Multiple complex diseases IL23R intron 17554300 rs41396545 chr1 67689608 A G 7.93E-10 Multiple complex diseases IL23R intron 17554300 rs41396545 chr1 67689608 A G 9.37E-05 Smoking quantity IL23R intron 24665060 rs2201841 chr1 67694202 A G 1.10E-14 Crohn's disease IL23R intron 17068223 rs2201841 chr1 67694202 A G 5.36E-12 Multiple complex diseases IL23R intron 17554300 rs2201841 chr1 67694202 A G 3.16E-08 Crohn's disease IL23R intron 17804789 rs2201841 chr1 67694202 A G 3.00E-08 Psoriasis IL23R intron 19169254 rs2201841 chr1 67694202 A G 1.00E-13 Ulcerative colitis IL23R intron 20228799 rs2201841 chr1 67694202 A G 3.00E-08 Psoriasis IL23R intron 20953187 rs2201841 chr1 67694202 A G 1.30E-13 Multiple sclerosis IL23R intron 22190364 rs12031203 chr1 67696547 G A 1.33E-06 Crohn's disease IL23R intron 17804789 rs11804284 chr1 67699254 T C 2.64E-17 Crohn's disease IL23R intron 17804789 rs12030948 chr1 67701765 G T 3.33E-05 Crohn's disease IL23R intron 17068223 rs11465804 chr1 67702526 T G 3.33E-16 Crohn's disease IL23R intron 17068223 rs11465804 chr1 67702526 T G 3.50E-15 Crohn's disease IL23R intron 17447842 rs11465804 chr1 67702526 T G 9.00E-04 Psoriasis IL23R intron 17587057 rs11465804 chr1 67702526 T G 2.08E-05 Crohn's disease IL23R intron 17804789 rs11465804 chr1 67702526 T G 7.00E-63 Crohn's disease IL23R intron 18587394 rs11465804 chr1 67702526 T G 1.00E-06 Crohn's disease IL23R intron 20570966 rs11465804 chr1 67702526 T G 7.00E-63 Asthma IL23R intron 21150878 rs11465804 chr1 67702526 T G 6.20E-06 Ankylosing spondylitis IL23R intron 21743469 rs11465804 chr1 67702526 T G 6.66E-63 Multiple sclerosis IL23R intron 22190364 rs10489628 chr1 67704107 G A 1.96E-04 Crohn's disease IL23R intron 17068223 rs10489628 chr1 67704107 G A 7.63E-07 Multiple complex diseases IL23R intron 17554300 rs10489628 chr1 67704107 G A 6.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) IL23R intron 17982456 rs11209026 chr1 67705958 G A 4.00E-11 Inflammatory bowel disease IL23R missense 17068223 rs11209026 chr1 67705958 G A 2.00E-18 Crohn's disease IL23R missense 17447842 rs11209026 chr1 67705958 G A 4.76E-04 Multiple complex diseases IL23R missense 17554300 rs11209026 chr1 67705958 G A 1.40E-04 Psoriasis IL23R missense 17587057 rs11209026 chr1 67705958 G A 2.17E-07 Crohn's disease IL23R missense 17684544 rs11209026 chr1 67705958 G A 1.32E-08 Crohn's disease IL23R missense 17804789 rs11209026 chr1 67705958 G A 2.15E-68 Crohn's disease IL23R missense 18587394 rs11209026 chr1 67705958 G A 7.00E-11 Inflammatory bowel disease IL23R missense 18758464 rs11209026 chr1 67705958 G A 1.00E-08 Ulcerative colitis IL23R missense 19122664 rs11209026 chr1 67705958 G A 3.00E-10 Ulcerative colitis IL23R missense 19915572 rs11209026 chr1 67705958 G A 9.00E-14 Ankylosing spondylitis IL23R missense 20062062 rs11209026 chr1 67705958 G A 7.00E-07 Psoriasis IL23R missense 20953190 rs11209026 chr1 67705958 G A 1.00E-64 Crohn's disease IL23R missense 21102463 rs11209026 chr1 67705958 G A 5.00E-28 Ulcerative colitis IL23R missense 21297633 rs11209026 chr1 67705958 G A 2.00E-17 Ankylosing spondylitis IL23R missense 21743469 rs11209026 chr1 67705958 G A 4.00E-21 Crohn's disease IL23R missense 22293688 rs11209026 chr1 67705958 G A 1.00E-18 Crohn's disease IL23R missense 22412388 rs11209026 chr1 67705958 G A 4.00E-14 Crohn's disease IL23R missense 22936669 rs11209026 chr1 67705958 G A 8.00E-161 Inflammatory bowel disease IL23R missense 23128233 rs6682033 chr1 67708670 A G 4.10E-04 Crohn's disease IL23R intron 17068223 rs6682033 chr1 67708670 A G 4.33E-05 Smoking quantity IL23R intron 24665060 rs1343151 chr1 67719129 G A 2.74E-12 Crohn's disease IL23R intron 17068223 rs1343151 chr1 67719129 G A 2.30E-09 Crohn's disease IL23R intron 17447842 rs1343151 chr1 67719129 G A 3.16E-08 Crohn's disease IL23R intron 17804789 rs1343151 chr1 67719129 G A 1.91E-05 Response to acetaminophen (hepatotoxicity) IL23R intron 21177773 rs1343151 chr1 67719129 G A 2.24E-04 Smoking quantity IL23R intron 24665060 rs1008193 chr1 67719911 C G 8.52E-05 Smoking quantity IL23R intron 24665060 rs6693831 chr1 67720867 T C 9.44E-05 HIV-1 viral setpoint IL23R intron 22174851 rs6693831 chr1 67720867 T C 0.0008156 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) IL23R intron 23233654 rs6693831 chr1 67720867 T C 8.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) IL23R intron 23233662 rs10889675 chr1 67722216 C A 1.36E-05 Multiple complex diseases IL23R intron 17554300 rs10889676 chr1 67722567 C A 3.36E-07 Crohn's disease IL23R intron 17804789 rs4655694 chr1 67723552 G A 0.0005315 Sarcoidosis IL23R intron 22952805 rs10889677 chr1 67725120 C A 3.40E-14 Crohn's disease IL23R UTR-3 17068223 rs10889677 chr1 67725120 C A 2.40E-06 Crohn's disease IL23R UTR-3 17447842 rs10889677 chr1 67725120 C A 2.00E-07 Crohn's disease IL23R UTR-3 17804789 rs10889677 chr1 67725120 C A 1.00E-08 Ulcerative colitis IL23R UTR-3 19122664 rs9988642 chr1 67726104 T C 3.16E-08 Crohn's disease IL23R nearGene-3 17804789 rs9988642 chr1 67726104 T C 1.10E-26 Psoriasis IL23R nearGene-3 23143594 rs2000252 chr1 67727555 C T 2.63E-04 Smoking quantity / / 24665060 rs12567232 chr1 67728018 G A 2.00E-07 Crohn's disease / / 17804789 rs6669582 chr1 67730055 A G 1.38E-07 Crohn's disease / / 17804789 rs10789230 chr1 67730628 G T 2.37E-08 Crohn's disease / / 17804789 rs7547569 chr1 67731368 T C 2.99E-05 Crohn's disease / / 17804789 rs7539328 chr1 67732603 G A 8.44E-07 Crohn's disease / / 17068223 rs11583760 chr1 67735948 C T 3.95E-05 Crohn's disease / / 17804789 rs11209032 chr1 67740092 G A 5.50E-13 Crohn's disease / / 17068223 rs11209032 chr1 67740092 G A 8.00E-05 Ankylosing spondylitis / / 21743469 rs11209033 chr1 67744500 C G 1.47E-10 Multiple complex diseases / / 17554300 rs11209033 chr1 67744500 C G 1.44E-06 Crohn's disease / / 17804789 rs6660226 chr1 67744601 G A 5.98E-08 Multiple complex diseases / / 17554300 rs6660226 chr1 67744601 G A 1.08E-05 Behcet's disease / / 23291587 rs12141431 chr1 67747023 G C 5.00E-13 Multiple complex diseases / / 17554300 rs12119179 chr1 67747415 A C 5.38E-11 Multiple complex diseases / / 17554300 rs12119179 chr1 67747415 A C 8.36E-05 Crohn's disease / / 17804789 rs7546245 chr1 67750474 T C 5.89E-11 Multiple complex diseases / / 17554300 rs7546245 chr1 67750474 T C 4.71E-06 Crohn's disease / / 17804789 rs7546245 chr1 67750474 T C 2.80E-04 Ankylosing spondylitis / / 21743469 rs11209039 chr1 67751193 A G 1.34E-07 Multiple complex diseases / / 17554300 rs11209040 chr1 67752671 G A,C 8.43E-05 Crohn's disease / / 17804789 rs1495966 chr1 67753353 T C 6.09E-05 Behcet's disease / / pha002888 rs1495965 chr1 67753508 C T 3.55E-09 Crohn's disease / / 17068223 rs1495965 chr1 67753508 C T 2.00E-11 Behcet's disease / / 20622879 rs1495965 chr1 67753508 C T 6.99E-05 Behcet's disease / / pha002888 rs924080 chr1 67760140 T C 3.83E-06 Crohn's disease / / 17068223 rs924080 chr1 67760140 T C 7.00E-09 Behcet's disease / / 20622878 rs924080 chr1 67760140 T C 5.36E-06 Behcet's disease / / 23291587 rs924080 chr1 67760140 T C 5.35E-06 Behcet's disease / / pha002888 rs3762317 chr1 67772582 A G 8.40E-04 Alcohol dependence / / 20201924 rs56194793 chr1 67790598 T C 2.24E-37 Primary biliary cirrhosis IL12RB2 intron 22961000 rs11209050 chr1 67791736 A C 9.60E-19 Primary biliary cirrhosis IL12RB2 intron 21399635 rs10489626 chr1 67793171 C G 0.0000048 Triglycerides IL12RB2 intron 23063622 rs191377276 chr1 67793935 T A 0.000033 Prostate cancer (advanced) IL12RB2 missense 23555315 rs72678531 chr1 67798445 T C 1.00E-23 Primary biliary cirrhosis (anti-mitochondrial antibody positive) IL12RB2 intron 22936693 rs72678531 chr1 67798445 T C 2.66E-23 Primary biliary cirrhosis IL12RB2 intron 22936693 rs72678531 chr1 67798445 T C 4.13E-19 Primary biliary cirrhosis in females IL12RB2 intron 22936693 rs72678531 chr1 67798445 T C 2.47E-38 Primary biliary cirrhosis IL12RB2 intron 22961000 rs11209051 chr1 67798895 C T 1.93E-36 Primary biliary cirrhosis IL12RB2 intron 22961000 rs10889681 chr1 67799170 T C 1.67E-36 Primary biliary cirrhosis IL12RB2 intron 22961000 rs6659932 chr1 67802371 A C 4.97E-19 Primary biliary cirrhosis IL12RB2 intron 22936693 rs3790566 chr1 67814440 T C 8.24E-08 Systemic lupus erythematosus and Systemic sclerosis IL12RB2 intron 23740937 rs3790567 chr1 67822377 A G 1.77E-05 Multiple complex diseases IL12RB2 intron 17554300 rs3790567 chr1 67822377 A G 3.00E-11 Primary biliary cirrhosis IL12RB2 intron 19458352 rs3790567 chr1 67822377 A G 8.00E-12 Primary biliary cirrhosis IL12RB2 intron 20639880 rs3790567 chr1 67822377 A G 1.97E-04 Systemic sclerosis IL12RB2 intron 21779181 rs3790567 chr1 67822377 A G 2.45E-05 Systemic lupus erythematosus and Systemic sclerosis IL12RB2 intron 23740937 rs3790568 chr1 67836060 G A 5.27E-04 Diabetic retinopathy IL12RB2 intron 20871662 rs12759271 chr1 67906853 G T 6.84E-04 Stroke / / 22306652 rs12116575 chr1 67912259 C T 7.82E-04 Stroke / / 22306652 rs1954118 chr1 67914487 T A 1.48E-04 Multiple complex diseases / / 17554300 rs6657603 chr1 67935310 T G 2.22E-04 Gallstones / / 17632509 rs12037907 chr1 67972435 A C 8.14E-05 Colorectal cancer / / 19723657 rs11209101 chr1 67989691 C A 5.60E-06 Hemoglobin / / pha003098 rs6686812 chr1 67991360 A G 6.13E-05 Hemoglobin / / pha003098 rs7524558 chr1 67993782 C T 4.33E-04 Multiple complex diseases / / 17554300 rs1340592 chr1 68021103 G A 8.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs6693292 chr1 68023168 A C 8.72E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4081356 chr1 68032769 G T 1.58E-04 Rheumatoid arthritis / / 21452313 rs11209119 chr1 68038390 G A 1.20E-04 Rheumatoid arthritis / / 21452313 rs12083789 chr1 68044856 A T 9.92E-04 Multiple complex diseases / / 17554300 rs9919329 chr1 68046274 C T 8.90E-04 Rheumatoid arthritis / / 21452313 rs787538 chr1 68050630 T C 6.00E-05 Asthma and hay fever / / 24388013 rs787539 chr1 68051023 C T 6.00E-04 Lymphocyte counts / / 22286170 rs787520 chr1 68055306 A G 3.77E-04 Multiple complex diseases / / 17554300 rs2105262 chr1 68058216 G A 9.45E-04 Type 2 diabetes / / 17463246 rs787498 chr1 68071100 C T 2.36E-04 Body mass index / / 21701565 rs787498 chr1 68071100 C T 3.61E-04 Body mass index / / 21701565 rs787499 chr1 68071382 C T 3.45E-04 Body mass index / / 21701565 rs787499 chr1 68071382 C T 4.16E-04 Body mass index / / 21701565 rs10789239 chr1 68101467 T C 6.79E-04 Type 2 diabetes / / 17463246 rs12129053 chr1 68105186 G A 3.29E-06 Schizophrenia / / 24253340 rs12129053 chr1 68105186 G A 1.53E-05 Hypertension / / pha003041 rs344924 chr1 68105453 A G 3.00E-07 non-small cell lung cancer / / 23478653 rs12076129 chr1 68106197 G T 9.97E-05 Waist Circumference / / pha003024 rs12076129 chr1 68106197 G T 5.89E-05 Waist Circumference / / pha003025 rs12076129 chr1 68106197 G T 7.87E-05 Weight / / pha003027 rs11209133 chr1 68106505 T C 1.88E-05 Waist Circumference / / pha003024 rs11209133 chr1 68106505 T C 1.27E-05 Waist Circumference / / pha003025 rs11209133 chr1 68106505 T C 3.72E-05 Weight / / pha003026 rs11209133 chr1 68106505 T C 5.20E-05 Weight / / pha003027 rs12134425 chr1 68117203 T G 6.60E-05 Insulin-related traits / / pha003063 rs344938 chr1 68126437 G A 7.71E-04 Obesity (extreme) / / 21935397 rs12748843 chr1 68128130 A C 4.20E-04 Multiple complex diseases / / 17554300 rs11209138 chr1 68128639 G A 4.68E-04 Multiple complex diseases / / 17554300 rs344931 chr1 68135838 T C 8.67E-04 Obesity (extreme) / / 21935397 rs3783468 chr1 68152363 G A 5.29E-04 Parkinson's disease GADD45A intron 17052657 rs598602 chr1 68161837 A G 9.39E-04 Obesity (extreme) / / 21935397 rs41335250 chr1 68162655 A G 2.57E-04 Multiple complex diseases / / 17554300 rs7419 chr1 68167491 C T 3.26E-04 Multiple complex diseases GNG12 UTR-3 17554300 rs12036629 chr1 68189166 G A 2.10E-04 Multiple complex diseases GNG12 intron 17554300 rs11209143 chr1 68189965 G A 2.46E-04 Multiple complex diseases GNG12 intron 17554300 rs604256 chr1 68191951 T C 2.05E-04 Type 2 diabetes GNG12 intron 17463246 rs2803461 chr1 68194025 A G 2.79E-04 Type 2 diabetes GNG12 intron 17463246 rs2803462 chr1 68194151 G A 2.09E-04 Type 2 diabetes GNG12 intron 17463246 rs632959 chr1 68197671 A G 2.07E-04 Type 2 diabetes GNG12 intron 17463246 rs3766272 chr1 68221471 A G 4.08E-04 Multiple complex diseases GNG12 intron 17554300 rs12121525 chr1 68223227 G A 7.10E-05 HIV-1 control GNG12 intron 20041166 rs12061806 chr1 68256929 C T 7.00E-04 Multiple complex diseases GNG12 intron 17554300 rs1276300 chr1 68258818 G A 5.20E-05 White matter hyperintensity burden GNG12 intron 21681796 rs1276301 chr1 68259402 T C 5.40E-05 White matter hyperintensity burden GNG12 intron 21681796 rs1276303 chr1 68260778 C T 6.30E-05 White matter hyperintensity burden GNG12 intron 21681796 rs1276304 chr1 68260901 G C 6.20E-05 White matter hyperintensity burden GNG12 intron 21681796 rs1276305 chr1 68262269 T C 6.00E-05 White matter hyperintensity burden GNG12 intron 21681796 rs1276309 chr1 68262903 A G 6.90E-05 White matter hyperintensity burden GNG12 intron 21681796 rs1276311 chr1 68264927 A G 6.60E-05 White matter hyperintensity burden GNG12 intron 21681796 rs11209156 chr1 68273407 C T 5.90E-05 White matter hyperintensity burden GNG12 intron 21681796 rs6671283 chr1 68282901 A G 1.31E-05 Response to tamoxifen in breast cancer GNG12 intron 22180457 rs12239301 chr1 68283171 A G 0.00038 Coronary artery calcification GNG12 intron 23727086 rs2492874 chr1 68283492 C A 6.80E-05 White matter hyperintensity burden GNG12 intron 21681796 rs12132247 chr1 68284145 C T 0.00005 Coronary artery calcification GNG12 intron 23727086 rs2154376 chr1 68327576 T C 8.50E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs1938446 chr1 68335624 G A 8.70E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs10157622 chr1 68337493 G A 8.60E-04 Multiple complex diseases LOC100289178 intron 17554300 rs10157622 chr1 68337493 G A 8.30E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs12143705 chr1 68342367 T G 1.10E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs7554886 chr1 68345009 G C 1.10E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs12095487 chr1 68346631 G A 2.60E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs12095488 chr1 68346632 G A 1.10E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs8179318 chr1 68352002 A G 1.20E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs1344148 chr1 68354321 G A 2.20E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs12132081 chr1 68354648 C T 1.20E-05 White matter hyperintensity burden LOC100289178 intron 21681796 rs1892525 chr1 68355614 G C 4.45E-04 Multiple complex diseases LOC100289178 intron 17554300 rs1892525 chr1 68355614 G C 7.20E-07 White matter hyperintensity burden LOC100289178 intron 21681796 rs1892525 chr1 68355614 G C 0.0000579 white matter hyperintensity burden LOC100289178 intron 23674528 rs11209171 chr1 68356836 A T 2.90E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs11209171 chr1 68356836 A T 0.000142 white matter hyperintensity burden LOC100289178 intron 23674528 rs11590313 chr1 68357032 G A 1.60E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs11590313 chr1 68357032 G A 0.0000737 white matter hyperintensity burden LOC100289178 intron 23674528 rs7520899 chr1 68358177 C T 1.70E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs7520899 chr1 68358177 C T 0.0000634 white matter hyperintensity burden LOC100289178 intron 23674528 rs7521135 chr1 68358247 G T 1.60E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs7521135 chr1 68358247 G T 0.0000625 white matter hyperintensity burden LOC100289178 intron 23674528 rs7521244 chr1 68358336 G C 1.20E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs7521244 chr1 68358336 G C 0.0000668 white matter hyperintensity burden LOC100289178 intron 23674528 rs12025677 chr1 68359887 T C 5.50E-04 Multiple complex diseases LOC100289178 intron 17554300 rs12025677 chr1 68359887 T C 1.90E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs12025677 chr1 68359887 T C 0.0000609 white matter hyperintensity burden LOC100289178 intron 23674528 rs10789247 chr1 68360980 A C 1.20E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs10789247 chr1 68360980 A C 0.0000621 white matter hyperintensity burden LOC100289178 intron 23674528 rs10889722 chr1 68361428 G A 1.20E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs10889722 chr1 68361428 G A 0.0000628 white matter hyperintensity burden LOC100289178 intron 23674528 rs12073947 chr1 68363490 A C 3.80E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs12073947 chr1 68363490 A C 0.0000233 white matter hyperintensity burden LOC100289178 intron 23674528 rs1317272 chr1 68363580 A G 3.80E-06 White matter hyperintensity burden LOC100289178 intron 21681796 rs1317272 chr1 68363580 A G 0.000032 white matter hyperintensity burden LOC100289178 intron 23674528 rs12405649 chr1 68386944 G C 7.08E-04 Smoking initiation LOC100289178 intron 24665060 rs17130402 chr1 68424715 C A 1.59E-04 Multiple complex diseases LOC100289178 intron 17554300 rs1926283 chr1 68448661 A G 2.29E-10 Common variable immunodeficiency LOC100289178 intron 21497890 rs1926278 chr1 68453859 C T 2.99E-05 Tuberculosis LOC100289178 intron 24057671 rs12141436 chr1 68463212 G A 7.23E-04 Alzheimer's disease LOC100289178 intron 22005930 rs1926289 chr1 68465932 T C 7.39E-04 Alzheimer's disease LOC100289178 intron 22005930 rs7553612 chr1 68479872 C T 4.33E-06 Liver disease in chronic hepatitis B virus infection LOC100289178 intron 24065354 rs12069862 chr1 68491995 G A 5.42E-04 Anorexia nervosa LOC100289178 intron 23568457 rs4433365 chr1 68500883 G C 3.79E-04 Multiple complex diseases LOC100289178 intron 17554300 rs269340 chr1 68561012 T C 2.28E-04 Major depressive disorder LOC100289178 intron 22472876 rs9436797 chr1 68567418 G A 4.81E-05 Vaspin levels WLS intron 22907691 rs9436797 chr1 68567418 G A 0.0000481 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - remission at 8 weeks WLS intron 22907730 rs11805150 chr1 68568921 T C 8.01E-05 Height WLS intron pha003010 rs6671127 chr1 68571220 A C 6.72E-05 Height WLS intron pha003010 rs6671127 chr1 68571220 A C 4.50E-05 Height WLS intron pha003011 rs1337406 chr1 68573853 G A 3.20E-05 Cognitive performance WLS intron 19734545 rs269352 chr1 68579397 G A 3.92E-05 Height WLS intron pha003010 rs269352 chr1 68579397 G A 5.41E-05 Height WLS intron pha003011 rs14130 chr1 68584745 A G 7.98E-07 Height WLS intron pha003010 rs14130 chr1 68584745 A G 1.74E-05 Height WLS intron pha003011 rs12046920 chr1 68586620 T G 7.43E-06 Height WLS intron pha003010 rs12046920 chr1 68586620 T G 1.70E-05 Weight WLS intron pha003027 rs10158352 chr1 68587777 T C 9.59E-05 Insulin-related traits WLS intron pha003063 rs2566784 chr1 68602735 G T 3.30E-08 Bone mineral density (spine) WLS intron 19801982 rs1864570 chr1 68604773 G A 7.32E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) WLS intron 23648065 rs9970306 chr1 68613579 C T 1.40E-08 Bone mineral density (spine) WLS intron 19801982 rs3762371 chr1 68620762 G A 2.20E-08 Bone mineral density (spine) WLS intron 19801982 rs12733835 chr1 68622994 C A 2.70E-09 Bone mineral density (spine) WLS intron 19801982 rs2566759 chr1 68631792 G A 1.40E-11 Bone mineral density (spine) WLS intron 19801982 rs2566758 chr1 68632483 C T 4.10E-09 Bone mineral density (spine) WLS intron 19801982 rs1367448 chr1 68633924 G A 5.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) WLS intron 23648065 rs1367447 chr1 68634030 C T 1.70E-12 Bone mineral density (spine) WLS intron 19801982 rs1864569 chr1 68634257 G A 6.43E-04 Alzheimer's disease WLS intron 24755620 rs1430742 chr1 68635075 T C 3.00E-13 Bone mineral density (spine) WLS intron 19801982 rs2566755 chr1 68635390 T C 2.00E-12 Bone mineral density (hip) WLS intron 19801982 rs2195682 chr1 68635743 C T 1.20E-12 Bone mineral density (spine) WLS intron 19801982 rs2772304 chr1 68636580 C A 2.10E-08 Bone mineral density (spine) WLS intron 19801982 rs4233320 chr1 68638451 G T 1.50E-12 Bone mineral density (spine) WLS intron 19801982 rs17482952 chr1 68639385 A G 3.66E-04 Bone mineral density (paediatric,total body less head) WLS intron 24945404 rs17482952 chr1 68639385 A G 3.92E-04 Bone mineral density (paediatric,skull) WLS intron 24945404 rs6677666 chr1 68640101 C T 3.80E-13 Bone mineral density (spine) WLS intron 19801982 rs878548 chr1 68640286 A G 4.30E-13 Bone mineral density (spine) WLS intron 19801982 rs891528 chr1 68640353 A G 3.50E-09 Bone mineral density (spine) WLS intron 19801982 rs891527 chr1 68641160 A T 4.10E-08 Bone mineral density (spine) WLS intron 19801982 rs2566754 chr1 68641238 T G 4.10E-08 Bone mineral density (spine) WLS intron 19801982 rs944082 chr1 68643091 T C 1.10E-11 Bone mineral density (spine) WLS intron 19801982 rs12407028 chr1 68647716 T C 3.60E-13 Bone mineral density (spine) WLS intron 19801982 rs12407028 chr1 68647716 T C 3.00E-45 Bone mineral density WLS intron 22504420 rs12407028 chr1 68647716 T C 0.000313 Lumbar spine bone mineral density (premenopausal) WLS intron 23074152 rs2772300 chr1 68648026 G A 5.70E-13 Bone mineral density (spine) WLS intron 19801982 rs1430740 chr1 68657510 T C 1.20E-08 Bone mineral density (spine) WLS intron 19801982 rs1430740 chr1 68657510 T C 1.00E-11 Bone mineral density WLS intron 24249740 rs2820500 chr1 68658961 T C 3.20E-10 Bone mineral density (spine) WLS intron 19801982 rs2820500 chr1 68658961 T C 4.66E-04 Obesity (extreme) WLS intron 21935397 rs1036066 chr1 68660205 A C 8.20E-10 Bone mineral density (spine) WLS intron 19801982 rs1036066 chr1 68660205 A C 4.53E-04 Obesity (extreme) WLS intron 21935397 rs12568456 chr1 68661486 T G 1.50E-12 Bone mineral density (spine) WLS intron 19801982 rs2116047 chr1 68661751 A G 1.10E-09 Bone mineral density (spine) WLS intron 19801982 rs2116047 chr1 68661751 A G 4.21E-04 Obesity (extreme) WLS intron 21935397 rs2116046 chr1 68662252 G A 1.20E-08 Bone mineral density (spine) WLS intron 19801982 rs2039154 chr1 68662813 G A 9.90E-10 Bone mineral density (spine) WLS intron 19801982 rs2039154 chr1 68662813 G A 4.36E-04 Obesity (extreme) WLS intron 21935397 rs919540 chr1 68663143 C T 9.30E-10 Bone mineral density (spine) WLS intron 19801982 rs919540 chr1 68663143 C T 4.48E-04 Obesity (extreme) WLS intron 21935397 rs17130567 chr1 68663847 A G 1.60E-12 Bone mineral density (spine) WLS intron 19801982 rs7554551 chr1 68665023 T C 4.30E-13 Bone mineral density (spine) WLS intron 19801982 rs2149823 chr1 68668292 C T 5.02E-04 Multiple complex diseases WLS intron 17554300 rs2772286 chr1 68685389 T C 4.80E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WLS intron 20877124 rs12563946 chr1 68692744 G A 3.49E-04 Multiple complex diseases WLS intron 17554300 rs12097456 chr1 68703087 C T 9.88E-04 Alcohol dependence / / 24277619 rs2772294 chr1 68703843 G A 1.91E-05 Psoriasis / / 18364390 rs3001033 chr1 68708808 G A 4.72E-04 Multiple complex diseases / / 17554300 rs1360181 chr1 68714135 T C 4.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12730489 chr1 68735304 C T 5.47E-05 Intelligence / / 21826061 rs1360182 chr1 68738278 T C 6.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs3923451 chr1 68757334 C T 4.40E-05 Osteoarthritis (knee and hip) / / 21177295 rs3923451 chr1 68757334 C T 4.91E-05 Osteoarthritis (knee and hip) / / 21177295 rs11209261 chr1 68785213 T A 3.00E-06 Airflow obstruction / / 22837378 rs4926354 chr1 68803646 T C 2.88E-04 Gallstones / / 17632509 rs4926381 chr1 68816800 C T 9.79E-05 ldl cholesterol / / pha003076 rs11209290 chr1 68871027 G A 9.41E-05 Cognitive test performance / / 20125193 rs11209290 chr1 68871027 G A 8.87E-10 Parkinson's disease / / 21812969 rs10518295 chr1 68884158 G A 6.30E-05 Endometriosis / / 21151130 rs10493443 chr1 68884722 T C 1.62E-04 Statin-induced myopathy / / 21826682 rs12030710 chr1 68899762 G A 6.50E-05 Endometriosis RPE65 intron 21151130 rs114379164 chr1 68905294 G A,C 0.00021 Prostate cancer RPE65 missense 23555315 rs17130691 chr1 68905981 T A 9.35E-05 Smoking cessation RPE65 intron 24665060 rs17130694 chr1 68909113 C T 6.82E-04 Smoking cessation RPE65 intron 24665060 rs2012235 chr1 68912755 T C 0.0000209 Uterine leiomyomata RPE65 intron 23040493 rs435066 chr1 68927513 T C 4.00E-06 IgG glycosylation / / 23382691 rs435066 chr1 68927513 T C 5.00E-06 IgG glycosylation / / 23382691 rs435066 chr1 68927513 T C 7.00E-06 IgG glycosylation / / 23382691 rs435066 chr1 68927513 T C 7.00E-06 IgG glycosylation / / 23382691 rs435066 chr1 68927513 T C 8.00E-06 IgG glycosylation / / 23382691 rs10889769 chr1 68931366 A G 2.96E-04 Multiple complex diseases / / 17554300 rs10789263 chr1 68949139 T C 5.06E-04 Multiple complex diseases DEPDC1 intron 17554300 rs1041046 chr1 69002658 C T 8.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1924529 chr1 69022171 G A 4.81E-04 Multiple complex diseases / / 17554300 rs12132065 chr1 69047142 T G 7.18E-06 Personality dimensions / / 22628180 rs10518303 chr1 69050472 A G 3.02E-04 Multiple complex diseases / / 17554300 rs7547034 chr1 69063771 T C 8.47E-06 Personality dimensions / / 22628180 rs2507205 chr1 69068554 T C 2.38E-04 Smoking cessation / / 24665060 rs11209332 chr1 69088662 G A 6.27E-04 Multiple complex diseases / / 17554300 rs12136070 chr1 69089971 C T 8.84E-04 Multiple complex diseases / / 17554300 rs1492075 chr1 69156133 A G 1.24E-04 Alzheimer's disease (late onset) / / 21379329 rs854285 chr1 69158190 T G 8.04E-05 Post-operative nausea and vomiting / / 21694509 rs12405430 chr1 69168941 T G 8.00E-05 Endometriosis / / 21151130 rs9988609 chr1 69315228 A G 5.78E-05 Telomere length / / 24795349 rs17435919 chr1 69439156 G A 3.44E-04 Multiple complex diseases / / 17554300 rs4650310 chr1 69445925 A G 9.64E-04 Prostate cancer / / 23023329 rs6588344 chr1 69446281 T G 3.05E-05 Duodenal ulcer / / 22387998 rs2842040 chr1 69516639 G A 9.79E-04 Alcohol dependence / / 24277619 rs1507860 chr1 69520596 G A 4.80E-05 Malaria / / 19465909 rs1507860 chr1 69520596 G A 9.00E-06 Soluble leptin receptor levels / / 20167575 rs906474 chr1 69526551 G C 9.63E-04 Response to TNF antagonist treatment / / 21061259 rs1567214 chr1 69526682 G C 1.20E-06 Soluble leptin receptor levels / / 20167575 rs12131089 chr1 69529365 C A 6.10E-06 Soluble leptin receptor levels / / 20167575 rs2456910 chr1 69554417 A G 9.21E-04 Multiple complex diseases / / 17554300 rs1281556 chr1 69568991 G A 2.76E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1281556 chr1 69568991 G A 4.19E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs17436927 chr1 69577933 C G 6.38E-04 Type 2 diabetes / / 17463246 rs4147141 chr1 69579252 G A 6.00E-06 Attention deficit hyperactivity disorder / / 18821565 rs4147141 chr1 69579252 G A 8.00E-06 Inattentive symptoms / / 18821565 rs12086324 chr1 69681190 C T 1.04E-04 Alcohol dependence / / 24277619 rs4650135 chr1 69684997 T C 5.00E-06 Inattentive symptoms / / 18821565 rs4650135 chr1 69684997 T C 3.71E-04 Smoking quantity / / 24665060 rs2901175 chr1 69688646 C G 2.30E-05 Urinary metabolites / / 21572414 rs5010843 chr1 69694205 G A 4.30E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12404688 chr1 69815440 G A 1.18E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs11209440 chr1 69851078 G A 1.18E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1926256 chr1 69879074 C T 4.12E-05 HDL cholesterol / / pha003074 rs4388647 chr1 69886702 T C 1.40E-05 Urinary metabolites / / 21572414 rs11209457 chr1 69894849 G A 0.000000485 Secreted IFN-gamma response to smallpox vaccine / / 22661280 rs12135013 chr1 69895080 T G 5.50E-05 HDL cholesterol / / pha003074 rs9326089 chr1 69909410 A C 1.01E-04 Hearing function / / 17255346 rs17495923 chr1 69915596 C A 2.30E-05 Urinary metabolites / / 21572414 rs10789294 chr1 69939539 G C 6.72E-05 Progressive supranuclear palsy / / 21685912 rs1952142 chr1 69948854 C G 7.92E-05 Progressive supranuclear palsy / / 21685912 rs1341795 chr1 69960136 T G 3.94E-05 Progressive supranuclear palsy / / 21685912 rs12048011 chr1 69969838 C T 8.38E-04 Type 2 diabetes / / 17463246 rs10889833 chr1 69975660 G A 2.54E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) / / 23648065 rs4589058 chr1 69993512 A G 3.33E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1935244 chr1 70003853 C A 9.41E-04 Alzheimer's disease / / 22005930 rs1341784 chr1 70007663 T C 8.63E-05 Lymphocyte counts / / pha003094 rs10889836 chr1 70010325 C T 7.32E-04 Alzheimer's disease / / 22005930 rs947420 chr1 70014986 C T 2.56E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs4650295 chr1 70029922 C T 9.44E-05 Lymphocyte counts / / pha003094 rs4650295 chr1 70029922 C T 7.95E-05 Neutrophil count / / pha003095 rs1245058 chr1 70048064 C T 4.10E-05 Lipid traits / / 17903299 rs1749517 chr1 70064870 G C 6.00E-05 Triglycerides / / 19074352 rs11809230 chr1 70084797 C T 1.20E-05 Urinary metabolites / / 21572414 rs12030270 chr1 70085637 G C 7.50E-04 Alzheimer's disease / / 22005930 rs11209505 chr1 70097194 A G 4.80E-05 Lymphocyte counts / / pha003094 rs2066296 chr1 70097708 T G 9.92E-05 Orofacial clefts / / 22419666 rs2066296 chr1 70097708 T G 4.80E-05 Lymphocyte counts / / pha003094 rs1245072 chr1 70115756 A T 1.80E-05 Blood Phenotypes / / 17903294 rs7515290 chr1 70116825 A G 5.15E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs12044761 chr1 70121115 G A 3.44E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs12023616 chr1 70121268 A G 2.93E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs800930 chr1 70126607 G A 1.10E-05 Urinary metabolites / / 21572414 rs800930 chr1 70126607 G A 2.77E-05 Response to cytidine analogues (gemcitabine) / / 24483146 rs800930 chr1 70126607 G A 4.70E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1417437 chr1 70154441 T C 4.00E-06 Orofacial clefts / / 22419666 rs1417437 chr1 70154441 T C 9.00E-06 Orofacial clefts / / 22419666 rs11209521 chr1 70157066 T C 5.81E-04 Multiple complex diseases / / 17554300 rs1417436 chr1 70160178 T C 1.16E-05 Orofacial clefts / / 22419666 rs10889850 chr1 70207079 T G 2.00E-06 Body mass index / / 24348519 rs17131023 chr1 70219191 T C 3.70E-27 Narcolepsy / / 19629137 rs17397812 chr1 70225832 G A 2.51E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs75115510 chr1 70243630 C T 2.79E-04 Acne (severe) LRRC7 intron 24927181 rs2175743 chr1 70295901 C T 3.58E-05 Parkinson's disease (motor and cognition) LRRC7 intron 22658654 rs2175743 chr1 70295901 C T 3.58E-05 Immune response to anthrax vaccine LRRC7 intron 22658931 rs12734666 chr1 70297051 A G 2.60E-05 Urinary metabolites LRRC7 intron 21572414 rs6686752 chr1 70302082 C T 1.61E-04 Multiple complex diseases LRRC7 intron 17554300 rs6691577 chr1 70302201 A G 9.23E-05 Multiple complex diseases LRRC7 intron 17554300 rs12086732 chr1 70313699 G A,T 7.59E-04 Multiple complex diseases LRRC7 intron 17554300 rs6703428 chr1 70316302 A G 1.22E-04 Multiple complex diseases LRRC7 intron 17554300 rs11209557 chr1 70319359 G C 1.09E-04 Multiple complex diseases LRRC7 intron 17554300 rs11209557 chr1 70319359 G C 2.40E-05 Urinary metabolites LRRC7 intron 21572414 rs2226284 chr1 70335682 T C 4.58E-04 Multiple complex diseases LRRC7 intron 17554300 rs2226284 chr1 70335682 T C 3.00E-08 Hypertension risk in short sleep duration LRRC7 intron 22322875 rs12037173 chr1 70355981 A G 4.00E-06 Attention deficit hyperactivity disorder LRRC7 intron 21784300 rs17131083 chr1 70359726 C T 0.000313 Salmonella-induced pyroptosis LRRC7 intron 22837397 rs1023008 chr1 70404540 A T 6.00E-06 Obesity-related traits LRRC7 intron 23251661 rs17131089 chr1 70415779 T C 0.000657 Salmonella-induced pyroptosis LRRC7 intron 22837397 rs12035355 chr1 70460238 C T 1.41E-04 Multiple complex diseases LRRC7 intron 17554300 rs721242 chr1 70492561 C T 3.95E-05 Bipolar disorder (mania) LRRC7 intron 23326512 rs17097485 chr1 70492884 T G 9.09E-06 Bipolar disorder (mania) LRRC7 intron 23326512 rs10493463 chr1 70493703 C T 1.72E-05 Bipolar disorder (mania) LRRC7 intron 23326512 rs17131142 chr1 70499912 G T 2.82E-04 Multiple complex diseases LRRC7 intron 17554300 rs10493467 chr1 70500691 G A 7.46E-05 Bipolar disorder (mania) LRRC7 intron 23326512 rs7547666 chr1 70594571 T G 2.00E-05 Urinary metabolites / / 21572414 rs654025 chr1 70602342 C T 2.60E-06 Urinary metabolites / / 21572414 rs2274913 chr1 70689215 T C 5.72E-05 Cognitive decline SRSF11 intron 22054870 rs3767207 chr1 70709759 G A 8.84E-05 Cognitive decline SRSF11 intron 22054870 rs3767206 chr1 70715093 G A 4.52E-04 Suicide,with and without major depression SRSF11 intron 22059935 rs664051 chr1 70869116 G A 2.94E-04 Alcohol dependence / / 24277619 rs672203 chr1 70887099 A G 2.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) CTH intron 24025145 rs17131304 chr1 70892915 A T 2.61E-11 HDL cholesterol CTH intron 23063622 rs145785987 chr1 70896038 T C 0.000031 Prostate cancer CTH missense 23555315 rs145785987 chr1 70896038 T C 0.000063 Prostate cancer (non-advanced prostate cancer) CTH missense 23555315 rs12561944 chr1 70910065 A G 4.60E-05 Alcohol dependence / / 20201924 rs12561944 chr1 70910065 A G 8.90E-05 Alcohol dependence / / 20201924 rs12561944 chr1 70910065 A G 4.65E-05 Alcoholism / / pha002892 rs12561944 chr1 70910065 A G 8.87E-05 Alcoholism / / pha002893 rs555671 chr1 70913726 G A 1.50E-05 Urinary metabolites / / 21572414 rs10458561 chr1 70921173 G A 4.00E-07 Antipsychotic-induced QTc interval prolongation / / 20921969 rs8179319 chr1 70934259 G A 6.32E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU) / / 24025145 rs17131317 chr1 70947746 A G 1.99E-05 Suicide attempts in bipolar disorder / / 21423239 rs17131318 chr1 70947851 A T 1.43E-05 Suicide attempts in bipolar disorder / / 21423239 rs12094445 chr1 70953934 C T 1.29E-05 Suicide attempts in bipolar disorder / / 21423239 rs2651248 chr1 70957413 G T 6.20E-04 Suicide attempts in bipolar disorder / / 21423239 rs1333680 chr1 70963368 T C 8.03E-04 Suicide attempts in bipolar disorder / / 21423239 rs1333680 chr1 70963368 T C 7.97E-05 Body Mass Index / / pha003006 rs1333680 chr1 70963368 T C 2.67E-05 Waist Circumference / / pha003024 rs2807907 chr1 70986488 A G 5.51E-05 Body Mass Index / / pha003020 rs2651244 chr1 70995562 G A 2.00E-08 Inflammatory bowel disease / / 23128233 rs2651244 chr1 70995562 G A 7.49E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs17131783 chr1 70997811 G A 6.51E-05 Cognitive impairment induced by topiramate / / 22091778 rs2780747 chr1 71002192 A G 7.30E-04 Multiple complex diseases / / 17554300 rs2780748 chr1 71002220 A T 5.34E-04 Multiple complex diseases / / 17554300 rs582435 chr1 71010207 C T 7.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9425029 chr1 71011845 C T 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs9424946 chr1 71011982 C T 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs6700601 chr1 71012395 C A 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4650061 chr1 71013233 A G 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4515743 chr1 71014024 T G 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4546874 chr1 71014538 C T 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs3121981 chr1 71014641 T C 4.13E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs4649923 chr1 71028151 G A 1.70E-05 Urinary metabolites / / 21572414 rs4649923 chr1 71028151 G A 4.98E-05 Post-operative nausea and vomiting / / 21694509 rs3121983 chr1 71028815 A G 2.10E-05 Urinary metabolites / / 21572414 rs11209658 chr1 71103816 T C 1.60E-04 Myopia (pathological) / / 21095009 rs10889884 chr1 71120020 C T 9.38E-05 Cognitive test performance / / 20125193 rs1334995 chr1 71127061 A G 2.29E-04 Osteoarthritis / / 19508968 rs1334995 chr1 71127061 A G 9.29E-04 Myopia (pathological) / / 21095009 rs6683555 chr1 71132536 C T 2.24E-04 Myopia (pathological) / / 21095009 rs2820529 chr1 71134588 T C 7.03E-04 Myopia (pathological) / / 21095009 rs2782763 chr1 71142202 T C 2.38E-04 Osteoarthritis / / 19508968 rs2820526 chr1 71153714 C A 2.86E-05 Heart Rate / / pha003053 rs1334997 chr1 71154117 T C 1.42E-05 Glucose levels / / pha003058 rs3001038 chr1 71163715 G A 2.59E-04 Myopia (pathological) / / 21095009 rs2820551 chr1 71163908 G A 5.41E-06 Glucose levels / / pha003058 rs2820551 chr1 71163908 G A 8.38E-05 Glucose levels / / pha003061 rs2421787 chr1 71195538 G A 6.84E-04 Myopia (pathological) / / 21095009 rs2421787 chr1 71195538 G A 3.19E-05 Glucose levels / / pha003058 rs11209689 chr1 71229637 G T 6.85E-05 Myopia (pathological) / / 21095009 rs7547597 chr1 71241232 C A 6.85E-05 Myopia (pathological) / / 21095009 rs10889889 chr1 71250352 A C 9.08E-05 Receptive language ability / / 24687471 rs10493479 chr1 71251704 T C 1.13E-04 Myopia (pathological) / / 21095009 rs2260454 chr1 71255441 G A 3.31E-04 Premature ovarian failure / / 19508998 rs1409982 chr1 71267891 C T 9.33E-05 Receptive language ability / / 24687471 rs1327455 chr1 71273323 T A 5.67E-05 Multiple complex diseases / / 17554300 rs2257772 chr1 71275174 G A 1.11E-04 Myopia (pathological) / / 21095009 rs4603079 chr1 71286947 C T 1.39E-05 Glucose levels / / pha003058 rs4603079 chr1 71286947 C T 9.87E-05 Glucose levels / / pha003061 rs1409988 chr1 71291825 G A 1.39E-05 Glucose levels / / pha003058 rs1409988 chr1 71291825 G A 9.87E-05 Glucose levels / / pha003061 rs2182707 chr1 71294542 G T 1.94E-04 Myopia (pathological) / / 21095009 rs17131450 chr1 71296002 G A 1.70E-06 Stevens-Johnson syndrome / / 20947153 rs959 chr1 71318261 T C 7.95E-05 Myopia (pathological) PTGER3 UTR-3 21095009 rs6664305 chr1 71321740 C T 2.94E-04 Myopia (pathological) PTGER3 intron 21095009 rs1409986 chr1 71331498 A G 0.00000101 Obstructive sleep apnea PTGER3 intron 23155414 rs1325949 chr1 71337193 T C 2.00E-04 Stevens-Johnson syndrome PTGER3 intron 20947153 rs7543182 chr1 71339973 C A 2.50E-04 Stevens-Johnson syndrome PTGER3 intron 20947153 rs7555874 chr1 71343960 C T 4.60E-04 Stevens-Johnson syndrome PTGER3 intron 20947153 rs1409978 chr1 71353104 T C 4.39E-04 Myopia (pathological) PTGER3 intron 21095009 rs4998697 chr1 71358190 T C 4.96E-05 Basophils PTGER3 intron pha003087 rs1327464 chr1 71366238 G A 1.00E-04 Response to interferon beta in multiple sclerosis PTGER3 intron 18195134 rs875727 chr1 71373738 T C 7.15E-19 Glaucoma (primary open-angle) PTGER3 intron 22419738 rs578096 chr1 71394683 T C 5.04E-04 Psoriasis PTGER3 intron 20953187 rs12097924 chr1 71398902 G T 4.70E-05 Orofacial clefts PTGER3 intron 22419666 rs13374231 chr1 71403260 G C 3.75E-05 Orofacial clefts PTGER3 intron 22419666 rs651265 chr1 71415135 A G 6.18E-04 Psoriasis PTGER3 intron 20953187 rs5697 chr1 71436747 C A 4.23E-04 Type 2 diabetes PTGER3 UTR-3 17463246 rs909848 chr1 71443150 T C 7.00E-06 IgG glycosylation PTGER3 intron 23382691 rs11209733 chr1 71471750 C G 9.30E-04 Type 2 diabetes PTGER3 UTR-3 17463246 rs12130153 chr1 71471875 T C 9.32E-04 Type 2 diabetes PTGER3 UTR-3 17463246 rs2268062 chr1 71485299 T C 3.97E-04 Type 2 diabetes PTGER3 intron 17463246 rs2817864 chr1 71503105 T G 1.07E-05 Platelet counts PTGER3 intron 21507922 rs2817866 chr1 71503447 G A 6.43E-05 Post-operative nausea and vomiting PTGER3 intron 21694509 rs12402425 chr1 71520017 G A 7.88E-04 Response to taxane treatment (placlitaxel) ZRANB2-AS1 intron 23006423 rs2796200 chr1 71658888 A G 2.45E-04 Menarche (age at onset) ZRANB2-AS2 intron 23599027 rs2796200 chr1 71658888 A G 4.23E-04 Menarche (age at onset) ZRANB2-AS2 intron 23599027 rs12131265 chr1 71712223 C T 1.34E-05 Alcohol dependence / / 23089632 rs11209757 chr1 71728900 T G 1.29E-05 Alcohol dependence / / 23089632 rs12405821 chr1 71876406 G T 2.33E-04 Type 2 diabetes NEGR1 intron 17463246 rs11209780 chr1 71876652 G A 1.78E-04 Multiple complex diseases NEGR1 intron 17554300 rs2056206 chr1 71936910 T C 2.42E-05 Blood pressure NEGR1 intron 24001895 rs6662613 chr1 71964277 G T 2.50E-05 Urinary metabolites NEGR1 intron 21572414 rs6675439 chr1 71986552 T C 9.10E-06 Urinary metabolites NEGR1 intron 21572414 rs12754625 chr1 71987496 C T 4.20E-06 Urinary metabolites NEGR1 intron 21572414 rs12754625 chr1 71987496 C T 8.18E-04 Alzheimer's disease NEGR1 intron 24755620 rs7535916 chr1 72018365 T C 1.69E-06 Multiple complex diseases NEGR1 intron 17554300 rs10889921 chr1 72045626 T C 7.25E-05 Progressive supranuclear palsy NEGR1 intron 21685912 rs1334992 chr1 72051206 C A 1.00E-04 Cognitive impairment induced by topiramate NEGR1 intron 22091778 rs10493485 chr1 72071129 A T 2.00E-06 Hemostatic factors and hematological phenotypes NEGR1 intron 17903294 rs10493486 chr1 72079898 G A 2.06E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) NEGR1 intron 20877124 rs12136092 chr1 72093635 G A 4.03E-04 Multiple complex diseases NEGR1 intron 17554300 rs10889923 chr1 72099161 G C 1.91E-05 Multiple complex diseases NEGR1 intron 17554300 rs1577396 chr1 72101417 T C 5.11E-06 Multiple complex diseases NEGR1 intron 17554300 rs1041676 chr1 72104447 C T 4.73E-05 Cognitive decline NEGR1 intron 22054870 rs17091720 chr1 72222002 T C 1.95E-04 Multiple complex diseases NEGR1 intron 17554300 rs12024388 chr1 72253577 T C 7.62E-05 Diabetic nephropathy NEGR1 intron pha002852 rs12141391 chr1 72274473 C A 7.00E-06 Systemic lupus erythematosus NEGR1 intron 18204098 rs1350648 chr1 72287866 G T 9.28E-04 Multiple complex diseases NEGR1 intron 17554300 rs546741 chr1 72289671 G A 8.25E-04 Multiple complex diseases NEGR1 intron 17554300 rs554161 chr1 72343350 T A 8.67E-04 Multiple complex diseases NEGR1 intron 17554300 rs2114213 chr1 72404727 C A 6.44E-04 Multiple complex diseases NEGR1 intron 17554300 rs11209875 chr1 72413527 T G 4.60E-04 Smoking initiation NEGR1 intron 24665060 rs6703903 chr1 72415949 C A 3.03E-04 Smoking initiation NEGR1 intron 24665060 rs6677919 chr1 72455832 G A 4.92E-04 Smoking initiation NEGR1 intron 24665060 rs6661979 chr1 72458685 C T 3.82E-04 Smoking initiation NEGR1 intron 24665060 rs111868476 chr1 72459050 G C 1.90E-11 Metabolite levels NEGR1 intron 22286219 rs1937186 chr1 72461042 A G 1.97E-04 Lung function (forced expiratory volume in 1 second) NEGR1 intron 17255346 rs147218787 chr1 72461269 T C 0.00054379 Sarcoidosis NEGR1 intron 22952805 rs12139692 chr1 72461382 C T 3.46E-05 Vascular dementia NEGR1 intron 22116812 rs12042679 chr1 72481896 T C 5.64E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines NEGR1 intron 21844884 rs1486087 chr1 72509490 T C 4.75E-04 Alzheimer's disease (late onset) NEGR1 intron 21379329 rs988421 chr1 72549836 C T 4.30E-05 Parkinson's disease NEGR1 intron 17052657 rs10493493 chr1 72569309 G T 3.14E-05 Lymphocyte counts NEGR1 intron pha003094 rs1486096 chr1 72584184 G A 1.92E-05 HDL cholesterol NEGR1 intron pha003075 rs1486096 chr1 72584184 G A 6.52E-05 Lymphocyte counts NEGR1 intron pha003094 rs1545932 chr1 72622312 T G 1.04E-04 Multiple complex diseases NEGR1 intron 17554300 rs1157072 chr1 72634912 A G 6.43E-04 Nicotine smoking NEGR1 intron 19268276 rs2298152 chr1 72654730 A G 9.31E-05 Erythrocyte counts NEGR1 intron pha003099 rs1675356 chr1 72683226 C T 6.31E-05 HDL cholesterol NEGR1 intron pha003075 rs1194269 chr1 72703860 G A 8.43E-05 HDL cholesterol NEGR1 intron pha003075 rs1776012 chr1 72717743 A G 8.90E-06 Smoking behavior NEGR1 intron 20418888 rs9424977 chr1 72725344 T C 4.60E-06 Smoking behavior NEGR1 intron 20418888 rs9424977 chr1 72725344 T C 9.32E-05 HDL cholesterol NEGR1 intron pha003075 rs1620977 chr1 72729142 A G 3.49E-04 Taste perception NEGR1 intron 22132133 rs1380995 chr1 72733841 A T 1.60E-04 Self-reported allergy NEGR1 intron 23817569 rs12137231 chr1 72735458 T C 1.80E-04 Self-reported allergy NEGR1 intron 23817569 rs9326098 chr1 72740734 C G 5.19E-04 Multiple complex diseases NEGR1 intron 17554300 rs3101336 chr1 72751185 T C 1.10E-07 Smoking behavior / / 20418888 rs3101336 chr1 72751185 T C 1.00E-13 Obesity / / 23563607 rs3101336 chr1 72751185 T C 2.00E-08 Obesity (early onset extreme) / / 23563609 rs2568958 chr1 72765116 G A 1.00E-11 Body mass index / / 19079260 rs2568958 chr1 72765116 G A 2.00E-08 Weight / / 19079260 rs2568958 chr1 72765116 G A 9.90E-08 Smoking behavior / / 20418888 rs2568958 chr1 72765116 G A 2.00E-14 Body mass index / / 23563607 rs2568958 chr1 72765116 G A 4.00E-16 Obesity / / 23563607 rs2815752 chr1 72812440 G A 6.00E-08 Body mass index / / 19079261 rs2815752 chr1 72812440 G A 6.00E-08 Smoking behavior / / 20418888 rs2815752 chr1 72812440 G A 2.00E-22 Body mass index / / 20935630 rs2815752 chr1 72812440 G A 5.90E-07 Menarche (age at onset) / / 21102462 rs2815752 chr1 72812440 G A 1.61E-22 Body mass index / / 23001569 rs990871 chr1 72823713 C T 4.00E-06 Subcutaneous adipose tissue / / 22589738 rs7531118 chr1 72837239 T C 2.00E-17 Obesity / / 23563607 rs10789336 chr1 72838406 G A 1.00E-06 Body mass index / / 23669352 rs1993709 chr1 72838529 A G 5.00E-13 Obesity (early onset extreme) / / 23563609 rs17092613 chr1 72871597 A G 1.36E-04 Multiple complex diseases / / 17554300 rs12406365 chr1 72874258 G A 4.36E-05 Major depressive disorder (broad) / / 20038947 rs17092663 chr1 72879614 G A 5.73E-04 Alzheimer's disease / / 22005930 rs10789340 chr1 72940273 A G 5.43E-04 Type 2 diabetes / / 17463246 rs1775368 chr1 72992580 A T 6.70E-05 Type 2 diabetes / / 17846125 rs17092900 chr1 73003410 A G 8.39E-04 Multiple complex diseases / / 17554300 rs2245438 chr1 73042360 G A 7.48E-04 Multiple complex diseases / / 17554300 rs4649963 chr1 73109325 A C 8.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs7524643 chr1 73135952 T A 1.17E-04 Body mass index / / 23669352 rs10127441 chr1 73150180 G T 4.98E-04 Multiple complex diseases / / 17554300 rs2841187 chr1 73236826 C T 4.70E-05 Iron levels / / 21208937 rs10889990 chr1 73245168 G A 5.10E-05 Malaria / / 19465909 rs10889991 chr1 73245256 G A 7.70E-05 Malaria / / 19465909 rs7546928 chr1 73311542 G A 3.94E-04 Multiple complex diseases / / 17554300 rs1405051 chr1 73348484 G A 1.40E-04 Longevity and age-related phenotypes / / 17903295 rs6689491 chr1 73352029 C A 2.00E-05 Longevity and age-related phenotypes / / 17903295 rs6657082 chr1 73353328 A T 5.50E-05 Longevity and age-related phenotypes / / 17903295 rs10789351 chr1 73373796 C A 7.77E-04 Alzheimer's disease / / 17998437 rs10493513 chr1 73379589 G A 1.50E-06 Longevity and age-related phenotypes / / 17903295 rs10493514 chr1 73380512 T C 2.80E-06 Longevity and age-related phenotypes / / 17903295 rs17093667 chr1 73394093 T A 8.75E-05 Alzheimer's disease / / 17998437 rs4274011 chr1 73482160 G A 6.89E-04 Alzheimer's disease / / 17998437 rs4650199 chr1 73652122 T C 0.000000598 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs11210177 chr1 73655821 A G 0.000000759 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs12069039 chr1 73658085 G C 0.00000119 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs7514832 chr1 73658507 A T 0.00000111 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs10890018 chr1 73662169 A G 0.00000114 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs7522520 chr1 73664563 C T 0.00000124 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs4650201 chr1 73665844 A G 0.00000103 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs6684841 chr1 73706449 A G 0.000000251 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs6684841 chr1 73706449 A G 0.00000154 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs11210187 chr1 73715233 T C 0.000000597 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs4650206 chr1 73720577 T C 0.00000062 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs4571923 chr1 73736562 G A 0.00000113 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs11210193 chr1 73743873 A G 0.000000897 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs11210193 chr1 73743873 A G 0.00000184 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs7549372 chr1 73755529 A G 0.000000459 Change in depression severity with antidepressants (NRI or SRI) / / 23091423 rs7549372 chr1 73755529 A G 0.000000833 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs10789368 chr1 73814159 A G 0.00000282 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs10493515 chr1 73815631 T G 2.30E-05 Longevity and age-related phenotypes / / 17903295 rs2340400 chr1 73821281 T C 6.87E-05 Blood Pressure / / pha003039 rs10789369 chr1 73824909 A G 4.00E-10 Schizophrenia / / 23974872 rs11210220 chr1 73849655 T G 6.55E-05 Major depressive disorder / / 22472876 rs11210222 chr1 73849687 T C 8.57E-05 Major depressive disorder / / 22472876 rs1923236 chr1 73853826 T C 5.38E-04 Insulin resistance / / 21901158 rs11210226 chr1 73854284 A G 2.74E-04 Insulin resistance / / 21901158 rs10493517 chr1 73858351 G A 4.20E-05 Longevity and age-related phenotypes / / 17903295 rs10493518 chr1 73860631 G A 3.60E-05 Longevity and age-related phenotypes / / 17903295 rs1885251 chr1 73866020 G T 0.000000233 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs7543202 chr1 73872885 A G,T 6.36E-04 Insulin resistance / / 21901158 rs11210235 chr1 73878194 T C 0.000000257 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs10465868 chr1 73880654 A G 0.000000243 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs7521446 chr1 73890390 T C 0.000000188 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs11210242 chr1 73897809 C T 0.000000393 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs11210243 chr1 73898030 C G 1.24E-04 Multiple complex diseases / / 17554300 rs4113050 chr1 73910055 T C 0.000000611 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs4350155 chr1 73911420 C G 5.95E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11210251 chr1 73912799 C G 0.00000041 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs505725 chr1 73930405 C A 0.00000328 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs622421 chr1 73930493 A G 0.00000498 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs11210255 chr1 73931737 G A 0.0000022 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs17570390 chr1 73938246 T C 5.29E-05 Major depressive disorder / / 21621269 rs12754690 chr1 73939898 C T 0.00000188 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs482063 chr1 73942338 G A 1.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1578022 chr1 73944277 C G 0.0000593 Major depressive disorder / / 23149448 rs17511652 chr1 73962827 C G 5.41E-04 Type 2 diabetes / / 17463246 rs17511652 chr1 73962827 C G 7.70E-04 Multiple complex diseases / / 17554300 rs11210266 chr1 73964312 G T 0.00000404 Change in depression severity with Serotonin reuptake inhibitors (SRI) / / 23091423 rs2341260 chr1 74054060 C T 4.00E-06 Cardiac Troponin-T levels / / 23247143 rs1566585 chr1 74069017 A C 2.93E-05 Creatinine levels / / pha003069 rs11210304 chr1 74074098 A G 2.99E-05 Creatinine levels / / pha003069 rs2341263 chr1 74083035 C T 3.00E-06 Metabolite levels (X-11787) / / 23934736 rs11210308 chr1 74084868 C A 4.49E-04 Aortic root size / / 21223598 rs11210317 chr1 74087657 T G 2.79E-05 Creatinine levels / / pha003069 rs7553862 chr1 74109213 G A 9.10E-06 Urinary metabolites / / 21572414 rs4606267 chr1 74112883 G A 2.23E-06 Common variable immunodeficiency / / 21497890 rs1909068 chr1 74116666 G A 7.70E-04 Multiple complex diseases / / 17554300 rs4584347 chr1 74141838 C T 4.66E-04 Sudden cardiac arrest / / 21658281 rs4478768 chr1 74151090 T G 2.65E-05 Hypertension / / pha003042 rs4326578 chr1 74157945 A G 4.49E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs2342207 chr1 74158592 T C 4.21E-05 Hypertension / / pha003042 rs9425128 chr1 74169283 C T 6.27E-04 Alcohol dependence / / 20201924 rs1497840 chr1 74174778 G A 7.91E-04 Heart Failure / / pha002884 rs2132999 chr1 74236657 G A 7.95E-04 Multiple complex diseases / / 17554300 rs7544208 chr1 74255352 A T 4.18E-04 Multiple complex diseases / / 17554300 rs1497842 chr1 74259955 G C 1.62E-04 Multiple complex diseases / / 17554300 rs1340430 chr1 74264128 A G 2.04E-05 Multiple complex diseases / / 17554300 rs1340429 chr1 74264228 A G 2.31E-04 Multiple complex diseases / / 17554300 rs1340428 chr1 74265781 A G 3.18E-04 Multiple complex diseases / / 17554300 rs7516730 chr1 74265891 A T 1.55E-04 Multiple complex diseases / / 17554300 rs72683874 chr1 74317594 T C 3.76E-11 Metabolite levels / / 22286219 rs6672527 chr1 74338530 C T 3.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs6672527 chr1 74338530 C T 6.15E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6672527 chr1 74338530 C T 6.02E-04 Myocardial Infarction / / pha002883 rs11210359 chr1 74339167 G A 8.00E-06 Bipolar disorder and schizophrenia / / 21057379 rs11210361 chr1 74339944 T C 3.47E-04 Suicide attempts in bipolar disorder / / 21041247 rs967881 chr1 74343741 G A 3.35E-04 Suicide attempts in bipolar disorder / / 21041247 rs17520168 chr1 74344519 T C 3.32E-04 Suicide attempts in bipolar disorder / / 21041247 rs17579506 chr1 74344710 T C 3.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs11210363 chr1 74349846 G A 3.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs2789708 chr1 74357210 T A 1.37E-05 Suicide attempts in bipolar disorder / / 21041247 rs2792075 chr1 74357362 C T 1.39E-05 Suicide attempts in bipolar disorder / / 21041247 rs10890086 chr1 74361786 C A 1.22E-04 Suicide attempts in bipolar disorder / / 21041247 rs1770494 chr1 74363716 A G 5.84E-04 Multiple complex diseases / / 17554300 rs12747535 chr1 74363988 A G 2.48E-04 Multiple complex diseases / / 17554300 rs17094575 chr1 74364041 G T 8.50E-06 Urinary metabolites / / 21572414 rs1340434 chr1 74365646 C T 2.85E-04 Multiple complex diseases / / 17554300 rs1340434 chr1 74365646 C T 4.97E-06 Suicide attempts in bipolar disorder / / 21041247 rs11210366 chr1 74367555 C T 7.11E-05 Suicide attempts in bipolar disorder / / 21041247 rs4650235 chr1 74370640 A G 9.50E-05 Suicide attempts in bipolar disorder / / 21041247 rs7544252 chr1 74376862 G C 4.69E-06 Suicide attempts in bipolar disorder / / 21041247 rs12062996 chr1 74377795 T C 4.66E-06 Suicide attempts in bipolar disorder / / 21041247 rs7550937 chr1 74379312 G A 4.63E-06 Suicide attempts in bipolar disorder / / 21041247 rs1768649 chr1 74379949 A G 4.62E-06 Suicide attempts in bipolar disorder / / 21041247 rs11210368 chr1 74380471 G A 4.60E-06 Suicide attempts in bipolar disorder / / 21041247 rs10493526 chr1 74385680 T C 5.38E-06 Suicide attempts in bipolar disorder / / 21041247 rs2733260 chr1 74387277 T C 4.53E-06 Suicide attempts in bipolar disorder / / 21041247 rs1340424 chr1 74387876 C G 1.56E-04 Suicide attempts in bipolar disorder / / 21041247 rs12076161 chr1 74388884 A C 5.11E-06 Suicide attempts in bipolar disorder / / 21041247 rs12077198 chr1 74388935 A G 5.09E-06 Suicide attempts in bipolar disorder / / 21041247 rs7533599 chr1 74393112 G A 4.21E-06 Suicide attempts in bipolar disorder / / 21041247 rs12081389 chr1 74395561 T A 4.19E-06 Suicide attempts in bipolar disorder / / 21041247 rs2733262 chr1 74396896 T C 1.36E-04 Suicide attempts in bipolar disorder / / 21041247 rs12082647 chr1 74398127 A C 4.29E-04 Multiple complex diseases / / 17554300 rs12082647 chr1 74398127 A C 3.52E-06 Suicide attempts in bipolar disorder / / 21041247 rs10890092 chr1 74402318 C T 1.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs10890093 chr1 74402825 G T 3.51E-06 Suicide attempts in bipolar disorder / / 21041247 rs10890094 chr1 74402888 A G 3.51E-06 Suicide attempts in bipolar disorder / / 21041247 rs2733265 chr1 74403128 G C 1.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs1340447 chr1 74403780 C A 4.31E-04 Multiple complex diseases / / 17554300 rs1340447 chr1 74403780 C A 1.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs2733267 chr1 74405054 G A 1.09E-04 Suicide attempts in bipolar disorder / / 21041247 rs10493528 chr1 74412652 T A 3.52E-06 Suicide attempts in bipolar disorder / / 21041247 rs2789706 chr1 74413924 T C 9.38E-05 Suicide attempts in bipolar disorder / / 21041247 rs1417259 chr1 74418437 T G 3.17E-06 Suicide attempts in bipolar disorder / / 21041247 rs7544238 chr1 74419407 C A 3.18E-06 Suicide attempts in bipolar disorder / / 21041247 rs1361463 chr1 74422211 T A 8.21E-05 Multiple complex diseases / / 17554300 rs1361463 chr1 74422211 T A 3.41E-06 Suicide attempts in bipolar disorder / / 21041247 rs11210377 chr1 74423383 G T 3.43E-06 Suicide attempts in bipolar disorder / / 21041247 rs12116914 chr1 74423618 T G 3.44E-06 Suicide attempts in bipolar disorder / / 21041247 rs12064944 chr1 74429944 A G 3.48E-06 Suicide attempts in bipolar disorder / / 21041247 rs12064998 chr1 74430102 A G 3.51E-06 Suicide attempts in bipolar disorder / / 21041247 rs11210383 chr1 74435508 C A 2.51E-04 Multiple complex diseases / / 17554300 rs11210383 chr1 74435508 C A 3.58E-06 Suicide attempts in bipolar disorder / / 21041247 rs6424568 chr1 74440382 G A 6.52E-05 Suicide attempts in bipolar disorder / / 21041247 rs12138557 chr1 74442523 C A 3.29E-04 Multiple complex diseases / / 17554300 rs12138557 chr1 74442523 C A 3.71E-06 Suicide attempts in bipolar disorder / / 21041247 rs10890101 chr1 74445584 C T 1.67E-04 Suicide attempts in bipolar disorder / / 21041247 rs9662322 chr1 74452323 G T 4.84E-06 Suicide attempts in bipolar disorder / / 21041247 rs11210389 chr1 74454701 A C 2.64E-05 Suicide attempts in bipolar disorder / / 21041247 rs11210390 chr1 74454776 C T 2.63E-05 Suicide attempts in bipolar disorder / / 21041247 rs2343194 chr1 74457400 G A 4.29E-04 Suicide attempts in bipolar disorder / / 21041247 rs4650237 chr1 74459849 T G 2.62E-05 Suicide attempts in bipolar disorder / / 21041247 rs6663201 chr1 74460997 T C 7.90E-06 Suicide attempts in bipolar disorder / / 21041247 rs6660710 chr1 74461136 A G 7.88E-06 Suicide attempts in bipolar disorder / / 21041247 rs4556311 chr1 74461828 G A 3.52E-04 Suicide attempts in bipolar disorder / / 21041247 rs2343196 chr1 74462422 T C 7.91E-06 Suicide attempts in bipolar disorder / / 21041247 rs1384883 chr1 74501477 C T 9.28E-05 Orofacial clefts LRRIQ3 intron 22419666 rs7535929 chr1 74560002 T G 8.72E-05 Orofacial clefts LRRIQ3 intron 22419666 rs10493529 chr1 74623448 A T 2.18E-04 Multiple complex diseases LRRIQ3 intron 17554300 rs10493529 chr1 74623448 A T 1.90E-05 Subclinical atherosclerosis LRRIQ3 intron 17903303 rs1483790 chr1 74627358 T C 2.74E-04 Multiple complex diseases LRRIQ3 intron 17554300 rs17591292 chr1 74646058 C T 5.38E-04 Alcohol dependence LRRIQ3 intron 21314694 rs518769 chr1 74699912 G A 1.96E-04 Suicide attempts in bipolar disorder FPGT-TNNI3K intron 21423239 rs12118620 chr1 74727955 C G 5.00E-16 Health and aging,CVD and cancer age of onset TNNI3K intron 22174011 rs12118620 chr1 74727955 C G 8.00E-12 Health and aging,CVD and cancer age of onset TNNI3K intron 22174011 rs516569 chr1 74782279 A G 5.87E-04 Myopia (pathological) TNNI3K intron 21095009 rs1527683 chr1 74822937 T C 8.71E-04 Suicide attempts in bipolar disorder TNNI3K intron 21423239 rs699842 chr1 74874431 T C 7.52E-04 Acute lung injury TNNI3K intron 22295056 rs7517677 chr1 74880189 T G 9.71E-05 Body Fat Distribution TNNI3K intron pha003018 rs17095295 chr1 74895901 G A 3.43E-04 Multiple complex diseases TNNI3K intron 17554300 rs17095295 chr1 74895901 G A 9.71E-05 Body Fat Distribution TNNI3K intron pha003018 rs477159 chr1 74898117 G A 0.0000338 post-traumatic stress disorder TNNI3K intron 22869035 rs477159 chr1 74898117 G A 3.38E-05 Schizophrenia TNNI3K intron 22883433 rs792884 chr1 74899573 T G 0.0000157 post-traumatic stress disorder TNNI3K intron 22869035 rs792884 chr1 74899573 T G 1.57E-05 Schizophrenia TNNI3K intron 22883433 rs643371 chr1 74900897 A C 0.0000987 post-traumatic stress disorder TNNI3K intron 22869035 rs643371 chr1 74900897 A C 9.87E-05 Schizophrenia TNNI3K intron 22883433 rs1325604 chr1 74907316 G A 0.000085 post-traumatic stress disorder TNNI3K intron 22869035 rs1325604 chr1 74907316 G A 8.50E-05 Schizophrenia TNNI3K intron 22883433 rs6690871 chr1 74977277 A G 9.69E-04 Obesity (extreme) TNNI3K intron 21935397 rs1040070 chr1 74977870 G C 9.94E-04 Obesity (extreme) TNNI3K intron 21935397 rs1040070 chr1 74977870 G C 1.07E-08 Obesity TNNI3K intron 22484627 rs984167 chr1 74981547 A T 8.20E-05 HDL particle features TNNI3K intron 21283740 rs1514177 chr1 74991402 C G 5.00E-09 Obesity TNNI3K intron 23563607 rs1514175 chr1 74991644 A G 8.00E-14 Body mass index TNNI3K intron 20935630 rs1514175 chr1 74991644 A G 6.38E-05 Body mass index TNNI3K intron 22344219 rs1514175 chr1 74991644 A G 8.16E-14 Body mass index TNNI3K intron 23001569 rs1514175 chr1 74991644 A G 3.00E-11 Body mass index TNNI3K intron 23669352 rs1514174 chr1 74993063 C T 6.00E-06 Pubertal anthropometrics TNNI3K intron 23449627 rs1514174 chr1 74993063 C T 1.00E-08 Obesity TNNI3K intron 23563607 rs113313252 chr1 75000011 A AT 4.32E-11 Body mass index TNNI3K intron 23669352 rs12142020 chr1 75000011 A T 4.32E-11 Body mass index TNNI3K intron 23669352 rs201167096 chr1 75000011 A AT 4.32E-11 Body mass index TNNI3K intron 23669352 rs3894212 chr1 75001683 T G 1.80E-04 Type 2 diabetes and 6 quantitative traits TNNI3K intron 17848626 rs7541513 chr1 75014195 G A 2.30E-04 Iris characteristics / / 21835309 rs10789396 chr1 75014362 T C 7.82E-04 Obesity (extreme) / / 21935397 rs4287129 chr1 75016147 T G 5.46E-05 Type 2 diabetes / / 17463246 rs3931879 chr1 75030642 A T 4.70E-04 Type 2 diabetes / / 17463246 rs2305549 chr1 75055419 T C 5.48E-04 Heart Failure C1orf173 missense pha002885 rs41337449 chr1 75099977 T C 9.08E-05 Multiple complex diseases C1orf173 intron 17554300 rs17095690 chr1 75106741 G A 1.65E-05 Attention deficit hyperactivity disorder C1orf173 intron 20732627 rs696666 chr1 75146093 T C 4.15E-04 Type 2 diabetes / / 17463246 rs696667 chr1 75149512 A G 3.07E-04 Type 2 diabetes / / 17463246 rs696668 chr1 75149922 G T 3.07E-04 Type 2 diabetes / / 17463246 rs575533 chr1 75155657 T C 8.76E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12061533 chr1 75158118 A G 5.37E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1340985 chr1 75160724 A G 3.44E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6662846 chr1 75170143 A C 4.20E-05 Glioma (high-grade) / / 19578366 rs17552114 chr1 75172652 T C 9.54E-04 Coronary Artery Disease CRYZ cds-synon 17634449 rs11485264 chr1 75197533 A G 1.00E-04 Cognitive impairment induced by topiramate CRYZ intron 22091778 rs3931020 chr1 75235317 T C 6.00E-12 Resistin levels / / 22843503 rs17095902 chr1 75240211 A G 9.70E-04 Major depressive disorder / / 22472876 rs1409785 chr1 75248122 G A 6.50E-07 Glioma (high-grade) / / 19578366 rs7547190 chr1 75252764 C T 4.98E-05 Cognitive impairment induced by topiramate / / 22091778 rs1575983 chr1 75262196 A C 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs11161851 chr1 75298782 T C 7.00E-06 Visceral fat / / 22589738 rs12747472 chr1 75311462 T C 5.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs12120668 chr1 75321017 G C 8.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs12033503 chr1 75326398 C T 9.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs12743570 chr1 75333502 G C 3.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs7552148 chr1 75340175 C T 3.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs6664850 chr1 75352327 G A 2.04E-04 Height / / 17255346 rs6664850 chr1 75352327 G A 6.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs1327098 chr1 75361993 G A 7.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs17562236 chr1 75374025 A G 6.15E-04 Suicide attempts in bipolar disorder / / 21041247 rs12755578 chr1 75374854 C G 6.14E-04 Suicide attempts in bipolar disorder / / 21041247 rs12121720 chr1 75386937 G A 5.99E-04 Suicide attempts in bipolar disorder / / 21041247 rs12127639 chr1 75395198 C G 6.01E-04 Suicide attempts in bipolar disorder / / 21041247 rs12129191 chr1 75395327 A G 6.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs12732265 chr1 75398270 T C 6.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs10782637 chr1 75403587 C A 6.11E-04 Suicide attempts in bipolar disorder / / 21041247 rs17096151 chr1 75425129 C T 8.45E-05 Aging (time to event) / / 21782286 rs11162286 chr1 75427397 A G 3.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs7522882 chr1 75442994 T A 4.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs2346344 chr1 75446663 T G 4.28E-04 Suicide attempts in bipolar disorder / / 21041247 rs3845358 chr1 75449592 A C 2.41E-04 Height / / 17255346 rs3845358 chr1 75449592 A C 4.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs12743802 chr1 75458806 G A 3.85E-05 Paclitaxel-induced neuropathy / / 23776197 rs10493550 chr1 75460333 G A 5.63E-04 Suicide attempts in bipolar disorder / / 21423239 rs3912426 chr1 75462461 A G 4.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs6693646 chr1 75466410 G T 4.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs12750340 chr1 75469124 C T 5.21E-04 Suicide attempts in bipolar disorder / / 21041247 rs696676 chr1 75479163 A G 9.69E-04 Type 2 diabetes / / 17463246 rs12089365 chr1 75486214 A G 4.77E-04 Multiple complex diseases / / 17554300 rs12089365 chr1 75486214 A G 6.28E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6703099 chr1 75534319 T C 8.69E-04 Type 2 diabetes / / 17463246 rs2077678 chr1 75534827 A G 4.40E-05 Kidney function and endocine traits / / 17903292 rs7541725 chr1 75549806 T C 7.21E-04 Multiple complex diseases / / 17554300 rs11162495 chr1 75555722 T G 8.83E-04 Type 2 diabetes / / 17463246 rs12138223 chr1 75615026 A G,T 6.82E-05 Serum metabolites LHX8 intron 19043545 rs7545324 chr1 75662563 A G 8.88E-05 Body Mass Index / / pha003015 rs1405311 chr1 75675047 T G 8.88E-05 Body Mass Index SLC44A5 intron pha003015 rs149696907 chr1 75693501 G A 0.000037 Breast cancer SLC44A5 missense 23555315 rs41385949 chr1 75702129 C T 7.43E-04 Multiple complex diseases SLC44A5 intron 17554300 rs616827 chr1 75703209 G T 1.61E-05 Body Mass Index SLC44A5 intron pha003015 rs596098 chr1 75722892 G A 8.73E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs1249675 chr1 75770625 C T 7.00E-06 Capecitabine sensitivity SLC44A5 intron 22864933 rs11163089 chr1 75778546 C T 7.71E-04 Type 2 diabetes SLC44A5 intron 17463246 rs1249667 chr1 75779988 G A 5.13E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs1262045 chr1 75781308 T G 3.09E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs1249666 chr1 75781855 T C 2.57E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs1249664 chr1 75785042 T C 3.31E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs17097953 chr1 75801795 A G 8.35E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs10493574 chr1 75803142 C T 6.74E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs17096776 chr1 75808190 C T 6.93E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs17097955 chr1 75811152 T C 6.89E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs17096782 chr1 75812191 T C 5.11E-04 Suicide attempts in bipolar disorder SLC44A5 intron 21423239 rs1249811 chr1 75863089 G A 1.50E-06 Urinary metabolites SLC44A5 intron 21572414 rs4540592 chr1 75883281 T C 3.33E-06 Total ventricular volume SLC44A5 intron 21116278 rs12410333 chr1 75895626 T C 5.12E-06 Total ventricular volume SLC44A5 intron 21116278 rs10493575 chr1 75903516 G A 3.42E-06 Total ventricular volume SLC44A5 intron 21116278 rs2040079 chr1 75906421 G T 3.29E-06 Total ventricular volume SLC44A5 intron 21116278 rs2040082 chr1 75906874 A G 3.23E-06 Total ventricular volume SLC44A5 intron 21116278 rs2347218 chr1 75911113 A G 1.40E-06 Urinary metabolites SLC44A5 intron 21572414 rs2587031 chr1 75911769 G A 1.60E-06 Urinary metabolites SLC44A5 intron 21572414 rs1857353 chr1 75913826 C T 2.00E-06 MRI atrophy measures SLC44A5 intron 21116278 rs4598448 chr1 75963934 G A 8.85E-04 Alzheimer's disease SLC44A5 intron 17998437 rs12401888 chr1 75967778 C T 8.68E-04 Glycemic traits (pregnancy) SLC44A5 intron 23903356 rs13373826 chr1 75970795 A G 2.93E-09 Multiple complex diseases SLC44A5 intron 17554300 rs211786 chr1 75992019 A G 6.81E-04 Multiple complex diseases SLC44A5 intron 17554300 rs7553832 chr1 76091427 G A 2.47E-04 Hemoglobin concentration / / 20534544 rs211718 chr1 76106675 T C 4.63E-06 Serum metabolites / / 19043545 rs211718 chr1 76106675 T C 1.00E-63 Metabolite levels / / 20037589 rs211718 chr1 76106675 T C 2.00E-71 Metabolic traits / / 21886157 rs2347540 chr1 76119468 G A 2.50E-05 Esophageal cancer (squamous cell) / / 22960999 rs1535740 chr1 76134765 C A 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs7552404 chr1 76135946 A G 1.00E-77 Blood metabolite levels / / 24816252 rs7552404 chr1 76135946 A G 3.00E-43 Blood metabolite levels / / 24816252 rs12045299 chr1 76154750 T C 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs12045299 chr1 76154750 T C 8.40E-04 Myopia (pathological) / / 21095009 rs4949874 chr1 76161889 T C 2.00E-172 Blood metabolite ratios / / 24816252 rs1391520 chr1 76174752 A C 9.60E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs1391520 chr1 76174752 A C 8.40E-04 Myopia (pathological) / / 21095009 rs1251079 chr1 76189445 T C 4.90E-04 Type 2 diabetes ACADM nearGene-5 17463246 rs12744608 chr1 76206490 G T 3.58E-04 Alzheimer's disease (late onset) ACADM intron 21379329 rs1146579 chr1 76209792 T A,C,G 1.80E-05 Serum metabolites ACADM intron 19043545 rs11161510 chr1 76210289 C T 1.72E-06 Serum metabolites ACADM intron 19043545 rs11161511 chr1 76210477 C T 3.33E-06 Serum metabolites ACADM intron 19043545 rs1146581 chr1 76213024 T G 7.96E-05 Attention deficit hyperactivity disorder ACADM intron 22420046 rs9660848 chr1 76214508 G A 3.58E-04 Alzheimer's disease (late onset) ACADM intron 21379329 rs11161521 chr1 76216330 T C 1.00E-63 Blood metabolite levels ACADM intron 24816252 rs11161521 chr1 76216330 T C 6.00E-100 Blood metabolite levels ACADM intron 24816252 rs1694419 chr1 76219801 G A 2.49E-05 Serum metabolites ACADM intron 19043545 rs1146586 chr1 76227974 C T 2.91E-10 LDL cholesterol ACADM intron 23063622 rs1146634 chr1 76252011 G A 1.70E-05 Urinary metabolites RABGGTB intron 21572414 rs5745309 chr1 76261914 T G 4.84E-04 Response to cytadine analogues (cytosine arabinoside) MSH4 nearGene-5 24483146 rs1146644 chr1 76264788 T C 2.50E-05 Urinary metabolites MSH4 intron 21572414 rs5745331 chr1 76273313 A G 3.47E-04 Alcohol dependence MSH4 intron 20201924 rs5745354 chr1 76275178 G A 9.22E-04 Myopia (pathological) MSH4 intron 21095009 rs1144337 chr1 76278877 T A,C,G 9.22E-04 Myopia (pathological) MSH4 intron 21095009 rs12024645 chr1 76284395 A G 5.71E-04 Myopia (pathological) MSH4 intron 21095009 rs1251272 chr1 76289004 C T 0.0003488 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs1251272 chr1 76289004 C T 3.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs12076093 chr1 76301656 G A 0.0003491 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs12076093 chr1 76301656 G A 3.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs10873738 chr1 76302233 A G 0.0003494 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs10873738 chr1 76302233 A G 3.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs9970840 chr1 76303720 A G 4.84E-04 Response to cytadine analogues (cytosine arabinoside) MSH4 intron 24483146 rs12090712 chr1 76304215 C T 0.0003494 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs12090712 chr1 76304215 C T 3.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs7514912 chr1 76307558 A G 0.0003499 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs7514912 chr1 76307558 A G 3.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs7548391 chr1 76307595 C T 0.0003502 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs7548391 chr1 76307595 C T 3.50E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs1603734 chr1 76311632 T C 0.0003512 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs1603734 chr1 76311632 T C 3.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs2047435 chr1 76313874 C A,T 0.0003518 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) MSH4 intron 23233654 rs2047435 chr1 76313874 C A,T 3.52E-04 Methotrexate clearance (acute lymphoblastic leukemia) MSH4 intron 23233662 rs12409592 chr1 76317549 G A 6.86E-04 Myopia (pathological) MSH4 intron 21095009 rs11161887 chr1 76386305 A G 4.50E-04 Myopia (pathological) ASB17 intron 21095009 rs10873804 chr1 76394150 C A 2.62E-04 Myopia (pathological) ASB17 intron 21095009 rs3795251 chr1 76397972 C T 2.62E-04 Myopia (pathological) ASB17 missense 21095009 rs1251594 chr1 76415210 A C 0.0003271 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1251594 chr1 76415210 A C 3.27E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6685657 chr1 76417440 G A 9.74E-04 Alzheimer's disease / / 17998437 rs1251588 chr1 76420745 C T 7.06E-04 Myocardial Infarction / / pha002883 rs12405994 chr1 76435420 A T 3.80E-07 Malaria / / 19465909 rs1251539 chr1 76436260 C A 0.0003236 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1251539 chr1 76436260 C A 3.24E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1417402 chr1 76437196 G A 5.00E-07 Malaria / / 19465909 rs12566984 chr1 76438011 G T 4.20E-04 Myopia (pathological) / / 21095009 rs1251560 chr1 76451190 T C 0.0003173 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1251560 chr1 76451190 T C 3.17E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1417403 chr1 76454816 C T 0.0003162 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1417403 chr1 76454816 C T 3.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1340686 chr1 76455075 G A 0.0003152 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1340686 chr1 76455075 G A 3.15E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1361488 chr1 76455765 A C 0.0003164 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1361488 chr1 76455765 A C 3.16E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1770878 chr1 76456329 C T 0.0003182 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1770878 chr1 76456329 C T 3.18E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1770879 chr1 76456512 C G 0.0003197 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1770879 chr1 76456512 C G 3.20E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12731410 chr1 76464725 C A 9.49E-04 Depression (quantitative trait) / / 20800221 rs12122440 chr1 76477207 A C 2.00E-06 Pubertal anthropometrics / / 23449627 rs12753569 chr1 76484014 G T 8.00E-06 Personality dimensions / / 20691247 rs3179693 chr1 76484827 G A 8.73E-05 Type 2 diabetes / / 17463246 rs6672844 chr1 76486884 A G 1.10E-04 Type 2 diabetes / / 17463246 rs17598972 chr1 76487108 T C 6.84E-04 Type 2 diabetes / / 17463246 rs10493577 chr1 76489223 A T 2.84E-04 Type 2 diabetes / / 17463246 rs11162069 chr1 76489779 A T 1.22E-04 Type 2 diabetes / / 17463246 rs17097922 chr1 76490425 C G 1.07E-04 Type 2 diabetes / / 17463246 rs17097929 chr1 76491041 G T 1.27E-04 Type 2 diabetes / / 17463246 rs1866254 chr1 76492334 T C 2.81E-05 Type 2 diabetes / / 17463246 rs946161 chr1 76510513 A G 3.04E-05 Multiple complex diseases / / 17554300 rs17097997 chr1 76510789 T A 3.25E-04 Type 2 diabetes / / 17463246 rs1251493 chr1 76518108 T A 1.35E-04 Type 2 diabetes / / 17463246 rs1340688 chr1 76520630 T G 1.45E-04 Type 2 diabetes / / 17463246 rs17098034 chr1 76532801 A C 7.12E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1251465 chr1 76538396 G A 7.41E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1251575 chr1 76557784 A G 6.05E-05 stroke (ischemic) ST6GAL/C3 intron 17434096 rs915404 chr1 76602662 A G 2.80E-09 Adiponectin levels ST6GAL/C3 intron 20887962 rs7548049 chr1 76608072 C T 0.00005091 Sarcoidosis ST6GAL/C3 intron 22952805 rs2706183 chr1 76617830 G A 7.80E-05 Adverse response to radiation therapy ST6GAL/C3 intron 23719583 rs2783658 chr1 76620313 C T 2.40E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs425110 chr1 76625747 A G 1.63E-04 Multiple complex diseases ST6GAL/C3 intron 17554300 rs3011997 chr1 76627054 C T 2.60E-04 Multiple complex diseases ST6GAL/C3 intron 17554300 rs1414403 chr1 76627868 G A 5.36E-04 Multiple complex diseases ST6GAL/C3 intron 17554300 rs517036 chr1 76680525 T C 3.25E-06 F-cell distribution ST6GAL/C3 intron 21326311 rs547342 chr1 76687275 A G 5.47E-04 Multiple complex diseases ST6GAL/C3 intron 17554300 rs547342 chr1 76687275 A G 1.09E-05 F-cell distribution ST6GAL/C3 intron 21326311 rs17098442 chr1 76700296 C G 5.26E-04 Response to cytadine analogues (cytosine arabinoside) ST6GAL/C3 intron 24483146 rs17098450 chr1 76700697 G A 5.26E-04 Response to cytadine analogues (cytosine arabinoside) ST6GAL/C3 intron 24483146 rs544858 chr1 76725259 A G 4.87E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) ST6GAL/C3 intron 24023788 rs6696780 chr1 76731907 G A 8.47E-08 Electroencephalogram traits,in brain ST6GAL/C3 intron 20421487 rs12079387 chr1 76746838 C A,T 3.99E-05 Orofacial clefts ST6GAL/C3 intron 22419666 rs10873876 chr1 76772328 T C 4.00E-06 Acute lymphoblastic leukemia (childhood) ST6GAL/C3 intron 19684603 rs10873876 chr1 76772328 T C 4.00E-06 Nasopharyngeal carcinoma ST6GAL/C3 intron 20512145 rs3884182 chr1 76774201 G A 8.38E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ST6GAL/C3 intron 20877124 rs2392030 chr1 76784636 T C 8.37E-05 ldl cholesterol ST6GAL/C3 intron pha003076 rs4421636 chr1 76785393 C T 8.46E-04 Myocardial Infarction ST6GAL/C3 intron pha002883 rs11585239 chr1 76785765 A G 0.0004475 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs11585239 chr1 76785765 A G 4.48E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs17098734 chr1 76787267 A G 0.000402 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs17098734 chr1 76787267 A G 4.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs17098736 chr1 76787466 G T 0.0003996 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs17098736 chr1 76787466 G T 4.00E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs4628548 chr1 76791163 G A 9.30E-04 Alzheimer's disease ST6GAL/C3 intron 24755620 rs10493590 chr1 76794327 C G 0.0001976 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs10493590 chr1 76794327 C G 1.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs10493591 chr1 76796785 A G 0.0001976 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs10493591 chr1 76796785 A G 1.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs4408196 chr1 76798359 A C 0.0001976 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs4408196 chr1 76798359 A C 1.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs17672606 chr1 76799446 G A 0.0001976 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs17672606 chr1 76799446 G A 1.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs1325290 chr1 76801781 C G 1.30E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs752819 chr1 76803522 G A 5.63E-04 Type 2 diabetes ST6GAL/C3 intron 17463246 rs752819 chr1 76803522 G A 0.0001976 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs752819 chr1 76803522 G A 1.98E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs7539896 chr1 76806274 C G 0.0007443 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs7539896 chr1 76806274 C G 7.44E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs7516680 chr1 76806409 G A 0.0007424 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs7516680 chr1 76806409 G A 7.42E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs17098793 chr1 76809752 A G 0.0007408 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs17098793 chr1 76809752 A G 7.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs12562911 chr1 76822600 A G 7.62E-04 Alcohol dependence ST6GAL/C3 intron 21314694 rs7524886 chr1 76826279 C T 6.00E-05 Immunoglobulin A ST6GAL/C3 intron 20694011 rs12239582 chr1 76837237 A C 2.70E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs12144344 chr1 76839536 C T 5.86E-04 Type 2 diabetes ST6GAL/C3 intron 17463246 rs12144344 chr1 76839536 C T 2.20E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs12144344 chr1 76839536 C T 6.00E-07 Serum vitamin D-binding protein levels ST6GAL/C3 intron 24740207 rs12144344 chr1 76839536 C T 3.52E-05 ldl cholesterol ST6GAL/C3 intron pha003076 rs1540964 chr1 76840728 A C 7.65E-04 Type 2 diabetes ST6GAL/C3 intron 17463246 rs1540964 chr1 76840728 A C 2.80E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs1359468 chr1 76851135 A G 7.18E-04 Type 2 diabetes ST6GAL/C3 intron 17463246 rs1359468 chr1 76851135 A G 2.80E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs6667721 chr1 76867853 G A 1.30E-05 Bone mineral density (BMD),in women ST6GAL/C3 intron 20164292 rs11577449 chr1 76869325 T A 0.000167 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) ST6GAL/C3 intron 23233654 rs11577449 chr1 76869325 T A 1.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) ST6GAL/C3 intron 23233662 rs7515898 chr1 76871716 G A 0.000709798 Hypertension (early onset hypertension) ST6GAL/C3 intron 22479346 rs4949631 chr1 76898955 G A 7.24E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ST6GAL/C3 intron 20877124 rs4949718 chr1 76899464 T C 2.23E-05 Type 2 diabetes ST6GAL/C3 intron 17463246 rs4949718 chr1 76899464 T C 1.00E-06 Liver enzyme levels (aspartate transaminase) ST6GAL/C3 intron 24124411 rs4949718 chr1 76899464 T C 2.00E-07 Liver enzyme levels (alanine transaminase) ST6GAL/C3 intron 24124411 rs1436086 chr1 76973245 G T 1.10E-05 Urinary metabolites ST6GAL/C3 intron 21572414 rs315087 chr1 76989264 T C 1.67E-05 Tuberculosis ST6GAL/C3 intron 24057671 rs410076 chr1 77001631 G A 1.03E-07 Electroencephalogram traits,in brain ST6GAL/C3 intron 20421487 rs172714 chr1 77015113 T C 7.34E-08 Electroencephalogram traits,in brain ST6GAL/C3 intron 20421487 rs172714 chr1 77015113 T C 5.24E-04 Depression (quantitative trait) ST6GAL/C3 intron 20800221 rs6675095 chr1 77016065 G A 3.57E-04 Depression (quantitative trait) ST6GAL/C3 intron 20800221 rs315049 chr1 77023273 G A 2.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315049 chr1 77023273 G A 3.85E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315049 chr1 77023273 G A 4.32E-06 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315049 chr1 77023273 G A 8.14E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315014 chr1 77033959 C A 2.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315014 chr1 77033959 C A 2.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315014 chr1 77033959 C A 4.63E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315014 chr1 77033959 C A 6.85E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs417415 chr1 77035168 T C 2.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs417415 chr1 77035168 T C 4.63E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs7513970 chr1 77041694 G A 5.95E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs369258 chr1 77042204 G A 1.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs369258 chr1 77042204 G A 2.81E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315029 chr1 77042405 G A 1.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315029 chr1 77042405 G A 2.81E-05 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs2117905 chr1 77052596 A G 1.00E-04 Cognitive impairment induced by topiramate ST6GAL/C3 intron 22091778 rs315039 chr1 77054590 T C 6.75E-05 Serum albumin level ST6GAL/C3 intron pha003084 rs56012468 chr1 77055776 C T 2.00E-05 Serum albumin level ST6GAL/C3 intron pha003084 rs2574775 chr1 77069228 G A 2.71E-04 Smoking initiation ST6GAL/C3 intron 24665060 rs2647389 chr1 77072458 T C 3.60E-05 Multiple sclerosis ST6GAL/C3 intron 17660530 rs665178 chr1 77075591 C T 0.000175 Salmonella-induced pyroptosis ST6GAL/C3 intron 22837397 rs485141 chr1 77083864 C A 7.38E-05 Coronary restenosis ST6GAL/C3 intron 21878436 rs3748712 chr1 77098483 A T 9.38E-04 Multiple complex diseases / / 17554300 rs12134580 chr1 77121319 T C 7.52E-05 Depression (quantitative trait) / / 23290196 rs551585 chr1 77126373 C A 3.00E-07 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs664576 chr1 77179690 T C 8.58E-05 Neuroblastoma / / pha002895 rs7534158 chr1 77188392 C T 6.40E-05 Blood pressure / / 19114657 rs619463 chr1 77196032 C A 9.43E-05 Cardiovascular disease / / pha003064 rs2221083 chr1 77221362 A G 4.28E-05 LDL lipoproteins / / pha002902 rs4506508 chr1 77256336 C A 1.15E-04 Multiple complex diseases / / 17554300 rs11162212 chr1 77256966 C A 6.42E-04 Body mass index / / 21701565 rs4586020 chr1 77265640 C A 4.85E-05 Odorant perception / / 23910658 rs17099699 chr1 77372136 C G 5.46E-04 Multiple complex diseases ST6GAL/C5 intron 17554300 rs12567699 chr1 77437423 G A 4.85E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ST6GAL/C5 intron 20877124 rs4949764 chr1 77462662 T C 1.45E-05 Response to Vitamin E supplementation ST6GAL/C5 intron 22437554 rs199698 chr1 77506217 C T 6.71E-04 Multiple complex diseases ST6GAL/C5 intron 17554300 rs199699 chr1 77507030 T C 2.49E-04 Multiple complex diseases ST6GAL/C5 intron 17554300 rs12084236 chr1 77507127 A G 1.68E-04 Multiple complex diseases ST6GAL/C5 intron 17554300 rs41515647 chr1 77517009 C A 6.67E-06 Multiple complex diseases ST6GAL/C5 intron 17554300 rs191827 chr1 77548518 T C 1.70E-05 Urinary metabolites / / 21572414 rs1048575 chr1 77558057 G C 9.89E-04 Obesity (extreme) PIGK UTR-3 21935397 rs2069224 chr1 77560216 C T 4.62E-04 Obesity (extreme) PIGK intron 21935397 rs11162271 chr1 77563988 G A 5.10E-04 Obesity (extreme) PIGK intron 21935397 rs11806823 chr1 77565415 A G 5.18E-04 Obesity (extreme) PIGK intron 21935397 rs4949766 chr1 77569489 C T 5.32E-04 Obesity (extreme) PIGK intron 21935397 rs7538430 chr1 77590961 A G 5.29E-04 Obesity (extreme) PIGK intron 21935397 rs1146675 chr1 77630053 G A 5.22E-04 Obesity (extreme) PIGK intron 21935397 rs1779174 chr1 77694640 C T 8.98E-04 Type 2 diabetes / / 17463246 rs12091579 chr1 77697013 C T 4.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs12407610 chr1 77707310 A T 5.06E-04 Suicide attempts in bipolar disorder / / 21423239 rs1592340 chr1 77719729 G A 4.05E-04 Suicide attempts in bipolar disorder / / 21423239 rs10518441 chr1 77726980 A G 9.67E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs10518441 chr1 77726980 A G 6.12E-05 Prostate cancer / / pha002878 rs2799549 chr1 77727898 T C 5.03E-05 Cognitive test performance / / 20125193 rs1167220 chr1 77729805 G A 6.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs1988302 chr1 77731287 C A 4.80E-06 Urinary metabolites / / 21572414 rs940283 chr1 77737217 C T 4.11E-04 Suicide attempts in bipolar disorder / / 21423239 rs10518446 chr1 77740836 G C 2.00E-04 Coronary Artery Disease / / 17634449 rs1851736 chr1 77747248 G T 2.40E-06 Urinary metabolites / / 21572414 rs7517698 chr1 77749363 G A,C 5.75E-07 Multiple sclerosis AK5 intron 17660530 rs10747353 chr1 77751193 A C 3.49E-04 Epilepsy AK5 intron 22116939 rs10782645 chr1 77754853 G A 2.67E-05 Cognitive impairment induced by topiramate AK5 intron 22091778 rs2689683 chr1 77755686 C T 4.60E-06 Urinary metabolites AK5 intron 21572414 rs2689676 chr1 77764869 G A 7.90E-06 Urinary metabolites AK5 intron 21572414 rs10493603 chr1 77768778 A G 8.78E-05 Cognitive impairment induced by topiramate AK5 intron 22091778 rs10493603 chr1 77768778 A G 3.26E-04 Epilepsy AK5 intron 22116939 rs2815319 chr1 77775066 A G 1.40E-05 Urinary metabolites AK5 intron 21572414 rs12751884 chr1 77784762 A G 3.11E-04 Epilepsy AK5 intron 22116939 rs2602951 chr1 77791025 T G 1.10E-05 Urinary metabolites AK5 intron 21572414 rs2815326 chr1 77798945 C T 8.90E-06 Urinary metabolites AK5 intron 21572414 rs17378915 chr1 77804242 A G 2.10E-05 Urinary metabolites AK5 intron 21572414 rs1463324 chr1 77806954 G A 7.40E-06 Urinary metabolites AK5 intron 21572414 rs1010196 chr1 77815566 C T 4.34E-04 Epilepsy AK5 intron 22116939 rs12073962 chr1 77817304 G C 5.20E-04 Suicide attempts in bipolar disorder AK5 intron 21423239 rs6672375 chr1 77818143 A G 4.20E-05 Leukocyte Counts AK5 intron pha003091 rs1377733 chr1 77819743 A G 6.20E-04 Heart Failure AK5 intron pha002885 rs10493604 chr1 77826732 T G 6.85E-05 Odorant perception AK5 intron 23910658 rs10493604 chr1 77826732 T G 2.37E-04 Stroke AK5 intron pha002887 rs7546131 chr1 77844602 G A 6.47E-06 Sodium levels AK5 intron pha003093 rs6663047 chr1 77865140 G A 3.24E-06 Sodium levels AK5 intron pha003093 rs4949802 chr1 77876353 T C 4.20E-05 Response to alcohol consumption (flushing response) AK5 intron 24277619 rs10873937 chr1 77879827 C T 1.31E-04 Nicotine smoking AK5 intron 19268276 rs12131772 chr1 77883671 C G 2.55E-04 Nicotine smoking AK5 intron 19268276 rs6658302 chr1 77908985 A G 5.18E-04 Multiple complex diseases AK5 intron 17554300 rs1498405 chr1 77927948 A G 8.73E-04 Obesity (extreme) AK5 intron 21935397 rs11162351 chr1 77944732 C G 5.65E-04 Multiple complex diseases AK5 intron 17554300 rs6695572 chr1 77945635 G A 2.63E-09 Narcolepsy AK5 intron 19629137 rs6695572 chr1 77945635 G A 2.76E-04 Obesity (extreme) AK5 intron 21935397 rs6698295 chr1 77945965 G A 2.76E-04 Obesity (extreme) AK5 intron 21935397 rs4949803 chr1 77951083 C T 1.52E-04 Response to statin treatment (atorvastatin),change in cholesterol levels AK5 intron 20031582 rs2088518 chr1 77951330 A T 2.80E-04 Obesity (extreme) AK5 intron 21935397 rs9324162 chr1 77954804 A G 1.46E-04 Obesity (extreme) AK5 intron 21935397 rs17380544 chr1 77958712 G A 4.79E-04 Obesity (extreme) AK5 intron 21935397 rs2803155 chr1 77958837 A C 6.27E-04 Obesity (extreme) AK5 intron 21935397 rs11162355 chr1 77961074 G T 6.70E-04 Obesity (extreme) AK5 intron 21935397 rs7514041 chr1 77964269 G A 6.44E-04 Obesity (extreme) AK5 intron 21935397 rs11806197 chr1 77964855 A G 3.33E-04 Obesity (extreme) AK5 intron 21935397 rs11806197 chr1 77964855 A G 2.56E-05 Brain structure AK5 intron 22504417 rs3112830 chr1 77966494 A T 5.68E-05 Multiple complex diseases AK5 intron 17554300 rs2803152 chr1 77966756 T C 6.44E-04 Obesity (extreme) AK5 intron 21935397 rs12049202 chr1 77967523 C T 2.95E-05 Brain structure AK5 intron 22504417 rs12040471 chr1 77968401 T A 3.42E-04 Obesity (extreme) AK5 intron 21935397 rs12042881 chr1 77968443 G A 3.45E-04 Obesity (extreme) AK5 intron 21935397 rs12042881 chr1 77968443 G A 2.66E-05 Brain structure AK5 intron 22504417 rs17380796 chr1 77976117 A G 7.04E-05 Obesity (extreme) AK5 intron 21935397 rs12729914 chr1 77980235 T C 4.00E-04 Obesity (extreme) AK5 intron 21935397 rs11811611 chr1 77982017 C T 3.99E-04 Obesity (extreme) AK5 intron 21935397 rs12042177 chr1 77986638 A G 3.63E-04 Obesity (extreme) AK5 intron 21935397 rs3509 chr1 78025551 C T 7.98E-04 Multiple complex diseases AK5 UTR-3 17554300 rs3509 chr1 78025551 C T 3.41E-04 Lymphocyte counts AK5 UTR-3 22286170 rs3509 chr1 78025551 C T 7.21E-04 Response to taxane treatment (placlitaxel) AK5 UTR-3 23006423 rs728741 chr1 78029365 A G 4.80E-05 Cognitive function / / 24684796 rs17381664 chr1 78048331 T C 3.00E-08 Obesity ZZZ3 intron 23563607 rs1389790 chr1 78089399 T C 5.90E-05 Cognitive function ZZZ3 intron 24684796 rs17100965 chr1 78206733 A G 6.71E-04 Multiple complex diseases USP33 intron 17554300 rs12085547 chr1 78295506 G A 9.69E-04 Suicide attempts in bipolar disorder FAM73A intron 21423239 rs9729667 chr1 78349214 C T 6.84E-05 Recombination rate NEXN-AS1 intron 21698098 rs1166706 chr1 78359029 T C 5.60E-05 Cognitive function NEXN intron 24684796 rs1166706 chr1 78359029 T C 8.70E-05 Cognitive function NEXN intron 24684796 rs11807240 chr1 78418776 G A 9.39E-04 Amyotrophic lateral sclerosis (sporadic) FUBP1 intron 24529757 rs17383213 chr1 78433531 T C 1.99E-04 Smoking initiation FUBP1 intron 24665060 rs11162405 chr1 78469660 A G 2.54E-05 Bipolar disorder / / 21926972 rs7524504 chr1 78494732 G T 3.75E-04 Multiple complex diseases / / 17554300 rs6424659 chr1 78501215 T C 7.55E-05 Cognitive impairment induced by topiramate / / 22091778 rs631045 chr1 78557514 G A 1.44E-06 Lymphocyte counts GIPC2 intron 22286170 rs718294 chr1 78564196 G A 3.35E-04 Alzheimer's disease GIPC2 intron 17998437 rs1022103 chr1 78589598 T C 2.43E-05 Personality dimensions GIPC2 intron 22628180 rs554298 chr1 78604614 G A 0.00000231 Sasang constitution (Soeum) / / 22394158 rs17101358 chr1 78605081 A G 3.74E-05 Multiple complex diseases / / 17554300 rs17391694 chr1 78623626 C T 6.82E-07 Lung adenocarcinoma / / 19836008 rs17391694 chr1 78623626 C T 2.00E-11 Height / / 20881960 rs17391694 chr1 78623626 C T 3.00E-09 Crohn's disease / / 23128233 rs1890850 chr1 78641967 G A 3.32E-05 Personality dimensions / / 22628180 rs17101475 chr1 78643674 C T 2.47E-04 Multiple complex diseases / / 17554300 rs4385660 chr1 78655779 G A 1.61E-05 Personality dimensions / / 22628180 rs11162429 chr1 78665643 A G 3.30E-05 Personality dimensions / / 22628180 rs12406019 chr1 78678130 A G 6.87E-04 Multiple complex diseases / / 17554300 rs2882801 chr1 78717850 G A 1.78E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) MGC27382 intron 24023788 rs10489948 chr1 78747540 T C 6.42E-04 Multiple complex diseases MGC27382 intron 17554300 rs6424762 chr1 78749908 C A 8.92E-04 Multiple complex diseases MGC27382 intron 17554300 rs6424762 chr1 78749908 C A 1.70E-05 Asthma MGC27382 intron 22561531 rs2882802 chr1 78762998 A G 2.45E-04 Birth weight MGC27382 intron 17255346 rs2104621 chr1 78772009 G C 2.15E-06 Serum metabolites MGC27382 intron 19043545 rs7545762 chr1 78772285 T A 8.88E-04 Type 2 diabetes MGC27382 intron 17463246 rs12064888 chr1 78805511 A G 5.30E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) MGC27382 intron 24236485 rs648425 chr1 78887208 T C 8.00E-07 Systolic blood pressure (alcohol consumption interaction) / / 24376456 rs674345 chr1 78894934 C T 6.87E-04 Alzheimer's disease / / 22005930 rs3753380 chr1 78956432 T C 1 Drug response to Latanoprost / / 17467803 rs3766354 chr1 78957550 G A 5.00E-04 Myocardial infarction PTGFR intron 21107343 rs1575397 chr1 78977962 G C 3.23E-04 Smoking initiation PTGFR intron 24665060 rs672561 chr1 78987302 T C 9.00E-06 IgG glycosylation PTGFR intron 23382691 rs3766345 chr1 78990275 C G 7.19E-05 Orofacial clefts PTGFR intron 22419666 rs473027 chr1 78992202 A G 8.44E-04 Multiple complex diseases PTGFR intron 17554300 rs473027 chr1 78992202 A G 7.12E-05 Serum metabolites PTGFR intron 19043545 rs1265663 chr1 78997913 C T 0.000000744 Triglycerides PTGFR intron 23063622 rs12060353 chr1 79001920 T G 7.28E-04 Coronary heart disease PTGFR intron 21606135 rs3766332 chr1 79001994 A T 2.90E-04 Multiple complex diseases PTGFR intron 17554300 rs3766332 chr1 79001994 A T 0.00028 Coronary artery calcification PTGFR intron 23727086 rs12074883 chr1 79002544 C T 2.94E-04 Coronary heart disease PTGFR UTR-3 21606135 rs12737480 chr1 79036992 C T 4.00E-05 Lung cancer / / 18978790 rs6424779 chr1 79041520 C T 8.00E-05 Lung cancer / / 18978790 rs3820093 chr1 79095526 G A 1.07E-05 Amyotrophic Lateral Sclerosis IFI44L missense 17827064 rs1981071 chr1 79102726 C T 2.50E-04 Amyotrophic Lateral Sclerosis IFI44L missense 17827064 rs273252 chr1 79106899 T C 8.93E-06 Serum metabolites IFI44L intron 19043545 rs4650590 chr1 79110518 A G 5.21E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) IFI44L UTR-3 23648065 rs1333971 chr1 79133774 C T 3.49E-04 Multiple complex diseases / / 17554300 rs4650376 chr1 79176868 C T 2.00E-06 IgG glycosylation / / 23382691 rs1033999 chr1 79211929 C T 9.86E-05 Waist-Hip Ratio / / pha003013 rs1033999 chr1 79211929 C T 3.58E-05 Waist-Hip Ratio / / pha003028 rs1751529 chr1 79214489 G A 9.12E-05 Waist-Hip Ratio / / pha003013 rs1751529 chr1 79214489 G A 3.30E-05 Waist-Hip Ratio / / pha003028 rs12133510 chr1 79221675 A G 2.31E-04 Coronary heart disease / / 21606135 rs10493613 chr1 79223199 T C 8.88E-05 Waist-Hip Ratio / / pha003028 rs1937023 chr1 79225626 C T 8.18E-05 Waist-Hip Ratio / / pha003028 rs1937020 chr1 79227956 C T 4.00E-06 Anorexia nervosa / / 23568457 rs4650608 chr1 79238015 T C 5.42E-04 Multiple complex diseases / / 17554300 rs4650608 chr1 79238015 T C 8.00E-09 Bipolar disorder / / 22182935 rs4650608 chr1 79238015 T C 8.49E-07 Major depressive disorder / / 22472876 rs4650608 chr1 79238015 T C 1.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs4650608 chr1 79238015 T C 0.000206 Schizophrenia / / 23637625 rs4650608 chr1 79238015 T C 1.22E-05 Bipolar disorder and schizophrenia / / 24280982 rs4650608 chr1 79238015 T C 1.77E-04 Bipolar disorder and schizophrenia / / 24280982 rs4650608 chr1 79238015 T C 8.00E-09 Bipolar disorder and schizophrenia / / 24280982 rs10873996 chr1 79246505 G A 8.11E-05 Waist-Hip Ratio / / pha003013 rs10873996 chr1 79246505 G A 9.80E-05 Waist-Hip Ratio / / pha003028 rs12730292 chr1 79254762 C G 5.00E-06 Bipolar disorder / / 21926972 rs10873998 chr1 79263805 T C 4.00E-06 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) / / 23453885 rs12034709 chr1 79272660 T C 9.31E-04 Myocardial Infarction / / pha002883 rs1937028 chr1 79277854 T C 7.00E-04 Parkinson's disease / / 17052657 rs12136365 chr1 79288819 T C 7.64E-05 Serum metabolites / / 19043545 rs12044353 chr1 79295415 G A 7.09E-05 Serum metabolites / / 19043545 rs2352513 chr1 79295552 A G,T 6.22E-05 Serum metabolites / / 19043545 rs6694893 chr1 79299115 T A 9.50E-05 Serum metabolites / / 19043545 rs6694893 chr1 79299115 T A 6.30E-04 Coronary heart disease / / 21606135 rs6680564 chr1 79300939 A C 7.80E-05 Serum metabolites / / 19043545 rs6680564 chr1 79300939 A C 5.40E-04 Coronary heart disease / / 21606135 rs12026347 chr1 79303750 C T 8.83E-04 Coronary heart disease / / 21606135 rs1248482 chr1 79319633 T A 4.25E-05 Serum metabolites / / 19043545 rs1248482 chr1 79319633 T A 6.67E-06 Recombination rate / / 21698098 rs1780731 chr1 79336024 C T 6.34E-05 Serum metabolites / / 19043545 rs2996691 chr1 79336607 T G 9.84E-05 Body Mass Index / / pha003020 rs2882958 chr1 79353290 A G 2.80E-05 Urinary metabolites / / 21572414 rs10518589 chr1 79353515 A T 2.40E-05 Self-reported allergy / / 23817569 rs17411879 chr1 79358211 A C 3.75E-05 Serum metabolites ELTD1 intron 19043545 rs17411879 chr1 79358211 A C 3.52E-04 Coronary heart disease ELTD1 intron 21606135 rs3811438 chr1 79403450 T C 1.68E-04 Arthritis (juvenile idiopathic) ELTD1 intron 22354554 rs12029928 chr1 79437368 C T 1.20E-04 Arthritis (juvenile idiopathic) ELTD1 intron 22354554 rs1352556 chr1 79460634 C G 1.10E-05 Urinary metabolites ELTD1 intron 21572414 rs1352556 chr1 79460634 C G 9.26E-04 Coronary heart disease ELTD1 intron 21606135 rs17406957 chr1 79500085 T C 4.81E-04 Type 2 diabetes / / 17463246 rs6687262 chr1 79509109 T C 2.00E-06 IgG glycosylation / / 23382691 rs6687262 chr1 79509109 T C 4.00E-07 IgG glycosylation / / 23382691 rs6687262 chr1 79509109 T C 5.00E-07 IgG glycosylation / / 23382691 rs17131734 chr1 79520923 T C 8.83E-04 Multiple complex diseases / / 17554300 rs1332829 chr1 79543571 C A 8.71E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17408443 chr1 79583385 T C 5.24E-05 Parent of origin effect on language impairment (child trend) / / 24571439 rs11162635 chr1 79587564 A G 8.66E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs228465 chr1 79613934 T C 3.93E-04 Multiple complex diseases / / 17554300 rs228563 chr1 79646219 C A 7.50E-04 Type 2 diabetes / / 17463246 rs228563 chr1 79646219 C A 2.73E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs41416051 chr1 79646680 A T 1.72E-04 Multiple complex diseases / / 17554300 rs7529406 chr1 79682535 A C 6.13E-05 Chronic obstructive pulmonary disease / / 19300482 rs12027718 chr1 79836598 C T 2.40E-05 Major depressive disorder (broad) / / 20038947 rs11811462 chr1 79839129 A G 2.36E-05 Major depressive disorder (broad) / / 20038947 rs3015033 chr1 79847236 G A 2.27E-05 Major depressive disorder (broad) / / 20038947 rs3015042 chr1 79851769 C T 2.20E-05 Major depressive disorder (broad) / / 20038947 rs3015046 chr1 79853343 G A 2.13E-05 Major depressive disorder (broad) / / 20038947 rs3015049 chr1 79853708 G A 2.10E-05 Major depressive disorder (broad) / / 20038947 rs3015063 chr1 79856108 A G 1.98E-05 Major depressive disorder (broad) / / 20038947 rs3015065 chr1 79856314 A G 1.96E-05 Major depressive disorder (broad) / / 20038947 rs3000157 chr1 79858023 T A 4.91E-05 Major depressive disorder (broad) / / 20038947 rs12030324 chr1 79861842 G A 2.10E-05 Major depressive disorder (broad) / / 20038947 rs3000162 chr1 79864610 C T 2.26E-05 Major depressive disorder (broad) / / 20038947 rs3000165 chr1 79870833 G A 2.81E-05 Major depressive disorder (broad) / / 20038947 rs3000166 chr1 79873161 C T 2.92E-05 Major depressive disorder (broad) / / 20038947 rs12046087 chr1 79886246 C A 3.34E-05 Major depressive disorder (broad) / / 20038947 rs12039488 chr1 79892025 G A 3.45E-05 Major depressive disorder (broad) / / 20038947 rs12041009 chr1 79896125 T C 3.49E-05 Major depressive disorder (broad) / / 20038947 rs3000140 chr1 80000648 G T 2.00E-06 Obesity-related traits / / 23251661 rs11162772 chr1 80116138 A G 6.89E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6698618 chr1 80129920 C T 1.35E-05 Bipolar disorder and schizophrenia / / 20889312 rs7533906 chr1 80134123 C T 4.00E-06 Bipolar disorder and schizophrenia / / 20889312 rs6681417 chr1 80147123 G A 3.78E-05 Bipolar disorder and schizophrenia / / 20889312 rs11162785 chr1 80148857 T G 9.31E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs1479739 chr1 80150038 A T 3.97E-05 Bipolar disorder and schizophrenia / / 20889312 rs12076080 chr1 80150181 T C 1.41E-05 Bipolar disorder and schizophrenia / / 20889312 rs10874059 chr1 80150246 G A 2.77E-05 Bipolar disorder and schizophrenia / / 20889312 rs1524174 chr1 80159221 A C 2.47E-05 Attention deficit hyperactivity disorder / / 20732627 rs722589 chr1 80174338 C G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs12569151 chr1 80176139 A G 3.30E-05 Monocyte chemoattractant protein-1 / / pha003071 rs1317042 chr1 80177985 C T 3.03E-04 Hearing function / / 17255346 rs1524183 chr1 80179889 G A,C 8.63E-05 Schizophrenia / / 19571809 rs1524183 chr1 80179889 G A,C 1.09E-05 Bipolar disorder and schizophrenia / / 20889312 rs1524183 chr1 80179889 G A,C 4.82E-05 Schizophrenia / / pha002857 rs6424669 chr1 80190866 G C 1.60E-05 Attention deficit hyperactivity disorder / / 20732627 rs6424669 chr1 80190866 G C 2.55E-05 Bipolar disorder and schizophrenia / / 20889312 rs7539380 chr1 80192565 A T 6.02E-05 Personality dimensions / / 18957941 rs6672282 chr1 80199565 G A 5.93E-05 Schizophrenia / / 19571809 rs6672282 chr1 80199565 G A 5.49E-06 Attention deficit hyperactivity disorder / / 20732627 rs6672282 chr1 80199565 G A 3.44E-05 Bipolar disorder and schizophrenia / / 20889312 rs10874067 chr1 80207766 A T 2.90E-05 Bipolar disorder and schizophrenia / / 20889312 rs7543390 chr1 80218574 A C 1.06E-05 Attention deficit hyperactivity disorder / / 20732627 rs7543390 chr1 80218574 A C 7.31E-06 Bipolar disorder and schizophrenia / / 20889312 rs1464732 chr1 80220979 A C 4.90E-05 Schizophrenia / / 19571809 rs1464732 chr1 80220979 A C 5.47E-05 Bipolar disorder and schizophrenia / / 20889312 rs7517325 chr1 80226910 G T 8.25E-05 Hearing function / / 17255346 rs3927739 chr1 80233281 C T 9.89E-05 Schizophrenia / / 19571809 rs3927739 chr1 80233281 C T 5.97E-05 Bipolar disorder and schizophrenia / / 20889312 rs12024204 chr1 80243001 A G 6.00E-06 Endometriosis / / 21151130 rs1568764 chr1 80258075 G A 5.63E-04 Smoking quantity / / 24665060 rs1916849 chr1 80267607 G A 6.01E-05 Glucose levels / / pha003058 rs1880268 chr1 80269886 A G 0.000705 Height (Pygmy height) / / 22570615 rs12046936 chr1 80271579 C T 9.02E-05 Personality dimensions / / 18957941 rs11162826 chr1 80276868 C T 5.94E-04 Smoking quantity / / 24665060 rs11577790 chr1 80277272 C A 4.63E-04 Premature ovarian failure / / 19508998 rs12744944 chr1 80278733 G A 2.67E-06 Post-operative nausea and vomiting / / 21694509 rs12744944 chr1 80278733 G A 9.60E-06 Endometriosis / / 23104006 rs7523939 chr1 80285992 C T 4.01E-05 Schizophrenia / / 20832056 rs12024531 chr1 80287742 C T 4.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs11162830 chr1 80289838 G T 3.29E-04 Schizophrenia / / 20832056 rs6424675 chr1 80324850 A G 9.98E-05 Schizophrenia / / 19571809 rs6424675 chr1 80324850 A G 1.31E-05 Bipolar disorder and schizophrenia / / 20889312 rs1830893 chr1 80361955 G T 2.65E-04 Multiple complex diseases / / 17554300 rs10493640 chr1 80365091 A T 1.95E-04 Multiple complex diseases / / 17554300 rs1325203 chr1 80369991 A G 7.44E-05 Multiple complex diseases / / 17554300 rs12123414 chr1 80384756 G A 8.67E-29 Narcolepsy / / 19629137 rs7518019 chr1 80388657 A G 0.00013 Cognitive impairment (no dementia) / / 23042215 rs12085600 chr1 80416562 A G 5.61E-04 Multiple complex diseases / / 17554300 rs7524563 chr1 80416987 G T 1.20E-04 Scoliosis / / 21216876 rs12031699 chr1 80435627 C T 2.98E-06 Scoliosis / / 21216876 rs17104170 chr1 80441636 A T 9.83E-04 Multiple complex diseases / / 17554300 rs2050470 chr1 80452405 T C 1.40E-06 Urinary metabolites / / 21572414 rs12085038 chr1 80460168 C T 6.33E-06 Obesity-related traits / / 23251661 rs1041705 chr1 80463537 T G 1.20E-05 Urinary metabolites / / 21572414 rs10493631 chr1 80477880 T C 5.00E-06 Obesity-related traits / / 23251661 rs1340682 chr1 80483406 A G 7.82E-05 Lactate dehydrogenase levels / / 20981236 rs4650447 chr1 80484171 A G 5.21E-04 Multiple complex diseases / / 17554300 rs10493658 chr1 80513706 A C 4.41E-04 Multiple complex diseases / / 17554300 rs10518631 chr1 80513790 A G 3.29E-06 Multiple complex diseases / / 17554300 rs12120142 chr1 80513847 T C 2.14E-04 Multiple complex diseases / / 17554300 rs7549131 chr1 80514496 A G 2.12E-04 Multiple complex diseases / / 17554300 rs6424682 chr1 80514544 G T 2.57E-04 Multiple complex diseases / / 17554300 rs6424683 chr1 80514574 T C 3.66E-04 Multiple complex diseases / / 17554300 rs6699236 chr1 80514706 T C 2.70E-06 Multiple complex diseases / / 17554300 rs6699329 chr1 80514773 T C 2.83E-04 Multiple complex diseases / / 17554300 rs12123981 chr1 80515241 G A 1.75E-04 Multiple complex diseases / / 17554300 rs10493660 chr1 80531263 A G 3.06E-04 Multiple complex diseases / / 17554300 rs981126 chr1 80531794 T A 2.09E-06 Multiple complex diseases / / 17554300 rs1572349 chr1 80537217 A G 2.48E-06 Multiple complex diseases / / 17554300 rs1572349 chr1 80537217 A G 8.93E-04 Premature ovarian failure / / 19508998 rs1414411 chr1 80538189 T C 5.20E-05 Malaria / / 19465909 rs6424687 chr1 80542078 G A 0.0000686 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs10782716 chr1 80544581 A G 1.13E-04 Multiple complex diseases / / 17554300 rs12087239 chr1 80552566 T G 1.60E-05 Urinary metabolites / / 21572414 rs6658821 chr1 80562482 T A 6.50E-04 Multiple complex diseases / / 17554300 rs6658821 chr1 80562482 T A 1.60E-07 Urinary metabolites / / 21572414 rs11162922 chr1 80572058 A G 1.80E-06 Multiple complex diseases / / 17554300 rs12401477 chr1 80582021 A C 1.30E-07 Urinary metabolites / / 21572414 rs4384179 chr1 80586993 G A 1.09E-05 Premature ovarian failure / / 19508998 rs4384179 chr1 80586993 G A 1.09E-05 Other erythrocyte phenotypes / / 19862010 rs11162928 chr1 80588364 C T 3.70E-06 Urinary metabolites / / 21572414 rs12119851 chr1 80589958 A C 6.40E-06 Urinary metabolites / / 21572414 rs7512762 chr1 80596275 C A 1.09E-04 Multiple complex diseases / / 17554300 rs4471217 chr1 80596899 A G 4.20E-06 Urinary metabolites / / 21572414 rs6673937 chr1 80606877 C T 7.75E-04 Multiple complex diseases / / 17554300 rs6686600 chr1 80606901 A G 7.20E-06 Urinary metabolites / / 21572414 rs12144259 chr1 80608086 C T 4.60E-06 Urinary metabolites / / 21572414 rs7544729 chr1 80613215 A G 7.56E-04 Premature ovarian failure / / 19508998 rs12407162 chr1 80613801 T C 2.80E-06 Urinary metabolites / / 21572414 rs11162943 chr1 80619109 C T 6.22E-05 Multiple complex diseases / / 17554300 rs10874118 chr1 80638947 G A 8.25E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4503307 chr1 80641525 C T 1.30E-05 Lung adenocarcinoma / / 22797724 rs7521092 chr1 80644813 C A 1.48E-04 Multiple complex diseases / / 17554300 rs17104471 chr1 80653552 A G 2.70E-06 Lung adenocarcinoma / / 22797724 rs10493661 chr1 80659055 G A 2.80E-05 Lung adenocarcinoma / / 22797724 rs12044546 chr1 80670378 C T 2.00E-05 Urinary metabolites / / 21572414 rs3014989 chr1 80710753 A T 3.10E-06 Urinary metabolites / / 21572414 rs1418818 chr1 80711659 T C 2.80E-06 Urinary metabolites / / 21572414 rs1687816 chr1 80734553 T A 1.30E-05 Urinary metabolites / / 21572414 rs11162963 chr1 80734581 C T 4.00E-06 Aging (time to event) / / 21782286 rs1954338 chr1 80741675 A G 5.09E-04 Parkinson's disease / / 17052657 rs1776286 chr1 80741898 C A 2.80E-05 Urinary metabolites / / 21572414 rs41338944 chr1 80793418 T C 1.95E-05 Multiple complex diseases / / 17554300 rs35020936 chr1 80804503 A G 2.12E-05 Multiple complex diseases / / 17554300 rs2389026 chr1 80811353 C G 2.52E-05 Multiple complex diseases / / 17554300 rs1781780 chr1 80825325 T C 8.37E-04 Multiple complex diseases / / 17554300 rs2997195 chr1 80838880 C T 3.85E-05 Cognitive impairment induced by topiramate / / 22091778 rs1896250 chr1 80857194 G A 7.89E-10 Multiple complex diseases / / 17554300 rs1549556 chr1 80858494 C T 6.11E-04 Multiple complex diseases / / 17554300 rs6424701 chr1 80867299 A T 9.99E-05 Multiple complex diseases / / 17554300 rs6677470 chr1 80869792 A G 5.81E-04 Smoking initiation / / 24665060 rs17390593 chr1 80876340 C A 2.59E-04 Multiple complex diseases / / 17554300 rs3909721 chr1 80877080 A G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1896251 chr1 80888808 C T 7.62E-05 Cognitive performance / / 19734545 rs12118390 chr1 80911114 G A 3.00E-07 Estradiol plasma levels (breast cancer) / / 23518928 rs718003 chr1 80956319 T C 5.05E-04 Alzheimer's disease / / 24755620 rs12022941 chr1 80984672 A G 2.90E-04 Multiple complex diseases / / 17554300 rs12026235 chr1 80992047 T C 5.27E-04 Multiple complex diseases / / 17554300 rs11163043 chr1 81002200 A G 6.50E-05 Multiple complex diseases / / 17554300 rs12080797 chr1 81014137 T C 1.50E-05 Urinary metabolites / / 21572414 rs10493664 chr1 81024403 T C 2.50E-04 Sarcoidosis / / 19165924 rs11163056 chr1 81039056 G A 1.82E-04 Alzheimer's disease / / 17998437 rs10874143 chr1 81042755 A C 1.65E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs10493672 chr1 81111793 G T 1.99E-04 Multiple complex diseases / / 17554300 rs7542755 chr1 81130780 G A 9.20E-05 Body Mass Index / / pha002896 rs17105337 chr1 81143088 T C 0.000843 Salmonella-induced pyroptosis / / 22837397 rs952756 chr1 81150622 A G 3.20E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs841671 chr1 81156849 C T 4.22E-04 Self-reported allergy / / 23817569 rs5020501 chr1 81208897 G A,T 7.23E-05 Cognitive test performance / / 20125193 rs2389062 chr1 81212060 A C 8.59E-04 Body mass index / / 21701565 rs41340345 chr1 81305845 G A 4.78E-04 Coronary Artery Disease / / 17634449 rs1953745 chr1 81355884 T C 7.83E-04 Smoking quantity / / 24665060 rs4650355 chr1 81376282 C T 4.99E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs12739375 chr1 81377308 A G 4.99E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10493682 chr1 81377571 G A 8.08E-04 Alzheimer's disease / / 17998437 rs10493682 chr1 81377571 G A 5.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1338129 chr1 81378256 C A 4.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1338128 chr1 81378292 A G 6.12E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10493683 chr1 81378769 G A 5.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10493684 chr1 81378929 C T 5.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2185044 chr1 81379082 T C 6.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs2152988 chr1 81379238 C T 7.28E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs2152988 chr1 81379238 C T 5.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1415929 chr1 81380131 T C 7.28E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1415929 chr1 81380131 T C 5.36E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1338127 chr1 81384148 C T 6.85E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1339118 chr1 81391273 T C,G 2.27E-04 Smoking initiation / / 24665060 rs1415936 chr1 81398439 C A 2.40E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1415935 chr1 81398711 A G 2.13E-04 Smoking initiation / / 24665060 rs10874182 chr1 81401098 C T 4.92E-04 Alcohol dependence / / 24277619 rs10874184 chr1 81401550 A G 1.27E-04 Smoking initiation / / 24665060 rs12751933 chr1 81404227 G A 1.34E-04 Smoking initiation / / 24665060 rs7515605 chr1 81430056 G A 3.83E-04 Suicide attempts in bipolar disorder / / 21041247 rs6684037 chr1 81432941 G A 7.04E-04 Rheumatoid arthritis (ACPA-negative) / / 24532677 rs7537835 chr1 81433165 G A 4.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs7537835 chr1 81433165 G A 1.41E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6694777 chr1 81436522 G T 9.19E-05 Body Composition / / pha003012 rs1863618 chr1 81450244 G A 7.37E-04 Suicide attempts in bipolar disorder / / 21041247 rs1863618 chr1 81450244 G A 5.23E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs919139 chr1 81450754 C T 6.69E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10874192 chr1 81452990 G A 4.64E-04 Myopia (pathological) / / 21095009 rs11163177 chr1 81453334 T G 1.60E-05 Urinary metabolites / / 21572414 rs1426787 chr1 81453585 G T 3.07E-05 Body Composition / / pha003012 rs1426787 chr1 81453585 G T 4.34E-05 Body Mass Index / / pha003021 rs6424732 chr1 81455333 G C 4.72E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1030414 chr1 81468442 A G 4.94E-04 Stroke / / pha002886 rs17105836 chr1 81526130 A G 3.77E-04 Tourette syndrome / / 22889924 rs11583080 chr1 81530739 T C 3.86E-04 Aortic root size / / 21223598 rs672797 chr1 81560554 C A 4.20E-08 Type 1 diabetes / / 17632545 rs11163194 chr1 81578784 A G 8.34E-04 Alzheimer's disease / / 22005930 rs1195693 chr1 81579076 A G 1.50E-05 Urinary metabolites / / 21572414 rs1146408 chr1 81581873 C T 2.70E-05 Urinary metabolites / / 21572414 rs1195699 chr1 81583172 A G 2.10E-05 Urinary metabolites / / 21572414 rs12128534 chr1 81586357 G A 9.19E-04 Alzheimer's disease / / 22005930 rs1648692 chr1 81588340 G C 8.98E-04 Alzheimer's disease / / 22005930 rs1648690 chr1 81589935 G C 7.72E-04 Alzheimer's disease / / 22005930 rs1768400 chr1 81591135 A G 7.58E-04 Alzheimer's disease / / 22005930 rs1426788 chr1 81592062 T C 7.62E-04 Alzheimer's disease / / 22005930 rs1648689 chr1 81592929 C T 7.67E-04 Alzheimer's disease / / 22005930 rs1768395 chr1 81594126 T G 2.60E-05 Urinary metabolites / / 21572414 rs1752219 chr1 81597906 C T 7.33E-04 Alzheimer's disease / / 22005930 rs1768389 chr1 81598101 T C 2.60E-05 Urinary metabolites / / 21572414 rs1768388 chr1 81598364 A G 6.98E-04 Alzheimer's disease / / 22005930 rs1146414 chr1 81601170 G C 7.30E-04 Body mass index / / 21701565 rs1146414 chr1 81601170 G C 8.75E-04 Body mass index / / 21701565 rs1146416 chr1 81601541 C T 9.33E-04 Alzheimer's disease / / 22005930 rs17106034 chr1 81609864 C T 2.63E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1327712 chr1 81614826 A C 4.47E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs1327712 chr1 81614826 A C 4.49E-05 Scoliosis / / 21216876 rs10493685 chr1 81622201 G A 1.60E-04 Type 2 diabetes / / 17846125 rs3898651 chr1 81622580 T G 4.13E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs17106106 chr1 81624781 C T 3.96E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs4120877 chr1 81656725 G T 3.66E-05 Cognitive performance / / 19734545 rs10874202 chr1 81688359 A G 4.30E-04 Suicide attempts in bipolar disorder / / 21423239 rs4650518 chr1 81699270 C T 4.10E-07 Urinary metabolites / / 21572414 rs9645301 chr1 81704582 A T 1.00E-04 Type 2 diabetes / / 17463246 rs4650519 chr1 81720233 C A 7.46E-04 Multiple complex diseases / / 17554300 rs1547674 chr1 81745893 C T 8.79E-05 Multiple complex diseases / / 17554300 rs10782752 chr1 81755537 G A 3.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs10782752 chr1 81755537 G A 7.00E-04 Smoking initiation / / 24665060 rs1327613 chr1 81764583 T A 9.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs12027847 chr1 81766037 G A 7.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs10158280 chr1 81768971 T C 9.39E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2182766 chr1 81796468 A G 9.14E-05 Acute lymphoblastic leukemia (childhood) / / 19684603 rs111722172 chr1 81811786 G T 2.80E-11 Metabolite levels / / 22286219 rs11163267 chr1 81843506 T A,C 7.76E-04 Smoking initiation / / 24665060 rs10874238 chr1 81872593 G A 8.53E-04 Suicide attempts in bipolar disorder / / 21423239 rs6681688 chr1 81881212 C T 8.74E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs4336893 chr1 81887417 T C 9.46E-04 Multiple complex diseases / / 17554300 rs4362026 chr1 81890814 T G 8.74E-05 Parent of origin effect on language impairment (maternal) / / 24571439 rs10782760 chr1 81896746 A G 6.93E-05 Serum metabolites / / 19043545 rs11163298 chr1 81924594 C T 2.15E-05 Type 2 diabetes / / 17463246 rs3924703 chr1 81944199 A G 0.000000068 Mean arterial pressure / / 22510845 rs12142040 chr1 81949079 A G 2.50E-05 Urinary metabolites / / 21572414 rs11163323 chr1 81986458 C T 0.000017 Diabetic retinopathy in Type 2 diabetes mellitus,ETDRS grade>=30 / / 21873659 rs11586072 chr1 81987161 C A 1.66E-04 Type 2 diabetes / / 17463246 rs17420488 chr1 81992020 G A 2.30E-05 Urinary metabolites / / 21572414 rs17454529 chr1 81995750 G A 3.74E-04 Multiple complex diseases / / 17554300 rs17454592 chr1 81996353 G A 5.60E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) / / 23648065 rs17106650 chr1 81999759 G A 3.42E-05 Response to TNF antagonist treatment / / 21061259 rs12022306 chr1 82026353 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7532624 chr1 82029505 G A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1924558 chr1 82061064 T G 9.75E-05 Height / / 17255346 rs6671683 chr1 82068875 G C 1.54E-04 Multiple complex diseases / / 17554300 rs17456217 chr1 82073276 G C 4.44E-04 Multiple complex diseases / / 17554300 rs11809789 chr1 82074852 G A 6.00E-06 Bilirubin levels / / 22085899 rs17456431 chr1 82086743 G C 4.24E-04 Multiple complex diseases / / 17554300 rs17423111 chr1 82103535 G A 9.23E-04 Multiple complex diseases / / 17554300 rs12117862 chr1 82110055 T C 1.11E-04 Coronary heart disease / / 21606135 rs480304 chr1 82123485 C A 5.92E-04 Smoking quantity / / 24665060 rs561278 chr1 82132298 A C 3.13E-04 Smoking quantity / / 24665060 rs11578678 chr1 82168757 T C 7.18E-04 Body mass index / / 21701565 rs11163350 chr1 82170329 C T 2.85E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11163350 chr1 82170329 C T 3.20E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12732009 chr1 82175317 G T 4.33E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12732009 chr1 82175317 G T 4.87E-06 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12129647 chr1 82182566 G A 4.83E-05 Intracerebral hemorrhage / / 24656865 rs9285611 chr1 82183055 C T 1.70E-05 Pulmonary function / / 17903307 rs9285611 chr1 82183055 C T 1.88E-04 Response to cholinesterase inhibitors in Alzheimer's disease / / 23374588 rs9324183 chr1 82195760 G T 6.10E-06 Height / / 17255346 rs9324183 chr1 82195760 G T 2.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12139644 chr1 82197327 G A 6.63E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1391475 chr1 82210952 T C 1.27E-04 IgE levels / / 17255346 rs1391475 chr1 82210952 T C 1.70E-05 Crohn's disease / / 20570966 rs9782905 chr1 82219539 A G 3.99E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs9324187 chr1 82225803 G T 1.77E-04 Response to TNF antagonist treatment / / 21061259 rs11163372 chr1 82247248 C T 3.00E-06 Temperament / / 22832960 rs1391478 chr1 82248794 A G 2.97E-04 Response to TNF antagonist treatment / / 21061259 rs1391478 chr1 82248794 A G 8.78E-04 Body mass index / / 21701565 rs371363 chr1 82349354 C T 2.80E-04 Type 2 diabetes and 6 quantitative traits LPHN2 intron 17848626 rs371363 chr1 82349354 C T 2.58E-06 Paclitaxel sensitivity in NCI60 cancer cell lines LPHN2 intron 21314952 rs12401346 chr1 82352612 T C 5.54E-04 Response to TNF antagonist treatment LPHN2 intron 21061259 rs1341260 chr1 82364661 T C 6.61E-04 Nicotine dependence LPHN2 intron 17158188 rs284227 chr1 82379446 C T 7.55E-05 Celiac disease LPHN2 intron 23936387 rs626085 chr1 82384574 C T 3.95E-04 Alzheimer's disease LPHN2 intron 22005930 rs993906 chr1 82390698 T C 1.89E-04 Alzheimer's disease LPHN2 intron 22005930 rs6681544 chr1 82398544 C T 6.00E-06 Metabolite levels (X-11787) LPHN2 intron 23934736 rs1475394 chr1 82412099 C T 9.31E-05 Triglycerides LPHN2 intron pha003080 rs385367 chr1 82415199 A G 7.65E-05 Celiac disease LPHN2 intron 23936387 rs1327022 chr1 82436281 G A 8.58E-04 Major depressive disorder LPHN2 intron 22472876 rs9438724 chr1 82438148 A C 7.56E-05 Celiac disease LPHN2 intron 23936387 rs10518658 chr1 82461630 T C 9.93E-05 Triglycerides / / pha003080 rs4970642 chr1 82465731 A G 2.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17472507 chr1 82479448 G A 4.27E-05 Triglycerides / / pha003080 rs4291539 chr1 82503816 C T 2.37E-05 Longevity / / 21612516 rs11163417 chr1 82517645 T C 3.98E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs4486485 chr1 82526505 G C 2.60E-05 Urinary metabolites / / 21572414 rs11163422 chr1 82566070 A T 7.80E-04 Multiple complex diseases / / 17554300 rs10493708 chr1 82571186 A G 4.80E-04 Multiple complex diseases / / 17554300 rs17436254 chr1 82762033 A G 8.68E-06 Obesity-related traits / / 23251661 rs785584 chr1 82762700 T C 7.43E-06 Obesity-related traits / / 23251661 rs1770678 chr1 82765052 T C 7.00E-06 Obesity-related traits / / 23251661 rs11579674 chr1 82836557 A G 2.13E-04 Insulin resistance / / 21901158 rs11163467 chr1 82848122 C T 5.77E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs1290281 chr1 82857453 G A 3.95E-04 Multiple complex diseases / / 17554300 rs10437023 chr1 82901026 G A 9.60E-05 Parkinson's disease (familial) / / 18985386 rs10437024 chr1 82901264 A C 9.60E-05 Parkinson's disease (familial) / / 18985386 rs10437024 chr1 82901264 A C 2.02E-05 Parkinson's disease / / pha002868 rs2225083 chr1 82960385 G A 9.58E-04 Eye color / / 23118974 rs7523716 chr1 82964864 G T 4.52E-04 Alzheimer's disease / / 17998437 rs7537124 chr1 82964897 A T 4.89E-04 Alzheimer's disease / / 17998437 rs10747397 chr1 82965159 T C 5.18E-04 Alzheimer's disease / / 17998437 rs12745149 chr1 82991633 T C 7.89E-04 Body mass index / / 21701565 rs318422 chr1 83019476 A G 1.61E-04 Multiple complex diseases / / 17554300 rs11579295 chr1 83036341 A G 8.18E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs9729834 chr1 83039338 G A 4.73E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17108556 chr1 83052706 G A 1.91E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs10874322 chr1 83054799 C T 2.00E-06 Response to taxane treatment (docetaxel) / / 23006423 rs1281400 chr1 83055625 C G 7.14E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2011057 chr1 83058155 C T 3.61E-05 Post-operative nausea and vomiting / / 21694509 rs2011057 chr1 83058155 C T 5.54E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11163526 chr1 83096605 A G 5.75E-04 Smoking initiation / / 24665060 rs1361196 chr1 83097024 T C 7.36E-05 Bipolar disorder / / 19488044 rs1416079 chr1 83097138 A G 1.09E-05 Bipolar disorder / / 19488044 rs1416078 chr1 83097228 T C 7.20E-05 Bipolar disorder / / 19488044 rs6604921 chr1 83098959 T C 1.57E-04 Alzheimer's disease (late onset) / / 21379329 rs17493817 chr1 83101655 A G 3.90E-05 Parkinson's disease (age of onset) / / 19772629 rs373905 chr1 83112722 C T 2.06E-05 Alcohol dependence / / 21703634 rs428943 chr1 83115057 A G 3.48E-04 Alzheimer's disease (late onset) / / 21379329 rs453456 chr1 83117369 G A 2.04E-05 Alcohol dependence / / 21703634 rs2787985 chr1 83118044 T G 4.62E-04 Alzheimer's disease (late onset) / / 21379329 rs2787985 chr1 83118044 T G 1.20E-05 Alcohol dependence / / 21703634 rs10874325 chr1 83118256 G C 5.37E-05 Serum metabolites / / 19043545 rs1433761 chr1 83132400 A C 9.33E-05 Alcohol dependence / / 21703634 rs3845616 chr1 83135055 A G 7.02E-04 Smoking cessation / / 24665060 rs12239057 chr1 83136159 C T 2.94E-04 Lung function (forced vital capacity) / / 24023788 rs10493722 chr1 83171994 C T 7.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs9324200 chr1 83172488 A G 4.10E-06 Erythrocyte counts / / pha003090 rs1469744 chr1 83173469 T C 2.22E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1469744 chr1 83173469 T C 3.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1469743 chr1 83178180 G T 5.92E-05 Alcohol dependence / / 21703634 rs12744723 chr1 83184129 C T 7.16E-05 Alcohol dependence / / 21703634 rs10493727 chr1 83188821 C T 4.51E-05 Alcohol dependence / / 21703634 rs1338361 chr1 83196421 T C 5.74E-05 Alcohol dependence / / 21703634 rs11588508 chr1 83202936 A G 5.61E-05 Alcohol dependence / / 21703634 rs11588936 chr1 83203139 T A 5.43E-05 Alcohol dependence / / 21703634 rs2060361 chr1 83204106 C T 7.46E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) / / 23648065 rs17109039 chr1 83221252 G T 2.53E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11807023 chr1 83225779 C T 3.41E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs320909 chr1 83227702 T G 7.97E-04 Type 2 diabetes / / 17463246 rs11163566 chr1 83230397 C A 4.08E-04 Alzheimer's disease (late onset) / / 21379329 rs6429835 chr1 83231866 C T 3.79E-05 Alcohol dependence / / 21703634 rs17505362 chr1 83233401 G A 1.24E-04 Multiple complex diseases / / 17554300 rs6429839 chr1 83266863 G A 0.0000829 Tuberculosis with late age of onset / / 22551897 rs17109259 chr1 83291401 C A 1.37E-04 Multiple complex diseases / / 17554300 rs11163585 chr1 83311835 C T 9.00E-07 Response to antipsychotic treatment / / 20195266 rs1146366 chr1 83358442 G A 4.97E-04 Lung function (forced expiratory volume in 1 second) / / 24023788 rs1440447 chr1 83412781 T C 9.77E-04 Type 2 diabetes / / 17463246 rs4146730 chr1 83444431 G A 2.10E-05 Urinary metabolites / / 21572414 rs2289445 chr1 83451691 C T 3.57E-05 Smoking initiation / / 24665060 rs7556305 chr1 83464725 A G 3.58E-04 Stroke / / pha002886 rs6702898 chr1 83465825 C T 2.66E-04 Stroke / / pha002886 rs6668833 chr1 83473598 T C 1.05E-05 Bipolar disorder,affective / / 20528957 rs1930278 chr1 83486078 A G 4.47E-04 Celiac disease / / 23936387 rs12742923 chr1 83489844 C T 8.00E-07 HIV-associated dementia / / 22628157 rs10487981 chr1 83530267 T C 3.32E-04 Parkinson's disease / / 16252231 rs323973 chr1 83535877 C A 5.91E-04 Type 2 diabetes / / 17463246 rs323973 chr1 83535877 C A 9.10E-04 Multiple complex diseases / / 17554300 rs17344386 chr1 83541990 T C 4.71E-05 Parkinson's disease / / 16252231 rs323932 chr1 83553972 A C 6.14E-04 Type 2 diabetes / / 17463246 rs6684000 chr1 83554149 A G 6.14E-04 Type 2 diabetes / / 17463246 rs6684000 chr1 83554149 A G 9.97E-04 Multiple complex diseases / / 17554300 rs6684000 chr1 83554149 A G 5.99E-04 Sarcoidosis / / 19165924 rs537877 chr1 83572881 G T 4.97E-05 Cognitive test performance / / 20125193 rs11163687 chr1 83665119 A G 3.60E-08 Glioma (high-grade) / / 19578366 rs11163695 chr1 83701382 A C 2.66E-04 Alzheimer's disease (late onset) / / 21379329 rs12403322 chr1 83701728 A G 8.36E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2077053 chr1 83716959 C T 1.10E-05 Iron levels / / 21208937 rs11163719 chr1 83792651 G A 4.27E-04 Multiple complex diseases / / 17554300 rs4907021 chr1 83857369 G A 9.77E-06 Bipolar disorder and schizophrenia / / 20889312 rs2260390 chr1 83871950 G A 3.22E-05 Bipolar disorder and schizophrenia / / 20889312 rs17130039 chr1 83964564 T A,G 9.73E-05 Multiple complex diseases / / 17554300 rs3861696 chr1 83975531 G A 7.38E-05 Coronary heart disease / / pha003032 rs10493740 chr1 83989898 G T 3.55E-04 Heart Failure / / pha002884 rs4142781 chr1 84024341 C T 8.85E-04 Multiple complex diseases / / 17554300 rs12097883 chr1 84059930 C T 5.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs4363435 chr1 84067452 G A 5.84E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11163783 chr1 84086070 T C 3.91E-04 Acute lung injury / / 22295056 rs10874398 chr1 84088645 G C 6.56E-04 Acute lung injury / / 22295056 rs6695005 chr1 84091702 G C 6.01E-04 Acute lung injury / / 22295056 rs11163786 chr1 84093452 A G 6.25E-04 Acute lung injury / / 22295056 rs10874400 chr1 84094265 G A 9.91E-04 Acute lung injury / / 22295056 rs12563303 chr1 84094411 G A 9.91E-04 Acute lung injury / / 22295056 rs12562642 chr1 84094604 T C 9.91E-04 Acute lung injury / / 22295056 rs12562651 chr1 84094868 A G 9.91E-04 Acute lung injury / / 22295056 rs11163788 chr1 84095392 C A 9.73E-04 Acute lung injury / / 22295056 rs11163794 chr1 84111016 T C 6.16E-04 Acute lung injury / / 22295056 rs11163795 chr1 84111208 C G 6.16E-04 Acute lung injury / / 22295056 rs8179422 chr1 84111398 C G 6.29E-04 Acute lung injury / / 22295056 rs8179462 chr1 84111468 T C 6.74E-04 Acute lung injury / / 22295056 rs4907033 chr1 84111799 T A 3.81E-04 Acute lung injury / / 22295056 rs4457599 chr1 84112891 G A 1.77E-05 Alzheimer's disease / / 21098978 rs4457599 chr1 84112891 G A 6.44E-04 Acute lung injury / / 22295056 rs4539154 chr1 84113159 G A 1.76E-05 Alzheimer's disease / / 21098978 rs2068611 chr1 84113646 C T 1.75E-05 Alzheimer's disease / / 21098978 rs4907035 chr1 84114899 A T 2.74E-07 Alzheimer's disease / / 21098978 rs4907035 chr1 84114899 A T 9.23E-04 Acute lung injury / / 22295056 rs12035245 chr1 84115574 T C 8.85E-04 Acute lung injury / / 22295056 rs12566397 chr1 84116576 G A 9.46E-04 Acute lung injury / / 22295056 rs10218575 chr1 84123370 G C 6.90E-04 Multiple complex diseases / / 17554300 rs17577039 chr1 84204198 A G 2.90E-05 HIV-1 control / / 20041166 rs6683294 chr1 84218373 G A 2.90E-05 HIV-1 control / / 20041166 rs17129137 chr1 84219787 C T 8.60E-05 Tunica Media / / pha003038 rs17129251 chr1 84228589 G A 3.49E-04 Alzheimer's disease / / 24755620 rs17129289 chr1 84232748 T C 7.00E-06 Obesity-related traits / / 23251661 rs11163843 chr1 84252434 C A 9.36E-04 Multiple complex diseases / / 17554300 rs7552393 chr1 84254551 A G 5.00E-07 Select biomarker traits / / 17903293 rs7539409 chr1 84254735 G A 1.00E-06 Alzheimer's Disease / / 20061627 rs6676587 chr1 84276429 T C 6.81E-04 Multiple complex diseases / / 17554300 rs2179763 chr1 84295861 A G 9.54E-04 Tourette syndrome / / 22889924 rs970457 chr1 84296540 C T 5.41E-04 Depression (quantitative trait) / / 20800221 rs3738575 chr1 84296983 A G 5.35E-04 Tourette syndrome / / 22889924 rs932448 chr1 84308491 C T 8.02E-04 Alzheimer's disease / / 24755620 rs6576951 chr1 84312493 T C 2.80E-05 Urinary metabolites / / 21572414 rs6692233 chr1 84327214 G A 1.02E-04 Multiple complex diseases / / 17554300 rs12118434 chr1 84328629 G A 5.58E-05 Multiple complex diseases / / 17554300 rs2024591 chr1 84329235 C T 1.95E-05 Multiple complex diseases / / 17554300 rs11163862 chr1 84355418 T A 2.39E-04 Multiple complex diseases TTLL7 intron 17554300 rs12142944 chr1 84380880 C T 9.72E-04 Suicide attempts in bipolar disorder TTLL7 intron 21423239 rs10465746 chr1 84387632 T G 8.00E-06 Obesity-related traits TTLL7 intron 23251661 rs481354 chr1 84409393 G C 2.60E-04 Multiple complex diseases TTLL7 intron 17554300 rs7551787 chr1 84419297 T C 2.47E-04 Multiple complex diseases TTLL7 intron 17554300 rs4907191 chr1 84444165 G A 6.37E-05 Multiple complex diseases TTLL7 intron 17554300 rs10493743 chr1 84444412 T C 8.53E-04 Suicide attempts in bipolar disorder TTLL7 intron 21423239 rs10493744 chr1 84444752 T C 7.32E-05 Multiple complex diseases TTLL7 intron 17554300 rs12042443 chr1 84444766 G A 4.67E-04 Multiple complex diseases TTLL7 intron 17554300 rs1886769 chr1 84471134 C A 0.00003 Alanine aminotransferase (ALT) elevation due to Lapatinib treatment of metastatic breast cancer / / 21245432 rs11163887 chr1 84474718 G A 6.01E-04 Multiple complex diseases / / 17554300 rs955524 chr1 84490456 G A 2.42E-04 Multiple complex diseases / / 17554300 rs669110 chr1 84498812 G A 2.40E-04 Multiple complex diseases / / 17554300 rs626376 chr1 84516043 T C 5.23E-04 Multiple complex diseases / / 17554300 rs810915 chr1 84516349 A C 6.50E-04 Multiple complex diseases / / 17554300 rs1811643 chr1 84527291 G A 3.61E-04 Multiple complex diseases / / 17554300 rs2892811 chr1 84527394 T C 9.18E-04 Multiple complex diseases / / 17554300 rs663521 chr1 84530053 T G 4.03E-04 Multiple complex diseases / / 17554300 rs12031680 chr1 84535297 C A 6.81E-04 Multiple complex diseases / / 17554300 rs1565823 chr1 84576620 G A 1.00E-04 Cognitive impairment induced by topiramate PRKACB intron 22091778 rs1016379 chr1 84590129 A G 2.21E-04 Multiple complex diseases PRKACB intron 17554300 rs12723299 chr1 84590315 C T 3.33E-04 Multiple complex diseases PRKACB intron 17554300 rs2139931 chr1 84590527 A G 2.01E-04 Multiple complex diseases PRKACB intron 17554300 rs11163905 chr1 84594399 G A 6.49E-04 Multiple complex diseases PRKACB intron 17554300 rs903263 chr1 84622513 G T 1.00E-06 Breast cancer (male) PRKACB intron 23001122 rs1057738 chr1 84670816 A C 3.88E-05 Cognitive impairment induced by topiramate PRKACB UTR-3 22091778 rs12088543 chr1 84717983 T C 3.31E-05 Male fertility / / 22633400 rs606816 chr1 84720376 C A 1.01E-06 Monocyte counts / / pha003089 rs621750 chr1 84721408 G A 1.01E-06 Monocyte counts / / pha003089 rs11163933 chr1 84728627 C T 9.04E-05 Male fertility / / 22633400 rs11163934 chr1 84728697 C A 3.49E-05 Male fertility / / 22633400 rs12047850 chr1 84729134 A C 3.46E-05 Type 2 diabetes / / 17463246 rs316672 chr1 84743949 T G 1.00E-05 Cognitive impairment induced by topiramate / / 22091778 rs316672 chr1 84743949 T G 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs316672 chr1 84743949 T G 6.76E-05 Cognitive impairment induced by topiramate / / 22091778 rs316669 chr1 84745099 A G 1.52E-06 Cognitive impairment induced by topiramate / / 22091778 rs316669 chr1 84745099 A G 1.74E-06 Cognitive impairment induced by topiramate / / 22091778 rs316669 chr1 84745099 A G 2.34E-05 Cognitive impairment induced by topiramate / / 22091778 rs316669 chr1 84745099 A G 2.47E-06 Cognitive impairment induced by topiramate / / 22091778 rs1983077 chr1 84745373 G A 2.40E-05 Cognitive impairment induced by topiramate / / 22091778 rs1983077 chr1 84745373 G A 2.42E-06 Cognitive impairment induced by topiramate / / 22091778 rs1983077 chr1 84745373 G A 3.57E-06 Cognitive impairment induced by topiramate / / 22091778 rs1983077 chr1 84745373 G A 6.14E-06 Cognitive impairment induced by topiramate / / 22091778 rs17373911 chr1 84745603 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs6697296 chr1 84759975 C A 2.42E-04 Multiple complex diseases / / 17554300 rs1085093 chr1 84761348 T C 3.00E-06 Metabolic syndrome / / 20694148 rs316662 chr1 84787312 A C 4.46E-07 Obesity-related traits SAMD13 intron 23251661 rs315553 chr1 84792973 G T 4.00E-06 Obesity-related traits SAMD13 intron 23251661 rs315540 chr1 84816587 A C 6.96E-06 Obesity-related traits / / 23251661 rs315535 chr1 84820409 C T 6.62E-05 Major depressive disorder (broad) / / 20038947 rs315535 chr1 84820409 C T 7.38E-06 Obesity-related traits / / 23251661 rs17478556 chr1 84852123 G C 1.02E-05 Bipolar disorder UOX intron 19488044 rs17478556 chr1 84852123 G C 2.93E-05 Bipolar Disorder UOX intron pha002863 rs12752696 chr1 84856633 C T 8.23E-05 Brain derived neurotrophic factor levels,in serum UOX intron 22047184 rs621869 chr1 84856784 T C 5.85E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) UOX intron 24192120 rs10082174 chr1 84859152 C G 6.92E-05 Brain derived neurotrophic factor levels,in serum UOX intron 22047184 rs12144715 chr1 84865230 A T 7.00E-06 Response to hepatitis C treatment D/SE2B intron 22095909 rs634531 chr1 84866855 T C 2.33E-04 Obesity (extreme) D/SE2B intron 21935397 rs604708 chr1 84868961 T C 8.00E-06 IgG glycosylation D/SE2B intron 23382691 rs3116406 chr1 84874242 C G 7.83E-05 Obesity (extreme) D/SE2B intron 21935397 rs3768250 chr1 84880380 T C 9.21E-05 Obesity (extreme) D/SE2B cds-synon 21935397 rs1506702 chr1 84894055 T C 9.51E-05 Obesity (extreme) / / 21935397 rs1340596 chr1 84896033 C A 8.30E-05 Diabetic retinopathy / / 21441570 rs7514800 chr1 84896441 G A 1.04E-04 Obesity (extreme) / / 21935397 rs959363 chr1 84898321 A C 1.27E-04 Obesity (extreme) / / 21935397 rs10874441 chr1 84899304 G A 1.32E-04 Obesity (extreme) / / 21935397 rs1340598 chr1 84904099 T C 2.72E-04 Obesity (extreme) / / 21935397 rs10493746 chr1 84904279 G A 4.14E-04 Obesity (extreme) / / 21935397 rs4345821 chr1 84907970 T C 2.64E-04 Obesity (extreme) / / 21935397 rs12755232 chr1 84918056 A C 2.38E-04 Obesity (extreme) / / 21935397 rs12729133 chr1 84922553 C T 1.28E-04 Obesity (extreme) / / 21935397 rs7540794 chr1 84924179 A T 1.29E-04 Obesity (extreme) / / 21935397 rs2794217 chr1 84962577 T C 4.30E-05 Intracerebral hemorrhage RPF1 intron 24656865 rs2659173 chr1 84981405 T A 4.78E-05 Intracerebral hemorrhage SPATA1 intron 24656865 rs17113057 chr1 85101762 C G 1.19E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs17113057 chr1 85101762 C G 8.03E-04 Smoking quantity / / 24665060 rs2911613 chr1 85111124 C A 2.59E-05 Progressive supranuclear palsy SSX2IP UTR-3 21685912 rs818526 chr1 85198264 T C 8.16E-05 Monocyte counts / / pha003089 rs12744552 chr1 85216685 T C 5.17E-05 Orofacial clefts / / 20023658 rs1750491 chr1 85226299 T C 2.00E-06 Dental caries / / 23064961 rs1770566 chr1 85227586 A G 1.40E-06 Glioma (high-grade) / / 19578366 rs9661368 chr1 85234868 A G 3.15E-05 Personality dimensions / / 18957941 rs1620453 chr1 85234978 C A 7.58E-04 Body mass index / / 21701565 rs1417296 chr1 85236777 G T 1.17E-05 Personality dimensions / / 18957941 rs11576745 chr1 85240246 C T 9.13E-04 Alcohol dependence / / 21314694 rs11576745 chr1 85240246 C T 7.70E-05 Coronary heart disease / / pha003055 rs10782529 chr1 85268243 C T 4.00E-06 Lipoprotein-associated phospholipase A2 activity change in response to statin therapy / / 23118302 rs10873658 chr1 85271091 C T 9.54E-04 Alzheimer's disease / / 22005930 rs4243771 chr1 85276032 A T 6.44E-04 Alzheimer's disease / / 22005930 rs9728717 chr1 85290409 T C 9.00E-06 Economic and political preferences (time) LPAR3 intron 22566634 rs11161467 chr1 85305197 A T 5.73E-04 Multiple complex diseases LPAR3 intron 17554300 rs1983853 chr1 85311192 C T 2.00E-06 Type 1 diabetes LPAR3 intron 18840781 rs12062882 chr1 85313108 C T 6.34E-04 Alzheimer's disease LPAR3 intron 24755620 rs4907103 chr1 85316840 G T 0.0000977 Schizophrenia LPAR3 intron 23637625 rs942683 chr1 85319741 C T 8.45E-04 Alzheimer's disease LPAR3 intron 22005930 rs942684 chr1 85319822 T C 8.50E-04 Alzheimer's disease LPAR3 intron 22005930 rs10873661 chr1 85328096 G A 6.11E-06 Coronary heart disease LPAR3 intron pha003055 rs1325273 chr1 85332120 T C 1.55E-05 Coronary heart disease LPAR3 intron pha003055 rs4243774 chr1 85356878 T C 2.00E-06 Smoking cessation LPAR3 intron 24665060 rs4579776 chr1 85357025 A G 8.64E-04 Type 2 diabetes LPAR3 intron 17463246 rs12057637 chr1 85392616 A C 1.94E-05 Personality dimensions MCOLN2 intron 18957941 rs12145073 chr1 85394258 T G 7.14E-06 Serum dimethylarginine levels (asymmetric) MCOLN2 intron 24159190 rs17117593 chr1 85398979 C T 7.77E-04 Type 2 diabetes MCOLN2 intron 17463246 rs1325277 chr1 85400114 C A 5.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs) MCOLN2 intron 23648065 rs597630 chr1 85419947 T C 5.47E-05 Lymphocyte counts MCOLN2 intron 22286170 rs41383647 chr1 85426256 T C 2.60E-05 Urinary metabolites MCOLN2 intron 21572414 rs6576739 chr1 85468319 T G 3.22E-04 Lymphocyte counts / / 22286170 rs17119333 chr1 85485170 C G 5.30E-06 Urinary metabolites MCOLN3 intron 21572414 rs41461649 chr1 85509512 C T 2.60E-05 Urinary metabolites MCOLN3 intron 21572414 rs6576745 chr1 85529628 T C 1.85E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WDR63 intron 20877124 rs6695223 chr1 85531711 C T 3.32E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) WDR63 intron 20877124 rs6695223 chr1 85531711 C T 5.00E-09 Venous thromboembolism (gene x gene interaction) WDR63 intron 23509962 rs17099213 chr1 85537706 T C 1.70E-05 Urinary metabolites WDR63 intron 21572414 rs17120570 chr1 85539127 G A 2.88E-04 Smoking initiation WDR63 intron 24665060 rs709764 chr1 85560264 G A 3.79E-05 Cognitive impairment induced by topiramate WDR63 intron 22091778 rs2050842 chr1 85582549 G A 4.60E-05 Diabetic retinopathy WDR63 intron 21441570 rs6576749 chr1 85583162 C G 4.60E-05 Diabetic retinopathy WDR63 intron 21441570 rs10873688 chr1 85605433 C T 3.26E-12 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10873688 chr1 85605433 C T 3.69E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs7532792 chr1 85609928 G A 1.44E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs930912 chr1 85617482 T A 4.43E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs11161535 chr1 85621174 A T 4.34E-10 Serum dimethylarginine levels (asymmetric) / / 24159190 rs7511739 chr1 85622457 G A 1.10E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs17122364 chr1 85627099 A G 7.13E-07 Serum dimethylarginine levels (asymmetric) SYDE2 intron 24159190 rs4907138 chr1 85628953 C T 8.17E-07 Serum dimethylarginine levels (asymmetric) SYDE2 intron 24159190 rs145522533 chr1 85646380 A G 2.99E-06 Serum dimethylarginine levels (asymmetric) SYDE2 intron 24159190 rs11161543 chr1 85653831 G A 1.63E-04 Alzheimer's disease SYDE2 intron 22005930 rs12144280 chr1 85654216 T C 1.85E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) SYDE2 intron 24159190 rs12144280 chr1 85654216 T C 3.58E-10 Serum dimethylarginine levels (asymmetric) SYDE2 intron 24159190 rs72722607 chr1 85654397 G A 1.00E-09 Serum dimethylarginine levels (asymmetric) SYDE2 intron 24159190 rs112356857 chr1 85657385 G A 6.77E-10 Serum dimethylarginine levels (asymmetric) SYDE2 intron 24159190 rs709788 chr1 85676959 A G 1.10E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs709788 chr1 85676959 A G 3.70E-11 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12028498 chr1 85677283 G C 6.88E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12732108 chr1 85678877 G A 6.16E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs7540356 chr1 85679100 A G 1.02E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs72722624 chr1 85681964 G A 9.27E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs72722628 chr1 85682652 G A 3.93E-09 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10782542 chr1 85683583 G T 1.30E-04 Alzheimer's disease / / 22005930 rs12125292 chr1 85685189 T C 2.55E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs10782543 chr1 85689134 G A 1.04E-04 Alzheimer's disease / / 22005930 rs72722632 chr1 85689491 G A 4.12E-09 Serum dimethylarginine levels (asymmetric) / / 24159190 rs72722638 chr1 85693127 G A 1.94E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs17123650 chr1 85694671 C T 1.34E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs11583836 chr1 85696534 T A 1.35E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs11161556 chr1 85701014 A T 1.28E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs6671589 chr1 85702868 C T 1.29E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs72722643 chr1 85703134 C T 1.29E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs72722644 chr1 85703544 A C 2.31E-09 Serum dimethylarginine levels (asymmetric) / / 24159190 rs7515154 chr1 85704435 C T 1.99E-05 Anxiety and major depressive disorder / / 24047446 rs10747317 chr1 85705346 G A 3.28E-04 Alzheimer's disease / / 22005930 rs6663690 chr1 85705801 C T 1.20E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs60156243 chr1 85706839 C T 1.09E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10782544 chr1 85707253 T C 1.98E-07 Serum dimethylarginine levels (symmetric) / / 24159190 rs4949892 chr1 85707822 C T 1.03E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs11577656 chr1 85708279 C T 1.66E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12065422 chr1 85715978 C G 5.70E-04 Lymphocyte counts C1orf52 UTR-3 22286170 rs10158486 chr1 85720007 T C 2.59E-06 Serum dimethylarginine levels (asymmetric) C1orf52 intron 24159190 rs10158486 chr1 85720007 T C 4.32E-08 Serum dimethylarginine levels (symmetric) C1orf52 intron 24159190 rs10158486 chr1 85720007 T C 6.18E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) C1orf52 intron 24159190 rs11161570 chr1 85721911 T C 2.42E-06 Serum dimethylarginine levels (symmetric) C1orf52 intron 24159190 rs11161570 chr1 85721911 T C 4.37E-06 Serum dimethylarginine levels (asymmetric) C1orf52 intron 24159190 rs17382844 chr1 85723318 A G 1.73E-07 Serum dimethylarginine levels (asymmetric) C1orf52 intron 24159190 rs17382844 chr1 85723318 A G 4.28E-08 Serum dimethylarginine levels (symmetric) C1orf52 intron 24159190 rs17382844 chr1 85723318 A G 8.89E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) C1orf52 intron 24159190 rs4949926 chr1 85724328 C T 6.45E-07 Serum dimethylarginine levels (asymmetric) C1orf52 cds-synon 24159190 rs71652692 chr1 85725426 G T 1.00E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs71652692 chr1 85725426 G T 1.17E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs71652692 chr1 85725426 G T 3.02E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161574 chr1 85727044 T C 2.73E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10493763 chr1 85727218 T C 1.73E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10493763 chr1 85727218 T C 4.66E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs10493763 chr1 85727218 T C 9.55E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs2647395 chr1 85728664 C G 8.92E-07 Serum dimethylarginine levels (symmetric) / / 24159190 rs2647394 chr1 85729987 A G 4.87E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs10873697 chr1 85730575 G A 1.29E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs10873697 chr1 85730575 G A 5.86E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12126112 chr1 85730595 C T 1.78E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs12126112 chr1 85730595 C T 6.29E-08 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12126112 chr1 85730595 C T 8.54E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs113428154 chr1 85730627 T C 2.63E-10 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12126141 chr1 85730696 C T 2.04E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs12126141 chr1 85730696 C T 4.53E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs12126141 chr1 85730696 C T 6.37E-08 Serum dimethylarginine levels (asymmetric) / / 24159190 rs2735590 chr1 85731310 T C 2.32E-06 Serum dimethylarginine levels (symmetric) BCL10 nearGene-3 24159190 rs1060846 chr1 85732065 A G 3.23E-06 Serum dimethylarginine levels (symmetric) BCL10 UTR-3 24159190 rs962409 chr1 85732941 A C 3.43E-06 Serum dimethylarginine levels (symmetric) BCL10 UTR-3 24159190 rs2252408 chr1 85733929 C T 2.20E-07 Serum dimethylarginine levels (asymmetric) BCL10 intron 24159190 rs12134420 chr1 85738308 C T 4.80E-08 Serum dimethylarginine levels (symmetric) BCL10 intron 24159190 rs144541104 chr1 85739751 T C 1.24E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) BCL10 intron 24159190 rs144541104 chr1 85739751 T C 5.91E-10 Serum dimethylarginine levels (asymmetric) BCL10 intron 24159190 rs2735594 chr1 85741921 G C 1.62E-07 Serum dimethylarginine levels (asymmetric) BCL10 intron 24159190 rs78416998 chr1 85742155 G A 1.86E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) BCL10 UTR-5 24159190 rs78416998 chr1 85742155 G A 1.93E-08 Serum dimethylarginine levels (asymmetric) BCL10 UTR-5 24159190 rs2735593 chr1 85742338 G C 1.61E-07 Serum dimethylarginine levels (asymmetric) LOC646626 missense 24159190 rs11555520 chr1 85743452 G A 6.79E-05 Body Mass Index LOC646626 UTR-3 pha003009 rs12136214 chr1 85745566 C T 3.51E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs116057745 chr1 85746632 A G 1.63E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs6698331 chr1 85746929 T C 3.28E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs6693365 chr1 85749715 C G 2.22E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs2133183 chr1 85750598 C T 1.01E-10 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12729231 chr1 85754207 C T 2.62E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161584 chr1 85755127 A G 6.04E-08 Serum dimethylarginine levels (asymmetric) / / 24159190 rs6668948 chr1 85757406 T C 1.30E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs12757160 chr1 85759668 A G 3.33E-09 Serum dimethylarginine levels (symmetric) / / 24159190 rs12757160 chr1 85759668 A G 6.25E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs34743622 chr1 85760353 A G 1.43E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs12754032 chr1 85760508 T C 2.50E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs35654640 chr1 85760543 T TG 3.79E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs57483398 chr1 85760543 T C 3.79E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs141922542 chr1 85761234 G A 2.38E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs141922542 chr1 85761234 G A 2.81E-11 Serum dimethylarginine levels (asymmetric) / / 24159190 rs11161585 chr1 85761663 G C 9.53E-04 Alzheimer's disease / / 22005930 rs11161585 chr1 85761663 G C 1.49E-07 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161586 chr1 85761786 T C 1.31E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11590047 chr1 85763154 C T 1.22E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161588 chr1 85763861 G A 1.19E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs2030075 chr1 85763899 C T 5.28E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs34983308 chr1 85764134 G A 1.35E-09 Serum dimethylarginine levels (asymmetric) / / 24159190 rs34983308 chr1 85764134 G A 6.37E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs11161589 chr1 85764886 A G 5.28E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161590 chr1 85764998 A G 5.30E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs10782547 chr1 85765293 C G 5.28E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11583827 chr1 85765682 G C 1.23E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11587512 chr1 85765798 A G 6.43E-05 Serum metabolites / / 19043545 rs11587512 chr1 85765798 A G 1.24E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161591 chr1 85765990 C T 1.46E-11 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161592 chr1 85766230 C A 1.18E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs7554249 chr1 85767794 C T 2.98E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs7554249 chr1 85767794 C T 6.37E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs186590599 chr1 85768633 G C 2.33E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs186590599 chr1 85768633 G C 2.80E-11 Serum dimethylarginine levels (asymmetric) / / 24159190 rs61771982 chr1 85768644 G A 5.29E-07 Serum dimethylarginine levels (symmetric) / / 24159190 rs12093484 chr1 85768860 A G 1.02E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs17125445 chr1 85769032 C T 1.01E-06 Serum dimethylarginine levels (symmetric) / / 24159190 rs11585614 chr1 85770620 T C 9.69E-08 Serum dimethylarginine levels (symmetric) / / 24159190 rs2012099 chr1 85771452 C T 8.21E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs2012099 chr1 85771452 C T 9.22E-07 Serum dimethylarginine levels (symmetric) / / 24159190 rs233100 chr1 85772009 G A 1.00E-06 Multiple sclerosis / / 21833088 rs233101 chr1 85772334 A G 2.01E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs233101 chr1 85772334 A G 6.21E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs233102 chr1 85772701 C A 2.08E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs233102 chr1 85772701 C A 6.19E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs138851971 chr1 85774687 G A 1.70E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs138851971 chr1 85774687 G A 3.62E-11 Serum dimethylarginine levels (asymmetric) / / 24159190 rs35240561 chr1 85775217 C G 1.00E-13 Serum dimethylarginine levels (symmetric) / / 24159190 rs35240561 chr1 85775217 C G 2.21E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs35240561 chr1 85775217 C G 5.65E-10 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12047189 chr1 85775448 A C 4.26E-11 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12122154 chr1 85775865 C T 8.53E-04 Alzheimer's disease / / 22005930 rs4949897 chr1 85776121 G C 9.33E-11 Serum dimethylarginine levels (asymmetric) / / 24159190 rs34561661 chr1 85777250 C T 1.48E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs34561661 chr1 85777250 C T 2.30E-13 Serum dimethylarginine levels (symmetric) / / 24159190 rs34561661 chr1 85777250 C T 8.80E-12 Serum dimethylarginine levels (asymmetric) / / 24159190 rs72722663 chr1 85777534 T G 7.90E-12 Serum dimethylarginine levels (asymmetric) / / 24159190 rs4949889 chr1 85778344 G A 5.18E-12 Serum dimethylarginine levels (asymmetric) / / 24159190 rs1874807 chr1 85779393 G A 1.62E-04 Alzheimer's disease / / 22005930 rs1874807 chr1 85779393 G A 4.60E-10 Serum dimethylarginine levels (symmetric) / / 24159190 rs72722665 chr1 85780781 T C 1.46E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs72722665 chr1 85780781 T C 2.96E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12042780 chr1 85780903 A G 2.41E-15 Serum dimethylarginine levels (asymmetric) / / 24159190 rs233108 chr1 85781720 C T 2.54E-18 Serum dimethylarginine levels (symmetric) / / 24159190 rs233108 chr1 85781720 C T 3.12E-08 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10489510 chr1 85782571 C G 8.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs10489510 chr1 85782571 C G 6.42E-04 Menopause (age at onset) / / 22267201 rs10489510 chr1 85782571 C G 1.17E-15 Serum dimethylarginine levels (asymmetric) / / 24159190 rs233109 chr1 85783101 T C 2.38E-18 Serum dimethylarginine levels (symmetric) / / 24159190 rs233109 chr1 85783101 T C 4.30E-06 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12138621 chr1 85783970 T C 1.08E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs12138621 chr1 85783970 T C 4.52E-13 Serum dimethylarginine levels (asymmetric) / / 24159190 rs12138621 chr1 85783970 T C 6.12E-14 Serum dimethylarginine levels (symmetric) / / 24159190 rs11161597 chr1 85784936 G A 1.12E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 UTR-3 24159190 rs11161597 chr1 85784936 G A 4.21E-13 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs11161597 chr1 85784936 G A 6.25E-14 Serum dimethylarginine levels (symmetric) DDAH1 UTR-3 24159190 rs233111 chr1 85785655 T C 1.20E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 UTR-3 24159190 rs233111 chr1 85785655 T C 3.65E-06 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs233112 chr1 85785751 T C 1.54E-06 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs233112 chr1 85785751 T C 4.39E-18 Serum dimethylarginine levels (symmetric) DDAH1 UTR-3 24159190 rs3813600 chr1 85786166 G A 3.33E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 UTR-3 24159190 rs3813600 chr1 85786166 G A 8.88E-08 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs233113 chr1 85786299 T A 3.22E-08 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs233113 chr1 85786299 T A 3.52E-18 Serum dimethylarginine levels (symmetric) DDAH1 UTR-3 24159190 rs233114 chr1 85786957 T G 3.18E-08 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs233114 chr1 85786957 T G 3.50E-18 Serum dimethylarginine levels (symmetric) DDAH1 UTR-3 24159190 rs233115 chr1 85786977 G A 3.13E-08 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs233115 chr1 85786977 G A 3.46E-18 Serum dimethylarginine levels (symmetric) DDAH1 UTR-3 24159190 rs3087894 chr1 85787118 G C 3.10E-08 Serum dimethylarginine levels (asymmetric) DDAH1 UTR-3 24159190 rs3087894 chr1 85787118 G C 3.44E-18 Serum dimethylarginine levels (symmetric) DDAH1 UTR-3 24159190 rs1498375 chr1 85787323 T A 3.09E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1498375 chr1 85787323 T A 3.43E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1498374 chr1 85787334 C T 3.11E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1498374 chr1 85787334 C T 4.11E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1498374 chr1 85787334 C T 6.76E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233118 chr1 85787967 T C 2.99E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233118 chr1 85787967 T C 4.46E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233119 chr1 85788052 T C 3.15E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233119 chr1 85788052 T C 3.44E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233120 chr1 85788490 A C 1.03E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233120 chr1 85788490 A C 8.32E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2300633 chr1 85788826 A G 2.31E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140272 chr1 85789757 G A 3.50E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12140272 chr1 85789757 G A 6.59E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140272 chr1 85789757 G A 7.09E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233121 chr1 85789913 G A 3.47E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233121 chr1 85789913 G A 3.56E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1498373 chr1 85790633 G A 3.58E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1498373 chr1 85790633 G A 3.63E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72722671 chr1 85791003 T C 1.50E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2300634 chr1 85791257 T C 3.57E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2300634 chr1 85791257 T C 3.82E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233124 chr1 85791658 T C 3.18E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233124 chr1 85791658 T C 5.21E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2284797 chr1 85792383 C T 1.11E-11 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2284797 chr1 85792383 C T 1.25E-16 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2284797 chr1 85792383 C T 1.72E-17 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12122816 chr1 85792384 C T 1.11E-11 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12122816 chr1 85792384 C T 1.26E-16 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12122816 chr1 85792384 C T 1.76E-17 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2268667 chr1 85793746 G A 3.68E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2268667 chr1 85793746 G A 3.90E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233127 chr1 85793801 A G 3.69E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233127 chr1 85793801 A G 3.71E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233128 chr1 85794413 G C 4.06E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233128 chr1 85794413 G C 8.04E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs18582 chr1 85794819 A G 2.39E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs18582 chr1 85794819 A G 3.30E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233130 chr1 85795112 T C 2.39E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233130 chr1 85795112 T C 3.30E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233131 chr1 85795259 G A 2.38E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233131 chr1 85795259 G A 3.30E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs731194 chr1 85795951 G A 3.06E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161599 chr1 85795965 G A 1.07E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11161599 chr1 85795965 G A 1.20E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161599 chr1 85795965 G A 6.34E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs423105 chr1 85796427 A G 2.33E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs423105 chr1 85796427 A G 3.35E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233132 chr1 85796545 A G 2.32E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233132 chr1 85796545 A G 3.37E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233133 chr1 85796557 G T 2.12E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233133 chr1 85796557 G T 3.16E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs28489187 chr1 85797110 A G 1.00E-20 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs28489187 chr1 85797110 A G 1.00E-40 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs761601 chr1 85797298 A G 2.19E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs761601 chr1 85797298 A G 3.57E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2474121 chr1 85798038 G A 2.46E-23 Narcolepsy DDAH1 intron 19629137 rs2389913 chr1 85798075 T C 3.96E-04 Multiple complex diseases DDAH1 intron 17554300 rs12121675 chr1 85798484 A G 3.40E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12121675 chr1 85798484 A G 7.82E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12121675 chr1 85798484 A G 9.04E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs233055 chr1 85798486 A C 7.21E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs233055 chr1 85798486 A C 8.58E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233055 chr1 85798486 A C 9.67E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233057 chr1 85798855 T C 2.03E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233057 chr1 85798855 T C 3.83E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233058 chr1 85798865 G T 2.02E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233058 chr1 85798865 G T 3.86E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233059 chr1 85798936 G A 2.01E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233059 chr1 85798936 G A 3.88E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233060 chr1 85798943 C T 2.00E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233060 chr1 85798943 C T 3.91E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233061 chr1 85799282 G A 2.41E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233061 chr1 85799282 G A 2.85E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72722677 chr1 85800179 G A 5.47E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72722677 chr1 85800179 G A 8.94E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs233062 chr1 85800385 T G 2.62E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233062 chr1 85800385 T G 6.30E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs3768227 chr1 85804087 A G 1.77E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs3768227 chr1 85804087 A G 4.44E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs173026 chr1 85804249 G A 1.76E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs173026 chr1 85804249 G A 4.47E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs190804399 chr1 85804743 A T 2.76E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs190804399 chr1 85804743 A T 3.02E-20 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12754297 chr1 85804745 A T 1.93E-19 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12754297 chr1 85804745 A T 4.28E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12754297 chr1 85804745 A T 4.54E-06 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs566641032 chr1 85804745 A AT 1.93E-19 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs566641032 chr1 85804745 A AT 4.28E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs566641032 chr1 85804745 A AT 4.54E-06 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs74599242 chr1 85804747 T A 4.42E-08 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12035116 chr1 85804837 C T 1.03E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233066 chr1 85804930 T C 1.51E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233066 chr1 85804930 T C 4.95E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233067 chr1 85804978 C G 1.49E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233067 chr1 85804978 C G 4.92E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233068 chr1 85805355 G A 2.21E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233068 chr1 85805355 G A 3.27E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233069 chr1 85805466 C T 1.40E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233069 chr1 85805466 C T 5.71E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233071 chr1 85806005 C T 1.39E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233071 chr1 85806005 C T 5.78E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233072 chr1 85807695 A G 2.18E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233072 chr1 85807695 A G 3.58E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233072 chr1 85807695 A G 2.50E-04 Renal cell carcinoma DDAH1 intron 24220910 rs12717763 chr1 85808164 T A 1.25E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12717763 chr1 85808164 T A 2.61E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12717763 chr1 85808164 T A 4.61E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233074 chr1 85809065 T C 1.36E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233074 chr1 85809065 T C 6.33E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs3768223 chr1 85809183 T C 1.24E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs3768223 chr1 85809183 T C 2.67E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs3768223 chr1 85809183 T C 4.73E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12120551 chr1 85810903 T C 1.26E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12120551 chr1 85810903 T C 2.51E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12120551 chr1 85810903 T C 4.56E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12124170 chr1 85811182 A G 1.34E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12124170 chr1 85811182 A G 6.48E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs4949898 chr1 85811652 A G 5.29E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233080 chr1 85814552 A G 5.59E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs233080 chr1 85814552 A G 5.81E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2284800 chr1 85815610 T C 1.66E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2284800 chr1 85815610 T C 2.74E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2230820 chr1 85816134 T C 1.33E-13 Serum dimethylarginine levels (symmetric) DDAH1 cds-synon 24159190 rs2230820 chr1 85816134 T C 2.12E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 cds-synon 24159190 rs2230820 chr1 85816134 T C 3.75E-14 Serum dimethylarginine levels (asymmetric) DDAH1 cds-synon 24159190 rs41301261 chr1 85816224 G A 1.48E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs41301261 chr1 85816224 G A 2.33E-06 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs41301261 chr1 85816224 G A 6.89E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2076699 chr1 85817295 G A 4.45E-05 Cognitive performance DDAH1 intron 19734545 rs2076699 chr1 85817295 G A 1.38E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2076699 chr1 85817295 G A 2.13E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2076699 chr1 85817295 G A 4.42E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs180841827 chr1 85817542 A G 1.60E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233087 chr1 85821000 T C 1.68E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233087 chr1 85821000 T C 6.99E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2300637 chr1 85822772 T C 1.27E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2300637 chr1 85822772 T C 6.74E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233091 chr1 85823044 G C 1.24E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233091 chr1 85823044 G C 6.69E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233093 chr1 85823120 G A 1.24E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233093 chr1 85823120 G A 6.74E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2300639 chr1 85823676 T A 1.39E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2300639 chr1 85823676 T A 2.19E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2300639 chr1 85823676 T A 3.89E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2300640 chr1 85823795 C G 1.40E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2300640 chr1 85823795 C G 2.27E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2300640 chr1 85823795 C G 4.13E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233095 chr1 85824816 T C 1.23E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233095 chr1 85824816 T C 6.86E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233097 chr1 85825473 G C 2.12E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233097 chr1 85825473 G C 4.33E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233099 chr1 85826194 T C 1.17E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233099 chr1 85826194 T C 6.88E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2474123 chr1 85827452 G A 1.08E-16 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs7520993 chr1 85828090 A C 2.08E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7520993 chr1 85828090 A C 2.29E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12130145 chr1 85828970 G C 1.42E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12130145 chr1 85828970 G C 2.03E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12130145 chr1 85828970 G C 3.60E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233046 chr1 85829405 A G 2.37E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233046 chr1 85829405 A G 2.53E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs111820059 chr1 85830429 G A 4.53E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs111820059 chr1 85830429 G A 8.21E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs233047 chr1 85830570 G A 1.22E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233047 chr1 85830570 G A 6.88E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs4949890 chr1 85830632 T C 2.31E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs4949890 chr1 85830632 T C 9.38E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs66811655 chr1 85831544 T G 4.71E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs66811655 chr1 85831544 T G 6.67E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12038426 chr1 85831790 A C 1.03E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs71652696 chr1 85831792 A C 1.39E-15 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs71652696 chr1 85831792 A C 1.99E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs71652696 chr1 85831792 A C 9.80E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs75481609 chr1 85834202 G C 3.02E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs141923044 chr1 85835078 G A 4.94E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs141923044 chr1 85835078 G A 6.26E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12758768 chr1 85835206 C T 4.60E-15 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12758768 chr1 85835206 C T 7.08E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12758768 chr1 85835206 C T 8.19E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72722691 chr1 85835439 T C 1.33E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs79695640 chr1 85836073 T C 3.94E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs79695640 chr1 85836073 T C 5.06E-15 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs79695640 chr1 85836073 T C 9.99E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs986639 chr1 85836392 G C 2.07E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs986639 chr1 85836392 G C 3.52E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs986639 chr1 85836392 G C 4.53E-08 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1498377 chr1 85836436 G A 1.54E-07 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72722692 chr1 85837169 G C 8.05E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233050 chr1 85837793 T C 3.69E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233050 chr1 85837793 T C 7.25E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs4949899 chr1 85838237 G A,T 2.46E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233051 chr1 85838413 G A 1.04E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs233051 chr1 85838413 G A 2.86E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs140056707 chr1 85838505 T G 2.93E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233053 chr1 85839507 G A 1.44E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs233053 chr1 85839507 G A 2.67E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233054 chr1 85840191 T G 3.61E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs233054 chr1 85840191 T G 7.05E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1391556 chr1 85841056 C G 2.02E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2012683 chr1 85841485 C T 3.54E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2012683 chr1 85841485 C T 6.87E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12139958 chr1 85842112 A G 2.39E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12139958 chr1 85842112 A G 3.78E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12139958 chr1 85842112 A G 5.73E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72722697 chr1 85843863 G C 2.56E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2064510 chr1 85844330 G C 1.60E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs729655 chr1 85844617 A C 1.88E-16 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs729655 chr1 85844617 A C 4.43E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs729655 chr1 85844617 A C 6.72E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2011825 chr1 85844671 T C 2.26E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2011825 chr1 85844671 T C 4.31E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs4512701 chr1 85844835 G A 1.51E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs4631749 chr1 85844852 T C 1.49E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs997251 chr1 85845367 T C 3.42E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs997251 chr1 85845367 T C 6.28E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs41289749 chr1 85845872 A G 2.35E-17 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs41289749 chr1 85845872 A G 3.31E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs41289749 chr1 85845872 A G 7.51E-07 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1884139 chr1 85845998 G T 1.00E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1884139 chr1 85845998 G T 2.22E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12044537 chr1 85846385 T A 1.43E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12044537 chr1 85846385 T A 3.04E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs67611930 chr1 85846592 A G 3.29E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs67611930 chr1 85846592 A G 6.00E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2207368 chr1 85847683 A G 3.29E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2207368 chr1 85847683 A G 5.51E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12568573 chr1 85848821 T C 1.05E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12568573 chr1 85848821 T C 2.31E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12047422 chr1 85848830 T G 3.23E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12047422 chr1 85848830 T G 5.58E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs3920521 chr1 85848866 A C 1.49E-16 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs3920521 chr1 85848866 A C 1.65E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11588128 chr1 85848998 G A 1.05E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11588128 chr1 85848998 G A 2.32E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140103 chr1 85849489 G A 8.46E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12140103 chr1 85849489 G A 9.50E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140170 chr1 85849723 G A 1.28E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12140170 chr1 85849723 G A 3.58E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140170 chr1 85849723 G A 5.21E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72724606 chr1 85850246 T C 3.20E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72724606 chr1 85850246 T C 5.45E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72724608 chr1 85852755 A G 1.25E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72724608 chr1 85852755 A G 4.29E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs36110608 chr1 85852936 A C 1.00E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs36110608 chr1 85852936 A C 4.37E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs36110608 chr1 85852936 A C 7.49E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161606 chr1 85853902 T C 3.84E-04 Alzheimer's disease DDAH1 intron 22005930 rs11161606 chr1 85853902 T C 1.59E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161606 chr1 85853902 T C 8.93E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10782548 chr1 85855098 T A 1.48E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10782548 chr1 85855098 T A 7.70E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs10489513 chr1 85855622 A G 3.75E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10489513 chr1 85855622 A G 7.28E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140935 chr1 85855716 G A 1.09E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12140935 chr1 85855716 G A 4.97E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12140935 chr1 85855716 G A 6.68E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161607 chr1 85855855 T C 1.92E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161607 chr1 85855855 T C 3.03E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72724610 chr1 85856396 G C 1.72E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1342323 chr1 85857574 A T 9.59E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs77529889 chr1 85857838 A G 3.29E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12033483 chr1 85858123 C T 9.67E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6576761 chr1 85858274 G A 1.10E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6576761 chr1 85858274 G A 5.03E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6671599 chr1 85858857 T C 2.82E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6671599 chr1 85858857 T C 5.45E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs35193119 chr1 85859265 T C 4.73E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs35193119 chr1 85859265 T C 4.78E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs35193119 chr1 85859265 T C 7.72E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs6576763 chr1 85859376 T C 1.13E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6576763 chr1 85859376 T C 2.09E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs7515261 chr1 85859804 C T 1.20E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10747318 chr1 85859910 A G 1.27E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12140457 chr1 85860170 G A 3.78E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12140457 chr1 85860170 G A 4.28E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12140457 chr1 85860170 G A 4.52E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10873701 chr1 85860374 C T 1.31E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs4949900 chr1 85861034 T G 2.72E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs4949900 chr1 85861034 T G 5.25E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs4428939 chr1 85861564 A G 1.42E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2177461 chr1 85861976 C G 2.60E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2177461 chr1 85861976 C G 5.16E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12564698 chr1 85862711 C A 1.09E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12564698 chr1 85862711 C A 1.97E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161609 chr1 85862736 G T 2.09E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs3949301 chr1 85863383 G A 2.56E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs3949301 chr1 85863383 G A 5.37E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12034249 chr1 85864391 C T 2.47E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12118950 chr1 85864519 T C 2.41E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12118950 chr1 85864519 T C 3.74E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12118950 chr1 85864519 T C 3.88E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161610 chr1 85865896 C T 1.08E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161610 chr1 85865896 C T 1.24E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161610 chr1 85865896 C T 3.62E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2892888 chr1 85866147 A G 3.80E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2892888 chr1 85866147 A G 7.11E-10 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2892888 chr1 85866147 A G 7.85E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs6576764 chr1 85866411 A T 2.48E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6576764 chr1 85866411 A T 5.28E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12125557 chr1 85867406 A G 1.99E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12125557 chr1 85867406 A G 2.32E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6704103 chr1 85868657 C A 2.50E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6704103 chr1 85868657 C A 4.00E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161611 chr1 85868679 C A 2.38E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161611 chr1 85868679 C A 5.39E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1357635 chr1 85868798 A G 9.48E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1357636 chr1 85869042 A C 5.63E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12758237 chr1 85870783 G A 1.57E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12758237 chr1 85870783 G A 2.29E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12758237 chr1 85870783 G A 3.30E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6576765 chr1 85871012 A T 1.13E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6576765 chr1 85871012 A T 1.66E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12133722 chr1 85873237 C T 1.52E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12133722 chr1 85873237 C T 1.63E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12133722 chr1 85873237 C T 4.52E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12564550 chr1 85874205 A C 1.16E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12564550 chr1 85874205 A C 2.51E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6657732 chr1 85874495 C T 3.11E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6657732 chr1 85874495 C T 3.16E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6657817 chr1 85874614 C T 1.66E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6657817 chr1 85874614 C T 3.66E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6576766 chr1 85876218 A G 1.11E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6576766 chr1 85876218 A G 7.53E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6576767 chr1 85876316 G A 1.68E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6576767 chr1 85876316 G A 3.72E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs6576767 chr1 85876316 G A 4.79E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs17127199 chr1 85876355 T C 1.08E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs17127199 chr1 85876355 T C 2.36E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1554597 chr1 85877098 C T 1.40E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1554597 chr1 85877098 C T 3.22E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12138852 chr1 85878208 C T 2.93E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12138852 chr1 85878208 C T 4.37E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12138852 chr1 85878208 C T 4.98E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1001604 chr1 85879524 C G 2.13E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1001604 chr1 85879524 C G 3.05E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12132677 chr1 85879613 A C 3.08E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12132677 chr1 85879613 A C 3.84E-12 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12132677 chr1 85879613 A C 4.91E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs7532508 chr1 85880468 C G 3.33E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7532508 chr1 85880468 C G 7.51E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs7546931 chr1 85880976 T C 6.88E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10782549 chr1 85881278 T G 6.39E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs56215900 chr1 85881759 T G 1.06E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs56215900 chr1 85881759 T G 2.28E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2016104 chr1 85882871 G A 7.83E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1975755 chr1 85882905 A G 2.09E-04 Alzheimer's disease DDAH1 intron 22005930 rs1975755 chr1 85882905 A G 6.90E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1006988 chr1 85883320 C G 2.05E-04 Alzheimer's disease DDAH1 intron 22005930 rs7525786 chr1 85884076 C T 8.87E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs7547571 chr1 85884091 G T 1.84E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7547571 chr1 85884091 G T 5.10E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10873702 chr1 85884101 T C 7.81E-05 Alzheimer's disease DDAH1 intron 22005930 rs10873702 chr1 85884101 T C 6.85E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs61783046 chr1 85884365 G A 5.31E-08 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2124139 chr1 85884370 T C 7.50E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs17384213 chr1 85884621 G A 7.49E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12123745 chr1 85884772 T C 2.71E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12123745 chr1 85884772 T C 3.49E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12123745 chr1 85884772 T C 4.15E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1965876 chr1 85885178 A G 7.45E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1608537 chr1 85885731 C G 7.42E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1608536 chr1 85885836 C T 2.40E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1608536 chr1 85885836 C T 2.54E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1608536 chr1 85885836 C T 2.93E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2840319 chr1 85886224 C T 1.93E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2840319 chr1 85886224 C T 3.84E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6697083 chr1 85887775 A T 1.99E-04 Alzheimer's disease DDAH1 intron 22005930 rs6697083 chr1 85887775 A T 1.59E-17 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6697083 chr1 85887775 A T 1.72E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6420965 chr1 85888480 C T 3.63E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1523995 chr1 85888986 A C 1.74E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7521189 chr1 85889596 G A 5.43E-04 Alzheimer's disease DDAH1 intron 22005930 rs7521189 chr1 85889596 G A 7.71E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12135333 chr1 85890494 C A 2.41E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12135333 chr1 85890494 C A 2.94E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12135333 chr1 85890494 C A 2.98E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1523994 chr1 85890726 G A 2.17E-04 Alzheimer's disease DDAH1 intron 22005930 rs1523994 chr1 85890726 G A 7.10E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12128907 chr1 85891385 A G 3.36E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12128907 chr1 85891385 A G 5.45E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12128907 chr1 85891385 A G 6.12E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs6672870 chr1 85891457 G T 7.10E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12129013 chr1 85891709 A C 5.27E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12129013 chr1 85891709 A C 7.00E-12 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs2389948 chr1 85892383 C G 8.16E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72724632 chr1 85892717 C T 1.03E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs72724632 chr1 85892717 C T 2.29E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7540393 chr1 85893728 C T 7.67E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12131926 chr1 85893955 A G 1.19E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12131926 chr1 85893955 A G 1.29E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12131926 chr1 85893955 A G 4.79E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12029221 chr1 85893977 G C 1.92E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146374 chr1 85894027 G A 1.45E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs561614 chr1 85894864 G A 2.32E-17 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs561422 chr1 85894932 T A 4.65E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146377 chr1 85895609 C T 5.27E-17 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs146482999 chr1 85895652 G A 1.24E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs146482999 chr1 85895652 G A 2.28E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12125900 chr1 85895781 G A 3.15E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12125900 chr1 85895781 G A 3.23E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12125900 chr1 85895781 G A 5.18E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146378 chr1 85895820 G A 1.72E-20 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146379 chr1 85896551 T C 1.31E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1146379 chr1 85896551 T C 6.21E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12743049 chr1 85897386 G A 1.24E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12743049 chr1 85897386 G A 2.47E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12743049 chr1 85897386 G A 2.67E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs17384381 chr1 85897570 C G 1.23E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs17384381 chr1 85897570 C G 2.46E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs17384381 chr1 85897570 C G 2.66E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11582061 chr1 85897781 G C 2.20E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11582061 chr1 85897781 G C 9.72E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs17388521 chr1 85897904 G A 2.21E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs17388521 chr1 85897904 G A 7.87E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs17388521 chr1 85897904 G A 8.02E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161614 chr1 85898160 T G 8.58E-04 Alcohol dependence DDAH1 intron 21314694 rs11161614 chr1 85898160 T G 3.34E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161614 chr1 85898160 T G 4.89E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11161614 chr1 85898160 T G 6.50E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs35956189 chr1 85898461 G A,T 8.46E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs990916 chr1 85898508 A G 1.42E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1523993 chr1 85899128 C T 6.44E-06 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1523993 chr1 85899128 C T 6.03E-05 Neuroblastoma DDAH1 intron pha002895 rs506082 chr1 85899215 A C 1.90E-18 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs506082 chr1 85899215 A C 8.32E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs669173 chr1 85899428 T C 1.14E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs669173 chr1 85899428 T C 2.60E-08 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12129502 chr1 85900727 T C 2.55E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12129502 chr1 85900727 T C 2.88E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12129502 chr1 85900727 T C 6.24E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs34749578 chr1 85900964 A G 1.16E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs34749578 chr1 85900964 A G 7.78E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12130380 chr1 85901309 T C 1.15E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12130380 chr1 85901309 T C 1.67E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12130380 chr1 85901309 T C 4.06E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12736004 chr1 85901367 G A 2.69E-14 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12736004 chr1 85901367 G A 3.50E-13 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12736004 chr1 85901367 G A 6.92E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs570121 chr1 85901598 C T 7.99E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs3851268 chr1 85901887 T A 7.97E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs483530 chr1 85901919 A T 9.05E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs71582955 chr1 85901919 AT A 9.05E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs539714 chr1 85904338 C T 2.15E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12130591 chr1 85904985 G A 6.99E-05 Cognitive performance DDAH1 intron 19734545 rs12130591 chr1 85904985 G A 3.68E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12130591 chr1 85904985 G A 3.90E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12130591 chr1 85904985 G A 5.24E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs591917 chr1 85905136 A G 3.68E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs591917 chr1 85905136 A G 6.15E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs17388696 chr1 85905427 G A 1.66E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs604974 chr1 85905705 A G 1.20E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12724823 chr1 85906385 G T 2.18E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12724823 chr1 85906385 G T 3.65E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12724823 chr1 85906385 G T 4.12E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs75778210 chr1 85906730 T C 2.18E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs75778210 chr1 85906730 T C 3.88E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11161615 chr1 85906816 G A 1.99E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11161615 chr1 85906816 G A 3.21E-11 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161616 chr1 85907625 C T 1.27E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11161616 chr1 85907625 C T 3.40E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161616 chr1 85907625 C T 3.77E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs499869 chr1 85907851 A T 1.36E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1261681 chr1 85908282 A G 9.07E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1240939 chr1 85908649 T G 1.01E-15 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10782550 chr1 85908784 T C 1.35E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs10782550 chr1 85908784 T C 2.04E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10782550 chr1 85908784 T C 8.71E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs661686 chr1 85909210 T C 5.13E-16 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs4949904 chr1 85909275 C T 3.18E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs4949904 chr1 85909275 C T 9.03E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs34278923 chr1 85909708 G A 3.14E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs34278923 chr1 85909708 G A 9.70E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12034839 chr1 85910777 G A 8.57E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12034839 chr1 85910777 G A 9.00E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12049529 chr1 85910893 C A 2.72E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12049529 chr1 85910893 C A 4.06E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12049529 chr1 85910893 C A 6.53E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs28529751 chr1 85910951 G A 1.83E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs28529751 chr1 85910951 G A 5.80E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs28529751 chr1 85910951 G A 8.23E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1146381 chr1 85911290 A G 2.43E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1146381 chr1 85911290 A G 8.81E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2124140 chr1 85912143 G T 1.36E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs600098 chr1 85912584 T C 2.38E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs530006 chr1 85913508 G T 6.85E-04 Alzheimer's disease DDAH1 intron 22005930 rs530006 chr1 85913508 G T 8.13E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11161617 chr1 85913538 T C 3.25E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11161617 chr1 85913538 T C 4.69E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161617 chr1 85913538 T C 4.77E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs72724639 chr1 85913632 C G 8.72E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs631817 chr1 85913740 T C 2.67E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs648216 chr1 85915057 C A 1.16E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs648216 chr1 85915057 C A 5.79E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs648310 chr1 85915134 T C 1.24E-06 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs648310 chr1 85915134 T C 3.84E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs659070 chr1 85915149 A G 2.66E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11587876 chr1 85915183 T C 4.15E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12726532 chr1 85915373 T C 2.73E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12726532 chr1 85915373 T C 3.36E-12 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12726532 chr1 85915373 T C 4.23E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11801146 chr1 85915374 C T 2.61E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs11801146 chr1 85915374 C T 3.33E-12 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs11801146 chr1 85915374 C T 4.13E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs35755993 chr1 85915374 C CT 2.61E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs35755993 chr1 85915374 C CT 3.33E-12 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs35755993 chr1 85915374 C CT 4.13E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2935 chr1 85917563 G A 7.11E-04 Myopia (pathological) DDAH1 intron 21095009 rs2935 chr1 85917563 G A 2.61E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs2935 chr1 85917563 G A 3.16E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs17127710 chr1 85918009 C T 4.36E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146382 chr1 85918101 C T 3.46E-04 Alzheimer's disease DDAH1 intron 22005930 rs1146382 chr1 85918101 C T 2.09E-15 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs35761966 chr1 85918357 G A 1.30E-09 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs35761966 chr1 85918357 G A 2.13E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs35761966 chr1 85918357 G A 2.97E-13 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs56216312 chr1 85918454 C T 1.21E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs56216312 chr1 85918454 C T 5.84E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1146384 chr1 85919710 G A,C 1.79E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1146384 chr1 85919710 G A,C 6.00E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12717764 chr1 85920219 G C 5.78E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs67644506 chr1 85920734 G C 2.80E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs67644506 chr1 85920734 G C 2.92E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs191306675 chr1 85921067 G A 1.62E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs191306675 chr1 85921067 G A 3.10E-08 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs506733 chr1 85922661 C T 2.21E-06 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs506733 chr1 85922661 C T 4.83E-19 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs506733 chr1 85922661 C T 6.31E-11 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs36104818 chr1 85923472 G A 2.38E-10 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs877041 chr1 85923920 G A 1.69E-10 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs877041 chr1 85923920 G A 2.92E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs582145 chr1 85923999 T C 5.09E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs582145 chr1 85923999 T C 7.49E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs560090 chr1 85924255 A G 1.42E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs560090 chr1 85924255 A G 2.67E-08 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12568675 chr1 85924464 T C 1.92E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12568675 chr1 85924464 T C 5.77E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs597168 chr1 85925028 T C 3.66E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs974874 chr1 85925108 T G 1.18E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs974874 chr1 85925108 T G 4.89E-31 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs974874 chr1 85925108 T G 5.46E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs17389112 chr1 85925235 C T 4.87E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1523991 chr1 85925978 T G 3.37E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1523991 chr1 85925978 T G 3.55E-08 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs6658151 chr1 85926281 A T 4.71E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs61783057 chr1 85926726 G A 9.89E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs56154783 chr1 85926818 G C 2.13E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs56154783 chr1 85926818 G C 6.49E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12032315 chr1 85927407 C T 7.00E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146386 chr1 85927482 C T 1.23E-15 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146386 chr1 85927482 C T 5.11E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1146386 chr1 85927482 C T 6.20E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1241320 chr1 85928237 A C 1.11E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs4949905 chr1 85928564 T C 3.46E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs11161619 chr1 85928811 C T 9.69E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs529582 chr1 85929008 T C 7.89E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs527762 chr1 85929214 C A 5.42E-12 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12044882 chr1 85931014 G T 2.67E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs61223539 chr1 85931843 T C 1.25E-09 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs55639236 chr1 85932800 G A 3.39E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs55639236 chr1 85932800 G A 6.18E-07 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs149635670 chr1 85934276 C T 1.34E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs665091 chr1 85935422 T G 1.67E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs535723 chr1 85936622 T G 4.18E-10 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs7539880 chr1 85938435 T C 4.89E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7539880 chr1 85938435 T C 9.92E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs7547650 chr1 85938436 G A 4.87E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7547650 chr1 85938436 G A 9.93E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12060713 chr1 85938487 G A 5.04E-10 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2210073 chr1 85938561 T C 4.26E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs2210073 chr1 85938561 T C 9.69E-05 Height DDAH1 intron pha003011 rs7540169 chr1 85938736 T C 6.31E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12134668 chr1 85938882 C T 1.00E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12134668 chr1 85938882 C T 2.25E-32 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12134668 chr1 85938882 C T 9.32E-17 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs12134672 chr1 85938901 C A 1.06E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs12134672 chr1 85938901 C A 2.88E-32 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs12134672 chr1 85938901 C A 3.48E-16 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs10157640 chr1 85939177 C T 2.03E-13 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10157640 chr1 85939177 C T 3.77E-08 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10157643 chr1 85939250 C T 1.95E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10157643 chr1 85939250 C T 2.57E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs10157643 chr1 85939250 C T 3.37E-16 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7538364 chr1 85939350 A G 1.53E-15 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs7538364 chr1 85939350 A G 2.29E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs7538364 chr1 85939350 A G 2.56E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10158333 chr1 85939476 T C 1.07E-31 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10158333 chr1 85939476 T C 1.57E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10158333 chr1 85939476 T C 2.23E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs10157511 chr1 85939854 T G 1.13E-31 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs10157511 chr1 85939854 T G 1.25E-09 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs10157511 chr1 85939854 T G 6.34E-15 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs975880 chr1 85939935 C A 6.10E-06 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1403955 chr1 85940105 T G 1.24E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1403955 chr1 85940105 T G 3.13E-31 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1403955 chr1 85940105 T G 4.62E-11 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1403954 chr1 85940157 C T 1.27E-14 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1403954 chr1 85940157 C T 2.03E-30 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1403954 chr1 85940157 C T 5.44E-11 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1403951 chr1 85940249 C A 1.68E-10 Serum dimethylarginine levels (symmetric) DDAH1 intron 24159190 rs1403951 chr1 85940249 C A 3.66E-06 Serum dimethylarginine levels (asymmetric/symetric ratio) DDAH1 intron 24159190 rs1403951 chr1 85940249 C A 9.43E-14 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs72724655 chr1 85940875 C G 1.13E-11 Serum dimethylarginine levels (asymmetric) DDAH1 intron 24159190 rs1146395 chr1 85951597 T C 0.000713015 Hypertension (early onset hypertension) DDAH1 intron 22479346 rs2066357 chr1 85971357 G A 3.00E-04 Psoriasis DDAH1 intron 20953189 rs677691 chr1 85974030 A C 4.85E-04 Suicide attempts in bipolar disorder DDAH1 intron 21423239 rs577177 chr1 85995113 A G 3.00E-04 Response to statin treatment (atorvastatin),change in cholesterol levels DDAH1 intron 20031582 rs17099678 chr1 86006208 C T 7.94E-04 Alzheimer's disease DDAH1 intron 17998437 rs17099679 chr1 86008398 A G 6.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) DDAH1 intron 23648065 rs12734233 chr1 86008536 G A 6.63E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) DDAH1 intron 23648065 rs17127884 chr1 86021696 G A 4.93E-04 Multiple complex diseases DDAH1 intron 17554300 rs7543409 chr1 86049823 C T 2.20E-06 Urinary metabolites / / 21572414 rs6576779 chr1 86061662 C T 3.20E-06 Urinary metabolites / / 21572414 rs11578464 chr1 86072408 T G 1.40E-05 Urinary metabolites / / 21572414 rs12566306 chr1 86074635 C A 1.47E-05 Cognitive impairment induced by topiramate / / 22091778 rs1999186 chr1 86085545 G A 6.51E-04 Alcohol dependence / / 24277619 rs143554335 chr1 86105750 C T 6.48E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) / / 24159190 rs2970548 chr1 86118447 A G 9.64E-04 Multiple complex diseases ZNHIT6 UTR-3 17554300 rs3753786 chr1 86175554 A G 2.00E-05 Urinary metabolites / / 21572414 rs6672312 chr1 86176188 C T 2.80E-05 Urinary metabolites / / 21572414 rs2389972 chr1 86190666 A G 0.000107 Oxaliplatin induced nausea/vomiting in response to colorectal cancer treatment / / 22310351 rs6682235 chr1 86208801 C T 2.26E-04 Multiple complex diseases COL24A1 intron 17554300 rs147783303 chr1 86210343 A G 7.29E-07 Serum dimethylarginine levels (asymmetric/symetric ratio) COL24A1 intron 24159190 rs392038 chr1 86233871 G A 1.68E-04 Smoking initiation COL24A1 intron 24665060 rs313728 chr1 86245155 C T 1.10E-04 Smoking initiation COL24A1 intron 24665060 rs10158651 chr1 86274325 G T 2.39E-06 Lipid levels COL24A1 intron 19913121 rs11161691 chr1 86319439 A G 8.51E-04 Type 2 diabetes COL24A1 intron 17463246 rs2046159 chr1 86330589 A G 1.20E-05 Height COL24A1 intron 21194676 rs2046159 chr1 86330589 A G 7.10E-07 Height COL24A1 intron 21194676 rs7554796 chr1 86331245 C T 7.47E-04 Type 2 diabetes COL24A1 intron 17463246 rs7542433 chr1 86351624 C A 9.84E-04 Self-reported allergy COL24A1 intron 23817569 rs1858556 chr1 86371149 T C 0.00007 Asthma COL24A1 intron 18401594 rs10493777 chr1 86377028 C T 0.00007 Asthma COL24A1 intron 18401594 rs12723176 chr1 86413022 C T 9.56E-04 Type 2 diabetes COL24A1 intron 17463246 rs2134411 chr1 86463640 G A 2.37E-05 Multiple complex diseases COL24A1 intron 17554300 rs10873740 chr1 86464262 T C 8.52E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) COL24A1 intron 24236485 rs11161717 chr1 86464981 A G 8.52E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) COL24A1 intron 24236485 rs17128651 chr1 86465736 G A 1.10E-04 Alcohol dependence COL24A1 intron 20201924 rs17128651 chr1 86465736 G A 7.70E-04 Alcohol dependence COL24A1 intron 20201924 rs12143304 chr1 86505755 A G 4.78E-05 Major depressive disorder COL24A1 intron 20516156 rs583315 chr1 86526618 C T 3.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) COL24A1 intron 20877124 rs17415692 chr1 86533142 C T 5.81E-05 Platelet counts COL24A1 intron pha003100 rs10873744 chr1 86549569 G A 9.76E-04 Lymphocyte counts COL24A1 intron 22286170 rs10493786 chr1 86553669 A C 9.90E-04 Type 2 diabetes and 6 quantitative traits COL24A1 intron 17848626 rs1605417 chr1 86563632 C G 8.37E-05 Acute lymphoblastic leukemia (childhood) COL24A1 intron 19684603 rs12044349 chr1 86566278 T C 3.79E-04 Multiple complex diseases COL24A1 intron 17554300 rs7540048 chr1 86622285 C T 0.000000285 LDL cholesterol / / 23063622 rs1507294 chr1 86637089 T G 1.90E-04 Multiple complex diseases / / 17554300 rs6687339 chr1 86638265 A G 8.42E-04 Type 2 diabetes / / 17463246 rs6576808 chr1 86638748 G A 7.33E-05 Parkinson's disease / / 21738487 rs12083520 chr1 86693196 A C 4.14E-04 Alzheimer's disease / / 17998437 rs11587664 chr1 86714346 G A 2.71E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs1323035 chr1 86784804 C A 5.47E-05 Lung function (forced expiratory volume in 1 second) / / pha003102 rs272500 chr1 86827633 A T 5.18E-13 Lymphocyte counts ODF2L intron 22286170 rs421105 chr1 86838158 C T 5.20E-04 Smoking initiation ODF2L cds-synon 24665060 rs272514 chr1 86845563 T C 6.45E-04 Multiple complex diseases ODF2L intron 17554300 rs1407719 chr1 86851420 A G 8.76E-05 Lung function (forced expiratory volume in 1 second) ODF2L intron pha003102 rs5026277 chr1 86885620 C T 1.89E-04 Smoking initiation / / 24665060 rs1334149 chr1 86899021 A G 8.58E-05 Socioeconomic Factors CLCA2 intron pha003067 rs17409304 chr1 86900372 C G 5.09E-04 Multiple complex diseases CLCA2 missense 17554300 rs11161828 chr1 86902967 A G 9.51E-04 Coronary heart disease CLCA2 intron 21971053 rs2390059 chr1 86909493 C T 9.77E-04 Coronary heart disease CLCA2 cds-synon 21971053 rs2791519 chr1 86934176 T G 3.68E-04 Suicide attempts in bipolar disorder / / 21423239 rs2791516 chr1 86938706 C T 1.05E-06 Systemic lupus erythematosus and Systemic sclerosis CLCA1 intron 23740937 rs5744329 chr1 86940715 G A 1.27E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CLCA1 intron 20031582 rs926064 chr1 86941348 G A 6.46E-04 Type 2 diabetes CLCA1 intron 17463246 rs1321695 chr1 86947747 C A 4.37E-04 Type 2 diabetes CLCA1 intron 17463246 rs2791508 chr1 86954398 T C 1.84E-05 Multiple complex diseases CLCA1 intron 17554300 rs1321689 chr1 86959796 C T 2.78E-04 Smoking initiation CLCA1 intron 24665060 rs1028575 chr1 86966851 T C 2.34E-04 Nicotine dependence / / 17158188 rs2791480 chr1 86968584 C G 4.38E-05 Nicotine dependence / / 17158188 rs17129266 chr1 86969110 G C 6.15E-04 Multiple complex diseases / / 17554300 rs7538979 chr1 86971778 A G 9.15E-04 Multiple complex diseases / / 17554300 rs1321687 chr1 86974034 C A 9.59E-04 Nicotine dependence / / 17158188 rs1321686 chr1 86974115 C T 9.72E-04 Nicotine dependence / / 17158188 rs12734135 chr1 86992633 C T 9.89E-04 Multiple complex diseases / / 17554300 rs12750427 chr1 86995816 A G 1.38E-04 Type 2 diabetes / / 17463246 rs1575177 chr1 87000484 T C 3.79E-05 Waist Circumference / / pha003023 rs11161841 chr1 87003472 T A 7.00E-07 Serum dimethylarginine levels (asymmetric) / / 24159190 rs10782575 chr1 87020617 G T 0.0003651 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) CLCA4 intron 23233654 rs10782575 chr1 87020617 G T 3.65E-04 Methotrexate clearance (acute lymphoblastic leukemia) CLCA4 intron 23233662 rs10782575 chr1 87020617 G T 7.44E-05 Amyotrophic lateral sclerosis (sporadic) CLCA4 intron 24529757 rs772605 chr1 87028669 A G 9.11E-04 Methotrexate clearance (acute lymphoblastic leukemia) CLCA4 intron 23233662 rs772601 chr1 87032324 A G 7.45E-04 Multiple complex diseases CLCA4 intron 17554300 rs772598 chr1 87039945 A G 7.57E-04 Type 2 diabetes CLCA4 intron 17463246 rs1953652 chr1 87051201 C T 4.00E-06 IgG glycosylation / / 23382691 rs1953652 chr1 87051201 C T 5.00E-06 IgG glycosylation / / 23382691 rs1953652 chr1 87051201 C T 9.00E-06 IgG glycosylation / / 23382691 rs539145 chr1 87122714 G T 3.83E-04 Multiple complex diseases / / 17554300 rs11161871 chr1 87140602 C A 8.92E-04 Type 2 diabetes / / 17463246 rs3766008 chr1 87184393 C T 6.48E-04 Depression (quantitative trait) SH3GLB1 intron 20800221 rs3766008 chr1 87184393 C T 2.13E-04 Suicide attempts in bipolar disorder SH3GLB1 intron 21423239 rs263462 chr1 87188921 G A 6.44E-04 Depression (quantitative trait) SH3GLB1 intron 20800221 rs263462 chr1 87188921 G A 1.02E-04 Suicide attempts in bipolar disorder SH3GLB1 intron 21423239 rs263482 chr1 87201299 T C 6.36E-04 Depression (quantitative trait) SH3GLB1 intron 20800221 rs263482 chr1 87201299 T C 1.01E-04 Suicide attempts in bipolar disorder SH3GLB1 intron 21423239 rs263480 chr1 87203757 C G 4.90E-04 Depression (quantitative trait) SH3GLB1 intron 20800221 rs263480 chr1 87203757 C G 9.19E-05 Suicide attempts in bipolar disorder SH3GLB1 intron 21423239 rs376906 chr1 87212934 G A 4.94E-04 Depression (quantitative trait) SH3GLB1 UTR-3 20800221 rs376906 chr1 87212934 G A 1.99E-04 Suicide attempts in bipolar disorder SH3GLB1 UTR-3 21423239 rs263491 chr1 87223804 T G 4.95E-04 Depression (quantitative trait) / / 20800221 rs263491 chr1 87223804 T G 4.92E-04 Suicide attempts in bipolar disorder / / 21423239 rs263489 chr1 87227431 A T 4.97E-04 Depression (quantitative trait) / / 20800221 rs263489 chr1 87227431 A T 3.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs263485 chr1 87234742 A G 5.05E-04 Depression (quantitative trait) / / 20800221 rs263485 chr1 87234742 A G 2.95E-04 Suicide attempts in bipolar disorder / / 21423239 rs166412 chr1 87242062 T G 1.43E-04 Multiple complex diseases / / 17554300 rs691531 chr1 87245278 C T 9.90E-07 Multiple complex diseases / / 17554300 rs691481 chr1 87246014 A G 2.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs691241 chr1 87246327 A G 2.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs692441 chr1 87255790 T C 7.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs525467 chr1 87256056 G A 9.74E-04 Suicide attempts in bipolar disorder / / 21423239 rs797979 chr1 87258974 G T 8.43E-04 Suicide attempts in bipolar disorder / / 21423239 rs12074463 chr1 87259306 T C 9.52E-04 Parkinson's disease / / 17052657 rs12074463 chr1 87259306 T C 0.0003261 Sarcoidosis / / 22952805 rs492895 chr1 87260215 A G 0.00058066 Sarcoidosis / / 22952805 rs797978 chr1 87263948 A G 0.00059295 Sarcoidosis / / 22952805 rs691396 chr1 87265806 T C 5.03E-05 C-Reactive Protein / / pha003070 rs691369 chr1 87266144 G A 8.75E-04 Suicide attempts in bipolar disorder / / 21423239 rs691135 chr1 87266383 T A 4.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs691155 chr1 87269292 C T 3.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs6698706 chr1 87276009 T A 3.17E-04 Suicide attempts in bipolar disorder / / 21423239 rs1335853 chr1 87288314 C T 3.26E-04 Suicide attempts in bipolar disorder / / 21423239 rs17129524 chr1 87288755 A G 3.15E-04 Suicide attempts in bipolar disorder / / 21423239 rs10782586 chr1 87292548 C G 6.21E-04 Suicide attempts in bipolar disorder / / 21423239 rs7539403 chr1 87297001 T C 8.18E-04 Suicide attempts in bipolar disorder / / 21423239 rs12142266 chr1 87297849 T C 9.89E-04 Obesity (extreme) / / 21935397 rs12142266 chr1 87297849 T C 1.20E-04 Suicidal ideation / / 22030708 rs17418454 chr1 87482713 G A 6.05E-04 HIV-1 viral setpoint HS2ST1 intron 17641165 rs6576860 chr1 87485257 C T 4.80E-04 Insulin resistance HS2ST1 intron 21901158 rs17452535 chr1 87488653 A G 5.49E-05 Stroke HS2ST1 intron pha002886 rs17452535 chr1 87488653 A G 4.14E-05 Glucose levels HS2ST1 intron pha003061 rs12120670 chr1 87577135 T A 3.71E-04 Depression (quantitative trait) / / 20800221 rs7553864 chr1 87613358 T C 3.00E-06 Smoking behavior LOC339524 intron 19247474 rs10873823 chr1 87660268 A T 2.79E-05 Bipolar disorder / / 19488044 rs6576874 chr1 87675036 G A 8.57E-05 Erythrocyte counts / / pha003101 rs7542364 chr1 87687466 A G 5.03E-05 Erythrocyte counts / / pha003101 rs10873824 chr1 87688394 A G 1.42E-05 Mathematical ability / / 24801482 rs7546843 chr1 87699558 A G 5.79E-04 Multiple complex diseases / / 17554300 rs6576878 chr1 87705031 A G 6.00E-06 White blood cell types / / 21738478 rs1109790 chr1 87710779 G A 3.31E-05 Multiple complex diseases / / 17554300 rs882573 chr1 87711640 A T 9.19E-04 Multiple complex diseases / / 17554300 rs4655937 chr1 87712256 C T 7.87E-04 Type 2 diabetes / / 17463246 rs4655937 chr1 87712256 C T 5.28E-04 Multiple complex diseases / / 17554300 rs10493797 chr1 87720928 G C 1.79E-04 Multiple complex diseases / / 17554300 rs1411705 chr1 87728263 G C 1.49E-04 Multiple complex diseases / / 17554300 rs11583437 chr1 87729323 A G 1.75E-04 Multiple complex diseases / / 17554300 rs1888340 chr1 87731239 G A 2.52E-04 Multiple complex diseases / / 17554300 rs12035326 chr1 87739930 A G 0.000138 Salmonella-induced pyroptosis / / 22837397 rs6576888 chr1 87746317 T G 4.72E-05 Serum metabolites / / 19043545 rs6576888 chr1 87746317 T G 5.87E-06 Post-operative nausea and vomiting / / 21694509 rs6576888 chr1 87746317 T G 4.30E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs10127691 chr1 87748856 T C 4.00E-05 Prostate cancer / / 21743057 rs6675584 chr1 87752776 C A 7.01E-06 Blood pressure (response to calcium channel blocker) / / 24192120 rs6688319 chr1 87752886 A C 6.02E-04 Type 2 diabetes / / 17463246 rs6688319 chr1 87752886 A C 3.52E-05 Blood pressure (response to calcium channel blocker) / / 24192120 rs6576889 chr1 87762304 C T 1.40E-05 Urinary metabolites / / 21572414 rs11161973 chr1 87769531 T C 2.50E-05 Urinary metabolites / / 21572414 rs879988 chr1 87774197 G T 2.50E-05 Urinary metabolites / / 21572414 rs4655952 chr1 87776842 G A 2.50E-05 Urinary metabolites / / 21572414 rs17422436 chr1 87834794 G A 8.60E-04 Type 2 diabetes LOC100505768 intron 23209189 rs11161992 chr1 87835674 C T 5.55E-04 Taste perception LOC100505768 intron 22132133 rs12094766 chr1 87836555 T C 8.62E-04 Multiple complex diseases LOC100505768 intron 17554300 rs11161993 chr1 87838608 A G 1.61E-04 Taste perception / / 22132133 rs11582903 chr1 87846054 C A 3.94E-06 Aging (time to event) / / 21782286 rs11162001 chr1 87862587 C T 9.59E-04 Alzheimer's disease / / 24755620 rs4655956 chr1 87868540 A G 8.56E-04 Alzheimer's disease / / 24755620 rs12758097 chr1 87877226 G A 2.26E-04 Tourette syndrome / / 22889924 rs12758097 chr1 87877226 G A 8.61E-04 Alzheimer's disease / / 24755620 rs1006625 chr1 87877540 A G 8.55E-04 Alzheimer's disease / / 24755620 rs10873844 chr1 87882213 C T 9.67E-04 Alzheimer's disease / / 24755620 rs12565028 chr1 87921397 C T 1.00E-05 Urinary metabolites / / 21572414 rs17131727 chr1 87950279 T C 2.64E-04 Tourette syndrome / / 22889924 rs12410191 chr1 88036573 T G 6.19E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs902296 chr1 88039284 C A 5.13E-04 Multiple complex diseases / / 17554300 rs902296 chr1 88039284 C A 4.31E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9433138 chr1 88055578 G A 6.42E-04 Depression (quantitative trait) / / 20800221 rs60417255 chr1 88055640 G T 0.0000469 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6696952 chr1 88071963 A G 2.51E-04 Schizophrenia / / 20832056 rs11162051 chr1 88078503 C T 4.79E-04 Smoking quantity / / 24665060 rs923545 chr1 88083782 G A 4.11E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs4655977 chr1 88086152 T C 3.73E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs4655978 chr1 88087990 C G 5.30E-06 Urinary metabolites / / 21572414 rs1490166 chr1 88119200 C T 1.40E-05 Urinary metabolites / / 21572414 rs1414648 chr1 88128663 T C 3.70E-04 Suicide attempts in bipolar disorder / / 21423239 rs12132154 chr1 88129038 C A 8.72E-05 Cognitive impairment induced by topiramate / / 22091778 rs6678935 chr1 88131531 G T 3.99E-04 Suicide attempts in bipolar disorder / / 21423239 rs983332 chr1 88132380 G T 5.00E-06 Response to TNF antagonist treatment / / 18615156 rs983332 chr1 88132380 G T 1.50E-04 Endometriosis / / 21151130 rs10922746 chr1 88149030 A C 7.83E-04 Suicide attempts in bipolar disorder / / 21423239 rs17130103 chr1 88150542 T C 1.89E-10 Multiple complex diseases / / 17554300 rs17130108 chr1 88154873 A C 8.71E-04 Multiple complex diseases / / 17554300 rs12568911 chr1 88166163 A G 3.01E-04 Suicide attempts in bipolar disorder / / 21423239 rs305467 chr1 88168623 T A 6.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs10801871 chr1 88176320 A G 3.70E-05 Primary sclerosing cholangitis / / 19944697 rs305445 chr1 88208135 G A 1.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs35214987 chr1 88226329 G C 2.40E-05 Urinary metabolites / / 21572414 rs35214987 chr1 88226329 G C 9.00E-07 Cognitive function / / 24684796 rs2436974 chr1 88240066 G A 5.63E-04 Iron levels / / pha002876 rs1369036 chr1 88261805 A G 3.42E-06 Multiple complex diseases / / 17554300 rs2491281 chr1 88287371 C T 8.45E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs) / / 23648065 rs6673871 chr1 88301277 A G 3.92E-04 Smoking initiation / / 24665060 rs2491302 chr1 88313724 T C 4.91E-04 Alzheimer's disease (late onset) / / 21379329 rs10218533 chr1 88335474 T C 0.000517 Salmonella-induced pyroptosis / / 22837397 rs41341750 chr1 88338185 A C 9.36E-05 Multiple complex diseases / / 17554300 rs3008440 chr1 88343418 A G 1.90E-04 Alzheimer's disease (late onset) / / 21379329 rs2503248 chr1 88358924 T C 1.45E-04 IgE levels / / 17255346 rs2503251 chr1 88363167 C A 3.50E-04 Multiple complex diseases / / 17554300 rs2503253 chr1 88363289 T C 3.78E-05 IgE levels / / 17255346 rs2503256 chr1 88364454 A G 1.24E-04 IgE levels / / 17255346 rs17130220 chr1 88399387 T C 2.98E-05 Multiple complex diseases / / 17554300 rs10489945 chr1 88413589 C T 8.39E-04 Schizophrenia / / 19197363 rs6691335 chr1 88416590 T C 6.58E-05 Cognitive impairment induced by topiramate / / 22091778 rs1413536 chr1 88423397 C T 1.64E-04 Coronary heart disease / / 21606135 rs2991716 chr1 88423966 T C 2.17E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1413527 chr1 88430037 T C 6.12E-05 Serum metabolites / / 19043545 rs1334331 chr1 88441066 C A 1.18E-04 Coronary heart disease / / 21606135 rs3008465 chr1 88453303 A C 8.07E-04 HIV-1 viral setpoint / / 17641165 rs12133568 chr1 88495250 A G 3.37E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs4265406 chr1 88497975 A G 7.02E-04 Suicide attempts in bipolar disorder / / 21041247 rs12133500 chr1 88499703 G C 6.87E-04 Suicide attempts in bipolar disorder / / 21041247 rs12567534 chr1 88500903 A G 6.72E-04 Suicide attempts in bipolar disorder / / 21041247 rs12143926 chr1 88504370 T C 2.39E-04 Suicide attempts in bipolar disorder / / 21041247 rs12566596 chr1 88506791 G C 2.69E-04 Suicide attempts in bipolar disorder / / 21041247 rs12117077 chr1 88512371 T C 2.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs10923014 chr1 88513365 C T 2.19E-04 Suicide attempts in bipolar disorder / / 21041247 rs4655998 chr1 88514186 A C 2.12E-04 Suicide attempts in bipolar disorder / / 21041247 rs4656000 chr1 88514400 G A 2.05E-04 Suicide attempts in bipolar disorder / / 21041247 rs4656001 chr1 88514430 A G 2.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs4656002 chr1 88514728 C T 1.94E-04 Suicide attempts in bipolar disorder / / 21041247 rs10923015 chr1 88514979 T A 1.93E-04 Suicide attempts in bipolar disorder / / 21041247 rs4656003 chr1 88515494 C T 1.92E-04 Suicide attempts in bipolar disorder / / 21041247 rs12568661 chr1 88519718 G A 5.64E-04 Suicide attempts in bipolar disorder / / 21041247 rs12118601 chr1 88521377 C T 1.24E-04 Suicide attempts in bipolar disorder / / 21041247 rs4655864 chr1 88521416 T A 5.08E-04 Multiple complex diseases / / 17554300 rs4656008 chr1 88524540 G T 5.23E-04 Suicide attempts in bipolar disorder / / 21041247 rs10754315 chr1 88529368 T C 5.20E-04 Suicide attempts in bipolar disorder / / 21041247 rs4656013 chr1 88604157 C T 6.57E-04 Obesity (extreme) / / 21935397 rs1336578 chr1 88610289 C T 6.58E-06 Serum metabolites / / 19043545 rs1336578 chr1 88610289 C T 6.44E-06 Stroke (ischemic) / / 22941190 rs17130276 chr1 88621694 A C 8.77E-04 Multiple complex diseases / / 17554300 rs12032672 chr1 88625636 A C 1.00E-06 Periodontal microbiota / / 22699663 rs1932754 chr1 88634245 G A 9.50E-05 Serum metabolites / / 19043545 rs1932754 chr1 88634245 G A 9.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs12041762 chr1 88641601 C T 3.30E-05 Diabetic retinopathy / / 21441570 rs12041762 chr1 88641601 C T 8.19E-05 Heart Rate / / pha003054 rs12567486 chr1 88645313 T C 7.70E-05 Diabetic retinopathy / / 21441570 rs4656020 chr1 88646891 G A 7.80E-05 Diabetic retinopathy / / 21441570 rs10923035 chr1 88647092 C T 2.01E-04 Taste perception / / 22132133 rs10923038 chr1 88651771 C A 4.00E-07 Serum protein levels (sST2) / / 23999434 rs12755168 chr1 88657007 T G 5.73E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1932757 chr1 88665329 T C 7.08E-05 Coronary heart disease / / 21606135 rs6698308 chr1 88666005 A G 2.74E-04 Multiple complex diseases / / 17554300 rs12032086 chr1 88673612 T C 6.70E-04 Type 2 diabetes / / 17463246 rs10493803 chr1 88673676 G T 1.85E-04 Coronary heart disease / / 21606135 rs12403601 chr1 88674545 G T 2.14E-04 Coronary heart disease / / 21606135 rs10923044 chr1 88681580 T C 7.72E-05 Coronary heart disease / / 21606135 rs6684410 chr1 88682190 C T 9.66E-05 Multiple complex diseases / / 17554300 rs4300194 chr1 88699950 T C 1.16E-04 Coronary heart disease / / 21606135 rs12730130 chr1 88701591 T A 1.21E-04 Coronary heart disease / / 21606135 rs673212 chr1 88728999 C G 3.40E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs472473 chr1 88738404 G A 4.37E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1295491 chr1 88740865 T C 1.69E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs1288671 chr1 88741916 G C 7.31E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs569619 chr1 88742010 T G 1.36E-04 Coronary heart disease / / 21606135 rs10923053 chr1 88743657 A G 1.33E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6679982 chr1 88757128 C T 3.24E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6692873 chr1 88760420 C T 3.10E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs608410 chr1 88770663 T C 7.44E-04 Coronary heart disease / / 21606135 rs591604 chr1 88779226 A C,G,T 1.90E-04 Coronary heart disease / / 21606135 rs589824 chr1 88779625 C T 6.17E-05 Coronary heart disease / / 21606135 rs555994 chr1 88780562 C T 1.11E-05 Coronary heart disease / / 21606135 rs473821 chr1 88781342 C T 3.09E-06 Coronary heart disease / / 21606135 rs687790 chr1 88786051 C T 5.57E-05 Orofacial clefts / / 22419666 rs127382 chr1 88788948 T C 4.21E-04 Coronary heart disease / / 21606135 rs127384 chr1 88790960 T C 1.43E-04 Coronary heart disease / / 21606135 rs127384 chr1 88790960 T C 6.04E-05 Orofacial clefts / / 22419666 rs480054 chr1 88791432 G A 1.97E-04 Coronary heart disease / / 21606135 rs2179965 chr1 88802012 A G 1.00E-06 Cognitive test performance / / 17903297 rs766353 chr1 88821516 A G 2.18E-04 Coronary heart disease / / 21606135 rs6682490 chr1 88825290 T A 6.25E-04 Coronary heart disease / / 21606135 rs9428070 chr1 88838394 G T 1.35E-04 Aortic root size / / 21223598 rs9287153 chr1 88840027 T A 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs400666 chr1 88855885 T C 4.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs507241 chr1 88855999 A G 7.00E-05 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs10801891 chr1 88906024 G A 7.33E-05 Monocyte chemoattractant protein-1 / / pha003071 rs12723729 chr1 88919469 A G 6.96E-05 Monocyte chemoattractant protein-1 / / pha003071 rs2044264 chr1 88965798 A G 0.000097 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs306336 chr1 88972879 A G 0.00000194 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs12409611 chr1 88973472 T C 0.0000102 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs6671025 chr1 88979447 C A 0.0000122 Narcolepsy (non-HLA narcolepsy) / / 23459209 rs10493815 chr1 89016499 G A 4.77E-05 Neutrophil count / / pha003095 rs306298 chr1 89020534 G A 7.70E-05 Parkinson's disease (age of onset) / / 19772629 rs642773 chr1 89040252 C T 0.000057 Tuberculosis with late age of onset / / 22551897 rs642773 chr1 89040252 C T 4.65E-04 Myocardial Infarction / / pha002883 rs12024611 chr1 89072924 G A 3.94E-05 Celiac disease / / 23936387 rs17130538 chr1 89079544 C T 1.79E-06 Retinopathy in non-diabetics / / 23393555 rs1373259 chr1 89081648 A G 4.40E-06 Urinary metabolites / / 21572414 rs662452 chr1 89104124 T C 7.67E-04 Multiple complex diseases / / 17554300 rs7534720 chr1 89116300 T C 5.44E-05 Celiac disease / / 23936387 rs6699417 chr1 89123443 C T 5.00E-09 Height / / 20881960 rs6699417 chr1 89123443 C T 3.33E-05 Monocyte counts / / pha003089 rs10493817 chr1 89126887 T G 1.54E-04 Celiac disease / / 23936387 rs10493817 chr1 89126887 T G 7.68E-05 Monocyte counts / / pha003089 rs10754252 chr1 89133812 G A 3.33E-05 Monocyte counts / / pha003089 rs1490738 chr1 89137605 A C 0.000148 Coronary artery disease / / 23202125 rs6698181 chr1 89143305 C T 5.30E-05 Type 2 diabetes / / 17463246 rs12145922 chr1 89146234 C A 2.40E-05 Height / / 21194676 rs12145922 chr1 89146234 C A 2.70E-08 Height / / 21194676 rs12145922 chr1 89146234 C A 3.30E-04 Height / / 21194676 rs12145922 chr1 89146234 C A 4.00E-11 Liver enzyme levels (gamma-glutamyl transferase) / / 22001757 rs3806340 chr1 89148793 G T 5.63E-05 Monocyte counts / / pha003089 rs430600 chr1 89225976 T C 1.72E-04 Celiac disease PKN2 cds-synon 23936387 rs12744822 chr1 89247191 A T 0.00018 Coronary artery calcification PKN2 intron 23727086 rs786911 chr1 89265248 T C 1.92E-04 Celiac disease PKN2 intron 23936387 rs786911 chr1 89265248 T C 7.53E-05 Monocyte counts PKN2 intron pha003089 rs786921 chr1 89286673 G A 2.87E-04 Celiac disease PKN2 intron 23936387 rs10801687 chr1 89307261 G A 2.38E-04 Celiac disease / / 23936387 rs10801687 chr1 89307261 G A 7.53E-05 Monocyte counts / / pha003089 rs17130643 chr1 89341408 C T 4.00E-06 Obesity-related traits GTF2B intron 23251661 rs7524919 chr1 89372589 G A 0.000678964 Hypertension (early onset hypertension) / / 22479346 rs10922510 chr1 89373702 C T 7.84E-05 Bipolar disorder / / 20451256 rs11805182 chr1 89375410 C T 7.78E-05 Bipolar disorder / / 20451256 rs13375223 chr1 89376633 C T 2.63E-05 Bipolar disorder / / 20451256 rs7538497 chr1 89384717 T G 0.000712901 Hypertension (early onset hypertension) / / 22479346 rs7524728 chr1 89384950 C T 0.000712901 Hypertension (early onset hypertension) / / 22479346 rs17472003 chr1 89409488 A G 6.44E-05 Bipolar disorder CCBL2 intron 20451256 rs10922530 chr1 89427252 G A 8.70E-07 Pulmonary function CCBL2 intron 17903307 rs3753683 chr1 89427571 G C 1.87E-06 Pulmonary function CCBL2 intron 17903307 rs1409149 chr1 89429149 T C 9.12E-06 Pulmonary function CCBL2 intron 17903307 rs10518418 chr1 89437113 G T 7.49E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CCBL2 intron 20031582 rs1409150 chr1 89473175 T C 4.28E-04 Prostate cancer mortality GBP3 UTR-3 20978177 rs4656078 chr1 89479074 C T 9.86E-04 Alzheimer's disease GBP3 missense 24755620 rs10801705 chr1 89500382 G A 2.07E-04 Parkinson's disease / / 17052657 rs2149186 chr1 89505043 G T 3.89E-04 Suicide attempts in bipolar disorder / / 21041247 rs6675866 chr1 89517810 T C 9.00E-04 Suicide attempts in bipolar disorder / / 21041247 rs12408132 chr1 89517918 C T 8.71E-04 Suicide attempts in bipolar disorder / / 21041247 rs12740160 chr1 89551004 G A 8.81E-04 Suicide attempts in bipolar disorder / / 21423239 rs12725861 chr1 89566096 G A 9.50E-04 Alzheimer's disease (late onset) / / 21460841 rs2209957 chr1 89583573 A G 8.52E-05 ldl cholesterol GBP2 intron pha003077 rs6428503 chr1 89584069 T C 6.70E-04 Alzheimer's disease (late onset) GBP2 intron 20885792 rs6428503 chr1 89584069 T C 6.70E-04 Alzheimer's disease (late onset) GBP2 intron 21460841 rs10922573 chr1 89588380 A G 8.30E-04 Alzheimer's disease (late onset) GBP2 intron 21460841 rs10922574 chr1 89589383 T C 6.53E-04 Suicide attempts in bipolar disorder GBP2 intron 21041247 rs2893089 chr1 89630721 G T 6.54E-04 Suicide attempts in bipolar disorder GBP7 intron 21041247 rs615739 chr1 89643644 A G 3.35E-05 Cholesterol / / pha003083 rs6703905 chr1 89656749 C T 1.43E-04 Bipolar disorder GBP4 intron 18317468 rs7547610 chr1 89696603 G A 6.99E-04 Myocardial Infarction / / pha002873 rs2209307 chr1 89723344 G A 7.62E-05 Multiple complex diseases / / 17554300 rs148301962 chr1 89726438 G A 0.000029 Breast cancer (ER positive) GBP5 cds-synon 23555315 rs1117177 chr1 89787286 A G 4.88E-05 Hypertension / / pha003041 rs6669828 chr1 89804195 G A 1.50E-05 Urinary metabolites / / 21572414 rs7511795 chr1 89842459 T C 9.70E-05 Iron levels GBP6 intron 21208937 rs928652 chr1 89849201 C G 7.80E-05 Parkinson's disease (familial) GBP6 intron 18985386 rs1984129 chr1 89857106 G A 5.20E-05 Parkinson's disease (familial) / / 18985386 rs1984129 chr1 89857106 G A 6.86E-05 Alzheimer's disease (late onset) / / 21379329 rs928656 chr1 89859768 C T 9.73E-05 Alzheimer's disease (late onset) / / 21379329 rs12098051 chr1 89890973 G T 3.60E-05 Intracerebral hemorrhage / / 24656865 rs12753970 chr1 89893138 A G 1.90E-05 Personality dimensions / / 22628180 rs7545722 chr1 89894471 A G 6.40E-05 Parkinson's disease (familial) / / 18985386 rs72953868 chr1 89896790 G A 1.43E-05 Intracerebral hemorrhage / / 24656865 rs72953868 chr1 89896790 G A 3.57E-05 Intracerebral hemorrhage / / 24656865 rs11577456 chr1 89899019 G A 2.43E-05 Intracerebral hemorrhage / / 24656865 rs11577456 chr1 89899019 G A 4.46E-05 Intracerebral hemorrhage / / 24656865 rs4259628 chr1 89927234 G A 1.43E-04 Coronary Artery Disease / / 17634449 rs3929231 chr1 89927727 C T 1.49E-04 Coronary Artery Disease / / 17634449 rs6692501 chr1 89935101 A G 1.50E-05 Urinary metabolites / / 21572414 rs1585364 chr1 89972062 G T 5.83E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs2125724 chr1 90000410 C G 1.46E-05 Personality dimensions LRRC8B intron 22628180 rs9428043 chr1 90005132 T C 4.26E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) LRRC8B intron 23648065 rs9428043 chr1 90005132 T C 9.25E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) LRRC8B intron 23648065 rs922107 chr1 90022796 A G 3.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) LRRC8B intron 23648065 rs6699344 chr1 90023768 G A 2.02E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LRRC8B intron 23648065 rs6699344 chr1 90023768 G A 2.73E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) LRRC8B intron 23648065 rs6699344 chr1 90023768 G A 4.13E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) LRRC8B intron 23648065 rs922106 chr1 90025519 C A 9.00E-07 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) LRRC8B intron 23648065 rs17099922 chr1 90027582 C T 0.000871 Salmonella-induced pyroptosis LRRC8B intron 22837397 rs10922664 chr1 90032940 A G 3.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LRRC8B intron 23648065 rs10922664 chr1 90032940 A G 5.80E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) LRRC8B intron 23648065 rs10922664 chr1 90032940 A G 9.28E-07 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) LRRC8B intron 23648065 rs7516314 chr1 90050831 A G 3.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LRRC8B intron 23648065 rs7516314 chr1 90050831 A G 3.77E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) LRRC8B intron 23648065 rs7516314 chr1 90050831 A G 5.80E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) LRRC8B intron 23648065 rs12135419 chr1 90053245 C T 3.70E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) LRRC8B intron 23648065 rs12135419 chr1 90053245 C T 3.77E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) LRRC8B intron 23648065 rs12135419 chr1 90053245 C T 5.80E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin) LRRC8B intron 23648065 rs6428557 chr1 90066090 T G 3.53E-04 Multiple complex diseases / / 17554300 rs6428558 chr1 90066415 T C 2.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1215494 chr1 90066806 G A 1.60E-05 Bone mineral density (BMD),in women / / 20164292 rs1215547 chr1 90072888 C T 3.67E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs6428561 chr1 90102619 G A 1.34E-04 Nicotine smoking LRRC8C intron 19268276 rs10754283 chr1 90112431 G T 5.00E-06 Amyotrophic lateral sclerosis (sporadic) LRRC8C intron 24529757 rs2390794 chr1 90125566 G A 1.23E-04 Nicotine smoking LRRC8C intron 19268276 rs2390794 chr1 90125566 G A 1.13E-08 Metabolite levels LRRC8C intron 23281178 rs10801766 chr1 90125934 C T 7.86E-09 Metabolite levels LRRC8C intron 23281178 rs17494625 chr1 90126393 G A 7.88E-04 Body mass index LRRC8C intron 21701565 rs10737709 chr1 90126813 A T 2.27E-08 Metabolite levels LRRC8C intron 23281178 rs2146338 chr1 90221128 C T 2.87E-07 Lymphocyte counts / / 22286170 rs1215582 chr1 90239551 A G 4.46E-05 Bipolar disorder / / 19488044 rs1215582 chr1 90239551 A G 8.52E-05 Bipolar Disorder / / pha002863 rs7549625 chr1 90251996 G A 9.57E-04 Multiple complex diseases / / 17554300 rs10754295 chr1 90322384 C T 6.56E-05 Serum metabolites LRRC8D intron 19043545 rs2802031 chr1 90339669 A G 4.68E-04 Coronary Artery Disease LRRC8D intron 17634449 rs4658342 chr1 90356770 T G 6.71E-04 Taste perception LRRC8D intron 22132133 rs1938032 chr1 90357651 G A 7.05E-04 Type 2 diabetes LRRC8D intron 17463246 rs2703986 chr1 90447918 G T 5.45E-05 Personality dimensions / / 18957941 rs2490113 chr1 90456097 C G 2.24E-05 Personality dimensions / / 18957941 rs10922743 chr1 90492517 A G 7.97E-05 Blood Pressure ZNF326 intron pha003046 rs2816855 chr1 90501669 A G 8.90E-05 Serum metabolites / / 19043545 rs17130950 chr1 90511157 C T 7.46E-04 Type 2 diabetes / / 17463246 rs2813746 chr1 90539764 C A 1.72E-06 Temporal lobe volumes / / 20197096 rs2813747 chr1 90539813 T G 8.91E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs2390866 chr1 90546731 A G 8.70E-05 Coronary heart disease / / pha003032 rs2390866 chr1 90546731 A G 8.56E-05 Fibrinogen / / pha003068 rs17130969 chr1 90556150 G T 3.77E-05 Height / / pha003011 rs2813760 chr1 90569361 A G 4.59E-05 Hypertension / / 19609347 rs2813760 chr1 90569361 A G 4.21E-05 Fibrinogen / / pha003068 rs1329644 chr1 90575147 T C 7.41E-05 Height / / pha003010 rs12409406 chr1 90582562 C T 2.58E-05 Fibrinogen / / pha003068 rs4456078 chr1 90594990 C T 1.38E-04 Body mass index / / 17255346 rs6428571 chr1 90600934 C T 1.19E-05 Colorectal cancer / / 21242260 rs6428572 chr1 90601121 T C 2.22E-05 Cognitive test performance / / 20125193 rs3922967 chr1 90626396 C T 3.15E-05 Gaucher disease severity / / 22388998 rs17130996 chr1 90660195 G C 5.08E-04 Type 2 diabetes / / 17463246 rs17130996 chr1 90660195 G C 5.80E-06 Urinary metabolites / / 21572414 rs17130997 chr1 90664986 A G 8.15E-05 Hearing function / / 17255346 rs10922809 chr1 90668256 G T 2.32E-04 Hearing function / / 17255346 rs7553296 chr1 90671625 C A 1.98E-04 Cholesterol / / 17255346 rs10754299 chr1 90674002 G A 2.28E-04 Cholesterol / / 17255346 rs4233435 chr1 90738800 C T 2.36E-04 Type 2 diabetes / / 17463246 rs3923534 chr1 90739291 C A 6.50E-04 Type 2 diabetes / / 17463246 rs12060187 chr1 90753594 G A 2.01E-04 Type 2 diabetes / / 17463246 rs4578202 chr1 90799813 C T 6.18E-05 Multiple complex diseases / / 17554300 rs10801805 chr1 90820257 G A 3.00E-06 Upper aerodigestive tract cancers / / 21437268 rs17131014 chr1 90830678 C G 7.10E-04 Multiple complex diseases / / 17554300 rs4658158 chr1 90849539 C T 8.92E-04 Bipolar disorder,schizoaffective / / 19567891 rs10218464 chr1 90866978 A T 9.47E-07 Response to antidepressants / / 20360315 rs6701608 chr1 90869227 A C 4.66E-07 Response to antidepressants / / 20360315 rs17131041 chr1 90873828 C T 9.89E-04 Multiple complex diseases / / 17554300 rs2136093 chr1 90875888 T C 4.00E-07 Response to antidepressants / / 20360315 rs1472887 chr1 90879608 T C 5.85E-07 Response to antidepressants / / 20360315 rs7522605 chr1 90894538 G C 7.72E-07 Response to antidepressants / / 20360315 rs1027854 chr1 90915627 A G 7.55E-07 Response to antidepressants / / 20360315 rs1337576 chr1 90916072 A G 2.35E-06 Response to antidepressants / / 20360315 rs506368 chr1 90920022 G A 7.49E-07 Response to antidepressants / / 20360315 rs2136094 chr1 90925982 C A 5.86E-07 Response to antidepressants / / 20360315 rs10801814 chr1 90931765 T C 9.17E-04 Coronary Artery Disease / / 17634449 rs2390582 chr1 90943907 A G 2.00E-05 Biomarkers / / 17903293 rs2390582 chr1 90943907 A G 1.00E-06 Coronary artery calcification / / 17903303 rs699526 chr1 90952184 G A 7.58E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10159226 chr1 91010959 G A 4.83E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs10922885 chr1 91091083 G A 3.53E-04 Multiple complex diseases / / 17554300 rs4233429 chr1 91099903 T G 9.23E-06 Personality dimensions / / 23658558 rs10754306 chr1 91132104 C T 5.62E-06 Lipid traits / / 21777205 rs12046571 chr1 91137786 G T 6.41E-04 Alzheimer's disease / / 24755620 rs12116456 chr1 91141196 G A 8.28E-05 Alcoholism / / pha002893 rs12116456 chr1 91141196 G A 4.99E-05 Soluble levels of adhesion molecules / / pha003072 rs17131133 chr1 91155931 A G 5.10E-05 Alcohol dependence / / 20201924 rs17131133 chr1 91155931 A G 5.10E-05 Alcoholism / / pha002893 rs17131133 chr1 91155931 A G 4.99E-05 Soluble levels of adhesion molecules / / pha003072 rs10922903 chr1 91159586 T C 2.80E-05 Urinary metabolites / / 21572414 rs12133004 chr1 91175419 T C 2.70E-05 Alcohol dependence / / 20201924 rs12133004 chr1 91175419 T C 8.80E-04 Alcohol dependence / / 20201924 rs12133004 chr1 91175419 T C 2.75E-05 Alcoholism / / pha002893 rs4101233 chr1 91238773 C T 4.66E-05 Serum metabolites / / 19043545 rs6676886 chr1 91244343 C G 5.90E-05 Serum metabolites / / 19043545 rs3845561 chr1 91246342 G A 5.15E-05 Serum metabolites / / 19043545 rs10922924 chr1 91252863 G A 9.46E-05 Serum metabolites LOC100505821 intron 19043545 rs3843306 chr1 91288130 T A 5.00E-06 Pulmonary function decline LOC100505821 intron 22424883 rs17131213 chr1 91291013 A T 1.76E-05 Serum metabolites LOC100505821 intron 19043545 rs2390647 chr1 91358183 T C 9.65E-14 Gender / / 22362730 rs165284 chr1 91523553 A T 8.60E-05 Longevity and age-related phenotypes / / 17903295 rs469846 chr1 91529589 G A 3.43E-05 Systemic lupus erythematosus / / pha002867 rs164898 chr1 91569689 G A 6.00E-06 Metabolic syndrome / / 20694148 rs458190 chr1 91600305 G A 2.99E-04 Smoking cessation / / 24665060 rs609256 chr1 91602617 A T 4.26E-05 Smoking cessation / / 24665060 rs17482259 chr1 91619499 G T 7.45E-06 Serum metabolites / / 19043545 rs613217 chr1 91620228 G A 5.38E-04 Smoking cessation / / 24665060 rs599513 chr1 91622835 T C 3.74E-04 Smoking cessation / / 24665060 rs616710 chr1 91626325 T C 4.56E-04 Smoking cessation / / 24665060 rs17542509 chr1 91636192 C A 9.85E-04 Type 2 diabetes / / 17463246 rs665484 chr1 91663930 C A 2.30E-04 Primary sclerosing cholangitis / / 19944697 rs635894 chr1 91667917 A G 2.43E-04 Smoking cessation / / 24665060 rs635894 chr1 91667917 A G 5.41E-06 Height / / pha003010 rs635894 chr1 91667917 A G 6.90E-05 Height / / pha003011 rs12563349 chr1 91683648 G A 2.22E-04 Type 2 diabetes / / 17463246 rs11487636 chr1 91695097 A C 4.58E-04 Alzheimer's disease (late onset) / / 21379329 rs12403887 chr1 91699151 A C 1.49E-04 Type 2 diabetes / / 17463246 rs281966 chr1 91738762 T C 3.75E-04 Alzheimer's disease (late onset) HFM1 intron 21379329 rs12567930 chr1 91800946 A G 4.65E-04 Type 2 diabetes HFM1 intron 17463246 rs11166001 chr1 91872374 C T 5.71E-04 Multiple complex diseases / / 17554300 rs383730 chr1 91881997 C G 5.40E-07 Intracranial aneurysm / / 20364137 rs17485896 chr1 91887372 T C 3.23E-04 Suicide attempts in bipolar disorder / / 21423239 rs12744237 chr1 91901342 T A 3.52E-04 Suicide attempts in bipolar disorder / / 21423239 rs6683496 chr1 91917977 T G 9.24E-04 Suicide attempts in bipolar disorder / / 21423239 rs7540260 chr1 91919533 A G 9.42E-04 Suicide attempts in bipolar disorder / / 21423239 rs505892 chr1 91937695 A G 6.25E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs497379 chr1 91938724 C T 3.59E-04 Suicide attempts in bipolar disorder / / 21423239 rs522712 chr1 91943207 T G 7.89E-04 Suicide attempts in bipolar disorder / / 21423239 rs10493847 chr1 91944713 C T 4.33E-04 Suicide attempts in bipolar disorder / / 21423239 rs6604023 chr1 91944897 G C 4.29E-06 Coronary artery calcification / / 22144573 rs546872 chr1 91970335 C T 5.15E-04 Multiple complex diseases CDC7 intron 17554300 rs483532 chr1 91980447 A G 2.07E-05 Body Mass Index CDC7 cds-synon pha003007 rs483532 chr1 91980447 A G 1.33E-05 Weight CDC7 cds-synon pha003027 rs1983170 chr1 91986482 G A 5.21E-05 Body Mass Index CDC7 intron pha003007 rs1983170 chr1 91986482 G A 2.15E-05 Weight CDC7 intron pha003027 rs6688261 chr1 91987034 C T 9.09E-04 Multiple complex diseases CDC7 intron 17554300 rs12127718 chr1 91997490 T A 9.40E-06 Digit length ratio / / 20303062 rs595801 chr1 91999640 A G 2.51E-04 Multiple complex diseases / / 17554300 rs17501381 chr1 92003919 T C 3.77E-05 Cognitive decline / / 23732972 rs17501512 chr1 92012481 G C 2.13E-04 Cognitive decline / / 23732972 rs963911 chr1 92014051 G T 2.01E-04 Glycosylated haemoglobin levels / / 17255346 rs963911 chr1 92014051 G T 1.22E-39 Narcolepsy / / 19629137 rs11164935 chr1 92015389 C A 1.48E-05 Glycosylated haemoglobin levels / / 17255346 rs1949009 chr1 92016653 T C 2.62E-05 Body Mass Index / / pha003007 rs1949009 chr1 92016653 T C 4.17E-06 Weight / / pha003027 rs17131491 chr1 92017649 A C 7.24E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12134245 chr1 92021464 C T 6.24E-05 Weight / / pha003027 rs6687904 chr1 92025262 A G 6.89E-05 Blood Pressure / / pha003043 rs4658231 chr1 92041502 A G 4.38E-04 Obesity (extreme) / / 21935397 rs4658232 chr1 92042039 G A 4.27E-04 Obesity (extreme) / / 21935397 rs17131499 chr1 92061160 C T 8.96E-04 Obesity (extreme) / / 21935397 rs12031250 chr1 92061445 T C 8.45E-04 Obesity (extreme) / / 21935397 rs12029135 chr1 92062074 C T 8.42E-04 Obesity (extreme) / / 21935397 rs4658238 chr1 92064082 C T 1.10E-05 Urinary metabolites / / 21572414 rs12028899 chr1 92064350 T C 8.41E-04 Obesity (extreme) / / 21935397 rs12024768 chr1 92065464 G T 7.62E-04 Obesity (extreme) / / 21935397 rs1192415 chr1 92077097 G A 3.00E-07 optic disc size (disc) / / 20395239 rs1192415 chr1 92077097 G A 3.00E-28 Optic disc parameters / / 20548946 rs1192415 chr1 92077097 G A 8.00E-17 Optic disc parameters / / 21307088 rs1192415 chr1 92077097 G A 9.31E-12 Glaucoma-related traits / / 22058429 rs1192419 chr1 92080059 A G 1.02E-11 Glaucoma-related traits / / 22058429 rs1192419 chr1 92080059 A G 8.22E-09 Glaucoma-related traits / / 22058429 rs1192419 chr1 92080059 A G 8.95E-12 Glaucoma-related traits / / 22058429 rs4658104 chr1 92087522 G A 9.53E-04 Alzheimer's disease / / 24755620 rs1887054 chr1 92099741 G A 6.93E-05 Asthma / / 23181788 rs2478168 chr1 92100560 A G 4.90E-04 Multiple complex diseases / / 17554300 rs12410523 chr1 92120137 G A 8.92E-05 Alcohol consumption / / 23743675 rs11165262 chr1 92153974 T C 2.39E-04 Response to taxane treatment (placlitaxel) TGFBR3 intron 23006423 rs12082710 chr1 92155337 T C 2.45E-04 Testicular dysgenesis syndrome TGFBR3 intron 22140272 rs12133463 chr1 92156208 C T 7.99E-04 Response to taxane treatment (placlitaxel) TGFBR3 intron 23006423 rs7549755 chr1 92157808 T C 9.95E-05 Postoperative ventricular dysfunction TGFBR3 intron 21980348 rs3754021 chr1 92158751 T C 8.65E-05 Postoperative ventricular dysfunction TGFBR3 intron 21980348 rs1926261 chr1 92162920 C T 8.25E-06 Celiac disease and Rheumatoid arthritis TGFBR3 intron 21383967 rs3767569 chr1 92173371 C T 3.25E-04 Type 2 diabetes TGFBR3 intron 17463246 rs2046736 chr1 92175008 C T 2.68E-04 Response to taxane treatment (placlitaxel) TGFBR3 intron 23006423 rs17512269 chr1 92177062 C T 5.82E-05 Diabetes (gestational) TGFBR3 intron 22233651 rs17512269 chr1 92177062 C T 3.27E-04 Response to taxane treatment (placlitaxel) TGFBR3 intron 23006423 rs17512269 chr1 92177062 C T 1.06E-04 Cognitive function TGFBR3 intron 24684796 rs11165354 chr1 92194322 C A 4.00E-06 Type 2 diabetes TGFBR3 intron 23209189 rs11165354 chr1 92194322 C A 3.34E-04 Heart Failure TGFBR3 intron pha002884 rs10783003 chr1 92195746 C T 2.60E-06 Type 2 diabetes TGFBR3 intron 23209189 rs7517044 chr1 92198162 A G 1.90E-06 Type 2 diabetes TGFBR3 intron 23209189 rs12403389 chr1 92208764 G C 9.63E-06 Bone mineral density TGFBR3 intron 19249006 rs2029356 chr1 92209311 T C 4.00E-04 Atrial fibrillation TGFBR3 intron 21846873 rs17131547 chr1 92211020 G A 9.98E-04 Multiple complex diseases TGFBR3 intron 17554300 rs17131547 chr1 92211020 G A 1.00E-06 Bone mineral density TGFBR3 intron 19249006 rs17131547 chr1 92211020 G A 3.60E-04 Atrial fibrillation TGFBR3 intron 21846873 rs284170 chr1 92214628 T C 5.72E-04 Suicide attempts in bipolar disorder TGFBR3 intron 21041247 rs284172 chr1 92214851 A T 5.16E-04 Suicide attempts in bipolar disorder TGFBR3 intron 21041247 rs11165441 chr1 92224347 G A 3.01E-05 Multiple sclerosis TGFBR3 intron 19525953 rs284198 chr1 92238167 G T 5.95E-04 White matter integrity TGFBR3 intron 22425255 rs12751910 chr1 92243307 G A 7.30E-06 Urinary metabolites TGFBR3 intron 21572414 rs17443164 chr1 92246048 C G 1.00E-05 Urinary metabolites TGFBR3 intron 21572414 rs6683840 chr1 92249817 A G 5.64E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) TGFBR3 intron 20877124 rs1329980 chr1 92254946 T C 0.00000109 HDL cholesterol TGFBR3 intron 23063622 rs1329980 chr1 92254946 T C 4.78E-08 LDL cholesterol TGFBR3 intron 23063622 rs2489188 chr1 92332489 C T 9.09E-04 Alcohol dependence TGFBR3 intron 21314694 rs6680614 chr1 92358371 G T 5.12E-04 Type 2 diabetes TGFBR3 intron 17463246 rs7550034 chr1 92364576 A G 8.81E-04 Alzheimer's disease TGFBR3 intron 17998437 rs34856868 chr1 92554283 G A 2.00E-06 Obesity-related traits BTBD8 missense 23251661 rs11166141 chr1 92561392 A G 9.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs6684317 chr1 92563120 C G 9.69E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs11166144 chr1 92563373 G A 9.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs2128646 chr1 92564147 A T 9.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs2128645 chr1 92564644 C T 9.21E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs981583 chr1 92571295 T A 0.000658 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs981583 chr1 92571295 T A 6.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs4658290 chr1 92572296 C G 0.0006583 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs4658290 chr1 92572296 C G 6.58E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs10875204 chr1 92579675 G A 0.0005029 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs10875204 chr1 92579675 G A 5.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs7533077 chr1 92584519 A G 0.0005404 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs7533077 chr1 92584519 A G 5.40E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs7542358 chr1 92587233 A G 0.0002718 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs7542358 chr1 92587233 A G 2.72E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs7542373 chr1 92587270 A G 0.0004574 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs7542373 chr1 92587270 A G 4.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs2391114 chr1 92587687 G A 0.000419 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs2391114 chr1 92587687 G A 4.19E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs6604080 chr1 92588993 T A 0.0004021 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs6604080 chr1 92588993 T A 4.02E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs3851273 chr1 92589511 G A 0.0003817 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs3851273 chr1 92589511 G A 3.82E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs10875209 chr1 92590826 A G 0.0003662 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs10875209 chr1 92590826 A G 3.66E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs3851272 chr1 92591916 G A 0.0003492 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs3851272 chr1 92591916 G A 3.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs3851271 chr1 92592222 T C 0.0003508 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs3851271 chr1 92592222 T C 3.51E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs10875214 chr1 92597344 G C 0.0003533 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs10875214 chr1 92597344 G C 3.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs1157469 chr1 92598705 T C 0.0003681 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs1157469 chr1 92598705 T C 3.68E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs1157470 chr1 92598807 T A 0.0003574 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs1157470 chr1 92598807 T A 3.57E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs1982720 chr1 92600183 C G 0.0003529 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs1982720 chr1 92600183 C G 3.53E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs12119246 chr1 92602477 A G 0.0002028 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs12119246 chr1 92602477 A G 2.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs2839877 chr1 92604320 G T 0.0003596 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs2839877 chr1 92604320 G T 3.60E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs2893200 chr1 92608029 G A 0.00038 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) BTBD8 intron 23233654 rs2893200 chr1 92608029 G A 3.80E-04 Methotrexate clearance (acute lymphoblastic leukemia) BTBD8 intron 23233662 rs6604082 chr1 92641607 C A 9.81E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIAA1107 intron 23233662 rs1483022 chr1 92646021 G A 9.03E-04 Methotrexate clearance (acute lymphoblastic leukemia) KIAA1107 cds-synon 23233662 rs565156 chr1 92647532 C A 6.95E-04 IgE levels KIAA1107 missense 17255346 rs12069690 chr1 92667250 T C 0.00060524 Sarcoidosis / / 22952805 rs191562237 chr1 92668558 T G 0.00061753 Sarcoidosis / / 22952805 rs77814661 chr1 92676992 G A 0.00062982 Sarcoidosis / / 22952805 rs146182052 chr1 92678371 A G 0.00064211 Sarcoidosis / / 22952805 rs3131824 chr1 92689936 G A 3.01E-05 Alcohol consumption C1orf146 intron 23953852 rs3122320 chr1 92705638 C T 4.76E-05 Alcohol consumption C1orf146 intron 23953852 rs61732740 chr1 92709824 G C 0.0006544 Sarcoidosis C1orf146 missense 22952805 rs149037808 chr1 92710088 A G 0.00066669 Sarcoidosis C1orf146 intron 22952805 rs1487539 chr1 92739699 C T 2.75E-05 Alcohol consumption GLMN intron 23953852 rs3103177 chr1 92756507 A G 2.54E-05 Alcohol consumption GLMN intron 23953852 rs116334257 chr1 92767507 C T 0.00067898 Sarcoidosis RPAP2 intron 22952805 rs146695390 chr1 92769759 T C 0.00069127 Sarcoidosis RPAP2 intron 22952805 rs147871470 chr1 92775941 G A 0.00070356 Sarcoidosis RPAP2 intron 22952805 rs145384375 chr1 92787153 T C 0.00071585 Sarcoidosis RPAP2 intron 22952805 rs6668685 chr1 92791812 G T 3.17E-05 Alcohol consumption RPAP2 intron 23953852 rs138848285 chr1 92797991 T C 0.00072814 Sarcoidosis RPAP2 intron 22952805 rs1906279 chr1 92816148 T C 2.41E-05 Alcohol consumption RPAP2 intron 23953852 rs2046616 chr1 92831569 G A 0.0005366 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) RPAP2 intron 23233654 rs2046616 chr1 92831569 G A 5.37E-04 Methotrexate clearance (acute lymphoblastic leukemia) RPAP2 intron 23233662 rs79703486 chr1 92846017 T C 0.00074043 Sarcoidosis RPAP2 intron 22952805 rs114670042 chr1 92863966 G A 0.00075272 Sarcoidosis / / 22952805 rs2025607 chr1 92890344 C T 2.89E-05 Alcohol consumption / / 23953852 rs11164607 chr1 92947138 A C 7.72E-05 Multiple sclerosis GFI1 intron 17660530 rs7540564 chr1 92957826 C A 3.09E-05 Schizophrenia / / 19571809 rs2031494 chr1 92965969 T C 4.08E-05 Alcohol consumption / / 23953852 rs4970698 chr1 92972933 T C 3.47E-05 Alcohol consumption / / 23953852 rs10782922 chr1 92974595 G A 3.03E-05 Alcohol consumption EVI5 UTR-3 23953852 rs4970700 chr1 92975493 A G 2.31E-04 Multiple sclerosis EVI5 UTR-3 17660530 rs4970700 chr1 92975493 A G 7.81E-05 Schizophrenia EVI5 UTR-3 19571809 rs1886682 chr1 92977275 A G 3.09E-05 Alcohol consumption EVI5 UTR-3 23953852 rs6603979 chr1 92979354 A G 4.00E-05 Alcohol consumption EVI5 cds-synon 23953852 rs1408916 chr1 92992627 G A 5.20E-05 Alcohol consumption EVI5 intron 23953852 rs4970712 chr1 92993547 A C 4.90E-05 Alcohol consumption EVI5 intron 23953852 rs6603981 chr1 92993807 C T 5.20E-05 Alcohol consumption EVI5 intron 23953852 rs7515577 chr1 93009438 C A 3.00E-08 Cholesterol,total EVI5 intron 20686565 rs7515577 chr1 93009438 C A 2.00E-08 Cholesterol,total EVI5 intron 24097068 rs4847377 chr1 93023150 A C 5.43E-05 Alcohol consumption EVI5 intron 23953852 rs1556562 chr1 93034023 G T 4.78E-05 Alcohol consumption EVI5 intron 23953852 rs12743520 chr1 93037112 C A 4.78E-05 Multiple sclerosis EVI5 intron 17660530 rs10782936 chr1 93041906 A G 8.11E-05 Schizophrenia EVI5 intron 19571809 rs11808092 chr1 93073228 C A 1.50E-05 Multiple sclerosis EVI5 missense 19525955 rs6682801 chr1 93074541 G A 6.61E-05 Schizophrenia EVI5 intron 19571809 rs1415296 chr1 93090476 G C 7.17E-05 Multiple sclerosis EVI5 intron 17660530 rs10735781 chr1 93121107 G C 1.68E-04 Multiple sclerosis EVI5 intron 17660530 rs10735781 chr1 93121107 G C 7.55E-06 Multiple sclerosis EVI5 intron 19525953 rs10735781 chr1 93121107 G C 6.97E-05 Schizophrenia EVI5 intron 19571809 rs10735781 chr1 93121107 G C 4.50E-09 Multiple sclerosis EVI5 intron 21833088 rs11800848 chr1 93127927 A C 2.88E-05 Multiple sclerosis EVI5 intron 17660530 rs77382266 chr1 93144726 G A 2.30E-09 Joint damage severity in rheumatoid arthritis EVI5 intron 23696630 rs11810217 chr1 93148377 C T 6.00E-15 Multiple sclerosis EVI5 intron 21833088 rs11810217 chr1 93148377 C T 3.20E-04 Multiple sclerosis EVI5 intron 24234648 rs4847267 chr1 93155347 C T 3.61E-04 Multiple sclerosis EVI5 intron 17660530 rs34202284 chr1 93160002 G A 4.49E-05 Multiple sclerosis EVI5 intron 17660530 rs6680578 chr1 93176878 T A 2.08E-04 Multiple sclerosis EVI5 intron 17660530 rs11164814 chr1 93261373 A G 1.99E-05 Multiple sclerosis / / 19525953 rs6604026 chr1 93303603 T C 8.00E-06 Multiple sclerosis RPL5 intron 17660530 rs6604026 chr1 93303603 T C 3.00E-06 Multiple sclerosis RPL5 intron 19525955 rs6604026 chr1 93303603 T C 3.61E-06 Bipolar disorder and schizophrenia RPL5 intron 20889312 rs6604026 chr1 93303603 T C 1.01E-05 Schizophrenia RPL5 intron pha002857 rs10782945 chr1 93304272 C T 9.52E-05 Schizophrenia RPL5 intron 19571809 rs10782945 chr1 93304272 C T 5.88E-06 Bipolar disorder and schizophrenia RPL5 intron 20889312 rs10782945 chr1 93304272 C T 7.36E-06 Schizophrenia RPL5 intron pha002857 rs10874744 chr1 93306317 G A 7.39E-05 Alcohol consumption RPL5 intron 23953852 rs7514280 chr1 93320869 C T 7.08E-05 Multiple sclerosis FAM69A intron 17660530 rs7514280 chr1 93320869 C T 1.36E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs7514280 chr1 93320869 C T 9.85E-06 Schizophrenia FAM69A intron pha002857 rs10874746 chr1 93323971 T C 1.09E-05 Multiple sclerosis FAM69A intron 17660530 rs10874746 chr1 93323971 T C 3.51E-05 Schizophrenia FAM69A intron 19571809 rs10874746 chr1 93323971 T C 7.00E-11 Height FAM69A intron 20881960 rs10874746 chr1 93323971 T C 6.38E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs10874746 chr1 93323971 T C 3.17E-05 Schizophrenia FAM69A intron pha002857 rs111536942 chr1 93332055 C T 0.00076501 Sarcoidosis FAM69A intron 22952805 rs2811600 chr1 93334138 C T 1.71E-05 Multiple sclerosis FAM69A intron 17660530 rs2811600 chr1 93334138 C T 8.28E-05 Schizophrenia FAM69A intron 19571809 rs2811600 chr1 93334138 C T 1.18E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs2811600 chr1 93334138 C T 1.59E-06 Schizophrenia FAM69A intron pha002857 rs77039154 chr1 93338642 G C 0.0007773 Sarcoidosis FAM69A intron 22952805 rs2811593 chr1 93343891 T C 2.24E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs2811593 chr1 93343891 T C 2.91E-06 Schizophrenia FAM69A intron pha002857 rs35183060 chr1 93346928 A T 4.91E-05 Multiple sclerosis FAM69A intron 17660530 rs35183060 chr1 93346928 A T 1.52E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs35183060 chr1 93346928 A T 5.50E-06 Schizophrenia FAM69A intron pha002857 rs7536563 chr1 93349046 A G 2.27E-05 Multiple sclerosis FAM69A intron 17660530 rs7536563 chr1 93349046 A G 5.09E-05 Schizophrenia FAM69A intron 19571809 rs7536563 chr1 93349046 A G 1.16E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs7536563 chr1 93349046 A G 2.24E-06 Schizophrenia FAM69A intron pha002857 rs10782946 chr1 93352669 G A 8.52E-05 Alcohol consumption FAM69A intron 23953852 rs2391177 chr1 93353943 G A 7.81E-05 Alcohol consumption FAM69A intron 23953852 rs2481713 chr1 93354889 G T 6.86E-05 Alcohol consumption FAM69A intron 23953852 rs2263247 chr1 93364067 T C 7.68E-05 Alcohol consumption FAM69A intron 23953852 rs2255723 chr1 93368309 G T 1.11E-05 Multiple sclerosis FAM69A intron 17660530 rs2255723 chr1 93368309 G T 1.39E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs2255723 chr1 93368309 G T 7.20E-05 Alcohol consumption FAM69A intron 23953852 rs2255723 chr1 93368309 G T 1.94E-06 Schizophrenia FAM69A intron pha002857 rs12066638 chr1 93375391 C G 7.38E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs12066638 chr1 93375391 C G 3.64E-06 Schizophrenia FAM69A intron pha002857 rs11164835 chr1 93379093 G A 5.36E-05 Multiple sclerosis FAM69A intron 17660530 rs11164835 chr1 93379093 G A 9.84E-07 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs11164835 chr1 93379093 G A 1.46E-06 Schizophrenia FAM69A intron pha002857 rs9651257 chr1 93385136 T C 3.40E-05 Multiple sclerosis FAM69A intron 17660530 rs9651257 chr1 93385136 T C 2.02E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs9651257 chr1 93385136 T C 4.49E-06 Schizophrenia FAM69A intron pha002857 rs7515257 chr1 93393718 G A 7.86E-05 Alcohol consumption FAM69A intron 23953852 rs11164838 chr1 93395378 C T 6.01E-05 Multiple sclerosis FAM69A intron 17660530 rs11164838 chr1 93395378 C T 6.81E-06 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs6698233 chr1 93397300 C T 7.62E-05 Alcohol consumption FAM69A intron 23953852 rs10493863 chr1 93399694 T C 7.95E-05 Alcohol consumption FAM69A intron 23953852 rs7542608 chr1 93401194 A G 7.18E-05 Alcohol consumption FAM69A intron 23953852 rs12745968 chr1 93401837 A G 8.01E-05 Multiple sclerosis FAM69A intron 17660530 rs12745968 chr1 93401837 A G 8.97E-05 Schizophrenia FAM69A intron 19571809 rs12745968 chr1 93401837 A G 8.00E-07 Bipolar disorder and schizophrenia FAM69A intron 20889312 rs12745968 chr1 93401837 A G 1.04E-06 Schizophrenia FAM69A intron pha002857 rs17380908 chr1 93402551 C T 5.74E-05 Multiple sclerosis FAM69A intron 17660530 rs4847386 chr1 93420907 G A 1.18E-04 Parkinson's disease FAM69A intron 17052657 rs10874753 chr1 93429087 C A 1.85E-06 Bipolar disorder and schizophrenia / / 20889312 rs10874753 chr1 93429087 C A 4.57E-06 Schizophrenia / / pha002857 rs514235 chr1 93438456 T C 6.81E-06 Bipolar disorder and schizophrenia / / 20889312 rs6671268 chr1 93439821 T C 1.97E-04 Parkinson's disease / / 17052657 rs660870 chr1 93445417 C A 4.81E-05 Schizophrenia / / 19571809 rs660870 chr1 93445417 C A 2.60E-06 Bipolar disorder and schizophrenia / / 20889312 rs660870 chr1 93445417 C A 3.16E-05 Schizophrenia / / pha002857 rs521428 chr1 93445497 G A 2.12E-05 Multiple sclerosis / / 17660530 rs521428 chr1 93445497 G A 5.65E-05 Schizophrenia / / 19571809 rs521428 chr1 93445497 G A 2.52E-06 Bipolar disorder and schizophrenia / / 20889312 rs521428 chr1 93445497 G A 4.57E-05 Schizophrenia / / pha002857 rs532834 chr1 93468062 A T 1.82E-07 Multiple sclerosis / / 17660530 rs496465 chr1 93474165 A G 9.75E-05 Multiple sclerosis / / 17660530 rs12067005 chr1 93543119 A G 3.97E-05 Intelligence / / 21826061 rs1856027 chr1 93544131 T C 4.36E-04 Type 2 diabetes / / 22158537 rs12128131 chr1 93546299 T G 4.60E-04 Type 2 diabetes MTF2 intron 22158537 rs2295423 chr1 93581024 T C 7.67E-04 Type 2 diabetes MTF2 intron 22158537 rs2391228 chr1 93606940 G A 4.19E-05 Intelligence / / 21826061 rs1572343 chr1 93616202 T C 4.74E-04 Type 2 diabetes TMED5 UTR-3 22158537 rs1060622 chr1 93620393 G A 6.46E-04 Type 2 diabetes TMED5 missense 22158537 rs2783489 chr1 93626984 C T 2.85E-04 Type 2 diabetes TMED5 intron 22158537 rs4847235 chr1 93627727 T C 4.09E-04 Type 2 diabetes TMED5 intron 22158537 rs2152358 chr1 93634009 G A 8.16E-04 Type 2 diabetes TMED5 intron 22158537 rs10874762 chr1 93639101 T G 6.04E-04 Type 2 diabetes TMED5 intron 22158537 rs1335679 chr1 93645182 C T 6.26E-04 Type 2 diabetes TMED5 intron 22158537 rs7535628 chr1 93648728 T C 3.32E-04 Type 2 diabetes CCDC18 intron 22158537 rs6682670 chr1 93649732 A G 6.09E-04 Type 2 diabetes CCDC18 intron 22158537 rs7517363 chr1 93652785 C T 5.04E-04 Type 2 diabetes CCDC18 intron 22158537 rs11164879 chr1 93655522 G A 6.66E-04 Type 2 diabetes CCDC18 intron 22158537 rs7513705 chr1 93666349 T C 3.14E-04 Type 2 diabetes CCDC18 intron 22158537 rs12030549 chr1 93669218 T C 6.01E-04 Type 2 diabetes CCDC18 intron 22158537 rs531358 chr1 93676011 C T 5.62E-04 Type 2 diabetes CCDC18 intron 22158537 rs2765545 chr1 93677269 G A 3.64E-04 Type 2 diabetes CCDC18 intron 22158537 rs661126 chr1 93678968 T G 5.83E-04 Type 2 diabetes CCDC18 intron 22158537 rs612037 chr1 93682878 G A 4.47E-04 Type 2 diabetes CCDC18 intron 22158537 rs797668 chr1 93694789 C G 5.83E-04 Type 2 diabetes CCDC18 intron 22158537 rs3754186 chr1 93711782 T A 7.77E-04 Type 2 diabetes CCDC18 intron 22158537 rs622608 chr1 93715219 G A 4.32E-04 Type 2 diabetes CCDC18 intron 22158537 rs693737 chr1 93724924 G A 5.29E-04 Type 2 diabetes CCDC18 intron 22158537 rs2296558 chr1 93736555 C T 7.59E-04 Type 2 diabetes CCDC18 intron 22158537 rs6541401 chr1 93738948 G A 7.98E-04 Type 2 diabetes CCDC18 intron 22158537 rs9432681 chr1 93761896 A G 7.49E-04 Type 2 diabetes / / 22158537 rs6680107 chr1 93770880 G A 7.78E-04 Type 2 diabetes / / 22158537 rs9432453 chr1 93771629 G A 6.64E-04 Type 2 diabetes / / 22158537 rs1000607 chr1 93772001 T C 7.37E-04 Type 2 diabetes / / 22158537 rs4240966 chr1 93774812 C A 7.02E-04 Type 2 diabetes / / 22158537 rs4000699 chr1 93779805 C T 5.53E-04 Type 2 diabetes LOC100131564 intron 22158537 rs2031226 chr1 93786764 G T 5.97E-04 Type 2 diabetes LOC100131564 intron 22158537 rs6703310 chr1 93788740 T G 6.01E-04 Type 2 diabetes LOC100131564 intron 22158537 rs2391254 chr1 93795166 A T 2.38E-04 Type 2 diabetes LOC100131564 intron 22158537 rs942196 chr1 93802264 T A 5.04E-04 Type 2 diabetes LOC100131564 intron 22158537 rs3767964 chr1 93815490 T C 2.86E-04 Type 2 diabetes DR1 intron 22158537 rs4847240 chr1 93817946 A G 2.59E-04 Type 2 diabetes DR1 intron 22158537 rs12044883 chr1 93820575 G A 3.09E-04 Type 2 diabetes DR1 intron 22158537 rs11164938 chr1 93939870 A G 5.49E-04 Alcohol dependence FNBP1L intron 21314694 rs4847428 chr1 93942442 A G 7.55E-05 Serum metabolites FNBP1L intron 19043545 rs4847431 chr1 93984804 G C 3.92E-05 Nicotine dependence FNBP1L intron 17158188 rs237425 chr1 94012287 G A 9.56E-05 Pancreatic cancer FNBP1L intron pha002874 rs2295330 chr1 94037329 C T 6.09E-04 Coronary heart disease BCAR3 cds-synon 21971053 rs6667494 chr1 94038847 G A 0.00007483 Sarcoidosis BCAR3 intron 22952805 rs17110111 chr1 94042207 C T 5.81E-05 Insulin resistance BCAR3 intron 21901158 rs236316 chr1 94044597 C T 1.27E-07 Intelligence BCAR3 intron 21826061 rs3950119 chr1 94049237 T C 3.04E-05 Intelligence BCAR3 intron 21826061 rs236322 chr1 94056279 G T 7.48E-05 Intelligence BCAR3 intron 21826061 rs236330 chr1 94059554 C T 5.40E-04 Intelligence (childhood) BCAR3 intron 23358156 rs6677770 chr1 94066635 T C 5.96E-05 Intelligence BCAR3 intron 21826061 rs12739747 chr1 94077247 T A 1.81E-04 Insulin resistance BCAR3 intron 21901158 rs236313 chr1 94089708 A C 2.24E-05 Asthma BCAR3 intron 23181788 rs236301 chr1 94113981 C T 8.72E-05 Intelligence BCAR3 intron 21826061 rs236292 chr1 94120564 T C 5.28E-04 Type 2 diabetes BCAR3 intron 17463246 rs11580965 chr1 94129664 A T 4.47E-05 Insulin resistance BCAR3 intron 21901158 rs236285 chr1 94132788 G A 5.92E-05 Intelligence BCAR3 intron 21826061 rs2102629 chr1 94172121 A G 2.62E-04 Smoking cessation / / 24665060 rs12132625 chr1 94213931 G C 1.28E-04 Multiple complex diseases / / 17554300 rs4240956 chr1 94223769 A T 3.90E-06 Urinary metabolites / / 21572414 rs2818164 chr1 94237195 G T 4.20E-06 Urinary metabolites / / 21572414 rs2143990 chr1 94249517 T C 4.20E-06 Urinary metabolites / / 21572414 rs17100392 chr1 94281597 A G 7.74E-05 Parkinson's disease (motor and cognition) / / 22658654 rs17100392 chr1 94281597 A G 7.74E-05 Immune response to anthrax vaccine / / 22658931 rs6664719 chr1 94334724 A C 9.50E-06 Urinary metabolites / / 21572414 rs11165029 chr1 94348081 C A 8.91E-04 Multiple complex diseases / / 17554300 rs11165029 chr1 94348081 C A 7.06E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs11165047 chr1 94440105 G A 4.60E-05 Multiple complex diseases / / 17554300 rs11165048 chr1 94440182 G A 4.13E-05 Multiple complex diseases / / 17554300 rs12404808 chr1 94440302 C T 2.80E-05 Multiple complex diseases / / 17554300 rs12404811 chr1 94440332 C T 5.64E-05 Multiple complex diseases / / 17554300 rs12410905 chr1 94444197 T C 3.12E-05 Multiple complex diseases / / 17554300 rs1413899 chr1 94444481 G A 2.53E-05 Multiple complex diseases / / 17554300 rs35550403 chr1 94445595 G A 2.75E-05 Multiple complex diseases / / 17554300 rs41351346 chr1 94445793 T C 3.14E-05 Multiple complex diseases / / 17554300 rs41353346 chr1 94445839 T C 3.35E-05 Multiple complex diseases / / 17554300 rs17110714 chr1 94457555 A G 1.99E-04 Multiple complex diseases / / 17554300 rs17110736 chr1 94462769 G A 5.00E-06 Dialysis-related mortality ABCA4 intron 21546767 rs1800555 chr1 94463617 C T 2.57E-04 Insulin resistance ABCA4 missense 21901158 rs12070273 chr1 94466088 A G 4.66E-05 Height ABCA4 intron pha003011 rs4147864 chr1 94467238 G A 4.66E-05 Height ABCA4 intron pha003011 rs4147863 chr1 94471154 C T 8.89E-04 Response to alcohol consumption (flushing response) ABCA4 intron 24277619 rs11165063 chr1 94477649 C G 9.70E-06 Urinary metabolites ABCA4 intron 21572414 rs567370 chr1 94478573 C T 7.30E-06 Urinary metabolites ABCA4 intron 21572414 rs915200 chr1 94481904 C T 3.30E-04 Type 2 diabetes ABCA4 intron 17463246 rs11806129 chr1 94482377 A G 1.17E-11 LDL cholesterol ABCA4 intron 23063622 rs11806129 chr1 94482377 A G 7.08E-08 Cholesterol,total ABCA4 intron 23063622 rs61754056 chr1 94486905 C T 0.000000163 Prostate-specific antigen ABCA4 missense 23555315 rs472908 chr1 94487354 G A 3.68E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) ABCA4 intron 20877124 rs1320502 chr1 94501799 C T 1.51E-04 Multiple complex diseases ABCA4 intron 17554300 rs12087003 chr1 94503183 A G 1.83E-09 LDL cholesterol ABCA4 intron 23063622 rs12087003 chr1 94503183 A G 1.86E-08 Cholesterol,total ABCA4 intron 23063622 rs17110922 chr1 94509045 A T 0.00000191 Cholesterol,total ABCA4 intron 23063622 rs17110922 chr1 94509045 A T 6.65E-10 LDL cholesterol ABCA4 intron 23063622 rs3789399 chr1 94511717 G C 8.67E-05 Meningococcal disease ABCA4 intron 20694013 rs544830 chr1 94512893 C T 3.60E-05 Meningococcal disease ABCA4 intron 20694013 rs4147836 chr1 94516474 C T 2.40E-04 Obesity (extreme) ABCA4 intron 21935397 rs1191231 chr1 94516985 A C 6.89E-05 Meningococcal disease ABCA4 intron 20694013 rs497511 chr1 94523113 G A 1.76E-05 Meningococcal disease ABCA4 intron 20694013 rs550060 chr1 94524784 A G 1.84E-05 Meningococcal disease ABCA4 intron 20694013 rs521538 chr1 94525623 A G 1.25E-05 Orofacial clefts ABCA4 intron 22863734 rs4147833 chr1 94528363 C T 1.50E-04 Obesity (extreme) ABCA4 intron 21935397 rs4847273 chr1 94529743 A G 1.82E-05 Obesity (extreme) ABCA4 intron 21935397 rs6661519 chr1 94530163 C A 1.87E-05 Obesity (extreme) ABCA4 intron 21935397 rs1007347 chr1 94530518 T C 2.06E-05 Obesity (extreme) ABCA4 intron 21935397 rs1191232 chr1 94531192 A G 8.67E-06 Orofacial clefts ABCA4 intron 22863734 rs3789405 chr1 94531324 T C 2.10E-05 Obesity (extreme) ABCA4 intron 21935397 rs3789407 chr1 94531606 G C 8.77E-05 Obesity (extreme) ABCA4 intron 21935397 rs4140392 chr1 94532013 C T 9.45E-05 Obesity (extreme) ABCA4 intron 21935397 rs1931575 chr1 94533014 T C 3.93E-05 Obesity (extreme) ABCA4 intron 21935397 rs1931575 chr1 94533014 T C 2.00E-06 Palmitoleic acid (16:1n-7) plasma levels ABCA4 intron 23362303 rs2151849 chr1 94535174 A G 3.62E-04 Obesity (extreme) ABCA4 intron 21935397 rs3789412 chr1 94536067 C T 3.95E-04 Obesity (extreme) ABCA4 intron 21935397 rs12759306 chr1 94537642 C A 2.68E-05 Tunica Media ABCA4 intron pha003034 rs1761375 chr1 94538011 G A 3.94E-04 Amyotrophic lateral sclerosis (sporadic) ABCA4 intron 24529757 rs4847274 chr1 94540069 G C 0.00084 Salmonella-induced pyroptosis ABCA4 intron 22837397 rs2275035 chr1 94545160 C T 3.74E-05 Cleft lip ABCA4 intron 20436469 rs2275035 chr1 94545160 C T 4.06E-05 Obesity (extreme) ABCA4 intron 21935397 rs4147827 chr1 94548080 C G 2.58E-05 Cleft lip ABCA4 intron 20436469 rs560426 chr1 94553438 C T 5.70E-12 Cleft lip ABCA4 intron 20436469 rs560426 chr1 94553438 C T 3.00E-12 Orofacial clefts ABCA4 intron 22863734 rs560426 chr1 94553438 C T 5.00E-10 Orofacial clefts ABCA4 intron 22863734 rs563429 chr1 94553866 A G 6.33E-05 Orofacial clefts ABCA4 intron 22863734 rs4847196 chr1 94554453 G A 2.27E-05 Cleft lip ABCA4 intron 20436469 rs4847196 chr1 94554453 G A 7.55E-04 Obesity (extreme) ABCA4 intron 21935397 rs4847196 chr1 94554453 G A 8.08E-05 Coronary heart disease ABCA4 intron pha003030 rs952499 chr1 94558425 T C 7.19E-07 Cleft lip ABCA4 intron 20436469 rs952499 chr1 94558425 T C 7.18E-08 Orofacial clefts ABCA4 intron 22863734 rs2068334 chr1 94559715 G A 6.13E-04 Obesity (extreme) ABCA4 intron 21935397 rs4147823 chr1 94561272 A C 7.51E-04 Obesity (extreme) ABCA4 intron 21935397 rs4147822 chr1 94561489 A G 2.68E-04 Obesity (extreme) ABCA4 intron 21935397 rs3789422 chr1 94566311 C T 0.000027 Coronary artery calcification ABCA4 intron 23727086 rs2297636 chr1 94568822 T C 5.83E-06 Cleft lip ABCA4 intron 20436469 rs481931 chr1 94570016 G T 8.57E-08 Cleft lip ABCA4 intron 20436469 rs570926 chr1 94570218 T C 3.24E-07 Cleft lip ABCA4 intron 20436469 rs1211213 chr1 94571420 A G 5.50E-05 Cleft lip ABCA4 intron 20436469 rs4147816 chr1 94574780 C T 3.01E-04 Type 2 diabetes ABCA4 intron 17463246 rs4147816 chr1 94574780 C T 6.51E-08 Cleft lip ABCA4 intron 20436469 rs4147812 chr1 94575043 A C 9.12E-08 Cleft lip ABCA4 intron 20436469 rs4147812 chr1 94575043 A C 9.90E-10 Orofacial clefts ABCA4 intron 22863734 rs4147811 chr1 94575056 C T 4.02E-08 Cleft lip ABCA4 intron 20436469 rs3827712 chr1 94575171 T C 8.57E-08 Cleft lip ABCA4 intron 20436469 rs3789432 chr1 94575308 T C 1.39E-07 Cleft lip ABCA4 intron 20436469 rs2297634 chr1 94576968 T C 2.50E-05 Age-related macular degeneration ABCA4 intron 20861866 rs2297634 chr1 94576968 T C 2.27E-05 Age-related macular degeneration ABCA4 intron 21197116 rs2297634 chr1 94576968 T C 4.39E-05 Orofacial clefts ABCA4 intron 22863734 rs2297634 chr1 94576968 T C 3.18E-05 Age-related macular degeneration ABCA4 intron pha002856 rs10782976 chr1 94581125 G A 4.77E-05 Cleft lip ABCA4 intron 20436469 rs4147804 chr1 94582227 G A 7.25E-06 Cleft lip ABCA4 intron 20436469 rs4147803 chr1 94582293 G C 4.67E-06 Cleft lip ABCA4 intron 20436469 rs4147799 chr1 94584459 A G 7.70E-05 HDL particle features ABCA4 intron 21283740 rs3789451 chr1 94586328 C T 8.45E-06 Cleft lip ABCA4 intron 20436469 rs3789451 chr1 94586328 C T 3.56E-07 Orofacial clefts ABCA4 intron 22863734 rs3789452 chr1 94587501 T A 7.30E-07 Cleft lip ABCA4 nearGene-5 20436469 rs2151846 chr1 94587687 T G 1.61E-07 Cleft lip ABCA4 nearGene-5 20436469 rs11802196 chr1 94594043 A C 9.98E-06 Cleft lip / / 20436469 rs11802196 chr1 94594043 A C 1.55E-06 Orofacial clefts / / 22863734 rs6686599 chr1 94596831 G A 3.73E-06 Cleft lip / / 20436469 rs6686599 chr1 94596831 G A 1.96E-06 Orofacial clefts / / 22863734 rs1931565 chr1 94596867 A G 1.02E-05 Orofacial clefts / / 22863734 rs2774920 chr1 94611300 A G 1.00E-06 D-dimer levels / / 21502573 rs1411701 chr1 94635028 G A 5.88E-07 Orofacial clefts ARHGAP29 UTR-3 22863734 rs2274788 chr1 94674726 T C 6.26E-05 Cognitive test performance ARHGAP29 intron 20125193 rs2274788 chr1 94674726 T C 1.00E-06 Thiazide-induced adverse metabolic effects in hypertensive patients ARHGAP29 intron 23400010 rs6541340 chr1 94678512 T C 1.45E-05 Orofacial clefts ARHGAP29 intron 22863734 rs3789688 chr1 94691240 T C 2.46E-06 Orofacial clefts ARHGAP29 intron 22863734 rs12750249 chr1 94721660 T C 4.00E-06 IgG glycosylation LOC100505940 intron 23382691 rs11165110 chr1 94752469 G A 1.02E-04 Orofacial clefts LOC100505940 intron 22863734 rs11584317 chr1 94792449 C T 7.63E-04 Smoking initiation LOC100505940 intron 24665060 rs2172133 chr1 94803032 A G 1.61E-05 Orofacial clefts / / 22863734 rs12057415 chr1 94829769 T C 3.52E-05 Cleft lip / / 20436469 rs12057415 chr1 94829769 T C 2.05E-06 Orofacial clefts / / 22863734 rs2391467 chr1 94850443 A G 2.11E-05 Cleft lip / / 20436469 rs2391467 chr1 94850443 A G 1.10E-06 Orofacial clefts / / 22863734 rs598962 chr1 94916649 A C,G,T 2.28E-10 Cholesterol,total ABCD3 intron 23063622 rs598962 chr1 94916649 A C,G,T 2.56E-13 LDL cholesterol ABCD3 intron 23063622 rs529642 chr1 94979573 G C 4.97E-04 Multiple complex diseases ABCD3 intron 17554300 rs1144302 chr1 95000114 C T 0.000000962 LDL cholesterol F3 intron 23063622 rs1144302 chr1 95000114 C T 0.00000227 Cholesterol,total F3 intron 23063622 rs3917608 chr1 95004486 T G 3.49E-06 Lipid levels F3 intron 19913121 rs3789685 chr1 95004938 T C 3.47E-06 Lipid levels F3 intron 19913121 rs3789685 chr1 95004938 T C 0.00000169 Cholesterol,total F3 intron 23063622 rs698945 chr1 95011785 A G 5.60E-04 Multiple complex diseases / / 17554300 rs1146509 chr1 95029581 G T 6.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs2022309 chr1 95052476 G T 4.00E-08 End-stage coagulation / / 23381943 rs12029080 chr1 95053353 T G 6.00E-52 D-dimer levels / / 21502573 rs698941 chr1 95055219 C T 1.90E-06 Urinary metabolites / / 21572414 rs12079330 chr1 95058953 G A 9.01E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1778214 chr1 95061355 G A 8.04E-05 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs1747649 chr1 95062032 G A 8.92E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs7542900 chr1 95070041 T C 6.00E-06 Type 2 diabetes / / 22238593 rs11807669 chr1 95070114 T C 2.30E-04 Lipopolysaccharide induced cytokine levels / / 23823136 rs4474258 chr1 95081445 C T 5.00E-06 Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+epirubicin+/-5FU) / / 24025145 rs12725598 chr1 95093341 G C 5.84E-04 Insulin resistance / / 21901158 rs2971940 chr1 95111759 A G 4.95E-04 Multiple complex diseases / / 17554300 rs947386 chr1 95117157 C T 5.68E-05 Alcohol and nictotine co-dependence / / 20158304 rs841361 chr1 95151813 C T 9.36E-07 Autism / / 22843504 rs841329 chr1 95169762 G A 8.25E-04 Suicide attempts in bipolar disorder / / 21041247 rs2391423 chr1 95240361 C T 4.62E-05 Major depressive disorder (broad) / / 20038947 rs12743267 chr1 95249306 C T 3.40E-04 Alcohol dependence / / 20201924 rs11165257 chr1 95302135 G T 2.74E-04 Alcohol dependence SLC44A3 intron 20201924 rs3849303 chr1 95320536 G A 8.43E-04 Amyotrophic lateral sclerosis (sporadic) SLC44A3 intron 24529757 rs859101 chr1 95324784 G T 7.00E-06 Type 2 diabetes SLC44A3 intron 17293876 rs859101 chr1 95324784 G T 7.00E-06 Type 2 diabetes SLC44A3 intron 19184112 rs859098 chr1 95330372 G A 6.04E-04 Premature ovarian failure SLC44A3 missense 19508998 rs859098 chr1 95330372 G A 8.21E-05 Cognitive impairment induced by topiramate SLC44A3 missense 22091778 rs859098 chr1 95330372 G A 4.58E-05 Blood Pressure SLC44A3 missense pha002903 rs859096 chr1 95333068 G T 3.60E-05 Response to Vitamin E supplementation SLC44A3 intron 22437554 rs859096 chr1 95333068 G T 9.47E-04 Iron levels SLC44A3 intron pha002876 rs859096 chr1 95333068 G T 3.28E-05 Blood Pressure SLC44A3 intron pha002903 rs17520351 chr1 95334187 C T 4.00E-06 Metabolite levels (Dihydroxy docosatrienoic acid) SLC44A3 intron 23934736 rs735937 chr1 95335769 T C 1.95E-05 Iron levels SLC44A3 intron 19880490 rs735937 chr1 95335769 T C 1.95E-05 Iron levels SLC44A3 intron pha002876 rs10493878 chr1 95337418 T C 2.96E-05 Lipoproteins SLC44A3 intron pha003079 rs7531174 chr1 95338091 A G 1.60E-04 Type 2 diabetes and 6 quantitative traits SLC44A3 intron 17848626 rs6700314 chr1 95346659 G A 3.91E-04 Multiple complex diseases SLC44A3 intron 17554300 rs12067920 chr1 95379758 A G 3.55E-04 Response to taxane treatment (placlitaxel) CNN3 intron 23006423 rs860873 chr1 95387208 G A 2.00E-14 Stearic acid (18:0) plasma levels CNN3 intron 23362303 rs11165281 chr1 95429780 G T 6.47E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6698046 chr1 95449282 A G 4.59E-04 Multiple complex diseases ALG14 intron 17554300 rs2391388 chr1 95485825 A C 3.00E-11 Palmitic acid (16:0) plasma levels ALG14 intron 23362303 rs6675668 chr1 95515637 T G 2.00E-18 Stearic acid (18:0) plasma levels ALG14 intron 23362303 rs6674604 chr1 95517539 C A 1.67E-05 Cleft lip ALG14 intron 20436469 rs12037609 chr1 95518483 C T 5.56E-04 Multiple complex diseases ALG14 intron 17554300 rs4630159 chr1 95543678 G T 8.03E-04 Multiple complex diseases / / 17554300 rs4950058 chr1 95548151 T C 8.65E-04 Multiple complex diseases / / 17554300 rs9437689 chr1 95549536 C T 5.00E-08 Phospholipid levels (plasma) / / 22359512 rs4950059 chr1 95551129 C T 2.01E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs7512953 chr1 95554294 T G 2.30E-05 Malaria / / 19465909 rs7512953 chr1 95554294 T G 2.55E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12562498 chr1 95555165 C T 2.58E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs12563154 chr1 95562187 C T 2.24E-04 Response to cytidine analogues (gemcitabine) TMEM56 intron 24483146 rs4950076 chr1 95577297 T C 7.04E-04 Response to cytidine analogues (gemcitabine) TMEM56 intron 24483146 rs11165315 chr1 95592609 A G 4.93E-04 Smoking initiation TMEM56 intron 24665060 rs7366121 chr1 95596496 G T 0.000253322 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs10874905 chr1 95598593 A C 1.82E-04 Smoking initiation TMEM56 intron 24665060 rs12039183 chr1 95611650 A G 0.00039702 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs10157405 chr1 95614838 T C 8.89E-05 Fibrinogen TMEM56 intron pha003068 rs997370 chr1 95619368 T G 0.000217114 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs11165321 chr1 95619743 G A 0.000208004 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs2148796 chr1 95622341 C T 0.000125941 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs10874906 chr1 95630658 T C 0.000291725 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs965314 chr1 95633722 A G 8.35E-05 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs11165334 chr1 95638667 A G 9.78E-05 Non-alcoholic fatty liver disease histology (other) TMEM56 intron 20708005 rs11165334 chr1 95638667 A G 0.00061292 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs10458508 chr1 95643224 T C 0.00061292 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs6703408 chr1 95656546 T C 0.00061292 Hypertension (early onset hypertension) TMEM56 intron 22479346 rs1556742 chr1 95674341 C A 7.43E-05 Hypertension (early onset hypertension) TMEM56-RWDD3 intron 22479346 rs1414896 chr1 95692310 G A 2.00E-06 Non-alcoholic fatty liver disease histology (AST) TMEM56-RWDD3 intron 20708005 rs6671200 chr1 95697529 A C 2.00E-15 Stearic acid (18:0) plasma levels TMEM56-RWDD3 intron 23362303 rs6671200 chr1 95697529 A C 6.72E-05 Fibrinogen TMEM56-RWDD3 intron pha003068 rs2182021 chr1 95769863 C T 3.52E-05 Fibrinogen / / pha003068 rs12118116 chr1 95774330 T C 2.75E-06 Fibrinogen / / pha003068 rs2236390 chr1 95776788 C T 7.89E-05 Stroke / / pha002886 rs17113360 chr1 95782459 T C 3.16E-04 Suicide attempts in bipolar disorder / / 21041247 rs17113368 chr1 95786229 C T 1.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs17113374 chr1 95789364 C T 1.78E-04 Suicide attempts in bipolar disorder / / 21041247 rs2391635 chr1 95794306 C T 5.36E-04 Type 2 diabetes / / 17463246 rs11165389 chr1 95815863 T G 3.47E-11 Schizophrenia / / 22037555 rs11590181 chr1 95818596 T G 3.17E-04 Suicide attempts in bipolar disorder / / 21041247 rs11165396 chr1 95823682 C T 2.50E-05 Urinary metabolites / / 21572414 rs11165403 chr1 95829158 T G 6.92E-04 Type 2 diabetes / / 17463246 rs11165406 chr1 95832611 G A 2.50E-05 Urinary metabolites / / 21572414 rs7531902 chr1 95835124 A G 2.82E-04 Alzheimer's disease (late onset) / / 21379329 rs11586346 chr1 95861202 A C 1.90E-04 Suicide attempts in bipolar disorder / / 21041247 rs17113478 chr1 95861722 C G 1.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs4950054 chr1 95890977 C T 2.10E-05 Urinary metabolites / / 21572414 rs4949963 chr1 95906877 T A 2.10E-05 Urinary metabolites / / 21572414 rs12032935 chr1 95915727 G T 2.30E-05 Urinary metabolites / / 21572414 rs12040149 chr1 95915823 C A 2.40E-05 Urinary metabolites / / 21572414 rs979015 chr1 95920476 A G 1.08E-05 C-Reactive Protein / / pha003070 rs12409850 chr1 95947820 A G 4.54E-05 Body Mass Index / / pha003019 rs12409850 chr1 95947820 A G 1.26E-05 Body Mass Index / / pha003020 rs1577863 chr1 95967757 G A 2.94E-04 HIV-1 viral setpoint / / 17641165 rs11165433 chr1 95976798 A G 8.79E-05 Obesity (extreme) / / 21935397 rs1582123 chr1 95977445 A G 1.00E-04 Obesity (extreme) / / 21935397 rs945827 chr1 95981576 G A 9.56E-05 Obesity (extreme) / / 21935397 rs876394 chr1 95982340 T C 8.36E-05 Body Mass Index / / pha003020 rs945826 chr1 95984156 G A 9.24E-04 Type 2 diabetes / / 17463246 rs945826 chr1 95984156 G A 9.45E-05 Obesity (extreme) / / 21935397 rs881713 chr1 95985066 G A 6.34E-04 Multiple complex diseases / / 17554300 rs881713 chr1 95985066 G A 4.03E-04 Suicide attempts in bipolar disorder / / 21041247 rs881713 chr1 95985066 G A 8.44E-04 Stroke / / pha002886 rs11165434 chr1 95986339 G T 4.04E-04 Suicide attempts in bipolar disorder / / 21041247 rs491043 chr1 95987974 A G 1.04E-04 Obesity (extreme) / / 21935397 rs12135050 chr1 95992463 G A 4.26E-04 Suicide attempts in bipolar disorder / / 21041247 rs7522301 chr1 95993281 C T 1.06E-04 Obesity (extreme) / / 21935397 rs611087 chr1 95995427 A G 1.07E-04 Obesity (extreme) / / 21935397 rs12136757 chr1 95997068 T C 4.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs12141480 chr1 95998883 G C 4.42E-04 Suicide attempts in bipolar disorder / / 21041247 rs1509178 chr1 96001525 T C 4.43E-04 Suicide attempts in bipolar disorder / / 21041247 rs563232 chr1 96008701 C T 9.95E-05 Obesity (extreme) / / 21935397 rs678378 chr1 96008944 A G 4.59E-04 Suicide attempts in bipolar disorder / / 21041247 rs1355136 chr1 96019439 C T 5.07E-04 Suicide attempts in bipolar disorder / / 21041247 rs519693 chr1 96023412 C T 5.66E-04 Suicide attempts in bipolar disorder / / 21041247 rs1396626 chr1 96025546 G A 3.36E-05 Partial epilepsies / / 20522523 rs1396626 chr1 96025546 G A 3.32E-05 Epilepsy / / 22116939 rs12145270 chr1 96025590 T A 7.73E-04 Suicide attempts in bipolar disorder / / 21041247 rs12125877 chr1 96025725 C G 7.91E-04 Suicide attempts in bipolar disorder / / 21041247 rs12125905 chr1 96025809 C G 8.38E-04 Suicide attempts in bipolar disorder / / 21041247 rs592158 chr1 96102889 G C 9.11E-04 Type 2 diabetes / / 17463246 rs6693882 chr1 96145968 A G 2.00E-06 Pain / / 19207018 rs12142219 chr1 96148182 A G 8.79E-05 Orofacial clefts / / 22419666 rs7554994 chr1 96152973 T C 4.26E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs1931260 chr1 96173170 T C 7.64E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1931255 chr1 96187319 G A 5.05E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs2051029 chr1 96309286 G A 5.92E-05 Platelet counts / / pha003100 rs12564173 chr1 96311796 T G 6.14E-05 Platelet counts / / pha003100 rs4949973 chr1 96316274 T C 9.70E-04 Multiple complex diseases / / 17554300 rs11165503 chr1 96317398 A G 6.77E-04 Suicide attempts in bipolar disorder / / 21423239 rs1342397 chr1 96343511 C T 8.80E-04 Suicide attempts in bipolar disorder / / 21423239 rs10874963 chr1 96343561 C G 9.39E-04 Suicide attempts in bipolar disorder / / 21423239 rs1539359 chr1 96347574 C T 9.19E-04 Suicide attempts in bipolar disorder / / 21423239 rs12122872 chr1 96348379 C T 4.66E-04 Suicide attempts in bipolar disorder / / 21423239 rs1418454 chr1 96357521 G A 8.67E-04 Suicide attempts in bipolar disorder / / 21423239 rs11165509 chr1 96359485 A G 6.35E-04 Suicide attempts in bipolar disorder / / 21423239 rs11165510 chr1 96365162 C T 7.55E-04 Suicide attempts in bipolar disorder / / 21423239 rs11165512 chr1 96366519 G A 3.51E-04 Gallstones / / 17632509 rs17420083 chr1 96422669 G A 9.78E-04 Type 2 diabetes / / 17463246 rs1889060 chr1 96425796 A T 3.40E-06 Urinary metabolites / / 21572414 rs619758 chr1 96481173 T C 2.90E-05 Urinary metabolites / / 21572414 rs10518593 chr1 96501069 C A 9.40E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs161110 chr1 96504076 G T 2.20E-05 Urinary metabolites / / 21572414 rs184412 chr1 96505335 G A 2.20E-05 Urinary metabolites / / 21572414 rs150892 chr1 96516252 C T 2.50E-05 Urinary metabolites / / 21572414 rs222887 chr1 96526728 G T 9.04E-05 Eosinophil counts / / pha003088 rs1144326 chr1 96541099 A G 2.20E-05 Urinary metabolites / / 21572414 rs223246 chr1 96551837 A C 1.40E-05 Urinary metabolites / / 21572414 rs223245 chr1 96552025 G A 1.40E-05 Urinary metabolites / / 21572414 rs12089599 chr1 96586426 C T 1.00E-05 Urinary metabolites / / 21572414 rs1222069 chr1 96595179 A C 1.60E-05 Cognitive function / / 24684796 rs2391735 chr1 96604969 A G 1.31E-04 Multiple complex diseases / / 17554300 rs321580 chr1 96647642 A G 2.43E-05 Smoking initiation / / 24665060 rs321564 chr1 96655156 C A,G,T 3.42E-05 Smoking initiation / / 24665060 rs321566 chr1 96656104 C T 4.13E-04 Type 2 diabetes / / 17463246 rs321567 chr1 96656207 C T 3.17E-04 Smoking initiation / / 24665060 rs17114704 chr1 96666138 T G 5.94E-05 Cognitive test performance / / 20125193 rs17374320 chr1 96673887 G T 3.49E-04 Alzheimer's disease / / 17998437 rs17365931 chr1 96679692 C T 8.05E-04 Alzheimer's disease / / 17998437 rs321588 chr1 96688818 G A 6.81E-05 Blood Pressure / / pha003040 rs901469 chr1 96723560 A G 5.71E-05 Cognitive test performance / / 20125193 rs324867 chr1 96755467 C T 8.78E-04 Multiple complex diseases / / 17554300 rs10874992 chr1 96775958 G A 8.80E-06 Urinary metabolites / / 21572414 rs11165585 chr1 96780748 A G 7.20E-06 Urinary metabolites / / 21572414 rs11165590 chr1 96791584 T G 8.50E-06 Urinary metabolites / / 21572414 rs17114928 chr1 96793488 C T 2.50E-05 Urinary metabolites / / 21572414 rs4000377 chr1 96802619 A T 2.10E-06 Urinary metabolites / / 21572414 rs324870 chr1 96803851 T C 1.00E-04 Tuberculosis / / 20694014 rs162018 chr1 96817319 C T 5.76E-04 Multiple complex diseases / / 17554300 rs12737060 chr1 96819473 T C 1.00E-05 Urinary metabolites / / 21572414 rs6593598 chr1 96908637 T C 6.06E-04 Insulin resistance / / 21901158 rs927512 chr1 96932939 A G 4.15E-04 Insulin resistance / / 21901158 rs1973993 chr1 96943994 T C 1.00E-06 Weight / / 19079260 rs1973993 chr1 96943994 T C 1.30E-05 Smoking behavior / / 20418888 rs1555543 chr1 96944797 A C 4.00E-10 Body mass index / / 20935630 rs1555543 chr1 96944797 A C 3.68E-10 Body mass index / / 23001569 rs1967769 chr1 96993449 T C 2.05E-04 Multiple complex diseases / / 17554300 rs3912027 chr1 96993603 G T 2.09E-04 Multiple complex diseases / / 17554300 rs12120893 chr1 97007132 C T 2.30E-05 Urinary metabolites / / 21572414 rs17426562 chr1 97036113 G A 9.25E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs10783050 chr1 97037083 T C 4.00E-06 Body mass index / / 19079260 rs10783050 chr1 97037083 T C 2.80E-06 Smoking behavior / / 20418888 rs11165690 chr1 97113731 T C 1.78E-06 Schizophrenia / / 19571811 rs12071951 chr1 97113915 T G 5.00E-07 Schizophrenia / / 22688191 rs6673531 chr1 97115049 G A 1.41E-05 Bipolar disorder / / 21771265 rs1496116 chr1 97152559 T C 1.78E-09 Narcolepsy / / 19629137 rs7544736 chr1 97164343 A G 6.00E-07 Schizophrenia / / 19571811 rs10875032 chr1 97198331 G T 8.99E-06 Bipolar disorder PTBP2 intron 21771265 rs10489798 chr1 97245046 A G 6.20E-05 Electrocardiographic traits and heart rate variability PTBP2 intron 17903306 rs12725199 chr1 97293792 C A 2.00E-04 Systolic blood pressure / / 19430483 rs12740489 chr1 97296935 G A 6.73E-05 Blood Pressure / / pha002903 rs635578 chr1 97304571 C A 5.72E-04 Type 2 diabetes / / 17463246 rs559734 chr1 97304868 G C 8.48E-04 Lymphocyte counts / / 22286170 rs11584143 chr1 97316690 G A 1.22E-04 Epilepsy / / 22116939 rs1401836 chr1 97332684 C T 1.82E-05 Type 2 diabetes / / 17463246 rs11165731 chr1 97340388 A G 1.02E-04 Type 2 diabetes / / 17463246 rs12069698 chr1 97352212 C G 9.96E-05 Type 2 diabetes / / 17463246 rs6675133 chr1 97353641 T C 1.50E-05 Type 2 diabetes / / 17463246 rs2681194 chr1 97365977 C T 9.67E-05 Blood Pressure / / pha002903 rs2681194 chr1 97365977 C T 2.42E-05 Height / / pha003011 rs950390 chr1 97374535 A T 9.55E-05 Type 2 diabetes / / 17463246 rs950390 chr1 97374535 A T 5.07E-04 Multiple complex diseases / / 17554300 rs4433451 chr1 97378162 C T 3.23E-05 Type 2 diabetes / / 17463246 rs2030342 chr1 97388226 C T 9.42E-05 Height / / pha003010 rs2030342 chr1 97388226 C T 1.27E-05 Height / / pha003011 rs6659733 chr1 97404744 A G 5.23E-05 Type 2 diabetes / / 17463246 rs10493887 chr1 97410506 T C 6.02E-05 Type 2 diabetes / / 17463246 rs10493887 chr1 97410506 T C 5.34E-04 Multiple complex diseases / / 17554300 rs11165745 chr1 97428382 T G 8.09E-05 Epilepsy (remission after treatment) / / 23962720 rs10493888 chr1 97434827 G C 3.29E-04 Type 2 diabetes / / 17463246 rs10493888 chr1 97434827 G C 9.06E-05 Epilepsy (remission after treatment) / / 23962720 rs3002273 chr1 97439491 G T 7.51E-05 Height / / pha003011 rs10493889 chr1 97447183 T C 8.00E-04 Colorectal cancer / / 17618283 rs182358 chr1 97463150 C T 8.90E-06 Major depressive disorder / / 21042317 rs290822 chr1 97469304 C G 3.38E-08 Pure-tone audiometry / / pha001964 rs290825 chr1 97477667 A G 8.99E-04 Multiple complex diseases / / 17554300 rs11165765 chr1 97490921 C T 9.87E-04 Multiple complex diseases / / 17554300 rs6656001 chr1 97498401 T A 3.35E-04 Multiple complex diseases / / 17554300 rs6664634 chr1 97498499 G A 2.91E-04 Multiple complex diseases / / 17554300 rs11165783 chr1 97569544 T C 7.50E-05 Tooth agenesis (third molar) DPYD intron 24172245 rs1399291 chr1 97576922 C T 2.55E-05 Hypertension DPYD intron 21082022 rs9437663 chr1 97585937 A G 6.49E-04 Suicide attempts in bipolar disorder DPYD intron 21423239 rs10493890 chr1 97588830 C T 6.33E-04 Cognition,early reading ability DPYD intron 17684495 rs6593634 chr1 97635212 A C 4.39E-04 HIV-1 viral setpoint DPYD intron 17641165 rs10875053 chr1 97636966 C G 3.74E-04 Coronary Artery Disease DPYD intron 17634449 rs7529372 chr1 97647338 C T 3.45E-08 Metabolite levels DPYD intron 23281178 rs6656660 chr1 97649209 G T 3.45E-08 Metabolite levels DPYD intron 23281178 rs4128473 chr1 97672838 T C 5.16E-08 Metabolite levels DPYD intron 23281178 rs17116566 chr1 97686367 A G 2.57E-04 Multiple complex diseases DPYD intron 17554300 rs17116594 chr1 97701403 C T 6.96E-04 Response to taxane treatment (placlitaxel) DPYD intron 23006423 rs12758854 chr1 97711561 G A 0.0000572 Tuberculosis with late age of onset DPYD intron 22551897 rs493517 chr1 97721227 A G 5.13E-05 Partial epilepsies DPYD intron 20522523 rs495257 chr1 97721392 A G 6.06E-05 Partial epilepsies DPYD intron 20522523 rs644428 chr1 97737704 C T 7.31E-04 Multiple complex diseases DPYD intron 17554300 rs7512040 chr1 97781640 G A,C,T 7.35E-04 Response to cytidine analogues (gemcitabine) DPYD intron 24483146 rs10875069 chr1 97793775 T G 3.48E-04 Response to cytidine analogues (gemcitabine) DPYD intron 24483146 rs1607779 chr1 97794265 C A 3.51E-05 Cognitive impairment induced by topiramate DPYD intron 22091778 rs11165846 chr1 97819667 C G 9.00E-06 Platelet counts DPYD intron 21507922 rs12403997 chr1 97832736 G A 2.24E-04 Vaspin levels DPYD intron 22907691 rs12403997 chr1 97832736 G A 0.0002237 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks DPYD intron 22907730 rs11165851 chr1 97845577 T A 4.63E-24 Narcolepsy DPYD intron 19629137 rs6665429 chr1 97853619 C T 3.25E-04 Amyotrophic Lateral Sclerosis DPYD intron 17362836 rs4950031 chr1 97854245 T G 1.16E-04 Vaspin levels DPYD intron 22907691 rs4950031 chr1 97854245 T G 0.0001162 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks DPYD intron 22907730 rs7538155 chr1 97855144 T C 1.16E-04 Vaspin levels DPYD intron 22907691 rs7538155 chr1 97855144 T C 0.0001162 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks DPYD intron 22907730 rs7530072 chr1 97856731 C T 7.57E-04 Myopia (pathological) DPYD intron 21095009 rs7530072 chr1 97856731 C T 1.16E-04 Vaspin levels DPYD intron 22907691 rs7530072 chr1 97856731 C T 0.0001162 Treatment outcomes for selective serotonin reuptake inhibitors (SSRIs) - response at 8 weeks DPYD intron 22907730 rs955850 chr1 97857761 T C 6.01E-04 Amyotrophic Lateral Sclerosis DPYD intron 17362836 rs11165870 chr1 97895762 T C 4.34E-05 Serum metabolites DPYD intron 19043545 rs11165870 chr1 97895762 T C 7.16E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs2225882 chr1 97896277 T G 4.94E-04 Multiple complex diseases DPYD intron 17554300 rs7517433 chr1 97898232 T C 3.50E-05 Left ventricular hypertrophy DPYD intron pha003052 rs12129397 chr1 97900552 A T 7.07E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs11165873 chr1 97902790 A T 7.05E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs4949953 chr1 97904780 T C 7.03E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs7517899 chr1 97907753 C T 6.48E-04 Alzheimer's disease DPYD intron 22005930 rs1415681 chr1 97908878 T G 4.08E-05 Left ventricular hypertrophy DPYD intron pha003052 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 12668918 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 15093568 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 17000684 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 17121937 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 17350823 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 18299612 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 19147868 rs3918290 chr1 97915614 C T 1 Drug response to Fluorouracil DPYD splice-3 9817272 rs3897854 chr1 97918306 C T 6.33E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs12354219 chr1 97920956 T C 6.32E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs7531138 chr1 97923499 T A 1.52E-04 Suicide attempts in bipolar disorder DPYD intron 21041247 rs7550959 chr1 97926839 G A 9.59E-05 Suicide attempts in bipolar disorder DPYD intron 21041247 rs4451581 chr1 97949431 A C 2.10E-05 Inflammatory demyelinating disease DPYD intron 19850125 rs2811182 chr1 97971440 G A 2.74E-05 Amyotrophic lateral sclerosis (sporadic) DPYD intron 24529757 rs11165887 chr1 97974659 G A 1.50E-05 Urinary metabolites DPYD intron 21572414 rs1801159 chr1 97981395 T C 1 Drug response to Fluorouracil DPYD missense 17848752 rs1801159 chr1 97981395 T C 1 Drug response to Fluorouracil DPYD missense 9918128 rs7519652 chr1 97984103 C A 2.70E-05 Urinary metabolites DPYD intron 21572414 rs2811173 chr1 97992257 C T 9.01E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin) DPYD intron 23648065 rs2786785 chr1 97997645 A T 2.00E-04 Cognitive impairment induced by topiramate DPYD intron 22091778 rs4950041 chr1 98003908 A G 4.34E-04 Alzheimer's disease (late onset) DPYD intron 21379329 rs6663357 chr1 98044939 A C 7.94E-04 Response to cytadine analogues (cytosine arabinoside) DPYD intron 24483146 rs7533902 chr1 98079228 T C 1.20E-04 Obesity-related traits DPYD intron 17903300 rs17117003 chr1 98082388 A C 1.34E-04 Multiple complex diseases DPYD intron 17554300 rs2786508 chr1 98141828 C T 4.42E-06 Sleep duration DPYD intron 22105623 rs2297595 chr1 98165091 T C 1 Drug response to Capecitabine DPYD missense 19104657 rs2297595 chr1 98165091 T C 1 Drug response to Fluorouracil DPYD missense 19104657 rs10493895 chr1 98271226 A C 1.60E-05 Blood Phenotypes DPYD intron 17903294 rs4246514 chr1 98297731 C G 4.21E-04 Multiple complex diseases DPYD intron 17554300 rs4421623 chr1 98316285 T G 9.57E-04 Multiple complex diseases DPYD intron 17554300 rs4372296 chr1 98320492 C A 9.17E-04 Multiple complex diseases DPYD intron 17554300 rs4379706 chr1 98322379 C T 9.29E-04 Multiple complex diseases DPYD intron 17554300 rs1801265 chr1 98348885 G A 1 Drug response to Fluorouracil / / 17848752 rs1801265 chr1 98348885 G A 1 Drug response to Fluorouracil / / 9918128 rs9324380 chr1 98461132 G C 2.20E-05 Urinary metabolites MIR137HG intron 21572414 rs77177281 chr1 98471702 A G 2.00E-06 PR interval in Tripanosoma cruzi seropositivity MIR137HG intron 24324551 rs1198572 chr1 98497176 A C 3.14E-05 Aging (time to event) MIR137HG intron 21782286 rs1625579 chr1 98502934 G T 2.00E-11 Schizophrenia MIR137HG intron 21926974 rs1625579 chr1 98502934 G T 2.00E-11 Autism spectrum disorder,attention deficit-hyperactivity disorder,bipolar disorder,major depressive disorder,and schizophrenia (combined) MIR137HG intron 23453885 rs1625579 chr1 98502934 G T 0.00000376 Schizophrenia MIR137HG intron 23637625 rs12410326 chr1 98546248 T C 1.64E-05 Multiple complex diseases / / 17554300 rs1198588 chr1 98552832 A T 5.00E-07 Schizophrenia / / 22688191 rs1198588 chr1 98552832 A T 2.00E-12 Schizophrenia / / 23974872 rs1507061 chr1 98569656 G A 1.61E-05 Major depressive disorder / / 21621269 rs6679864 chr1 98579211 A G 6.45E-04 Suicide attempts in bipolar disorder / / 21423239 rs355374 chr1 98588753 A G 0.000317882 Hypertension (early onset hypertension) / / 22479346 rs17117765 chr1 98601247 T C 5.26E-04 Multiple complex diseases / / 17554300 rs2632303 chr1 98617672 T C 5.85E-04 Multiple complex diseases / / 17554300 rs2660309 chr1 98622407 C T 4.35E-05 Hypertension (early onset hypertension) / / 22479346 rs12734505 chr1 98627901 A G 2.34E-05 Major depressive disorder / / 21621269 rs10493900 chr1 98645213 A G 7.10E-05 Cardiovascular disease / / 17903304 rs698997 chr1 98659529 C T 5.85E-04 Suicide attempts in bipolar disorder / / 21423239 rs11577139 chr1 98666125 C A 8.00E-07 Prostate cancer / / 21743057 rs11165973 chr1 98719851 G A 4.03E-07 Multiple complex diseases LOC729987 intron 17554300 rs6664206 chr1 98840567 A T 1.13E-04 Alzheimer's disease (late onset) / / 21460841 rs17118281 chr1 98848697 A G 5.96E-05 Alzheimer's disease (late onset) / / 21460841 rs1328306 chr1 98882770 T C 2.40E-05 Urinary metabolites / / 21572414 rs17118459 chr1 98925555 T C 5.55E-05 Multiple complex diseases / / 17554300 rs4950128 chr1 98927114 C A,G 4.78E-04 Type 2 diabetes / / 17463246 rs1434364 chr1 98927742 C T 3.78E-04 Type 2 diabetes / / 17463246 rs770918 chr1 98928937 A G 9.10E-04 Crohn's disease / / 17684544 rs648124 chr1 98937092 C T 1.56E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs591520 chr1 98964498 A G 6.50E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs591545 chr1 98964518 T C 6.27E-04 Suicide attempts in bipolar disorder / / 21041247 rs3867319 chr1 98964760 G A 8.84E-04 Suicide attempts in bipolar disorder / / 21041247 rs12064487 chr1 99021875 G A 0.00080188 Sarcoidosis / / 22952805 rs12129212 chr1 99096771 T C 1.00E-04 Prostate cancer / / 21743057 rs4402170 chr1 99129503 C G 6.98E-04 Multiple complex diseases SNX7 intron 17554300 rs6577322 chr1 99164434 G A 5.71E-04 Multiple complex diseases SNX7 cds-synon 17554300 rs9727115 chr1 99177253 G A 2.00E-07 Proinsulin levels SNX7 intron 21873549 rs12725220 chr1 99184798 G A 3.08E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all anthracycline-based drugs) SNX7 intron 23648065 rs17118895 chr1 99209996 A G 9.15E-05 Multiple complex diseases SNX7 intron 17554300 rs6674890 chr1 99231152 A T 8.50E-04 Multiple complex diseases / / 17554300 rs4908035 chr1 99236025 T C 1.01E-04 Multiple complex diseases / / 17554300 rs1384168 chr1 99242320 C T 6.07E-05 Multiple complex diseases / / 17554300 rs7524208 chr1 99290670 C T 4.40E-04 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) / / 24023788 rs11166132 chr1 99317472 A C 4.36E-04 Fibrinogen / / 17255346 rs11166132 chr1 99317472 A C 6.22E-04 Type 2 diabetes / / 17463246 rs1358432 chr1 99318760 G A 4.36E-04 Fibrinogen / / 17255346 rs1358431 chr1 99318835 A G 4.36E-04 Fibrinogen / / 17255346 rs10493905 chr1 99334877 A G 4.44E-04 Multiple complex diseases / / 17554300 rs11166135 chr1 99348836 A G 1.00E-06 Dental caries / / 23064961 rs984271 chr1 99358358 G T 4.63E-04 Alzheimer's disease LPPR5 UTR-3 22005930 rs1481501 chr1 99359944 A G 3.18E-04 Alzheimer's disease LPPR5 intron 22005930 rs10875195 chr1 99365922 C T 1.84E-04 Alzheimer's disease LPPR5 intron 22005930 rs1871786 chr1 99366163 T C 5.01E-04 Alzheimer's disease LPPR5 intron 22005930 rs6679030 chr1 99366837 T C 6.49E-04 Alzheimer's disease LPPR5 intron 22005930 rs6675949 chr1 99366952 A G 1.09E-04 Taste perception LPPR5 intron 22132133 rs1383832 chr1 99367844 G A 4.86E-04 Alzheimer's disease LPPR5 intron 22005930 rs10875196 chr1 99378914 G A 9.57E-05 Rheumatoid arthritis LPPR5 intron 17804836 rs1471581 chr1 99382491 A G 8.93E-04 Coronary Artery Disease LPPR5 intron 17634449 rs1571500 chr1 99386293 T C 2.00E-06 Dental caries LPPR5 intron 23259602 rs2497750 chr1 99407351 A G 3.07E-04 Height LPPR5 intron 17255346 rs382051 chr1 99426616 C T 6.19E-04 Suicide attempts in bipolar disorder LPPR5 intron 21423239 rs6682665 chr1 99433123 T G 4.94E-04 Multiple complex diseases LPPR5 intron 17554300 rs1360152 chr1 99440212 A T 4.90E-04 Multiple complex diseases LPPR5 intron 17554300 rs309061 chr1 99443077 T G 7.57E-04 Suicide attempts in bipolar disorder LPPR5 intron 21423239 rs12084355 chr1 99449969 T C 6.38E-04 Multiple complex diseases LPPR5 intron 17554300 rs10443196 chr1 99453287 T C 9.00E-06 Obesity-related traits LPPR5 intron 23251661 rs10489924 chr1 99458974 T C 7.00E-04 Crohn's disease LPPR5 intron 17684544 rs10489925 chr1 99461323 T C 4.90E-04 Multiple complex diseases LPPR5 intron 17554300 rs7413228 chr1 99484386 A C 6.83E-04 Heart Failure LOC100129620 intron pha002885 rs12030123 chr1 99486885 G A 1.38E-04 Heart Failure LOC100129620 intron pha002885 rs1350176 chr1 99495135 G T 5.78E-04 Heart Failure LOC100129620 intron pha002885 rs7530449 chr1 99515902 T G 7.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) LOC100129620 intron 23648065 rs10493907 chr1 99516241 C G 4.90E-04 Multiple complex diseases LOC100129620 intron 17554300 rs897603 chr1 99518345 A G 5.16E-06 Obesity-related traits LOC100129620 intron 23251661 rs10747502 chr1 99524047 A G 1.00E-09 Myopia (pathological) LOC100129620 intron 23049088 rs10747502 chr1 99524047 A G 5.00E-07 Obesity-related traits LOC100129620 intron 23251661 rs12409665 chr1 99530067 T G 3.18E-05 Parkinson's disease (motor and cognition) LOC100129620 intron 22658654 rs12409665 chr1 99530067 T G 3.18E-05 Immune response to anthrax vaccine LOC100129620 intron 22658931 rs17119481 chr1 99533944 A C 2.39E-04 Alzheimer's disease (late onset) LOC100129620 intron 21379329 rs17119481 chr1 99533944 A C 7.66E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel) LOC100129620 intron 23648065 rs12411241 chr1 99551140 A G 2.44E-05 Blood Pressure LOC100129620 intron pha003050 rs17119565 chr1 99583493 C A 6.03E-04 Multiple complex diseases LOC100129620 intron 17554300 rs303386 chr1 99589379 C T 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (all topoisomerase inhibitors) LOC100129620 intron 23648065 rs303386 chr1 99589379 C T 4.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (camptothecin) LOC100129620 intron 23648065 rs302748 chr1 99597328 A G 7.57E-04 Myopia (pathological) LOC100129620 intron 21095009 rs302748 chr1 99597328 A G 7.47E-05 Blood Pressure LOC100129620 intron pha003044 rs863686 chr1 99610153 A G 9.73E-06 Hearing function LOC100129620 intron 21493956 rs587509 chr1 99615714 C T 4.86E-06 Hearing function / / 21493956 rs621215 chr1 99619424 G A 3.73E-06 Hearing function / / 21493956 rs687101 chr1 99637572 G A 6.25E-07 Hearing function / / 21493956 rs604876 chr1 99641020 T C 1.91E-06 Hearing function / / 21493956 rs638723 chr1 99641669 A G 6.59E-07 Hearing function / / 21493956 rs668206 chr1 99643963 G T 9.64E-07 Hearing function / / 21493956 rs6577368 chr1 99644223 A G 4.72E-04 Insulin resistance / / 21901158 rs712937 chr1 99645446 A G 3.15E-07 Hearing function / / 21493956 rs712936 chr1 99647039 T C 2.84E-07 Hearing function / / 21493956 rs712934 chr1 99648976 T A 2.33E-07 Hearing function / / 21493956 rs712932 chr1 99651500 G C 2.32E-07 Hearing function / / 21493956 rs12080341 chr1 99653855 A G 3.30E-04 Insulin resistance / / 21901158 rs712931 chr1 99654168 G T 2.38E-07 Hearing function / / 21493956 rs819786 chr1 99654527 G A 2.39E-07 Hearing function / / 21493956 rs819785 chr1 99655620 G A 2.41E-07 Hearing function / / 21493956 rs3911410 chr1 99660145 G A 2.44E-06 Hearing function / / 21493956 rs664835 chr1 99663968 T A 4.74E-07 Hearing function / / 21493956 rs819778 chr1 99665186 A G 5.00E-07 Hearing function / / 21493956 rs645441 chr1 99670057 T G 5.65E-07 Hearing function / / 21493956 rs685267 chr1 99671349 A C 8.37E-07 Hearing function / / 21493956 rs819797 chr1 99687402 G A 5.74E-06 Ankle-brachial index / / 22199011 rs7530667 chr1 99691732 T C 8.43E-06 Ankle-brachial index / / 22199011 rs819746 chr1 99693744 C A 5.04E-06 Ankle-brachial index / / 22199011 rs819748 chr1 99695168 C A 4.19E-06 Ankle-brachial index / / 22199011 rs819750 chr1 99697063 G T 5.11E-04 Ankle-brachial index / / 22199011 rs819756 chr1 99701930 C T 9.71E-06 Ankle-brachial index / / 22199011 rs6577370 chr1 99711864 C A 8.71E-71 Multiple complex diseases / / 17554300 rs6577370 chr1 99711864 C A 4.29E-04 Smoking initiation / / 24665060 rs819910 chr1 99764226 C T 1.14E-05 Lung function (forced vital capacity) LPPR4 intron pha003104 rs819914 chr1 99765872 G A 2.15E-05 Lung function (forced vital capacity) LPPR4 intron pha003104 rs712878 chr1 99780284 T C 1.91E-05 Lung function (forced vital capacity) / / pha003104 rs12135248 chr1 99780891 A G 8.36E-04 Suicide attempts in bipolar disorder / / 21423239 rs12743824 chr1 99782957 C A 5.00E-06 Non-alcoholic fatty liver disease histology (other) / / 23213074 rs12140879 chr1 99793111 G A 6.44E-04 Suicide attempts in bipolar disorder / / 21423239 rs1325957 chr1 99794023 T C 6.07E-04 Suicide attempts in bipolar disorder / / 21423239 rs1419059 chr1 99911058 T C 0.0007631 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs1419059 chr1 99911058 T C 7.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs713265 chr1 99937037 A G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs17120530 chr1 99952060 A G 0.000141 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17120530 chr1 99952060 A G 1.41E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12032219 chr1 99953165 G A 0.00006866 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12032219 chr1 99953165 G A 6.87E-05 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4623724 chr1 99954032 C G 0.0004875 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs4623724 chr1 99954032 C G 4.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4908327 chr1 99993077 C T 5.89E-04 Multiple complex diseases / / 17554300 rs11166266 chr1 99999237 C T 1.87E-14 Gender / / 22362730 rs12135239 chr1 100041459 G A 3.24E-04 Lymphocyte counts / / 22286170 rs6702619 chr1 100046246 T G 0.000000577 Colorectal cancer / / 22532847 rs6702619 chr1 100046246 T G 3.29E-08 Colorectal cancer vs. adenoma controls / / 22532847 rs7543130 chr1 100049785 C A 1.00E-07 Aortic root size / / 19584346 rs1361378 chr1 100071637 T C 7.87E-04 Multiple complex diseases / / 17554300 rs11166284 chr1 100087539 A T 2.80E-05 Urinary metabolites / / 21572414 rs12077588 chr1 100089604 T G 5.61E-05 Multiple complex diseases / / 17554300 rs4908005 chr1 100161691 G T 1.00E-05 Urinary metabolites / / 21572414 rs6679943 chr1 100163271 T C 2.74E-04 Alzheimer's disease / / 24755620 rs12024467 chr1 100190830 G A 0.000242 Salmonella-induced pyroptosis FRRS1 intron 22837397 rs17121183 chr1 100248380 T C 9.68E-04 Alzheimer's disease / / 22005930 rs12023333 chr1 100267478 T C 3.93E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs6689305 chr1 100268991 G A 9.00E-06 White matter integrity (interaction) / / 23218918 rs1493617 chr1 100270735 C A 3.07E-05 Personality dimensions / / 22628180 rs11166344 chr1 100272171 G C 3.93E-05 Blood pressure (response to angiotensin-converting enzyme inhibitor) / / 24192120 rs9887771 chr1 100276744 C G 1.04E-04 Alzheimer's disease / / 24755620 rs11166358 chr1 100305320 T C 7.37E-05 Hearing impairment / / 19047183 rs17121403 chr1 100335977 A G 7.00E-06 Pulmonary function decline AGL missense 22424883 rs903125 chr1 100352470 C A 3.64E-04 Alzheimer's disease AGL intron 24755620 rs3753494 chr1 100358103 C T 3.30E-04 Alzheimer's disease AGL missense 24755620 rs3818568 chr1 100377789 C T 9.50E-06 Urinary metabolites AGL intron 21572414 rs17121644 chr1 100385430 C T 4.78E-05 Age-related macular degeneration AGL intron pha002890 rs2149194 chr1 100401929 G T 1.00E-05 Urinary metabolites / / 21572414 rs1541044 chr1 100411287 T C 6.59E-04 Alzheimer's disease / / 24755620 rs6701658 chr1 100426978 A G 4.60E-05 Glioma (high-grade) / / 19578366 rs7530361 chr1 100462860 T C 5.40E-05 Glioma (high-grade) SLC35A3 intron 19578366 rs7518943 chr1 100463422 C A 1.27E-04 Alzheimer's disease SLC35A3 intron 17998437 rs7518943 chr1 100463422 C A 1.96E-04 Alzheimer's disease SLC35A3 intron pha002879 rs11166389 chr1 100466279 G A 6.10E-08 Glioma (high-grade) SLC35A3 intron 19578366 rs495871 chr1 100474456 C T 3.21E-05 Age-related macular degeneration SLC35A3 intron pha002890 rs575323 chr1 100482396 G A 3.32E-05 Age-related macular degeneration SLC35A3 intron pha002890 rs501700 chr1 100520311 G A 2.40E-05 Glioma (high-grade) HIAT1 intron 19578366 rs560659 chr1 100523536 G A 1.92E-04 Alzheimer's disease HIAT1 intron 17998437 rs560659 chr1 100523536 G A 1.01E-04 Alzheimer's disease HIAT1 intron pha002879 rs644835 chr1 100543962 A G 3.10E-05 Glioma (high-grade) HIAT1 intron 19578366 rs640030 chr1 100574992 C T 3.10E-05 Glioma (high-grade) SASS6 intron 19578366 rs663519 chr1 100592653 A G 5.59E-05 Vascular dementia SASS6 intron 22116812 rs687513 chr1 100598867 C T 5.10E-05 Glioma (high-grade) CCDC76 missense 19578366 rs6681721 chr1 100609639 C T 2.47E-05 Age-related macular degeneration CCDC76 cds-synon pha002890 rs12733952 chr1 100611571 C T 4.78E-05 Alzheimer's disease CCDC76 intron pha002879 rs506044 chr1 100611931 A G 2.60E-05 Glioma (high-grade) CCDC76 intron 19578366 rs6677080 chr1 100633469 T A 1.44E-04 Alzheimer's disease LRRC39 intron pha002879 rs11166407 chr1 100637708 G A 2.00E-05 Alzheimer's disease LRRC39 intron 17998437 rs11166407 chr1 100637708 G A 2.01E-05 Alzheimer's disease LRRC39 intron pha002879 rs11166412 chr1 100656265 C T 2.16E-04 Alzheimer's disease DBT UTR-3 pha002879 rs2810424 chr1 100663679 T C 6.30E-06 Glioma (high-grade) DBT intron 19578366 rs12021720 chr1 100672060 T C 1.50E-07 Glioma (high-grade) DBT missense 19578366 rs4143055 chr1 100690122 T C 1.42E-04 Alzheimer's disease DBT intron 17998437 rs4143055 chr1 100690122 T C 2.54E-05 Alzheimer's disease DBT intron pha002879 rs3806237 chr1 100715782 T C 2.00E-04 Cognitive impairment induced by topiramate DBT nearGene-5 22091778 rs17454070 chr1 100732855 T C 1.00E-04 Information processing speed RTCD1 intron 21130836 rs3119186 chr1 100781537 T C 7.42E-04 Multiple complex diseases / / 17554300 rs478859 chr1 100796120 T C 0.00000573 Colorectal adenoma / / 23677573 rs478859 chr1 100796120 T C 0.00000573 Colorectal adenoma (including hyperplasic) / / 23677573 rs478859 chr1 100796120 T C 0.0000274 Colorectal adenoma (excluding hyperplasic) / / 23677573 rs7534479 chr1 100798137 G A 6.30E-04 Depression (quantitative trait) / / 20800221 rs4907906 chr1 100802399 T C 3.70E-06 Urinary metabolites / / 21572414 rs10783130 chr1 100806897 C G 3.41E-08 Metabolite levels / / 23281178 rs11166439 chr1 100808286 G C 3.20E-08 Metabolite levels / / 23281178 rs529224 chr1 100818178 G C 1.57E-05 Response to statin treatment (atorvastatin),change in cholesterol levels CDC14A UTR-5 20031582 rs17420882 chr1 100818728 T G 6.98E-04 Response to statin treatment (atorvastatin),change in cholesterol levels CDC14A intron 20031582 rs630646 chr1 100822776 G A 3.40E-06 Urinary metabolites CDC14A intron 21572414 rs17122341 chr1 100843757 C A 1.30E-05 Urinary metabolites CDC14A intron 21572414 rs7512321 chr1 100862989 C G 3.38E-04 Multiple complex diseases CDC14A intron 17554300 rs584350 chr1 100908324 A G 5.20E-06 Urinary metabolites CDC14A intron 21572414 rs10493923 chr1 100930254 C T 1.20E-05 Urinary metabolites CDC14A intron 21572414 rs17122625 chr1 100944262 G A 1.38E-04 Multiple complex diseases CDC14A intron 17554300 rs2809823 chr1 101003762 C A 1.80E-05 Post-operative nausea and vomiting GPR88 UTR-5 21694509 rs2030048 chr1 101006577 A G 3.99E-05 Response to statin treatment (atorvastatin),change in cholesterol levels GPR88 UTR-3 20031582 rs1874779 chr1 101012512 G A 3.40E-06 Urinary metabolites / / 21572414 rs12038174 chr1 101013455 C T 1.60E-06 Urinary metabolites / / 21572414 rs11166474 chr1 101015181 C T 1.70E-06 Urinary metabolites / / 21572414 rs10875308 chr1 101024423 T C 8.76E-05 Kawasaki disease / / 22081228 rs1335751 chr1 101027524 T C 2.00E-06 Urinary metabolites / / 21572414 rs10875310 chr1 101027566 C T 9.90E-06 Urinary metabolites / / 21572414 rs1542837 chr1 101029768 T C 3.15E-05 Kawasaki disease / / 22081228 rs2809791 chr1 101039059 C T 5.30E-04 Multiple complex diseases / / 17554300 rs2647327 chr1 101041766 G A 1.80E-05 Urinary metabolites / / 21572414 rs10493929 chr1 101043928 A C 1.60E-05 Urinary metabolites / / 21572414 rs10875317 chr1 101045438 G T 1.80E-05 Urinary metabolites / / 21572414 rs7524322 chr1 101047730 C G 7.60E-06 Urinary metabolites / / 21572414 rs12728424 chr1 101055002 G A 7.27E-05 Kawasaki disease / / 22081228 rs11583008 chr1 101085094 A G 1.11E-06 Kawasaki disease / / 22081228 rs17412243 chr1 101094662 G A 6.91E-05 Tardive dyskinesia LOC100128787 intron 20939080 rs2484535 chr1 101107748 C T 5.24E-06 Kawasaki disease LOC100128787 intron 22081228 rs955336 chr1 101108982 G A 4.00E-04 Type 2 diabetes LOC100128787 intron 17463246 rs17412577 chr1 101109431 C T 4.00E-05 Tardive dyskinesia LOC100128787 intron 20939080 rs10493934 chr1 101124201 T A 2.75E-05 Tardive dyskinesia / / 20939080 rs1932351 chr1 101142049 C T 1.79E-06 Kawasaki disease / / 22081228 rs2050471 chr1 101175651 C T 9.08E-06 Kawasaki disease / / 22081228 rs3783599 chr1 101183887 C T 0.00000017 Triglycerides VCAM1 nearGene-5 23063622 rs3176860 chr1 101187219 A G 6.24E-04 Depression (quantitative trait) VCAM1 intron 20800221 rs3917056 chr1 101195902 G C 2.61E-09 Triglycerides VCAM1 intron 23063622 rs3181088 chr1 101198708 C T 3.61E-04 Suicide attempts in bipolar disorder VCAM1 intron 21423239 rs3176874 chr1 101199886 A G 2.18E-05 Alcohol dependence VCAM1 intron 21703634 rs3783621 chr1 101204495 C A 9.03E-04 Multiple complex diseases VCAM1 UTR-3 17554300 rs11586136 chr1 101236137 T C 8.35E-06 Primary biliary cirrhosis / / 21399635 rs17123397 chr1 101276999 A G 8.17E-05 Smoking cessation / / 24665060 rs7541397 chr1 101322866 A G 4.61E-05 Smoking cessation / / 24665060 rs11812031 chr1 101327772 A G 5.72E-04 Smoking cessation / / 24665060 rs12048904 chr1 101331536 T C 4.00E-08 Multiple sclerosis / / 21833088 rs7543296 chr1 101348100 C A 4.42E-04 Smoking cessation EXTL2 intron 24665060 rs2893468 chr1 101355549 A G 5.62E-04 Smoking cessation EXTL2 intron 24665060 rs3737580 chr1 101360215 C T 1.53E-04 Depression (quantitative trait) EXTL2 UTR-5 20800221 rs11579723 chr1 101396743 G T 3.03E-04 Smoking cessation SLC30A7 intron 24665060 rs11581062 chr1 101407519 A G 3.00E-10 Multiple sclerosis SLC30A7 intron 21833088 rs12023712 chr1 101462232 G A 1.82E-04 Depression (quantitative trait) DPH5 intron 20800221 rs12119832 chr1 101463138 G A 1.82E-04 Depression (quantitative trait) DPH5 intron 20800221 rs11166536 chr1 101476712 G C 1.82E-04 Depression (quantitative trait) DPH5 intron 20800221 rs17409729 chr1 101535778 T G 7.00E-05 Response to lithium treatment in bipolar disorder LOC100506051 intron 19448189 rs17450029 chr1 101540999 T C 3.00E-06 QT interval (interaction) LOC100506051 intron 23459443 rs950038 chr1 101549316 A G 4.80E-04 Type 2 diabetes and 6 quantitative traits LOC100506029 intron 17848626 rs17410015 chr1 101551926 T C 2.00E-06 Response to antipsychotic treatment LOC100506029 intron 20195266 rs12756986 chr1 101604753 T C 2.00E-04 Blood pressure / / 17255346 rs17417367 chr1 101620729 A G 6.70E-05 Alcohol dependence / / 22096494 rs17123757 chr1 101622960 T C 7.57E-05 Blood pressure / / 17255346 rs1999134 chr1 101681468 A C 4.50E-05 Heart Rate / / pha003053 rs12404070 chr1 101682050 T C 4.95E-04 Multiple complex diseases / / 17554300 rs12404070 chr1 101682050 T C 1.13E-05 Personality dimensions / / 22628180 rs33967958 chr1 101701481 T C 1.00E-04 Cognitive impairment induced by topiramate S1PR1 nearGene-5 22091778 rs17100954 chr1 101704029 G A 0.000026 Coronary artery calcification S1PR1 intron 23727086 rs12090529 chr1 101707126 T C 1.20E-05 HIV-1 control S1PR1 nearGene-3 20041166 rs12097137 chr1 101709445 G T 1.87E-13 HDL cholesterol / / 23063622 rs12097137 chr1 101709445 G T 2.64E-11 Cholesterol,total / / 23063622 rs2031959 chr1 101711783 T G 8.70E-04 Atrial fibrillation / / 21846873 rs765344 chr1 101716688 C T 8.46E-05 Cognitive test performance / / 20125193 rs7532171 chr1 101724951 C T 3.81E-05 Alcohol and nictotine co-dependence / / 20158304 rs7520706 chr1 101751884 T G 1.69E-04 Amyotrophic lateral sclerosis / / 20801718 rs13376006 chr1 101768580 G C 1.15E-04 Type 2 diabetes / / 17463246 rs17124135 chr1 101770101 A G 8.44E-04 Multiple complex diseases / / 17554300 rs9433784 chr1 101784340 G T 7.19E-04 Alcohol dependence / / 21314694 rs12564407 chr1 101809218 A G 4.00E-05 Bipolar disorder / / 24387768 rs12564407 chr1 101809218 A G 4.00E-05 Bipolar disorder / / 24387768 rs11802191 chr1 101834723 C A 7.86E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1491643 chr1 101849423 G A 2.86E-05 Cholesterol / / pha003083 rs6577245 chr1 101849830 G A 1.03E-04 Amyotrophic Lateral Sclerosis / / 17362836 rs12403551 chr1 101864215 G A 3.28E-06 Alopecia areata / / 22027810 rs10493947 chr1 101868793 G A 5.83E-04 Multiple complex diseases / / 17554300 rs10493947 chr1 101868793 G A 8.03E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1826316 chr1 101872865 C T 1.50E-06 Parkinson's disease / / 20711177 rs2338971 chr1 101880005 T C 4.00E-10 Parkinson's disease / / 24511991 rs2338971 chr1 101880005 T C 5.00E-10 Parkinson's disease / / 24511991 rs4908144 chr1 101889855 T C 0.0000153 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs6662461 chr1 101891186 C G 0.0000121 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs11581429 chr1 101913527 C T 9.34E-04 Multiple complex diseases / / 17554300 rs12118351 chr1 101919802 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs10493955 chr1 101922436 A T 6.79E-04 Multiple complex diseases / / 17554300 rs10493955 chr1 101922436 A T 1.30E-05 Urinary metabolites / / 21572414 rs1777877 chr1 101930897 G T 7.70E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1777867 chr1 101937782 C T 1.52E-04 Multiple complex diseases / / 17554300 rs1777867 chr1 101937782 C T 5.40E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1948368 chr1 101938477 G A 6.00E-06 Bipolar disorder / / 18711365 rs1948368 chr1 101938477 G A 5.40E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs726646 chr1 101938663 T G 5.40E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1361812 chr1 101939689 T G 1.26E-05 Cognitive impairment induced by topiramate / / 22091778 rs1419103 chr1 101940656 A T 5.60E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1777894 chr1 101940809 C T 5.60E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1777894 chr1 101940809 C T 9.73E-06 Cognitive impairment induced by topiramate / / 22091778 rs1776911 chr1 101941385 A T 5.70E-05 Bipolar disorder and major depressive disorder (combined) / / 20351715 rs1776907 chr1 101945977 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1776905 chr1 101947657 T A 5.70E-05 Multiple complex diseases / / 17554300 rs387176 chr1 101963766 G A 7.32E-05 Multiple complex diseases / / 17554300 rs396954 chr1 101964376 T A 2.76E-05 Multiple complex diseases / / 17554300 rs374982 chr1 101973050 G A 4.53E-04 Insulin resistance / / 21901158 rs263908 chr1 101973613 C A 9.03E-05 Cognitive impairment induced by topiramate / / 22091778 rs263912 chr1 101975151 T G 2.20E-06 Parkinson's disease / / 20711177 rs263906 chr1 101978334 T C 2.42E-05 Bipolar disorder / / 21926972 rs263906 chr1 101978334 T C 0.000483 Bipolar disorder / / 23070075 rs263918 chr1 101984932 C T 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs263918 chr1 101984932 C T 8.97E-04 Major depressive disorder / / 22472876 rs1688582 chr1 101992222 A G 2.33E-05 Cognitive impairment induced by topiramate / / 22091778 rs12137486 chr1 101994207 C T 5.58E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1199575 chr1 101996097 G A 3.65E-05 Cognitive impairment induced by topiramate / / 22091778 rs12748695 chr1 102000069 C A 6.96E-04 Type 2 diabetes / / 17463246 rs721021 chr1 102016643 T A 9.37E-04 Multiple complex diseases / / 17554300 rs721018 chr1 102016712 G A 5.98E-04 Multiple complex diseases / / 17554300 rs4626910 chr1 102017100 T C 9.03E-04 Multiple complex diseases / / 17554300 rs6665373 chr1 102017438 T G 8.78E-04 Multiple complex diseases / / 17554300 rs984132 chr1 102030001 C T 2.47E-04 Multiple complex diseases / / 17554300 rs11164278 chr1 102184478 T C 0.0000468 Polycystic ovary syndrome / / 22951595 rs11164278 chr1 102184478 T C 4.68E-05 Intracranial aneurysm / / 22961961 rs2225904 chr1 102193896 G A 8.68E-04 Alzheimer's disease / / 24755620 rs1445227 chr1 102199014 A G 3.50E-05 Squamous cell carcinoma / / 23341777 rs1445227 chr1 102199014 A G 8.95E-04 Alzheimer's disease / / 24755620 rs12565816 chr1 102200090 T G 8.95E-04 Alzheimer's disease / / 24755620 rs10493963 chr1 102222083 T C 3.30E-05 Relative hand skill in reading disability / / 24068947 rs12022918 chr1 102225750 C T 2.36E-05 Relative hand skill in reading disability / / 24068947 rs7536591 chr1 102226863 T C 5.24E-05 Relative hand skill in reading disability / / 24068947 rs959163 chr1 102228731 G A 2.88E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs12026998 chr1 102229779 C A 7.27E-04 Multiple complex diseases / / 17554300 rs4908181 chr1 102233475 T C 3.39E-04 Coronary heart disease / / 21971053 rs10874514 chr1 102234964 C T 2.00E-09 Lipid levels / / 18193044 rs1470438 chr1 102239205 G A 5.78E-05 Relative hand skill in reading disability / / 24068947 rs1020368 chr1 102241441 C T 4.35E-05 Relative hand skill in reading disability / / 24068947 rs11164301 chr1 102243101 G A 4.49E-04 Lung function (forced vital capacity) / / 24023788 rs10782852 chr1 102249785 C T 2.48E-05 Relative hand skill in reading disability / / 24068947 rs559183695 chr1 102249785 C CTTCTTTCTAAAGAAAGAGTTTGATGGTTTATCAT 2.48E-05 Relative hand skill in reading disability / / 24068947 rs11164304 chr1 102256943 T C 2.39E-05 Relative hand skill in reading disability / / 24068947 rs10493976 chr1 102263909 C T 8.16E-04 Schizophrenia / / 19197363 rs1854169 chr1 102274276 C T 6.53E-06 Osteoarthritis OLFM3 intron 22763110 rs4907956 chr1 102312703 G T 5.83E-06 Alcohol dependence OLFM3 intron 20202923 rs4907956 chr1 102312703 G T 2.40E-05 Alcohol dependence OLFM3 intron 21703634 rs4907956 chr1 102312703 G T 0.0000507 Nicotine dependence (smoking) OLFM3 intron 22377092 rs1336798 chr1 102351870 T C 0.0000374 Nicotine dependence (smoking) D/JA1P5 intron 22377092 rs12731963 chr1 102382404 T C 0.000047 Nicotine dependence (smoking) OLFM3 intron 22377092 rs755181 chr1 102404247 T C 7.67E-04 Amyotrophic Lateral Sclerosis OLFM3 intron 17362836 rs1415088 chr1 102413524 C A 4.92E-04 Amyotrophic Lateral Sclerosis OLFM3 intron 17362836 rs4907957 chr1 102423144 T C 2.70E-07 Urinary metabolites OLFM3 intron 21572414 rs4907957 chr1 102423144 T C 0.00000068 Common carotid artery thickness (far walls) OLFM3 intron 23487405 rs4907957 chr1 102423144 T C 0.00000114 Common carotid artery thickness (average of near and far wall measures) OLFM3 intron 23487405 rs10782865 chr1 102453599 A T 8.84E-04 Type 2 diabetes OLFM3 intron 17463246 rs10493964 chr1 102484211 A G 2.91E-06 Varicose Veins / / pha001413 rs6675297 chr1 102548118 G C 3.54E-04 Multiple complex diseases / / 17554300 rs11578152 chr1 102577021 A G 2.30E-05 Urinary metabolites / / 21572414 rs11164386 chr1 102578097 T G 8.57E-05 Multiple complex diseases / / 17554300 rs10493978 chr1 102579307 C T 7.16E-04 Multiple complex diseases / / 17554300 rs2022858 chr1 102608577 G A 6.11E-04 Multiple complex diseases / / 17554300 rs2022858 chr1 102608577 G A 2.20E-05 Urinary metabolites / / 21572414 rs1938355 chr1 102677845 T C 1.18E-04 Bipolar disorder / / 19259986 rs10874555 chr1 102687572 G A 1.80E-05 Urinary metabolites / / 21572414 rs12731867 chr1 102699430 G A 4.26E-04 Type 2 diabetes / / 17463246 rs11164428 chr1 102706193 C G 2.50E-06 Stroke (ischemic) / / 21957438 rs10782879 chr1 102708517 A G 1.12E-04 Multiple complex diseases / / 17554300 rs11804344 chr1 102722923 C G 3.37E-04 Gallstones / / 17632509 rs17126268 chr1 102726399 T C 1.58E-05 Glomerular filtration rate / / 24351856 rs17126268 chr1 102726399 T C 9.64E-05 Chronic kidney disease / / 24351856 rs7539242 chr1 102726802 G A 1.58E-05 Glomerular filtration rate / / 24351856 rs7539242 chr1 102726802 G A 1.58E-05 Glomerular filtration rate / / 24351856 rs7539242 chr1 102726802 G A 9.64E-05 Chronic kidney disease / / 24351856 rs7539242 chr1 102726802 G A 9.64E-05 Chronic kidney disease / / 24351856 rs12120258 chr1 102734951 G T 1.58E-05 Glomerular filtration rate / / 24351856 rs12120258 chr1 102734951 G T 9.64E-05 Chronic kidney disease / / 24351856 rs12140211 chr1 102739517 C T 1.48E-05 Glomerular filtration rate / / 24351856 rs12140211 chr1 102739517 C T 7.59E-04 Chronic kidney disease / / 24351856 rs2889234 chr1 102742475 T C 6.13E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12407943 chr1 102760382 G T 9.31E-04 Heart Failure / / pha002884 rs1261698 chr1 102794417 C A 3.31E-05 Vitiligo / / 19890347 rs1272970 chr1 102829724 T G 6.43E-04 Multiple complex diseases / / 17554300 rs1572999 chr1 102830435 A G 8.28E-04 Multiple complex diseases / / 17554300 rs1573002 chr1 102830754 G A 8.74E-04 Multiple complex diseases / / 17554300 rs200979159 chr1 102830754 GTC G 8.74E-04 Multiple complex diseases / / 17554300 rs1418096 chr1 102830849 T C 5.70E-04 Multiple complex diseases / / 17554300 rs1361461 chr1 102925321 C T 9.16E-04 Multiple complex diseases / / 17554300 rs12752401 chr1 102967150 C T 1.90E-04 Cholesterol / / 17255346 rs12035823 chr1 102995218 T C 5.81E-04 Tourette syndrome / / 22889924 rs1517426 chr1 103040474 G T 5.75E-04 Type 2 diabetes / / 17463246 rs11164556 chr1 103080187 G A 6.17E-05 Blood Pressure / / pha003050 rs11164559 chr1 103088742 G T 7.74E-05 Bone mineral density / / 19181680 rs7533876 chr1 103110933 G A 5.17E-06 Response to metformin / / 21186350 rs7533876 chr1 103110933 G A 1.60E-06 Urinary metabolites / / 21572414 rs10874639 chr1 103133909 A G 3.00E-06 Protein quantitative trait loci / / 18464913 rs10493982 chr1 103171983 G A 2.42E-05 Bilirubin levels,in serum / / 19389676 rs720315 chr1 103175049 T A 2.89E-05 Bilirubin levels,in serum / / 19389676 rs1376359 chr1 103203107 T C 8.78E-05 Coronary restenosis / / 21878436 rs1376359 chr1 103203107 T C 9.00E-06 QRS duration in Tripanosoma cruzi seropositivity / / 24324551 rs478830 chr1 103230040 A C 8.47E-04 Suicide attempts in bipolar disorder / / 21423239 rs514077 chr1 103231606 T C 5.09E-06 Bilirubin levels,in serum / / 19389676 rs606756 chr1 103238392 C T 3.90E-04 Multiple complex diseases / / 17554300 rs11164597 chr1 103238444 T C 3.72E-04 Schizophrenia / / 20832056 rs2598461 chr1 103298338 C A 2.11E-04 Lung function (forced vital capacity) / / 24023788 rs1241181 chr1 103347865 G A 1.18E-04 Multiple complex diseases COL11A1 intron 17554300 rs1241182 chr1 103348100 A C 2.00E-04 Alcohol dependence COL11A1 intron 20201924 rs1241182 chr1 103348100 A C 4.30E-04 Alcohol dependence COL11A1 intron 20201924 rs17446095 chr1 103372775 C A 3.09E-05 Bipolar disorder,affective COL11A1 intron 20528957 rs3753841 chr1 103379918 G A 9.00E-10 Glaucoma (primary open-angle) COL11A1 missense 22922875 rs4908274 chr1 103389914 A T 1.09E-04 Schizophrenia COL11A1 intron 20832056 rs12138977 chr1 103393457 C T 8.30E-05 Information processing speed COL11A1 intron 21130836 rs3102053 chr1 103422730 T C 3.00E-04 Pseudoexfoliation syndrome COL11A1 intron 20808326 rs1012281 chr1 103427407 T C 2.60E-05 Urinary metabolites COL11A1 intron 21572414 rs2615977 chr1 103452392 A C 3.88E-06 Osteoarthritis (knee and hip) COL11A1 intron 21177295 rs2615977 chr1 103452392 A C 9.91E-05 Osteoarthritis (knee and hip) COL11A1 intron 21177295 rs12756627 chr1 103457229 A G 7.20E-04 Depression (quantitative trait) COL11A1 intron 20800221 rs12724152 chr1 103458395 C A 7.20E-04 Depression (quantitative trait) COL11A1 intron 20800221 rs11809524 chr1 103459537 C T 9.00E-06 Bone mineral density COL11A1 intron 22504420 rs12723167 chr1 103463624 G A 7.26E-04 Depression (quantitative trait) COL11A1 intron 20800221 rs12733933 chr1 103465596 G A 7.29E-04 Depression (quantitative trait) COL11A1 intron 20800221 rs11164661 chr1 103541331 G A 2.76E-05 Schizophrenia COL11A1 intron 19571811 rs1415363 chr1 103552935 A G 6.73E-04 Smoking initiation COL11A1 intron 24665060 rs1572521 chr1 103562868 T G 1.42E-11 Triglycerides COL11A1 intron 23063622 rs4338381 chr1 103572927 A G 1.60E-10 Height COL11A1 intron 21194676 rs4338381 chr1 103572927 A G 3.40E-05 Height COL11A1 intron 21194676 rs4338381 chr1 103572927 A G 9.00E-07 Height COL11A1 intron 21194676 rs6577357 chr1 103589265 T A 1.13E-04 Aortic root size / / 21223598 rs1572516 chr1 103591909 A C 5.94E-04 Multiple complex diseases / / 17554300 rs1572516 chr1 103591909 A C 4.60E-06 Urinary metabolites / / 21572414 rs10874684 chr1 103596035 C T 9.86E-04 Multiple complex diseases / / 17554300 rs10874684 chr1 103596035 C T 3.60E-06 Urinary metabolites / / 21572414 rs17127531 chr1 103601156 G A 7.40E-04 Multiple complex diseases / / 17554300 rs17127531 chr1 103601156 G A 2.90E-06 Urinary metabolites / / 21572414 rs872317 chr1 103609693 T C 1.22E-05 Bilirubin levels,in serum / / 19389676 rs1337199 chr1 103611252 G A 1.73E-05 Bilirubin levels,in serum / / 19389676 rs12131191 chr1 103621727 G A 3.00E-06 Urinary metabolites / / 21572414 rs3861744 chr1 103622234 A G 2.77E-05 Bilirubin levels,in serum / / 19389676 rs1358459 chr1 103636607 C T 2.60E-05 Urinary metabolites / / 21572414 rs1528202 chr1 103662258 C T 2.70E-05 Urinary metabolites / / 21572414 rs6683683 chr1 103671460 G A 9.51E-04 Suicide attempts in bipolar disorder / / 21423239 rs1406139 chr1 103683335 G A 1.84E-05 Bilirubin levels,in serum / / 19389676 rs10493998 chr1 103728254 C T 2.40E-05 Urinary metabolites / / 21572414 rs4907992 chr1 103763252 A G 4.85E-04 Alcohol dependence / / 20201924 rs7524694 chr1 104019631 T C 7.00E-06 Obesity-related traits / / 23251661 rs1930212 chr1 104324819 A G 6.69E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs10881490 chr1 104381824 C T 3.17E-04 Tourette syndrome / / 22889924 rs1930206 chr1 104393357 C G 3.78E-04 Blood pressure / / 17255346 rs1579026 chr1 104405855 G A 8.50E-04 HIV-1 viral setpoint / / 17641165 rs1930192 chr1 104408821 A C 9.57E-04 HIV-1 viral setpoint / / 17641165 rs1999480 chr1 104419830 T C 8.55E-04 HIV-1 viral setpoint / / 17641165 rs12143917 chr1 104433984 G A 4.68E-04 Iron levels / / pha002876 rs6683918 chr1 104446681 G A 1.62E-06 Iron levels / / 19880490 rs6683918 chr1 104446681 G A 1.62E-06 Iron levels / / pha002876 rs1182580 chr1 104446782 C T 2.37E-05 Multiple sclerosis / / 19525953 rs41419745 chr1 104452958 T A 4.41E-06 Multiple sclerosis / / 17660530 rs11185337 chr1 104476678 C A 3.49E-05 Multiple sclerosis / / 17660530 rs551284 chr1 104484407 A G 1.02E-05 Iron levels / / 19880490 rs551284 chr1 104484407 A G 1.02E-05 Iron levels / / pha002876 rs619879 chr1 104487148 G A 1.23E-05 Iron levels / / 19880490 rs619879 chr1 104487148 G A 1.23E-05 Iron levels / / pha002876 rs144192269 chr1 104488097 G A 0.00000196 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs41445945 chr1 104489522 G C 3.64E-04 Multiple complex diseases / / 17554300 rs1330388 chr1 104492281 T C 6.77E-04 Iron levels / / pha002876 rs12725332 chr1 104509012 G A 3.84E-05 Iron levels / / 19880490 rs12725332 chr1 104509012 G A 3.84E-05 Iron levels / / pha002876 rs12126657 chr1 104511450 G A,C 9.28E-04 Obesity (extreme) / / 21935397 rs517139 chr1 104522097 T C 6.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs6586440 chr1 104534262 C T 7.09E-04 Multiple complex diseases / / 17554300 rs1330408 chr1 104546820 C T 7.32E-04 Iron levels / / pha002876 rs4141899 chr1 104547617 T C 2.88E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12026645 chr1 104562381 A G 9.09E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs12031508 chr1 104572622 A T 8.75E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1330402 chr1 104580557 A G 1.49E-05 Iron levels / / 19880490 rs1330402 chr1 104580557 A G 1.49E-05 Iron levels / / pha002876 rs3934285 chr1 104598941 G A 2.00E-06 Obesity-related traits / / 23251661 rs10494003 chr1 104621168 G C 1.60E-04 Multiple complex diseases / / 17554300 rs11185373 chr1 104621467 A T 2.57E-04 Multiple complex diseases / / 17554300 rs1999228 chr1 104629019 A G 1.85E-04 Multiple complex diseases / / 17554300 rs11800756 chr1 104637412 C T 2.83E-04 Multiple complex diseases / / 17554300 rs10494007 chr1 104638728 A G 2.43E-04 Type 2 diabetes / / 17846124 rs12144936 chr1 104682747 C G 9.59E-04 Obesity (extreme) / / 21935397 rs1932466 chr1 104706300 G A 0.000041 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs1932465 chr1 104706506 G C 5.61E-06 Type 2 diabetes / / 17846124 rs1932465 chr1 104706506 G C 5.60E-06 Type 2 diabetes / / 21647700 rs10494009 chr1 104710766 G C 1.06E-04 Type 2 diabetes / / 17846124 rs200895163 chr1 104719055 C CT 0.0000505 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs7523109 chr1 104719055 C T 0.0000505 Normoxic and mild-hypoxic adaptation in populations residing at low and moderate altitudes / / 22628534 rs12407548 chr1 104731827 A G 2.10E-04 Multiple complex diseases / / 17554300 rs7527726 chr1 104736011 C A 5.16E-05 Post-operative nausea and vomiting / / 21694509 rs11185389 chr1 104747846 A G 7.56E-04 Alzheimer's disease / / 17998437 rs59602554 chr1 104748342 C A 0.0000321 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs1928327 chr1 104770475 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1928327 chr1 104770475 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1928327 chr1 104770475 G A 3.25E-05 Cognitive impairment induced by topiramate / / 22091778 rs3866247 chr1 104778806 C T 6.83E-05 Cognitive impairment induced by topiramate / / 22091778 rs12067058 chr1 104779012 G A 1.82E-04 Multiple complex diseases / / 17554300 rs4633297 chr1 104798629 G A 6.17E-04 Multiple complex diseases / / 17554300 rs12407649 chr1 104798853 C A 5.10E-05 Cortisol secretion,in saliva / / 21316860 rs12086216 chr1 104800294 C T 9.30E-05 HIV-1 control / / 20041166 rs7555154 chr1 104818279 G C 5.69E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs1497676 chr1 104820635 C T 6.93E-04 Response to statin treatment (atorvastatin),change in cholesterol levels / / 20031582 rs6586471 chr1 104846498 T C 7.61E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs11185422 chr1 104849763 G A 1.20E-05 Telomere length / / 23001564 rs10881542 chr1 104852738 T C 2.00E-06 Glaucoma (primary open-angle) / / 22922875 rs10785866 chr1 104887259 G A 7.53E-05 Cortisol secretion,in saliva / / 21316860 rs9662111 chr1 104894847 G A 4.85E-05 Telomere length / / 23001564 rs2646709 chr1 104954647 C T 6.37E-04 Alzheimer's disease / / 17998437 rs1448395 chr1 104966942 T C 9.44E-04 HIV-1 viral setpoint / / 17641165 rs11184169 chr1 104978179 C T 3.43E-04 Type 2 diabetes / / 17463246 rs11184173 chr1 104986052 C T 2.50E-04 IgE levels / / 17255346 rs11184173 chr1 104986052 C T 2.99E-05 Multiple sclerosis (brain glutamate levels) / / 20802204 rs12744616 chr1 104987296 G T 8.12E-04 Type 2 diabetes / / 17463246 rs7411648 chr1 104997471 C T 6.97E-05 Heart Rate / / pha003053 rs12090634 chr1 104997692 G T 6.90E-05 Heart Rate / / pha003053 rs12035511 chr1 105051438 A C 4.66E-04 Acute lung injury / / 22295056 rs12752353 chr1 105054589 T G 4.66E-04 Acute lung injury / / 22295056 rs381728 chr1 105055075 T A 3.33E-04 Insulin resistance / / 21901158 rs12042136 chr1 105063644 A G 7.33E-04 Acute lung injury / / 22295056 rs316951 chr1 105076810 C T 2.48E-05 Celiac disease / / 23936387 rs11184197 chr1 105081773 G A 3.22E-05 Cortisol secretion,in saliva / / 21316860 rs12022925 chr1 105081913 T G 8.83E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6695172 chr1 105086051 T C 2.61E-05 Cortisol secretion,in saliva / / 21316860 rs12026360 chr1 105088785 G A 5.19E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2121956 chr1 105089396 A G 2.03E-05 Cortisol secretion,in saliva / / 21316860 rs2121956 chr1 105089396 A G 1.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs316942 chr1 105090738 A G 2.36E-04 Insulin resistance / / 21901158 rs316942 chr1 105090738 A G 2.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1448378 chr1 105091696 T C 2.51E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11578246 chr1 105095501 T G 5.16E-05 Response to taxane treatment (placlitaxel) / / 23006423 rs2084447 chr1 105102314 A G 3.68E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7553985 chr1 105106498 T C 2.70E-05 Type 2 diabetes / / 17460697 rs7553985 chr1 105106498 T C 2.77E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7553985 chr1 105106498 T C 7.75E-04 Iron levels / / pha002876 rs12172730 chr1 105111535 G A 4.87E-05 Parkinson's disease / / 19915575 rs2166890 chr1 105112356 C T 2.40E-05 Type 2 diabetes / / 17460697 rs7552405 chr1 105113849 C T 3.00E-05 Type 2 diabetes / / 17460697 rs7552405 chr1 105113849 C T 1.21E-05 Cortisol secretion,in saliva / / 21316860 rs11184211 chr1 105115188 A G 3.27E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1448394 chr1 105118613 G A 4.30E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs11184213 chr1 105119392 C T 8.32E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs114152980 chr1 105119612 C T 0.000074 Nonsyndromic striae distensae (stretch marks) / / 23633020 rs12568560 chr1 105140299 G A 6.81E-05 Cortisol secretion,in saliva / / 21316860 rs4847178 chr1 105144179 T C 3.10E-05 Personality dimensions / / 18957941 rs10494020 chr1 105189711 A G 3.41E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs7532749 chr1 105219763 T G 8.81E-04 Type 2 diabetes / / 17463246 rs7532749 chr1 105219763 T G 9.25E-04 Multiple complex diseases / / 17554300 rs7532749 chr1 105219763 T G 7.46E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12725071 chr1 105220965 C T 4.52E-06 Asthma / / 20698975 rs7543757 chr1 105227914 T C 5.37E-04 Amyotrophic Lateral Sclerosis / / 17827064 rs7543757 chr1 105227914 T C 4.60E-06 Adiposity / / 19461586 rs7543757 chr1 105227914 T C 1.64E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs6702883 chr1 105243080 A G 3.24E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs12117597 chr1 105282847 T C 1.26E-05 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11578700 chr1 105292119 A C 5.07E-05 Paget's disease / / 20436471 rs11578700 chr1 105292119 A C 5.26E-05 Paget's disease / / 21623375 rs1481397 chr1 105303590 C T 2.60E-05 Urinary metabolites / / 21572414 rs1871782 chr1 105304918 C A 1.80E-05 Urinary metabolites / / 21572414 rs11184300 chr1 105312623 A G 9.64E-05 Waist Circumference / / pha003023 rs7523359 chr1 105324488 C T 1.70E-05 Urinary metabolites / / 21572414 rs12036613 chr1 105325538 G A 9.50E-06 Urinary metabolites / / 21572414 rs12043310 chr1 105332372 G A 1.20E-05 Urinary metabolites / / 21572414 rs12042214 chr1 105344196 T C 1.50E-05 Urinary metabolites / / 21572414 rs12038712 chr1 105395417 T C 7.20E-06 Urinary metabolites / / 21572414 rs11811929 chr1 105396240 C T 5.12E-04 Prostate cancer mortality / / 20978177 rs11811929 chr1 105396240 C T 2.30E-05 Urinary metabolites / / 21572414 rs12029384 chr1 105425455 C G 1.80E-06 Urinary metabolites / / 21572414 rs1376368 chr1 105449139 C T 4.25E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs7526166 chr1 105453412 T G 2.64E-04 Multiple complex diseases / / 17554300 rs2084670 chr1 105469987 C T 3.53E-05 Suicide attempts in bipolar disorder / / 21423239 rs6702908 chr1 105475361 C T 8.39E-04 Multiple complex diseases / / 17554300 rs1466154 chr1 105476957 A C 4.06E-05 Suicide attempts in bipolar disorder / / 21423239 rs1466153 chr1 105476963 C A 4.84E-05 Suicide attempts in bipolar disorder / / 21423239 rs11184372 chr1 105489615 T C 1.82E-04 Multiple complex diseases / / 17554300 rs4548451 chr1 105502327 T A 1.65E-04 Suicide attempts in bipolar disorder / / 21423239 rs994239 chr1 105505952 T G 5.31E-05 Multiple complex diseases / / 17554300 rs12136584 chr1 105507435 C A 3.29E-04 Multiple complex diseases / / 17554300 rs7550524 chr1 105507848 A G 1.99E-04 Multiple complex diseases / / 17554300 rs991024 chr1 105508155 T C 9.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs9729540 chr1 105509351 T C 9.20E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs6657473 chr1 105511033 C A,T 4.34E-05 Multiple complex diseases / / 17554300 rs4466665 chr1 105525087 T A 4.21E-04 Multiple complex diseases / / 17554300 rs12039264 chr1 105537204 A G 6.95E-04 Multiple complex diseases / / 17554300 rs11184409 chr1 105541666 A T 8.49E-06 Personality dimensions / / 22628180 rs1158909 chr1 105552128 T A 5.04E-04 Multiple complex diseases / / 17554300 rs11184413 chr1 105552936 A C 4.25E-04 Multiple complex diseases / / 17554300 rs2923300 chr1 105561345 A G 3.24E-04 Multiple complex diseases / / 17554300 rs2122691 chr1 105568426 G T 3.24E-04 Multiple complex diseases / / 17554300 rs2923297 chr1 105569484 T C 6.00E-04 Multiple complex diseases / / 17554300 rs2034525 chr1 105574256 T C 0.0000038 Efavirenz pharmacokinetics (log-transformed trough efavirenz concentration) / / 23080225 rs12410176 chr1 105593913 C T 2.32E-04 White matter integrity / / 22425255 rs1584633 chr1 105612342 C T 7.58E-04 Prostate cancer mortality / / 20978177 rs11184448 chr1 105688179 A G 7.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs17015466 chr1 105688537 G A 7.78E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs4601631 chr1 105720963 A C 8.93E-05 Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced) / / 24236485 rs6667576 chr1 105725458 C T 7.86E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) / / 23648065 rs11184469 chr1 105735780 A G 4.31E-05 Substance dependence / / 21818250 rs6583163 chr1 105993658 T C 8.92E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12118827 chr1 106001235 G A 9.47E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12735409 chr1 106001606 G A 9.39E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs7512514 chr1 106002632 C T 8.90E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs12144596 chr1 106005296 T A 8.99E-05 Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy) / / 22566498 rs2501603 chr1 106007141 A G 8.25E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs12740181 chr1 106007454 C T 8.53E-05 Cisplatin and carboplatin cytotoxicity,in blood cell lines / / 21844884 rs1516156 chr1 106032070 A G 1.00E-04 Rheumatoid Arthritis (Cyclic citrullinated peptide positive) / / 17982456 rs1516155 chr1 106034597 G A 7.11E-04 Obesity (extreme) / / 21935397 rs11184596 chr1 106057617 T C 1.83E-05 Duodenal ulcer / / 22387998 rs12120660 chr1 106086980 A G 6.40E-06 Urinary metabolites / / 21572414 rs12120660 chr1 106086980 A G 6.50E-04 Smoking initiation / / 24665060 rs777080 chr1 106099097 A C 2.25E-04 Coronary Artery Disease / / 17634449 rs10785759 chr1 106124761 C T 5.52E-04 Smoking initiation / / 24665060 rs11807640 chr1 106161451 C T 1.99E-05 Coronary heart disease / / pha003030 rs2842597 chr1 106172488 G A 1.92E-05 Coronary heart disease / / pha003030 rs12743318 chr1 106195966 C T 0.000446678 Hypertension (early onset hypertension) / / 22479346 rs1163495 chr1 106242233 G A 8.62E-04 Multiple complex diseases / / 17554300 rs1163499 chr1 106243931 G C 8.94E-04 Suicide attempts in bipolar disorder / / 21423239 rs790966 chr1 106244640 A G 7.46E-04 Suicide attempts in bipolar disorder / / 21423239 rs1163521 chr1 106328719 T C 3.45E-22 Narcolepsy / / 19629137 rs11184708 chr1 106430287 A T 2.00E-06 Waist-to-hip circumference ratio (interaction) / / 23192594 rs17016501 chr1 106438336 C T 3.77E-05 Coronary heart disease / / pha003056 rs17016501 chr1 106438336 C T 6.03E-06 Diabetes Mellitus / / pha003060 rs7515037 chr1 106446157 T G 2.09E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs940426 chr1 106449970 C T 2.34E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs1380289 chr1 106453318 C T 2.02E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs11184717 chr1 106477681 A C 9.30E-06 Urinary metabolites / / 21572414 rs498428 chr1 106570045 G T 3.51E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs11184734 chr1 106590173 C T 1.95E-04 Multiple complex diseases / / 17554300 rs11184738 chr1 106599395 G A 1.72E-04 Multiple complex diseases / / 17554300 rs11184738 chr1 106599395 G A 5.94E-13 Esophageal cancer / / 21642993 rs12408810 chr1 106640943 C T 9.00E-06 Obesity (early onset extreme) / / 23563609 rs1889463 chr1 106653622 T C 7.85E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1031339 chr1 106701386 T A 9.81E-04 Multiple complex diseases / / 17554300 rs11184786 chr1 106726037 C T 1.55E-06 Common variable immunodeficiency / / 21497890 rs10881372 chr1 106753277 C T 7.88E-05 Blood Pressure / / pha003043 rs12724740 chr1 106780771 A G 0.0007921 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs12724740 chr1 106780771 A G 7.92E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs12733837 chr1 106781522 T A 9.67E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs4431871 chr1 106810236 A G 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs2150037 chr1 106832596 C G 9.27E-05 Tuberculosis / / 20694014 rs7517409 chr1 106833140 C A 1.50E-05 Urinary metabolites / / 21572414 rs2210094 chr1 106833610 C G 7.77E-05 Tuberculosis / / 20694014 rs1330225 chr1 106835943 T C 1.00E-08 Blood pressure measurement (low sodium intervention) / / 24165912 rs1330225 chr1 106835943 T C 1.22E-04 Blood pressure measurement (low sodium intervention) / / 24165912 rs1330225 chr1 106835943 T C 7.00E-09 Blood pressure measurement (low sodium intervention) / / 24165912 rs1330226 chr1 106843175 C T 2.70E-05 Bone mineral traits,in men / / 21427758 rs1330226 chr1 106843175 C T 4.64E-05 Bone mineral traits,in men / / 21427758 rs1330226 chr1 106843175 C T 8.56E-05 Bone mineral traits,in men / / 21427758 rs12117640 chr1 106878317 G T 2.11E-04 Alzheimer's disease (late onset) / / 21379329 rs7538613 chr1 106882826 G A 3.19E-04 Alzheimer's disease (late onset) / / 21379329 rs11184870 chr1 106887181 C T 3.39E-04 Alzheimer's disease (late onset) / / 21379329 rs11184871 chr1 106887450 G A 2.73E-06 Left ventricular mass / / 21212386 rs11184871 chr1 106887450 G A 2.87E-04 Alzheimer's disease (late onset) / / 21379329 rs12565323 chr1 106906072 G A 2.35E-04 Alzheimer's disease (late onset) / / 21379329 rs2026790 chr1 106914392 A C 8.76E-05 Non-alcoholic fatty liver disease histology (other) / / 20708005 rs17433090 chr1 106933198 G A 0.0004882 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17433090 chr1 106933198 G A 4.88E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs6582965 chr1 106937705 C G 4.76E-05 Odorant perception / / 23910658 rs2988394 chr1 106963817 T A 5.51E-05 Multiple complex diseases / / 17554300 rs10881403 chr1 106990083 T A 4.24E-05 Glaucoma (primary open-angle) / / 22605921 rs1575738 chr1 107031734 C T 2.70E-05 Urinary metabolites / / 21572414 rs12045753 chr1 107056847 G A 1.62E-06 Glaucoma (primary open-angle) / / 22605921 rs12025734 chr1 107075244 G A 6.17E-05 Glaucoma (primary open-angle) / / 22605921 rs11184922 chr1 107106193 C T 7.29E-04 Taste perception / / 22132133 rs4440890 chr1 107110129 G A 5.79E-05 Personality dimensions / / 18957941 rs10494045 chr1 107112572 C A 6.61E-05 AIDS progression / / 19115949 rs4915129 chr1 107113504 C T 9.40E-05 Personality dimensions / / 18957941 rs4915129 chr1 107113504 C T 6.60E-05 AIDS progression / / 19115949 rs12121466 chr1 107149412 A C 2.52E-04 Longevity / / 22279548 rs10785799 chr1 107191485 A G 6.11E-05 Cervical cancer / / 24700089 rs10494048 chr1 107195059 G T 9.66E-05 Prostate cancer / / pha002878 rs10881442 chr1 107219644 C T 8.91E-05 Intelligence / / 21826061 rs10881442 chr1 107219644 C T 5.65E-05 Lipoproteins / / pha003079 rs6703591 chr1 107222150 G A 6.68E-05 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4342878 chr1 107227063 T A 2.65E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4462181 chr1 107230730 A G 1.30E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4336881 chr1 107232816 A C 1.30E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs10785805 chr1 107233800 G A 5.15E-05 Intelligence / / 21826061 rs10785805 chr1 107233800 G A 5.32E-05 Lipoproteins / / pha003079 rs4914986 chr1 107255899 T A 1.38E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs4436418 chr1 107264055 T C 2.17E-04 Multiple complex diseases / / 17554300 rs9887893 chr1 107279889 G A 7.26E-05 Intelligence / / 21826061 rs2176758 chr1 107281362 C T 1.37E-04 Lung function (forced expiratory volume in 1 second) / / 17255346 rs6686425 chr1 107289810 C T 9.96E-04 Type 2 diabetes / / 17463246 rs1519883 chr1 107291768 C T 3.51E-05 Intelligence / / 21826061 rs12097821 chr1 107336301 G T 6.00E-10 Non-obstructive azoospermia / / 22197933 rs12119184 chr1 107338996 G A 6.02E-05 Intelligence / / 21826061 rs12024651 chr1 107404931 G A 6.36E-06 Glaucoma (primary open-angle) / / 22605921 rs3968588 chr1 107425864 G A 3.42E-04 Multiple complex diseases / / 17554300 rs1519881 chr1 107432265 A G 7.00E-06 Urinary metabolites / / 21572414 rs12726652 chr1 107432576 G A 5.00E-07 Response to antipsychotic treatment in schizophrenia (working memory) / / 21107309 rs12726652 chr1 107432576 G A 0.000248 Salmonella-induced pyroptosis / / 22837397 rs10494055 chr1 107449940 T C 8.17E-04 Multiple complex diseases / / 17554300 rs12125971 chr1 107463643 C T 7.00E-06 Intelligence / / 22449649 rs17495607 chr1 107501181 T C 4.08E-05 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17496332 chr1 107546375 A G 1.00E-11 Sex hormone-binding globulin levels / / 22829776 rs17496332 chr1 107546375 A G 2.00E-07 Sex hormone-binding globulin levels / / 22829776 rs10494056 chr1 107547919 C A 4.29E-06 AIDS / / 19754311 rs6675948 chr1 107557477 C G 3.80E-04 Iris characteristics / / 21835309 rs10047147 chr1 107561147 C T 6.70E-05 Height / / pha003010 rs10881455 chr1 107561546 G A 6.70E-05 Height / / pha003010 rs4118325 chr1 107577832 G A 6.00E-07 AIDS / / 19754311 rs4118325 chr1 107577832 G A 5.82E-05 Height / / pha003010 rs11185057 chr1 107596964 T C 6.23E-05 Height / / pha003010 rs17018290 chr1 107609774 C G 5.85E-04 Multiple complex diseases / / 17554300 rs1762495 chr1 107634116 T C 3.40E-05 AIDS / / 19754311 rs1762495 chr1 107634116 T C 1.94E-04 Scoliosis / / 21216876 rs6583007 chr1 107676684 C T 2.49E-04 Fibrinogen / / 17255346 rs4481881 chr1 107686418 T C 3.08E-05 Orofacial clefts NTNG1 intron 20023658 rs4307594 chr1 107693167 T C 2.00E-05 Orofacial clefts NTNG1 intron 20023658 rs6681613 chr1 107717689 G A 5.39E-07 Lymphocyte counts NTNG1 intron 22286170 rs6694986 chr1 107829678 T C 4.00E-04 Pulmonary function NTNG1 intron 23932459 rs10494067 chr1 107830858 A C 6.00E-06 Anorexia nervosa NTNG1 intron 21079607 rs4604720 chr1 107837159 G A 3.15E-05 Asthma NTNG1 intron 23181788 rs17509160 chr1 107855013 C T 6.70E-05 Pulmonary function NTNG1 intron 23932459 rs7411507 chr1 107865978 G A 1.91E-05 Prostate cancer NTNG1 intron 18264096 rs6672549 chr1 107874959 G A 2.07E-04 Celiac disease NTNG1 intron 23936387 rs12747408 chr1 107920219 C T 1.95E-05 Parkinson's disease (motor and cognition) NTNG1 intron 22658654 rs12747408 chr1 107920219 C T 1.95E-05 Immune response to anthrax vaccine NTNG1 intron 22658931 rs7544259 chr1 107929543 A G 1.51E-05 Parkinson's disease (motor and cognition) NTNG1 intron 22658654 rs7544259 chr1 107929543 A G 1.51E-05 Immune response to anthrax vaccine NTNG1 intron 22658931 rs2587899 chr1 107946650 G T 9.87E-04 Multiple complex diseases NTNG1 intron 17554300 rs17018944 chr1 107955428 A G 4.20E-04 Multiple complex diseases NTNG1 intron 17554300 rs12731224 chr1 107961159 A G 3.49E-06 Body Mass Index NTNG1 intron pha003007 rs12731224 chr1 107961159 A G 5.07E-05 Body Mass Index NTNG1 intron pha003015 rs480392 chr1 107979396 A C 1.38E-08 Triglycerides NTNG1 cds-synon 23063622 rs480392 chr1 107979396 A C 1.77E-08 HDL cholesterol NTNG1 cds-synon 23063622 rs1373337 chr1 107980407 G A 2.04E-05 Body Mass Index NTNG1 intron pha003007 rs1444038 chr1 107981316 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) NTNG1 intron 20189245 rs1444038 chr1 107981316 G A 1.82E-05 Body Mass Index NTNG1 intron pha003007 rs12735678 chr1 107984135 T C 1.76E-05 Body Mass Index NTNG1 intron pha003007 rs17019069 chr1 107985632 G A 9.00E-04 Acute lymphoblastic leukemia (childhood) NTNG1 intron 20189245 rs590987 chr1 107986409 G A 4.08E-04 Multiple complex diseases NTNG1 intron 17554300 rs17531774 chr1 107987328 C T 9.00E-04 Acute lymphoblastic leukemia (childhood) NTNG1 intron 20189245 rs17531997 chr1 107992327 C G 6.55E-04 Smoking quantity NTNG1 intron 24665060 rs17466589 chr1 107992571 A G 5.00E-04 Acute lymphoblastic leukemia (childhood) NTNG1 intron 20189245 rs521721 chr1 108001448 G A 1.99E-04 Multiple complex diseases NTNG1 intron 17554300 rs96501 chr1 108018847 C T 2.90E-05 Urinary metabolites NTNG1 intron 21572414 rs96501 chr1 108018847 C T 1.79E-04 Celiac disease NTNG1 intron 23936387 rs653383 chr1 108021506 C T 2.00E-04 Cognitive impairment induced by topiramate NTNG1 intron 22091778 rs650251 chr1 108026510 T G 1.16E-04 Multiple complex diseases / / 17554300 rs11808800 chr1 108040994 T C 9.41E-06 Mathematical ability / / 24801482 rs533165 chr1 108070545 C T 8.89E-04 Multiple complex diseases / / 17554300 rs521420 chr1 108074669 C G 2.60E-05 Urinary metabolites / / 21572414 rs17535067 chr1 108074954 G A 9.90E-06 Urinary metabolites / / 21572414 rs608827 chr1 108076343 C T 5.13E-04 Aortic root size / / 21223598 rs12565052 chr1 108079880 G C 6.70E-05 Response to statin therapy / / 20339536 rs12564555 chr1 108085686 T C 3.30E-05 Response to statin therapy / / 20339536 rs12566146 chr1 108091675 T C 5.80E-05 Response to statin therapy / / 20339536 rs2769668 chr1 108115145 T C 1.30E-05 Urinary metabolites VAV3 UTR-3 21572414 rs1410403 chr1 108123685 C T 3.33E-04 Schizophrenia VAV3 intron 20832056 rs1328199 chr1 108127895 C T 1.76E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) VAV3 intron 24023788 rs11803410 chr1 108141478 G A 5.68E-04 Multiple complex diseases VAV3 intron 17554300 rs1410406 chr1 108156360 G A 0.000650658 Hypertension (early onset hypertension) VAV3 intron 22479346 rs11185151 chr1 108173844 C T 9.50E-06 Digit length ratio VAV3 intron 20303062 rs4915061 chr1 108176019 G A 2.17E-04 Multiple complex diseases VAV3 intron 17554300 rs12752530 chr1 108176582 A C 2.50E-04 Multiple complex diseases VAV3 intron 17554300 rs6693140 chr1 108181947 C T 2.83E-04 Suicide attempts in bipolar disorder VAV3 intron 21041247 rs4914952 chr1 108184270 C A 9.60E-06 Digit length ratio VAV3 intron 20303062 rs12410676 chr1 108185309 G A 1.52E-05 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) VAV3 missense 24023788 rs4557997 chr1 108192390 C T 9.16E-05 Heart rate VAV3 intron 23583979 rs12077977 chr1 108199479 C T 1.35E-04 Multiple complex diseases VAV3 intron 17554300 rs17479604 chr1 108203647 C A 6.98E-04 Suicide attempts in bipolar disorder VAV3 intron 21041247 rs2494047 chr1 108212860 T C 7.00E-04 Multiple complex diseases VAV3 intron 17554300 rs12140510 chr1 108213416 C T 8.74E-04 Suicide attempts in bipolar disorder VAV3 intron 21423239 rs2494052 chr1 108218925 G T 1.40E-04 Multiple complex diseases VAV3 intron 17554300 rs6677871 chr1 108238325 T C 5.14E-04 Parkinson's disease VAV3 intron 16252231 rs17019729 chr1 108245664 T C 4.10E-05 Hypothyroidism VAV3 intron 22493691 rs6583042 chr1 108246246 A G 5.60E-06 Hypothyroidism VAV3 intron 22493691 rs2494069 chr1 108246853 C T 4.52E-04 Multiple complex diseases VAV3 intron 17554300 rs4503375 chr1 108250282 A G 1.37E-04 Multiple complex diseases VAV3 intron 17554300 rs4503375 chr1 108250282 A G 1.80E-05 Hypothyroidism VAV3 intron 22493691 rs17019810 chr1 108268801 C T 8.41E-04 Myopia (pathological) VAV3 intron 21095009 rs17019810 chr1 108268801 C T 2.00E-06 Hypothyroidism VAV3 intron 22493691 rs17019823 chr1 108269953 A C 6.46E-04 Multiple complex diseases VAV3 intron 17554300 rs17019823 chr1 108269953 A C 8.41E-04 Myopia (pathological) VAV3 intron 21095009 rs17019823 chr1 108269953 A C 8.00E-09 Hypothyroidism VAV3 intron 22493691 rs17019828 chr1 108270130 T C 3.40E-04 Multiple complex diseases VAV3 intron 17554300 rs6674340 chr1 108273631 A G 5.00E-05 Hypothyroidism VAV3 intron 22493691 rs7519428 chr1 108281720 G A 3.60E-05 Cognitive function VAV3 intron 24684796 rs12031375 chr1 108286368 A G 3.20E-05 Cognitive function VAV3 intron 24684796 rs6583045 chr1 108286971 A G 2.57E-05 Major depression (suicidal thoughts and behavior) VAV3 intron 21750702 rs41486546 chr1 108298979 T A 1.60E-05 Urinary metabolites VAV3 intron 21572414 rs12142335 chr1 108302922 G A 8.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) VAV3 intron 23648065 rs7417283 chr1 108303686 C T 4.51E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs7417283 chr1 108303686 C T 5.59E-06 Glycemic traits (pregnancy) VAV3 intron 23903356 rs7514025 chr1 108307642 C T 6.52E-04 Glycemic traits (pregnancy) VAV3 intron 23903356 rs6690837 chr1 108312656 T C 8.31E-04 Glycemic traits (pregnancy) VAV3 intron 23903356 rs6583048 chr1 108313258 C T 5.44E-04 Glycemic traits (pregnancy) VAV3 cds-synon 23903356 rs4462178 chr1 108315137 C T 8.45E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin) VAV3 intron 23648065 rs4914959 chr1 108319079 G A 3.76E-04 Glycemic traits (pregnancy) VAV3 intron 23903356 rs4914960 chr1 108321313 A G 5.31E-04 Glycemic traits (pregnancy) VAV3 intron 23903356 rs7521681 chr1 108322535 G A 7.00E-07 Asthma and hay fever VAV3 intron 24388013 rs4514263 chr1 108325510 G A 3.87E-04 Glycemic traits (pregnancy) VAV3 intron 23903356 rs11185177 chr1 108325738 G A 3.04E-04 Glycemic traits (pregnancy) VAV3 intron 23903356 rs11185178 chr1 108329926 T G 8.14E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs11185178 chr1 108329926 T G 8.95E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs4914961 chr1 108333763 T C 7.31E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs4914961 chr1 108333763 T C 9.14E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs4244133 chr1 108334622 T C 5.89E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs4244133 chr1 108334622 T C 7.01E-05 Glycemic traits (pregnancy) VAV3 intron 23903356 rs17020055 chr1 108336533 A C 6.50E-09 Hypothyroidism VAV3 intron 22493691 rs10494076 chr1 108338327 A G 3.10E-05 Blood Phenotypes VAV3 intron 17903294 rs17020088 chr1 108351812 T C 5.40E-09 Hypothyroidism VAV3 intron 22493691 rs4612651 chr1 108356293 C T 1.21E-04 Celiac disease VAV3 intron 23936387 rs12126655 chr1 108356820 A G 2.00E-08 Thyroid stimulating hormone VAV3 intron 24722205 rs4915076 chr1 108359505 T C 8.00E-10 Hypothyroidism VAV3 intron 22493691 rs4915077 chr1 108366016 T C 8.00E-10 Hypothyroidism VAV3 intron 22493691 rs7537000 chr1 108376302 A G 3.00E-04 Cognitive impairment induced by topiramate VAV3 intron 22091778 rs7537000 chr1 108376302 A G 2.11E-04 Celiac disease VAV3 intron 23936387 rs9787296 chr1 108382827 A G 4.66E-04 Thyroid stimulating hormone VAV3 intron 24852370 rs10494080 chr1 108402075 C A 7.37E-04 Multiple complex diseases VAV3 intron 17554300 rs10494080 chr1 108402075 C A 9.72E-05 Celiac disease VAV3 intron 23936387 rs10494081 chr1 108402103 C T 9.76E-04 Type 2 diabetes VAV3 intron 17463246 rs1360564 chr1 108411794 T C 7.58E-05 Waist-Hip Ratio VAV3 intron pha003028 rs11185191 chr1 108418552 T A 6.95E-04 Multiple complex diseases VAV3 intron 17554300 rs11185215 chr1 108450627 A G 3.96E-04 Alzheimer's disease (late onset) VAV3 intron 21379329 rs345314 chr1 108462844 C T 2.14E-04 Alzheimer's disease (late onset) VAV3 intron 21379329 rs1571965 chr1 108519529 C T 0.00001 HDL cholesterol particle diameter / / 23263444 rs12121990 chr1 108523670 G T 0.00035 Prostate cancer / / 23555315 rs2336645 chr1 108524174 T G 7.67E-05 AIDS progression / / 19115949 rs1219765 chr1 108541909 A G 9.77E-05 Sodium levels / / pha003093 rs12071280 chr1 108555998 T C 5.37E-04 Multiple complex diseases / / 17554300 rs1781070 chr1 108569698 G A 1.62E-04 Alzheimer's disease (late onset) / / 21379329 rs12569350 chr1 108588372 G A 7.82E-04 Substance dependence / / 21818250 rs1777454 chr1 108596968 T G 8.55E-04 Substance dependence / / 21818250 rs1777478 chr1 108612220 C T 9.23E-04 Multiple complex diseases / / 17554300 rs1781064 chr1 108615524 G A 4.25E-04 Taste perception / / 22132133 rs2996918 chr1 108621812 A G 1.52E-05 Cognitive performance / / 19734545 rs10881502 chr1 108641819 T C 8.12E-04 Coronary Artery Disease / / 17634449 rs11185272 chr1 108662219 C T 5.01E-05 Information processing speed / / 21130836 rs1777450 chr1 108663295 T C 4.41E-05 Cognitive performance / / 19734545 rs665659 chr1 108663841 C G 8.26E-05 Serum metabolites / / 19043545 rs17513833 chr1 108680234 C T 6.50E-04 Amyotrophic lateral sclerosis (sporadic) SLC25A24 intron 24529757 rs10494090 chr1 108693336 A G 5.30E-13 Glioma (high-grade) SLC25A24 intron 19578366 rs559761 chr1 108700637 C A 4.58E-04 Alzheimer's disease (late onset) SLC25A24 intron 21379329 rs662590 chr1 108719572 G A 7.93E-05 Multiple complex diseases SLC25A24 intron 17554300 rs490680 chr1 108724518 A G 9.46E-05 Blood Pressure SLC25A24 intron pha003045 rs490680 chr1 108724518 A G 2.18E-05 Blood Pressure SLC25A24 intron pha003047 rs491785 chr1 108724693 G A 9.46E-05 Blood Pressure SLC25A24 intron pha003045 rs491785 chr1 108724693 G A 2.18E-05 Blood Pressure SLC25A24 intron pha003047 rs828999 chr1 108744934 G A 5.70E-05 Glioma (high-grade) / / 19578366 rs7418288 chr1 108754099 G A 1.63E-04 Alzheimer's disease (late onset) / / 21379329 rs6694641 chr1 108755582 T C 1.99E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs6583070 chr1 108756690 G A 1.18E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs2152560 chr1 108762012 G A 5.86E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs11185305 chr1 108763904 C T 5.75E-04 Response to cytidine analogues (gemcitabine) / / 24483146 rs4970822 chr1 108859231 C A 1.60E-05 White matter hyperintensity burden / / 21681796 rs4970821 chr1 108859314 T C 3.06E-07 Esophageal cancer (squamous cell) / / 22960999 rs12117427 chr1 108863863 A G 1.80E-05 White matter hyperintensity burden / / 21681796 rs949905 chr1 108870158 T C 1.90E-05 White matter hyperintensity burden / / 21681796 rs2275563 chr1 108877608 G T 1.40E-05 White matter hyperintensity burden / / 21681796 rs12404827 chr1 108888654 A G 4.60E-05 Major depressive disorder / / 21042317 rs7512836 chr1 109052161 C T 6.08E-05 Multiple complex diseases / / 17554300 rs7515114 chr1 109052264 C A 8.93E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs6666724 chr1 109084300 C T 6.07E-04 Alzheimer's disease / / 24755620 rs1353722 chr1 109098737 A C 6.51E-04 Alzheimer's disease / / 24755620 rs1353725 chr1 109098932 A G 6.51E-04 Alzheimer's disease / / 24755620 rs11102031 chr1 109101851 C T 7.97E-04 Alzheimer's disease / / 24755620 rs943806 chr1 109156284 C T 1.62E-06 Asthma (childhood onset) FAM102B intron 23829686 rs17026815 chr1 109271037 T C 0.0007494 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) FNDC7 intron 23233654 rs17026815 chr1 109271037 T C 7.49E-04 Methotrexate clearance (acute lymphoblastic leukemia) FNDC7 intron 23233662 rs4970810 chr1 109273610 G A 6.14E-04 Response to cytidine analogues (gemcitabine) FNDC7 intron 24483146 rs1690726 chr1 109330016 G A 6.73E-04 Multiple complex diseases STXBP3 intron 17554300 rs1149160 chr1 109336794 G C 9.90E-04 Multiple complex diseases STXBP3 intron 17554300 rs17555669 chr1 109356394 T A 0.0006625 Anti-TNF treatment response in rheumatoid arthritis (by DAS-28 score change at 3 months) / / 23233654 rs17555669 chr1 109356394 T A 6.63E-04 Methotrexate clearance (acute lymphoblastic leukemia) / / 23233662 rs1277216 chr1 109359231 A C 4.70E-04 Pulmonary function AK/D1 intron 23932459 rs1277213 chr1 109359502 A G 3.27E-04 Response to cytidine analogues (gemcitabine) AK/D1 intron 24483146 rs6683747 chr1 109376539 C A 6.44E-04 Amyotrophic lateral sclerosis (sporadic) AK/D1 intron 24529757 rs1277014 chr1 109386466 A G 2.76E-04 Multiple complex diseases AK/D1 intron 17554300 rs1277203 chr1 109392837 C T 9.00E-06 Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin) AK/D1 intron 23648065 rs11583007 chr1 109392853 C T 8.00E-05 Prostate cancer AK/D1 intron 21743057 rs9440631 chr1 109394524 G A 1.45E-05 Tuberculosis AK/D1 missense 22306650 rs6667820 chr1 109400568 A G 5.44E-04 Multiple complex diseases SRG7 intron 17554300 rs12752417 chr1 109400639 G T 4.47E-04 Aortic root size SRG7 intron 21223598 rs11587109 chr1 109405971 C T 9.68E-04 Acute lung injury / / 22295056 rs7523050 chr1 109417679 C A 3.70E-06 Subcutaneous adipose tissue volume in HIV-infected men GPSM2 nearGene-5 21897333 rs7523050 chr1 109417679 C A 4.80E-06 Subcutaneous adipose tissue volume in HIV-infected men GPSM2 nearGene-5 21897333 rs7523050 chr1 109417679 C A 9.90E-07 Subcutaneous adipose tissue volume in HIV-infected men GPSM2 nearGene-5 21897333 rs839854 chr1 109471634 T G 1.59E-04 Response to taxane treatment (placlitaxel) GPSM2 intron 23006423 rs12030 chr1 109472813 T C 1.90E-05 Urinary metabolites CLCC1 UTR-3 21572414 rs10607 chr1 109473017 C T 3.67E-05 Smoking quantity CLCC1 UTR-3 24665060 rs193139 chr1 109483975 T C 3.20E-06 Subcutaneous adipose tissue volume in HIV-infected men CLCC1 intron 21897333 rs193139 chr1 109483975 T C 3.90E-06 Subcutaneous adipose tissue volume in HIV-infected men CLCC1 intron 21897333 rs193139 chr1 109483975 T C 9.50E-06 Subcutaneous adipose tissue volume in HIV-infected men CLCC1 intron 21897333 rs338466 chr1 109486196 A G 4.62E-05 Response to taxane treatment (placlitaxel) CLCC1 cds-synon 23006423 rs839547 chr1 109494147 A G 1.42E-04 Response to taxane treatment (placlitaxel) CLCC1 intron 23006423 rs28634276 chr1 109611326 T G 7.45E-04 Response to taxane treatment (placlitaxel) TAF13 intron 23006423 rs531842 chr1 109689314 C T 1.08E-04 Multiple complex diseases KIAA1324 intron 17554300 rs609031 chr1 109692890 C T 8.94E-04 Multiple complex diseases KIAA1324 intron 17554300 rs609031 chr1 109692890 C T 2.36E-04 Lymphocyte counts KIAA1324 intron 22286170 rs648673 chr1 109727284 C G 4.26E-04 Multiple complex diseases KIAA1324 intron 17554300 rs4268379 chr1 109778237 C T 0.000000732 Coronary artery disease SARS intron 23202125 rs611060 chr1 109782190 C T 2.55E-04 Obesity (extreme) / / 21935397 rs4246519 chr1 109783555 A G 1.60E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs586254 chr1 109784781 A G 4.76E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel) / / 23648065 rs585362 chr1 109789795 C T 7.97E-09 Triglycerides / / 19060911 rs585362 chr1 109789795 C T 1.29E-20 Cholesterol,total / / 23063622 rs585362 chr1 109789795 C T 3.76E-25 LDL cholesterol / / 23063622 rs10858082 chr1 109798721 G A 7.00E-05 Response to statin therapy CELSR2 intron 20339536 rs10858082 chr1 109798721 G A 1.80E-08 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 intron 22003152 rs10858082 chr1 109798721 G A 1.28E-20 LDL cholesterol CELSR2 intron 23063622 rs10858082 chr1 109798721 G A 2.64E-23 Cholesterol,total CELSR2 intron 23063622 rs4970833 chr1 109804646 G A 1.06E-14 Cholesterol,total CELSR2 intron 23063622 rs4970833 chr1 109804646 G A 1.23E-14 LDL cholesterol CELSR2 intron 23063622 rs4970833 chr1 109804646 G A 9.17E-07 Non-small cell lung cancer (survival) CELSR2 intron 23704207 rs6698843 chr1 109806834 C T 2.91E-14 LDL cholesterol CELSR2 cds-synon 23063622 rs6698843 chr1 109806834 C T 7.82E-15 Cholesterol,total CELSR2 cds-synon 23063622 rs6689614 chr1 109807099 G A 1.15E-14 Cholesterol,total CELSR2 cds-synon 23063622 rs6689614 chr1 109807099 G A 3.71E-14 LDL cholesterol CELSR2 cds-synon 23063622 rs6657811 chr1 109807283 A T 2.00E-08 LDL cholesterol CELSR2 intron 18262040 rs6657811 chr1 109807283 A T 6.60E-07 Response to statin therapy CELSR2 intron 20339536 rs6657811 chr1 109807283 A T 2.40E-08 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 intron 22003152 rs6657811 chr1 109807283 A T 3.02E-30 LDL cholesterol CELSR2 intron 23063622 rs6657811 chr1 109807283 A T 8.92E-31 Cholesterol,total CELSR2 intron 23063622 rs41279714 chr1 109813485 C T 7.08E-12 Metabolite levels CELSR2 intron 22286219 rs17035665 chr1 109813719 C T 0.000000283 Cholesterol,total CELSR2 intron 23063622 rs17035665 chr1 109813719 C T 4.19E-08 LDL cholesterol CELSR2 intron 23063622 rs4970834 chr1 109814880 C T 1.19E-04 Type 2 diabetes CELSR2 intron 17463246 rs4970834 chr1 109814880 C T 1.44E-05 Multiple complex diseases CELSR2 intron 17554300 rs4970834 chr1 109814880 C T 3.43E-04 Coronary Artery Disease CELSR2 intron 17634449 rs4970834 chr1 109814880 C T 1.70E-06 Cardiovascular disease CELSR2 intron 18179892 rs4970834 chr1 109814880 C T 3.00E-11 LDL cholesterol CELSR2 intron 18262040 rs4970834 chr1 109814880 C T 9.53E-09 Triglycerides CELSR2 intron 19060911 rs4970834 chr1 109814880 C T 2.00E-14 Lipid levels CELSR2 intron 19802338 rs4970834 chr1 109814880 C T 4.60E-17 Lipid levels CELSR2 intron 19802338 rs4970834 chr1 109814880 C T 2.00E-08 Lipid levels CELSR2 intron 19913121 rs4970834 chr1 109814880 C T 5.18E-09 Lipid levels CELSR2 intron 19913121 rs4970834 chr1 109814880 C T 4.00E-08 Lipoprotein A [Lp(a)] levels and coronary artery disease CELSR2 intron 20032323 rs4970834 chr1 109814880 C T 4.10E-07 Response to statin therapy CELSR2 intron 20339536 rs4970834 chr1 109814880 C T 1.29E-10 Lipid levels CELSR2 intron 20370913 rs4970834 chr1 109814880 C T 6.85E-13 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 intron 20442857 rs4970834 chr1 109814880 C T 4.41E-13 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 intron 22003152 rs4970834 chr1 109814880 C T 0.000000175 HDL cholesterol CELSR2 intron 23063622 rs4970834 chr1 109814880 C T 1.78E-64 LDL cholesterol CELSR2 intron 23063622 rs4970834 chr1 109814880 C T 4.70E-59 Cholesterol,total CELSR2 intron 23063622 rs4970834 chr1 109814880 C T 0.000157 LDL cholesterol CELSR2 intron 23236364 rs611917 chr1 109815252 A G 1.50E-10 LDL cholesterol CELSR2 intron 18262040 rs611917 chr1 109815252 A G 9.63E-13 Triglycerides CELSR2 intron 19060911 rs611917 chr1 109815252 A G 2.20E-09 Lipid levels CELSR2 intron 19802338 rs611917 chr1 109815252 A G 2.90E-12 Lipid levels CELSR2 intron 19802338 rs611917 chr1 109815252 A G 1.97E-06 Lipid levels CELSR2 intron 19913121 rs611917 chr1 109815252 A G 6.69E-07 Lipid levels CELSR2 intron 19913121 rs611917 chr1 109815252 A G 2.50E-05 Response to statin therapy CELSR2 intron 20339536 rs611917 chr1 109815252 A G 4.71E-13 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 intron 22003152 rs611917 chr1 109815252 A G 1.19E-39 Cholesterol,total CELSR2 intron 23063622 rs611917 chr1 109815252 A G 4.78E-40 LDL cholesterol CELSR2 intron 23063622 rs611917 chr1 109815252 A G 2.49E-07 LDL lipoproteins CELSR2 intron pha002902 rs7528419 chr1 109817192 A G 2.41E-09 Lipid levels CELSR2 UTR-3 19913121 rs7528419 chr1 109817192 A G 8.09E-09 Lipid levels CELSR2 UTR-3 19913121 rs7528419 chr1 109817192 A G 3.00E-07 Lipoprotein A [Lp(a)] levels and coronary artery disease CELSR2 UTR-3 20032323 rs7528419 chr1 109817192 A G 6.10E-08 Response to statin therapy CELSR2 UTR-3 20339536 rs7528419 chr1 109817192 A G 1.65E-08 Cardiovascular disease risk factors CELSR2 UTR-3 21943158 rs7528419 chr1 109817192 A G 1.00E-17 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 UTR-3 22003152 rs7528419 chr1 109817192 A G 1.12E-11 Metabolite levels CELSR2 UTR-3 22286219 rs7528419 chr1 109817192 A G 1.69E-51 LDL cholesterol CELSR2 UTR-3 22629316 rs7528419 chr1 109817192 A G 3.44E-31 LDL cholesterol (female) CELSR2 UTR-3 22629316 rs7528419 chr1 109817192 A G 6.28E-25 LDL cholesterol (male) CELSR2 UTR-3 22629316 rs7528419 chr1 109817192 A G 1.48E-68 LDL cholesterol CELSR2 UTR-3 23063622 rs7528419 chr1 109817192 A G 8.70E-67 Cholesterol,total CELSR2 UTR-3 23063622 rs7528419 chr1 109817192 A G 9.02E-09 HDL cholesterol CELSR2 UTR-3 23063622 rs11102967 chr1 109817245 C A,G,T 0.000000411 Cholesterol,total CELSR2 UTR-3 23063622 rs12740374 chr1 109817590 G T 3.20E-14 LDL cholesterol CELSR2 UTR-3 18262040 rs12740374 chr1 109817590 G T 2.00E-42 LDL cholesterol CELSR2 UTR-3 19060906 rs12740374 chr1 109817590 G T 1.82E-09 Lipid levels CELSR2 UTR-3 19913121 rs12740374 chr1 109817590 G T 4.70E-09 Lipid levels CELSR2 UTR-3 19913121 rs12740374 chr1 109817590 G T 2.00E-07 Lipoprotein A [Lp(a)] levels and coronary artery disease CELSR2 UTR-3 20032323 rs12740374 chr1 109817590 G T 5.50E-08 Response to statin therapy CELSR2 UTR-3 20339536 rs12740374 chr1 109817590 G T 9.00E-29 Coronary heart disease CELSR2 UTR-3 21347282 rs12740374 chr1 109817590 G T 6.61E-14 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) CELSR2 UTR-3 21541012 rs12740374 chr1 109817590 G T 8.70E-09 Cardiovascular disease risk factors CELSR2 UTR-3 21943158 rs12740374 chr1 109817590 G T 1.46E-17 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 UTR-3 22003152 rs12740374 chr1 109817590 G T 3.60E-13 Metabolic syndrome phenotype CELSR2 UTR-3 22022282 rs12740374 chr1 109817590 G T 8.00E-16 Metabolic syndrome phenotype CELSR2 UTR-3 22022282 rs12740374 chr1 109817590 G T 1.24E-11 Metabolite levels CELSR2 UTR-3 22286219 rs12740374 chr1 109817590 G T 2.89E-51 LDL cholesterol CELSR2 UTR-3 22629316 rs12740374 chr1 109817590 G T 5.06E-31 LDL cholesterol (female) CELSR2 UTR-3 22629316 rs12740374 chr1 109817590 G T 7.47E-25 LDL cholesterol (male) CELSR2 UTR-3 22629316 rs12740374 chr1 109817590 G T 1.35E-08 HDL cholesterol CELSR2 UTR-3 23063622 rs12740374 chr1 109817590 G T 3.00E-66 Cholesterol,total CELSR2 UTR-3 23063622 rs12740374 chr1 109817590 G T 3.75E-69 LDL cholesterol CELSR2 UTR-3 23063622 rs12740374 chr1 109817590 G T 2.00E-22 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 UTR-3 23118302 rs12740374 chr1 109817590 G T 1.63E-17 LDL cholesterol CELSR2 UTR-3 23236364 rs12740374 chr1 109817590 G T 4.43E-13 Cholesterol,total CELSR2 UTR-3 23236364 rs660240 chr1 109817838 T C 3.80E-14 LDL cholesterol CELSR2 UTR-3 18262040 rs660240 chr1 109817838 T C 8.10E-08 Response to statin therapy CELSR2 UTR-3 20339536 rs660240 chr1 109817838 T C 1.00E-26 LDL cholesterol CELSR2 UTR-3 20864672 rs660240 chr1 109817838 T C 2.00E-22 Cardiovascular disease risk factors CELSR2 UTR-3 21943158 rs660240 chr1 109817838 T C 7.39E-17 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 UTR-3 22003152 rs660240 chr1 109817838 T C 2.38E-12 Metabolite levels CELSR2 UTR-3 22286219 rs660240 chr1 109817838 T C 4.09E-11 LDL cholesterol CELSR2 UTR-3 23063622 rs660240 chr1 109817838 T C 6.59E-12 Cholesterol,total CELSR2 UTR-3 23063622 rs3832016 chr1 109818158 C CT 1.67E-13 Cholesterol,total CELSR2 UTR-3 23063622 rs3832016 chr1 109818158 C CT 6.18E-13 LDL cholesterol CELSR2 UTR-3 23063622 rs57677983 chr1 109818158 C A,G,T 1.67E-13 Cholesterol,total CELSR2 UTR-3 23063622 rs57677983 chr1 109818158 C A,G,T 6.18E-13 LDL cholesterol CELSR2 UTR-3 23063622 rs629301 chr1 109818306 G T 3.10E-14 LDL cholesterol CELSR2 UTR-3 18262040 rs629301 chr1 109818306 G T 2.01E-08 Triglycerides CELSR2 UTR-3 19060911 rs629301 chr1 109818306 G T 1.76E-08 Lipid levels CELSR2 UTR-3 19913121 rs629301 chr1 109818306 G T 6.50E-09 Lipid levels CELSR2 UTR-3 19913121 rs629301 chr1 109818306 G T 5.40E-08 Response to statin therapy CELSR2 UTR-3 20339536 rs629301 chr1 109818306 G T 1.00E-170 LDL cholesterol CELSR2 UTR-3 20686565 rs629301 chr1 109818306 G T 6.00E-131 Cholesterol,total CELSR2 UTR-3 20686565 rs629301 chr1 109818306 G T 1.17E-11 Multiple traits (coronary heart disease,T2D,LDL cholesterol,HDL cholesterol) CELSR2 UTR-3 21541012 rs629301 chr1 109818306 G T 1.78E-17 Lipoprotein-associated phospholipase A2 activity and mass CELSR2 UTR-3 22003152 rs629301 chr1 109818306 G T 2.62E-12 Metabolite levels CELSR2 UTR-3 22286219 rs629301 chr1 109818306 G T 1.19E-07 Coronary heart disease CELSR2 UTR-3 22319020 rs629301 chr1 109818306 G T 1.44E-43 LDL cholesterol CELSR2 UTR-3 23063622 rs629301 chr1 109818306 G T 1.57E-08 HDL cholesterol CELSR2 UTR-3 23063622 rs629301 chr1 109818306 G T 5.68E-38 Cholesterol,total CELSR2 UTR-3 23063622 rs629301 chr1 109818306 G T 0.00016 Coronary artery calcification CELSR2 UTR-3 23727086 rs629301 chr1 109818306 G T 2.00E-170 Cholesterol,total CELSR2 UTR-3 24097068 rs629301 chr1 109818306 G T 5.00E-241 LDL cholesterol CELSR2 UTR-3 24097068 rs646776 chr1 109818530 C T 3.00E-29 LDL cholesterol / / 18193044 rs646776 chr1 109818530 C T 4.80E-20 LDL cholesterol / / 18262040 rs646776 chr1 109818530 C T 2.00E-12 LDL cholesterol / / 19060910 rs646776 chr1 109818530 C T 8.00E-23 LDL cholesterol / / 19060911 rs646776 chr1 109818530 C T 9.00E-22 Cholesterol,total / / 19060911 rs646776 chr1 109818530 C T 8.00E-12 Myocardial infarction (early onset) / / 19198609 rs646776 chr1 109818530 C T 3.50E-24 Lipid levels / / 19802338 rs646776 chr1 109818530 C T 4.90E-19 Lipid levels / / 19802338 rs646776 chr1 109818530 C T 1.03E-08 Lipid levels / / 19913121 rs646776 chr1 109818530 C T 2.40E-08 Lipid levels / / 19913121 rs646776 chr1 109818530 C T 1.20E-32 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 1.60E-13 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 1.77E-53 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 2.20E-20 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 2.40E-27 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 3.70E-39 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 4.97E-46 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 5.00E-09 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 6.00E-09 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 6.29E-19 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 7.10E-11 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 9.20E-12 Lipid levels / / 19936222 rs646776 chr1 109818530 C T 2.00E-07 Lipoprotein A [Lp(a)] levels and coronary artery disease / / 20032323 rs646776 chr1 109818530 C T 4.00E-06 Response to statin therapy / / 20339536 rs646776 chr1 109818530 C T 2.00E-30 Progranulin levels / / 21087763 rs646776 chr1 109818530 C T 2.41E-06 Cardiovascular disease risk factors / / 21239051 rs646776 chr1 109818530 C T 8.00E-12 Coronary heart disease / / 21347282 rs646776 chr1 109818530 C T 6.00E-10 Coronary heart disease / / 21378988 rs646776 chr1 109818530 C T 9.37E-09 Cardiovascular disease risk factors / / 21943158 rs646776 chr1 109818530 C T 3.10E-17 Coronary heart disease / / 21966275 rs646776 chr1 109818530 C T 2.15E-17 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs646776 chr1 109818530 C T 2.65E-12 Metabolite levels / / 22286219 rs646776 chr1 109818530 C T 1.20E-68 Cholesterol,total / / 23063622 rs646776 chr1 109818530 C T 6.19E-09 HDL cholesterol / / 23063622 rs646776 chr1 109818530 C T 7.90E-74 LDL cholesterol / / 23063622 rs646776 chr1 109818530 C T 0.00000024 Apolipoprotein B levels response after 40mg daily simvastatin treatment / / 23100282 rs646776 chr1 109818530 C T 0.000095 LDL cholesterol response after 40mg daily simvastatin treatment / / 23100282 rs646776 chr1 109818530 C T 3.90E-41 Apolipoprotein B levels / / 23100282 rs646776 chr1 109818530 C T 6.10E-28 LDL cholesterol / / 23100282 rs646776 chr1 109818530 C T 6.10E-28 Multiple cancers (lung cancer,gastric cancer,and squamous cell carcinoma) / / 23103227 rs646776 chr1 109818530 C T 3.96E-08 Cholesterol,total / / 23236364 rs646776 chr1 109818530 C T 0.00021 Coronary artery calcification / / 23727086 rs646776 chr1 109818530 C T 2.19E-12 LDL lipoproteins / / pha002902 rs646776 chr1 109818530 C T 7.39E-05 Cholesterol / / pha003073 rs646776 chr1 109818530 C T 2.68E-05 Cholesterol / / pha003078 rs3902354 chr1 109819296 C A 1.00E-08 Cholesterol,total / / 24886709 rs55882046 chr1 109819981 C T 2.27E-10 Cholesterol,total / / 23063622 rs55882046 chr1 109819981 C T 6.94E-10 LDL cholesterol / / 23063622 rs11577931 chr1 109820884 A G 1.02E-08 LDL cholesterol / / 23063622 rs11577931 chr1 109820884 A G 1.96E-09 Cholesterol,total / / 23063622 rs583104 chr1 109821307 G T 1.15E-08 Lipid levels / / 19913121 rs583104 chr1 109821307 G T 2.18E-08 Lipid levels / / 19913121 rs583104 chr1 109821307 G T 3.00E-07 Lipoprotein A [Lp(a)] levels and coronary artery disease / / 20032323 rs583104 chr1 109821307 G T 5.37E-12 Metabolite levels / / 22286219 rs583104 chr1 109821307 G T 0.000000141 HDL cholesterol / / 23063622 rs583104 chr1 109821307 G T 3.58E-67 LDL cholesterol / / 23063622 rs583104 chr1 109821307 G T 6.01E-65 Cholesterol,total / / 23063622 rs602633 chr1 109821511 T G 4.80E-14 Lipid levels / / 18193043 rs602633 chr1 109821511 T G 5.70E-14 LDL cholesterol / / 18262040 rs602633 chr1 109821511 T G 2.21E-07 Lipid levels / / 19913121 rs602633 chr1 109821511 T G 3.15E-08 Lipid levels / / 19913121 rs602633 chr1 109821511 T G 9.00E-08 Lipoprotein A [Lp(a)] levels and coronary artery disease / / 20032323 rs602633 chr1 109821511 T G 8.40E-08 Response to statin therapy / / 20339536 rs602633 chr1 109821511 T G 5.00E-08 LDL cholesterol / / 21977987 rs602633 chr1 109821511 T G 1.38E-16 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs602633 chr1 109821511 T G 5.44E-12 Metabolite levels / / 22286219 rs602633 chr1 109821511 T G 0.000000128 HDL cholesterol / / 23063622 rs602633 chr1 109821511 T G 5.86E-65 Cholesterol,total / / 23063622 rs602633 chr1 109821511 T G 6.92E-65 LDL cholesterol / / 23063622 rs602633 chr1 109821511 T G 0.0000342 Coronary artery disease (CAD) (females) / / 23202125 rs602633 chr1 109821511 T G 1.32E-18 Coronary artery disease (CAD) (males) / / 23202125 rs602633 chr1 109821511 T G 2.23E-16 Coronary artery disease with myocardial infarction / / 23202125 rs602633 chr1 109821511 T G 2.77E-20 Coronary artery disease (CAD) age <=50 / / 23202125 rs602633 chr1 109821511 T G 4.97E-08 Coronary artery disease (CAD) age >50 / / 23202125 rs602633 chr1 109821511 T G 1.00E-08 Coronary artery disease / / 24262325 rs1277930 chr1 109822143 G A 5.75E-12 Metabolite levels / / 22286219 rs1277930 chr1 109822143 G A 2.64E-12 LDL cholesterol / / 23063622 rs1277930 chr1 109822143 G A 9.43E-14 Cholesterol,total / / 23063622 rs599839 chr1 109822166 G A 9.00E-08 Type 2 diabetes / / 17463246 rs599839 chr1 109822166 G A 2.19E-05 Multiple complex diseases / / 17554300 rs599839 chr1 109822166 G A 4.00E-09 Coronary heart disease / / 17634449 rs599839 chr1 109822166 G A 1.00E-07 LDL cholesterol / / 18179892 rs599839 chr1 109822166 G A 6.00E-33 LDL cholesterol / / 18193043 rs599839 chr1 109822166 G A 3.00E-21 Lipid levels / / 18193044 rs599839 chr1 109822166 G A 1.00E-33 LDL cholesterol / / 18262040 rs599839 chr1 109822166 G A 4.31E-08 Lipid levels / / 19913121 rs599839 chr1 109822166 G A 4.79E-08 Lipid levels / / 19913121 rs599839 chr1 109822166 G A 6.00E-08 Response to statin therapy / / 20339536 rs599839 chr1 109822166 G A 3.70E-16 Lipid levels / / 20370913 rs599839 chr1 109822166 G A 3.00E-15 Lipoprotein-associated phospholipase A2 activity and mass / / 20442857 rs599839 chr1 109822166 G A 2.82E-04 Cardiovascular disease risk factors / / 21239051 rs599839 chr1 109822166 G A 4.00E-09 Coronary heart disease / / 21347282 rs599839 chr1 109822166 G A 3.00E-10 Coronary heart disease / / 21378990 rs599839 chr1 109822166 G A 2.00E-19 Metabolite levels / / 21909109 rs599839 chr1 109822166 G A 1.12E-08 Cardiovascular disease risk factors / / 21943158 rs599839 chr1 109822166 G A 2.63E-17 Lipoprotein-associated phospholipase A2 activity and mass / / 22003152 rs599839 chr1 109822166 G A 4.13E-12 Metabolite levels / / 22286219 rs599839 chr1 109822166 G A 2.89E-10 Pericardial fat / / 22589742 rs599839 chr1 109822166 G A 0.000000153 HDL cholesterol / / 23063622 rs599839 chr1 109822166 G A 1.21E-57 Cholesterol,total / / 23063622 rs599839 chr1 109822166 G A 1.43E-59 LDL cholesterol / / 23063622 rs599839 chr1 109822166 G A 0.000000556 HDL cholesterol / / 23202125 rs599839 chr1 109822166 G A 2.94E-168 LDL cholesterol / / 23202125 rs599839 chr1 109822166 G A 4.12E-130 Cholesterol,total / / 23202125 rs599839 chr1 109822166 G A 1.00E-08 Coronary artery disease or ischemic stroke / / 24262325 rs599839 chr1 109822166 G A 8.00E-17 Coronary artery disease or large artery stroke / / 24262325 rs35358959 chr1 109824250 G A 6.63E-11 Metabolite levels PSRC1 cds-synon 22286219 rs657420 chr1 109826136 C T 3.94E-16 LDL cholesterol / / 23063622 rs657420 chr1 109826136 C T 8.38E-15 Cholesterol,total / / 23063622 rs655246 chr1 109832283 A G 2.07E-12 Cholesterol,total / / 23063622 rs655246 chr1 109832283 A G 4.11E-16 LDL cholesterol / / 23063622 rs17645031 chr1 109834938 C T 7.05E-19 LDL cholesterol / / 23063622 rs17645031 chr1 109834938 C T 7.81E-21 Cholesterol,total / / 23063622 rs41306199 chr1 109835163 C T 1.43E-20 Cholesterol,total MYBPHL UTR-3 23063622 rs41306199 chr1 109835163 C T 8.49E-18 LDL cholesterol MYBPHL UTR-3 23063622 rs12127701 chr1 109838264 A G 7.31E-11 Cholesterol,total MYBPHL intron 23063622 rs12127701 chr1 109838264 A G 8.07E-12 LDL cholesterol MYBPHL intron 23063622 rs12127701 chr1 109838264 A G 0.000271 Coronary artery disease MYBPHL intron 23202125 rs629001 chr1 109838918 C T 2.87E-12 Cholesterol,total MYBPHL missense 23063622 rs629001 chr1 109838918 C T 6.36E-13 LDL cholesterol MYBPHL missense 23063622 rs7515901 chr1 109839896 C T 0.0000073 Coronary artery disease MYBPHL intron 23202125 rs592107 chr1 109848726 A T 8.16E-05 Cognitive test performance MYBPHL intron 20125193 rs413582 chr1 109851126 C T 1.02E-09 Cholesterol,total / / 23063622 rs413582 chr1 109851126 C T 3.67E-11 LDL cholesterol / / 23063622 rs2228604 chr1 109884775 T G 4.67E-04 Multiple complex diseases SORT1 cds-synon 17554300 rs4970843 chr1 109887191 T C 0.00032 LDL cholesterol (female) SORT1 intron 23063622 rs4970843 chr1 109887191 T C 1.47E-11 LDL cholesterol SORT1 intron 23063622 rs4970843 chr1 109887191 T C 1.47E-11 LDL cholesterol (male) SORT1 intron 23063622 rs4970843 chr1 109887191 T C 1.83E-09 Cholesterol,total SORT1 intron 23063622 rs17646665 chr1 109912051 A G 1.52E-11 Cholesterol,total SORT1 intron 23063622 rs17646665 chr1 109912051 A G 4.71E-13 LDL cholesterol SORT1 intron 23063622 rs17646731 chr1 109919525 G A 1.97E-11 LDL cholesterol SORT1 intron 23063622 rs17646731 chr1 109919525 G A 1.98E-09 Cholesterol,total SORT1 intron 23063622 rs1149175 chr1 109922377 G A 4.48E-04 Multiple complex diseases SORT1 intron 17554300 rs10858092 chr1 109943893 C T 2.69E-04 Multiple complex diseases PSMA5 UTR-3 17554300 rs7518013 chr1 109944078 T C 2.91E-04 Multiple complex diseases PSMA5 UTR-3 17554300 rs17586966 chr1 109955569 T C 1.61E-04 Type 2 diabetes PSMA5 intron 17463246 rs17586966 chr1 109955569 T C 4.17E-25 Narcolepsy PSMA5 intron 19629137 rs10776807 chr1 109956156 G A,C 2.42E-04 Multiple complex diseases PSMA5 intron 17554300 rs4970760 chr1 109985439 A G 2.97E-04 Multiple complex diseases / / 17554300 rs1933182 chr1 109999838 A C 1.00E-07 Chronic kidney disease / / 20383146 rs1933182 chr1 109999838 A C 3.18E-07 Chronic kidney disease / / 22479191 rs10857787 chr1 110010289 C T 9.44E-04 Multiple complex diseases SYPL2 intron 17554300 rs12049330 chr1 110031188 T G 6.00E-06 Major depressive disorder ATXN7L2 intron 20125088 rs1043274 chr1 110042444 C T 9.00E-06 Obesity-related traits CYB561D1 UTR-3 23251661 rs6677291 chr1 110056126 C T 9.35E-05 Alcohol withdrawal symptoms / / 22072270 rs528815 chr1 110061479 C T 1.50E-05 Multiple complex diseases / / 17554300 rs534135 chr1 110061625 T C 1.24E-04 Multiple complex diseases / / 17554300 rs534135 chr1 110061625 T C 9.00E-04 Response to cytadine analogues (cytosine arabinoside) / / 24483146 rs475381 chr1 110062040 A T 1.16E-05 Multiple complex diseases / / 17554300 rs2692705 chr1 110063313 G C 1.41E-05 Multiple complex diseases / / 17554300 rs6537803 chr1 110063540 G A 7.54E-05 Alcohol withdrawal symptoms / / 22072270 rs528077 chr1 110065752 C A 1.43E-04 Multiple complex diseases / / 17554300 rs529773 chr1 110065906 A G 1.03E-04 Multiple complex diseases / / 17554300 rs474234 chr1 110070814 A C 2.30E-04 Multiple complex diseases / / 17554300 rs474234 chr1 110070814 A C 4.03E-04 Lymphocyte counts / / 22286170 rs558370 chr1 110071113 A G 2.76E-04 Multiple complex diseases / / 17554300 rs7536291 chr1 110075608 G A 4.29E-05 Multiple complex diseases / / 17554300 rs1434285 chr1 110080809 G T 2.26E-09 Lymphocyte counts / / 22286170 rs7550711 chr1 110082886 C T 5.00E-06 Stearic acid (18:0) plasma levels GPR61 intron 23362303 rs6537837 chr1 110119732 C T 1.00E-06 Major depressive disorder G/I3 intron 20125088 rs17024258 chr1 110147321 C T 9.00E-12 Obesity G/T2 intron 23563607 rs510619 chr1 110157364 C T 2.03E-04 Amyotrophic Lateral Sclerosis G/T2 nearGene-5 17362836 rs2071487 chr1 110233081 T C 2.00E-05 Urinary metabolites GSTM1 cds-synon 21572414 rs10857796 chr1 110235032 A G 6.68E-05 Femoral neck bone geometry GSTM1 intron 22087292 rs11101992 chr1 110266754 A C 0.00048 Coronary artery calcification / / 23727086 rs3814309 chr1 110277403 T C 4.01E-09 Lymphocyte counts GSTM3 UTR-3 22286170 rs146952826 chr1 110280921 C T 0.0000044 Breast cancer(er negative) GSTM3 missense 23555315 rs11591171 chr1 110298107 A C 3.14E-05 Cognitive test performance EPS8L3 intron 20125193 rs11581614 chr1 110329003 T C 2.00E-04 Systolic blood pressure / / 19430483 rs11581614 chr1 110329003 T C 0.00081417 Sarcoidosis / / 22952805 rs17024863 chr1 110331262 C T 8.45E-04 Multiple complex diseases / / 17554300 rs10494112 chr1 110352477 A G 1.67E-14 Paget's disease / / 20436471 rs10494112 chr1 110352477 A G 7.00E-35 Paget's disease / / 21623375 rs3887891 chr1 110358890 C T 2.10E-05 Lipid levels / / 18193043 rs499345 chr1 110361682 C A 3.02E-16 Paget's disease / / 20436471 rs484959 chr1 110366083 T C 5.00E-24 Paget's disease / / 20436471 rs525566 chr1 110375695 G A 7.41E-05 Parkinson's disease / / 17052657 rs6537883 chr1 110405271 T C 3.00E-06 Sensory disturbances after bilateral sagittal split ramus osteotomy / / 23834954 rs6695237 chr1 110415626 G A 4.00E-05 Coronary Artery Disease / / 17634449 rs453577 chr1 110426778 G A 6.17E-04 Multiple complex diseases / / 17554300 rs333960 chr1 110439480 C T 2.00E-07 Obesity-related traits / / 23251661 rs185460835 chr1 110447555 A T 0.00082646 Sarcoidosis / / 22952805 rs333949 chr1 110451043 C T 7.63E-06 Obesity-related traits / / 23251661 rs333951 chr1 110451690 T C 7.71E-05 Serum metabolites CSF1 nearGene-5 19043545 rs333970 chr1 110466338 C A 0.000740986 Hypertension (early onset hypertension) CSF1 cds-synon 22479346 rs333947 chr1 110470764 G A 9.55E-04 Multiple complex diseases CSF1 intron 17554300 rs7540934 chr1 110483773 G A 3.43E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs390923 chr1 110499669 A G 5.90E-04 Endometriosis / / 23104006 rs11577194 chr1 110500175 T C 6.54E-04 Type 2 diabetes / / 17463246 rs1466788 chr1 110618730 A G 3.00E-16 Blood metabolite levels / / 24816252 rs17025426 chr1 110645327 C T 2.00E-06 Visceral adipose tissue/subcutaneous adipose tissue ratio / / 22589738 rs493039 chr1 110646246 A T 4.72E-04 Smoking cessation / / 24665060 rs11576956 chr1 110646858 A G 3.00E-04 Endometriosis / / 23104006 rs514341 chr1 110652880 C T 6.00E-06 Alcohol dependence (age at onset) / / 24962325 rs4641310 chr1 110654498 G A 2.01E-05 Type 2 diabetes / / 17463246 rs2168144 chr1 110657532 G A 1.42E-05 Type 2 diabetes / / 17463246 rs11102055 chr1 110662374 A G 1.29E-04 Type 2 diabetes / / 17463246 rs11102058 chr1 110666410 A G 1.70E-05 Type 2 diabetes / / 17463246 rs7518801 chr1 110677921 A C 3.58E-04 Alzheimer's disease (late onset) / / 21379329 rs924181 chr1 110680114 G A 4.91E-04 Alzheimer's disease (late onset) / / 21379329 rs4839165 chr1 110681542 T G 4.59E-04 Alzheimer's disease (late onset) / / 21379329 rs10494113 chr1 110684287 T C 4.10E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs1123250 chr1 110686356 A G 9.70E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs975512 chr1 110690577 G A 6.16E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs2002384 chr1 110698651 A G 3.59E-04 Alzheimer's disease (late onset) SLC6A17 intron 21379329 rs4838931 chr1 110701071 T C 2.26E-04 Alzheimer's disease (late onset) SLC6A17 intron 21379329 rs1010891 chr1 110712154 G A 2.08E-04 Alzheimer's disease (late onset) SLC6A17 intron 21379329 rs6689641 chr1 110720400 A G 7.10E-04 Pulmonary function SLC6A17 intron 23932459 rs12128502 chr1 110723699 G A 1.50E-05 Urinary metabolites SLC6A17 intron 21572414 rs11802526 chr1 110724507 G A 4.03E-04 Alzheimer's disease (late onset) SLC6A17 intron 21379329 rs4839223 chr1 110728459 A G 9.69E-04 HIV-1 viral setpoint SLC6A17 intron 17641165 rs4839225 chr1 110729248 C T 9.69E-04 HIV-1 viral setpoint SLC6A17 intron 17641165 rs2011688 chr1 110729404 C T 0.00000442 VLDL cholesterol particle diameter SLC6A17 intron 23263444 rs495959 chr1 110732133 C T 1.26E-05 Alzheimer's disease (late onset) SLC6A17 intron 21379329 rs17025524 chr1 110733674 C T 2.20E-06 Urinary metabolites SLC6A17 intron 21572414 rs2784140 chr1 110738296 G A 6.12E-05 Cytomegalovirus antibody response SLC6A17 cds-synon 21993531 rs2784140 chr1 110738296 G A 4.26E-06 Acute lymphoblastic leukemia (B-cell precursor) SLC6A17 cds-synon 23996088 rs642655 chr1 110738990 A C 4.43E-04 HIV-1 viral setpoint SLC6A17 intron 17641165 rs2761442 chr1 110739864 A G 4.86E-05 Cytomegalovirus antibody response SLC6A17 intron 21993531 rs958798 chr1 110770223 G T 6.27E-04 Parkinson's disease KCNC4 intron 17052657 rs958798 chr1 110770223 G T 4.00E-07 Self-rated health KCNC4 intron 20707712 rs12138917 chr1 110791822 C T 8.71E-04 Multiple complex diseases / / 17554300 rs2209158 chr1 110795018 A C 1.10E-05 Urinary metabolites / / 21572414 rs4839282 chr1 110814129 T A 3.00E-04 Pseudoexfoliation syndrome / / 20808326 rs6682717 chr1 110815623 G C 3.00E-04 Pseudoexfoliation syndrome / / 20808326 rs3904626 chr1 110816491 T C 1.75E-04 Cholesterol / / 17255346 rs3904626 chr1 110816491 T C 7.46E-04 Multiple complex diseases / / 17554300 rs2885145 chr1 110817219 A G 1.75E-04 Cholesterol / / 17255346 rs2885145 chr1 110817219 A G 6.03E-04 Multiple complex diseases / / 17554300 rs2361047 chr1 110819387 A G 1.75E-04 Cholesterol / / 17255346 rs2361047 chr1 110819387 A G 6.08E-04 Multiple complex diseases / / 17554300 rs11102076 chr1 110819974 C T 1.75E-04 Cholesterol / / 17255346 rs11102076 chr1 110819974 C T 9.39E-04 Multiple complex diseases / / 17554300 rs3849178 chr1 110820295 A G 1.75E-04 Cholesterol / / 17255346 rs3849178 chr1 110820295 A G 5.60E-04 Multiple complex diseases / / 17554300 rs3820662 chr1 110821383 G A 8.20E-05 Cholesterol / / 17255346 rs3820662 chr1 110821383 G A 7.76E-04 Multiple complex diseases / / 17554300 rs4838977 chr1 110823116 G A 1.75E-04 Cholesterol / / 17255346 rs4838977 chr1 110823116 G A 5.49E-04 Multiple complex diseases / / 17554300 rs638531 chr1 110829417 G A 9.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs638531 chr1 110829417 G A 2.42E-05 Alzheimer's disease / / 22832961 rs626971 chr1 110831331 T C 4.25E-04 Insulin resistance LOC440600 intron 21901158 rs637686 chr1 110839445 A T 3.70E-05 Immunoglobulin A LOC440600 intron 20694011 rs4112315 chr1 110842415 C T 6.51E-04 Multiple complex diseases LOC440600 intron 17554300 rs532121 chr1 110844894 T C 2.12E-04 Suicide attempts in bipolar disorder LOC440600 intron 21423239 rs650290 chr1 110846510 T A 6.15E-04 Suicide attempts in bipolar disorder LOC440600 intron 21423239 rs473411 chr1 110846616 C T 6.15E-04 Suicide attempts in bipolar disorder LOC440600 intron 21423239 rs17358933 chr1 110849205 G A 1.62E-04 Multiple complex diseases LOC440600 intron 17554300 rs17358933 chr1 110849205 G A 8.37E-04 Alcohol dependence LOC440600 intron 21314694 rs9645348 chr1 110854963 G A 5.50E-06 Urinary metabolites LOC440600 intron 21572414 rs1466806 chr1 110861927 C T 8.40E-06 Urinary metabolites LOC440600 intron 21572414 rs1160505 chr1 110863039 G C 2.64E-04 Response to platinum-based chemotherapy in small-cell lung cancer LOC440600 intron 20463552 rs4838992 chr1 110864149 A G 6.17E-04 Multiple sclerosis LOC440600 intron 17660530 rs12568839 chr1 110877085 C T 1.54E-04 Response to platinum-based chemotherapy in small-cell lung cancer LOC440600 intron 20463552 rs12022711 chr1 110880586 C T 6.92E-05 Response to platinum-based chemotherapy in small-cell lung cancer LOC440600 intron 20463552 rs1572263 chr1 110885736 G A 7.81E-04 Suicide attempts in bipolar disorder RBM15 intron 21423239 rs4501839 chr1 110895987 T G 6.86E-04 Suicide attempts in bipolar disorder / / 21423239 rs6669004 chr1 110906780 G A 5.22E-04 Suicide attempts in bipolar disorder SLC16A4 intron 21423239 rs12028977 chr1 110907716 C T 5.96E-04 Suicide attempts in bipolar disorder SLC16A4 intron 21423239 rs6673423 chr1 110916018 T C 6.50E-04 Suicide attempts in bipolar disorder SLC16A4 intron 21423239 rs12126890 chr1 110922814 G A 3.08E-04 Suicide attempts in bipolar disorder SLC16A4 intron 21423239 rs814759 chr1 110930882 C G 5.17E-04 Suicide attempts in bipolar disorder SLC16A4 intron 21423239 rs7556440 chr1 110931112 A G 4.56E-04 Suicide attempts in bipolar disorder SLC16A4 intron 21423239 rs6657333 chr1 110960311 T G 3.73E-04 Suicide attempts in bipolar disorder / / 21423239 rs6537657 chr1 110961722 T C 4.76E-04 Suicide attempts in bipolar disorder / / 21423239 rs11102104 chr1 110966784 T G 3.57E-04 Suicide attempts in bipolar disorder / / 21423239 rs2132989 chr1 110967354 A T 3.96E-04 Suicide attempts in bipolar disorder / / 21423239 rs6687382 chr1 110969946 C T 7.90E-04 Suicide attempts in bipolar disorder / / 21423239 rs12048154 chr1 110974489 A G 2.10E-05 Urinary metabolites / / 21572414 rs7534322 chr1 110989088 A C 3.38E-04 Alzheimer's disease / / 17998437 rs62623571 chr1 110996652 C T 0.00028 Breast cancer PROK1 missense 23555315 rs11102110 chr1 111003201 C T 9.47E-05 Alzheimer's disease / / 22832961 rs12407530 chr1 111003777 T C 2.40E-05 Urinary metabolites / / 21572414 rs12407530 chr1 111003777 T C 8.34E-05 Alzheimer's disease / / 22832961 rs4839431 chr1 111033809 T C 2.00E-07 Immune reponse to smallpox (secreted IFN-alpha) / / 22610502 rs6537663 chr1 111034818 T C 2.21E-04 Fibrinogen / / 17255346 rs12031009 chr1 111040235 G A 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs7543509 chr1 111051999 A G 5.34E-05 Parkinson's disease / / 17052657 rs1281179 chr1 111056389 T C 3.11E-04 Amyotrophic lateral sclerosis (sporadic) / / 24529757 rs17025957 chr1 111062049 C T 3.34E-04 Response to taxane treatment (placlitaxel) / / 23006423 rs17025978 chr1 111069611 G A 6.60E-06 Type 2 diabetes / / 17463248 rs17025982 chr1 111070294 T C 7.80E-06 Type 2 diabetes / / 17463248 rs7522150 chr1 111077162 G T 4.75E-04 Myopia (pathological) / / 21095009 rs7553144 chr1 111084462 C T 6.53E-04 Myopia (pathological) / / 21095009 rs2790372 chr1 111087124 C A 7.50E-05 Type 2 diabetes / / 17463248 rs2790372 chr1 111087124 C A 7.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs2799765 chr1 111088151 T C 8.50E-05 Type 2 diabetes / / 17463248 rs1626078 chr1 111089239 C T 8.90E-05 Type 2 diabetes / / 17463248 rs1625029 chr1 111089405 C T 7.52E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs1622675 chr1 111089642 A T 8.30E-05 Type 2 diabetes / / 17463248 rs1627572 chr1 111089670 G A 8.90E-05 Type 2 diabetes / / 17463248 rs1281173 chr1 111094802 C T 8.77E-04 Suicide attempts in bipolar disorder / / 21041247 rs903050 chr1 111098766 T C 1.74E-04 Multiple complex diseases / / 17554300 rs903050 chr1 111098766 T C 8.01E-05 Suicide attempts in bipolar disorder / / 21041247 rs903050 chr1 111098766 T C 8.56E-05 Suicide attempts in bipolar disorder / / 21041247 rs6537668 chr1 111100562 T C 4.12E-05 Adverse response to chemotherapy (neutropenia/leucopenia) (all platinum-based drugs) / / 23648065 rs12407862 chr1 111102214 C T 3.46E-04 Suicide attempts in bipolar disorder / / 21041247 rs6656346 chr1 111103688 G A 4.61E-04 Suicide attempts in bipolar disorder / / 21041247 rs1105101 chr1 111104913 C G 5.70E-04 Suicide attempts in bipolar disorder / / 21041247 rs6537671 chr1 111106530 T C 5.74E-04 Suicide attempts in bipolar disorder / / 21041247 rs7526907 chr1 111111368 A G 7.10E-04 Suicide attempts in bipolar disorder / / 21041247 rs923826 chr1 111114154 A G 0.000706 Salmonella-induced pyroptosis / / 22837397 rs17684735 chr1 111131424 T C 2.87E-05 Birth weight / / 17255346 rs4839069 chr1 111137811 A G 6.05E-05 Lung function (forced expiratory volume in 1 second to forced vital capacity ratio) KC/2 intron 24023788 rs41404544 chr1 111142811 T C 5.58E-05 Response to metformin KC/2 intron 21186350 rs12047887 chr1 111144007 G A 2.81E-05 Cognitive test performance KC/2 intron 20125193 rs4839542 chr1 111155595 C T 1.25E-05 Cognitive test performance KC/2 intron 20125193 rs2172514 chr1 111166960 G A 9.19E-04 Response to TNF antagonist treatment KC/2 intron 21061259 rs41451648 chr1 111176693 T C 3.69E-04 Type 2 diabetes / / 17463246 rs41451648 chr1 111176693 T C 1.24E-04 Multiple complex diseases / / 17554300 rs7513434 chr1 111186329 C T 2.95E-04 Bipolar disorder,schizoaffective / / 19567891 rs2797533 chr1 111186784 C T 4.60E-04 Alcohol dependence / / 20201924 rs12084550 chr1 111198184 T C 2.20E-05 Urinary metabolites / / 21572414 rs2640487 chr1 111206885 C T 3.20E-04 Alcohol dependence / / 20201924 rs1319782 chr1 111211533 C T 8.60E-04 Alcohol dependence / / 20201924 rs2640480 chr1 111213248 C A 4.30E-04 Alcohol dependence / / 20201924 rs12061304 chr1 111237685 A G 1.00E-06 Panic disorder / / 19165232 rs12061304 chr1 111237685 A G 0.0000613 Panic disorder / / 23149450 rs12061304 chr1 111237685 A G 6.13E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs11102149 chr1 111240982 G C 3.14E-06 Panic disorder / / 19165232 rs11102149 chr1 111240982 G C 0.0000615 Panic disorder / / 23149450 rs11102149 chr1 111240982 G C 6.15E-05 Serum tamsulosin hydrochloride concentration / / 23151678 rs12085135 chr1 111243375 C G 4.69E-04 Fibrinogen / / 17255346 rs12085135 chr1 111243375 C G 5.04E-04 Multiple complex diseases / / 17554300 rs343602 chr1 111257724 A G 2.88E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs343602 chr1 111257724 A G 5.39E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs343604 chr1 111258770 T C 4.32E-05 Acute lymphoblastic leukemia (childhood) / / 22076464 rs4839556 chr1 111262340 G A 3.60E-04 Myasthenia gravis / / 23055271 rs343614 chr1 111276629 G A 1.69E-04 Lung function (forced expiratory flow between 25% and 75% of forced vital capacity) / / 24023788 rs343778 chr1 111281285 A G 0.00002168 Sarcoidosis / / 22952805 rs41453452 chr1 111295050 G C 3.09E-04 Alcohol dependence / / 21314694 rs420033 chr1 111295674 G A 6.17E-05 Alcohol dependence / / 19581569 rs440156 chr1 111295948 G A 4.23E-04 Type 2 diabetes / / 17463246 rs508446 chr1 111309830 C T 4.38E-04 Type 2 diabetes / / 17463246 rs574508 chr1 111311541 C T 3.49E-04 Type 2 diabetes / / 17463246 rs528752 chr1 111312272 A G 3.58E-04 Type 2 diabetes / / 17463246 rs526874 chr1 111312489 T C 6.31E-04 Type 2 diabetes / / 17463246 rs488147 chr1 111319892 A G 9.17E-04 Type 2 diabetes / / 17463246 rs1999511 chr1 111322419 C A 6.60E-05 Myasthenia gravis / / 23055271 rs343810 chr1 111330896 C T 8.49E-05 Bipolar disorder and schizophrenia / / 20889312 rs343819 chr1 111342490 C T 1.50E-04 Alcohol dependence / / 20201924 rs343819 chr1 111342490 C T 8.00E-06 Alcohol dependence / / 20201924 rs343819 chr1 111342490 C T 7.98E-06 Alcoholism / / pha002893 rs518785 chr1 111359802 G A 1.57E-11 Lymphocyte counts / / 22286170 rs6685538 chr1 111393622 G A 4.00E-04 Alcohol dependence / / 20201924 rs6677149 chr1 111393713 T A 8.64E-04 Type 2 diabetes / / 17846124 rs6677149 chr1 111393713 T A 4.89E-05 Bipolar disorder and schizophrenia / / 20889312 rs17688638 chr1 111394866 T C 3.93E-05 Bipolar disorder and schizophrenia / / 20889312 rs17688644 chr1 111395110 T C 4.31E-05 Bipolar disorder and schizophrenia / / 20889312 rs12566518 chr1 111395388 G T 4.45E-05 Bipolar disorder and schizophrenia / / 20889312 rs4631693 chr1 111396088 C T 3.10E-04 Alcohol dependence / / 20201924 rs4631693 chr1 111396088 C T 7.50E-05 Alcohol dependence / / 20201924 rs4631693 chr1 111396088 C T 7.53E-05 Alcoholism / / pha002892 rs718463 chr1 111396606 G A 2.30E-04 Alcohol dependence / / 20201924 rs718463 chr1 111396606 G A 5.30E-05 Alcohol dependence / / 20201924 rs718463 chr1 111396606 G A 5.28E-05 Alcoholism / / pha002892 rs12730405 chr1 111396915 A G 2.80E-04 Alcohol dependence / / 20201924 rs12730405 chr1 111396915 A G 6.40E-05 Alcohol dependence / / 20201924 rs12730405 chr1 111396915 A G 6.44E-05 Alcoholism / / pha002892 rs6672672 chr1 111397090 C T 3.10E-04 Alcohol dependence / / 20201924 rs6672672 chr1 111397090 C T 7.20E-05 Alcohol dependence / / 20201924 rs6672672 chr1 111397090 C T 7.22E-05 Alcoholism / / pha002892 rs6687919 chr1 111397176 T G 1.50E-04 Alcohol dependence / / 20201924 rs6687919 chr1 111397176 T G 4.40E-04 Alcohol dependence / / 20201924 rs6687898 chr1 111397316 A G 1.50E-04 Alcohol dependence / / 20201924 rs6687898 chr1 111397316 A G 4.40E-04 Alcohol dependence / / 20201924 rs6690536 chr1 111397451 T C 1.70E-04 Alcohol dependence / / 20201924 rs6690536 chr1 111397451 T C 4.80E-04 Alcohol dependence / / 20201924 rs11102170 chr1 111401239 T C 5.24E-05 Bipolar disorder and schizophrenia / / 20889312 rs17637944 chr1 111401704 T C 2.54E-05 Bipolar disorder and schizophrenia / / 20889312 rs6696248 chr1 111404291 T C 4.24E-05 Bipolar disorder and schizophrenia / / 20889312 rs6701134 chr1 111406899 A G 2.90E-04 Alcohol dependence / / 20201924 rs6701134 chr1 111406899 A G 6.60E-05 Alcohol dependence / / 20201924 rs6701134 chr1 111406899 A G 6.65E-05 Alcoholism / / pha002892 rs7513168 chr1 111412912 T C 1.50E-05 Alcohol dependence / / 20201924 rs7513168 chr1 111412912 T C 1.90E-04 Alcohol dependence / / 20201924 rs7513168 chr1 111412912 T C 1.49E-05 Alcoholism / / pha002893 rs2885805 chr1 111417915 C A 5.00E-06 Cytomegalovirus antibody response CD53 intron 21993531 rs2885805 chr1 111417915 C A 0.000000215 Tuberculosis with late age of onset CD53 intron 22551897 rs1494320 chr1 111422188 T C 0.00000279 Tuberculosis with late age of onset CD53 intron 22551897 rs4839583 chr1 111433622 C T 1.33E-04 Multiple complex diseases CD53 intron 17554300 rs2070748 chr1 111434711 C T 2.35E-05 Multiple complex diseases CD53 intron 17554300 rs1712675 chr1 111463053 G C 3.16E-04 Multiple complex diseases / / 17554300 rs12567355 chr1 111463624 G A 9.00E-06 Obesity-related traits / / 23251661 rs1774766 chr1 111466602 T C 2.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1774766 chr1 111466602 T C 1.38E-05 Body Mass Index / / pha003021 rs1418425 chr1 111468886 T C 0.00000964 Aging / / 22445811 rs1418425 chr1 111468886 T C 0.0000535 Tuberculosis with late age of onset / / 22551897 rs12724986 chr1 111595360 T A 7.08E-04 Alzheimer's disease / / 22005930 rs12087782 chr1 111602976 A T 8.11E-04 Alzheimer's disease / / 22005930 rs12752511 chr1 111641712 A G 8.93E-04 Alzheimer's disease / / 22005930 rs11102212 chr1 111642031 A G 6.36E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs17026872 chr1 111646770 G A 8.98E-04 Alzheimer's disease / / 22005930 rs325894 chr1 111652548 T C 2.87E-05 Bipolar disorder / / 21771265 rs325921 chr1 111664343 A G 2.74E-05 Bipolar disorder DRAM2 intron 21771265 rs1335645 chr1 111684276 A G 7.00E-09 Liver enzyme levels (gamma-glutamyl transferase) CEPT1 intron 22001757 rs17026995 chr1 111706368 A G 5.85E-04 Multiple complex diseases CEPT1 intron 17554300 rs608881 chr1 111730901 C T 4.90E-04 Type 2 diabetes DENND2D cds-synon 17463246 rs2764546 chr1 111762482 G A 2.00E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs2182114 chr1 111784227 C T 9.00E-04 Type 2 diabetes and 6 quantitative traits CHI3L2 intron 17848626 rs2182114 chr1 111784227 C T 8.20E-05 Lipid traits CHI3L2 intron 17903299 rs942697 chr1 111791503 G C 5.02E-15 Lymphocyte counts / / 22286170 rs6691256 chr1 111796627 C A 7.70E-04 Type 2 diabetes and 6 quantitative traits / / 17848626 rs17654531 chr1 111799685 A G 1.16E-05 Parkinson's disease / / pha002868 rs4838896 chr1 111821777 T C 5.87E-06 Nephrolithiasis / / 22396660 rs12027550 chr1 111821946 C G 8.84E-05 Longevity / / 20304771 rs4323713 chr1 111823220 G T 4.70E-04 Crohn's disease RP11-165H20.1 intron 17684544 rs4240529 chr1 111824744 A G 8.32E-06 Paget's disease / / 20436471 rs12401767 chr1 111829797 G A 3.36E-05 Nephrolithiasis / / 22396660 rs3806448 chr1 111832205 G A 1.88E-05 Cognitive impairment induced by topiramate / / 22091778 rs3806446 chr1 111832291 T C 4.96E-05 Cognitive impairment induced by topiramate / / 22091778 rs3806446 chr1 111832291 T C 2.35E-05 Nephrolithiasis / / 22396660 rs4240530 chr1 111853581 C T 8.40E-04 Alcohol dependence CHIA intron 20201924 rs4839122 chr1 111854207 T C 5.05E-04 Alcohol dependence CHIA intron 21314694 rs11590452 chr1 111863942 C T 7.06E-04 Multiple complex diseases / / 17554300 rs11102249 chr1 111864700 G A 7.17E-08 Metabolite levels / / 23281178 rs12029516 chr1 111884013 C T 8.74E-04 Blood pressure,CVD RF and other traits (body mass index (BMI),waist:hip ratio,renin activity in plasma,aldosterone concentration in plasma,BNP levels in plasma,alcohol consumption) / / 20877124 rs9645351 chr1 111894870 G A 2.49E-04 Response to cytadine analogues (cytosine arabinoside) C1orf88 UTR-3 24483146 rs2050605 chr1 111903304 T C 3.89E-05 Vitiligo / / 19890347 rs17027501 chr1 111905989 C A 1.00E-04 Cognitive impairment induced by topiramate / / 22091778 rs1764807 chr1 111956206 C T 6.75E-04 Type 2 diabetes / / 17463246 rs1419093 chr1 111962152 T C 0.000294 Salmonella-induced pyroptosis OVGP1 intron 22837397 rs1264913 chr1 111974935 A G 2.08E-04 Type 2 diabetes / / 17463246 rs6692745 chr1 112019159 A G 1.66E-04 Lymphocyte counts C1orf162 intron 22286170 rs7737 chr1 112026152 C T 1.63E-04 Heart rate ADORA3 UTR-3 23583979 rs1361133 chr1 112027033 G T 4.39E-06 Cornea